SN,KP,PMID,Triple,Category,Gene Symbol,Cell type,Disease,Drugs,Pathway,Symptoms,Patient characteristics,Expression level,Markers,Environmental factors,Metabolites,Fact or Inference,一级标签,二级标签,三级标签,四级标签,五级标签,最具体的标签描述
205,KP1,11407596,CDK4#positively regulates#proliferation and cell cycle progression,Mechanism of Action,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
6201,KP1,11407596,CDK6#positively regulates#proliferation and cell cycle progression,Mechanism of Action,CDK6,-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
6364,KP1,11407596,p53#negatively regulates#proliferation and cell cycle progression,Mechanism of Action,TP53,-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
5085,KP1,11407596,p16INK4a#negatively regulates#proliferation and cell cycle progression,Mechanism of Action,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
7611,KP1,11407596,p14ARF#negatively regulates#proliferation and cell cycle progression,Mechanism of Action,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
4519,KP1,11407596,p15INK4b#negatively regulates#proliferation and cell cycle progression,Mechanism of Action,CDKN2B,-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
7452,KP1,11407596,Rb#negatively regulates#proliferation and cell cycle progression,Mechanism of Action,RB1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
7792,KP1,11407596,PTEN#negatively regulates#proliferation and cell cycle progression,Mechanism of Action,PTEN,-,-,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
3703,KP1,18413728,Genomic aberrations in CDK4#indicate#dysregulation of the G1 entry checkpoint in neuroblastoma,Cancer Association,CDK4,-,Neuroblastoma,-,G1 entry checkpoint,-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.1,-,G1/S检查点失控
2701,KP1,18413728,Genomic aberrations in CDK6#indicate#dysregulation of the G1 entry checkpoint in neuroblastoma,Cancer Association,CDK6,-,Neuroblastoma,-,G1 entry checkpoint,-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.1,-,G1/S检查点失控
4393,KP1,18413728,Cyclin D1#is overexpressed in#primary neuroblastic tumors,Expression Patterns,CCND1,-,Neuroblastic tumors,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
2997,KP1,18413728,Cyclin D1 overexpression#correlates with#histologic subgroups,Expression Patterns,CCND1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3121,KP1,20653773,CDKN2A alterations#were found in#seven melanoma kindred,Cancer Association,CDKN2A,-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
4059,KP1,33049397,PIK3CA mutations#contribute to#endocrine resistance in breast cancer,Mechanisms of Resistance,PIK3CA,-,Breast cancer,-,PI3K pathway,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
3727,KP1,33049397,"PIK3CA#is frequently mutated in#HR+, HER2- advanced breast cancer",Cancer Association,PIK3CA,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.4,-,PIK3CA突变
3366,KP1,33049397,Mechanisms of resistance to CDK4/6i#have been identified in#breast cancer,Mechanisms of Resistance,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
5376,KP1,33049397,PIK3CA mutations#are associated with#Ki67 expression in primary lesions,Expression Patterns,PIK3CA,-,-,-,-,-,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,7.3.1.1.1,Ki67指数
6831,KP1,32913968,Abiraterone-resistant tumors#harbor#alterations in AR and MYC,Mechanisms of Resistance,"AR,MYC",-,-,Abiraterone,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
6815,KP1,32913968,Enzalutamide-resistant tumors#gain#alterations in CDKN2A,Mechanisms of Resistance,CDKN2A,-,-,Enzalutamide,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
5398,KP1,32913968,Enzalutamide-resistant tumors#gain#amplifications in CDK6,Mechanisms of Resistance,CDK6,-,-,Enzalutamide,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
818,KP1,32913968,CDK4/6 amplifications#promote#enzalutamide resistance in CRPC,Mechanisms of Resistance,"CDK4,CDK6",-,Castration-resistant prostate cancer (CRPC),Enzalutamide,-,-,-,-,-,-,-,Inference,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
5444,KP1,10733595,Oncogenic Ras#induces#p15INK4b expression,Regulation,p15INK4B,-,-,-,Ras pathway,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
4750,KP1,10733595,p15INK4b#is frequently inactivated by#homozygous deletion in tumors,Cancer Association,CDKN2B,-,Tumors,-,-,-,-,silenced,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
884,KP1,10733595,p15INK4b#is inactivated by#hypermethylation in hematopoietic malignancies,Cancer Association,CDKN2B,-,Hematopoietic malignancies,-,-,-,-,silenced,-,-,-,Fact,1,1.5,1.5.1,1.5.1.2,-,DNA甲基化
4145,KP1,10733595,Ras-dependent induction of p15INK4b and p16INK4a#is mediated by#Raf-Mek-Erk pathway,Pathway & Network Categories,"CDKN2B,CDKN2A",-,-,-,Raf-Mek-Erk pathway,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
2409,KP1,10939591,CDKN2A and CDKN2B#are frequently homozygously deleted in#glioblastomas,Cancer Association,"CDKN2A,CDKN2B",-,Glioblastomas,-,-,-,-,silenced,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
2486,KP1,8724524,p16INK4a and p15INK4b#inhibit#cyclin D-CDK4 and -CDK6 complexes,Mechanism of Action,"CDKN2A,CDKN2B","Cyclin D-CDK4,CDK6",-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
1282,KP1,8724524,p16INK4a and p15INK4b#are deleted in#human cell lines and fresh solid tumors,Cancer Association,"CDKN2A,CDKN2B",-,Solid tumors,-,-,-,-,silenced,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
2692,KP1,8724524,Point mutations in p16INK4a#are sequenced in#familial melanomas and digestive cancers,Cancer Association,CDKN2A,-,"Melanomas,Digestive cancers",-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
1473,KP1,8724524,p16ink4a deletions#occur more frequently than#p15ink4b deletions in hematological malignancies,Cancer Association,"CDKN2A,CDKN2B",-,"ALL, CML, ATL",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
3802,KP1,8724524,"Homozygous deletions of p16ink4a and p15ink4b#are associated with#T-lineage, 9p abnormalities, and prognostic factors in ALL",Cancer Association,"CDKN2A,CDKN2B",-,ALL,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
7970,KP1,33177839,NCAPG overexpression#correlates with#poor prognosis in multiple cancer types,Expression Patterns,NCAPG,-,Multiple cancer types,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
528,KP1,33177839,NCAPG overexpression#was found in#CA tissues and cell lines,Expression Patterns,NCAPG,-,CA,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
1695,KP1,33177839,NCAPG upregulation#promoted#cell proliferation,Mechanism of Action,NCAPG,-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
1175,KP1,33177839,Overexpressed NCAPG#activated#PI3K/AKT signaling pathway in CA cells,Signaling Networks,"NCAPG,PIK3CA,AKT1",-,CA,-,PI3K/AKT,-,-,upregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
5103,KP1,33177839,"NCAPG overexpression#increased#phosphorylated PI3K, AKT, and GSK3β levels in CA cells",Signaling Networks,"NCAPG,PIK3CA,AKT1,GSK3B",-,CA,-,PI3K/AKT,-,-,upregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,1.3.1.3,协同效应
3034,KP1,33177839,NCAPG#regulated#cell cycle through PI3K/AKT signaling pathway activation,Cell Cycle Control,"NCAPG,PIK3CA,AKT1",-,-,-,PI3K/AKT,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
1867,KP1,33427211,"CDK4/6 inhibitors#are an established treatment for#hormone receptor-positive, HER2-negative metastatic breast cancers",Therapeutic Development,"CDK4,CDK6,ERBB2",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2070,KP1,14645011,Disruption of p18INK4c#impairs#B-cell terminal differentiation,Immune Cell Functions,CDKN2C,B cells,Tumor,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.2,1.4.2.2,-,分化标志物表达
4613,KP1,14645011,Disruption of p18INK4c#confers#increased susceptibility to tumor development,Cancer Pathways,CDKN2C,-,Tumor,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.1,-,增殖信号整合
3320,KP1,14645011,p18INK4c immunostaining#correlates with#shorter overall survival in negative cases,Prognostic Associations,CDKN2C,-,-,-,-,Negative cases,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.3,p16表达
6594,KP1,31988001,BRG1 inactivation#increases#tumor aggressiveness,Cancer Association,SMARCA4,-,Tumor,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
1153,KP1,31988001,BRG1 inactivation#enhances#sensitivity to drugs targeting CDK4 or CDK6,Therapeutic Response,"SMARCA4,CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
703,KP1,31988001,"Deficient BRG1 expression#is detected in#adenocarcinomas with co-occurring KRAS, TP53, KEAP1, and STK11 mutations",Expression Patterns,"SMARCA4,KRAS,TP53,KEAP1,STK11",-,Adenocarcinomas,-,-,-,-,Downregulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.3,-,抑制复合物
7021,KP1,35100692,"Pathways#were identified as#aberrant if there were copy number aberrations or mutations in CCND1, CCND2, CCND3, CDK4, CDK6",Signaling Networks,"CCND1,CCND2,CCND3,CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
4369,KP1,15994928,Homozygous deletion near PTPRD locus#was found in#small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC),Cancer Pathways,PTPRD,-,"SCLC, NSCLC",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.4,-,肿瘤抑制子缺失
7212,KP1,15994928,High-level amplification of EGFR#was identified in#NSCLC specimens,Cancer Pathways,EGFR,-,NSCLC,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
1094,KP1,9101469,p16 (MST1)#binds to#CDK4 and CDK6,Protein Complex Dynamics,"CDKN2A,CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
1876,KP1,9101469,p16 (MST1)#prevents#interaction of CDK4/CDK6 with cyclin D1,Cell Cycle Control,"CDKN2A,CDK4,CDK6",Cyclin D1,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
3861,KP1,9101469,p16 gene sequencing#showed#no mutation resulting in coding error in ovarian tumors,Mutation Frequencies,CDKN2A,-,Ovarian tumor,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.4,-,剪切位点突变
90,KP1,27276112,Loss of CDKN2A promoter methylation#coincides with#epigenetic transdifferentiation of uterine myosarcomatous cells,Epigenetic Modifications,CDKN2A,-,Uterine myosarcoma,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,微小RNA
1388,KP1,27276112,Transdifferentiation from smooth muscle#coincides with#striated muscle phenotype,Mechanism of Action,CDKN2A,-,Uterine leiomyosarcoma,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.2,1.4.2.1,-,谱系特异性分化
6949,KP1,27276112,Methylation-specific polymerase chain reaction#revealed#presence of methylated and unmethylated alleles in leiomyosarcomatous cells,Regulation,CDKN2A,Leiomyosarcomatous cells,Uterine leiomyosarcoma,-,-,-,-,-,-,-,-,Fact,5,5.6,5.6.3,5.6.3.1,-,表观遗传调控
2900,KP1,27276112,Two unmethylated alleles#were detected#in rhabdomyosarcomatous cells,Regulation,CDKN2A,Rhabdomyosarcomatous cells,Uterine leiomyosarcoma,-,-,-,-,-,-,-,-,Fact,5,5.6,5.6.3,5.6.3.1,-,表观遗传调控
6187,KP1,27276112,Loss of heterozygosity methylation in CDKN2A promoter region#occurred only in#rhabdomyosarcomatous cells,Regulation,CDKN2A,Rhabdomyosarcomatous cells,Uterine leiomyosarcoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.6,5.6.3,5.6.3.1,-,表观遗传调控
3622,KP1,27276112,Inhibition of cdk4/cdk6 activity#stabilizes#p53 tumor suppressor protein,Mechanism of Action,"CDKN2A, CDK4, CDK6, TP53",-,Uterine leiomyosarcoma,-,-,-,-,-,-,-,-,Inference,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
4322,KP1,11156381,Germ-line CDKN2A mutations#are present in#kindreds with hereditary cutaneous melanoma,Cancer Association,CDKN2A,-,Hereditary cutaneous melanoma,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
5215,KP1,11156381,CDKN2A alterations#may contribute to#melanoma predisposition,Cancer Association,CDKN2A,-,Melanoma,-,-,-,-,-,-,-,-,Inference,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
5731,KP1,11156381,A 24-bp deletion in CDKN2A#was detected in#a patient with family history of melanoma,Cancer Association,CDKN2A,-,Melanoma,-,-,-,Family history,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
2514,KP1,11156381,Mutant p16 protein#was unable to bind#cyclin-dependent kinase 4 and cyclin-dependent kinase 6,Mechanism of Action,"CDKN2A, CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
4451,KP1,11156381,Proportion of CDKN2A mutation carriers#was significantly higher in#patients with three or more primary melanomas,Cancer Association,CDKN2A,-,Melanoma,-,-,-,Three or more primary melanomas,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
4206,KP1,8934552,p16INK4a and p15INK4b#are frequently mutated in#human tumors,Cancer Association,"CDKN2A, CDKN2B",-,Human tumors,-,-,-,Mutated,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
3620,KP1,37044053,Correlation between RAB7A#and#development and immune infiltration of hepatocellular carcinoma is rarely studied,Signaling Networks,RAB7A,-,Hepatocellular carcinoma,-,-,-,-,-,-,-,-,Inference,6,6.1,6.1.1,6.1.1.2,-,髓系细胞浸润
1740,KP1,37044053,Immunohistochemistry (IHC)#was used to evaluate#correlation between RAB7A and immune checkpoints,Technical Methods,RAB7A,-,Hepatocellular carcinoma,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.3,-,免疫检查点表达
1155,KP1,37044053,RAB7A#was significantly positively correlated with#infiltration of macrophages and cancer-associated fibroblasts,Signaling Networks,RAB7A,"Macrophages, cancer-associated fibroblasts",Hepatocellular carcinoma,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.2,-,髓系细胞浸润
1211,KP1,37044053,RAB7A#was negatively correlated with#M2-type macrophages in most tumors,Signaling Networks,RAB7A,M2-type macrophages,Hepatocellular carcinoma,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.2,-,髓系细胞浸润
6954,KP1,37044053,Single-cell atlas#revealed#distribution and proportion of RAB7A in immune cells of HCC,Signaling Networks,RAB7A,Immune cells,Hepatocellular carcinoma,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.2,-,髓系细胞浸润
293,KP1,37044053,Knockdown of RAB7A#inhibited#activation of the PIK3CA-AKT pathway,Signaling Networks,"RAB7A,PIK3CA,AKT",-,-,-,PIK3CA-AKT,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
5964,KP1,37044053,"Knockdown of RAB7A#suppressed#expression of CDK4, CDK6, and CCNA2",Regulation,"RAB7A,CDK4,CDK6,CCNA2",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
2473,KP1,37044053,RAB7A#may serve as#a tumor prognostic and immune infiltration-related biomarker,Biomarker Analysis,RAB7A,-,"Cancer, HCC",-,-,-,-,-,-,-,-,Inference,7,7.2,7.2.1,7.2.1.3,-,免疫标志物
7159,KP1,37044053,"RAB7A#predicts#immunotherapy efficacy in certain cancer types, especially HCC",Predictive Biomarkers,RAB7A,-,HCC,-,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.1,-,基因突变
1216,KP1,11369633,RNA representing exon 2 of p16(INK4a) and p14(ARF)#was enhanced by#2.8- to 15.9-fold in 11 patients with PV,Expression Patterns,"CDKN2A (p16),CDKN2A (p14)",-,PV,-,-,-,11 patients,upregulated,-,-,-,Fact,5,5.3,5.3.3,5.3.3.1,-,基因表达改变
2588,KP1,11369633,mRNAs from first exons of INK4a and ARF#were increased in#erythroid and granulocyte-macrophage cells,Expression Patterns,"CDKN2A (INK4a),CDKN2A (ARF)","Erythroid cells, Granulocyte-macrophage cells",-,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.3,5.3.3.1,-,基因表达改变
3440,KP1,11369633,INK4a protein (p16(INK4a))#was increased in#PV ECFCs,Expression Patterns,CDKN2A (INK4a),Endothelial colony-forming cells (ECFCs),PV,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.3,5.3.3.1,-,基因表达改变
1308,KP1,11369633,p16(INK4a)#is an#important negative cell-cycle regulator,Cell Cycle Control,CDKN2A (INK4a),-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
5781,KP1,11369633,p16(INK4a) expression#was dramatically increased in#PV ECFCs,Expression Patterns,CDKN2A (INK4a),Endothelial colony-forming cells (ECFCs),PV,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.3,5.3.3.1,-,基因表达改变
4268,KP1,14551738,CDK6 oncogene#is overexpressed and disrupted in#many hematological malignancies,Cancer Association,CDK6,-,Hematological malignancies,-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
4276,KP1,14551738,CDK6 expression#was detected#in myeloid leukemia,Expression Patterns,CDK6,-,Myeloid leukemia,-,-,-,-,-,-,-,-,Fact,2,2.3,2.3.3,2.3.3.2,-,蛋白表达量
3474,KP1,22932448,"Deregulation of the p16/CDK4/cyclin D1 complex#has been established in#a variety of human tumors including gliomas, sarcomas, melanoma, breast and colorectal cancer",Cancer Association,"CDKN2A (p16),CDK4,CCND1",-,"Gliomas, Sarcomas, Melanoma, Breast cancer, Colorectal cancer",-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
5299,KP1,22932448,CDK4 mutation#may play a major role in#development and progression of squamous cell carcinoma of head and neck,Cancer Association,CDK4,-,Squamous cell carcinoma of head and neck,-,-,-,-,-,-,-,-,Inference,2,2.1,2.1.1,2.1.1.4,-,关键基因突变
6875,KP1,11828258,Two genes#have been implicated in#melanoma pathogenesis,Cancer Association,"CDKN2A (p16),CDK4",-,Melanoma,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
3571,KP1,35108033,Selective CDK4/6 inhibitors#are clinically evaluated in#sarcomas,Clinical Trial Data,"CDK4,CDK6",-,Sarcomas,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1384,KP1,35108033,CDK4/6 inhibitors#are supported by#current clinical data in subsets of sarcoma,Therapeutic Response,"CDK4,CDK6",-,Sarcomas,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
555,KP1,35108033,Strategies to identify responders and resistance mechanisms#are important to maximize#clinical utility of CDK4/6 inhibitors in sarcoma,Resistance Management,"CDK4,CDK6",-,Sarcomas,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
7404,KP1,35108033,CDK4/6 inhibitors#indicate sensitivity in#sarcoma,Cancer Association,"CDK4,CCND,CCNE,RB1,E2F1,CDKN2A",-,Sarcoma,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3054,KP1,35108033,CDK4/6 inhibitors#represent#a major breakthrough for targeted cancer treatment,Therapeutic Development,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7394,KP1,31592235,Cyclin B1 and CCND1#are overexpressed in#seminal vesicle tumors of TRAMP mice,Expression Patterns,"CCNB1,CCND1",-,Seminal vesicle tumors,-,-,-,"TRAMP mice, age-related",Upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
2825,KP1,31592235,P21 and P27#are augmented in#TRAMP mice seminal vesicle tumors,Expression Patterns,"CDKN1A,CDKN1B",-,Seminal vesicle tumors,-,-,-,TRAMP mice,Upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
715,KP1,31592235,"CDK4, CDK6, and phosphorylated RB#increase in#TRAMP mice seminal vesicle tumors",Expression Patterns,"CDK4,CDK6,RB1",-,Seminal vesicle tumors,-,-,-,TRAMP mice,Upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2508,KP1,31592235,EGFR and AKT#increase in#TRAMP mice seminal vesicle tumors,Expression Patterns,"EGFR,AKT1",-,Seminal vesicle tumors,-,-,-,TRAMP mice,Upregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
1815,KP1,30718927,Selection in 551 esophageal adenocarcinomas#defines#genomic biomarkers for the clinic,Biomarker Analysis,-,-,Esophageal adenocarcinoma,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,RB1突变
3424,KP1,30718927,77 EAC driver genes#were discovered in#a cohort of genomically characterized EACs,Biomarker Analysis,-,-,Esophageal adenocarcinoma,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,RB1突变
3616,KP1,30718927,Driver events in EAC#are derived from#mutations more commonly than copy number alterations,Molecular Event,-,-,Esophageal adenocarcinoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
1812,KP1,30718927,Mutual exclusivity or co-occurrence of events#suggests#strong functional relationships in dysregulated EAC pathways,Pathway & Network Categories,-,-,Esophageal adenocarcinoma,-,-,-,-,-,-,-,-,Inference,1,1.3,1.3.3,1.3.3.2,-,DNA修复机制
6346,KP1,30718927,Sensitizing events for CDK4/6 inhibitors#are correlated with#clinically relevant sensitivity in EAC cell lines and organoids,Therapeutic Response,"CDK4,CDK6",-,Esophageal adenocarcinoma,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3155,KP1,21910158,CDK4 amplification#is substituted by#alterations in liposarcomas,Cancer Association,CDK4,-,Liposarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
367,KP1,10861313,"CDKN2A#encodes#p16, which inhibits cyclin D1-CDK4 complex",Mechanism of Action,"CDKN2A,CDK4,CCND1",-,Melanoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
5057,KP1,19946100,Supernumerary chromosomes#are amplified in#MDM2 and CDK4 genes in WDLPS and DDLPS,Cancer Association,"MDM2,CDK4",-,"Well-differentiated liposarcoma, Dedifferentiated liposarcoma",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
2966,KP1,23546221,CDKN2A#is comprehensively analyzed in#Latvian familial melanoma probands,Biomarker Analysis,CDKN2A,-,Melanoma,-,-,-,Latvian familial melanoma probands,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,RB1突变
5071,KP1,19626636,Well-differentiated and undifferentiated liposarcomas#are characterized by#high-level amplifications of chromosome 12 regions including CDK4 and MDM2 genes,Cancer Association,"CDK4,MDM2",-,Liposarcomas,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
4940,KP1,9426066,p16/CDKN2A and CDK4#determine#progression from G1 to S phase,Cell Cycle Control,"CDKN2A,CDK4",-,-,-,Cell cycle pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
7441,KP1,9426066,"Alterations in p16/CDKN2A#have been documented in#multiple cancers, including melanoma",Cancer Association,CDKN2A,-,"Melanoma, multiple cancers",-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,-,-,基因组改变
691,KP1,9426066,Two alterations at codon 24 in CDK4#include#arginine-to-cysteine and arginine-to-histidine substitutions,Molecular Event triples,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6531,KP1,9426066,Two alterations in exon 2 of CDK4#were detected in#cell lines derived from metastatic melanomas,Molecular Event triples,CDK4,-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6161,KP1,24965044,Tumor-specific translocations and fusion genes#have been identified in#ALT/WDL with amplified MDM2 and CDK4 genes,Cancer Association,"MDM2,CDK4",-,"Adipocytic tumors, atypical lipomatous tumors/well-differentiated liposarcomas (ALT/WDL)",-,Retinoblastoma pathway,-,-,upregulated,-,-,-,Fact,5,5.4,5.4.1,5.4.1.3,-,断裂点特征
5596,KP1,19011513,Mutations in CDKN2A and CDK4 genes#are associated with#predisposition to familial cutaneous malignant melanoma,Cancer Association,"CDKN2A,CDK4",-,Familial cutaneous malignant melanoma,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,-,-,基因组改变
7465,KP1,39457497,CDK4/6 inhibitors#are used in#treatment of women with breast cancer undergoing HT,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,细胞周期阻滞
7192,KP1,39457497,The MAF of detected alterations#decreased or disappeared during#CDK4/6i treatment in patients with stable disease or partial response,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,-,-,细胞周期阻滞
2782,KP1,9416844,Germline mutations in CDKN2A and CDK4 genes#have been identified in#a proportion of melanoma kindreds,Cancer Association,"CDKN2A,CDK4",-,Melanoma,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,-,-,基因组改变
6693,KP1,31375512,anti-PD-1 therapy#triggers#innate resistance,Therapeutic Response,-,-,Advanced melanoma,anti-PD-1,-,-,-,-,-,-,-,Inference,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
2334,KP1,31375512,"CDK4, CCND1, and CDKN2A#were assayed for#copy-number variations",Regulation,"CDK4, CCND1, CDKN2A",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,-,-,基因扩增
820,KP1,31375512,CDK4-normal cell lines and tumors#showed#altered transcriptional output in TNF伪 signaling via NF-魏B,Pathway & Network Categories,CDK4,-,-,-,"TNF伪, NF-魏B, IFN纬",-,-,-,-,-,-,Fact,1,1.3,1.3.2,-,-,MAPK信号通路
1973,KP1,10398427,CDKN2A germline mutations#were identified in#10 different cases,Cancer Association,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,-,-,基因组改变
2562,KP1,16938516,ALT/WDL and DDL#are reported to have#MDM2 and CDK4 amplification,Cancer Association,"CDK4, MDM2",-,"ALT/WDL, DDL",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
4772,KP1,23529275,Atypical lipomatous tumors#represent#a subset of mesenchymal neoplasms,Cancer Association,-,-,Atypical lipomatous tumors,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.3,-,关键基因突变
4028,KP1,37875500,CDK4/6 inhibitors#demonstrated#activity in progression-free survival in DD-LPS,Drug Development,"CDK4, CDK6",-,DD-LPS,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6379,KP1,37875500,CDK4 overexpression#is#a predictive factor for palbociclib efficacy in sarcomas,Therapeutic Response,CDK4,-,Sarcomas,Palbociclib,-,-,-,Upregulated,-,-,-,Fact,7,7.1,7.1.2,7.1.2.1,-,CDK4扩增
6486,KP1,37875500,Sarcoma patients#overexpressed#CDK4 but not CDKN2A at baseline biopsy,Expression Patterns,"CDK4, CDKN2A",-,Sarcoma,-,-,-,-,Upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,Cyclin D1表达
3698,KP1,37875500,CDK4 mRNA and protein expression#showed#a significant correlation,Biomarker Analysis,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,-,细胞周期标志物
4717,KP1,11505267,SAS gene#showed#amplification but not MDM2 or CDK4,Cancer Association,"CDK4, MDM2, SAS",-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
3761,KP1,28477272,"MDM2, CDK4, and p16 positivity#do not necessarily indicate#malignant neoplasm",Biomarker Analysis,"CDK4, MDM2",-,Dedifferentiated liposarcoma,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.4,-,RB蛋白表达
3465,KP1,11172613,CDK4#was screened for#activating point mutations in malignant mesotheliomas,Molecular Event triples,CDK4,-,Malignant mesotheliomas,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
5958,KP1,11172613,"tumors#were screened for#deletions and point mutations in p53, p16INK4a (CDKN2A), and p14ARF (exon-1beta)",Genomic Analysis,"TP53,CDKN2A,CDKN2B",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
4584,KP1,11172613,disarrangement of the Rb1 pathway#may be involved in#mesothelioma formation,Cancer Pathways,RB1,-,Mesothelioma,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
7275,KP1,31672072,lipomatous tumor#harbored#amplification of MDM2 and CDK4,Genomic Alterations,"CDK4,MDM2",-,Lipomatous tumor,-,-,-,69-year-old woman,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
360,KP1,34483306,mucosal melanoma#has#a worse prognosis than other melanoma subtypes,Clinical Correlation,CDK4,-,Mucosal melanoma,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,症状改善
7389,KP1,34483306,molecular landscape of mucosal melanoma#remains distinct from#cutaneous melanoma,Molecular Analysis,CDK4,-,"Mucosal melanoma, Cutaneous melanoma",-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.2,-,热点区域
736,KP1,34483306,CDK4/6 inhibitors#have been approved for#clinical application in breast cancer,Drug Development,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2798,KP1,34483306,targeting of CDK4#is#a promising direction for precision cancer treatment,Therapeutic Development,CDK4,-,Mucosal melanoma,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1019,KP1,26110554,genetic alterations#may contribute toward#melanoma development,Cancer Pathways,"CDK4,CDKN2A,MC1R",-,Melanoma,-,-,-,-,-,-,-,-,Inference,5,5.5,5.5.2,5.5.2.3,-,基因组重排
7856,KP1,26110554,CDKN2A and CDK4#are#high-penetrance genes for melanoma,Cancer Association,"CDKN2A,CDK4",-,Melanoma,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,RB1突变
5819,KP1,26110554,BRAF#is#a validated therapeutic target in melanoma,Therapeutic Development,BRAF,-,Melanoma,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
2254,KP1,17214366,patients with DDLPS and high mitotic rate#died or experienced#recurrences more frequently,Patient Outcomes,CDK4,-,DDLPS,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
2992,KP1,19816710,amplification of CDK4 gene#was found in#one case,Genomic Alterations,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1772,KP1,38003483,oncogene amplification#has been described in#several models,Genomic Alterations,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,-,-,基因扩增
7840,KP1,38003483,MCF-7 luminal breast cancer cell line#showed#cross-resistance to abemaciclib,Mechanisms of Resistance,"CDK4,CDK6",-,Breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,2.6.1.1,-,药物外排增加
358,KP1,38003483,resistant cell line#strongly activates#epithelial-to-mesenchymal transition,Mechanism of Action,"CDK4,CDK6",-,Breast cancer,-,EMT,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.2,-,细胞衰老诱导
7940,KP1,38003483,CDKN2B#is#dramatically downregulated in resistant cells,Expression Patterns,CDKN2B,-,Breast cancer,-,-,-,-,downregulated,-,-,-,Fact,7,7.5,7.5.1,7.5.1.2,-,原发性耐药
3060,KP1,38003483,TWIST1 transcription factor#is#upregulated in resistant cells,Expression Patterns,TWIST1,-,Breast cancer,-,-,-,-,upregulated,-,-,-,Fact,7,7.5,7.5.1,7.5.1.2,-,原发性耐药
1054,KP1,38003483,mechanisms of resistance to CDK4/6 inhibitors#suggest#potential new markers for patient follow-up care,Mechanisms of Resistance,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,2,2.5,2.5.2,2.5.2.4,-,生物标志物指导
5225,KP1,18497076,chromosomal aberrations#gains were found on#rat chromosome 4 (RNO4),Genomic Alterations,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.3,-,重复
7488,KP1,32026050,"Cytotoxic chemotherapy agents, including doxorubicin, ifosfamide, gemcitabine, and docetaxel#showed efficacy in#patients with soft tissue sarcomas",Therapeutic Response,-,-,Soft tissue sarcomas,"Doxorubicin,Ifosfamide,Gemcitabine,Docetaxel",-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.2,-,协同增效作用
3528,KP1,32026050,Trabectedin and eribulin along with pazopanib#establish#clinical benefit in advanced liposarcoma and DDLPS,Therapeutic Response,-,-,"Advanced liposarcoma,DDLPS","Trabectedin,Eribulin,Pazopanib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3827,KP1,32026050,MDM2 and CDK4#show#highly amplified expression in DDLPS tumors,Expression Patterns,"MDM2,CDK4",-,DDLPS,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
4784,KP1,32026050,Current standard-of-care options and newer therapies#are being compared for#localized DDLPS,Clinical Implementation,-,-,Localized DDLPS,-,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
5197,KP1,15928671,Genotyping of CDKN2A/ARF and CDK4 loci#was performed in#Jewish melanoma families with or without neural system tumors,Preclinical Models,"CDKN2A,CDK4",-,"Melanoma,Neural system tumors",-,-,-,Jewish families,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
3733,KP1,15928671,CDKN2A/ARF deletion detection#was performed using#D9S1748 marker,Technical Methods,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
4260,KP1,15928671,Point mutations in CDKN2A/ARF and CDK4#were detected using#dHPLC and direct sequencing,Technical Methods,"CDKN2A,CDK4",-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6950,KP1,30159138,Desmoplastic fibroma (DF) and low-grade central osteosarcoma (DF-like LGCOS)#are rare#fibrous bone tumors,Disease & Clinical Categories,-,-,"Desmoplastic fibroma,Low-grade central osteosarcoma",-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
1327,KP1,30159138,DF-LGCOS#had amplification of#CDK4,Expression Patterns,CDK4,-,Low-grade central osteosarcoma,-,-,-,-,upregulated,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
6866,KP1,30159138,RB1 tumor suppressor gene#was lost due to#chromosome 13 deletion in DF-LGCOS,Cancer Pathways,RB1,-,Low-grade central osteosarcoma,-,-,-,downregulated,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.2,5.3.2.2.2,RB1缺失
1085,KP1,15154619,CDK4#is involved in#tumorigenesis process of WDL,Cancer Pathways,CDK4,-,Well-differentiated liposarcoma,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.3,1.1.1.3.3,增殖抑制
4513,KP1,17895748,MDM2 and CDK4#are amplified in#ALT/WDL and DDLPS,Cancer Association,"MDM2, CDK4",-,"ALT/WDL, DDLPS",-,-,-,-,upregulated,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
1728,KP1,29123414,MDM2 and CDK4#provide#sensitive markers for the diagnosis of low-grade central osteosarcoma,Biomarker Analysis,"MDM2, CDK4",-,Low-grade central osteosarcoma,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
7684,KP1,29416732,hMSCs#harbor#CDK4 and MDM2 amplifications,Expression Patterns,"CDK4, MDM2",hMSCs,"Osteosarcoma, Liposarcoma",-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
4875,KP1,29416732,CDK4 and MDM2 amplifications#occur frequently in#osteosarcoma and liposarcoma,Disease Association,"CDK4, MDM2",-,"Osteosarcoma, Liposarcoma",-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
5560,KP1,38883740,Patients with recurrent high-grade glioma#harbor#CDK4/6 amplification,Cancer Association,"CDK4, CDK6",-,High-grade glioma,-,-,-,"Wild-type retinoblastoma protein (Rb), PTEN loss, PIK3CA mutations",-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
2380,KP1,20063101,ALT area#exhibits#high-level amplification of MDM2/CDK4 gene,Expression Patterns,"MDM2, CDK4",-,ALT,-,-,-,-,Upregulated,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
2351,KP1,14519639,CDK4#is involved in#Rb1 pathway,Pathway & Network Categories,"CDK4, RB1",-,-,-,Rb1,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,1.1.1.1.1,RB蛋白磷酸化
1096,KP1,12115352,"Families with increased risk of melanoma#carry#differing germline mutations in CDKN2A, CDK4, or unknown genes",Cancer Association,"CDKN2A, CDK4",-,Melanoma,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,2.2.1.4.4,关键基因突变
7243,KP1,27272683,CDK4 and p16#showed#strong and diffuse nuclear expression in hibernoma-like areas,Expression Patterns,"CDK4, CDKN2A",-,Hibernoma-like areas,-,-,-,-,Upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
797,KP1,12242528,Amplification of CDK4 gene#was detected using#FISH analysis,Technical Methods,CDK4,-,-,-,-,-,-,Amplified,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
4391,KP1,31020219,Amplification of 12q including CDK4#identified#Palbociclib as a potential therapeutic option,Drug Development,CDK4,-,-,Palbociclib,-,-,-,Amplified,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3228,KP1,38369555,Preclinical studies#implied#potential applicability of CDK4/6 inhibitor for chordoma,Cancer Association,"CDK4, CDK6",-,Chordoma,CDK4/6 inhibitor,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
69,KP1,38369555,CDK4/6 inhibitor#showed#partial response in chordoma patient,Therapeutic Response,"CDK4, CDK6",-,Chordoma,CDK4/6 inhibitor,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,8.5.1.1.1,CT扫描
430,KP1,38369555,E2F amplification#induces#CDK4/6 independent cell-cycle progression,Mechanism of Action,"E2F, CDK4, CDK6",-,-,-,-,-,-,Amplified,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
7030,KP1,30782616,CDK4 amplification#co-occurs with#MDM2 and TERT amplification in MM patients,Cancer Association,"CDK4, MDM2, TERT",-,Malignant melanoma,-,-,-,-,Amplified,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
1905,KP1,39013131,Palbociclib#shows#antitumor effects in soft tissue sarcoma with CDK4 amplifications,Drug Development,CDK4,-,Soft tissue sarcoma,Palbociclib,-,-,-,Amplified,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3533,KP1,39013131,Palbociclib#causes#grade 3 to 4 adverse events,Adverse Event,CDK4,-,-,Palbociclib,-,"Alanine aminotransferase increase, anemia, fatigue, hypophosphatemia, leukopenia, neutropenia, thrombocytopenia",-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
3160,KP1,32404308,CDK4/6i exposure#reveals#candidate resistance mechanisms,Mechanisms of Resistance,"CDK4, CDK6, RB1, AKT1, RAS, AURKA, CCNE2, ERBB2, FGFR2",-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
2881,KP1,15604268,hTERT and CDK4#enable#generation of replicating HBEC lines,Cell Line Development,"CDK4, hTERT",Bronchial epithelial cells,Lung cancer,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.1,-,DSB识别
3295,KP1,15604268,Cyclin-dependent kinase 4 and hTERT#result in#continuously growing cultures,Cell Line Development,"CDK4, hTERT",Bronchial epithelial cells,Lung cancer,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.1,-,DSB识别
3721,KP1,15604268,Immortalized bronchial cells#did not form#colonies in soft agar or tumors in nude mice,Cell Line Development,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.1,-,DSB识别
5845,KP1,15604268,Immortalized HBECs#express#epithelial markers and p63,Expression Patterns,CDK4,-,-,-,-,-,-,High levels of p16(INK4a),p63,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
5962,KP1,15604268,Immortalized HBECs#have#duplication of chromosomes 5 and 20,Genomic Alterations,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
6904,KP1,35922164,MDM2/CDK4#are amplified in#MPLPS cases,Cancer Association,"CDK4, MDM2",-,MPLPS,-,-,-,-,Amplified,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
2021,KP1,35349366,CCND1 and EGFR#are amplified in#cell cycle regulation,Expression Patterns,"CCND1, EGFR",-,-,-,-,-,-,Amplified,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
5912,KP1,28060055,CDKN2A and CDK4#are associated with#genetic susceptibility to PCM,Genetic Susceptibility,"CDKN2A, CDK4",-,Primary cutaneous melanoma (PCM),-,FAMMM,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
6080,KP1,28060055,CDKN2A and CDK4#were screened by#direct bidirectional sequencing,Technical Methods,"CDKN2A, CDK4",-,Primary cutaneous melanoma (PCM),-,FAMMM,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
4601,KP1,28060055,Dysplastic nevi excision#prevents#PCM development,Preventive Strategies,-,-,Primary cutaneous melanoma (PCM),-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
6370,KP1,28060055,CDKN2A p.D84V mutation#is associated with#PCM in three families,Genetic Susceptibility,CDKN2A,-,Primary cutaneous melanoma (PCM),-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
4805,KP1,31154837,MDM2 and CDK4#are associated with#DLOS diagnosis,Diagnostic Markers,"MDM2,CDK4",-,DLOS,-,-,-,Median age 32 years (IQR 27 to 38),Amplified,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
2330,KP1,31154837,Histological evaluation after chemotherapy#shows#poor response in DLOS cases,Treatment Outcomes,-,-,DLOS,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,8.5.1.3.1,症状改善
1361,KP1,31154837,One DLOS patient#developed#local recurrence,Clinical Correlation triples,-,-,DLOS,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,8.5.1.3.3,生活质量
3960,KP1,31154837,Five DLOS patients#developed#distant metastases,Clinical Correlation triples,-,-,DLOS,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,8.5.1.3.2,体能状态
5448,KP1,18023021,Mutations in CDKN2A#were found in#6.9% of respondents,Molecular Event triples,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
5887,KP1,18023021,A large deletion encompassing exon 1alpha and 5' part of exon 2#was detected in#six patients with a family history of melanoma,Molecular Event triples,CDKN2A,-,Melanoma,-,-,-,Family history,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
5485,KP1,14735200,Germline anomalies of INK4a-ARF and Cdk4#were sought in#89 patients suspected of genetic predisposition to melanoma,Disease & Clinical Categories,CDK4,-,Melanoma,-,-,-,Genetic predisposition,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.2,-,缺失
5342,KP1,14735200,"Three variants of uncertain significance#were detected in#one MPM patient, one patient <25 years, and one NPIM patient",Molecular Event triples,-,-,"MPM, NPIM",-,-,-,<25 years,-,-,-,-,Fact,5,5.5,5.5.2,5.5.2.3,-,基因组重排
4226,KP1,14735200,No germline deletion of INK4a-ARF#was found in#71 patients,Molecular Event triples,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
540,KP1,23637631,EWSR1/CREM fusion#is involved in#melanoma,Genomic Event triples,EWSR1,-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
7785,KP1,23637631,FAM133B/CDK6 fusion#is involved in#T-cell acute lymphoblastic leukemia,Genomic Event triples,CDK6,-,T-cell acute lymphoblastic leukemia,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
7084,KP1,23637631,CLTC/VMP1 fusion#is involved in#breast cancer,Genomic Event triples,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
6488,KP1,32641004,NGS using a 381-gene panel#disclosed#CDK4 amplification,Genomic Event triples,CDK4,-,Spinal cord astrocytoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7638,KP1,32641004,A triplet regimen containing palbociclib#achieved#complete response in spinal cord astrocytoma,Treatment triples,CDK4,-,Spinal cord astrocytoma,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,细胞周期阻滞
4293,KP1,36140560,NGS on neoplastic tissue#showed co-amplification of#MDM2 and CDK4,Genomic Event triples,"MDM2,CDK4",-,Neoplastic tissue,-,-,-,-,upregulated,"MDM2,CDK4",-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5234,KP1,31471681,Mechanisms of endocrine resistance#have been identified in#ER+/HER2- advanced breast cancers,Mechanisms of Resistance triples,"ESR1,ERBB2",-,Breast cancer,-,Cell cycle pathway,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
787,KP1,31471681,CDK4/6 inhibitors#have shown#improvement in progression-free survival in ER+/HER2- breast cancer,Therapeutic Response triples,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3154,KP1,24786129,Amplification of CDK4 and MDM2 genes#may serve as#markers for molecular diagnosis,Biomarker Analysis triples,"CDK4,MDM2",-,-,-,-,-,-,upregulated,"CDK4,MDM2",-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
1001,KP1,11115584,p53#has#negative mutations in exons 5-9 by SSCP analysis,Mutation triples,TP53,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
2428,KP1,11115584,"RB, CDK4, MDM2, c-myc, c-fos, and p53#are involved in#osteosarcoma susceptibility",Cancer Association,"RB1,CDK4,MDM2,MYC,FOS,TP53",-,Osteosarcoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
1806,KP1,11115584,Cdk4#has#increased expression in osteosarcoma,Expression Patterns,CDK4,-,Osteosarcoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7540,KP1,11115584,MDM2#has#increased expression in osteosarcoma,Expression Patterns,MDM2,-,Osteosarcoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3990,KP1,11115584,c-fos#has#increased expression in osteosarcoma,Expression Patterns,FOS,-,Osteosarcoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3347,KP1,11115584,c-myc#has#increased expression in osteosarcoma,Expression Patterns,MYC,-,Osteosarcoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3647,KP1,11115584,Rb protein#has#a total loss of expression in osteosarcoma,Expression Patterns,RB1,-,Osteosarcoma,-,-,-,-,silenced,-,-,-,Fact,5,5.3,5.3.2,5.3.2.2,-,RB1缺失
2403,KP1,34315006,Cetuximab-treated patients with metastatic colorectal cancer#mCRC#have recurrent gene mutations and copy number alterations,Mutation triples,-,-,Metastatic colorectal cancer,Cetuximab,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
7353,KP1,34315006,CDK6#has#emergent gene mutations in postprogression samples,Mutation triples,CDK6,-,Metastatic colorectal cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
1005,KP1,34315006,MYC#has#emergent gene mutations in postprogression samples,Mutation triples,MYC,-,Metastatic colorectal cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
2721,KP1,34315006,CDK4#has#copy number alterations in postprogression samples,Mutation triples,CDK4,-,Metastatic colorectal cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
6290,KP1,34405078,MDM2#is amplified in#a regulator of p53 on chromosome 12q15,Regulation,"MDM2,TP53",-,-,-,-,-,-,amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
7561,KP1,34405078,CDK4#shows#positive immunostain in tumors,Expression Patterns,CDK4,-,-,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
7647,KP1,18551309,MDM2#is amplified in#atypical lipomatous tumor/well-differentiated liposarcoma,Cancer Association,MDM2,-,"Atypical lipomatous tumor, Well-differentiated liposarcoma",-,-,-,-,amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
4098,KP1,18551309,CDK4#is amplified in#atypical lipomatous tumor/well-differentiated liposarcoma,Cancer Association,CDK4,-,"Atypical lipomatous tumor, Well-differentiated liposarcoma",-,-,-,-,amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1726,KP1,18551309,CHOP#has#translocations in myxoid/round cell liposarcoma,Mutation triples,CHOP,-,"Myxoid liposarcoma, Round cell liposarcoma",-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
7036,KP1,18551309,FUS#has#translocations in myxoid/round cell liposarcoma,Mutation triples,FUS,-,"Myxoid liposarcoma, Round cell liposarcoma",-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
214,KP1,23308321,CDK4#is not amplified in#a well-differentiated liposarcoma,Cancer Association,CDK4,-,Well-differentiated liposarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7802,KP1,30857767,MDM2#is amplified in#well- and dedifferentiated liposarcoma,Cancer Association,MDM2,-,"Well-differentiated liposarcoma, Dedifferentiated liposarcoma",-,-,-,-,amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
2893,KP1,30857767,CDK4#is amplified in#well- and dedifferentiated liposarcoma,Cancer Association,CDK4,-,"Well-differentiated liposarcoma, Dedifferentiated liposarcoma",-,-,-,-,amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7590,KP1,31987696,CDK4#has#copy number alterations in acral and mucosal melanomas,Mutation triples,CDK4,-,"Acral melanoma, Mucosal melanoma",-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
2278,KP1,31859178,CDK4#is amplified in#copy-number alterations in cancers,Mutation triples,CDK4,-,-,-,-,-,-,amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1421,KP1,19339902,CDKN2A mutations#were found in#both AM and PM melanomas,Genetic Mutation,CDKN2A,-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
2159,KP1,19339902,A p14ARF splice germline mutation#was detected in#an Italian family with AM,Genetic Mutation,CDKN2A,-,Amelanotic melanoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.2,5.5.2.2,-,非移码突变
3678,KP1,19339902,A rare p14ARF mutation#may be involved in#predisposition to the amelanotic phenotype,Genetic Predisposition,"CDKN2A,MC1R",-,Amelanotic melanoma,-,-,-,-,-,-,-,-,Inference,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
6256,KP1,15991843,Large polymorphic nuclei#displayed#amplified MDM2/CDK4 gene copies in dedifferentiated tumor cells,Genetic Amplification,"MDM2,CDK4",Lymphoid cells,Tumor,-,-,-,-,amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
2914,KP1,25993159,CDK4 and MDM2#are overexpressed in#well-differentiated and dedifferentiated liposarcomas,Expression Patterns,"CDK4,MDM2",-,Liposarcoma,-,-,-,-,overexpressed,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
7020,KP1,7845688,"MTS-1#encodes#p16, an inhibitor of CDK4",Molecular Function,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
6755,KP1,32791064,"Immunohistochemical staining of CDK4, MDM2, and p16#helps distinguish#liposarcoma from lipoma",Diagnostic Method,"CDK4,MDM2",-,"Liposarcoma, Lipoma",-,-,-,-,-,"CDK4, MDM2, p16",-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
5466,KP1,30382607,CDK4 and MDM2#are amplified in#well-differentiated and dedifferentiated liposarcomas,Genetic Amplification,"CDK4,MDM2",-,Liposarcoma,-,-,-,-,amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
3428,KP1,37298520,WDLPS and DDLPS#exhibit#amplification of chromosome region 12q13-15 containing CDK4 and MDM2,Genetic Amplification,"CDK4,MDM2",-,"WDLPS, DDLPS",-,-,-,-,amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
7777,KP1,28337832,MDM2 and CDK4#are immunohistochemically positive in#abundant atypical stromal cells,Biomarker Analysis,"MDM2,CDK4",stromal cells,-,-,-,-,upregulated,"MDM2,CDK4",-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
4882,KP1,28337832,MDM2 gene#demonstrates#amplification,Expression Patterns,MDM2,-,-,-,-,-,upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
4817,KP1,35053440,Focal amplifications#target#oncogenes such as MDM2 or CDK4,Cancer Association,"MDM2,CDK4",-,-,-,-,-,upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
1531,KP1,17895758,"Immunostainings#were performed for#MDM2, CDK4, alpha smooth actin, desmin, caldesmon, myogenin, c-kit, and progesterone receptor",Biomarker Analysis,"MDM2,CDK4",-,-,-,-,-,-,"MDM2,CDK4",-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
5981,KP1,17895758,Amplification status of MDM2 and CDK4#could be evaluated with#quantitative polymerase chain reaction,Technical Methods,"MDM2,CDK4",-,-,-,-,-,upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
6282,KP1,38360887,Transactivation of Met signaling by oncogenic Gnaq#drives#the evolution of melanoma in Hgf-Cdk4 mice,Signaling Networks,"GNAQ,CDK4",melanocytes,Melanoma,-,Met signaling,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
3323,KP1,38360887,Oncogenic mutations in Gnaq/11 genes#arise mostly in#melanocytic lesions of the dermis or the uvea,Cancer Pathways,"GNAQ,GNA11",melanocytes,Melanocytic lesions,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
3118,KP1,38360887,Trp53 gene#accumulates#single base substitutions and structural chromosomal aberrations,Genetic Alterations,TP53,-,Tumor,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
7648,KP1,38360887,Met receptor gene#accumulates#amplifications during serial tumor transplantation,Genetic Alterations,MET,-,Tumor,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
6588,KP1,38360887,Gnaq(Q209L) mutation#transactivates#Met receptor,Mechanism of Action,"GNAQ,MET",-,-,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
1241,KP1,26650572,Absence of germline CDKN2A mutation#is observed in#Sicilian patients with familial malignant melanoma,Genetic Alterations,CDKN2A,-,Familial malignant melanoma,-,-,-,Sicilian patients,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
2758,KP1,26650572,Mutation testing#revealed absence of#CDK4 mutations in families,Genetic Alterations,CDK4,-,Familial melanoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDK4缺失
6868,KP1,26650572,Mutation testing#revealed presence of#CDKN2A p.R87W mutation in one patient,Genetic Alterations,CDKN2A,-,Familial melanoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
678,KP1,26650572,High mutation rate of CDKN2A#was not found in#patients with familial or multiple melanoma,Genetic Alterations,CDKN2A,-,"Familial melanoma, multiple melanoma",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
6614,KP1,16012847,Amplification of mdm2 and cdk4#was confirmed in#well-differentiated and dedifferentiated areas with rhabdomyoblasts,Genetic Alterations,"MDM2,CDK4",-,Rhabdomyosarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3488,KP1,11135432,Amplification of 12q sequences (MDM2 and CDK4)#was revealed by#FISH,Genetic Alterations,"MDM2,CDK4",-,Salivary gland tumor,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1076,KP1,26418953,CDK4 and MDM2 amplifications#were observed in#lung adenocarcinoma and liposarcoma,Genetic Alterations,"CDK4,MDM2",-,"Lung adenocarcinoma, liposarcoma",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7502,KP1,33419898,Recurrent copy number gains in CCND1 and CDK4#support#use of CDK4/6 inhibitors in treatment,Therapeutic Implications,"CCND1,CDK4",-,Cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
825,KP1,33419898,"Recurrent deletions in CDKN2A/CDKN2B, ATM, and RAD51#support#use of PARP inhibitors in treatment",Therapeutic Implications,"CDKN2A,CDKN2B,ATM,RAD51",-,Cancer,PARP inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2040,KP1,25822339,Liposarcoma#is characterized by#amplifications of MDM2 and CDK4,Genetic Alteration,"MDM2,CDK4",-,Liposarcoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
7400,KP1,16291983,Melanomas with wild-type BRAF or N-RAS#frequently exhibit#increases in the number of copies of CDK4 and CCND1,Genetic Alteration,"BRAF,NRAS,CDK4,CCND1",-,Melanoma,-,RAS-BRAF,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
930,KP1,16291983,CDK4 and CCND1#are implicated as#independent oncogenes in melanomas without BRAF or N-RAS mutations,Cancer Association,"CDK4,CCND1",-,Melanoma,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
5335,KP1,11668523,"Mutational analysis#was performed on#CDKN2B, CDKN2C, CDK4, and TP53 genes in sporadic primary melanomas",Genetic Study,"CDKN2B,CDKN2C,CDK4,TP53",-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6189,KP1,11668523,A CC>T* deletion-mutation in codon 151-152 of TP53#was detected in#1 melanoma,Genetic Alteration,TP53,-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.2,5.5.2.1,-,移码突变
5116,KP1,11668523,The last codon of exon 2 of CDKN2C#is identified as#the first codon of exon 3,Genetic Annotation,CDKN2C,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.2,5.5.2.4,-,功能影响
847,KP1,39357811,"Patients with FD including MAS, PFD, and MFD#accompanied by#malignant transformation",Patient Characteristics,GNAS,-,"Fibrous dysplasia (FD), McCune-Albright syndrome (MAS), polyostotic fibrous dysplasia (PFD), monostotic fibrous dysplasia (MFD)",-,Malignant transformation,-,Adults,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.3,-,凋亡阈值调节
2584,KP1,39357811,"Malignant neoplasms arising in FD#include#osteosarcoma, chondrosarcoma, and high-grade sarcoma of uncertain differentiation",Disease Association,GNAS,-,"Osteosarcoma, Chondrosarcoma, High-grade sarcoma",-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
1537,KP1,14581362,"Chromosome 9p21 region#harbors#tumor suppressor genes p14(ARF), p15(INK4b), and p16(INK4a)",Genomic Location,"CDKN2A,CDKN2B",-,Low-grade gliomas,-,"RB1,TP53",-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.2,-,缺失
7988,KP1,32767231,Osteosarcoma#is characterized by#few recurrent single-nucleotide mutations or in-frame fusions,Genetic Alteration,-,osteosarcoma cells,Osteosarcoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
5613,KP1,32767231,"Structural alterations in osteosarcoma#include#copy number changes, chromothripsis, kataegis, and LOH",Genetic Alteration,-,osteosarcoma cells,Osteosarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
3876,KP1,32767231,Structural alterations#lead to#activation of oncogenes and loss of tumor suppressors,Molecular Mechanism,-,osteosarcoma cells,Osteosarcoma,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
6795,KP1,32767231,Few targeted therapies for osteosarcoma#have been#identified,Therapeutic Development,-,osteosarcoma cells,Osteosarcoma,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
886,KP1,32767231,Effectiveness of targeted therapies#varies greatly in#tumors with distinct key driver events,Therapeutic Response,-,Tumors,-,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
182,KP1,30322893,Comprehensive sequencing analyses#were performed on#sacral and clivus chordoma specimens,Technical Methods,-,-,Chordoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
104,KP1,34428613,"IDH-mutant lower grade astrocytomas#can be stratified by#PDGFRA amplification, CDK4 amplification, and CDKN2A deletion",Cancer Association,"PDGFRA, CDK4, CDKN2A",-,Astrocytomas,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
2610,KP1,34428613,Loss of PMS2#is correlated with#shorter OS and PFS,Prognostic Associations,PMS2,-,-,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
2715,KP1,34428613,MMR genes#have potential application in#stratification of IDH-mutant lower grade astrocytomas,Biomarker Analysis,-,-,Astrocytomas,-,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.1,-,RB1突变
4316,KP1,27936934,High-throughput sequencing technologies#facilitated#understanding of tumorigenesis,Technical Methods,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6625,KP1,27936934,CDK4 amplification and CDKN2A deletion#constitute#a single early causal event in glioblastoma,Cancer Pathways,"CDK4, CDKN2A",-,Glioblastoma,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
1402,KP1,29358476,Atypical lipomatous tumor#shows#retention of pRb but overexpression and amplification of MDM2,Expression Patterns,MDM2,-,Lipomatous tumor,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,MDM2扩增
5715,KP1,29358476,"Fatty tumors with spindle cells#require#immunohistochemical workup with pRb, MDM2, desmin, CD34, and p16",Biomarker Analysis,"MDM2, pRb, desmin, CD34, p16",-,Fatty tumors,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,MDM2扩增
2855,KP1,12497626,Melanoma-prone individuals#carry#inactivating mutations in CDKN2A or CDK4,Cancer Association,"CDKN2A, CDK4",-,Melanoma,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
3665,KP1,10665922,Loss of p16INK4a gene#has been documented in#a wide range of human tumors,Cancer Association,CDKN2A,-,Human tumors,-,-,-,-,downregulated,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
802,KP1,10665922,Loss of p16INK4a gene#has been documented in#one third of glioblastomas,Cancer Association,CDKN2A,-,Glioblastomas,-,-,-,-,downregulated,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
7304,KP1,10665922,Deletion of p14ARF gene#was assessed in#pediatric and adult high-grade astrocytomas and glioma cell lines,Cancer Association,CDKN2A,-,"High-grade astrocytomas, glioma",-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
2340,KP1,10665922,"Homozygous deletions of exon 1alpha and exon 1beta#were found in#pediatric cases, adult cases, and glioma cell lines",Cancer Association,CDKN2A,-,"Astrocytomas, glioma",-,-,-,-,downregulated,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
667,KP1,27753448,Defects in DNA repair genes#sensitize#patients to therapy with PARP inhibition,Therapeutic Response,"BRCA1,BRCA2",-,-,PARP inhibitors,-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.1,-,同源重组修复
4294,KP1,8970601,"Nonrandom cytogenetic changes#are characterized by#monosomy 3, trisomy 8, and abnormalities of chromosome 6 in uveal melanoma",Genetic Alteration triples,-,-,Uveal melanoma,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.1,-,结构异常
4213,KP1,8970601,Alterations of chromosome 9p#are less frequently observed in#uveal melanoma,Genetic Alteration triples,-,-,Uveal melanoma,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.2,-,缺失
4761,KP1,8970601,CDKN2 gene#is probably not#a uveal melanoma predisposition gene,Disease Association,CDKN2A,-,Uveal melanoma,-,-,-,-,-,-,-,-,Inference,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
3429,KP1,20406234,Genetic alterations#included#loss of p16INK4a/p14ARF at 9p21.1-24.3,Genetic Alteration triples,CDKN2A,-,-,-,-,-,-,downregulated,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
2926,KP1,20406234,Genetic alterations#included#gains at 12q13.3-12q14.1 (CDK4),Genetic Alteration triples,CDK4,-,-,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
2634,KP1,39664374,Clonal events and genetic alterations#are pivotal in#pathogenesis of MM,Disease Association,-,-,Multiple myeloma (MM),-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.3,-,驱动突变
6810,KP1,39664374,Gene mutations#are prevalent in#MM,Genetic Alteration triples,"KRAS,TP53,RB1",-,Multiple myeloma (MM),-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
881,KP1,39664374,High-risk genetic factors#underscore#prognostic significance in MM,Disease Association,-,-,Multiple myeloma (MM),-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
2224,KP1,39664374,RB1 gene#encodes#retinoblastoma protein (pRB),Molecular Event triples,RB1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
5386,KP1,39664374,Deletion of RB1#contributes to#tumorigenesis by disrupting cell cycle control,Mechanism of Action,RB1,-,Multiple myeloma (MM),-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
3551,KP1,39664374,RB1 loss#is implicated in#progression of MM through IL-6 secretion and cell proliferation,Mechanism of Action,"RB1,IL6",-,Multiple myeloma (MM),-,-,-,-,downregulated,-,-,-,Inference,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
1309,KP1,39553226,PDX model#revealed#consistent genetic abnormalities including BRAF V600E mutation and CDKN2A deletion,Cancer Association,"BRAF, CDKN2A",-,eGBM,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
5629,KP1,23832711,"Dedifferentiated liposarcoma#expresses#p16, MDM2, and CDK4 strongly and diffusely",Expression Patterns,"CDK4, MDM2",-,Dedifferentiated liposarcoma,-,-,-,"Female, 61 years of age",upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
1179,KP1,25690861,MDM2 gene amplification#was detected by#fluorescence in situ hybridization (FISH),Regulation,MDM2,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
7932,KP1,25690861,Tumor cells#were positive for#MDM2 and CDK4,Markers,"MDM2, CDK4",-,-,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
5307,KP1,8882887,"Amplified genes#included#GLI, WNT1, MDM2, SAS, CDK4, OS-4, GAS16, GAS27, GAS41, GAS56, GAS64, and GAS89",Cancer Association,"GLI, WNT1, MDM2, SAS, CDK4, OS-4, GAS16, GAS27, GAS41, GAS56, GAS64, GAS89",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
1787,KP1,35949590,Comprehensive genomic profiling of GBM tissues#revealed#CDK4 amplification and MDM2 amplification among other alterations,Cancer Association,"CDK4, MDM2",-,GBM,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
6613,KP1,27476724,Rare CNVs#involved#known melanoma genes like CDKN2A and PARP1,Cancer Association,"CDKN2A, PARP1",-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
1831,KP1,35804935,"FGFR1 amplification, PTEN loss, and DNA repair pathway gene mutations#show#associations with shorter PFS for patients receiving CDK4/6 inhibitor therapy",Cancer Association,"FGFR1,PTEN,CDK4,CDK6",-,PFS,-,DNA repair pathway,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.1,-,DSB识别
3867,KP1,16986124,Genetic analysis#includes#a search for amplification of CDK4 and MDM2 genes,Molecular Event triples,"CDK4,MDM2",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
6220,KP1,32724874,Eight draggable genes#are described as#having evidence of therapeutic impact for BTC,Therapeutic Development,"ERBB2,NTRK1,RNF43,CDK6,CDKN2B,FGFR2,IDH1,IDH2",-,BTC,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1293,KP1,23830351,"Significant deletion aberrations#include#CDH1, GLTSCR2, EGR1, CTSB, GATA3, SULT2A1, HMMR/RHAMM, LICAM2, MMP13, p16/INK4a, RASSF2, NM-23H1, and TP53",Molecular Event triples,"CDH1,GLTSCR2,EGR1,CTSB,GATA3,SULT2A1,HMMR/RHAMM,LICAM2,MMP13,p16/INK4a,RASSF2,NM-23H1,TP53",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
6946,KP1,32381938,CDK4 and MDM2#test positive on#immunohistological staining,Expression Patterns,"CDK4,MDM2",-,-,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,7.2.1.2.1,PI3K/AKT活性
4582,KP1,38545846,"CNVs#were observed in#CCND1, RB1, FGF19, and IL7R",Genetic Alteration triples,"CCND1,RB1,FGF19,IL7R",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
2620,KP1,38545846,CNVs in CDK4 and TERT#occurred less frequently in#patients with a history of trauma (Type 1 and Type 3),Genetic Alteration triples,"CDK4,TERT",-,-,-,-,-,patients with a history of trauma (Type 1 and Type 3),-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1443,KP1,38545846,Type 2 patients#demonstrated#the highest CDK4 CNVs,Genetic Alteration triples,CDK4,-,-,-,-,-,Type 2 patients,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1640,KP1,9166859,p16 gene#encodes#an inhibitor of cyclin-dependent kinase 4 (CDK4),Function triples,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3220,KP1,9166859,"p16 gene#has been found to be#deleted in various types of tumors, including leukemia",Genetic Alteration triples,CDKN2A,-,Leukemia,-,-,-,-,deleted,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
3172,KP1,9166859,p16 gene#is thought to code for#a tumor suppressor gene,Function triples,CDKN2A,-,-,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
295,KP1,9166859,clinical outcome for pediatric ALL patients#is correlated with#the presence or absence of the p16 gene,Clinical Correlation triples,CDKN2A,-,Pediatric ALL,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,Cyclin D1表达
5067,KP1,16442827,Detection of MDM2 and CDK4 gene amplifications#may be useful in#well-differentiated and dedifferentiated liposarcomas diagnosis,Diagnostic triples,"MDM2,CDK4",-,Well-differentiated and dedifferentiated liposarcomas,-,-,-,-,amplified,-,-,-,Inference,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3277,KP1,7850781,"human malignant gliomas#show#amplification and overexpression of CDK4, SAS, and MDM2",Genetic Alteration triples,"CDK4,SAS,MDM2",-,Malignant gliomas,-,-,-,-,"amplified, overexpressed",-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1960,KP1,28844173,"Copy number aberrations, including CDK4 amplification and NF1 deletion,#were detected in#3 cases",Genetic Alteration triples,"CDK4,NF1",-,-,-,-,-,-,"amplified, deleted",-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
4042,KP1,31110422,Significantly altered genes#were identified in#tumor samples and samples showing recurrence,Genetic Alteration triples,-,-,OSCC,-,-,-,-,-,-,-,-,Fact,2,2.3,2.3.1,2.3.1.1,-,基因拷贝数变异
7453,KP1,31110422,"CCNA1, CCNB2, CCND2, CCNE1, CCNF, CDC2, CDK6, CHEK1, and TGFA#found to significantly alter in#tumor samples of oral cancer patients",Genetic Alteration triples,"CCNA1,CCNB2,CCND2,CCNE1,CCNF,CDC2,CDK6,CHEK1,TGFA",-,Oral cancer,-,-,-,-,altered,-,-,-,Fact,2,2.4,2.4.1,2.4.1.1,-,激活性突变
6100,KP1,31110422,Down-expression of CDKN2A and CDKN2B#found to associate with#recurrence of disease in oral cancer patients,Clinical Correlation triples,"CDKN2A,CDKN2B",-,Oral cancer,-,-,-,-,downregulated,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
790,KP1,31110422,Loss of CDKN2A and CDKN2B#significantly associated with#recurrence in head and neck cancer patients,Clinical Correlation triples,"CDKN2A,CDKN2B",-,Head and neck cancer,-,-,-,-,lost,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
6542,KP1,32054529,p.E318K variant of MITF#has been implicated in#genetic predisposition to melanoma,Genetic Alteration triples,MITF,-,Melanoma,-,-,-,-,-,-,-,-,Inference,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
3376,KP1,11801559,"1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A#are analyzed in#astrocytic and oligodendroglial tumors",Molecular Event triples,"TP53, EGFR, CDK4, CDKN2A",-,"Astrocytic tumor, Oligodendroglial tumor",-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.1,-,DSB识别
4132,KP1,34488370,EGFR mutations#have#mutation rates of 85.0% in primary and 72.5% in metastatic lesions,Cancer Association,EGFR,-,"Primary lesion, Metastatic lesion",-,-,-,-,-,-,-,-,Fact,2,2.3,2.3.1,2.3.1.2,-,突变谱特征
7619,KP1,34488370,TP53 mutations#have#mutation rates of 52.5% in primary and 67.5% in metastatic lesions,Cancer Association,TP53,-,"Primary lesion, Metastatic lesion",-,-,-,-,-,-,-,-,Fact,2,2.3,2.3.1,2.3.1.2,-,突变谱特征
5983,KP1,34488370,"FRS2, CDK4, and MDM2 amplification#is accompanied by#metastases to the pelvis and spine",Cancer Association,"FRS2, CDK4, MDM2",-,Metastases to pelvis and spine,-,-,-,-,Amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
6718,KP1,34488370,CDKN2A deletion#is accompanied by#metastases to the pelvis and spine,Cancer Association,CDKN2A,-,Metastases to pelvis and spine,-,-,-,-,Deleted,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,基因缺失
7872,KP1,33550612,"Missense mutations in CDK4, CDKN2A, TCL1A, and MAPK1#are enriched in#known cancer genes",Cancer Association,"CDK4, CDKN2A, TCL1A, MAPK1",-,Cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
4071,KP1,20570930,CDK6 amplification#is revealed in#low-frequency events,Cancer Association,CDK6,-,-,-,-,-,-,Amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
5114,KP1,20570930,CCND1 amplification#is revealed in#low-frequency events,Cancer Association,CCND1,-,-,-,-,-,-,Amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
5506,KP1,32068239,MDM2 or CDK4 amplification#is absent in#molecular studies,Cancer Association,"MDM2, CDK4",-,-,-,-,-,-,Not amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
7748,KP1,11810181,CDK4 amplification#is not observed in#molecular genetic analysis of one tumor,Cancer Association,CDK4,-,-,-,-,-,-,Not amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
4415,KP1,24834200,CDK4 amplification#is not observed in#molecular cytogenetic analyses of liposarcoma,Cancer Association,CDK4,-,Liposarcoma,-,-,-,-,Not amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
10,KP1,38201285,Somatic mutations including CDKN2A#are present in#primary tumor and cell line,Cancer Association,CDKN2A,-,Primary tumor,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
2499,KP1,21523718,CDKN2A (p16-INK4a)#inhibits#CDK4,Molecular Event triples,"CDKN2A, CDK4",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3938,KP1,20572039,CDK inhibitor 2B (p15)#inhibits#CDK4,Molecular Event triples,"CDKN2B, CDK4",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7445,KP1,20572039,These genes#may be involved in#early stages of adenoma formation,Disease & Clinical Categories,"CDKN2A, p53",-,Adenoma,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
4585,KP1,20572039,Epigenetic alterations in these markers#may be caused by#smoking and/or age,Regulation,-,-,-,-,-,-,-,-,"Smoking, age",Smoking,-,Inference,2,2.1,2.1.3,2.1.3.2,-,组蛋白修饰异常
1950,KP1,11960918,"CDKN2A gene#is affected through#mutations, deletions, and promoter hypermethylation in OSCC",Cancer Association,"CDKN2A, p53",-,OSCC,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
1571,KP1,26464734,"Neoplastic cells#were strongly positive for#p16, MDM2, and CDK4",Markers,"CDK4, MDM2",-,-,-,-,-,-,-,"p16, MDM2, CDK4",-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
821,KP1,26464734,MDM2 gene#showed#amplification in all tumor components,Cancer Association,MDM2,-,Tumor,-,-,-,upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
6426,KP1,27883322,Key changes in melanoma tumorogenesis#influence#regulation of cell proliferation and vitality,Pathway & Network Categories,"CDKN2A, CDK4, RB",-,Melanoma,-,p16INK4/CDK4/RB,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
5558,KP1,27883322,"Mutations of NRAS, BRAF, and PTEN#occur in#malignant melanoma",Cancer Association,"NRAS, BRAF, PTEN, CDKN2A",-,Malignant melanoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
1120,KP1,27883322,Research results#focus on#improvement of melanoma patient prognosis by personalized targeted therapy,Therapeutic Development,-,-,Melanoma,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7712,KP1,10534762,"Genomic amplification of MYCN, MDM2, CDK4, and PAX7-FKHR#is a feature of#alveolar subtype",Cancer Association,"MYCN, MDM2, CDK4, PAX7",-,Alveolar subtype,-,-,-,upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
6928,KP1,20096196,CDK4 gene#represents#another melanoma susceptibility locus due to activation mutations,Cancer Association,CDK4,-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
179,KP1,20096196,Melanoma tumors#are characterized by#activation of the RAS-RAF-MEK-ERK pathway,Pathway & Network Categories,"BRAF, NRAS",-,Melanoma,-,RAS-RAF-MEK-ERK,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
6857,KP1,20096196,Somatic mutations in B-RAF#are complemented by#mutations in N-RAS,Genetic Alterations,"BRAF, NRAS",-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.2,5.5.2.1,-,移码突变
2668,KP1,20096196,Somatic mutations in B-RAF and N-RAS#represent#major genetic alterations,Genetic Alterations,"BRAF, NRAS",-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
13,KP1,23661264,MDM2 amplifications#are identified in#well-differentiated and dedifferentiated liposarcomas,Cancer Association,MDM2,-,"Well-differentiated liposarcomas, Dedifferentiated liposarcomas",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
7715,KP1,23661264,NAB2:STAT6 translocation#is identified in#solitary fibrous tumors,Cancer Association,"NAB2, STAT6",-,Solitary fibrous tumors,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
3370,KP1,23661264,Angiopoietin-TIE2 pathway#is involved in#angiosarcoma,Signaling Networks,-,-,Angiosarcoma,-,Angiopoietin-TIE2,-,-,-,-,-,-,Fact,6,6.2,6.2.1,6.2.1.2,-,PDGF信号
4175,KP1,23661264,Suppression of Mcl1#is observed in#X:18/synovial sarcomas,Cancer Association,MCL1,-,Synovial sarcomas,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.2,-,无义突变
2238,KP1,23661264,mTOR pathway#is implicated in#malignant peripheral nerve sheath tumors,Signaling Networks,MTOR,-,Malignant peripheral nerve sheath tumors,-,mTOR,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
1325,KP1,23661264,Lack of argininosuccinate synthetase 1 expression#is seen in#most sarcomas,Cancer Association,ASS1,-,Sarcomas,-,-,-,-,Silenced,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
3045,KP1,18036403,"Amplification of MDM2, SAS, and CDK4#is observed in#molecular cytogenetic analysis",Cancer Association,"MDM2,SAS,CDK4",-,-,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
2928,KP1,18036403,"Amplification of HMGA2, ATF1, and DDIT3#is not observed in#molecular cytogenetic analysis",Cancer Association,"HMGA2,ATF1,DDIT3",-,-,-,-,-,-,Silenced,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
7115,KP1,32359372,"Focal high-level amplifications of CDK4, NBN, DAXX, and MYC#are detected in#LPD lesions",Cancer Association,"CDK4,NBN,DAXX,MYC",-,Lymphoproliferative disorder (LPD),-,Amplifications,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7444,KP1,29996110,Somatic structural variant breakpoint presence#is associated with#altered expression of hundreds of genes,Expression Patterns,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.3,-,驱动突变
7941,KP1,29996110,"Overexpressed cancer driver genes (TERT, ERBB2, CDK12, CDK4)#show#SV-associated deregulation independent of CNA",Cancer Association,"TERT,ERBB2,CDK12,CDK4",-,-,-,-,-,-,Upregulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
6787,KP1,26642854,Homozygous p53 gene deletion#leads to#thymic lymphomas in mice by 9 weeks,Cancer Association,TP53,-,Thymic lymphomas,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.3,-,TP53缺失
6735,KP1,26642854,T-cell clone#selects#gene amplifications in cyclin D and cdk-6,Genetic Alterations,CDK6,-,-,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,基因扩增
4017,KP1,36874157,"Oncogenes MET, CDK6, KRAS, and EGFR#are amplified in#multiple cancer types",Cancer Association,"MET,CDK6,KRAS,EGFR",-,Multiple cancer types,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,基因扩增
1824,KP1,30561760,"Amplifications of druggable kinases CDK4, ERBB2, and KIT#are identified in#CNVs among one-third of patient samples",Cancer Association,"CDK4,ERBB2,KIT",-,-,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
2237,KP1,39786420,IDH-mutant low-grade gliomas (LGGs)#progress to#high-grade gliomas,Cancer Progression,IDH,-,"Low-grade gliomas, High-grade gliomas",-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
7213,KP1,39786420,CDK4 amplifications#drive#tumor progression in neural precursor-like cells,Cancer Association,CDK4,-,Gliomas,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7414,KP1,35997352,BRAF and NRAS mutations#are common in#Acral melanocytic nevus,Genetic Alteration triples,"BRAF, NRAS",-,Acral melanocytic nevus,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
5726,KP1,35997352,"Acral melanoma#shows lower rates of#KIT, NF1, BRAF, and NRAS mutations",Genetic Alteration triples,"KIT, NF1, BRAF, NRAS",-,Acral melanoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
2099,KP1,35997352,"Acral melanoma#shows#remarkable copy number variations in CCND1, CDK4, hTERT, PAK1, and GAB2",Genetic Alteration triples,"CCND1, CDK4, hTERT, PAK1, GAB2",-,Acral melanoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
2626,KP1,35997352,"Contemporary treatments for melanoma#include#targeted therapy for mutations and immunotherapy, such as anti-PD1 inhibitors",Therapeutic Development triples,-,-,Melanoma,anti-PD1 inhibitors,-,-,-,-,-,-,-,Fact,3,3.3,3.3.2,3.3.2.1,-,PD-1/PD-L1表达调控
7974,KP1,9205100,Separate amplified regions#are found around#MDM2 and CDK4 genes in most cases,Genetic Alteration triples,"MDM2, CDK4",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
4339,KP1,21352266,Monosomy of chromosome 9 and BRAF V600E mutation#were detected in#primary tumor and macro-dissected secondary lesions,Genetic Alteration triples,BRAF,-,"Primary tumor, Secondary lesions",-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
15,KP1,28447036,Translational research#focuses on#targeted therapy for liposarcoma,Therapeutic Development triples,-,-,Liposarcoma,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3810,KP1,28447036,"Genetic aberrations#involve#12q13-15 amplicon, MDM2, CDK4, TOP2A, PTK7, CHEK1, CTNNB1, CDH1, FBXW7, EPHA1, FUS-DDIT3, EWSR1-DDIT3 in LPS",Genetic Alteration triples,"MDM2, CDK4, TOP2A, PTK7, CHEK1, CTNNB1, CDH1, FBXW7, EPHA1, FUS-DDIT3, EWSR1-DDIT3",-,Liposarcomas,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
5131,KP1,10862042,Breakpoints in chromosome 12#are localized to#HMGIC and CHOP regions in uterine leiomyoma and myxoid liposarcoma,Genetic Alteration triples,"HMGIC, CHOP",-,"Uterine leiomyoma, Myxoid liposarcoma",-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.1,-,基因内融合
4558,KP1,10862042,Amplification of MDM2 and CDK4#is observed in#ring chromosomes from malignant fibrous histiocytoma,Genetic Alteration triples,"MDM2, CDK4",-,Malignant fibrous histiocytoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
3993,KP1,34163522,"Two subtypes#are driven by#different gene sets including EGFR, CDKN2A, CDKN2B, INFA8, INFA5, CDK4, AVIL, and DTX3",Genetic Alteration triples,"EGFR, CDKN2A, CDKN2B, INFA8, INFA5, CDK4, AVIL, DTX3",-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
2042,KP1,33704522,Spindle cells and cartilaginous cells#are positive for#MDM2 and CDK4,Biomarker Analysis triples,"MDM2, CDK4",-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,Cyclin D1表达
7776,KP1,33704522,MDM2 gene amplification#is detected in#spindle cells and cartilaginous cells by fluorescence in situ hybridization,Genetic Alteration triples,MDM2,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
3613,KP1,10850867,"Specific alterations#are analyzed in#EGFR, CDK4, CDKN2A, TP53, DMBT1, NF2, and PTEN genes",Genetic Alteration triples,"EGFR, CDK4, CDKN2A, TP53, DMBT1, NF2, PTEN",-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
5027,KP1,38751441,"ctDNA biomarkers#are investigated for#alterations including CDK6, EFGR, MYC, BRAF, TP53, KRAS, CCND1",Biomarker Analysis triples,"CDK6, EFGR, MYC, BRAF, TP53, KRAS, CCND1",-,-,-,-,-,-,-,-,-,-,Fact,7,7.6,7.6.1,7.6.1.1,-,突变检测
717,KP1,38531793,CDK4#is amplified in#progression on CT+EVE,Cancer Association,CDK4,-,Acquired resistance,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
3021,KP1,38531793,EGFR#is amplified in#progression on CT+EVE,Cancer Association,EGFR,-,Acquired resistance,-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
2573,KP1,38531793,NF1#is mutated in#progression on CT+EVE,Cancer Association,NF1,-,Acquired resistance,-,-,-,-,mutated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
2273,KP1,28903138,CDK4#is associated with#high susceptibility to melanoma,Cancer Association,CDK4,-,Melanoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2608,KP1,28903138,CDKN2A#is associated with#high susceptibility to melanoma,Cancer Association,CDKN2A,-,Melanoma,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
839,KP1,38411299,CDK4/6#is amplified in#melanomas,Cancer Association,"CDK4,CDK6",-,Melanoma,-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
6070,KP1,38411299,CDKN2A/B#is deleted in#melanomas,Cancer Association,"CDKN2A,CDKN2B",-,Melanoma,-,-,-,-,deleted,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
1927,KP1,34449585,CDKN2A#is associated with#cancer predisposition syndrome,Cancer Association,CDKN2A,-,Cancer predisposition syndrome,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
457,KP1,34449585,CDK4#is associated with#cancer predisposition syndrome,Cancer Association,CDK4,-,Cancer predisposition syndrome,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
525,KP1,33976638,CDK4#is amplified in#neuroblastoma,Cancer Association,CDK4,-,Neuroblastoma,-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
3028,KP1,33976638,MDM2#is amplified in#neuroblastoma,Cancer Association,MDM2,-,Neuroblastoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
6334,KP1,26482321,CDK4#is amplified in#cancers,Cancer Association,CDK4,-,Cancer,-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
2534,KP1,26482321,CDKN2A#is deleted in#cancers,Cancer Association,CDKN2A,-,Cancer,-,-,-,-,deleted,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
3110,KP1,11734312,CDK4#is amplified in#tumors,Cancer Association,CDK4,-,Tumors,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
6227,KP1,11734312,MDM2#is amplified in#tumors,Cancer Association,MDM2,-,Tumors,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
7582,KP1,39188168,Tumor cells#are negative for#MDM2 and CDK4,Expression Patterns,"MDM2,CDK4",Tumor cells,-,-,-,-,Silenced,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.4,-,肿瘤抑制子缺失
2236,KP1,30372389,"Papillary RCCs#are characterized by#distinct gene expression profiles, chromatin remodeling genes, cell cycle changes, and alterations of the MET pathway",Molecular Event triples,MET,-,Papillary RCC,-,MET,-,-,-,-,-,-,Fact,5,5.6,5.6.3,5.6.3.4,-,转录调控
6490,KP1,7630635,p15 and p16 CDK4 inhibitor genes#map within#chromosome band 9p21 region,Regulation,"CDKN2B,CDKN2A",-,"Malignant mesothelioma, Other cancers",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
5893,KP1,7630635,Chromosome band 9p21 deletions#are detected more often in#established cell lines than in primary tumor specimens,Genomic Alteration,CDKN2A,-,Malignant mesothelioma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
4396,KP1,36898668,Tumor cells#showed#monoallelic RB1 gene loss without amplification of MDM2 and CDK4 genes,Genomic Alteration,"RB1,MDM2,CDK4",Tumor cells,-,-,-,-,Silenced,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.2,-,RB1缺失
6158,KP1,17713569,Mutations in CDKN2A and CDK4#were detected in#patients with melanoma,Genomic Alteration,"CDKN2A,CDK4",-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,RB1突变
4112,KP1,11986936,"Centrosome replication, genomic instability#are associated with#cancer",Cancer Pathways,-,-,Cancer,-,-,-,-,-,-,-,-,Inference,5,5.2,5.2.1,5.2.1.2,-,染色体不稳定性
1742,KP1,11986936,Karyotypic alterations#are common in#cancer cells,Cancer Pathways,-,Cancer cells,Cancer,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.3,-,染色体异常
2378,KP1,11986936,Supernumerary centrosomes#are observed in#almost all solid human tumors,Cancer Pathways,-,-,Solid tumors,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.4,-,染色体异常
5814,KP1,11986936,Cyclin-dependent kinase 2 (CDK2) activity#couples#centriole duplication to the onset of DNA replication at the G1/S phase transition,Cell Cycle Control,CDK2,-,-,-,G1/S phase,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
4976,KP1,11986936,Alterations in G1/S phase regulating proteins#are observed in#human malignancies,Cancer Pathways,"RB1,CDK4,CDK6,CDKN2A,CDKN2B,TP53,CCND1,CCNE1",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
6991,KP1,11763427,"Amplification of CCND1 and CDK4, p27/Kip1 degradation and TP53 mutations#did not correlate with#anaplasia",Genomic Alteration,"CCND1,CDK4,TP53",-,Anaplasia,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,-,-,基因扩增
4650,KP1,37487352,"Immunohistochemistry#showed expression of#p16, CDK4, CD34, S-100, and MDM2",Expression Patterns,"CDKN2A,CDK4,CD34,MDM2",-,-,-,-,-,Upregulated,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.3,p16表达
4961,KP1,37487352,MDM2 gene amplification#was detected in#well-differentiated sclerosing liposarcoma,Genomic Alteration,MDM2,-,Sclerosing liposarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
1825,KP1,37444470,Gli1#is often co-amplified with#MDM2 and CDK4 along chromosome 12q13-12q15,Genomic Alteration,"GLI1,MDM2,CDK4",-,Dedifferentiated liposarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,-,-,基因扩增
3134,KP1,32346746,"Higher risk susceptibility genes#have been identified as#CDKN2A, CDK4, POT1, TERT, and shelterin complex genes",Genetic Variant Identification,"CDKN2A,CDK4,POT1,TERT",-,Melanoma,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,-,-,基因突变
5947,KP1,32346746,BRAF#is the most common driver mutation#at a somatic level,Cancer Association,BRAF,-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
6255,KP1,32346746,NRAS#is the second most common driver mutation#at a somatic level,Cancer Association,NRAS,-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
2364,KP1,32346746,NF1#is the third most common driver mutation#at a somatic level,Cancer Association,NF1,-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
666,KP1,32346746,TP53#is identified as#a rarer mutation,Cancer Association,TP53,-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
1092,KP1,18036404,MDM2 and CDK4#are strongly amplified#in pleural tumors,Cancer Association,"MDM2,CDK4",-,Pleural tumor,-,-,-,Upregulated,-,-,-,-,Fact,5,5.3,5.3.1,-,-,基因扩增
6265,KP1,16174859,"CDKN2A, CDK4, BRCA1, BRCA2#have no germline mutations#in Danish pedigrees",Cancer Association,"CDKN2A,CDK4,BRCA1,BRCA2",-,Melanoma,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,-,-,基因突变
6737,KP1,16174859,RASEF expression#is decreased#in 70% of sporadic CMM tumors,Expression Patterns,RASEF,-,CMM,-,-,-,Downregulated,-,-,-,-,Fact,7,7.2,7.2.1,-,-,蛋白表达
4086,KP1,8634085,Genes involved in cellular growth control#are frequently amplified#in human tumors,Cancer Association,-,-,Human tumors,-,-,-,Upregulated,-,-,-,-,Fact,5,5.3,5.3.1,-,-,基因扩增
1633,KP1,8634085,OS-9#is co-amplified with#CDK4 in sarcoma tissues,Cancer Association,"OS-9,CDK4",-,Sarcoma,-,-,-,Upregulated,-,-,-,-,Fact,5,5.3,5.3.1,-,-,基因扩增
2697,KP1,35251319,"MDM2, CDK4, and HMGA2#are amplified#in WDLPS and DDLPS",Cancer Association,"MDM2,CDK4,HMGA2",-,Liposarcoma,-,-,-,Upregulated,-,-,-,-,Fact,5,5.3,5.3.1,-,-,基因扩增
6611,KP1,28485764,"CDK4, TERT, POT1, ACD, and TERF2IP#are mutated#in melanoma families",Cancer Association,"CDK4,TERT,POT1,ACD,TERF2IP",-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
3284,KP1,28258518,MDM2 and CDK4#are negative#in immunohistochemical stains,Molecular Biology,"MDM2,CDK4",-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.2,CDK4/6表达
6799,KP1,18008011,Glioblastomas#may develop#de novo (primary glioblastoma) or by progression from low-grade,Cancer Association,"TP53,MDM2,CDK4,CDKN2A,RB1,P16INK4",Astrocytes,"Glioblastoma, low-grade astrocytoma, anaplastic astrocytoma",-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.1,-,G1/S检查点失控
6997,KP1,18008011,Loss of heterozygosity on chromosome 10#is associated with#tumor suppressor genes in glioblastomas,Cancer Association,"TP53,MDM2,CDK4,CDKN2A,RB1,P16INK4",-,Glioblastoma,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.3,5.2.3.2,-,双链断裂
5418,KP1,18008011,The TP53/MDM2/P14ARF and CDK4/RB1/P16INK4 pathways#are deregulated in#the majority of gliomas,Cancer Pathways,"TP53,MDM2,CDK4,CDKN2A,RB1,P16INK4",-,Glioma,-,Cell cycle control,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
4839,KP1,34545084,14q loss#is associated with#PDGFRA and CDK4 gain and CDKN2A and BCOR loss,Cancer Association,"CDK4,CDKN2A,PDGFRA,BCOR",-,Glioma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3131,KP1,34545084,Chromothripsis#is associated with#extrachromosomal circular DNA-mediated amplification of PDGFRA and CDK4,Molecular Event,"CDK4,PDGFRA",-,Glioma,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.2,5.4.2.3,-,DNA修复错误
4565,KP1,31832685,CDK4 amplification#is associated with#retinoblastoma pathway gene alterations,Cancer Pathways,"CDK4,RB1",-,Retinoblastoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
2661,KP1,28546131,MDM2 and CDK4 amplifications#are tested in#spindle cell lipomas and pleomorphic lipomas,Biomarker Analysis,"MDM2,CDK4",-,"Spindle cell lipoma, pleomorphic lipoma",-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
4136,KP1,8060323,MTS1/CDK4l#is identified as#a candidate tumor suppressor gene in chromosome 9p21-22,Cancer Association,CDK4,-,Non-small cell lung carcinoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6058,KP1,8060323,Somatic mutations in MTS1/CDK4l#are detected in#19 of 64 primary NSCLC tumors,Cancer Association,CDK4,-,Non-small cell lung carcinoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6639,KP1,19654500,Fluorescence in situ hybridization#failed to identify amplification of#CDK4,Expression Patterns,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
119,KP1,8751388,Band 12q13#contains#several genes occasionally amplified in sarcomas,Cancer Association,-,-,Sarcomas,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5636,KP1,35491655,Tumor cells#were negative for expression of#CDK4,Expression Patterns,CDK4,-,Tumor,-,-,-,Silenced,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,CDK4/6表达
7474,KP1,35681700,FDA-approved drugs and those in clinical studies#target#genomic alterations present in ACC patients,Drug Development,-,-,ACC,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5853,KP1,35681700,155 FDA-approved drugs and 905 clinical trial drugs#were linked to#375 genes of 89 TCGA patients,Drug Development,-,-,-,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5634,KP1,35681700,CDK4#is among#the most frequent potentially targetable genetic alterations,Cancer Association,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5191,KP1,33860102,Copy number alterations#occurred in#CDK4 and other genes targeted by molecular-targeted drugs,Cancer Association,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5515,KP1,38028061,Clear cell tumor#was confirmed as#liposarcoma by immunohistochemistry,Cancer Association,CDK4,-,Liposarcoma,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.2,-,缺失
5356,KP1,38028061,Tumor cells#were positive for#CDK4 and MDM2,Markers,"CDK4,MDM2",-,Liposarcoma,-,-,-,-,-,"CDK4,MDM2",-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,CDK4/6表达
324,KP1,28138639,FISH results#were negative for#CDK4 and MDM2 genes,Expression Patterns,"CDK4, MDM2",-,Lipoma,-,-,-,-,Silenced,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
2056,KP1,12170781,Amplification of CDK4 and MDM2#occurs frequently in#ARMS,Cancer Association,"CDK4, MDM2",-,ARMS,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
2594,KP1,12170781,Amplification of CDK4 and MDM2#occurs rarely in#ERMS,Cancer Association,"CDK4, MDM2",-,ERMS,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
644,KP1,34996885,Tumor cells#were positive for#CDK4 and MDM2 by immunohistochemistry,Markers,"CDK4, MDM2",-,RP sarcoma,-,-,-,-,-,"CDK4, MDM2",-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,Cyclin D1表达
4190,KP1,9209389,Homozygous deletions of p16 gene#occurred in#20% of lymphoid tumors,Cancer Association,CDKN2A,-,Lymphoid tumors,-,-,-,-,Silenced,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
5617,KP1,9209389,Loss of Rb protein#occurred in#28% of lymphoid tumors,Cancer Association,RB1,-,Lymphoid tumors,-,-,-,-,Silenced,-,-,-,Fact,5,5.3,5.3.2,5.3.2.2,-,RB1缺失
1892,KP1,9209389,p53 gene alterations#occurred in#8% of lymphoid tumors,Cancer Association,TP53,-,Lymphoid tumors,-,-,-,-,Altered,-,-,-,Fact,5,5.3,5.3.2,5.3.2.3,-,TP53缺失
3142,KP1,28710771,Chr7 gain and Chr10 loss#occurred as#repeated events in glioma stem cells,Cancer Association,-,Glioma stem cells,Glioma,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.2,5.2.2.2,-,非整倍体
1793,KP1,28710771,Chromosome 7 gain and chromosome 10 loss#are observed in#primary and recurrent disease,Molecular Event triples,-,-,Primary and recurrent cancer,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.2,5.2.2.2,-,非整倍体
742,KP1,28710771,Chromosome 7 gain and chromosome 10 loss#produce#similar alterations in mRNA expression profiles,Expression Patterns,-,-,Primary and recurrent tumors,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.2,5.2.2.2,-,非整倍体
3338,KP1,28710771,"chr7 gain and chr10 loss#affect#ETV1, CDK6, NFKB, IL1B, IL6, Akt, and VEGF",Signaling Networks,"ETV1, CDK6, NFKB, IL1B, IL6, AKT, VEGF",-,-,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
4356,KP1,34103301,FLT3-ITD mutations#are treated with#pexidartinib in relapsed/refractory AML,Therapeutic Development,FLT3,-,Acute Myeloid Leukemia (AML),Pexidartinib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4635,KP1,34103301,29 patients with FLT3-ITD mutations#were treated with#pexidartinib at phase II dose,Clinical Trial Data,FLT3,-,Acute Myeloid Leukemia (AML),Pexidartinib,-,-,29 patients,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
6252,KP1,34103301,"Mutations in NRAS, TP53, IDH2#are identified in#non-responders",Cancer Association,"NRAS, TP53, IDH2",-,Acute Myeloid Leukemia (AML),-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
6026,KP1,34103301,Cyclin D3 (CCND3)#is frequently mutated in#non-responders,Cancer Association,CCND3,-,Acute Myeloid Leukemia (AML),-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
4194,KP1,34103301,No CCND3 mutations#are found in#pexidartinib responders,Cancer Association,CCND3,-,Acute Myeloid Leukemia (AML),Pexidartinib,-,-,-,-,-,-,-,Fact,2,2.3,2.3.1,2.3.1.2,-,突变谱特征
1507,KP1,35008570,"KIT mutations#are targeted with#tyrosine kinase inhibitors (e.g., imatinib)",Drug Development,KIT,-,Mucosal melanoma,Imatinib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,靶向药物联合
5546,KP1,35008570,CDK4 amplifications and CDKN2A deletions#are under investigation in#clinical trials,Cancer Association,"CDK4, CDKN2A",-,Mucosal melanoma,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
2509,KP1,35008570,Combination of immune checkpoint inhibitors#might improve#survival outcomes in mucosal melanoma,Therapeutic Response,-,-,Mucosal melanoma,-,-,-,-,-,-,-,-,Inference,3,3.3,3.3.2,3.3.2.3,-,免疫逃逸抑制
303,KP1,25088201,Nevus and melanoma age of onset#varies among#CC strains,Patient Characteristics,-,-,Melanoma,-,-,-,Age of onset,-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.2,-,评估内容
7626,KP1,25078331,"CDK4, CCND2, APC, RB1#are altered in#two cases (7%)",Cancer Association,"CDK4, CCND2, APC, RB1",-,Cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
3769,KP1,38166443,GLI1 amplifications#are associated with#GLI1-altered soft tissue tumors,Cancer Association,GLI1,-,GLI1-altered soft tissue tumors,-,-,-,-,-,-,-,-,Fact,2,2.4,2.4.1,2.4.1.3,-,基因扩增
928,KP1,38166443,FISH for GLI1 translocation#is positive in#a rare mesenchymal neoplasm,Molecular Event triples,GLI1,-,Mesenchymal neoplasm,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
899,KP1,11307615,oligodendrogliomas#showed#no hypermethylation of p16INK4a,Epigenetic Regulation,CDKN2A,-,Oligodendroglioma,-,-,-,-,-,-,-,-,Fact,5,5.6,5.6.1,5.6.1.1,-,甲基化
2353,KP1,11307615,1 out of 20 anaplastic oligodendrogliomas#showed#hypermethylation of p16INK4a,Epigenetic Regulation,CDKN2A,-,Anaplastic oligodendroglioma,-,-,-,-,-,-,-,-,Fact,5,5.6,5.6.1,5.6.1.1,-,甲基化
3369,KP1,11307615,homozygous deletion#was detected in#5/20 anaplastic oligodendrogliomas,Genetic Alteration,"CDKN2A,CDKN2B",-,Anaplastic oligodendroglioma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
819,KP1,11307615,p14ARF hypermethylation#was detected in#WHO grade II area,Epigenetic Regulation,CDKN2A,-,WHO grade II oligodendroglioma,-,-,-,-,-,-,-,-,Fact,5,5.6,5.6.1,5.6.1.1,-,甲基化
1558,KP1,11307615,homozygous co-deletion of p14ARF and p16INK4a#was found in#region with anaplastic features,Genetic Alteration,CDKN2A,-,Anaplastic oligodendroglioma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
7446,KP1,34939467,"TP53, MDM2, CDK4, KDR, and NF1#were#most frequent mutation genes in Chinese STS patients",Genetic Alteration,"TP53,MDM2,CDK4,KDR,NF1",-,Soft tissue sarcoma,-,-,-,Chinese patients,-,-,-,-,Fact,2,2.3,2.3.1,2.3.1.2,-,突变谱特征
217,KP1,22034077,CCND1 and CDK4#were amplified or gained in#chromosomal regions,Genetic Alteration,"CCND1,CDK4",-,-,-,-,-,upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
5862,KP1,22034077,CDKN2 (INK4) group of CDKIs#were frequently deleted#in chromosomal regions,Genetic Alteration,"CDKN2A,CDKN2B",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
7787,KP1,16547504,11q gain#correlated with#amplification of cyclin D1 locus,Genetic Alteration,CCND1,-,-,-,-,-,upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
616,KP1,16547504,cyclin D1 protein#was overexpressed in#25/31 cases,Expression Patterns,CCND1,-,-,-,-,-,upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
5267,KP1,38492514,amplification of MDM2 and CDK4 genes#characterized#both types of liposarcomas,Genetic Alteration,"MDM2,CDK4",-,Liposarcoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
7944,KP1,38492514,25%-30% of patients#have#local or distant recurrence in WDLPS and DDLPS,Clinical Outcomes,-,-,Liposarcoma,-,-,-,Patients with perioperative treatment,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
4149,KP1,34008925,MDM2 and CDK4 expression#was observed in#2 out of 3 cases,Expression Patterns,"MDM2,CDK4",-,Osteosarcoma,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
7704,KP1,34008925,low-grade osteosarcoma#explains#favorable prognosis in gnathic osteosarcomas,Clinical Outcomes,-,-,Low-grade osteosarcoma,-,-,-,Gnathic osteosarcoma patients,-,-,-,-,Inference,8,8.5,8.5.1,8.5.1.3,8.5.1.3.1,症状改善
1500,KP1,28705709,MDM2 gene amplification#was revealed in#all tumor components,Genetic Alteration,MDM2,-,-,-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
3162,KP1,20834238,HMGA2#encodes#a protein that alters chromatin structure and regulates the transcription of many genes,Gene Function,HMGA2,-,"Benign neoplasias, Malignant neoplasias, Mesenchymal tumors",-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
3117,KP1,20834238,HMGA2 rearrangements#are a feature of#development of several mesenchymal tumors,Genetic Alteration,HMGA2,-,Mesenchymal tumors,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
1587,KP1,20606735,No immunoreactivity for MDM2 or CDK4#was detected in#a sarcomatoid CRCC,Expression Analysis,"MDM2, CDK4",-,Sarcomatoid CRCC,-,-,-,-,Silenced,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.4,RB蛋白表达
4762,KP1,20479417,MYC/MYCN oncogene amplifications#had#a high prognostic value in pediatric MB,Prognostic Marker,"MYC, MYCN",-,Pediatric medulloblastoma (MB),-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,7.2.1.2.1,PI3K/AKT活性
4329,KP1,20479417,MYC/MYCN oncogene amplifications#were rarely observed in#adult tumors,Expression Patterns,"MYC, MYCN",-,Adult tumors,-,-,-,-,Downregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,7.2.1.2.3,mTOR信号活性
7659,KP1,35411369,Germline findings#are examined in#precision medicine for Japanese cancer patients,Precision Medicine,-,-,Cancer,-,-,-,Japanese patients,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,8.5.1.3.3,生活质量
4444,KP1,34797454,Tumor cells#were nonreactive for#CDK4,Expression Analysis,CDK4,-,Tumors,-,-,-,-,Silenced,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.4,RB蛋白表达
783,KP1,27776349,"Genes (CDKN2A, CDK4, MC1R, MITF, POT1, RB1, MGMT, BRCA1, BRCA2)#are involved in#melanoma predisposition",Genetic Predisposition,"CDKN2A, CDK4, MC1R, MITF, POT1, RB1, MGMT, BRCA1, BRCA2",-,Melanoma,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,RB1突变
4043,KP1,26892651,Germline variants in CDKN2A and CDK4#are associated with#melanoma-predisposing mutations,Genetic Predisposition,"CDKN2A, CDK4",-,Melanoma,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
1896,KP1,36716688,CDK4/CCND1 amplifications#were identified in#patients with AM,Cancer Association,"CDK4,CCND1",-,AM,-,-,-,-,amplified,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
5231,KP1,20182587,Class A HCC#shows#strong expression of cell proliferation and antiapoptosis genes,Expression Patterns,"CDK4,CCNB1,CCNA2,CKS2,PNCA",-,HCC,-,-,-,-,upregulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
7487,KP1,38306361,All SLGC lines#expressed#EGFR and EGFR ligands,Expression Patterns,EGFR,-,"GBM, GS",-,-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.1,1.4.1.1,-,增殖信号整合
2383,KP1,38306361,All SLGC lines#displayed#a neural signature and IDH1 wildtype,Neural Cell Regulation,IDH1,-,GBM,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.2,1.4.2.1,-,谱系特异性分化
5216,KP1,38306361,"Sox2 expression#is positively associated with#FABP7, Musashi, CD133, GFAP",Expression Patterns,"SOX2,FABP7,CD133,GFAP",-,GBM,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
530,KP1,38306361,"Spherical growth#is positively correlated with#high levels of Hif1伪, CDK4, PTEN, and PDGFR尾",Expression Patterns,"HIF1A,CDK4,PTEN,PDGFRA",-,GBM,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
5425,KP1,36881068,CNV analysis#identified#amplifications in chromosomes 12q14.1-12q15 including CDK4 and MDM2,Cancer Association,"CDK4,MDM2",-,Tumors,-,-,-,-,amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7541,KP1,36881068,"CNV analysis#identified#amplifications in chromosomes 11q13.3 including CCND1, FGF19, FGF3, and FGF4",Cancer Association,"CCND1,FGF19,FGF3,FGF4",-,Tumors,-,-,-,-,amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
2850,KP1,34089125,Tumor cells#were immunoreactive for#CDK4,Markers,CDK4,-,Tumor,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7228,KP1,30738431,CDK4 amplification#is associated with#glioblastoma,Cancer Association,CDK4,-,Glioblastoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3691,KP1,30738431,CDKN2A/B loss#is associated with#glioblastoma,Cancer Association,"CDKN2A,B",-,Glioblastoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
3098,KP1,15185075,CDKN2A#encodes for#p16INK4a and p14ARF,Molecular Event,CDKN2A,-,-,-,"Rb-CDK4,p53",-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
1217,KP1,15185075,p16INK4a and p14ARF#regulate#Rb-CDK4 and p53 pathways,Signaling Networks,CDKN2A,-,-,-,"Rb-CDK4,p53",-,-,-,-,-,-,Fact,1,1.2,1.2.1,1.2.1.2,-,激素信号通路
6180,KP1,15185075,p16INK4a methylation#is detected in#Barrett's adenocarcinomas,Biomarker Analysis,CDKN2A,-,Barrett's adenocarcinomas,-,-,-,-,methylated,-,-,-,Fact,1,1.5,1.5.1,1.5.1.2,-,DNA甲基化
4667,KP1,32731384,cfDNA samples#contain#1112 variants,Biomarker Analysis,-,-,Breast Cancer,-,-,-,-,-,-,-,-,Fact,7,7.6,7.6.1,7.6.1.1,-,突变检测
2905,KP1,32731384,CDK4 amplification#is found in#stage III and IV tumors,Cancer Association,CDK4,-,Stage III and IV tumors,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
6600,KP1,26592504,CDK4 amplification#is associated with#UAs,Cancer Association,CDK4,-,Uterine Adenosarcomas,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
6373,KP1,26592504,MDM2 amplification#is associated with#UAs,Cancer Association,MDM2,-,Uterine Adenosarcomas,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
1121,KP1,20497911,MDM2/CDK4 amplification#is associated with#liposarcomas,Cancer Association,"MDM2,CDK4",-,Liposarcomas,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
3628,KP1,33228609,Pulmonary hypertrophic osteoarthropathy#is associated with#lung cancer,Cancer Pathways,-,-,Lung cancer,-,-,-,-,-,-,-,-,Fact,6,6.4,6.4.1,6.4.1.1,-,促炎因子
2020,KP1,7677168,Neoplastic diseases#are characterized by#uncoordinated cell growth,Molecular Event,-,-,Neoplastic diseases,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.1,-,增殖信号整合
4394,KP1,7677168,Mutations and overexpression of cyclins and cyclin-dependent kinases#have been reported as#oncogenic events,Cancer Association,"CDK4, CCND1",-,Cancer,-,-,-,-,Upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7584,KP1,37580773,"Patients#received#ribociclib with ET (letrozole, fulvestrant, or tamoxifen with goserelin)",Drug Development,"CDK4, CDK6",-,Cancer,"Ribociclib, letrozole, fulvestrant, tamoxifen, goserelin",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
2434,KP1,37580773,Gene alterations and total ctDNA fraction#increased with#disease progression and new lesion development,Biomarker Analysis,-,-,Cancer,-,-,Upregulated,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,-,获得性耐药
7562,KP1,35626060,"IDH-wildtype glioblastoma#showed#frequent genomic aberrations in TERT promoter, CDKN2A, CDKN2B, MTAP, TP53, EGFR, PTEN, NF1, BRAF, PDGFRA, CDK4, and PIK3CA",Cancer Association,"TERT, CDKN2A, CDKN2B, MTAP, TP53, EGFR, PTEN, NF1, BRAF, PDGFRA, CDK4, PIK3CA",-,IDH-wildtype glioblastoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
4170,KP1,7923152,"CDK4I (p16INK4, CDKN2)#has been mapped to#9p21 and shown to be mutated or deleted in many tumor types",Cancer Association,CDKN2A,-,"Melanoma, tumors",-,-,Silenced,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
3022,KP1,7923152,Somatic mutations in CDK4I#were tested in#30 surgically resected melanomas,Cancer Association,CDKN2A,-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
4361,KP1,7923152,A deletion in the second exon of CDK4I#was found in#a familial melanoma patient,Cancer Association,CDKN2A,-,Melanoma,-,-,Familial melanoma,-,-,-,-,-,Fact,5,5.5,5.5.2,5.5.2.1,-,移码突变
5711,KP1,30381447,Drug responses of cell lines#were related to#frequent mutations in oncogenes and tumor-suppressor genes,Drug Development,"BRAF, ALK, CDKN2A, CDK4",-,Cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
4201,KP1,30381447,Cell lines harboring actionable mutations#are more sensitive to#mutant BRAF(V600E) for cobimetinib or ALK translocation for ALK inhibitors,Drug Development,"BRAF, ALK",-,Cancer,"Cobimetinib, ALK inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
7733,KP1,30381447,CDKN2A loss#is less sensitive to#CDK4/6 inhibitors,Drug Development,"CDKN2A, CDK4, CDK6",-,Cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
718,KP1,38469735,Melanoma#is associated with#exposure to UV radiation and skin pigmentation,Environmental Factors,-,-,Melanoma,-,-,Skin pigmentation,-,-,UV radiation,-,-,Fact,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
4891,KP1,38469735,Mutational signature 12#was identified as#the most prevalent variant in Asian melanoma patients,Cancer Association,-,-,Melanoma,-,-,Asian patients,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.1,-,突变签名
5770,KP1,38469735,Ingenuity pathway analysis#revealed#differences in gene expression and regulatory pathways between AM and NAM,Expression Patterns,-,"AM, NAM",-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
974,KP1,38469735,Genes involved in cell cycle signaling#are differentially expressed in#NAM and AM,Cell Cycle Control,CDK4,-,-,-,Cell cycle signaling,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
1391,KP1,38469735,Genes involved in immune modulation and PD-1/PD-L1 signaling#are differentially expressed in#NAM and AM,Immune Cell Functions,"PDCD1, CD274",-,-,-,PD-1/PD-L1 signaling,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.3,-,免疫检查点表达
2292,KP1,38469735,High CDK4 expression#is observed in#AM,Expression Patterns,CDK4,-,-,-,-,-,-,Upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,Cyclin D1表达
7074,KP1,38469735,Cell cycle variability#is observed in#AM,Cell Cycle Control,-,-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
2051,KP1,32249949,CDKN2A mutations#are responsible for#majority of hereditary melanoma,Cancer Association,CDKN2A,-,Hereditary melanoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
3903,KP1,16596382,FISH analyses#confirmed#loss of p53 gene locus on chromosome 17 homolog,Cancer Pathways,TP53,-,Cancer,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.3,-,TP53缺失
2693,KP1,16596382,"FISH analyses#were negative for#amplification of MDM2, CDK4, c-MYC, HER-2/neu, CCND1, and COPS3",Cancer Pathways,"MDM2, CDK4, MYC, ERBB2, CCND1, COPS3",-,Cancer,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
381,KP1,37888062,Markers#were positive for#MDM2 and CDK4,Biomarker Analysis,"MDM2, CDK4",-,Liposarcoma,-,-,-,-,-,"MDM2, CDK4",-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
5081,KP1,33924080,CDKN2A deletion/mutation or CDK4 amplification#is associated with#worse median OS,Cancer Association,"CDKN2A, CDK4",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3362,KP1,33924080,RB1 deletion/mutation#is associated with#better median PFS,Cancer Association,RB1,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.2,-,RB1缺失
7833,KP1,33924080,CDKN2A/CDK4 alterations#are#mutually exclusive with RB1 alterations,Cancer Association,"CDKN2A, CDK4, RB1",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增与RB1缺失互斥
1359,KP1,31667475,CDK4#is amplified in#12.3% of tumors,Cancer Association,CDK4,-,Tumors,-,-,-,-,Amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3642,KP1,32657779,metastases#preferentially inactivate#pRB,Regulation,RB1,-,Metastases,-,-,-,-,Inactivated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
6839,KP1,32657779,metastases#upregulate#mTORC1 and WNT signaling pathways,Pathway & Network Categories,"MTORC1, WNT",-,Metastases,-,"mTORC1, WNT",-,Upregulated,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
4382,KP1,34210658,amplification of CDK4 and FGFR1#points toward#acquired lorlatinib resistance,Mechanisms of Resistance,"CDK4, FGFR1",-,Relapsed neuroblastoma,Lorlatinib,-,-,-,-,-,-,-,Inference,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
6025,KP1,31177992,CDK4 amplification and CDKN2A/B deletion#are prognostic factors for#IDH-mutant astrocytomas,Cancer Association,"CDK4, CDKN2A/B",-,IDH-mutant astrocytomas,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1799,KP1,37232011,CDK4#is associated with#amplification in metastases,Cancer Association,CDK4,-,Metastases,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5717,KP1,37232011,CDK4 amplification#is enriched in#metastases,Cancer Association,CDK4,-,Metastases,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
2510,KP1,21353380,hTERT immortalized urothelial cells#lose#responsiveness to PPAR signaling,Mechanism of Action,TERT,Urothelial cells,-,-,PPAR,-,-,downregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.3,-,p38通路交互
3917,KP1,21353380,hTERT overexpression#promotes#immortalized differentiation-insensitive urothelial cell phenotype,Phenotype triples,TERT,Urothelial cells,-,-,-,-,-,upregulated,-,-,-,Inference,1,1.4,1.4.2,1.4.2.2,-,分化标志物表达
2017,KP1,36826152,TP53#has#highest number of molecular alterations,Genomic Analysis,TP53,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.3,-,驱动突变
3694,KP1,36826152,CDK4#has#highest number of molecular alterations,Genomic Analysis,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3279,KP1,35972693,CDK4#is evaluated for#expression in immunohistochemical slides,Biomarker Analysis,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
7413,KP1,29954777,DNA repair genes BRCA1/2 or ATM mutations#are associated with#8.4% of alterations in actionable findings,Genomic Alterations,"BRCA1,BRCA2,ATM",-,-,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.2,-,末端切除
5201,KP1,29954777,Cell-cycle genes CCND1/2/3 or CDK4/6 alterations#are associated with#8.1% of alterations in actionable findings,Genomic Alterations,"CCND1,CCND2,CCND3,CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
3505,KP1,24931142,"Aberrations in cell cycle control genes CDK4, CCND1, CDKN2A#are implicated in#apoptosis and cell cycle control",Cell Cycle Control,"CDK4,CCND1,CDKN2A",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
1367,KP1,32532875,Sequential DNA and RNA sequencing#identified#RET mutations and coexisting pathway alterations in rhabdomyosarcoma,Genomic Alterations,RET,-,Rhabdomyosarcoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
578,KP1,32532875,Somatic genetic abnormalities#identified#CDK4 amplification and FGFR4 G388R polymorphism,Genomic Alterations,"CDK4,FGFR4",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
148,KP1,11704835,DNA of hepatocellular carcinomas#was analyzed for#INK4-ARF inactivation and p53 mutation,Genomic Alterations,"CDKN2A,TP53",-,Hepatocellular carcinoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
1392,KP1,11704835,Inactivation of p14(ARF)#was found in#11/71 hepatocellular carcinoma cases,Genomic Alterations,CDKN2A,-,Hepatocellular carcinoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
7746,KP1,11704835,Alterations of p16(INK4a)#correlated with#loss of mRNA transcription in 47/71 carcinomas,Expression Patterns,CDKN2A,-,Carcinomas,-,-,-,-,downregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.3,p16表达
198,KP1,11704835,Homozygous deletions of INK4a-ARF locus#occurred in#5 tumors,Genomic Alterations,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
6166,KP1,39820556,Homozygous loss of CDKN2A gene locus#warranted treatment with#CDK4/6 inhibitor palbociclib,Therapeutic Development,"CDKN2A,CDK4,CDK6",-,Osteosarcoma,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
7351,KP1,37503540,Absence of CDKN2A deletion or CDK4 amplification#was associated with#prognostic factors in tumors,Prognostic Associations,"CDKN2A,CDK4",-,Tumors,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,CDK4/6表达
1280,KP2,34921235,Overexpression of CDK4 and CDK6#was observed in#a subset of patients with intact Rb but defective p16,Expression Patterns,"CDK4,CDK6,CDKN2A",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
3479,KP2,18413728,Cyclin D1#was overexpressed in#neuroblasts,Expression Patterns,CCND1,Neuroblasts,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
5259,KP2,18413728,Cyclin D1#was expressed at low levels in#all cell types in ganglioneuroma,Expression Patterns,CCND1,-,Ganglioneuroma,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
7501,KP2,33732653,Homozygous deletion of CDKN2A#was identified in#soft tissue metastasis,Genomic Alterations,CDKN2A,-,Soft tissue metastasis,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
2283,KP2,33732653,Amplification of CCNE1 and CDK6#was identified in#soft tissue metastasis,Genomic Alterations,"CCNE1,CDK6",-,Soft tissue metastasis,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
6851,KP2,33732653,Loss of p16#was confirmed by#immunohistochemical staining,Expression Patterns,CDKN2A,-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
1709,KP2,33732653,High expression of CDK6 and Cyclin D1#was confirmed by#immunohistochemical staining,Expression Patterns,"CDK6,CCND1",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.2,-,Cyclin D-CDK6复合物
3069,KP2,33732653,binimetinib and ribociclib#induce#senescence in cells,Therapeutic Response,"CDK4,CDK6",-,-,"binimetinib, ribociclib",-,senescence,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
1643,KP2,10595915,INK4A gene#encodes#p16 and p19(ARF),Molecular Event,INK4A,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6661,KP2,10595915,p16#inhibits#CDK4 and CDK6,Mechanism of Action,"CDK4,CDK6",-,-,-,Rb pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
5569,KP2,10595915,p16#prevents#pRB phosphorylation,Mechanism of Action,CDKN2A,-,-,-,Rb pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
5994,KP2,10595915,Loss of INK4A#is involved in#the genesis of several neoplasms,Cancer Association,INK4A,-,"Neoplasms, tumors of neuroectodermal origin",-,-,-,-,-,-,-,-,Inference,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
4025,KP2,10595915,INK4A gene and p19(ARF)-specific exon 1beta#were studied in#MPNST and neurofibroma samples,Preclinical Models,INK4A,-,"MPNST, neurofibroma",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
1130,KP2,10595915,INK4A deletions#were assessed by#Southern blotting hybridization and multiplex PCR,Technical Methods,INK4A,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
444,KP2,10595915,p16 promoter methylation status#was determined by#PCR amplification of bisulfite-treated DNA,Technical Methods,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,5,5.6,5.6.3,5.6.3.1,-,DNA甲基化
5163,KP2,39497720,Fluorescence in situ hybridization (FISH)#is the gold standard for#MET amplification detection,Technical Methods,MET,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
1143,KP2,39497720,"Optimal model#was constructed based on#MET, BRAF, CDK6, and CYP3A4 GCN",Biomarker Analysis,"MET,BRAF,CDK6,CYP3A4",-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,基因拷贝数
2241,KP2,39497720,"Known resistance mechanisms#include#MET amplification, EGFR, TP53, CDK4, CDK6, CDKN2A, BRAF, KRAS, NRAS, PIK3CA mutations",Mechanisms of Resistance,"MET,EGFR,TP53,CDK4,CDK6,CDKN2A,BRAF,KRAS,NRAS,PIK3CA",-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
3948,KP2,33314017,TP53 gene#was mutated in#10 out of 30 cases,Cancer Association,TP53,-,B-cell neoplasms,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
3418,KP2,33314017,7q deletion#was detected in#only one case,Cancer Association,-,-,B-cell neoplasms,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.2,5.2.2.3,-,染色体丢失
2063,KP2,33314017,t(CDK6)+ neoplasms#correspond to#a subgroup of indolent marginal zone B-cell lymphomas,Cancer Association,CDK6,-,Marginal zone B-cell lymphomas,-,-,-,-,-,-,-,-,Inference,5,5.4,5.4.1,5.4.1.1,-,基因内融合
4272,KP2,33797827,Fluorescence in situ hybridization#analyzed#CDK4 and TERT amplification,Technical Methods,"CDK4,TERT",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1283,KP2,33797827,Immunohistochemistry#analyzed#CDK4 and TERT protein expression patterns,Technical Methods,"CDK4,TERT",-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
2918,KP2,31358010,CDK4 amplification rate#was#47.0% in 213 samples,Expression Patterns,CDK4,-,-,-,-,-,upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
387,KP2,31358010,CCND1 amplification rate#was#27.7% in 213 samples,Expression Patterns,CCND1,-,-,-,-,-,upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
3799,KP2,31358010,P16(INK4a) deletion rate#was#57.7% in 213 samples,Expression Patterns,CDKN2A,-,-,-,-,-,downregulated,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
533,KP2,31358010,AT7519 and PD0332991#exhibited#higher inhibitory effects on CDK4 signaling pathway abnormal mucosal melanoma cells-derived PDX tumors growth,Drug Development,CDK4,-,Mucosal melanoma,"AT7519,PD0332991",CDK4 signaling,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5651,KP2,8746340,p16INK4#encodes#a specific inhibitor of cyclin-dependent kinase 4 (CDK4),Molecular Event,"CDKN2A,CDK4",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
2425,KP2,8746340,p16INK4 and CDK4 proteins#were examined in#melanocytic neoplasms,Expression Patterns,"CDKN2A,CDK4",-,Melanocytic neoplasms,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,Cyclin D1表达
3372,KP2,8746340,CDK4 overexpression#is characteristic for#malignant melanoma,Expression Patterns,CDK4,-,Malignant melanoma,-,-,-,upregulated,-,-,-,-,Inference,7,7.2,7.2.1,7.2.1.1,-,Cyclin D1表达
6116,KP2,12904177,Cell cycle dysregulation#is#a defining feature of cancer,Cancer Pathways,-,-,Cancer,-,Cell cycle,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
556,KP2,12904177,CDK4#is expressed in#pituitary and pancreatic samples,Expression Patterns,CDK4,"pituitary cells, pancreatic cells",-,-,-,-,upregulated,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
4503,KP2,11311493,Cyclin D1 and CDK4 genes#are altered in#carcinoma of uterine cervix,Cancer Association,"CDK4,CCND1",-,Cervical carcinoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
5139,KP2,11311493,Cyclin D1 and CDK4 genes#are amplified and overexpressed in#cervical carcinoma,Cancer Association,"CDK4,CCND1",-,Cervical carcinoma,-,-,-,upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
6789,KP2,11311493,Cyclin D1 and CDK4 genes#are amplified in#24% and 26% of tumors respectively,Cancer Association,"CDK4,CCND1",-,Tumors,-,-,-,upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
7722,KP2,11311493,Tumor specimens#showed neither#amplification nor overexpression,Cancer Association,"CDK4,CCND1",-,Tumors,-,-,-,-,silenced,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
733,KP2,11311493,Overexpression of cyclin D1#is associated with#poor prognosis in cervical carcinoma,Cancer Association,CCND1,-,Cervical carcinoma,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
2276,KP2,15781632,12q13 locus amplification#involves#CDK4 and MDM2 genes in mantle cell lymphoma,Cancer Association,"CDK4,MDM2",-,Mantle cell lymphoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
4883,KP2,8988060,Cyclin D1 immunoreactivity#is restricted to#adenomatous areas in intestinal epithelium,Expression Patterns,CCND1,intestinal epithelial cells,Adenoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3374,KP2,8760309,Dysfunction of genes#occurs during#recurrence of glial tumors,Cancer Association,"CDK4,p16,p15",glial cells,Glial tumors,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.2,-,缺失
312,KP2,8760309,Recurrence of tumors#sustains#deletion of p16 or codeletion of p16 and p15 or amplification of CDK4,Cancer Association,"CDK4,p16,p15",tumor cells,Glial tumors,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
297,KP2,8760309,Molecular differences between primary and recurrent glial tumors#may provide#better therapeutic options,Therapeutic Development,"CDK4,p16,p15",glial cells,Glial tumors,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2676,KP2,28629371,Targeting MDM2 and CDK4#is synergistic in#dedifferentiated liposarcomas,Therapeutic Response,"CDK4,MDM2",-,Dedifferentiated liposarcoma,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
7420,KP2,28629371,MDM2 and CDK4 genes#are co-amplified in#WDLPS/DDLPS,Cancer Association,"CDK4,MDM2",-,"Well-differentiated liposarcoma, Dedifferentiated liposarcoma",-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
515,KP2,39021492,CDK4/6 inhibitor palbociclib#is combined with#letrozole and triptorelin for treatment of metastatic breast NEC,Combination Therapies,CDK4,-,Metastatic breast NEC,"Palbociclib, Letrozole, Triptorelin",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
1000,KP2,39021492,Hormonal therapy#may play#a leading role in treating NECs,Therapeutic Development,-,-,Neuroendocrine carcinoma,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
5208,KP2,8621248,No amplification of CDK4 and cyclin D1 genes#is observed in#neoplasms,Cancer Association,"CDK4,CCND1",-,Neoplasms,-,-,-,-,silenced,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
7891,KP2,12940460,Mitotic recombination events#lead to#LOH in pituitary adenomas,Molecular Event triples,RB1,pituitary cells,Pituitary adenomas,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.3,5.2.3.2,-,双链断裂
1164,KP2,31733156,IDH mutation#is a main classifier for#lower grade astrocytomas,Cancer Association,IDH,-,Lower grade astrocytomas,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,RB1突变
6015,KP2,31733156,"PDGFRA amplification, CDKN2A deletion, and CDK4 amplification#were examined by#FISH analysis",Technical Methods,"PDGFRA,CDKN2A,CDK4",-,Lower grade astrocytomas,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7496,KP2,31733156,"PDGFRA amplification, CDKN2A homozygous deletion, and CDK4 amplification#occurred in#a mutually exclusive fashion",Cancer Association,"PDGFRA,CDKN2A,CDK4",-,Lower grade astrocytomas,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5951,KP2,18484097,Cyclin D1 and CDK4 overexpression#was inversely associated with#lymph node metastasis and depth of invasion,Expression Patterns,"CCND1,CDK4",-,"Lymph node metastasis, depth of invasion",-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
60,KP2,39535168,Inhibitors of amplified CDK4 and MDM2#were tested for#targeted therapies in liposarcoma subtypes,Drug Development,"CDK4,MDM2",-,Liposarcoma,Inhibitors of CDK4 and MDM2,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,CDK4/6抑制剂的作用机制
3605,KP2,8797766,Cyclin D1 and CDK4/CDK6#mediate#phosphorylation and inactivation of pRb,Mechanism of Action,"CCND1,CDK4,CDK6,RB1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
3702,KP2,12117781,Cyclin D1 and CDK4#showed staining in#>80% of nuclei in adenocarcinomas,Expression Patterns,"CCND1,CDK4",-,Adenocarcinomas,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
4600,KP2,36920905,"EGFR, CDK4, and PDGFRA#were analyzed using#spatial protein profiling and single-cell FISH",Technical Methods,"EGFR,CDK4,PDGFRA",-,GBM,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.2,5.5.2.3,-,基因组重排
6384,KP2,36920905,Amplifications of EGFR and CDK4#co-occur in#tumors with higher infiltration of CD163(+) macrophages,Signaling Networks,"EGFR,CDK4",-,GBM,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.2,6.1.1.2.1,巨噬细胞
5138,KP2,10969811,"Expression of p16ink4a, cyclin D1, Cdk4, and Rb#was characterized in#esophagi after NMBA treatment",Expression Patterns,"CDKN2A,CCND1,CDK4,RB1",-,Esophageal conditions,NMBA,-,-,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,7.3.1.1.2,pRB水平
7242,KP2,10969811,p16INK4a#showed#reduced nuclear staining in ZD esophagi compared with ZS esophagi,Expression Patterns,CDKN2A,-,-,-,-,-,-,downregulated,-,-,-,Fact,7,7.5,7.5.1,7.5.1.2,7.5.1.2.1,CDKN2A缺失
3685,KP2,30782616,genomic landscape of MM#was characterized for#prognostic and/or therapeutic implications,Clinical Trial Data,-,-,Multiple Myeloma (MM),-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.1,7.4.1.1.3,免疫反应基因集
6003,KP2,30782616,Whole-genome sequencing (WGS)#was performed on#65 MM samples,Technical Methods,-,-,Multiple Myeloma (MM),-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.2,5.5.2.3,-,基因组重排
7221,KP2,11515790,CDK4#is associated with#high-grade astrocytic tumors,Cancer Association,CDK4,-,High-grade astrocytic tumors,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
4318,KP2,11515790,PTEN#is associated with#high-grade astrocytic tumors,Cancer Association,PTEN,-,High-grade astrocytic tumors,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
6447,KP2,34921024,WDLPS and DDLPS liposarcoma#are characterized by#co-amplification of MDM2 and CDK4 oncogenes,Cancer Association,"MDM2,CDK4",-,"Liposarcoma (WDLPS, DDLPS)",-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
5588,KP2,36739402,Acral melanoma (AM)#is the most common subtype in#Chinese melanoma patients,Disease-Specific Categories,-,-,Acral melanoma (AM),-,-,-,Chinese patients,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.3,黑色素瘤
3600,KP2,36739402,"Copy number variations (CNV)#were commonly found in#CCND1, CDK4, MDM2, and FGF19",Molecular Event triples,"CCND1,CDK4,MDM2,FGF19",-,Acral melanoma (AM),-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7343,KP2,36739402,CDK4 amplification#is associated with#shorter OS in AM patients,Prognostic Associations,CDK4,-,Acral melanoma (AM),-,-,-,-,upregulated,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,7.5.1.1.4,CDK6扩增
5661,KP2,36739402,CDK4-amplified patients#tended to have#a low level of M1 macrophage infiltration in the invasive margin,Immune Cell Functions,CDK4,M1 macrophages,Acral melanoma (AM),-,-,-,-,downregulated,-,-,-,Fact,6,6.1,6.1.1,6.1.1.2,6.1.1.2.1,巨噬细胞
7570,KP2,11119125,"Protein expression of p16, p53, CDK4, and PTEN#was examined by#immunohistochemistry",Technical Methods,"CDKN2A,TP53,CDK4,PTEN",-,-,-,-,-,-,-,-,-,-,Fact,-,7,7.3,7.3.1,7.3.1.1,7.3.1.1.2
3152,KP2,8857999,Homozygous CDKN2/p16 deletions#may have#a more deleterious effect on cell cycle control than other aberrations in the p16-cdk4-cyclin D1-pRb pathway,Cell Cycle Control,"CDKN2A,CDK4,CCND1,RB1",-,High-grade astrocytomas,-,p16-cdk4-cyclin D1-pRb,-,-,downregulated,-,-,-,Inference,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
292,KP2,25852058,CDKN2A/p16 loss#implicates#CDK4 as a therapeutic target in imatinib-resistant dermatofibrosarcoma protuberans,Therapeutic Development,"CDKN2A,CDK4",-,Dermatofibrosarcoma protuberans,Imatinib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3999,KP2,25852058,Dermatofibrosarcoma protuberans (DFSP)#is characterized by#infiltrative growth and frequent local recurrences,Cancer Association,PDGFB,-,Dermatofibrosarcoma protuberans (DFSP),-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
2200,KP2,25852058,Some DFSP#progress to#a higher-grade fibrosarcomatous form with rapid growth and increased risk of metastasis,Cancer Association,-,-,Fibrosarcomatous DFSP,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
2927,KP2,25852058,SNP analysis of DFSP105#revealed#a homozygous deletion encompassing CDKN2A and CDKN2B,Genetic Alterations,"CDKN2A, CDKN2B",-,Fibrosarcomatous DFSP,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
5179,KP2,25852058,PD-0332991#inhibited#xenograft growth in DFSP105-treated mice,Therapeutic Response,-,-,DFSP,PD-0332991,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4239,KP2,16568472,Molecular alterations#could be#predictive of survival in glioblastomas,Cancer Association,-,-,Glioblastomas,-,-,-,-,-,-,-,-,Inference,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
6194,KP2,16568472,"Loss of heterozygosity (LOH) on chromosome 1p, 9p, 10q, 19q#was studied in#a series of 220 primary glioblastomas",Genetic Alterations,"EGFR, CDK4, MDM2, CDKN2A",-,Glioblastomas,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.3,5.2.3.2,-,双链断裂
4344,KP2,22740238,"KRAS, BRAF, and p53 mutations#were analyzed in#a nasal mixed exocrine-neuroendocrine carcinoma",Genetic Alterations,"KRAS, BRAF, TP53",-,Nasal mixed exocrine-neuroendocrine carcinoma,-,-,-,79-year-old male,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
1133,KP2,21777578,CDK4 and Cyclin D1 expressions#increased along with#progression of gallbladder mucosa hyperplasia and showed highest expression in cancer group,Expression Patterns,"CDK4, CCND1",-,Gallbladder cancer,-,-,-,-,Upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
4400,KP2,31963499,The prognostic impact of gene expression profiles#remains#controversial in glioblastoma multiforme (GBM),Cancer Association,-,-,Glioblastoma multiforme (GBM),-,-,-,-,-,-,-,-,Inference,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
3270,KP2,31963499,"RNA gene expression profiles of EGFR, CDK4, MDM4, and PDGFRA#were investigated in#83 primary GBM tumors",Expression Patterns,"EGFR, CDK4, MDM4, PDGFRA",-,Glioblastoma multiforme (GBM),-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7132,KP2,31963499,Gene expression profiles and intragenic EGFR deletions#showed no significant impact on#overall survival in GBM,Cancer Association,EGFR,-,Glioblastoma multiforme (GBM),-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
7484,KP2,38066633,BRAF fusions#are#a subtype of oncogenic BRAF genetic abnormalities reported in brain tumors,Genetic Alterations,BRAF,-,Brain tumors,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
2096,KP2,11406642,"Cyclin D1, MDM2, and CDK4 amplification#was not observed#in the study",Genetic Alterations,"CDK4, CCND1, MDM2",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
7962,KP2,34356494,CDK4#is amplified in#a high frequency of dedifferentiated liposarcoma,Cancer Association,CDK4,-,Dedifferentiated liposarcoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1125,KP2,20505263,"The gained region at 7q22-q34#includes#loci of MDM2, CDK4, c-MYC, and PDGF-B genes",Genomic Profiles,"MDM2, CDK4, MYC, PDGFB",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
3803,KP2,15526363,"10 genes including CDH1, CDH13, COX2, and CDK4#were assessed for#in situ expression in colorectal cancer",Biomarker Analysis,"CDH1,CDH13,COX2,CDK4",-,Colorectal cancer,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
6739,KP2,28877884,"Levels of pSmad3L, JNK, CDK4, and c-MYC protein#are significantly higher in#cpk mice than in controls",Expression Patterns,"SMAD3,CDK4,MYC,JNK",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.1,1.4.1.1,-,增殖信号整合
3327,KP2,28877884,Smad3#was cophosphorylated in#cpk mice,Post-translational Modifications,SMAD3,-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
3972,KP2,20544847,CDK4 amplification#was observed in#8% of cases,Cancer Association,CDK4,-,-,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5973,KP2,39917758,CDK4 amplification#led to#palliative treatment with abemaciclib in tumor recurrence,Therapeutic Development,CDK4,-,Tumor,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
1586,KP2,19609742,EGFR#is amplified in#22.7% of GBM tumors,Cancer Association,EGFR,-,GBM,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
99,KP2,19609742,CDKN2A/CDKN2B#is homozygously deleted in#29% of cases,Cancer Association,"CDKN2A,CDKN2B",-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.3,CDKN2A缺失
5040,KP2,19609742,EGFR#is amplified in#35.7% of combined studies,Cancer Association,EGFR,-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
7027,KP2,19609742,GLI/CDK4#is amplified in#13.4% of combined studies,Cancer Association,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
1049,KP2,19609742,MDM2#is amplified in#9.2% of combined studies,Cancer Association,MDM2,-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.4,MDM2扩增
1985,KP2,19609742,"p53 control, growth signaling, and cell cycle control pathways#are represented in#GBM tumor formation",Pathway & Network Categories,TP53,-,GBM,-,"p53 control, growth signaling, cell cycle control",-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
2423,KP2,10022821,CDK4#is amplified and/or overexpressed in#GBM,Cancer Association,CDK4,-,GBM,-,-,-,-,upregulated,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
629,KP2,36082279,CDK4#is amplified in#10.0% of MET Exon 14 wild-type tumors,Cancer Association,CDK4,-,MET Exon 14 wild-type tumors,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
6990,KP2,31147264,CDK4#is targetable in#LCTs using cell-cycle inhibitors,Drug Development,CDK4,-,LCTs,Cell-cycle inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,细胞周期阻滞
6754,KP2,10671694,CDK4#is overexpressed in#tumors,Cancer Association,CDK4,-,Tumors,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
3487,KP2,10671694,EGFR#is overexpressed in#tumors,Cancer Association,EGFR,-,Tumors,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,7.2.1.2.1,PI3K/AKT活性
437,KP2,10671694,VEGF#is overexpressed in#tumors,Cancer Association,VEGFA,-,Tumors,-,-,-,-,upregulated,-,-,-,Fact,6,6.2,6.2.1,6.2.1.1,6.2.1.1.1,VEGF表达
4174,KP2,33863325,SHMT2#catalyzes#conversion of serine to glycine,Function triples,SHMT2,-,Tumors,-,-,-,-,-,-,-,-,Fact,4,4.6,4.6.2,4.6.2.2,-,丝氨酸代谢
1139,KP2,33863325,SHMT2 knockdown#decreased#CDK4 and cyclinD1 expression levels,Regulation,"CDK4,CCND1,p21,p27",-,-,-,-,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
1822,KP2,15892297,CDK4 gene#was not amplified in#pituitary adenomas,Genomic Alterations,CDK4,-,Pituitary adenomas,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
543,KP2,15892297,Promoter hypermethylation of p15(INK4b)#coincided with#p16(INK4a) alteration and/or RB1 methylation,Epigenetic Regulation,"CDKN2B,CDKN2A,RB1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
1451,KP2,26670561,CDK4 amplification#was identified in#penile squamous cell carcinoma,Genomic Alterations,CDK4,-,Penile squamous cell carcinoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
4123,KP2,26670561,12q14 amplification#was detected in#sarcomas without CDK4 or MDM2 amplification,Genomic Alterations,"CDK4,MDM2",-,Sarcomas,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
495,KP2,24266804,CDK4 and MDM2 inhibitors#are#promising drugs in earlier stages of development,Drug Development,"CDK4,MDM2",-,Sarcomas,"CDK4 inhibitors, MDM2 inhibitors, cediranib, eribulin, crizotinib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1753,KP2,26670561,EGFR amplification#was identified in#penile squamous cell carcinoma,Genomic Alterations,EGFR,-,Penile squamous cell carcinoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
4372,KP2,26670561,HRAS#mutations occurred in#8 of 43 cases,Mutation triples,HRAS,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
1038,KP2,11854069,"Protein expression of PCNA, bcl-2, CDK4, p53, and MDM2#was detected by#immunohistochemistry and quantitative real-time PCR analysis",Expression patterns,"PCNA,BCL2,CDK4,TP53,MDM2",-,-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
2446,KP2,11854069,MDM2 amplification#was detected in#the second case,Genomic alteration,MDM2,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
2647,KP2,12036902,"Matrix-CGH#revealed copy number gains of#CCND1, MDM2, GLI, CDK4, MYB, ESR1, and AIB1",Genomic alteration,"CCND1,MDM2,GLI,CDK4,MYB,ESR1,AIB1",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
499,KP2,12036902,Copy number gains of oncogenes#correlate with#a high level of transcripts from the respective gene,Expression patterns,-,-,-,-,-,-,-,upregulated,-,-,-,Inference,5,5.3,5.3.3,5.3.3.1,-,基因表达改变
1458,KP2,18262049,Recurrent gene amplifications#were detected in#human type I endometrial adenocarcinoma,Genomic alteration,-,-,Endometrial adenocarcinoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
3606,KP2,18262049,Certain chromosome regions#exhibit#recurrent amplification in tumors in inbred BDII rats,Genomic alteration,-,-,Endometrial adenocarcinoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
3480,KP2,18262049,A subset of human EAC tumors#exhibited#increased copy numbers in chromosomal regions 2p21-p25 and 7q21-q31,Genomic alteration,-,-,Endometrial adenocarcinoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
4359,KP2,18262049,"Amplification#targeted#SDC1, CYP1B1, CDK6, and MET in chromosomal regions 2p21-p25 and 7q21-q31",Genomic alteration,"SDC1,CYP1B1,CDK6,MET",-,Endometrial adenocarcinoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
3550,KP2,27343443,"MDM2, CDK4, and EGFR amplifications#were observed in#35%, 21%, and 6.4% of METex14 patients, respectively",Genomic alteration,"MDM2,CDK4,EGFR",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
3491,KP2,17260012,"Major melanoma genes, including BRAF, NRAS, CDKN2A, TP53, CTNNB1, CDK4, and PTEN#were examined for#mutations",Mutation triples,"BRAF,NRAS,CDKN2A,TP53,CTNNB1,CDK4,PTEN",-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,-,-,点突变
3604,KP2,17260012,"Distinct copy number alterations#were detected, including#loss or gain of whole chromosomes and minute amplifications or deletions",Genomic alteration,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,-,-,基因扩增
2628,KP2,17260012,"Amplifications#delineated to#MITF, CCND1, MDM2, CCNE1, and NOTCH2 oncogenes",Genomic alteration,"MITF,CCND1,MDM2,CCNE1,NOTCH2",-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
6257,KP2,17260012,Mutations in BRAF and NRAS#were mutually exclusive with#mutations in BRAF and PTEN,Mutation triples,"BRAF,NRAS,PTEN",-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,-,-,点突变
3722,KP2,32974204,"Tumor#harbored#monosomy of chromosomes 3 and 11, gain of Xp (ATRX) arm, and chromoanasynthesis regions",Genomic alteration,ATRX,-,-,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.2,5.2.2.2,-,非整倍体
3684,KP2,32974204,MDM2 and CDK4 oncogenes#exhibited#copy number gains,Genomic alteration,"MDM2,CDK4",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
1681,KP2,14646620,Mutation analysis#was performed on#candidate genes in MM families,Mutation triples,-,-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,-,-,点突变
7935,KP2,14646620,Screening among sporadic MM cases#revealed#two additional CDKN2A mutations at low prevalence,Mutation triples,CDKN2A,-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,-,-,点突变
7235,KP2,14646620,Large shared haplotype at 9p21#suggests#other CDKN-inactivating mechanisms in MM,Cancer Association,CDKN,-,MM (malignant melanoma),-,-,-,-,-,-,-,-,Inference,5,5.4,5.4.2,5.4.2.2,-,基因组重排
3712,KP2,14646620,D9S171 locus#may be involved in#MM pathogenesis,Cancer Pathways,-,-,MM (malignant melanoma),-,-,-,-,-,-,-,-,Inference,5,5.4,5.4.2,5.4.2.2,-,基因组重排
5355,KP2,39680198,EWSR1-FLI1 fusion#is associated with#Ewing sarcoma,Cancer Association,"EWSR1, FLI1",-,Ewing sarcoma,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
3296,KP2,39680198,NAB2-STAT6 fusion#is associated with#solitary fibrous tumors,Cancer Association,"NAB2, STAT6",-,Solitary fibrous tumors,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
7631,KP2,39680198,Genomic alterations#frequently co-occur in#cell cycle regulators like CDK4 and MDM2,Regulation,"CDK4, MDM2",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
510,KP2,31826903,CDK4 and MDM2#were negative in#stains for liposarcomatous differentiation,Biomarker Analysis,"CDK4, MDM2",-,Liposarcomatous differentiation,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
4399,KP2,11763427,CDKN2A/p16 inactivation#was studied in#16 cases of ependymoma,Cancer Association,CDKN2A,-,Ependymoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,-,-,点突变
808,KP2,11763427,One ependymoma case#showed#CDKN2A HD and high Ki-67/MIB-1 LI,Biomarker Analysis,CDKN2A,-,Ependymoma,-,-,-,-,-,Ki-67,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.3,p16表达
7565,KP2,11763427,CDKN2A inactivation#may not play#an important role in malignant transformation of ependymomas,Cancer Pathways,CDKN2A,-,Ependymoma,-,-,-,-,-,-,-,-,Inference,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
4677,KP2,34091389,Liposarcomatous differentiation#had no#CDK4 and MDM2 amplifications,Biomarker Analysis,"CDK4, MDM2",-,Liposarcomatous differentiation,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
831,KP2,11351043,"CDK4, GLI, MYCN, MYC, MDM2, and PDGFRA#were identified with#high-level amplifications",Cancer Association,"CDK4, GLI, MYCN, MYC, MDM2, PDGFRA",-,-,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3063,KP2,11106817,"Amplification of CDK4, MDM2, and GLI/CHOP genes#was noted in#two GBM tumors",Cancer Association,"CDK4, MDM2, GLI",-,GBM (glioblastoma),-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
4603,KP2,33865660,Biopsy#allowed#MDM2 and CDK4 amplification investigations in parosteal osteosarcoma,Biomarker Analysis,"MDM2, CDK4",-,Parosteal osteosarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
2474,KP2,18332873,MDM2#is implicated in#oncogene targeting at 12q15,Cancer Pathways,MDM2,-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
5223,KP2,37205634,Liposarcoma#is characterized by#amplification of MDM2 and CDK4 oncogenes,Cancer Association,"MDM2, CDK4",-,Liposarcoma,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
209,KP2,8751388,Double minutes#contained#MDM2 gene but not CDK4 gene,Cancer Pathways,"MDM2, CDK4",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
2376,KP2,15167009,CDK4 and MDM2#co-amplification was observed in#1 case (3%),Expression Patterns,"CDK4, MDM2",-,-,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5929,KP2,15167009,All patients with genetic alterations in the G1/S-phase checkpoint#died during#their clinical follow-up,Prognostic Associations,-,-,-,-,-,-,Patients with G1/S-phase checkpoint alterations,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
1884,KP2,10632344,"Amplifications of EGFR, CDK4, and MDM2#were examined in#PMA",Genomic Alteration,"EGFR, CDK4, MDM2",-,PMA,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7529,KP2,37931683,Osteosarcoma#is associated with#TP53 alterations and chromosomal rearrangements,Cancer Association,TP53,-,Osteosarcoma,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.3,5.4.3.2,-,抑癌基因失活
1887,KP2,37931683,Genetic subgroups of osteosarcoma#are defined by#TP53 structural variants or MDM2 and/or CDK4 amplification,Genomic Alteration,"TP53, MDM2, CDK4",-,Osteosarcoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3080,KP2,36059685,"CDK4/6 inhibitor, abemaciclib#was used in combination with#SINE compounds",Combination Therapies,CDK4,PDX models,Chordoma,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,-,-,靶向药物联合
4167,KP2,36059685,Selinexor treatment#resulted in#apoptosis induction and reduced cell proliferation,Therapeutic Response,-,-,Tumor,Selinexor,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
5839,KP2,36059685,"Selinexor treatment#altered#WNT signaling, E2F pathways, and glucocorticoid receptor signaling",Pathway Alteration,-,-,-,Selinexor,"WNT, E2F, Glucocorticoid receptor",-,-,-,-,-,-,Fact,1,1.3,1.3.1,-,-,PI3K/AKT/mTOR通路
7551,KP2,37671310,Oncogenes#are characterized by#a broad spectrum of chromosomal and gene alterations,Genomic Alteration,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,-,-,突变特征
6557,KP2,37671310,SGC histotypes#demonstrate#specific combinations of mutated/amplified genes,Cancer Association,-,-,Salivary gland carcinoma (SGC),-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,-,-,突变特征
140,KP2,37671310,Amplified oncogenes#impact#biological behavior of SGCS,Cancer Association,-,-,Salivary gland carcinoma (SGC),-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5525,KP2,9405679,CDK4#is amplified in#tumor,Cancer Association,CDK4,-,Tumor,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3140,KP2,9405679,MDM2#is amplified in#tumor,Cancer Association,MDM2,-,Tumor,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,MDM2扩增
7076,KP2,29731991,CDK4 amplification#is universally present in#tested samples,Cancer Association,CDK4,-,Tumor,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
4621,KP2,29731991,MDM2 amplification#is universally present in#tested samples,Cancer Association,MDM2,-,Tumor,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,MDM2扩增
7946,KP2,36530080,"FGFR-altered IGs#commonly harbor#mutations in CDK4, MDM2, TP53, TERTp, CDKN2A/B, PTEN",Cancer Association,"CDK4, MDM2, TP53, TERT, CDKN2A, PTEN",-,FGFR-altered IGs,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,-,-,突变特征
2448,KP2,36751054,CDK6 amplification#is associated with#worse survival,Prognostic associations,CDK6,-,Glioma,-,RB pathway,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
359,KP2,31480474,CDK4 amplification#is notable in#intimal sarcomas,Cancer Association,CDK4,-,Intimal sarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7357,KP2,31480474,MDM2 amplification#is notable in#intimal sarcomas,Cancer Association,MDM2,-,Intimal sarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,MDM2扩增
5693,KP2,27409346,CDK4 amplification#is characteristic of#this disease,Cancer Association,CDK4,-,Tumor,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
6433,KP2,27409346,MDM2 amplification#is characteristic of#this disease,Cancer Association,MDM2,-,Tumor,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,MDM2扩增
1227,KP2,12210082,INK4a-ARF locus#encodes#p16(INK4a) and p14(ARF),Molecular Event,"CDKN2A, CDKN2B",-,-,-,"Rb-CDK4, p53 pathways",-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
3959,KP2,12210082,p16(INK4a)#shows#aberrant promoter methylation,Regulation,CDKN2A,-,-,-,-,-,-,Silenced,-,-,-,Fact,1,1.5,1.5.1,1.5.1.2,-,DNA甲基化
7535,KP2,12210082,p14(ARF)#shows#aberrant promoter methylation,Regulation,CDKN2B,-,-,-,-,-,-,Silenced,-,-,-,Fact,1,1.5,1.5.1,1.5.1.2,-,DNA甲基化
6568,KP2,12210082,"INK4a-ARF locus, pRB, or p53 status#could not be established as#independent prognostic factors in tumors",Cancer Association,"CDKN2A,RB1,TP53",-,Tumors,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
664,KP2,12210082,INK4a-ARF locus#is frequently inactivated in#cholangiocarcinoma of the liver,Cancer Association,CDKN2A,-,Cholangiocarcinoma,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
4770,KP2,36592415,MYB::QKI fusion-positive DPedHGG#was accompanied by#TP53 mutation and amplification of CDK6 and KRAS,Cancer Pathways,"MYB,TP53,CDK6,KRAS",-,DPedHGG,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.3,5.4.3.1,-,原癌基因激活
2120,KP2,36592415,Adult AG with MYBL1::QKI fusion#mimicked#ependymoma based on histopathology,Cancer Pathways,MYBL1,-,Ependymoma,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.3,5.4.3.1,-,原癌基因激活
4442,KP2,35586877,"Top 11 frequently altered genes#include#TP53, MCL1, MDM2, CDK4, MYC, CDKN2A, GNAS, RB1, ATRX, CDKN2B, and FGFR1",Cancer Association,"TP53,MCL1,MDM2,CDK4,MYC,CDKN2A,GNAS,RB1,ATRX,CDKN2B,FGFR1",-,Cancer,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
7264,KP2,32736279,CDK4 amplification#was revealed by#molecular tumor profiling in 7 patients,Biomarker Analysis,CDK4,-,Tumors,-,-,-,-,upregulated,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,CDK4扩增
1289,KP2,39692003,All tumors#were IDH-wildtype with#TERT promoter mutations,Molecular Event triples,TERT,-,Tumors,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
5514,KP2,39692003,Chromosome 9p loss#was observed with#CDKN2A/B homozygous deletion,Cancer Pathways,"CDKN2A,CDKN2B",-,Cancer,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
2648,KP2,39692003,CDK4/GLI1 amplification#was observed in#one case,Cancer Pathways,"CDK4,GLI1",-,Cancer,-,-,-,-,upregulated,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,CDK4扩增
5865,KP2,39692003,DNA methylation profiling#revealed a match to#glioblastoma family and mesenchymal typical class,Molecular Event triples,-,-,Glioblastoma,-,-,-,-,-,-,-,-,Fact,5,5.6,5.6.3,5.6.3.1,-,DNA甲基化
7530,KP2,20601955,shRNA-based knockdown of CDK4 and YEATS4#decreased#cell proliferation,Regulation,"CDK4,YEATS4",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7857,KP2,19235922,Genomic copy number#affects#gene expression levels,Regulation,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.3,5.3.3.1,-,基因表达改变
1277,KP2,19235922,CDK4 and MYCN#are#amplified and overexpressed in RMS tumorigenesis,Cancer Association,"CDK4,MYCN",-,RMS,-,-,-,-,upregulated,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,CDK4扩增
3991,KP2,12325066,Amplification of CDK4 or MDM2#was not detected in#samples,Regulation,"CDK4,MDM2",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
6668,KP2,31667475,CDKN2A and/or MET alteration#separated IDH-mutant glioblastomas into#different groups,Cancer Pathways,"CDKN2A,MET",-,Glioblastoma,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.3,5.4.3.3,-,信号通路改变
6156,KP2,7867008,Deletions of chromosomal band 9p21#have been detected in#various tumor types,Genomic Alterations,-,-,"Melanoma, glioma, lung cancer, mesothelioma, bladder cancer",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
968,KP2,7867008,Interphase FISH with CDKN2 cosmid contig#detected#all 9p deletions identified by molecular analysis,Genomic Alterations,CDKN2,-,"Glioma, melanoma, non-small cell lung cancer, bladder cancer",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
5319,KP2,7867008,FISH analysis of primary glioblastoma tumors#revealed#homozygous deletions of CDKN2 region,Genomic Alterations,CDKN2,-,Glioblastoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
5005,KP2,34829431,Nivolumab combined with metronomic vinorelbine#resulted in#a clinical response for ~7 months,Combination Therapies,-,-,Bartholin gland adenocarcinoma (BGA),"Nivolumab, vinorelbine",-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.1,-,时序性联合
1646,KP2,34829431,PTEN loss#predicts#benefit from mTOR inhibitor,Predictive Markers,PTEN,-,-,mTOR inhibitor,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
7114,KP2,34829431,CCND1 amplification#predicts#sensitivity to CDK4/6 inhibitors,Predictive Markers,"CCND1, CDK4",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
2288,KP2,30657954,Immunohistochemistry#confirmed#loss of tumor suppressors p16 and NF1,Genomic Alterations,"CDKN2A (p16), NF1",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
4015,KP2,30657954,"Amplifications#affected#CDK4, CCND1, PAK1, GAB2, EP300, YAP1, MDM2, TERT",Genomic Alterations,"CDK4, CCND1, PAK1, GAB2, EP300, YAP1, MDM2, TERT",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7,KP2,25927147,"Alterations#occurred in#TP53, PIK3CA, MYC, MLL2, PTEN, CDKN2A/B, CCND3, CCNE1, EGFR, KDM6A",Genomic Alterations,"TP53, PIK3CA, MYC, MLL2, PTEN, CDKN2A/B, CCND3, CCNE1, EGFR, KDM6A",-,Metaplastic breast carcinoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
2494,KP2,36010842,"Amplifications#included#ERBB2, FGFR1, CDK4, EGFR, MET, MDM2",Genomic Alterations,"ERBB2, FGFR1, CDK4, EGFR, MET, MDM2",-,Hepatoid adenocarcinoma of the stomach (HAS),-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3147,KP2,19158841,Pediatric lesions#show#CDKN2A locus homozygous deletions and a null p16 immunophenotype,Expression Patterns,CDKN2A,-,-,-,-,-,Pediatric patients,Silenced,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
7819,KP2,17213017,Multicolor fluorescence in situ hybridization#revealed#a complex hyperdiploid karyotype,Technical Methods,-,-,-,-,-,-,-,-,Marker chromosomes,-,-,Fact,5,5.2,5.2.2,5.2.2.2,-,非整倍体
2372,KP2,38689362,Pembrolizumab#is used for#triple-negative breast cancer and solid tumors with high microsatellite instability,Clinical Implementation,-,-,"Triple-negative breast cancer, solid tumors",-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
5850,KP2,38689362,"The patient#was treated with#fulvestrant, a CDK4/6 inhibitor, and an anticancer drug (TS1)",Therapeutic Development,CDK4,-,Metastatic breast cancer,"Fulvestrant, CDK4/6 inhibitor, TS1",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2605,KP2,38689362,Asymptomatic brain metastasis#was detected and treated with#gamma knife,Clinical Implementation,-,-,Brain metastasis,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,-,黑色素瘤
7048,KP2,36778271,"Dual immunohistochemical evaluation#used#ER, PR, and Ki67 as clinical markers",Biomarker Analysis,"ESR1,PGR,MKI67",-,Breast cancer,-,-,-,-,-,"ER, PR, Ki67",-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
1462,KP2,9355981,Tumors with positive pRb staining#over-expressed#nuclear localized cyclin D1,Expression Patterns,CCND1,-,Tumors,-,-,-,-,Upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3535,KP2,9355981,Amplification of cyclin D1 gene#was observed in#8 tumors,Cancer Association,CCND1,-,Tumors,-,-,-,-,Amplified,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
281,KP2,9377576,Deletion of CDKN2/p16#occurs in#approximately one-half of MCLs,Cancer Association,CDKN2,-,Mantle cell lymphomas (MCLs),-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
2147,KP2,9377576,Deletion of CDKN2/p16#is a relevant indicator of#proliferative features,Biomarker Analysis,CDKN2,-,Mantle cell lymphomas (MCLs),-,-,-,-,-,-,-,-,Inference,2,2.3,2.3.1,2.3.1.1,-,基因拷贝数变异
1765,KP2,37284196,Copy number variation#was identified in#CDK4 amplification in one case,Cancer Association,CDK4,-,Solid tumor,-,-,-,-,Amplified,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
1966,KP2,22374332,CDK4#is known to be#amplified in well- and dedifferentiated liposarcoma,Cancer Association,CDK4,-,Well- and dedifferentiated liposarcoma,-,-,-,-,Amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1486,KP2,38170436,RET fusion#was most frequent in#two classic subtype cases,Cancer Association,RET,-,Papillary thyroid carcinoma,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
3212,KP3,35304604,"CDK4 and CDK6#are important for#initiation, growth, and survival of many cancer types",Cancer Pathways,"CDK4, CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
6746,KP3,35304604,Pharmacological inhibitors of CDK4/6#have become#a new standard of care for advanced HR-positive breast cancer,Therapeutic Development,"CDK4, CDK6",-,Advanced hormone receptor-positive breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7884,KP3,38943828,Three CDK4/6 inhibitors#are approved for#first-line treatment of HR(+)/HER2(-) breast cancer with ET,Clinical Implementation,"CDK4, CDK6",-,HR(+)/HER2(-) breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
7295,KP3,39136283,CDK4/6 inhibitors#are widely used in#breast cancer and other cancer types,Therapeutic Development,"CDK4, CDK6",-,"Breast cancer, other cancer types",-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2542,KP3,39136283,CDK4/6 inhibitors palbociclib or ribociclib#combined with#chemotherapeutic drugs significantly inhibit SCLC tumor growth,Combination Optimization,"CDK4, CDK6",-,Small cell lung cancer,"Palbociclib, Ribociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.1,-,时序性联合
7950,KP3,32346095,CDK4 and CDK6#have attracted#considerable interest as cancer therapy targets,Therapeutic Development,"CDK4, CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5512,KP3,32346095,"Three inhibitors (palbociclib, abemaciclib, ribociclib)#are approved for#breast cancer treatment and tested in other cancers",Therapeutic Development,"CDK4, CDK6",-,"Breast cancer, other solid and hematological malignancies","Palbociclib, Abemaciclib, Ribociclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1631,KP3,26658964,FDA#approved#CDK4/6 inhibitor palbociclib for breast cancer treatment,Drug Development,"CDK4,CDK6",-,Breast cancer,"Palbociclib, Letrozole",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6856,KP3,26658964,CDK4/6 biology#translated to#positive clinical outcomes,Mechanism of Action,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6801,KP3,39437014,Amplification of CDK4 and CDK6#is a feature of#a variety of malignancies,Cancer Association,"CDK4,CDK6",-,Malignancies,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
6235,KP3,39437014,Inhibition of CDK4/6#is a plausible treatment strategy for#tumors,Therapeutic Development,"CDK4,CDK6",-,Tumors,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2696,KP3,38403110,CD63(+) cancer-associated fibroblasts#confer#CDK4/6 inhibitor resistance to breast cancer cells,Mechanism of Resistance,"CDK4,CDK6","Cancer-associated fibroblasts, breast cancer cells",Breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
2214,KP3,38403110,CDK4/6 inhibitors#received#FDA approval for advanced hormone receptor-positive breast cancer,Drug Development,"CDK4,CDK6",-,Hormone receptor-positive breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
6808,KP3,34573335,Ph+ ALL#is driven by#BCR-ABL1 oncogene,Cancer Association,BCR-ABL1,-,Ph+ ALL,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
1819,KP3,34573335,Tyrosine Kinase inhibitors#are#drugs of choice in therapy of Ph+ ALL,Drug Development,-,-,Ph+ ALL,Tyrosine Kinase inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
2939,KP3,34573335,New therapies#are needed to address#relapsed/TKI-resistant Ph+ ALL,Therapeutic Resistance,-,-,Relapsed/TKI-resistant Ph+ ALL,-,-,-,-,-,-,-,-,Inference,2,2.5,2.5.2,2.5.2.4,-,生物标志物指导
3444,KP3,34573335,CDK6 silencing#is more effective than#CDK4/6 inhibitor palbociclib in leukemia suppression,Therapeutic Development,"CDK4,CDK6",-,Leukemia,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.3,-,E2F转录因子活性下调
3629,KP3,34573335,CDK6-selective PROTACs#may be valuable for#chemotherapy-free protocols for Ph+ ALL,Therapeutic Development,CDK6,-,Ph+ ALL,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
5849,KP3,38619193,CDK4/6 inhibitor therapy#causes#decreased leukopenia and neutropenia,Safety Monitoring,CDK6,"Leukocyte, neutrophil precursors",-,-,-,"Leukopenia, neutropenia",-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,中性粒细胞减少
3321,KP3,32781837,CDK4/6 inhibitors#increase#progression-free survival in HR+ and HER2- breast metastatic cancer,Therapeutic Response,"CDK4,CDK6",-,HR+ and HER2- metastatic breast cancer,"Abemaciclib, Palbociclib, Ribociclib",-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
323,KP3,30389903,CDK4/6 inhibitors#increase#progression-free survival in ER+ breast cancer,Therapeutic Response,"CDK4,CDK6",-,ER+ breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
5707,KP3,35804842,CDK4 and CDK6#are#promising targets in oncology,Therapeutic Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5954,KP3,34271137,Three CDK4/6 inhibitors#are approved by#FDA,Drug Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
7906,KP3,34271137,"FDA#approved#palbociclib, abemaciclib, and ribociclib for advanced hormone receptor-positive breast cancer",Drug Development,"CDK4,CDK6",-,Hormone receptor-positive breast cancer,"Palbociclib, Abemaciclib, Ribociclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
4744,KP3,34271137,CDK4/6 inhibitor-based treatment#shows#therapeutic effects in triple-negative breast cancer,Therapeutic Response,"CDK4,CDK6",-,Triple-negative breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
4527,KP3,30038670,CDK4/6 inhibitors#are approved for#treatment of advanced ER-positive breast cancer,Clinical Implementation,"CDK4,CDK6",-,Advanced ER-positive breast cancer,CDK4/6 inhibitors,-,-,ER-positive,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
131,KP3,32504067,Specific inhibitors targeting CDK4 and CDK6#are approved for#treatment of ER(+) HER2(-) breast cancer in combination with endocrine therapy,Clinical Implementation,"CDK4,CDK6",-,ER(+) HER2(-) breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,"ER(+), HER2(-)",-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
1389,KP3,26306734,New drugs targeting CDK4/CDK6#have#'breakthrough therapy' designation at the US FDA,Drug Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
5385,KP3,34204543,Inhibition of CDK4/6#is a therapeutic approach for#ovarian cancer patients,Therapeutic Development,"CDK4,CDK6",-,Ovarian cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5104,KP3,34204543,CDK4/CDK6 inhibitors#confirmed#CDKs as valid therapeutic targets in some types of cancer,Cancer Association,"CDK4,CDK6",-,Cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
967,KP3,34204543,CDK4/CDK6 inhibitors#are used for#treatment of ER-positive metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,ER-positive metastatic breast cancer,CDK4/6 inhibitors,-,-,ER-positive,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4024,KP3,29097609,Cell-cycle inhibitor therapies#are advancing for#pediatric cancer,Therapeutic Development,-,-,Pediatric cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5493,KP3,29097609,Cell-cycle and checkpoint regulators#play pivotal roles in#therapeutic development for pediatric cancer,Mechanism of Action,-,-,Pediatric cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
5759,KP3,29097609,"Drugs targeting CDK4/CDK6 (palbociclib, ribociclib, abemaciclib)#are presented for#pediatric patients",Drug Development,"CDK4,CDK6",-,Pediatric cancer,"Palbociclib, Ribociclib, Abemaciclib",-,-,Pediatric,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
1317,KP3,28042706,CDK4/6 inhibitor palbociclib#showed clinical efficacy in combination with#cetuximab in HNSCC patients,Combination Optimization,"CDK4,CDK6",-,HNSCC,"Palbociclib, Cetuximab",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1582,KP3,34654798,CDK inhibitor p27(kip1)#affects#response to CDK4/6 inhibitor palbociclib in colorectal cancer,Mechanism of Action,"CDK4,CDK6,CDKN1B",-,Colorectal cancer,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
4951,KP3,29408328,"B-ALL cell lines#are treated with#ribociclib, a specific CDK4/6 inhibitor",Preclinical Models,"CDK4,CDK6",B-ALL cell lines,B-ALL,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7528,KP3,29408328,Combined treatment with ribociclib and dexamethasone#increases#glucocorticoid receptor (GR) expression,Mechanism of Action,"CDK4,CDK6",B-ALL cell lines,-,"Ribociclib, Dexamethasone",-,-,-,Upregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
7376,KP3,38670537,Abemaciclib#has#more tolerable adverse effects in metastatic breast cancer patients,Therapeutic Response,"CDK4,CDK6",-,Metastatic breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
178,KP3,28947133,Targeting cyclin D-CDK4/6 kinase complexes#increases#survival of ER-positive breast cancer patients,Therapeutic Response,"CDK4,CDK6",-,ER-positive breast cancer,-,Cyclin D-CDK4/6 pathway,-,ER-positive,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3495,KP3,28947133,CDK4/6 inhibitors#are tested for#treatment of malignancies with hyper-activation of cyclin D-CDK4/6 complexes,Cancer Association,"CDK4,CDK6",-,Cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3050,KP3,37451269,Combination of endocrine therapy and CDK4/6 inhibitors#is a hallmark in#metastatic luminal breast cancer,Combination Optimization,"CDK4,CDK6",-,Metastatic luminal breast cancer,"CDK4/6 inhibitors, Endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
2480,KP3,26149830,Targeting CDK4/CDK6-cyclin D1-Rb-p16/ink4a pathway#has potential for#treating glioblastoma and brain metastases,Cancer Pathways,"CDK4,CDK6,CCND1,RB1,CDKN2A",-,"Glioblastoma, Brain metastases",-,CDK4/CDK6-cyclin D1-Rb-p16/ink4a pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
7291,KP3,26149830,Orally dosed abemaciclib#increases#survival in a rat orthotopic U87MG xenograft model,Preclinical Models,"CDK4,CDK6",-,-,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1677,KP3,31448056,CDK4/6 inhibitors#exhibited#remarkable results for ER-positive breast cancer patients in clinical trials,Therapeutic Response,"CDK4,CDK6",-,ER-positive breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5778,KP3,31448056,Mechanism of CDK4/6 inhibitor resistance#remains#unclear,Resistance Mechanisms,"CDK4,CDK6",-,ER-positive breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.3,2.1.3.3,-,非编码RNA表达变化
6115,KP3,38302240,CDK4/6 inhibitors#promote#cell cycle arrest in the G1 phase,Cell Cycle Control,"CDK4,CDK6",-,Cancer,-,G1 phase,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
7685,KP3,38302240,CDK4/6 inhibitors#inhibit#cancer cell proliferation,Cancer Pathways,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
5380,KP3,34890965,Tamoxifen and fulvestrant#are used for#endocrinal therapy,Clinical Implementation,-,-,-,"Tamoxifen, Fulvestrant",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
6723,KP3,34948218,CDK4/6 inhibition#is beneficial in#ER-positive breast cancer treatment,Therapeutic Response,"CDK4,CDK6",-,ER-positive breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2941,KP3,34948218,CDK4/6 inhibition#improves#progression-free survival of patients,Therapeutic Response,"CDK4,CDK6",-,ER-positive breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4082,KP3,26264704,Palbociclib#is#a first-in-class CDK4/6 inhibitor,Drug Development,"CDK4,CDK6",-,Advanced breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3042,KP3,26264704,"Palbociclib#was approved by#FDA for HR-positive, HER2-negative advanced breast cancer",Clinical Implementation,"CDK4,CDK6",-,"HR-positive, HER2-negative advanced breast cancer",Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
6863,KP3,26264704,Palbociclib#is used in combination with#letrozole for postmenopausal women,Combination Optimization,"CDK4,CDK6",-,"HR-positive, HER2-negative advanced breast cancer","Palbociclib, Letrozole",-,-,Postmenopausal,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
3707,KP3,26264704,Palbociclib with fulvestrant#resulted in#superior outcome than fulvestrant alone,Combination Optimization,"CDK4,CDK6",-,Advanced breast cancer,"Palbociclib, Fulvestrant",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,8.2.1.2.1,氟维司群
139,KP3,26264704,Current development of CDK4/6 inhibitors#focuses on#advanced hormone-receptor-positive breast cancer treatment,Therapeutic Development,"CDK4,CDK6",-,Advanced hormone-receptor-positive breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
480,KP3,31612739,CDK9 and CDK4/6 inhibitors#are#a promising therapeutic approach in AML,Therapeutic Development,"CDK9,CDK4,CDK6",-,Acute myeloid leukemia (AML),-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3176,KP3,31612739,Greater comprehension of disease mechanisms#drives#investigation of new targeted treatments,Therapeutic Development,-,-,Acute myeloid leukemia (AML),-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5463,KP3,31612739,Targeting the CDK pathway#is#a promising therapeutic strategy in AML,Therapeutic Development,"CDK4,CDK6,CDK9",-,Acute myeloid leukemia (AML),-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2654,KP3,31612739,CDK4/6 inhibition#has#selective activity in KMT2A-rearrangements and FLT3 mutations,Molecular Event,"CDK4,CDK6,KMT2A,FLT3",-,Acute myeloid leukemia (AML),-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
2024,KP3,36033522,GLR2007#demonstrates#activity against IDH wild-type glioblastoma and other solid tumors,Drug Development,"CDK4,CDK6",-,"Glioblastoma, solid tumors",GLR2007,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2891,KP3,36033522,CDK4/6 inhibitors#showed#preclinical efficacy in solid tumors,Preclinical Models,"CDK4,CDK6",-,Solid tumors,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
212,KP3,36033522,Poor blood-brain barrier penetration#limits#efficacy in GBM,Resistance Mechanisms,"CDK4,CDK6",-,Glioblastoma (GBM),Abemaciclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
7321,KP3,36033522,GLR2007#was evaluated in#human GBM and breast cancer orthotopic xenograft models,Preclinical Models,"CDK4,CDK6",-,"Glioblastoma, breast cancer",GLR2007,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3705,KP3,39379427,FDA#has approved#CDK4/6 inhibitors for metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
6065,KP3,30343527,"CDK4/6 inhibitors#are effective for#HR-positive, HER2-negative advanced breast cancer",Therapeutic Response,"CDK4,CDK6",-,"HR-positive, HER2-negative advanced breast cancer",-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5258,KP3,39885369,CDK4/6 inhibitors#have shown#clinical activity in HR-positive metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,HR-positive metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5292,KP3,39885369,Effectiveness of CDK4/6 inhibitors#remains#limited in other cancer types,Resistance Mechanisms,"CDK4,CDK6",-,Other cancer types,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
3020,KP3,36003783,GFI1-36N leukemic cells#exhibit#higher protein levels of CDK4 and CDK6,Expression Patterns,"CDK4,CDK6",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7069,KP3,36003783,Increased CDK4/6 levels#lead to#faster proliferation of GFI1-36N leukemic cells in vitro,Cell Cycle Control,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
3180,KP3,36003783,GFI1-36N leukemic cells#are more susceptible to#palbociclib treatment,Therapeutic Response,"CDK4,CDK6",-,Leukemia,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
710,KP3,36003783,GFI1-36N variant#increases#proliferation of leukemic cells,Mechanism of Action,GFI1,-,Acute Myeloid Leukemia (AML),Palbociclib,CDK4/CDK6 pathway,-,Specific subset of AML patients,-,Marker for sensitivity to CDK4/6 inhibitors,-,-,Inference,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7338,KP3,31823286,Palbociclib#is used to treat#ER-positive and HER2-negative advanced breast cancer,Therapeutic Response,"CDK4,CDK6",-,Advanced breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
908,KP3,35075231,Oncogenic splice variant of PDGFRA#is a therapeutic target for#selective CDK4/6 inhibitors,Cancer Association,PDGFRA,-,Glioblastoma,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
621,KP3,35075231,PDGFRA-mutated HEK293T cells#exhibited#higher proliferative activity via CDK4/CDK6-cyclin D1 signaling pathway,Mechanism of Action,"PDGFRA,CDK4,CDK6,CCND1",HEK293T cells,-,-,CDK4/CDK6-cyclin D1 pathway,-,-,Upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
42,KP3,35075231,PDGFRA-mutated HEK293T cells#showed#higher sensitivity to CDK4/CDK6 inhibitors,Therapeutic Response,"PDGFRA,CDK4,CDK6",HEK293T cells,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7008,KP3,27571378,Palbociclib#is approved for#ER-positive and HER2-negative breast cancer,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3748,KP3,32934206,Palbociclib#has been granted#accelerated approval by US FDA for hormone receptor-positive HER2-negative metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,Metastatic breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1272,KP3,39196911,Resistance to traditional treatments#necessitates#novel treatment strategies,Therapeutic Development,-,-,Cancer,-,-,-,-,-,-,-,-,Inference,2,2.5,2.5.2,2.5.2.3,-,个体化方案
6519,KP3,39196911,20% of HR+ breast cancer patients#develop#primary resistance to CDK4/6 inhibitors,Therapeutic Resistance,"CDK4,CDK6",-,HR+ breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
5482,KP3,39196911,Cells#were treated with#ribociclib at two time points,Technical Methods,"CDK4,CDK6",-,-,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5034,KP3,39196911,CDON mRNA expression#increased#significantly,Expression Patterns,CDON,-,-,-,-,-,-,Upregulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
788,KP3,27167191,Combined inhibition of MEK and CDK4/6#is effective in#KRAS mutant CRC preclinical models,Combination Therapies,"CDK4,CDK6,KRAS",-,Colorectal cancer (CRC),"MEK inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
5035,KP3,31207004,Palbociclib#is assessed for#treating canine mammary tumors,Preclinical Models,"CDK4,CDK6",-,Canine mammary tumors,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2259,KP3,31207004,Therapy of canine mammary tumors with classical drugs#is problematic due to#limited efficacy,Therapeutic Development,-,-,Canine mammary tumors,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5185,KP3,31207004,"Palbociclib#inhibits#CDK4 and CDK6, key regulators of cell cycle machinery",Mechanism of Action,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5670,KP3,31207004,Palbociclib#has#antitumor effects on CMT cells,Therapeutic Response,"CDK4,CDK6",-,Canine mammary tumors,Palbociclib,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2491,KP3,27099147,30% of AML patients#have#FLT3 receptor tyrosine kinase ITDs,Cancer Association,FLT3,-,Acute Myeloid Leukemia (AML),-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
6101,KP3,27099147,Palbociclib#induces#apoptosis of FLT3-ITD leukemic cells,Therapeutic Response,"CDK4,CDK6,FLT3",-,Acute Myeloid Leukemia (AML),Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.3,-,生存信号抑制
4700,KP3,34739066,ERBB2-low expression#is associated with#efficacy of CDK4/6 inhibitors,Therapeutic Response,"CDK4,CDK6,ERBB2",-,Metastatic breast cancer,-,-,-,-,Low (ERBB2),-,-,-,Inference,7,7.2,7.2.1,7.2.1.2,7.2.1.2.4,ER/PR状态
1271,KP3,34739066,Low levels of ERBB2 expression#are associated with#progression-free survival,Clinical Correlation,"ERBB2,CDK4,CDK6",-,Metastatic breast cancer,-,-,-,-,Low (ERBB2),-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,7.2.1.2.4,ER/PR状态
6722,KP3,31399936,Ribociclib#penetrates#tumor tissue,Drug Development,"CDK4,CDK6",Tumor tissue,Glioblastoma,Ribociclib,Rb,Recurrent,Upregulated,-,-,-,-,Fact,3,3.6,3.6.1,3.6.1.4,-,组织渗透增强
4979,KP3,31399936,Ribociclib#modulates#Rb signaling pathway,Pathway & Network Categories,"CDK4,CDK6",Tumor tissue,Glioblastoma,Ribociclib,Rb,Recurrent,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
5532,KP3,31399936,Pharmacodynamic markers of Ribociclib#showed#inconsistent modulation,Biomarker Analysis,"CDK4,CDK6",Tumor tissue,Glioblastoma,Ribociclib,-,Recurrent,-,Pharmacodynamic,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,7.3.1.1.4,细胞周期分布
4014,KP3,29852762,Palbociclib#treated#metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,Metastatic breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1584,KP3,27939057,CDK4/6 inhibitors#improve#progression-free survival in advanced breast cancer,Therapeutic Response,"CDK4,CDK6",-,Advanced breast cancer,CDK4/6 inhibitors,-,Progression-free survival,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1835,KP3,37946508,Patients#were treated with#CDK4/6 inhibitor and endocrine therapy,Combination Optimization,"CDK4,CDK6",-,HR+/HER2- metastatic breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
4549,KP3,33732653,NRAS mutant melanoma patients#have#limited treatment options,Therapeutic Resistance,NRAS,-,Metastatic melanoma,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
6720,KP3,29847850,CDK4/6 inhibitors#transform#care for HR+/HER2- advanced breast cancer,Therapeutic Development,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2761,KP3,30685576,CDK4/6 inhibitors#treat#women with HR+/HER2- advanced breast cancer,Therapeutic Development,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1715,KP3,39271490,CDK4/6 inhibitors#increase#risk of adverse events when combined with endocrine drugs,Safety Monitoring,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,"CDK4/6 inhibitors, endocrine drugs",-,Adverse events,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
5752,KP3,39271490,"Abemaciclib#results in#highest risk of discontinuation, dose reduction, and serious adverse events",Safety Monitoring,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,Abemaciclib,-,Serious adverse events,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.3,-,预防和处理
7182,KP3,39271490,Ribociclib#caused#highest risk of death,Safety Monitoring,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,Ribociclib,-,Death,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.3,-,预防和处理
5077,KP3,33663223,CDK4/6 inhibitors#are approved for#HR+/HER2- advanced breast cancer,Regulatory Documentation,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
185,KP3,35373292,CDK4 and CDK6#phosphorylate#RB1 to release E2F,Mechanism of Action,"CDK4,CDK6,RB1,E2F",-,-,-,G1/S transition,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
752,KP3,35373292,CDK4/6 inhibitors#enhance#immune-mediated cell killing via DR5 upregulation,Immune Cell Functions,"CDK4,CDK6,DR5",-,-,CDK4/6 inhibitors,-,-,Upregulated,-,-,-,-,Fact,3,3.3,3.3.2,3.3.2.2,-,T细胞活化增强
6413,KP3,34065376,Specific CDKIs#have activity in#selected patients dependent on rearrangements and mutations,Biomarker Analysis,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.2,-,分子亚型
2061,KP3,34065376,FDA-approved CDK4/6 inhibitors#include#traditional and novel pan-CDKIs and dual kinase inhibitors,Drug Development,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
6120,KP3,34997364,Barriers and facilitators#affect#adherence to CDK4/6 inhibitors among MBC patients,Patient Behavior Analysis,"CDK4,CDK6",-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.2,-,评估内容
3194,KP3,34094661,CDK4/6 inhibitors#are approved for#treatment of metastatic hormone receptor-positive breast cancer,Clinical Implementation,"CDK4,CDK6",-,Metastatic hormone receptor-positive breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
2846,KP3,34094661,First-generation pan-CDKIs and second-generation CDKIs#target#cancers during clinical trials,Drug Development,"CDK4,CDK6",-,Cancer,"Flavopiridol, Roscovitine, Dinaciclib, P276-00, AT7519, TG02, Roniciclib, RGB-286638",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6699,KP3,34094661,Combination therapy of CDK inhibitors with PD1/PDL1 antibodies#might give insights into#promising cancer treatment strategies,Combination Optimization,"CDK4,CDK6",-,Cancer,PD1/PDL1 antibodies,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3199,KP3,30143968,CDK4/6 inhibitors#improve#progression-free survival in patients with ER-positive advanced breast cancer,Therapeutic Response,"CDK4,CDK6",-,Endocrine receptor-positive advanced breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4793,KP3,28778953,Epithelial ovarian cancer (EOC)#is treated with#platinum-based therapies,Therapeutic Development,-,-,Epithelial ovarian cancer,Platinum-based therapies,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6388,KP3,28778953,Improved response to platinum#could significantly impact#patient survival,Therapeutic Response,-,-,-,Platinum,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4280,KP3,28778953,Silencing or pharmacological inhibition of CDK6#increases#EOC cell sensitivity to platinum,Mechanisms of Resistance,CDK6,EOC cells,Epithelial ovarian cancer,Platinum,-,-,-,Downregulated,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
2789,KP3,28778953,CDK6#phosphorylates and stabilizes#FOXO3 upon platinum treatment,Mechanism of Action,"CDK6,FOXO3",-,-,Platinum,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
3885,KP3,28778953,CDK6#represents#an actionable target to improve platinum efficacy in EOC patients,Therapeutic Development,CDK6,-,Epithelial ovarian cancer,Platinum,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5347,KP3,28778953,CDK4/6 inhibitors#are successfully used in#cancer patients to improve EOC outcomes,Clinical Implementation,"CDK4,CDK6",-,Epithelial ovarian cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5249,KP3,34588615,Abemaciclib or palbociclib treatment#decreases#cell proliferation in all evaluated cell models,Therapeutic Response,"CDK4,CDK6",-,-,"Abemaciclib, Palbociclib",-,-,-,Downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3856,KP3,38896996,CDK4/6 inhibitors#impact#breast cancer brain metastasis outcomes,Therapeutic Response,"CDK4,CDK6",-,Breast cancer brain metastasis,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3951,KP3,38896996,CDK4/6 inhibitors#are recommended as#1st line treatment in HR+HER2- metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR+HER2- metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5450,KP3,31926467,Overexpression and amplification of CDK4/6#may cause#resistance to CDK4/6 inhibitors in preclinical models,Mechanisms of Resistance,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,Upregulated,-,-,-,Inference,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
7706,KP3,31926467,Palbociclib#is approved to treat#ER+/HER2- breast cancer in combination with letrozole,Clinical Implementation,"CDK4,CDK6",-,ER+/HER2- breast cancer,"Palbociclib, Letrozole",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
5111,KP3,34145036,JAK2 inhibitors ruxolitinib and fedratinib#are approved for#treatment of myelofibrosis,Clinical Trial Data,JAK2,-,Myelofibrosis,"Ruxolitinib, Fedratinib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
2738,KP3,28325261,Selective CDK4/6 inhibitors#received#FDA approval in combination with letrozole and fulvestrant for ER-positive advanced and metastatic BC,Clinical Trial Data,"CDK4,CDK6",-,"Advanced breast cancer, Metastatic breast cancer","Letrozole, Fulvestrant",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
2531,KP3,39153252,CDK4/6 inhibitors#extend#tumor response in metastatic luminal A breast cancer,Therapeutic Response,"CDK4,CDK6",-,Metastatic luminal A breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4626,KP3,39153252,Intrinsic and acquired resistance#remains#a prevalent issue with CDK4/6 inhibitors,Therapeutic Resistance,"CDK4,CDK6",-,Metastatic luminal A breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
6438,KP3,35201661,CDK4/6 inhibitors#improve#progression-free survival in ER-positive/HER2-negative metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,ER-positive/HER2-negative metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6090,KP3,39667501,Combination of CDK4/6 inhibitors and endocrine therapy#is#first-line therapy for ER+/HER2- breast cancer,Clinical Implementation,"CDK4,CDK6",-,ER+/HER2- breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
3578,KP3,39667501,Drug resistance#limits#efficacy of CDK4/6 inhibitors and endocrine therapy,Therapeutic Resistance,"CDK4,CDK6",-,ER+/HER2- breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
6358,KP3,29844123,CDK4/6-Rb-E2F axis and RTK signaling#are deregulated in#most GBM,Cancer Pathways,"CDK4,CDK6,RB1,E2F",-,Glioblastoma (GBM),-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2810,KP3,29160310,CDK4/6 inhibitor treatment combined with anti-PD-1 immunotherapy#enhances#tumor regression and improves survival rates in mouse tumor models,Combination Therapies,"CDK4,CDK6,PDCD1",-,Tumor,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.2,-,协同增效作用
5066,KP3,29160310,Combination treatment with CDK4/6 inhibitors and PD-1-PD-L1 immune checkpoint blockade#enhances#therapeutic efficacy for human cancers,Combination Therapies,"CDK4,CDK6,PDCD1,CD274",-,Human cancers,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.3,3.2.3.2,-,协同增效作用
3430,KP3,36548336,CDK4/6 inhibitors#are not helpful in#treatment of patients with TNBC,Therapeutic Response,"CDK4,CDK6",-,Triple-negative breast cancer (TNBC),-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1445,KP3,28453226,"Palbociclib, a CDK4/6 inhibitor,#is approved for#hormone receptor-positive breast cancer",Clinical Trial Data,"CDK4,CDK6",-,Hormone receptor-positive breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
7220,KP3,28453226,CDK4/6 inhibitors ribociclib and abemaciclib#had minimal effects on#HCC cell viability and the PP5/AMPK axis,Preclinical Models,"CDK4,CDK6",-,Hepatocellular carcinoma (HCC),"Ribociclib, Abemaciclib",AMPK,-,-,-,-,-,-,Fact,4,4.2,4.2.2,4.2.2.3,-,下游效应器激活
2839,KP3,32297248,CDK4/6 inhibitors#represent#a significant advancement in treatment of ER-positive HER2-negative advanced breast cancer,Therapeutic Development,"CDK4,CDK6",-,ER-positive HER2-negative advanced breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2847,KP3,39060086,CDK4/6 inhibitors with endocrine therapy#show potential in#enhancing anti-tumor immune responses in metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.3,3.3.1,3.3.1.4,-,免疫抑制缓解
3850,KP3,34655298,"Abemaciclib, a CDK4/6 inhibitor,#is approved for#treatment of advanced breast cancer as single agent therapy",Clinical Trial Data,"CDK4,CDK6",-,Advanced breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
6480,KP3,34655298,Abemaciclib#is under investigation for#treatment of several solid tumors,Clinical Trial Data,"CDK4,CDK6",-,Solid tumors,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
5708,KP3,34655298,Abemaciclib#inhibits#tumor formation and growth in a dose-dependent manner,Therapeutic Response,"CDK4,CDK6",-,Tumor,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7360,KP3,34655298,Abemaciclib in combination with doxorubicin#is being investigated for#efficacy in osteosarcoma patients,Clinical Trial Data,"CDK4,CDK6",-,Osteosarcoma,"Abemaciclib, doxorubicin",-,-,Osteosarcoma patients,-,-,-,-,Inference,8,8.2,8.2.1,8.2.1.2,8.2.1.2.3,卵巢功能抑制
2553,KP3,27986745,Drug combinations#target#neuroblastomas with mutations in ALK,Drug Development,ALK,-,Neuroblastoma,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7871,KP3,27986745,"Ribociclib and ceritinib combination therapy#enhances#growth inhibition, cell-cycle arrest, and caspase-independent cell death",Combination Therapies,"CDK4,CDK6,ALK",-,Neuroblastoma,"Ribociclib, ceritinib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1210,KP3,35817775,Palbociclib#prolongs#progression-free survival in hormone receptor-positive breast cancer patients,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,Palbociclib,-,-,Hormone receptor-positive patients,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4048,KP3,35817775,Datasets#inform#future use of CDK4/6 inhibitors in TNBC subtypes,Biomarker Analysis,"CDK4,CDK6",-,Triple-negative breast cancer (TNBC),CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,基因突变
1619,KP3,32661093,Concurrent MEK and CDK4/6 inhibition#shows promise in#advanced-stage mutant BRAF/NRAS solid tumors,Combination Therapies,"CDK4,CDK6,BRAF,NRAS",-,Solid tumors,"MEK inhibitors, CDK4/6 inhibitors",-,-,Advanced-stage patients,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1346,KP3,32661093,CDK4/6 inhibitors in combination with BRAF/MEK-targeting agents#affect#tumor immune microenvironment in melanoma,Signaling Networks,"CDK4,CDK6,BRAF,MEK",-,Melanoma,"CDK4/6 inhibitors, BRAF/MEK-targeting agents",-,-,-,-,-,-,-,Inference,6,6.1,6.1.1,6.1.1.1,6.1.1.1.4,细胞毒性活性
3497,KP3,39707711,CDK4/6 inhibitors plus endocrine therapy#are utilized as#first-line treatment for HR+/HER2- advanced breast cancer,Clinical Implementation,"CDK4,CDK6","HR+,HER2-",Breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1040,KP3,29243224,Increased CDK4 activity#occurs in#the majority of melanomas,Expression Patterns,CDK4,-,Melanoma,-,-,-,-,Upregulated,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
779,KP3,29243224,CDK4/6 inhibitors in combination with BRAF and MEK inhibitors#are in#clinical trials for melanoma treatment,Clinical Trial Data,"CDK4,CDK6,BRAF,MEK",-,Melanoma,"CDK4/6 inhibitors, BRAF inhibitors, MEK inhibitors",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.3,黑色素瘤
4095,KP3,29243224,"Melanoma patients with resistance to BRAF inhibition#are less likely to respond to#triplet combination of BRAF, MEK, and CDK4/6 inhibitors",Therapeutic Resistance,"CDK4,CDK6,BRAF,MEK",-,Melanoma,"BRAF inhibitors, MEK inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
5782,KP3,20577054,Selective CDK4/6 inhibitors#increase#radioresistance in human cell lines and mice,Regulation,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,2.6.1.1,-,药物外排增加
5719,KP3,20577054,CDK4/6-dependent cell lines#are resistant to#IR and DNA-damaging agents when treated with CDK4/6 inhibitors,Mechanisms of Resistance,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
2630,KP3,39499997,Acquired resistance to CDK4/6 inhibitors#frequently emerges in#triple-negative breast cancer,Therapeutic Resistance,"CDK4,CDK6",-,Triple-negative breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
7166,KP3,38443662,CDK4/6 inhibitors#revolutionized#breast cancer therapy,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2590,KP3,39487364,CDK6#drives#cell cycle deregulation in endothelial cell proliferation and HHT pathology,Cell Cycle Control,CDK6,Endothelial cells,HHT,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
262,KP3,39487364,Phosphorylated RB1#accumulates in#endothelial cells from retinal AVMs of HHT mice,Markers,RB1,Endothelial cells,HHT,-,-,-,-,Upregulated,pRB1,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
662,KP3,39487364,CDK4/6 inhibitors#block#increases in pRB1 and retinal AVMs in HHT mice,Strategies to Overcome Resistance,"CDK4,CDK6",-,HHT,"Palbociclib, Ribociclib",-,-,-,-,pRB1,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
2300,KP3,39487364,CDK4/6 inhibitors#might be repurposed for#HHT,Drug Development,"CDK4,CDK6",-,HHT,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3280,KP3,35301407,High-risk patients#may die from#multidrug-resistant disease,Therapeutic Resistance,-,-,Multidrug-resistant disease,-,-,-,High-risk patients,-,-,-,-,Fact,2,2.6,2.6.1,2.6.1.4,-,细胞凋亡抑制
1528,KP3,35301407,Increased CDK4 expression#suggests#CDK4 inhibition as a strategy to treat MTX-resistant choriocarcinoma,Therapeutic Resistance,CDK4,-,MTX-resistant choriocarcinoma,-,-,-,-,Upregulated,-,-,-,Inference,2,2.5,2.5.2,2.5.2.1,-,新型抑制剂开发
7450,KP3,35301407,CDK4/6 inhibition#induces#growth inhibition in vitro and in an in vivo model,Preclinical Models,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4152,KP3,39603379,Resistance to CDK4/6 inhibitors#remains#a significant clinical obstacle,Therapeutic Resistance,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
2152,KP3,39572000,CDK4/6 inhibitors#induce#long-term response in multiple metastases of breast cancer,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
417,KP3,37894292,CDK4/6 inhibitors#are combined with#endocrine therapy for HR+/HER2- advanced breast cancer,Combination Therapies,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
649,KP3,38889643,"Combining PI3K, FGFR, and CDK4/6 inhibitors#has#synergistic effects in NB cell lines",Combination Therapies,"CDK4,CDK6,PIK3CA,FGFR",NB cell lines,-,"PI3K inhibitors, FGFR inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4752,KP3,39083396,Adverse events (AEs)#are associated with#CDK4/6 inhibitors,Safety Monitoring,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.3,-,预防和处理
5083,KP3,28760782,CDK4 deletion#is associated with#pancreatic beta cell loss and glucose dysregulation in rodents,Disease-Specific Categories,CDK4,Pancreatic beta cells,Glucose dysregulation,-,-,-,-,-,-,-,-,Fact,4,4.1,4.1.3,4.1.3.4,-,酶稳定性控制
4825,KP3,28151717,Cyclin D3 (CCND3) and CDK6#are highly expressed in#T-ALL,Expression Patterns,"CCND3,CDK6",T cells,T-ALL,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.2,-,Cyclin D-CDK6复合物
4749,KP3,39431459,Older patients with HR+/HER2-negative breast cancer#derive#clinical benefit from CDK4/6 inhibitors,Therapeutic Response,"CDK4,CDK6",-,HR+/HER2-negative breast cancer,CDK4/6 inhibitors,-,-,Older patients,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2875,KP3,31924739,CDK4 and CDK6 activation#is observed in#HPV-negative SCCHN,Disease & Clinical Categories,"CDK4,CDK6",-,HPV-negative squamous cell carcinoma of the head and neck (SCCHN),-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
6430,KP3,31924739,CDK4/6 inhibitors#should be investigated in#HPV-negative SCCHN with high Rb expression,Therapeutic Response,"CDK4,CDK6",Epithelial cells,HPV-negative SCCHN,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
7183,KP3,31924739,Biomarkers#may enrich#population benefiting from CDK4/6 inhibitors,Biomarker Analysis,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
2441,KP3,39500869,CDK4/6 inhibition#is combined with#endocrine therapy for ER-positive breast cancer,Combination Optimization,"CDK4,CDK6",-,ER-positive breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
3774,KP3,26923330,Palbociclib#is combined with#aromatase inhibitors for ER-positive breast cancer,Combination Optimization,"CDK4,CDK6",-,ER-positive breast cancer,"Palbociclib, aromatase inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
6835,KP3,38262581,Treatment options for liver cancer#provide#limited long-term clinical benefits,Clinical Implementation,"CDK4,CDK6",-,Liver cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
1519,KP3,38262581,Compound screen#identified#inhibitors synergizing with CDK4/6 inhibitors to induce senescence,Drug Development,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
6064,KP3,39090361,CDK4 amplification#was observed in#9.8% of ER-/HER2- mBCs pretreated population,Cancer Association,CDK4,-,ER-/HER2- metastatic breast cancer,-,-,-,-,amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5668,KP3,31555743,CDK4/6 kinase#is dysregulated in#melanoma,Cancer Association,"CDK4,CDK6",-,Melanoma,-,-,-,-,dysregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
1961,KP3,31555743,CDK4/6 inhibitors#are being evaluated for#melanoma and additional cancers,Clinical Trial Data,"CDK4,CDK6",-,Melanoma,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.3,黑色素瘤
3735,KP3,31555743,Combination of CDK4/6 inhibitor with mTORC1 inhibitor#has#increased therapeutic efficacy in aggressive melanoma,Combination Optimization,"CDK4,CDK6",-,Melanoma,"CDK4/6 inhibitors, mTORC1 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
396,KP3,38266771,Metabolic reprogramming in breast cancer#offers#personalized treatment targets,Therapeutic Development,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,4,4.1,4.1.1,4.1.1.1,-,有氧糖酵解增强
7402,KP3,38266771,ERα-positive BC patients undergoing endocrine therapy#can develop#ET-resistant metastatic disease,Therapeutic Resistance,ESR1,-,Metastatic breast cancer,-,-,-,ERα-positive,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
852,KP3,38266771,PMM2 reduction#affects#hyperactive phenotype of mutant and proliferation when combined with metastatic BC treatment drugs,Mechanism of Action,PMM2,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
6686,KP3,38266771,Reducing PMM2 levels#re-sensitizes#ERα Y537S-expressing cells to ET drugs and CDK4/6 inhibitors,Mechanisms of Resistance,"PMM2,CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.4,-,生物标志物指导
7813,KP3,29739788,CDK4/6 kinase inhibitors#target#G1-S cell-cycle checkpoint via RB tumor suppressor activity,Mechanism of Action,"CDK4,CDK6, RB1",-,-,CDK4/6 inhibitors,G1-S checkpoint,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
1932,KP3,29739788,CDK4/6 inhibitors#were FDA-approved for#treatment of breast cancer,Regulatory Documentation,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
2103,KP3,29739788,Palbociclib resistance#acquires#broad resistance to CDK4/6 inhibitors,Therapeutic Resistance,"CDK4,CDK6",-,Cancer,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.5,2.5.2,2.5.2.4,-,生物标志物指导
1881,KP3,27124835,Toxic effects of treatment#include#neutropenia,Safety Monitoring,-,-,-,-,-,Neutropenia,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
6151,KP3,39730704,Combination of CDK4/6 inhibitor and endocrine therapy#is standard for#HR+/HER2-low advanced breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2-low breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
5750,KP3,31444334,Combination of CDK4/6 inhibitors#is used to treat#HER2+ breast cancer,Clinical Trial Data,"CDK4,CDK6",-,HER2+ breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
5621,KP3,31444334,Acquired resistance#emerges rapidly to#anti-HER2/neu antibody and CDK4/6 inhibitor Palbociclib,Therapeutic Resistance,"CDK4,CDK6,ERBB2",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
4659,KP3,31444334,Combination of cabozantinib and immune checkpoint blockade#overcomes#drug resistance,Strategies to Overcome Resistance,-,-,-,Cabozantinib,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.4,-,生物标志物指导
4285,KP3,39617889,CDK4/6 inhibitors#display#anti-tumor efficacy due to mutual exclusive dependency on CDK4 or CDK6,Mechanism of Action,"CDK4,CDK6",-,Cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1545,KP3,39617889,AMBRA1#acts as#context-specific inhibitor of cell cycle progression,Regulation,AMBRA1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
958,KP3,39617889,AMBRA1#regulates#key components of mitosis including aurora kinases,Regulation,"AMBRA1,AURKA,AURKB",-,-,-,Mitosis,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
4512,KP3,39769028,Ribociclib#shows#limited efficacy as monotherapy in colorectal cancer,Therapeutic Response,"CDK4,CDK6",-,Colorectal cancer,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3729,KP3,32377705,CDK4/6 inhibitors#are effective against#luminal androgen receptor subtype of TNBC,Therapeutic Response,"CDK4,CDK6",-,Triple-negative breast cancer (TNBC),CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3672,KP3,32391377,"Cyclin-dependent kinase (CDK)4, CDK6, ERBB2#show#transcriptional differences among immune subtypes",Expression Patterns,"CDK4,CDK6,ERBB2",-,-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
2362,KP3,32629666,Palbociclib#is indicated for#HR-positive/HER2-negative metastatic breast cancer in combination with fulvestrant,Clinical Implementation,"CDK4,CDK6",Postmenopausal women,Metastatic breast cancer,"Palbociclib,Fulvestrant",-,-,Postmenopausal,Selective,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
2892,KP3,37330448,Palbociclib#is effective in#treatment of metastatic or unresectable liposarcoma,Therapeutic Response,"CDK4,CDK6",-,Liposarcoma,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6153,KP3,39322687,High phosphorylation levels of PI3K/AKT/mTOR downstream target p70S6 Kinase (T389)#are associated with#shorter PFS in patients treated with CDK4/6 inhibitors and ET,Prognostic Associations,"CDK4,CDK6,MTOR",PI3K/AKT/mTOR pathway,-,"CDK4/6 inhibitors,ET",PI3K/AKT/mTOR,-,-,Prognostic,-,-,-,Fact,2,2.3,2.3.3,2.3.3.1,-,磷酸化水平
1110,KP3,26455641,ESR1 gene product#is expressed in#largest molecular subtype of breast cancer,Expression Patterns,ESR1,-,Breast cancer,-,-,-,Detectable,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
3186,KP3,26455641,Antiestrogens and aromatase inhibitors#improve#overall survival in ERα+ breast cancer,Therapeutic Response,ESR1,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
7556,KP3,26455641,Tamoxifen resistance#is explained by#pharmacogenetic factors,Mechanisms of Resistance,ESR1,-,Breast cancer,Tamoxifen,-,-,-,-,-,-,-,Inference,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
4988,KP3,26455641,Drug combinations with CDK4/CDK6 inhibitors#extend#recurrence-free survival,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3109,KP3,26455641,Improvements with immunotherapy in other cancers#may translate to#ERα+ breast cancer,Therapeutic Development,ESR1,-,Breast cancer,-,-,-,-,-,-,-,-,Inference,3,3.3,3.3.2,3.3.2.4,-,协同免疫激活
5076,KP3,33812473,Neoadjuvant combination therapy#is#a standard of care for HER2-positive and TNBC,Clinical Implementation,ERBB2,-,Breast cancer,Neoadjuvant therapy,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
7914,KP3,33812473,ER-positive tumours#are treated with#endocrine therapy and chemotherapy,Clinical Implementation,ER,-,ER-positive tumours,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
478,KP3,33812473,CDK4 and CDK6 inhibitors#are used in#metastatic breast cancer treatment,Drug Development,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1870,KP3,33812473,PI3K inhibitors#are used in#metastatic breast cancer treatment,Drug Development,PIK3CA,-,Metastatic breast cancer,PI3K inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
7259,KP3,33812473,PARP inhibitors#are used in#metastatic breast cancer treatment,Drug Development,PARP1,-,Metastatic breast cancer,PARP inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
2638,KP3,33812473,Anti-PD-L1 immunotherapy#is used in#metastatic breast cancer treatment,Drug Development,CD274,-,Metastatic breast cancer,Anti-PD-L1 immunotherapy,-,-,-,-,-,-,-,Fact,3,3.3,3.3.2,3.3.2.1,-,PD-1/PD-L1表达调控
1525,KP3,35100692,Mutational and copy number aberration biomarkers#represent#the cyclin D/CDK pathway,Biomarker Analysis,"CCND,CDK",-,-,-,Cyclin D/CDK pathway,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
5644,KP3,35100692,Mutational and copy number aberration biomarkers#represent#the FGFR/FGF pathway,Biomarker Analysis,"FGFR,FGF",-,-,-,FGFR/FGF pathway,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
6128,KP3,35100692,Mutational and copy number aberration biomarkers#represent#the PI3K/AKT pathway,Biomarker Analysis,"PIK3CA,AKT",-,-,-,PI3K/AKT pathway,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
581,KP3,37143728,Metabolic pathway inhibitors#could be used as#anti-ER伪 breast cancer drugs,Drug Development,ER,-,Breast cancer,-,Metabolic pathways,-,-,-,-,-,-,Inference,4,4.1,4.1.3,4.1.3.1,-,关键酶活性调节
4085,KP3,37143728,GART inhibition#induces#ER伪 degradation,Mechanism of Action,"GART,ER",-,Breast cancer,-,Purine de novo biosynthetic pathway,-,-,-,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,微小RNA
4342,KP3,37143728,GART inhibition#prevents#BC cell proliferation,Mechanism of Action,GART,-,Breast cancer,-,Purine de novo biosynthetic pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
529,KP3,37143728,GART expression#is increased in#receptor-positive IDCs of high grade and stage,Expression Patterns,GART,-,Invasive ductal carcinomas (IDCs),-,Purine de novo biosynthetic pathway,-,-,upregulated,-,-,-,Fact,5,5.2,5.2.1,5.2.1.3,-,重复
2081,KP3,37143728,Lometrexol (LMX)#exerts#synergic antiproliferative effects in BC cells,Combination Therapies,GART,-,Breast cancer,"Lometrexol (LMX), CDK4/CDK6 inhibitors, 4OH-tamoxifen",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6309,KP3,39616836,CDK4/6 inhibitors#are combined with#aromatase inhibitors or fulvestrant,Combination Therapies,"CDK4,CDK6",-,-,"Palbociclib, Ribociclib, Abemaciclib, Anastrozole, Letrozole, Fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,联合芳香化酶抑制剂
2342,KP3,38781103,CDK4/6 inhibition#is the standard treatment for#ER+ breast cancer,Clinical Implementation,"CDK4,CDK6,ER",-,ER+ breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5860,KP3,38781103,Drug resistance#is common in#CDK4/6 inhibition for ER+ breast cancer,Therapeutic Resistance,"CDK4,CDK6,ER",-,ER+ breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,2.6.1.1,-,药物外排增加
933,KP3,38781103,PKMYT1#is regulated by#estradiol (E2) in E2-dependent PDXs,Regulation,PKMYT1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.1,1.2.1.2,-,激素信号通路
5255,KP3,38781103,PKMYT1#is constitutively expressed in#E2-independent PDXs,Expression Patterns,PKMYT1,-,-,-,-,-,-,constitutively expressed,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
2688,KP3,29893769,Palbociclib#is a new standard treatment in#hormone-receptor positive breast cancer,Drug Development,CDK4,-,Hormone-receptor positive breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1987,KP3,27146558,CDK4 and CDK6#were recently approved for#efficacy in patient subpopulations,Clinical Trial Data,"CDK4,CDK6",-,-,-,-,-,patient subpopulations,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,-,患者选择
1574,KP3,27146558,No predictive biomarkers#have been found for#CDK4 and CDK6,Biomarker Analysis,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
2541,KP3,31101835,A third of TNBC patients#have#relapsed disease within 2-5 years,Disease Progression,TNBC,-,Triple negative breast cancer,-,-,-,TNBC patients,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
4211,KP3,31101835,TNBC#frequently harbors#alterations of the PI3K/AKT/mTOR pathway,Cancer Pathways,"PIK3CA,AKT,MTOR",-,Triple negative breast cancer,-,PI3K/AKT/mTOR,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
5846,KP3,31101835,Single agent PI3K/AKT/mTOR inhibitors#have not shown#marked efficacy in TNBC,Drug Development,"PIK3CA,AKT,MTOR",-,Triple negative breast cancer,-,PI3K/AKT/mTOR,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
608,KP3,31101835,Persistent phosphorylation of RB#reduces#inhibition of p-S6 in TNBC,Mechanism of Action,RB1,-,Triple negative breast cancer,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2182,KP3,31101835,CDK4/6 inhibitor LEE011#enhanced#the inhibitory effect of BYL719 on p-RB and p-S6,Combination Therapies,"CDK4,CDK6",-,Triple negative breast cancer,"LEE011,BYL719",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2355,KP3,31101835,CDK4/6 inhibitor LEE011#caused#decreased expression of MCL-1 and induction of apoptosis,Mechanism of Action,"CDK4,CDK6,MCL1",-,Triple negative breast cancer,LEE011,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.3,-,线粒体通路调控
2485,KP3,31101835,Inhibition of p-RB and p-S6#is important for#effective TNBC treatment response,Mechanism of Action,RB1,-,Triple negative breast cancer,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7330,KP3,31101835,Combination therapy with BYL719 and LEE011#provides#a strong rationale for metastatic TNBC treatment,Combination Therapies,"CDK4,CDK6",-,Metastatic triple negative breast cancer,"BYL719,LEE011",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
6018,KP3,35780240,Enzalutamide#delays#progression of metastatic CRPC,Therapeutic Response,-,-,Metastatic castration-resistant prostate cancer,Enzalutamide,-,-,-,-,-,-,-,Fact,3,3.3,3.3.1,3.3.1.1,-,免疫细胞浸润增加
766,KP3,35780240,CDK6#is highly expressed in#EnzR LNCaP cells and PCa patients,Expression Patterns,CDK6,LNCaP cells,-,-,-,-,PCa patients,upregulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
1535,KP3,24710307,CDK6#is targeted by#CDK4/6 inhibitors,Drug Development,CDK6,-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4555,KP3,37310540,"CDK4/6 inhibitors#transformed#management of HR+, HER2- metastatic breast cancer",Therapeutic Development,"CDK4,CDK6",-,"HR+, HER2- metastatic breast cancer",CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
558,KP3,34828525,CDK4#binds to#cyclin D to promote G1/2 transition,Mechanism of Action,CDK4,-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3380,KP3,34828525,CDK4/6 inhibitors#are in#clinical trials for PC,Clinical Trial Data,"CDK4,CDK6",-,Prostate cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
5538,KP3,39026843,CDK4/6 inhibitors#showed#poor antitumor activity as monotherapy in NSCLC,Therapeutic Response,"CDK4,CDK6",-,Non-small cell lung cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1648,KP3,39026843,PARP1 expression#is upregulated in#NSCLC,Expression Patterns,PARP1,-,Non-small cell lung cancer,-,-,-,-,upregulated,-,-,-,Fact,5,5.1,5.1.1,5.1.1.2,-,末端切除
7056,KP3,39026843,Combined PARP and CDK4/6 inhibition#was analyzed in#NSCLC models,Combination Therapies,"PARP1,CDK4,CDK6",-,Non-small cell lung cancer,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
2569,KP3,39026843,Combining CDK4/6i with PARPi#could be#a promising therapeutic strategy for RB-proficient NSCLC,Therapeutic Development,"CDK4,CDK6,PARP1",-,RB-proficient non-small cell lung cancer,"CDK4/6 inhibitors,PARP inhibitors",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
5186,KP3,36446794,"CDK4/6 inhibitors#are relevant for#HR+, HER2- advanced breast cancer treatment",Therapeutic Development,"CDK4,CDK6",-,"HR+, HER2- advanced breast cancer",CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
863,KP3,36446794,CDK4/6 inhibitors#stabilize#primed CDK4-cyclin D complex and displace p21,Mechanism of Action,"CDK4,CDK6,CDKN1A",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
630,KP3,36446794,Active CDK4-cyclin D1 complex#can lead to#pathway reactivation following alternate dosing,Regulation,"CDK4,CCND1",-,-,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
1321,KP3,39225211,CDK4/6 inhibitors#revolutionized#breast cancer treatment,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1431,KP3,39225211,CDK4/6 inhibitors#have#some bone marrow toxicity,Safety Monitoring,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,血液学毒性
4425,KP3,39225211,CDK9 and CDK4/6 pathways inhibition#justifies#increased drug efficacy,Combination Therapies,"CDK9,CDK4,CDK6",-,-,myrtleciclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7873,KP3,39593745,The U.S FDA#has approved#three CDK4/6 inhibitors for HR(+) or HER2(-) advanced or metastatic breast cancer,Regulatory Documentation,"CDK4,CDK6",-,"Advanced breast cancer, Metastatic breast cancer",CDK4/6 inhibitors,-,-,"Hormone receptor-positive, HER2-negative",-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
628,KP3,35917168,Pharmacologic inhibitors of CDK4 and CDK6#are approved for#hormone receptor-positive breast cancer,Drug Development,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,Hormone receptor positive,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4620,KP3,38633610,Reports of DILI#are associated with#CDK4/6 inhibitor use,Safety Monitoring,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
1851,KP3,38633610,Ribociclib#showed#the highest risk of liver injury among CDK4/6 inhibitors,Safety Monitoring,"CDK4,CDK6",-,-,Ribociclib,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
7998,KP3,38633610,Palbociclib#appeared#relatively safe compared to other CDK4/6 inhibitors,Safety Monitoring,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,血液学毒性
4947,KP3,38633610,Regular liver function monitoring#is recommended for#long-term CDK4/6 inhibitor use,Treatment Monitoring,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,8,8.5,8.5.1,8.5.1.2,-,生物标志物监测
2198,KP3,31396487,CDK4/6 inhibitors#doubled#progression-free survival in advanced breast cancer,Therapeutic Response,"CDK4,CDK6",-,Advanced breast cancer,CDK4/6 inhibitors,-,-,"Hormone receptor-positive, HER2-negative",-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4114,KP3,29234249,"CDK4/6 inhibitors#are effective in#HR+, HER2- metastatic breast cancer in combination with endocrine therapy",Combination Therapies,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,"Hormone receptor-positive, HER2-negative",-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
896,KP3,24795392,Nonselective CDK inhibitors#led to#toxicity and little efficacy,Drug Development,CDK4,-,-,Nonselective CDK inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
2964,KP3,36185294,CDK4/6 inhibitors#are effective in#breast cancer treatment,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7249,KP3,36185294,CDK4/6 inhibitors#are being developed in#other solid tumors,Drug Development,"CDK4,CDK6",-,Solid tumors,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7236,KP3,31358010,CDK4/6 inhibitors#significantly suppress#PDX tumor growth with abnormal CDK4 pathway,Therapeutic Response,"CDK4,CDK6",-,PDX tumor,CDK4/6 inhibitors,CDK4,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
300,KP3,34804982,CDK4/6 inhibitors#are standard of care for#ER+ advanced breast cancer in combination with endocrine therapy,Clinical Implementation,"CDK4,CDK6",-,Advanced breast cancer,CDK4/6 inhibitors,-,-,Estrogen receptor positive,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4539,KP3,30180747,Metastatic melanoma patients with CNVs of CDK4 pathway-related genes#achieved#tumor control with palbociclib,Therapeutic Response,CDK4,-,Metastatic melanoma,Palbociclib,CDK4,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
1651,KP3,35444175,CDK4/6 inhibitors#are under investigation in#clinical trials for a range of cancer types,Drug Development,"CDK4,CDK6",-,Cancer types,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
4286,KP3,35444175,CDK4/6i dosing regimen#alters#positive and negative effects,Regulation,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,8,8.3,8.3.1,8.3.1.2,-,不良反应管理
6711,KP3,32357912,CDK4/6 inhibitors#block#G1 to S phase transition of the cell cycle,Cell Cycle Control,"CDK4,CDK6",-,HR+/HER2- breast cancer,CDK4/6 inhibitors,"Rb phosphorylation, E2F release",-,HR+/HER2- breast cancer patients,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
7948,KP3,34439268,CDK4/6 inhibitors#have emerged as#novel treatment options for advanced or metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,Advanced or metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
562,KP3,34327891,"Palbociclib, Ribociclib, and Abemaciclib#are used as#targeted cancer therapeutic agents",Drug Development,"CDK4,CDK6",-,"Endocrine therapy-resistant breast cancer, other cancers","Palbociclib, Ribociclib, Abemaciclib",-,-,Patients with endocrine therapy resistance,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6123,KP3,36060025,CDK4/6 inhibitors#are increasingly used in#combination with hormonal agents for HR+/HER2- breast cancer,Combination Optimization,"CDK4,CDK6",-,HR+/HER2- breast cancer,"CDK4/6 inhibitors, hormonal agents",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
2778,KP3,35479560,Cyclin-dependent kinases (CDK)#regulate#the cell cycle process,Cell Cycle Control,CDK,-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6547,KP3,35479560,CDK4/6 inhibitors#are promising#cancer therapy,Therapeutic Development,"CDK4,CDK6",-,Cancer,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1162,KP3,37835528,CDK4/6 inhibitors#improve#survival outcomes in advanced HR+ breast cancer patients,Therapeutic Response,"CDK4,CDK6",-,Advanced HR+ breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,Advanced HR+ breast cancer patients,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6862,KP3,38248101,Abemaciclib#increases#probability of MRONJ occurrence,Safety Monitoring,"CDK4,CDK6",-,MRONJ,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,8.4.1.2.4,皮肤反应
3120,KP3,34036394,Recurrent gain of chromosome 12q14.1#is more frequent in#poor responder cohort than good responder cohort,Genomic Profiles,CDK4,-,Chemoresistant tumors,-,-,-,Poor responder cohort,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
7980,KP3,34036394,CDK4 overexpression#attenuates#cisplatin (CDDP) sensitivity in OS cell lines,Mechanisms of Resistance,CDK4,OS cell lines,-,Cisplatin,-,-,-,Upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
159,KP3,34036394,Palbociclib#facilitates#apoptosis and decreases cell viability in CDK4-overexpressing U2OS cells,Mechanisms of Resistance,CDK4,U2OS cells,-,Palbociclib,-,-,-,Downregulated,-,-,-,Fact,3,3.1,3.1.3,3.1.3.3,-,线粒体通路调控
3934,KP3,28050067,Investigational CDK inhibitors#fail#due to excessive toxicity,Drug Development,CDK,-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
2086,KP3,28050067,Patients with advanced RB-expression#demonstrate#dose-limiting toxicities like neutropenia and thrombocytopenia,Patient Stratification,RB1,-,Breast cancer,-,-,"Neutropenia, thrombocytopenia",Advanced RB-expression,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
6709,KP3,37475713,CDK4/6 inhibitors#play#a crucial role in breast cancer treatment,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,3.1.1.1.1,G1/S期转换抑制
4065,KP3,38138549,Dysregulated CDK activation#drives#cell proliferation in cancer,Cancer Pathways,CDK,-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7708,KP3,38138549,Selective CDK4/6 inhibitors#show#clinical success in ER-positive and HER2-negative breast cancer,Therapeutic Response,"CDK4,CDK6",-,"ER-positive, HER2-negative breast cancer",CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,3.1.1.1.1,G1/S期转换抑制
5471,KP3,37500128,Patient#was treated with#abemaciclib,Clinical Implementation,"CDK4,CDK6",-,-,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1398,KP3,37500128,CDK4/6 inhibitors#can cause#pulmonary toxicity,Adverse Events,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,8.4.1.2.2,肝功能异常
5505,KP3,37500128,CDK4/6 inhibitors#increase risk for#pneumonitis,Safety Monitoring,"CDK4,CDK6",-,Pneumonitis,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
3894,KP3,35330128,CDK4/6 inhibitors#followed by#treatment strategies for HR+/HER2- metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
4273,KP3,35330128,CDK4/6 inhibitors#represent#best therapeutic choice for HR+ advanced breast cancer,Therapeutic Development,"CDK4,CDK6",-,Hormone receptor-positive advanced breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,3.1.1.1.1,G1/S期转换抑制
1393,KP3,32541838,CDK4/6#phosphorylate and inhibit#retinoblastoma (RB) family proteins,Mechanism of Action,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,1.1.1.1.1,RB蛋白磷酸化
4775,KP3,32541838,CDK4/6 inhibitors in combination with antiestrogens#produce#significant benefit in ER(+)/HER2(-) breast cancer,Combination Therapies,"CDK4,CDK6",-,ER(+)/HER2(-) breast cancer,"CDK4/6 inhibitors, antiestrogens",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,3.2.1.1.1,雌激素信号阻断
3297,KP3,32541838,Clinical trials#are investigating#CDK4/6 inhibitors for other cancer types,Clinical Trial Data,"CDK4,CDK6",-,Other cancer types,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,8.5.1.1.1,CT扫描
1029,KP3,33995631,CDK4/6 inhibitors#are used as#anti-cancer agents in HR+ breast cancers,Therapeutic Development,"CDK4,CDK6",-,Hormone receptor-positive breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,3.1.1.1.1,G1/S期转换抑制
6450,KP3,33364954,CDK4/6 inhibitors combined with endocrine therapy#are successful for#treating advanced ER+ breast cancer,Combination Therapies,"CDK4,CDK6",-,Estrogen receptor-positive advanced breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,3.2.1.1.1,雌激素信号阻断
4713,KP3,33364954,Various resistance mechanisms#are reviewed for#CDK4/6 inhibitors in luminal breast cancer,Mechanisms of Resistance,"CDK4,CDK6",-,Luminal breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,2.1.2.2.4,替代性生存通路
3496,KP3,33532179,Dysregulation of the cell cycle and CDKs#sustain#cell proliferation in cancer,Molecular Event,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
603,KP3,33532179,Third-generation CDK inhibitors#selectively inhibit#CDK4/6 to regulate the cell cycle,Mechanism of Action,"CDK4,CDK6",-,-,Third-generation CDK inhibitors,G1 to S phase transition,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,1.1.1.1.1,RB蛋白磷酸化
1989,KP3,33532179,15 CDK4/6 inhibitors#are in#clinical trials for cancer treatment,Clinical Trial Data,"CDK4,CDK6",-,Cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,8.5.1.1.1,CT扫描
12,KP3,33532179,CDK4/6 inhibitors#regulate#cell cycle and cancer cells,Mechanism of Action,"CDK4,CDK6",-,Cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,1.1.1.1.1,RB蛋白磷酸化
4738,KP3,35920011,Breast cancer#expresses#estrogen/progesterone receptors in 75% of patients,Expression Patterns,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,7.2.1.2.4,ER/PR状态
4592,KP3,35920011,Tamoxifen therapy#reduces#mortality in breast cancer by 33%,Therapeutic Development,-,-,Breast cancer,Tamoxifen,-,-,-,-,-,-,-,Fact,-,3,3.2,3.2.1,3.2.1.2,3.2.1.2.2
7164,KP3,37460715,CDK4/6 inhibitors#are recommended for#advanced HR(+)HER2(-) breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR(+)HER2(-) breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
17,KP3,37460715,FSIP1 expression level#predicts#response of TNBC to CDK4/6 inhibitors,Biomarker Analysis,"CDK4,CDK6",-,Triple-negative breast cancer,CDK4/6 inhibitors,-,-,-,Predictive,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.3,ESR1突变
4804,KP3,37460715,FSIP1 downregulation#leads to#slower tumor growth and reduced lung metastasis in TNBC,Therapeutic Response,-,-,Triple-negative breast cancer,-,-,-,-,Downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
859,KP3,37460715,FSIP1 expression#correlates with#CDK4/6 inhibitor suitability,Biomarker Analysis,FSIP1,-,TNBC,CDK4/6 inhibitors,-,-,-,high,-,-,-,Inference,7,7.1,7.1.1,7.1.1.1,7.1.1.1.3,ESR1突变
3825,KP3,32523378,"CDK4/6 inhibitors#improve#prognosis of HR-positive, HER2-negative ABC/mBC patients",Therapeutic Response,"CDK4,CDK6",-,"HR-positive, HER2-negative advanced or metastatic breast cancer","CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1872,KP3,39199640,"CDK4/6 inhibitors#are approved for#HER2-negative, HR-positive breast cancer treatment",Clinical Implementation,"CDK4,CDK6",-,"HER2-negative, HR-positive breast cancer",CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4743,KP3,33144339,PI3K and CDK4/6 inhibitors#are approved to treat#advanced breast cancer,Drug Development,"CDK4,CDK6,PIK3CA",-,Advanced breast cancer,"PI3K inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
3139,KP3,33144339,PI3K pathway#is implicated in#CDK4/6 resistance,Cancer Pathways,"PIK3CA,CDK4,CDK6",-,Breast cancer,"PI3K inhibitors, CDK4/6 inhibitors",PI3K,-,-,-,-,-,-,Inference,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
5339,KP3,28566333,PD0332991 (palbociclib)#was approved for#treatment of advanced ER-positive breast tumors,Drug Development,"CDK4,CDK6",-,ER-positive breast tumors,PD0332991 (palbociclib),-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
6896,KP3,28566333,Gene expression signature#identifies#tumors unlikely to respond to CDK4/6 inhibitors,Biomarker Analysis,"CDK4,CDK6",-,"HER2-positive, basal-like tumors",CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.4,PIK3CA突变
2347,KP3,34631586,"PI3K, FGFR, and CDK#play critical roles in#cancer",Cancer Pathways,"PIK3CA,FGFR,CDK4,CDK6",-,Cancer,PI3K inhibitors,-,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
1442,KP3,36176758,"CDK4/6 inhibitors with endocrine therapy#transform#treatment of ER-positive, HER2-negative metastatic breast cancer",Therapeutic Response,"CDK4,CDK6",-,"ER-positive, HER2-negative metastatic breast cancer","CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
386,KP3,35082402,Oncogenic RAS mutations#are detected in#50% of de novo and 70% of relapsed MM patients,Molecular Event triples,RAS,-,Multiple myeloma,-,-,-,"de novo, relapsed",-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
4352,KP3,35082402,Erk1/2 and CDK4/6 inhibitors#show#high potency in metastatic relapsed cancers,Therapeutic Response,"CDK4,CDK6,MAPK1,MAPK3",-,Metastatic relapsed cancers,"Erk1/2 inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
850,KP3,35082402,Erk1/2i-CDK4/6i combination#targets#Ras+CDK pathways in MM,Combination Therapies,"CDK4,CDK6,MAPK1,MAPK3,RAS",-,Multiple myeloma,"Erk1/2 inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Inference,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
2662,KP3,35786092,"CDK4/6 inhibitors#achieve#clinical success in HR-positive, HER2-negative metastatic breast cancer",Therapeutic Response,"CDK4,CDK6",-,"HR-positive, HER2-negative metastatic breast cancer",CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
6597,KP3,37865915,Drug resistance#limits#long-term efficacy of CDK4/6 inhibitors,Therapeutic Resistance,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,2,2.5,2.5.2,2.5.2.4,-,生物标志物指导
2295,KP3,26649278,PD0332991#a specific CDK4/6 inhibitor#obtained accelerated FDA approval for ER-positive and HER2-negative advanced breast cancer,Regulatory Documentation,"CDK4,CDK6",-,Advanced breast cancer,PD0332991,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3141,KP3,37779425,CDK4/6 inhibitors#have transformed#treatment landscape of HR-positive breast cancers,Therapeutic Development,"CDK4,CDK6",-,Hormone receptor-positive breast cancers,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6093,KP3,36978197,Palbociclib#a CDK4/6 inhibitor#regulated fate of active or quiescent ISCs and accelerated gastrointestinal epithelium recovery,Function,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.3,-,凋亡阈值调节
458,KP3,36978197,CDK4/6 inhibitors with chemotherapy#reduce#damage to gastrointestinal epithelium in patients,Combination Therapies,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,3,3.2,3.2.3,3.2.3.2,-,协同增效作用
7396,KP3,34072070,CDK4/6 inhibitors with endocrine therapy#are#standard treatment for HR-positive and HER2-negative metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
568,KP3,33309572,"Development of CDK4/6 inhibitors#represented#a breakthrough in ER-positive, HER2-negative metastatic breast cancer treatment",Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2752,KP3,37801505,LncRNA EILA#promotes#CDK4/6 inhibitor resistance in breast cancer,Mechanism of Action,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.3,2.1.3.3,-,非编码RNA表达变化
2389,KP3,37801505,LncRNA EILA#stabilizes#cyclin E1 protein,Mechanism of Action,CCNE1,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
6619,KP3,37801505,CDK4/6 inhibitors plus endocrine therapy#are#standard first-line therapy for advanced HR(+)/HER2(-) breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR(+)/HER2(-) breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
319,KP3,37801505,Resistance to CDK4/6 inhibitors#develops#over time in HR(+)/HER2(-) breast cancer patients,Therapeutic Resistance,"CDK4,CDK6",-,HR(+)/HER2(-) breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
682,KP3,28418845,"G1T38#a novel, potent and selective inhibitor of#cyclin-dependent kinases 4/6",Drug Development,"CDK4,CDK6",-,CDK4/6-sensitive tumors,G1T38,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1947,KP3,28418845,Inhibition of p16INK4a/cyclin D/CDK4/6/RB pathway#is#an effective therapeutic strategy for ER+ breast cancer,Therapeutic Development,"CDK4,CDK6,RB1,CDKN2A",-,ER+ breast cancer,-,p16INK4a/cyclin D/CDK4/6/RB pathway,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2165,KP3,39457497,HR+/HER2- metastatic breast cancer patients#receive#hormonal therapy combined with CDK4/6 inhibitors,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
2192,KP3,37841752,"FDA-approved drugs palbociclib, ribociclib, and abemaciclib#are used for#hormone receptor-positive metastatic breast cancer in combination with specific endocrine therapies",Drug Development,"CDK4,CDK6",-,Hormone receptor-positive metastatic breast cancer,"Palbociclib,Ribociclib,Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
4321,KP3,30180865,Inhibitors of ubiquitin-proteasome system (UPS)#show#promising results in preclinical studies and MCL patients,Preclinical Models,-,-,MCL,-,Ubiquitin-proteasome system,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
2049,KP3,30180865,Cyclin D1 overexpression and aberrant CDK4 activity#affect#NOXA stabilization and treatment efficacy of UPS inhibitors in MCL,Mechanism of Action,"CDK4,CCND1",-,MCL,-,Ubiquitin-proteasome system,-,-,Upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3459,KP3,30180865,Silencing of autophagy-related genes#was performed using#siRNA and MCL cells were treated with autophagy inhibitors in combination with proteasome and CDK4 inhibition,Preclinical Models,CDK4,-,MCL,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
1499,KP3,30180865,Combined treatment with bortezomib and autophagy inhibitors#enhanced#NOXA stability leading to super-induction of NOXA protein,Combination Therapies,-,-,MCL,Bortezomib,-,-,-,-,-,-,-,Fact,3,3.4,3.4.3,3.4.3.1,-,自噬启动
6727,KP3,39103896,CDK4 and its inhibitors#emerged as#potential agents for ALT/WDLPS and DDLPS,Therapeutic Development,CDK4,-,"ALT/WDLPS,DDLPS",-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2549,KP3,39103896,CDK4 inhibitor palbociclib#showed#antagonistic effect when combined with other chemotherapeutics,Combination Optimization,CDK4,-,"ALT/WDLPS,DDLPS",Palbociclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.2,-,协同增效作用
7158,KP3,39103896,CDK4 inhibitor palbociclib#exhibited#synergy when administered sequentially with lenvatinib,Combination Optimization,CDK4,-,"ALT/WDLPS,DDLPS","Palbociclib,Lenvatinib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.1,-,时序性联合
7592,KP3,15867383,Cooperation between Cdk4 and p27kip1#is observed in#tumor development,Mechanism of Action,"CDK4,CDKN1B",-,Tumor,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6131,KP3,15867383,"Tumor-associated alterations#frequently affect#cyclin-dependent kinases, their regulators, and substrates",Cancer Pathways,"CDK4,CDK6",-,Tumor,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
1883,KP3,15867383,No cooperation#is observed between#Cdk4 R24C and p18INK4c absence in this model,Mechanism of Action,"CDK4,CDKN2C",-,Tumor,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6732,KP3,15867383,Flavopiridol#a wide-spectrum Cdk inhibitor#significantly delays tumor progression,Drug Development,"CDK4,CDK6",-,Tumor,Flavopiridol,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2167,KP3,15867383,Genetically engineered tumor models#are valuable for#evaluating drugs with potential therapeutic benefit in human cancer,Preclinical Models,-,-,Human cancer,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
2038,KP3,31832106,HER2-positive breast cancer#was associated with#an aggressive clinical course and poor survival outcomes,Cancer Association,ERBB2,-,HER2-positive breast cancer,-,-,-,Upregulated,-,-,-,-,Fact,2,2.3,2.3.1,2.3.1.2,-,突变谱特征
392,KP3,31832106,Targeting cyclin-dependent kinases 4/6#is a strategy for#overcoming resistance to HER2-targeted therapies,Therapeutic Resistance,"CDK4,CDK6",-,HER2-positive breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.2,2.5.2.4,-,生物标志物指导
2706,KP3,27429659,Palbociclib#is used in#metastatic luminal breast cancer,Drug Development,"CDK4,CDK6",-,Metastatic luminal breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6556,KP3,27429659,Palbociclib#is combined with#endocrine therapy,Combination Therapies,"CDK4,CDK6",-,Metastatic luminal breast cancer,"Palbociclib, endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
5078,KP3,27493617,Letrozole#is combined with#CDK4/6 inhibitor for advanced breast cancer,Combination Therapies,"CDK4,CDK6",-,Advanced hormone receptor-positive HER2-negative breast cancer,"Letrozole, CDK4/6 inhibitor",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
5184,KP3,27493617,FDA#approved#CDK4/6 inhibitor as first-line treatment,Regulatory Documentation,"CDK4,CDK6",-,Advanced hormone receptor-positive HER2-negative breast cancer,CDK4/6 inhibitor,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
7094,KP3,31375512,Palbociclib#increased#PD-L1 protein levels,Expression Patterns,"CDK4,CDK6",-,Melanoma,Palbociclib,-,-,Upregulated,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.2,-,细胞死亡标志物
7844,KP3,31375512,Palbociclib#enhanced#efficacy in melanoma models,Therapeutic Development,"CDK4,CDK6",C57BL/6-hPD-1 melanoma cells,Melanoma,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4491,KP3,27055371,Palbociclib#is used for#refractory germ cell tumors,Drug Development,"CDK4,CDK6",-,Refractory germ cell tumors,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4089,KP3,27055371,Refractory germ cell tumors#express#retinoblastoma protein,Expression Patterns,-,-,Refractory germ cell tumors,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
1766,KP3,29266182,CDK4/6 inhibitors#target#SMAD3 and CCND1 signaling,Signaling Networks,"CDK4,CDK6,SMAD3,CCND1",-,Antiandrogen-resistant disease,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
631,KP3,29266182,CDK4/6 inhibitors#could provide#new therapeutic options for antiandrogen-resistant disease,Therapeutic Development,"CDK4,CDK6",-,Antiandrogen-resistant disease,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5073,KP3,28704762,Palbociclib#was tested in#MPM cells,Preclinical Models,"CDK4,CDK6",-,Malignant pleural mesothelioma (MPM),Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
875,KP3,32102134,CDK4/6 inhibitors#achieved#good effect in hormone receptor-positive breast cancer,Therapeutic Response,"CDK4,CDK6",-,Hormone receptor-positive breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,G1/S期转换抑制
29,KP3,32102134,CDK4/6 inhibitors#are combined with#endocrine therapy as standard treatment,Combination Therapies,"CDK4,CDK6",-,Hormone receptor-positive breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,-,-,内分泌治疗联合
995,KP3,33300617,CDK4/6 inhibitors#have#off-target landscapes,Mechanism of Action,"CDK4,CDK6",-,-,"Palbociclib, ribociclib, abemaciclib",-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
3711,KP3,38389643,Palbociclib#is combined with#anastrozole for treatment,Combination Therapies,"CDK4,CDK6",-,-,"Palbociclib, anastrozole",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,-,-,内分泌治疗联合
7135,KP3,28629371,Palbociclib#induces#apoptosis in DDLPS cells,Mechanism of Action,CDK4,-,DDLPS,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.3,-,线粒体通路调控
6650,KP3,28629371,Combination regimen#reduced#tumor growth rate,Therapeutic Development,-,-,Tumor,"Palbociclib, RG7388",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5622,KP3,28629371,Combination regimen#increased#progression-free survival,Therapeutic Response,-,-,Tumor,"Palbociclib, RG7388",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4524,KP3,28629371,CDK4 inhibitors#potentiate#MDM2 antagonists in DDLPS,Combination Therapies,CDK4,-,DDLPS,"Palbociclib, RG7388",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5055,KP3,37568211,AML cells#express#CDK4,Expression Patterns,CDK4,AML cells,AML,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.4,-,染色质重塑
4990,KP3,37568211,Palbociclib and abemaciclib#inhibit#AML cellular growth,Therapeutic Response,"CDK4,CDK6",AML cells,AML,"Palbociclib, abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6996,KP3,37568211,CDK4/6 inhibitors#are combined with#FLT3 or pan-PI3K inhibitors for AML,Combination Therapies,"CDK4,CDK6,FLT3,PIK3CA",AML cells,AML,"CDK4/6 inhibitors, FLT3 inhibitors, pan-PI3K inhibitors",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
7636,KP3,39695080,CDK4/6 inhibitors#suppress#Braf(V600E) melanoma growth,Therapeutic Response,"CDK4,CDK6,BRAF",Melanoma cells,Melanoma,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6807,KP3,39695080,CDK4/6 inhibitors#induce#cellular senescence in melanoma,Mechanism of Action,"CDK4,CDK6",Melanoma cells,Melanoma,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.2,-,细胞衰老诱导
2322,KP3,39695080,Senescence#suppresses#cell proliferation,Cell Cycle Control,"CDK4,CDK6",-,Tumor,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
7381,KP3,39695080,Prolonged senescence#leads to#tumor relapse,Cancer Pathways,"CDK4,CDK6",-,Tumor,-,Tumor microenvironment,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
4422,KP3,39695080,Removal of senescent cells#facilitates#clinical response,Therapeutic Resistance,"CDK4,CDK6",-,Tumor,-,-,-,-,-,-,-,-,Inference,2,2.5,2.5.3,2.5.3.4,-,疫苗治疗
7567,KP3,39695080,GLS1 expression#is upregulated in#CDK4/6i-induced senescent Braf(V600E) melanoma cells,Expression Patterns,GLS1,Braf(V600E) melanoma cells,Melanoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.3,1.4.3.2,-,衰老程序激活
5399,KP3,39695080,Senolytic approach#targets#upregulated GLS1 expression,Therapeutic Development,GLS1,-,Melanoma,Vemurafenib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
2112,KP3,39695080,Senolytic approach#is applicable to#vemurafenib-resistant melanoma cells,Therapeutic Resistance,GLS1,-,Melanoma,Vemurafenib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
1032,KP3,39695080,Low-dose vemurafenib#induces#senescence in Braf(V600E) melanoma cells,Therapeutic Response,BRAF,Braf(V600E) melanoma cells,Melanoma,Vemurafenib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
4609,KP3,39695080,Senescence#renders#Braf(V600E) melanoma cells susceptible to GLS1i,Therapeutic Response,"BRAF,GLS1",Braf(V600E) melanoma cells,Melanoma,GLS1i,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
3214,KP3,39695080,Senolytic therapy#may be applicable to#a wide range of cancer types,Therapeutic Development,GLS1,-,Cancer,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
913,KP3,38425459,PI3K and CDK4/6 inhibitors#enhance#efficacy of hormonal therapy,Combination Optimization,"PI3K,CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
3248,KP3,38425459,PI3K and CDK4/6 inhibitors#overcome#resistance to their blockade,Mechanisms of Resistance,"PI3K,CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
6343,KP3,38425459,"Combination of abemaciclib, letrozole, and LY3023414#was evaluated in#recurrent endometrial cancer",Combination Optimization,"CDK4,CDK6",Endometrial cells,Endometrial cancer,"Abemaciclib,Letrozole,LY3023414",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
648,KP3,36728357,CDK4/6 inhibitors#are standard-of-care agents for#HR-positive HER2-negative metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,"Palbociclib,Ribociclib,Abemaciclib",-,-,HR-positive HER2-negative patients,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
964,KP3,31600301,Combining ribociclib and palbociclib#does not enhance#cytotoxicity,Combination Optimization,"CDK4,CDK6",-,Cancer,"Ribociclib,Palbociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4548,KP3,29935901,CDK4/6 inhibitors#impact#treatment of breast cancer,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1585,KP3,29935901,Palbociclib#is the first CDK4/6 inhibitor approved for#breast cancer,Drug Development,"CDK4,CDK6",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2125,KP3,29229752,Ribociclib#prolonged#survival in HR-positive HER2-negative breast cancer,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,Ribociclib,-,-,Premenopausal and perimenopausal women,Prolonged survival,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
272,KP3,28794284,Letrozole#was used to treat#early breast cancers,Therapeutic Development,-,-,Breast cancer,Letrozole,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
1823,KP3,27493616,Palbociclib#is the first CDK4/6 inhibitor in#clinical practice for HR-positive breast cancer,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4647,KP3,27493616,Palbociclib#is the first inhibitor of#CDK4 and CDK6 introduced into clinical practice,Drug Development,"CDK4,CDK6",-,Cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3792,KP3,27493616,Preclinical investigations#led to#clinical development of Palbociclib,Preclinical Models,"CDK4,CDK6",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3031,KP3,33072590,Palbociclib#might improve#efficacy of regorafenib in HCC,Combination Optimization,"CDK4,CDK6",-,Hepatocellular carcinoma,"Palbociclib,Regorafenib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7939,KP3,39812054,CDK4/6 inhibitors combined with endocrine therapy#are used for#HR-positive HER2-negative breast cancer,Combination Optimization,"CDK4,CDK6",-,Breast cancer,"Palbociclib,Ribociclib,Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,联合芳香化酶抑制剂
1928,KP3,39461947,Treatment regimen#consists of#a combination with endocrine therapy,Therapeutic Development,-,-,-,Endocrine therapy,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,-,-,内分泌治疗联合
4576,KP3,37886029,CDK4/6 inhibitors#are combined with#endocrine therapy for metastatic first-line setting,Combination Optimization,"CDK4,CDK6",-,Breast cancer,"Endocrine therapy, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
3187,KP3,35800379,Molecular vulnerabilities#contribute to#therapeutic resistance in HR-positive and HER2-dependent breast cancer,Mechanisms of Resistance,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
6861,KP3,35800379,CDK4/6 inhibitors#are identified as#a potential treatment option for advanced breast cancer,Cancer Association,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3837,KP3,35800379,Resistance mechanisms#are identified in#combination endocrine therapies with CDK4/6 inhibitors,Mechanisms of Resistance,"CDK4,CDK6",-,Breast cancer,"Endocrine therapies, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.3,-,mTOR信号增强
5676,KP3,36575782,CDK4/6 inhibitors#are used as#anti-tumor agents for hormone receptor-positive breast cancer,Cancer Association,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5117,KP3,35530846,"Palbociclib, ribociclib, and abemaciclib#are more efficient when combined with#aromatase inhibitors and fulvestrant",Combination Optimization,-,-,Breast cancer,"Palbociclib, Ribociclib, Abemaciclib, Aromatase inhibitors, Fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,联合芳香化酶抑制剂
1520,KP3,30619511,CDK4/6 inhibitors#improve#progression-free survival in HR-positive/HER2-negative breast cancers,Clinical Trial Data,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
364,KP3,37455486,Palbociclib and abemaciclib#are used in#patients treated with CDK4/6 inhibitors,Drug Development,-,-,-,"Palbociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,细胞周期阻滞
5663,KP3,33826903,CDK4/6 inhibitors#promote#chemokine-mediated recruitment of T cells into mammary tumors,Immune Cell Functions,"CDK4,CDK6",T cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.3,3.3.1,3.3.1.1,-,免疫细胞浸润增加
1501,KP3,33826903,CDK4/6 inhibitors#delay#progression of metastatic breast cancer,Cancer Association,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4986,KP3,33826903,CDK4/6 inhibitors#enhance#efficacy of T cell-based therapies in murine breast cancer models,Combination Optimization,"CDK4, CDK6",T cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,协同抗增殖作用
658,KP3,32506263,Combination of CDK and immune checkpoint inhibitors#is used for#bladder cancer treatment,Combination Optimization,"CDK4, CDK6",-,Bladder cancer,Immune checkpoint inhibitors,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.3,-,联合降雌激素药物
2555,KP3,38778166,Tumor cells#develop#resistance against targeted therapies,Therapeutic Resistance,-,-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
4788,KP3,38778166,"A 61-year-old male patient with metastatic NSCLC#harbors#EGFR exon 19 deletion, PIK3CA mutation, and CDK4 amplification",Patient Characteristics,"EGFR, PIK3CA, CDK4",-,NSCLC,-,-,-,61-year-old male,Amplified,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
817,KP3,38778166,Osimertinib#progressed#disease in 4 months,Therapeutic Response,EGFR,-,Disease progression,Osimertinib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4895,KP3,38778166,Osimertinib with palbociclib#was used for#combined treatment,Combination Therapies,"CDK4, CDK6",-,Disease progression,"Osimertinib, Palbociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5953,KP3,38854937,CDK4/6 inhibitors#reduce#phosphorylation of Rb protein,Mechanism of Action,"CDK4, CDK6, RB1",-,Solid tumors,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
3597,KP3,38854937,CDK4/6 inhibitors#have unclear effects on#Rb-deficient tumors,Therapeutic Response,"CDK4, CDK6, RB1",-,Rb-deficient tumors,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
4023,KP3,38854937,Abemaciclib with LDRT and anti-PD-1 antibody#potentiated#CD8(+) T cell infiltration,Immune Cell Functions,"CDK4, CDK6",-,Tumor growth,Abemaciclib,PD-1,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,6.1.1.1.1,CD8+效应T细胞
5084,KP3,38854937,Abemaciclib with LDRT and anti-PD-1 antibody#inhibited#tumor growth,Therapeutic Response,"CDK4, CDK6",-,Tumor,Abemaciclib,PD-1,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4358,KP3,35187951,CDK4/6 inhibitors with endocrine therapy#improve#progression-free and overall survival,Therapeutic Response,"CDK4, CDK6",-,Metastatic ER-positive breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
4020,KP3,28099935,WDLPS and DDLPS#are characterized by#MDM2/CDK4 amplification,Cancer Association,"CDK4, MDM2",-,"WDLPS, DDLPS",-,-,-,-,Amplified,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
7578,KP3,28099935,Targeted genomic sequencing#identified#novel therapeutic targets,Biomarker Analysis,"CDK4, MDM2",-,"WDLPS, DDLPS",-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.3,-,基因融合
4589,KP3,28099935,Gene amplification events#were identified in#30 samples,Genomic Alterations,"CDK4, MDM2",-,-,-,-,-,-,Amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
1161,KP3,28099935,Simultaneous inhibition of CDK4 and IGF1R#suppressed#growth of WDLPS cell line,Therapeutic Response,"CDK4, IGF1R",-,WDLPS,"Palbociclib, NVP-AEW541",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2412,KP3,28099935,Combination therapy with CDK4 and RTK inhibitors#may be#effective for WDLPS/DDLPS patients,Therapeutic Development,CDK4,-,"WDLPS, DDLPS",-,-,-,-,-,-,-,-,Inference,8,8.2,8.2.2,8.2.2.4,-,多靶点抑制策略
3346,KP3,37995303,CDK4/6 inhibitors#prolong#progression-free survival,Therapeutic Response,"CDK4, CDK6",-,HR(+) metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
247,KP3,34087775,CDK4/6 inhibitors#are used in#advanced HR(+) HER2(-) breast cancer,Therapeutic Development,"CDK4, CDK6",-,HR(+) HER2(-) breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3559,KP3,30745839,Androgen receptor blockade#overcomes#resistance to palbociclib,Therapeutic Resistance,"CDK4, CDK6",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.4,-,生物标志物指导
5861,KP3,30745839,CDK4/6 inhibitors#show#effective activity in advanced breast cancer,Therapeutic Response,"CDK4, CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2178,KP3,30745839,Prolonged exposure to palbociclib#detected#loss of ER signaling,Therapeutic Resistance,"CDK4, CDK6",-,Breast cancer,Palbociclib,-,-,-,Loss,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
1504,KP3,36070391,CDK4/6 inhibitors#are#standard treatments for metastatic ER(+) breast cancer,Clinical Implementation,"CDK4, CDK6",-,Metastatic ER(+) breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
531,KP3,32614252,"MTOR inhibitors#are suggested for#post-CDK4/6 inhibitor HR+, HER2- breast cancer",Therapeutic Development,"CDK4, CDK6, MTOR",-,"HR+, HER2- breast cancer",MTOR,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
6104,KP3,36373891,CDK4/6 inhibitors#are#standard treatment for advanced HR(+) breast cancer,Clinical Implementation,"CDK4, CDK6",-,Advanced HR(+) breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1993,KP3,37131684,CDK4/6 pathway alterations#led to#clinical trials of palbociclib,Clinical Trial Data,"CDK4, CDK6",-,Acral lentiginous melanoma,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,-,生物标志物监测
1539,KP3,37131684,CDK4/6 inhibitors#showed#median progression-free survival of 2.2 months,Therapeutic Response,"CDK4, CDK6",-,Acral lentiginous melanoma,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
2310,KP3,34592265,Combination of CDK4/6 inhibitors and anti-PD-1 treatment#markedly suppressed#tumor growth,Combination Therapies triples,"CDK4, CDK6",-,Tumor,"Abemaciclib, Palbociclib, anti-PD-1",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
5007,KP3,29306194,Cyclin-dependent kinases#are#a therapeutic target for cancer treatment,Cancer Association triples,"CDK4, CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3922,KP3,29306194,CDK4/6 inhibitors#caused#cell cycle arrest in the G1 phase,Cell Cycle Control triples,"CDK4, CDK6",Non-small lung cancer cells,Non-small lung cancer,"Ribociclib, Palbociclib",-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6653,KP3,29306194,CDK4/6 inhibitors#suppressed#PARP1 transcription,Regulation triples,"CDK4, CDK6, PARP1",Non-small lung cancer cells,Non-small lung cancer,"Ribociclib, Palbociclib",-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.3,-,抑制复合物
7794,KP3,33941591,Palbociclib or Abemaciclib#were used to treat#breast cancer patients,Clinical Implementation triples,"CDK4, CDK6",CD8(+) T cells,Breast cancer,"Palbociclib, Abemaciclib",-,-,Breast cancer patients,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1682,KP3,33356791,Palbociclib#is approved for#treatment of advanced ER+ breast cancer,Clinical Implementation triples,"CDK4, CDK6",-,Advanced ER+ breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1412,KP3,39732370,Self-assembled natural triterpenoids#enhance#delivery of CDK4/6 inhibitors,Drug Delivery Innovation triples,"CDK4, CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.6,3.6.1,3.6.1.2,-,靶向配体修饰
1565,KP3,39732370,Palbociclib#is an ideal candidate for#fabricating a highly efficient ICD inducer for TNBC chemoimmunotherapy,Therapeutic Development triples,"CDK4, CDK6",-,TNBC,Palbociclib,-,-,-,-,-,-,-,Inference,3,3.3,3.3.2,3.3.2.3,-,免疫逃逸抑制
1730,KP3,36291780,"FCN-437c#was evaluated for#safety, tolerability, and MTD/RP2D in advanced/metastatic solid tumors",Clinical Trial Data triples,"CDK4, CDK6",-,Advanced/metastatic solid tumors,FCN-437c,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,-,生物标志物监测
1516,KP3,25494820,Cyclin-dependent kinases#play a role in#pathogenesis of MM,Cancer Pathways triples,"CDK4, CDK6",-,MM,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
4203,KP3,25494820,PD0332991#enhances#cytotoxic effect of other agents in MM,Combination Therapies triples,"CDK4, CDK6",-,MM,"PD0332991, Bortezomib, Lenalidomide",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
3478,KP3,30898650,PARP inhibitors and CDK4/6 inhibitors#have shown#promising clinical benefits,Clinical Trial Data triples,"CDK4, CDK6, PARP1",-,Cancer,"PARP inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,-,生物标志物监测
163,KP3,30898650,Biomarkers#are required for#predictive treatment response in combination drug development,Biomarker Analysis triples,-,-,Cancer,-,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.1,-,基因突变
6217,KP3,30898650,Olaparib and Palbociclib#were examined in#ovarian cancer cell lines,Preclinical Models triples,"CDK4,CDK6,PARP1",Ovarian cancer cells,Ovarian cancer,"Olaparib, Palbociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
4033,KP3,30898650,Palbociclib#induces#HR deficiency through downregulation of MYC-regulated HR pathway genes,Mechanism of Action triples,"CDK4,CDK6,MYC",-,Cancer,Palbociclib,HR,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
3521,KP3,30898650,MYC expression#determines#sensitivity to combinatorial treatment with Olaparib and Palbociclib,Biomarker Analysis triples,MYC,Ovarian cancer cells,Ovarian cancer,"Olaparib, Palbociclib",-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.1,-,基因突变
3300,KP3,30898650,High MYC expression#provides rationale for#clinical evaluation of therapeutic synergy of PARP and CDK4/6 inhibitors,Clinical Implementation triples,"MYC,CDK4,CDK6,PARP1",-,Ovarian cancer,"Olaparib, Palbociclib",-,-,-,-,-,-,-,Inference,8,8.2,8.2.2,8.2.2.1,-,PI3K抑制剂协同
891,KP3,36817127,"Palbociclib#is approved for#ER-positive, HER2-negative breast cancer in combination with fulvestrant",Clinical Implementation triples,"CDK4,CDK6,ERBB2",-,"ER-positive, HER2-negative breast cancer","Palbociclib, Fulvestrant",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
4274,KP3,28814434,Single-agent CDK4/6 inhibitors#failed to provide#durable responses in GBM,Therapeutic Resistance triples,"CDK4,CDK6",-,GBM,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
4785,KP3,28814434,Combination of CDK4/6 and mTOR inhibition#suppresses#activity of downstream mediators of the mTOR pathway,Combination Therapies triples,"CDK4,CDK6,MTOR",Primary GBM cell lines,GBM,"Palbociclib, Everolimus",MTOR,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7781,KP3,28814434,Everolimus#increases#brain concentration of palbociclib,Drug Development,"CDK4,CDK6",-,Brain cancers,"Everolimus, Palbociclib",mTOR,-,-,upregulated,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
3636,KP3,28814434,Combination of CDK4/6 and mTOR inhibition#has#therapeutic potential against GBM,Therapeutic Development,"CDK4,CDK6",-,GBM,"Everolimus, Palbociclib",mTOR,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
1612,KP3,39548257,CDK4/6 inhibitors#have#acute protective effects in AKI,Therapeutic Development,"CDK4,CDK6",-,Acute kidney injury (AKI),CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5025,KP3,39548257,Palbociclib#examines#long-term effects of CDK4/6 inhibition in ischemic AKI,Preclinical Models,"CDK4,CDK6",-,Ischemic acute kidney injury (AKI),Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4541,KP3,37369022,CDK4/6 inhibitors#improve#progression-free survival in HR+ advanced or metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,Hormone receptor-positive advanced or metastatic breast cancer,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3901,KP3,37369022,Ribociclib and Abemaciclib#improve#overall survival in HR+ advanced or metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,Hormone receptor-positive advanced or metastatic breast cancer,"Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2831,KP3,37502925,CDK4/6 inhibitors#improve#survival of ER+ breast cancer patients,Therapeutic Response,"CDK4,CDK6",-,Estrogen receptor-positive (ER+) breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5228,KP3,37502925,Patients treated with CDK4/6 inhibitors#develop#drug resistance,Therapeutic Resistance,"CDK4,CDK6",-,Estrogen receptor-positive (ER+) breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
326,KP3,37502925,Pemrametostat and fulvestrant#synergistically inhibit#growth of ER+/RB-deficient breast cancer xenografts,Combination Therapies,"CDK4,CDK6",RB-deficient cells,ER+/RB-deficient breast cancer,"Pemrametostat, Fulvestrant",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
4858,KP3,33353034,CDK4/6 inhibitors#are used among#cancer patients in MRONJ cohort,Clinical Implementation,"CDK4,CDK6",-,Cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
3383,KP3,38883740,Combined ribociclib and everolimus treatment#was investigated in#a clinical trial for recurrent high-grade glioma,Clinical Trial Data,"CDK4,CDK6",-,Recurrent high-grade glioma,"Ribociclib, Everolimus",mTOR,-,-,-,-,-,-,Fact,8,8.2,8.2.2,8.2.2.2,-,mTOR抑制剂联用
7552,KP3,38883740,Neoadjuvant ribociclib and everolimus treatment#showed#no dose-limiting toxicities,Safety Monitoring,"CDK4,CDK6",-,Recurrent high-grade glioma,"Ribociclib, Everolimus",-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.3,-,剂量调整
1642,KP3,38883740,IDH-wild-type recurrences#showed#a lower fraction of cycling and NPC-like malignant cells,Cell Type-Specific Categories,"CDK4,CDK6",Neural progenitor-like (NPC-like) cells,Recurrent glioma,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
7816,KP3,36797347,Endocrine therapy plus CDK4/6 inhibition#is used as#first-line treatment for HR+/HER2- metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
475,KP3,36797347,A protein/phosphoprotein-based approach#identified#predictive markers of response to ET plus CDK4/6 inhibition,Biomarker Analysis,"CDK4,CDK6",-,HR+/HER2- metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,RB1突变
6214,KP3,36797347,Functional protein-based signaling analyses#may become#critical for response prediction in MBC patients,Biomarker Analysis,"CDK4,CDK6",-,Metastatic breast cancer (MBC),-,-,-,-,-,-,-,-,Inference,7,7.3,7.3.1,7.3.1.1,7.3.1.1.1,Ki67指数
7415,KP3,34725098,CDK4/6 inhibitors#are used with#antiestrogen therapy for HR+/HER2- advanced breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,8.2.1.2.2,他莫昔芬
1004,KP3,33599863,Management of TNBC#remains#a significant clinical challenge,Disease-Specific Categories,-,-,Triple-negative breast cancer (TNBC),-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
2136,KP3,33599863,CDK4/6 inhibitors#are emerging as#therapeutic agents against TNBC,Therapeutic Development,"CDK4,CDK6",-,Triple-negative breast cancer (TNBC),CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2462,KP3,33599863,Cells#can acquire#resistance to CDK4/6 inhibitors,Therapeutic Resistance,"CDK4,CDK6",-,Triple-negative breast cancer (TNBC),CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
1954,KP3,33599863,Determining resistance mechanisms to CDK4/6 inhibition#is crucial to#develop combination therapies,Therapeutic Resistance,"CDK4,CDK6",-,Triple-negative breast cancer (TNBC),CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
3482,KP3,33599863,Lipid metabolic rewiring#may be exploited to#overcome therapy resistance in TNBC,Metabolic Integration,"CDK4,CDK6",-,Triple-negative breast cancer (TNBC),-,-,-,-,-,-,-,-,Inference,4,4.4,4.4.1,4.4.1.2,-,脂肪酸氧化
6820,KP3,33330073,Triple negative breast cancer (TNBC)#is characterized by#lack of expression of estrogen and progesterone receptors and HER2,Disease Mechanism,ERBB2,-,Triple negative breast cancer,-,-,-,-,silenced,-,-,-,Fact,2,2.2,2.2.2,2.2.2.4,-,周期素表达失衡
7232,KP3,37186799,Combination of CDK4/6 inhibitor and endocrine therapy#improves#progression-free survival and overall survival in HR+/HER2- breast cancer patients,Therapeutic Response,"CDK4,CDK6",-,HR+/HER2- breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,"hormone receptor-positive, HER2-negative",-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
2788,KP3,35906806,"Cyclin-dependent kinase 4/6 inhibitors, endocrine monotherapy, chemotherapy, or other anti-cancer therapy#affect#productivity measured by work absence and disability claims",Economic & Access,"CDK4,CDK6",-,-,"CDK4/6 inhibitors, endocrine monotherapy, chemotherapy, other anti-cancer therapy",-,-,-,-,-,-,-,Fact,-,8,8.3,8.3.1,8.3.1.2,8.3.1.2.1
5751,KP3,33803309,Inhibition of CDK4 and CDK6#plays a role in#aromatase inhibitor-resistant metastatic breast cancer,Therapeutic Resistance,"CDK4,CDK6",-,Aromatase inhibitor-resistant metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.3,-,mTOR信号增强
3062,KP3,36949066,Combination of an endocrine agent with a CDK4/6 inhibitor#is the standard of care for#HR+/HER2- metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- metastatic breast cancer,"CDK4/6 inhibitors, endocrine agents",-,-,"hormone receptor-positive, HER2-negative",-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
5422,KP3,31020219,CDK4 inhibitors#are better tolerated than#chemotherapy options,Drug Development,CDK4,-,-,CDK4 inhibitors,-,-,-,-,-,-,-,Fact,-,8,8.4,8.4.1,8.4.1.3,8.4.1.3.3
561,KP3,25177151,Combination with letrozole#prolongs#progression-free survival in estrogen receptor-positive metastatic breast cancer,Therapeutic Response,ESR1,-,Estrogen receptor-positive metastatic breast cancer,Letrozole,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,3.2.1.1.1,来曲唑联合治疗方案
2867,KP3,36980794,Stromal senescence following palbociclib treatment#alters#lung metastatic niche and increases metastasis of drug-resistant mammary cancer cells,Tumor Microenvironment,"CDK4, CDK6",-,Drug-resistant mammary cancer,Palbociclib,-,-,-,-,-,-,-,Fact,6,6.6,6.6.1,6.6.1.1,6.6.1.1.4,氧浓度维持
3414,KP3,36980794,CDK4/6 inhibitors#improve#disease control in HR+/HER2- metastatic breast cancer,Therapeutic Response,"CDK4, CDK6",-,HR+/HER2- metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,3.1.1.1.4,增殖信号阻断
2146,KP3,38861295,Aromatase inhibitor monotherapy#correlates with#anticipated treatment compliance,Clinical Implementation,-,-,-,Aromatase inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,8.1.1.3.4,耐受性评估
7608,KP3,22049316,ER-positive breast cancers#become#estrogen-independent and recur,Disease Mechanism,ESR1,-,ER-positive breast cancer,-,-,-,-,-,-,-,-,Inference,1,1.4,1.4.3,1.4.3.1,1.4.3.1.1,存活信号调控
6500,KP3,22049316,CDK4#is required for#estrogen-independent cell growth,Mechanism of Action,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.1,1.4.1.1.1,增殖信号整合
4897,KP3,22049316,Fulvestrant combined with BKM120#induces#regression of ER+ xenografts,Combination Therapies,ESR1,-,ER+ xenografts,"Fulvestrant, BKM120",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,3.2.2.3.1,MEK抑制剂组合
6411,KP3,33990344,Short-term CDK4/6 inhibitor priming#promotes#long-term antitumor T-cell immunity and persistence of CAR T cells,Immune Cell Functions,"CDK4, CDK6",T cells,Melanoma,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.3,3.3.1,3.3.1.2,3.3.1.2.1,抗原提呈增强
1284,KP3,38480701,PRMT5 inhibitor pemrametostat and fulvestrant#synergistically inhibit#growth of ER+/RB-deficient xenografts,Combination Therapies,"ESR1, PRMT5",RB-deficient cells,ER+/RB-deficient xenografts,"Pemrametostat, Fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,3.2.2.3.1,MEK抑制剂组合
5917,KP3,38385117,CDK4/6 inhibitors#prolong#progression-free survival in advanced breast cancer patients when combined with endocrine therapy,Therapeutic Response,"CDK4, CDK6",-,Advanced breast cancer,"Palbociclib, Ribociclib, Abemaciclib",Endocrine therapy,-,Advanced breast cancer patients,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,3.2.1.4.1,耐药机制克服
4386,KP3,30647837,Aberrant activation of CDK4/6 kinase#is the most common#somatic event in non-small cell lung cancer,Cancer Association,"CDK4, CDK6",-,Non-small cell lung cancer,-,-,-,-,Upregulated,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,2.1.2.2.1,MAPK通路激活
3008,KP3,30647837,Palbociclib#inhibits#cell cycle progression and promotes cellular senescence,Mechanism of Action,"CDK4, CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,3.1.1.1.1,G1/S期转换抑制
1663,KP3,26857361,Palbociclib#validates#CDK4/6 as a potential target in estrogen receptor-positive breast cancers,Therapeutic Development,"CDK4, CDK6",-,Estrogen receptor-positive breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,3.1.1.1.1,G1/S期转换抑制
5969,KP3,29261702,Palbociclib#is approved for#metastatic estrogen receptor-positive and HER2-negative breast cancer,Clinical Implementation,"CDK4, CDK6",-,"Metastatic ER-positive, HER2-negative breast cancer",Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5107,KP3,38817360,CDK4/6 inhibitors#are recommended for#HR+/HER2- metastatic breast cancer in combination with endocrine therapy,Clinical Implementation,"CDK4, CDK6",-,HR+/HER2- metastatic breast cancer,"Palbociclib, Ribociclib, Abemaciclib",Endocrine therapy,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,联合芳香化酶抑制剂
6523,KP3,37524106,Cyclin-dependent kinase 4/6 inhibitors#are used for#hormone receptor-positive and HER2-negative metastatic breast cancer,Clinical Implementation,"CDK4, CDK6",-,HR+/HER2- metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4038,KP3,38277141,CDK4/6 inhibitors#show activity against#KRAS-mutant non-small cell lung cancer,Therapeutic Response,"CDK4, CDK6",-,KRAS-mutant NSCLC,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,3.1.1.1.1,G1/S期转换抑制
6414,KP3,28978559,"FDA#approves#abemaciclib for ER+, HER2- breast cancer",Regulatory Documentation,"CDK4, CDK6",-,"ER+, HER2- breast cancer",Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
2386,KP3,28978559,"FDA#approves#abemaciclib for advanced or metastatic ER-positive, HER2-negative breast cancer after progression on endocrine therapy",Regulatory Documentation,"CDK4,CDK6",-,"Advanced/metastatic ER+, HER2- breast cancer",Abemaciclib,Endocrine therapy,-,Progressed on endocrine therapy,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5694,KP3,28978559,Abemaciclib#is the third#CDK4/6 inhibitor approved in 2.5 years,Regulatory Documentation,"CDK4,CDK6",-,-,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3595,KP3,35941421,"Patients#were stratified into#five groups based on cancer treatment, including CDK4/6 inhibitors",Patient Stratification,"CDK4,CDK6",-,Cancer,-,-,-,Cancer treatment stratified,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
2677,KP3,34937317,Patients with resistant or relapsed B- and T-cell ALL#fare poorly#despite outcome improvements,Disease Prognosis,-,"B-ALL,T-ALL","Resistant or relapsed B-ALL, T-ALL",-,-,-,Resistant or relapsed,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
4691,KP3,34937317,Palbociclib and ribociclib#were evaluated in#B- and T-ALL as single agents and in combination with chemotherapy,Preclinical Models,"CDK4,CDK6",-,"B-ALL,T-ALL","Palbociclib,Ribociclib",Chemotherapy,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.1,-,时序性联合
7339,KP3,34937317,Simultaneous treatment of CDKi with chemotherapy#led to#improved efficacy compared to monotherapy,Combination Optimization,"CDK4,CDK6",-,-,"Palbociclib,Ribociclib",Chemotherapy,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.2,-,协同增效作用
6345,KP3,36118250,"Variations in tumor markers (CEA, CA15.3)#play#prognostic roles in metastatic breast cancer treated with CDK4/6 inhibitors",Biomarker Analysis,"CDK4,CDK6",-,Metastatic breast cancer,-,-,"CEA,CA15.3",-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.3,-,免疫标志物
2101,KP3,36901954,Alpelisib and capivasertib#are approved in combination with#fulvestrant for ER+ advanced breast cancer after progression on aromatase inhibitor,Drug Development,-,-,ER+ advanced breast cancer,"Alpelisib,Capivasertib,Fulvestrant",Aromatase inhibitor,-,Progressed on aromatase inhibitor,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
3626,KP3,31451564,CDK4/6 inhibition#has#short- and long-term effects on early-stage breast cancer,Therapeutic Response,"CDK4,CDK6",-,Early-stage breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5363,KP3,31451564,CDK4/6 inhibitors#are used for#advanced estrogen receptor-positive breast cancer,Clinical Implementation,"CDK4,CDK6",-,Advanced ER+ breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1107,KP3,31451564,Efficacy of CDK4/6 inhibitors#is under investigation in#ER(-) and early-stage breast cancer,Clinical Trial Data,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5544,KP3,31451564,Cell cycle and senescence genes#are repressed during#treatment,Expression Patterns,"CDK4,CDK6",-,Cancer,-,"Cell cycle, Senescence",-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.2,-,细胞衰老诱导
2168,KP3,31451564,MUC16#is repressed during#treatment,Expression Patterns,MUC16,-,Ovarian cancer,-,-,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
118,KP3,38082107,CDK4/6 inhibition in combination with endocrine therapy#is the standard-of-care treatment for#HR(+)HER2(-) advanced-stage breast cancer,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6311,KP3,27106898,Standalone single agents targeting cell cycle regulation#demonstrated#modest efficacy in unselected patients,Therapeutic Development,"CDK4,CDK6",-,Cancer,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
6967,KP3,27106898,Specific CDK4/6 inhibitors#target#the G1-S transition,Mechanism of Action,"CDK4,CDK6",-,-,-,G1-S transition,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,G1/S期转换调控
302,KP3,27106898,Specific CDK4/6 inhibitors#have#an improved therapeutic index,Drug Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1356,KP3,27106898,CDK4/6 inhibitors#show#potential synergy with therapies targeting the MAPK pathway,Combination Optimization,"CDK4,CDK6",-,Metastatic melanoma,CDK4/6 inhibitors,MAPK,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
7971,KP3,27106898,CDK4/6 inhibitors#are effective in#NRAS and BRAF mutant metastatic melanomas,Cancer Association,"CDK4,CDK6,NRAS,BRAF",-,Metastatic melanoma,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
618,KP3,30167331,CDK4/6 inhibitors#are used in#the treatment of breast cancer,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3956,KP3,30167331,"Palbociclib, ribociclib, and abemaciclib#are used in#treatment of metastatic and early-stage breast cancer",Clinical Implementation,"CDK4,CDK6",-,Breast cancer,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5391,KP3,29527939,"Aromatase inhibitor#associates with#ribociclib, palbociclib, and abemaciclib in efficacy",Combination Therapies,"CDK4,CDK6",-,Breast cancer,"Ribociclib, Palbociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
5855,KP3,39006687,CDK4/6 inhibitors#are essential for#managing HR(+)HER2(-) advanced or metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1021,KP3,38067367,"CDK4/6, CYP17 lyase, and PI3K/AKT pathway#are prevalent biomarkers in#combination therapy with AR inhibitors",Biomarker Analysis,"CDK4,CDK6,CYP17A1,PIK3CA,AKT1",-,Cancer,-,PI3K/AKT,-,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.3,-,代谢标志物
6833,KP3,38067367,AR#is unsuccessful as#the sole drug target for TNBC,Mechanism of Action,AR,-,Triple-negative breast cancer (TNBC),-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
6204,KP3,38067367,Analyzing clinical benefit rate (CBR)#is imperative for#improving treatment options and prognoses,Clinical Trial Data,-,-,Cancer,-,-,-,-,-,-,-,-,Inference,8,8.5,8.5.1,8.5.1.3,-,临床评估
2176,KP3,37068524,Estrogen Receptor#is the driving transcription factor in#75% of all breast cancers,Molecular Event triples,ESR1,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
5669,KP3,37068524,ESR1 point mutations#are identified in#metastatic tumors and ctDNA from ER-positive breast cancer patients,Biomarker Analysis,ESR1,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.3,ESR1突变
3884,KP3,37068524,Endocrine therapy and CDK4/6 inhibitor therapy#demonstrate#preclinical and clinical benefits for breast cancer,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
5606,KP3,37068524,Resistance#remains#a significant challenge in advanced breast cancer,Therapeutic Resistance,-,-,Breast cancer,-,-,-,-,-,-,-,-,Inference,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
2637,KP3,32947780,"Treatments#include#surgery, chemotherapy, radiotherapy, or endocrine therapy",Clinical Implementation,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,治疗线别
6318,KP3,32947780,Gene-expression signatures#are used to#evaluate chemotherapy regimen benefit,Biomarker Analysis,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.1,-,基因表达谱
4566,KP3,32947780,Chemotherapies#can be avoided or used#only combined with other treatments,Therapeutic Optimization,-,-,Cancer,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.3,3.2.3.4,-,耐药预防
5848,KP3,32947780,molecules#can be used with#chemotherapeutic drugs to improve treatment outcomes,Combination Therapies,"CDK4,CDK6",-,-,chemotherapeutic drugs,-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.2,-,协同增效作用
2228,KP3,32947780,"therapeutic molecules#include#tyrosine kinase inhibitors, CDK4/6 inhibitors, monoclonal antibodies",Therapeutic Development,"CDK4,CDK6",-,-,"tyrosine kinase inhibitors, CDK4/6 inhibitors, monoclonal antibodies",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7049,KP3,32947780,substitution treatments#can contribute to#personalized medicine,Personalized Medicine,-,-,-,-,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.3,-,患者选择
1002,KP3,36698435,68-year-old patient with ICC metastasis#achieved#partial response with palbociclib,Therapeutic Response,"CDK4,CDK6",-,ICC metastasis,palbociclib,-,-,68-year-old,upregulated,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
3266,KP3,38046373,CDK4/6 inhibitors#improved#management of HR+ and HER2- advanced breast cancer,Therapeutic Development,"CDK4,CDK6",-,"HR+ breast cancer, HER2- breast cancer",ribociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
7293,KP3,32876928,CDK4/6 inhibitors#are used in#front-line setting for HR+ HER2- breast cancer,Clinical Implementation,"CDK4,CDK6",-,"HR+ breast cancer, HER2- breast cancer",CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5268,KP3,34906954,elacestrant#improved#progression-free survival in ER+ HER2- breast cancer patients,Therapeutic Response,"CDK4,CDK6",-,"ER+ breast cancer, HER2- breast cancer",elacestrant,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3795,KP3,33939324,CDK4/6 inhibitors#demonstrated#anti-tumor effects,Therapeutic Development,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1440,KP3,33472910,CDKN2A/B alterations#upregulate#CDK4/6,Regulation,"CDK4,CDK6,CDKN2A,CDKN2B",-,-,"palbociclib, trametinib",MEK,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
4939,KP3,33472910,patients with pancreatic cancer#achieved#partial remission with palbociclib and trametinib,Therapeutic Response,"CDK4,CDK6",-,pancreatic cancer,"palbociclib, trametinib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
2560,KP3,30692638,ribociclib and abemaciclib#present#lysosomal trapping behavior like palbociclib,Mechanism of Action,"CDK4,CDK6",-,-,"ribociclib, abemaciclib, palbociclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5790,KP3,33213401,resistance#develops to#CDK4/6 inhibitors in HR+ HER2- breast cancer,Therapeutic Resistance,"CDK4,CDK6",-,"HR+ breast cancer, HER2- breast cancer",ribociclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
544,KP3,38870830,CDK4/6 inhibitors#are combined with#AIs or SERDs for advanced ER+ breast cancer,Combination Therapies,"CDK4,CDK6",-,ER+ breast cancer,"aromatase inhibitors (AIs), SERDs",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
3818,KP3,28939653,CDK4/6 inhibitor#improved#progression-free survival with letrozole,Combination Therapies,"CDK4,CDK6",-,-,letrozole,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
3841,KP3,38066089,CDK4/6 pathway gene alterations#are identified in#>60% of ALMs,Expression Patterns,"CDK4,CDK6",-,ALM,palbociclib,CDK4/6,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,RB1突变
7883,KP3,33917020,thromboembolic events#are associated with#CDK4/6 inhibitors,Safety Monitoring,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,thromboembolic events,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.4,感染风险
1510,KP3,33917020,thromboembolic events#are analyzed in#FDA adverse event reporting system,Safety Monitoring,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,thromboembolic events,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.4,感染风险
2385,KP3,33917020,VTE reporting#increased for#CDK4/6 inhibitors,Safety Monitoring,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,VTE,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.4,感染风险
6112,KP3,33917020,oncologists#should monitor#VTE occurrence with CDK4/6 inhibitors,Safety Monitoring,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,VTE,-,-,-,-,-,Inference,8,8.4,8.4.1,8.4.1.1,8.4.1.1.4,感染风险
418,KP3,32626773,ribociclib#is approved for#breast cancer treatment,Clinical Implementation,"CDK4,CDK6",-,breast cancer,ribociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
7652,KP3,26390342,Several selective CDK4/6 inhibitors#are in clinical trials for#non-small cell lung cancer,Clinical Trial Data,"CDK4,CDK6",-,Non-small cell lung cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
7852,KP3,26390342,CDK9#is observed as#a potent target of both drugs,Mechanism of Action,CDK9,-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3640,KP3,26390342,Palbociclib#interacted with#casein kinase 2 and PIK3R4,Interaction triples,PIK3R4,-,-,Palbociclib,-,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
4331,KP3,26123925,Palbociclib#is approved for#breast cancer treatment,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5874,KP3,36087253,PD-0332991#inhibits#tumor growth by suppressing Rb phosphorylation,Mechanism of Action,"CDK4,CDK6",Rb,-,PD-0332991,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
2126,KP3,36087253,PD-0332991#is commonly used in combination with#other drugs,Combination Therapies,"CDK4,CDK6",-,-,PD-0332991,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,-,-,靶向药物联合
2606,KP3,36087253,Combination treatments#inhibit#tumor proliferation more effectively,Combination Therapies,"CDK4,CDK6",-,Tumor,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,-,-,靶向药物联合
5012,KP3,32582803,Abemaciclib#induces#cytotoxicity in human anaplastic thyroid carcinoma cells,Mechanism of Action,"CDK4,CDK6",Human anaplastic thyroid carcinoma cells,Thyroid cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,-,-,细胞凋亡调控
4103,KP3,32582803,Patients#develop#resistance to therapeutic agents and tumor relapse,Therapeutic Resistance,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,-,-,多药耐药
4259,KP3,37189701,Visceral crisis#requires#urgent treatment,Clinical Implementation,-,-,Visceral crisis,-,-,Life-threatening condition,-,-,-,-,-,Fact,8,8.1,8.1.1,-,-,适应症选择
2002,KP3,37189701,International guidelines#recommend#combined chemotherapy as first-line treatment for visceral crisis,Clinical Implementation,-,-,Visceral crisis,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,-,-,内分泌治疗联合
9,KP3,37189701,CDK4/6 inhibitors#question#the role of chemotherapy in visceral crisis,Therapeutic Development,"CDK4,CDK6",-,Visceral crisis,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,细胞周期阻滞
7170,KP3,28226315,Ribociclib#demonstrates#antitumoral efficacy in neuroendocrine tumors in vitro,Preclinical Models,"CDK4,CDK6",-,Neuroendocrine tumors,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,细胞周期阻滞
19,KP3,31709901,Bi-allelic CDKN2A mutation or homozygous deletion#is#a rare event,Genetic Alterations,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,-,-,点突变
7847,KP3,31709901,Initial trials with palbociclib#showed#modest benefit in serous ovarian cancer,Clinical Trial Data,"CDK4,CDK6",-,Serous ovarian cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,-,-,适应症选择
6633,KP3,31709901,homozygous deletion of CDKN2A#is associated with#prolonged clinical benefit from CDK4/6 inhibitors,Cancer Association,CDKN2A,-,Serous ovarian tumor,"Palbociclib, Letrozole",-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,-,-,基因突变
7119,KP3,31709901,homozygous deletion of CDKN2A#could predict#response to CDK4/6 inhibitors,Prognostic markers,CDKN2A,-,-,-,-,-,-,-,-,-,-,Inference,7,7.2,7.2.1,-,-,蛋白表达
2525,KP3,34098219,NRAS-driven melanomas#develop#intrinsic and acquired resistance to CDK4/6 inhibitors,Mechanisms of Resistance,NRAS,-,Melanoma,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,-,-,信号通路激活
1637,KP3,26236140,"Palbociclib#could usher in#a new wave of combination therapies for HR+, HER2- breast cancer",Combination Therapies,"CDK4,CDK6",-,"HR+, HER2- breast cancer",Palbociclib,-,-,-,-,-,-,-,Inference,3,3.2,3.2.1,-,-,内分泌治疗联合
4102,KP3,26236140,"Palbociclib#provides#new options for HR+, HER2- breast cancer",Therapeutic Development,"CDK4,CDK6",-,"HR+, HER2- breast cancer",Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,细胞周期阻滞
7629,KP3,39011477,"Abemaciclib, Palbociclib, and Ribociclib#were tested on#a panel of DPM cell lines and MET-5A cells",Preclinical Models,"CDK4,CDK6","DPM cells, MET-5A cells",-,"Abemaciclib, Palbociclib, Ribociclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,细胞周期阻滞
5619,KP3,37529698,A prognostic cuproptosis-related lncRNA model#was constructed for#detecting survival and sensitivity to CDK4/6 inhibitors,Biomarker Analysis,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,-,-,耐药基因标志物
3184,KP3,32898333,Pyrotinib combined with CDK4/6 inhibitors#is a promising strategy for#HER2-positive metastatic gastric cancer,Combination Therapies,"CDK4,CDK6",HER2-positive cells,Metastatic gastric cancer,"Pyrotinib, CDK4/6 inhibitors",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,-,-,靶向药物联合
62,KP3,36598514,CDK4/6 inhibitors#provide#promising results for treating HR+ breast cancer,Therapeutic Development,"CDK4,CDK6",-,HR+ breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,细胞周期阻滞
6383,KP3,34207648,CDK4/6 inhibitors#increase#progression-free and overall survival in HR+/HER2- BC,Therapeutic Response,"CDK4,CDK6",-,HR+/HER2- breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3119,KP3,32565737,Ribociclib#is becoming#widely used in HR+/HER2- breast cancer,Therapeutic Development,"CDK4,CDK6",-,HR+/HER2- breast cancer,Ribociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3510,KP3,29564714,Palbociclib#has been approved for#HR+/HER2- locally advanced or metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5100,KP3,37611074,Brain metastases#are associated with#high morbidity and resistance to immune checkpoint inhibitors,Cancer Association,-,-,Brain metastases,Immune checkpoint inhibitors,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,2.6.1.4,-,细胞凋亡抑制
606,KP3,37611074,Abemaciclib#sensitizes#intracranial tumors to PD-1 inhibition,Combination Therapies,"CDK4,CDK6",-,Intracranial tumors,"Abemaciclib, PD-1 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1578,KP3,37611074,Treatment#affects#intracranial and extracranial tumor-immune microenvironments,Preclinical Models,-,Immune cells,Tumors,Abemaciclib,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
517,KP3,37611074,CDK4/6 inhibitors#are combined with#PD-1 inhibitors in patients with brain metastases,Combination Therapies triples,"CDK4,CDK6",-,Brain metastases,"PD-1 inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1261,KP3,28653662,CDK4/6 inhibitors#are FDA approved for#treating advanced estrogen receptor-positive breast cancer,Clinical Implementation triples,"CDK4,CDK6",-,Advanced estrogen receptor-positive breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
1014,KP3,28653662,Adverse events#lead to#therapy discontinuation,Quality of Life triples,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.3,-,剂量调整
7653,KP3,28653662,Lack of reliable biomarkers#is a challenge in#therapy,Biomarker Analysis triples,-,-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
5181,KP3,37330596,"Hormone receptor-positive, HER2-negative advanced breast cancers#exhibit#high sensitivity to CDK4/6 inhibitors",Clinical Correlation triples,"CDK4,CDK6",-,"Hormone receptor-positive, HER2-negative advanced breast cancer",Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5686,KP3,38562645,A premenopausal woman with oligometastatic breast large cell neuroendocrine carcinoma#is characterized as#ER-positive and HER2-negative,Patient Characteristics triples,-,-,Oligometastatic breast large cell neuroendocrine carcinoma,-,-,-,Premenopausal woman,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
452,KP3,38562645,The patient#has been treated with#endocrine therapy and CDK4/6 inhibitors,Clinical Implementation triples,"CDK4,CDK6",-,Malignant disease,"Endocrine therapy, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
137,KP3,34830800,"Tamoxifen, aromatase inhibitors, and fulvestrant#are used for#therapy of hormone-receptor-positive breast cancer",Clinical Implementation triples,-,-,Hormone-receptor-positive breast cancer,"Tamoxifen, Aromatase inhibitors, Fulvestrant",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
2907,KP3,34830800,CDK4/6 inhibitors#mTOR inhibitors#were approved for overcoming resistance mechanisms,Mechanisms of Resistance triples,"CDK4,CDK6,MTOR",-,Resistance in hormone-receptor-positive breast cancer,"CDK4/6 inhibitors, mTOR inhibitors","PI3K/AKT/mTOR, CDK4/6",-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.3,-,mTOR信号增强
2585,KP3,29250202,Adding CDK4/6 inhibitors to endocrine therapy#results in#clinically relevant prolongation of progression-free survival,Therapeutic Response triples,"CDK4,CDK6",-,Hormone-receptor-positive metastatic disease,"Endocrine therapy, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5626,KP3,38003555,Ribociclib in combination with endocrine therapy#improves#invasive disease-free survival in HR+/HER2- early breast cancer,Therapeutic Response triples,"CDK4,CDK6",-,HR+/HER2- early breast cancer,"Ribociclib, Endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7564,KP3,38174170,Endobronchial metastases of breast cancers#are characterized as#isolated without other visceral metastases,Patient Characteristics triples,-,-,Endobronchial metastases of breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
4676,KP3,38174170,The patient#was treated with#palbociclib and aromatase inhibitors,Clinical Implementation triples,"CDK4,CDK6",-,Breast cancer,"Palbociclib, Aromatase inhibitors",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
2729,KP3,33677841,"Advanced breast cancer patients with HR-positive, HER2-negative tumors#are treated with#endocrine therapy and CDK4/6 inhibitors",Clinical Implementation triples,"CDK4,CDK6",-,"HR-positive, HER2-negative advanced breast cancer","Endocrine therapy, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
6698,KP3,37875421,CDK4/6 inhibitors#mTOR inhibitors#are targeted drugs combined with endocrine therapy,Therapeutic Response triples,"CDK4,CDK6,MTOR",-,HR+/HER2- breast cancer,"CDK4/6 inhibitors, mTOR inhibitors",CDK4/6,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
1084,KP3,30724426,Inhibition of CDK4/6-RB pathway#is effective against#cancer,Mechanism of Action triples,"CDK4,CDK6,RB1",-,Cancer,-,CDK4/6-RB,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
6785,KP3,34885226,"CDK4/6 inhibitors#reduce#cell proliferation and tumor growth in HR-positive, HER2-negative advanced and metastatic breast cancers",Therapeutic Response triples,"CDK4,CDK6",-,"HR-positive, HER2-negative advanced and metastatic breast cancers",CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
527,KP3,31609762,CDK4/6 inhibitors with aromatase inhibitors#led to#a paradigm shift in the management of metastatic hormone-receptor-positive breast cancer,Therapeutic Development triples,"CDK4,CDK6",-,Metastatic hormone-receptor-positive breast cancer,"CDK4/6 inhibitors, Aromatase inhibitors",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
1771,KP3,31609762,CDK4/6 inhibitors#cause#liver toxicity,Adverse Effects,"CDK4,CDK6",-,Liver toxicity,-,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
1495,KP3,31609762,Palbociclib#was used successfully in#a metastatic hormone receptor-positive breast cancer patient,Clinical Implementation,"CDK4,CDK6",-,Metastatic hormone receptor-positive breast cancer,Palbociclib,-,-,Metastatic hormone receptor-positive breast cancer patient,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
6637,KP3,31609762,Ribociclib#was interrupted due to#grade 4 liver toxicity,Adverse Effects,"CDK4,CDK6",-,Liver toxicity,Ribociclib,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
5620,KP3,30948930,CDK4/6 inhibitors#represent#targeted therapy for ER+ HER2- metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,ER+ HER2- metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1082,KP3,36675501,Cyclin D1#drives#oncogenesis in cancers,Cancer Association,CCND1,-,Cancer,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3216,KP3,36675501,Cyclin D1/CDK4/6 axis#is targeted for#cancer therapy,Therapeutic Development,"CDK4,CDK6,CCND1",-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7795,KP3,36675501,CDK4/6 inhibitors#target#altered cyclin D1 expression in tumors,Therapeutic Development,"CDK4,CDK6,CCND1",-,Tumors,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2401,KP3,36675501,Cyclin D1 expression#is associated with#clinicopathological factors in CRC,Cancer Association,CCND1,-,Colorectal cancer (CRC),-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
1081,KP3,36675501,Cyclin D1#is highly expressed in#389 CRC cases,Expression Patterns,CCND1,-,Colorectal cancer (CRC),-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
5000,KP3,36675501,Cyclin D1(High)#is associated with#higher OS rate in young patients,Prognostic Marker,CCND1,-,Colorectal cancer (CRC),-,-,-,Young patients,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
3239,KP3,36675501,Cyclin D1(High)#is associated with#better RFS in chemotherapy-treated females without nodal metastasis,Prognostic Marker,CCND1,-,Colorectal cancer (CRC),-,-,-,"Females, chemotherapy-treated, absence of nodal metastasis",upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
4945,KP3,36675501,Cyclin D1#is overexpressed in#CRCs,Expression Patterns,CCND1,-,Colorectal cancer (CRC),-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3565,KP3,36675501,Cyclin D1 overexpression#predicts#response to CDK4/6 inhibitors,Prognostic Marker,"CDK4,CDK6,CCND1",-,Colorectal cancer (CRC),-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
507,KP3,39650068,HER2 mutations#lead to#resistance to endocrine and CDK4/6 inhibitors,Mechanisms of Resistance,"ERBB2,CDK4,CDK6",-,Endocrine resistance,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
4367,KP3,37797138,Piqray#is not recommended for#PIK3CA-mutated advanced breast cancer in combination with fulvestrant,Clinical Implementation,PIK3CA,-,PIK3CA-mutated advanced breast cancer,"Piqray, Fulvestrant",-,-,"Postmenopausal women, men",-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4837,KP3,32842890,Endocrine therapy#mimics#aromatase inhibitor effects,Mechanism of Action,-,-,-,Aromatase inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
7303,KP3,33413549,SERMs and SERDs#are standard therapies for#ER-positive breast cancer,Clinical Implementation,-,-,ER-positive breast cancer,"SERMs, SERDs",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1218,KP3,33413549,Small molecule inhibitors#target#PI3K-AKT-mTOR pathway or CDK4/6 in combination with anti-estrogen drugs,Combination Therapies,"CDK4,CDK6",-,Endocrine resistance,-,PI3K-AKT-mTOR,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
4472,KP3,33413549,Immune microenvironment#influences#tumor development and treatment response in breast cancer,Tumor Microenvironment,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.3,-,免疫检查点表达
4168,KP3,34152061,Dalpiciclib#extends#progression-free survival in HR+/HER2- advanced breast cancer,Clinical Trial Data,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,Dalpiciclib,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
3544,KP3,34152061,Dalpiciclib#improves#progression-free survival in HR+ HER2- advanced breast cancer with fulvestrant,Combination Therapies,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,"Dalpiciclib, Fulvestrant",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
374,KP3,35269621,"Palbociclib, ribociclib, and abemaciclib#are approved for#advanced or metastatic HR+/HER2- breast cancer",Therapeutic Development,"CDK4,CDK6",-,Advanced or metastatic HR+/HER2- breast cancer,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
6975,KP3,36643309,MIBC#has#poor prognosis,Disease Characteristics,-,-,Muscle invasive urothelial bladder cancer (MIBC),-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,CDK4/6表达
6504,KP3,36643309,Post-NAC tumors#respond to#dual EGFR and HER2 inhibitors,Therapeutic Development,"EGFR,ERBB2",-,NAC-resistant tumors,EGFR and HER2 inhibitors,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,8.2.1.2.1,氟维司群
7058,KP3,36643309,Post-NAC tumors#show no response to#CDK4/6 or FGFR inhibition,Therapeutic Resistance,"CDK4,CDK6,FGFR",-,NAC-resistant tumors,-,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,2.6.1.3,-,靶点修饰
1850,KP3,36643309,Proteogenomic informed kinase inhibitor use#suggests#a benefit from integration of rapid in vivo testing of novel therapeutics,Therapeutic Development,-,MIBC CAM-PDX models,-,-,-,-,Patients with limited treatment options,-,-,-,-,Inference,8,8.3,8.3.1,8.3.1.1,-,标准剂量
2184,KP3,31875860,PD-L1 expression#was found to be#relevant in the use of atezolizumab in first-line therapy of patients with metastatic triple-negative breast cancer,Biomarker Analysis,CD274,-,Triple-negative breast cancer,Atezolizumab,-,-,Metastatic patients,-,PD-L1,-,-,Fact,7,7.2,7.2.1,7.2.1.3,7.2.1.3.1,PD-L1表达
2232,KP3,36508589,"Combination of fulvestrant and capivasertib#more than doubled#progression-free survival compared with fulvestrant alone in patients with hormone receptor-positive, HER2-negative breast cancer",Combination Therapies,ERBB2,-,"Hormone receptor-positive, HER2-negative breast cancer","Fulvestrant, Capivasertib",-,-,Patients resistant to aromatase inhibitors and CDK4/6 inhibitors,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
3058,KP3,38338777,Panel of miRNAs#was identified as#associated with response to treatment in tumor tissues of patients treated with endocrine therapy and CDK4/6 inhibitor palbociclib,Biomarker Analysis,"CDK4,CDK6",-,Hormone receptor-positive/HER2-negative metastatic breast cancer,Palbociclib,-,-,-,-,miRNAs,-,-,Fact,7,7.3,7.3.1,7.3.1.3,7.3.1.3.1,miRNAs
219,KP3,35164144,"CDK4/6 inhibitor palbociclib combined with endocrine therapy#has been shown to be#effective in postmenopausal women with ER-positive, HER2-negative advanced or metastatic breast cancer",Therapeutic Response,"CDK4,CDK6",-,"ER-positive, HER2-negative advanced or metastatic breast cancer",Palbociclib,-,-,Postmenopausal women,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
3301,KP3,29059492,Ribociclib#showed#clinical activity in a phase I study for patients with solid tumors and lymphomas,Drug Development,"CDK4,CDK6",-,"Solid tumors, Lymphomas",Ribociclib,-,-,-,-,-,-,-,Fact,8,8.3,8.3.1,8.3.1.1,-,标准剂量
5059,KP3,33902205,First CDK4/6 inhibitor Palbociclib#changed#clinical treatment pattern of HR-positive and HER2-negative advanced breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR-positive and HER2-negative advanced breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4135,KP3,36661374,"Fulvestrant#significantly prolonged#progression-free survival in postmenopausal women with advanced estrogen receptor-positive, HER2-negative breast cancer",Therapeutic Response,ESR1,-,"Advanced estrogen receptor-positive, HER2-negative breast cancer",Fulvestrant,-,-,Postmenopausal women,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
378,KP3,36661374,Camizestrant#bested#fulvestrant in subgroup analyses of patients who previously received a CDK4/6 inhibitor,Therapeutic Response,"CDK4,CDK6",-,Metastatic breast cancer,"Fulvestrant, Camizestrant",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.2,二线治疗
2338,KP3,36661374,Camizestrant#bested#fulvestrant in patients with ESR1 mutations,Therapeutic Response,ESR1,-,Metastatic breast cancer,"Fulvestrant, Camizestrant",-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
1475,KP3,30374008,Endocrine therapy#depletes#estrogen in ER-positive breast cancer,Mechanism of Action,ESR1,-,Breast cancer,"LH-RH agonist, aromatase inhibitor",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6429,KP3,30374008,Endocrine therapy#inhibits#estrogen-dependent growth in ER-positive breast cancer,Mechanism of Action,ESR1,-,Breast cancer,"LH-RH agonist, aromatase inhibitor",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6956,KP3,30374008,CDK4/6 inhibitors#are used in combination with#endocrine therapy for ER-positive metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,Metastatic breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
6484,KP3,34180575,Ribociclib#inhibits#cyclin-dependent kinases 4 and 6,Mechanism of Action,"CDK4,CDK6",-,-,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1416,KP3,34180575,Ribociclib#is used in combination with#an aromatase inhibitor for advanced hormone receptor-positive and HER2-negative breast cancer,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,"Ribociclib, aromatase inhibitor",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
3365,KP3,38381406,Resistance to endocrine therapy and CDK4/6 inhibitors#is a clinical challenge in#ER-positive breast cancer,Therapeutic Resistance,"CDK4,CDK6",-,Breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,2,2.4,2.4.2,2.4.2.4,-,通路重编程
4244,KP3,27721716,"Systemic therapy of metastatic breast cancer#may include#chemotherapy, endocrine therapy, and targeted therapies",Therapeutic Development,-,-,Metastatic breast cancer,"Chemotherapy, endocrine therapy, targeted therapies",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.3,-,疗效监测
4220,KP3,27721716,Therapeutic agents#may be employed in combination based on#the patient's breast cancer subtype,Personalized Medicine,-,-,Breast cancer,-,-,-,Patient subtype,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,-,患者选择
3725,KP3,27721716,"Novel therapeutic approaches#include#immunologic therapies, PARP inhibitors, PI3K inhibitors, and CDK4/6 inhibitors",Therapeutic Development,"CDK4,CDK6",-,Breast cancer,"PARP inhibitors, PI3K inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
600,KP3,31142370,Clinical outcomes after palbociclib#are evaluated in#postmenopausal women with HR-positive and HER2-negative metastatic breast cancer,Clinical Trial Data,"CDK4,CDK6",-,Metastatic breast cancer,Palbociclib,-,-,Postmenopausal women,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,-,患者选择
3408,KP3,31142370,Limited data#exist regarding#effectiveness of therapies after progression on CDK4/6 inhibitor-based regimens,Therapeutic Resistance,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.4,2.4.2,2.4.2.4,-,通路重编程
6793,KP3,30498279,Therapeutic developments#focus on#identifying patients eligible for targeted therapies and immune therapies,Therapeutic Development,-,-,Advanced breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.3,-,疗效监测
6680,KP3,30498279,"The data on CDK4/6 inhibitors#are complete and consistent for#palbociclib, ribociclib, and abemaciclib",Therapeutic Development,"CDK4,CDK6",-,Breast cancer,"Palbociclib, ribociclib, abemaciclib",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.3,-,疗效监测
7812,KP3,30498279,PI3K and AKT signaling pathways#are under investigation for#their inhibition in breast cancer,Pathway & Network Categories,"PIK3CA,AKT1",-,Breast cancer,-,"PI3K, AKT",-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
6972,KP3,30498279,Initial study results#were presented on#mechanisms of action,Mechanism of Action,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7186,KP3,38327984,Therapeutic evolution in HR+/HER2- breast cancer#progressed from#targeted therapy to endocrine therapy,Therapeutic Response,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
7093,KP3,38327984,Breast cancer#has#four distinct subtypes based on ER and HER2 levels,Cancer Association,"ESR1,ERBB2",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.2,7.4.1.2.1,Luminal亚型
5690,KP3,38327984,Clinical trials of drugs#are included in#completed or ongoing studies,Clinical Trial Data,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
7527,KP3,39487929,Trastuzumab#improved#outcome of patients with HER2-positive metastatic breast cancer,Therapeutic Response,ERBB2,-,Metastatic breast cancer,Trastuzumab,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6081,KP3,27753448,Inhibitors of CDK4/6#are being tested in#prostate cancer clinical trials,Clinical Trial Data,"CDK4,CDK6",-,Prostate cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
1814,KP3,27753448,Deletions of CHD1#associate with#increased AR activity and genomic instability,Cancer Association,"CHD1,AR",-,Prostate cancer,-,-,Downregulated,-,-,-,-,-,Inference,5,5.3,5.3.2,5.3.2.2,-,RB1缺失
2371,KP3,27753448,CHD1-deleted tumors#could benefit from#DNA-damaging therapies,Therapeutic Response,CHD1,-,Prostate cancer,-,-,-,-,-,-,-,-,Inference,3,3.4,3.4.2,3.4.2.1,-,内源性途径激活
4302,KP3,36859416,Patients with metastatic breast cancer#were treated with#endocrine therapy and a CDK4/6 inhibitor,Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,"Endocrine therapy, CDK4/6 inhibitors",-,-,Metastatic,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
573,KP3,34953442,CDK4/6 inhibitors#significantly improved#clinical outcomes in HR+ breast cancer patients,Therapeutic Response,"CDK4,CDK6",-,HR+ breast cancer,CDK4/6 inhibitors,-,-,Advanced,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7370,KP3,34953442,CDK4/6 inhibitors#demonstrated#favorable antitumor immune responses in preclinical studies,Therapeutic Response,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.3,3.3.1,3.3.1.4,-,免疫抑制缓解
2712,KP3,35834030,Cyclin-dependent kinase 4/6 inhibitors#are used in#breast cancer treatment,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,Cyclin-dependent kinase 4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1045,KP3,37379213,NRAS-mutant melanoma#was treated with#MEK1/2 plus CDK4/6 inhibitors,Therapeutic Development,"NRAS,CDK4,CDK6",Melanoma cells,NRAS-mutant melanoma,"MEK1/2 inhibitors, CDK4/6 inhibitors",-,-,NRAS-mutant,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
3100,KP3,34204797,Combination of EGFR blockers and CDK4/6 inhibitors#was used for#nasopharyngeal carcinoma treatment,Combination Therapies,"EGFR,CDK4,CDK6",-,Nasopharyngeal carcinoma,"EGFR blockers, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
487,KP3,34204797,NPC PDX tumors#were inhibited by#EGFR inhibitors and palbociclib,Therapeutic Response,"EGFR,CDK4,CDK6",-,NPC (nasopharyngeal carcinoma),"Cetuximab, Afatinib, Palbociclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1854,KP3,35989889,Palbociclib#is approved for#HR+ HER2- metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,HR+ HER2- metastatic breast cancer,Palbociclib,-,-,Locally advanced or metastatic,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1262,KP3,27810861,Combination of antiestrogen therapy and ribociclib#led to#improved outcomes in HR+ HER2- metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,HR+ HER2- metastatic breast cancer,"Ribociclib, Antiestrogen therapy",-,-,Metastatic,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
7455,KP3,27810861,Combination of ribociclib and letrozole#significantly increased#progression-free survival in HR+ HER2- metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,HR+ HER2- metastatic breast cancer,"Ribociclib, Letrozole",-,-,Metastatic,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
5695,KP3,28815764,CDK6 amplification#is associated with#high PD-L1 IHC expression in tumor cells,Molecular Event,"CDK6,PD-L1",-,-,-,-,-,Amplified,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.3,7.2.1.3.1,PD-L1表达
4156,KP3,28815764,CDK6 amplification#co-occurs with#CMYC amplification and CCND1-PIK3CA co-amplification,Molecular Event,"CDK6,CMYC,CCND1,PIK3CA",-,-,-,-,-,Amplified,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
2115,KP3,28815764,FGFR1 amplification#is associated with#negative PD-L1 expression in tumor cells,Molecular Event,"FGFR1,PD-L1",-,-,-,-,-,Amplified,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.3,7.2.1.3.1,PD-L1表达
3461,KP3,28815764,patients with SCCs#are candidates for#immune checkpoint inhibitors,Clinical Implementation,-,SCCs,SCCs,immune checkpoint inhibitors,-,-,-,-,-,-,-,Inference,8,8.4,8.4.1,8.4.1.3,8.4.1.3.4,长期管理
5379,KP3,29508248,combination of palbociclib and erlotinib#was investigated for#efficacy in GBM cell systems with different p53 status,Preclinical Models,"CDK4,CDK6,EGFR,TP53",GBM cells,GBM,"palbociclib, erlotinib",-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3090,KP3,33686114,CDK4/6 specific inhibitor palbociclib#has been identified as#an effective option for MB cells,Preclinical Models,"CDK4,CDK6",-,MB,palbociclib,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
328,KP3,33683521,"palbociclib#has demonstrated#improved progression-free survival in HR-positive, HER2-negative advanced breast cancer patients when combined with letrozole or fulvestrant",Therapeutic Development,"CDK4,CDK6",HR-positive breast cancer cells,"HR-positive, HER2-negative advanced breast cancer","palbociclib, letrozole, fulvestrant",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7927,KP3,32322108,CDK4/6 inhibitors#have been introduced as#new therapies for locally advanced or metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,locally advanced or metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4741,KP3,26486823,"palbociclib#significantly prolonged#progression-free survival in metastatic ER-positive, HER2-negative breast cancer patients in combination with letrozole or fulvestrant",Therapeutic Development,"CDK4,CDK6",-,"metastatic ER-positive, HER2-negative breast cancer","palbociclib, letrozole, fulvestrant",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5982,KP3,38422625,adjuvant CDK4/6 inhibitors#showed#sustained benefit in high-risk HR-positive disease,Therapeutic Development,"CDK4,CDK6",-,high-risk HR-positive disease,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3754,KP3,37675540,CDK4/6 inhibitors#have provided#abundant treatment options for HR-positive HER2-negative advanced breast cancer,Therapeutic Development,"CDK4,CDK6",-,HR-positive HER2-negative advanced breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7630,KP3,30207163,patients with advanced or metastatic breast cancer#receive#palbociclib plus an aromatase inhibitor or palbociclib plus fulvestrant in a real-world setting,Clinical Implementation,-,-,Advanced or metastatic breast cancer,"Palbociclib, aromatase inhibitor, fulvestrant",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
7850,KP3,36358625,cyclin-dependent kinase 4/6 and PI3K/AKT/mTOR inhibitors#improve#survival in advanced ER+ breast cancer,Therapeutic Response,"CDK4, CDK6, PIK3CA, AKT1, MTOR",-,Advanced ER+ breast cancer,-,PI3K/AKT/mTOR,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3651,KP3,39880705,CDK4/6 inhibitors#are used to treat#HR+/HER2- metastatic breast cancer,Clinical Implementation,"CDK4, CDK6",-,HR+/HER2- metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4936,KP3,29623577,HR+/HER2- aromatase inhibitor-resistant metastatic breast cancer#can be treated with#everolimus and a second aromatase inhibitor,Therapeutic Response,-,-,HR+/HER2- aromatase inhibitor-resistant metastatic breast cancer,"Everolimus, aromatase inhibitor",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
671,KP3,32308409,monotherapy of immunoagents against PD1/PD-L1 or CTLA-4#shows#little efficacy in these patients,Therapeutic Response,"PDCD1, CD274, CTLA4",-,-,-,-,-,-,-,-,-,-,Fact,3,3.3,3.3.2,3.3.2.1,-,PD-1/PD-L1表达调控
4027,KP3,32308409,clinical trials#are developing#immunotherapy combinations,Clinical Trial Data,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
6300,KP3,32308409,"immunoagents in combination with chemotherapy, radiotherapy, HER2-targeted therapy, CDK4/6 inhibitors, PARP inhibitors, and other checkpoint immunoagents#are being established for#safety and efficacy",Combination Therapies,"CDK4, CDK6",-,-,PARP inhibitors,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.3,-,疗效监测
1958,KP3,38293306,abemaciclib#is the standard of care for#adjuvant therapy in ER+/HER2- tumors at high risk of recurrence,Clinical Implementation,"CDK4, CDK6",-,ER+/HER2- tumors,-,-,high risk of recurrence,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4433,KP3,36071983,endocrine resistance#is a hurdle in#the treatment of ER-positive breast cancer,Therapeutic Resistance,-,-,ER-positive breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
1240,KP3,36071983,"molecular signals from MAPK, PI3K/AKT, mTOR, CDK4/6, and aberrant ER function#contribute to#endocrine resistance",Signaling Networks,"MAPK, PIK3CA, AKT1, MTOR, CDK4, CDK6",-,Endocrine resistance,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
4072,KP3,36071983,clinical trials#target#these molecular signals for endocrine-resistant breast cancer,Clinical Trial Data,"MAPK, PIK3CA, AKT1, MTOR, CDK4, CDK6",-,Endocrine-resistant breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.3,-,疗效监测
3011,KP3,32157006,endocrine therapy (fulvestrant)#decreases#FDG uptake in metastatic lesions,Therapeutic Response,-,-,Metastatic lesions,Fulvestrant,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
867,KP3,32157006,combination therapy with aromatase inhibitors and CDK4/6 inhibitors#is used for#treatment after tumor marker elevation,Combination Therapies,"CDK4, CDK6",-,Tumor marker elevation,Aromatase inhibitors,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
4013,KP3,27286459,CDK4/6 and IGF-1R inhibitors#show#efficacy in Ewing's sarcoma PDOX,Therapeutic Response,"CDK4, CDK6, IGF1R",-,Ewing's sarcoma,"CDK4/6 inhibitors, IGF-1R inhibitors",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6864,KP3,33373867,CDK4/6 inhibitors plus endocrine therapies#are the standard of care for#HR+/HER2-negative metastatic breast cancer,Clinical Implementation,"CDK4, CDK6",-,HR+/HER2-negative metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
6924,KP3,36164943,pazopanib#aids in#treatment of refractory soft tissue sarcoma,Therapeutic Response,-,-,Soft tissue sarcoma,Pazopanib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1763,KP3,36164943,pazopanib-based treatment#achieves#a partial response in 27.3% of patients,Therapeutic Response,-,-,Soft tissue sarcoma,Pazopanib,-,-,partial response,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1779,KP3,36164943,molecular predictors of pazopanib efficacy#can be used for#future clinical trials,Clinical Trial Data,-,-,Soft tissue sarcoma,Pazopanib,-,-,-,-,-,-,-,Inference,8,8.2,8.2.1,8.2.1.3,-,疗效监测
5992,KP3,27729458,neuroblastoma#is treated with#aggressive multimodal therapy,Therapeutic Response,-,-,Neuroblastoma,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7923,KP3,27729458,Relapsed neuroblastomas#harbor#mutations leading to hyperactivated ERK signaling,Cancer Pathways,ERK,-,Neuroblastoma,-,ERK,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
1061,KP3,27729458,"Sensitivity to binimetinib and ribociclib#is inversely related#(r = -0.58, P = 0.009)",Mechanisms of Resistance,"CDK4,CDK6",-,-,"Binimetinib,Ribociclib",-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
919,KP3,27729458,Combined binimetinib and ribociclib treatment#shows#therapeutic synergy in high-risk neuroblastoma models,Combination Therapies,"CDK4,CDK6",-,Neuroblastoma,"Binimetinib,Ribociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
27,KP3,29156680,Patients#develop#resistance to CDK4/6 inhibitors despite promising clinical trial results,Therapeutic Resistance,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
1390,KP3,33976037,"A 72-year-old woman with ER(+), PgR(+), HER2(-) metastatic breast cancer#had#liver involvement",Clinical Correlation triples,"ESR1,PGR,ERBB2",-,Breast cancer,-,-,-,72-year-old woman,-,-,-,-,Fact,-,7,7.2,7.2.1,7.2.1.1,7.2.1.1.4
146,KP3,33976037,The patient#received#palbociclib and fulvestrant as second-line endocrine therapy,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,"Palbociclib,Fulvestrant",-,-,72-year-old woman,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
106,KP3,33976037,Abemaciclib#may be useful for#breast cancer resistant to palbociclib,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,"Abemaciclib,Palbociclib",-,-,-,-,-,-,-,Inference,2,2.5,2.5.2,2.5.2.3,-,个体化方案
4178,KP3,37695642,Therapy-induced senescence#contributes to#efficacy of abemaciclib in dedifferentiated liposarcoma,Therapeutic Response,"CDK4,CDK6",-,Liposarcoma,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
7784,KP3,37695642,CDK4/6 inhibitors#influence#tumor growth through senescence in humans,Mechanism of Action,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
3193,KP3,36333737,HR-positive luminal cancer models#exhibited#upregulation of PI3K signaling and sensitivity to pathway inhibition,Pathway & Network Categories,PIK3CA,-,Breast cancer,-,PI3K,-,-,Upregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
115,KP3,34049239,CDK4/6 inhibitor palbociclib#was used prior to#gemcitabine/AZD6738 in a synergistic schedule,Combination Therapies,"CDK4,CDK6",-,-,"Palbociclib,Gemcitabine,AZD6738",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3041,KP3,34049239,Drug treatments targeting G1 or S/G2 phases#may benefit from#scheduling after CDK4/6 inhibitors,Therapeutic Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5905,KP3,28699811,CDK inhibitors#emerge as#efficacious agents in hormone-positive metastatic breast cancer,Cancer Association,"CDK4,CDK6",-,Hormone-positive metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2262,KP3,36603130,CDK4/6 inhibitors#reactivate#tumor suppressor retinoblastoma (Rb) to suppress cell-cycle progression,Mechanism of Action,"CDK4,CDK6",Rb,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
3866,KP3,35982453,New generation CDK4/6 inhibitors#have been developed and approved for#breast cancer therapy in combination with endocrine therapeutics,Drug Development,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
3083,KP3,37158934,Hormone receptor-positive HER2-negative breast cancer#remains associated with#a poor prognosis for recurrence cases,Cancer Association,HER2,-,Hormone receptor-positive HER2-negative breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,Cyclin D1表达
4485,KP3,37158934,A 74-year-old Asian woman with multiple lung and liver metastases#was treated with#two different CDK4/6 inhibitors sequentially in combination with endocrine therapy,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,-,-,-,74-year-old Asian woman,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
95,KP3,33640871,Everolimus#is an established therapy for#well-differentiated (WD) foregut neuroendocrine tumors (NETs),Drug Development,-,-,Well-differentiated foregut neuroendocrine tumors (WDNETs),Everolimus,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
1564,KP3,33640871,Cyclin-dependent kinase 4/6 inhibition#demonstrates#a potential synergistic role with everolimus to treat WDNETs,Combination Therapies,"CDK4,CDK6",-,Well-differentiated foregut neuroendocrine tumors (WDNETs),Everolimus,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
4918,KP3,33640871,Patients with advanced foregut WDNETs#received#combination ribociclib and everolimus,Combination Therapies,"CDK4,CDK6",-,Well-differentiated foregut neuroendocrine tumors (WDNETs),"Ribociclib,Everolimus",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
2903,KP3,33640871,The trial#was put on hold due to#unexpected hematologic and infectious toxicities,Safety Monitoring,-,-,-,"Ribociclib,Everolimus",-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,血液学毒性
3044,KP3,33640871,Twenty-one patients#were treated with#ribociclib and everolimus,Clinical Trial Data,-,-,Well-differentiated foregut neuroendocrine tumors (WDNETs),"Ribociclib,Everolimus",-,-,Median age: 56 (range: 24 to 77),-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
261,KP3,33640871,Genetic testing in archival tumor tissue samples#failed to identify#a predictive biomarker of disease stabilization,Biomarker Analysis,-,-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
4151,KP3,31117035,The TAILORx trial#helped refine#the use of genetic expression assays in assigning patients to therapies,Biomarker Analysis,-,-,-,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.1,-,基因表达谱
4889,KP3,31117035,The NCCN Guidelines#reinforce#the benefit of CDK4/6 inhibitors in metastatic disease,Clinical Implementation,"CDK4,CDK6",-,Metastatic disease,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
268,KP3,36146552,Breast cancer patients#were treated with#cyclin D kinase 4/6 inhibitors and hormonal therapy,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
7178,KP3,35350768,Palbociclib#was approved by#the FDA for use in ER+/HER2- metastatic breast cancer,Drug Development,"CDK4,CDK6",-,ER+/HER2- metastatic breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
5123,KP3,37757816,Cyclin-Dependent Kinase 4 and 6 inhibitors#are associated with#Axillary Web Syndrome,Disease & Clinical Categories,"CDK4,CDK6",-,Axillary Web Syndrome,Ribociclib,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
1062,KP3,36612173,Tyrosine kinase inhibitors (TKIs)#combined with#other agents increases clinical benefit,Combination Therapies,-,-,-,Tyrosine kinase inhibitors (TKIs),-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
4420,KP3,36612173,CDK4/6 inhibitors#offer#therapeutic potential,Therapeutic Development,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7191,KP3,35614407,Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)#provide#a better prognosis in EGFR-mutant non-small cell lung cancer,Therapeutic Response,EGFR,-,Non-small cell lung cancer,EGFR-TKIs,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,8.5.1.3.1,症状改善
611,KP3,35614407,"CDK4, CDKN2A, PIK3CG, and PIK3CA#are associated with#poor prognosis in cohort 1",Cancer Association,"CDK4,CDKN2A,PIK3CG,PIK3CA",-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
4266,KP3,30206110,CDK4/6 inhibition with endocrine therapy#is a standard of care for#advanced estrogen receptor-positive breast cancer,Clinical Implementation,"CDK4,CDK6",-,Estrogen receptor-positive breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
6404,KP3,30206110,Mechanisms of CDK4/6 inhibitor resistance#have been described in#preclinical models,Therapeutic Resistance,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
2522,KP3,27849562,Palbociclib#demonstrates#efficacy in preclinical models of HCC,Preclinical Models,"CDK4,CDK6",-,Hepatocellular carcinoma (HCC),Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2989,KP3,27849562,Palbociclib#combined with#sorafenib impairs tumor growth and increases survival in HCC,Combination Therapies triples,"CDK4,CDK6",-,Hepatocellular carcinoma (HCC),"Palbociclib, Sorafenib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7362,KP3,27849562,Palbociclib#could benefit#patients with RB1-proficient tumors,Patient Stratification,RB1,-,Tumors,Palbociclib,-,-,-,-,-,-,-,Inference,7,7.5,7.5.1,7.5.1.2,-,原发性耐药
3757,KP3,27343443,MET exon 14 skipping (METex14)#is described as#a driver alteration in lung cancer,Cancer Pathways,MET,-,Lung cancer,-,MET,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
4708,KP3,27343443,METex14 alterations#are harbored in#2.7% of lung cancer cases,Cancer Association,MET,-,Lung cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,RB1突变
3666,KP3,27343443,Hybrid capture-based molecular profiling#identifies#patients benefiting from MET TKIs,Technical Methods,MET,-,Lung cancer,MET TKIs,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,-,MRI检查
5194,KP3,39232441,Elacestrant#is approved for#ESR1-mutant metastatic breast cancer,Clinical Implementation,ESR1,-,Metastatic breast cancer,Elacestrant,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
4642,KP3,36908287,Genomic studies#report#efficacy and resistance mechanisms in CDK4/6 inhibitor-treated patients,Mechanisms of Resistance,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.5,2.5.2,2.5.2.1,-,新型抑制剂开发
4657,KP3,39035768,CDK4/6 inhibitors#are used for#women with estrogen receptor-positive tumors,Therapeutic Development,"CDK4,CDK6",-,Estrogen receptor-positive tumors,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5535,KP3,28860801,Immune checkpoint inhibitors and targeted therapies#are transforming#the treatment of BRAF-mutant melanoma,Therapeutic Development,BRAF,-,Melanoma,-,-,-,-,-,-,-,-,Fact,3,3.3,3.3.2,3.3.2.3,-,免疫逃逸抑制
1492,KP3,28860801,Combining MEK inhibitors with agents inhibiting cell cycling and the PI3K-AKT pathway#provides#additional benefit,Combination Optimization,"PIK3CA,AKT1",-,Melanoma,-,PI3K-AKT,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
6031,KP3,28860801,MEK inhibition and CDK4/6 inhibition#is likely to be#a viable treatment option,Combination Optimization,"CDK4,CDK6",-,Melanoma,-,"MEK,CDK4/6",-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
7604,KP3,38303227,Abemaciclib combined with endocrine therapy#was significantly effective as#a first-line treatment for premenopausal women with metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,Abemaciclib,-,-,Premenopausal women,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
2808,KP3,35969265,Resistance mechanisms#can be clarified for#endocrine therapy or CDK4/6 inhibitors,Mechanisms of Resistance,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,-,-,信号通路激活
2614,KP3,29862232,Nab-paclitaxel#has enriched#therapeutic options for advanced squamous cell lung cancer,Therapeutic Development,-,-,Squamous cell lung cancer,Nab-paclitaxel,-,-,-,-,-,-,-,Fact,3,-,-,-,-,治疗机制
4166,KP3,29862232,"Necitumumab, afatinib, and erlotinib#target#epidermal growth factor receptor (EGFR) axis",Therapeutic Development,EGFR,-,Squamous cell lung cancer,"Necitumumab, afatinib, erlotinib",EGFR,-,-,-,-,-,-,Fact,3,-,-,-,-,治疗机制
816,KP3,29862232,Ramucirumab#inhibits#VEGF-induced angiogenesis,Mechanism of Action,VEGF,-,-,Ramucirumab,VEGF,-,-,-,-,-,-,Fact,6,6.2,6.2.1,6.2.1.1,-,VEGF信号通路
6510,KP3,29862232,"Nivolumab, pembrolizumab, atezolizumab, and durvalumab#are approved in#the field of immunotherapies",Therapeutic Development,-,-,-,"Nivolumab, pembrolizumab, atezolizumab, durvalumab",-,-,-,-,-,-,-,Fact,3,-,-,-,-,治疗机制
318,KP3,29862232,"Agents targeting FGFR, IGF-1, PI3K, CDK4/6, MET, and PARP inhibitors#are under investigation#to open new treatment prospects in SqCLC",Therapeutic Development,"FGFR1,IGF1,PIK3CA,CDK4,CDK6,MET,PARP",-,Squamous cell lung cancer,-,-,-,-,-,-,-,-,Fact,3,-,-,-,-,治疗机制
7591,KP3,32210163,"Breast cancers#are subdivided based on#activation of hormone receptors, HER2, or BRCA mutations",Molecular Subtypes,"ESR1,PGR,ERBB2,BRCA1,BRCA2",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,-,-,分子分型标志物
4191,KP3,32210163,"Molecular studies#developed#therapeutic approaches targeting HER2, CDK4/6, PI3K, or PARP inhibitors for BRCA mutation carriers",Therapeutic Development,"ERBB2,CDK4,CDK6,PIK3CA,BRCA1,BRCA2",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,-,-,-,-,治疗机制
636,KP3,36330468,92 (69.18%) of metastasis breast cancer subtypes#were#HR-positive and HER2-negative,Molecular Subtypes,"ERBB2,ESR1,PGR",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,-,-,分子分型标志物
98,KP3,36330468,20 (15.04%) of metastasis breast cancer subtypes#had#HER2 overexpression,Molecular Subtypes,ERBB2,-,Breast cancer,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
2280,KP3,36330468,21 (15.78%) of metastasis breast cancer subtypes#were#triple-negative,Molecular Subtypes,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,-,-,分子分型标志物
943,KP3,38592590,Systemic treatment intensification with docetaxel#improves#outcomes including survival in men with mCSPC,Therapeutic Development,-,-,Metastatic castration-sensitive prostate cancer,Docetaxel,-,-,Men,-,-,-,-,Fact,3,-,-,-,-,治疗机制
1467,KP3,38592590,Second-generation androgen receptor pathway inhibitor (ARPI)#combined with#androgen deprivation therapy (ADT) improves outcomes,Combination Optimization,AR,-,Metastatic castration-sensitive prostate cancer,-,AR pathway,-,-,-,-,-,-,Fact,3,-,-,-,-,治疗机制
3875,KP3,38592590,"Triplet systemic therapy (ADT, ARPI, and docetaxel)#further improves#outcomes including survival",Combination Optimization,AR,-,Metastatic castration-sensitive prostate cancer,Docetaxel,-,-,-,-,-,-,-,Fact,3,-,-,-,-,治疗机制
4131,KP3,34150798,"Abemaciclib plus fulvestrant (ABE + FUL)#was compared with#PAL + FUL, RIB + FUL, and FUL monotherapy as second-line treatment for HR-positive, HER2-negative advanced breast cancer",Therapeutic Development,"CDK4,CDK6,ERBB2",-,Breast cancer,"Abemaciclib, fulvestrant, palbociclib, ribociclib",-,-,-,-,-,-,-,Fact,3,-,-,-,-,治疗机制
1972,KP3,39687977,"CDK4/6 inhibitors and immune checkpoint inhibitors#are in clinical use or trials for#adjuvant and neoadjuvant settings in HR-positive, HER2-negative breast cancers",Therapeutic Development,"CDK4,CDK6,ERBB2",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,-,-,-,-,治疗机制
7348,KP3,35402243,"Targeting agent therapy#includes#anti-HER2 drugs, CDK4/6 inhibitors, PARP inhibitors, PI3K/AKT/mTOR inhibitors, ER targeting drugs, and aromatase inhibitors for breast cancer",Therapeutic Development,"ERBB2,CDK4,CDK6,PIK3CA,AKT1,MTOR,ESR1",-,Breast cancer,-,PI3K/AKT/mTOR,-,-,-,-,-,-,Fact,3,-,-,-,-,治疗机制
5056,KP3,31591187,NF1 loss#promoted#ER-independent cyclin D1 expression,Molecular Event,"NF1,CCND1",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
7486,KP3,31591187,Cyclin D1 expression#could be targeted with#CDK4/6 inhibitors in vitro,Therapeutic Response,"CCND1,CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1839,KP3,31591187,Patients with NF1 mutations in circulating tumor DNA#had#a good outcome on palbociclib and fulvestrant,Therapeutic Response,NF1,-,-,"Palbociclib, fulvestrant",-,-,Patients with NF1 mutations,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4811,KP3,33243298,Palbociclib#was evaluated for#therapeutic efficacy and compatibility with other chemotherapeutic drugs for NPC,Therapeutic Development,"CDK4,CDK6",-,Nasopharyngeal carcinoma,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6546,KP3,34625531,Alpelisib#has been approved by#FDA to treat PIK3CA mutant breast cancers,Therapeutic Development,PIK3CA,-,Breast cancer,Alpelisib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4556,KP3,34625531,Alpelisib#synergized with#mTOR inhibitor MLN0128 or CDK4/6 inhibitor palbociclib to suppress HCC cell growth,Combination Optimization,"PIK3CA,MTOR,CDK4,CDK6",-,Hepatocellular carcinoma,"Alpelisib, MLN0128, palbociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7727,KP3,34625531,Combining alpelisib with mTOR or CDK4/6 inhibitors#has#a synergistic efficacy against PIK3CA-mutated HCC,Combination Optimization,"PIK3CA,MTOR,CDK4,CDK6",-,Hepatocellular carcinoma,Alpelisib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7821,KP3,27311401,Palbociclib#is#a selective cyclin-dependent kinase 4/6 inhibitor,Drug Development,"CDK4, CDK6",-,Head and neck squamous cell carcinoma,"Palbociclib, cetuximab",-,Recurrent/metastatic,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
258,KP3,27311401,Phase I trial#determined#dose-limiting toxicity and maximum tolerated dose of palbociclib with cetuximab,Clinical Trial Data,-,-,-,"Palbociclib, cetuximab",-,-,-,-,-,-,-,Fact,8,8.3,8.3.1,8.3.1.1,8.3.1.1.1,标准剂量
972,KP3,27311401,Palbociclib#was administered#orally days 1-21 every 28 days,Drug Development,-,-,-,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.3,8.3.1,8.3.1.1,8.3.1.1.1,标准剂量
4887,KP3,27311401,Tumor responses#were observed#even in cetuximab- or platinum-resistant disease,Therapeutic Response,-,-,Cetuximab- or platinum-resistant cancer,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.3,2.5.3.4,-,疫苗治疗
1409,KP3,31849236,"Endocrine therapy#extends#endocrine sensitivity in hormone receptor-positive, HER2-negative metastatic breast cancer",Therapeutic Development,-,-,Metastatic breast cancer,-,-,"Hormone receptor-positive, HER2-negative",-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
1365,KP3,31849236,Targeted agents#prolong#survival and improve response rates in hormone receptor-positive/HER2-negative metastatic breast cancer,Therapeutic Response,-,-,Metastatic breast cancer,-,-,"Hormone receptor-positive, HER2-negative",-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
4312,KP3,31849236,"Personalized sequential strategies#consider#response to previous treatments, disease symptoms, and safety issues",Clinical Implementation,-,-,-,-,Disease symptoms,-,-,-,-,-,-,Inference,8,8.6,8.6.1,8.6.1.2,8.6.1.2.2,不良反应
5965,KP3,34836764,Trials#test#addition of adjuvant CDK4/6 inhibitors to standard endocrine therapy,Clinical Trial Data,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,"Hormone receptor-positive, HER2-negative",-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
3693,KP3,34729098,"Targeted therapies#expand#to include EGFR, PARP, and CDK4/6 pathways",Pathway & Network Categories,"CDK4, CDK6",-,-,-,"EGFR, PARP, CDK4/6",-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
3363,KP3,32226926,Resistance to HER2 and CDK4/6 inhibitors#limits#durable clinical responses,Mechanisms of Resistance,"HER2, CDK4, CDK6",-,-,HER2 and CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
4926,KP3,32226926,PI3K/AKT/mTOR pathway hyperactivation#bypasses#upstream growth factor receptor inhibition,Pathway & Network Categories,"PI3K, AKT, MTOR",-,-,-,PI3K/AKT/mTOR,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
7858,KP3,32226926,Altered lipid metabolism#mediates#development of acquired drug resistance to HER2-targeted therapies,Metabolic Integration,HER2,-,Breast cancer,HER2-targeted therapies,-,-,-,-,-,-,-,Fact,4,4.4,4.4.1,4.4.1.2,-,脂肪酸氧化
7032,KP3,32226926,Lipid metabolism#is#a potential therapeutic target to overcome acquired drug resistance,Metabolic Integration,-,-,-,-,-,-,-,-,-,-,-,Inference,4,4.4,4.4.1,4.4.1.2,-,脂肪酸氧化
3548,KP3,37813650,CDK4/6 inhibitors#improve#outcome of patients with hormone receptor-positive breast cancer,Therapeutic Development,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,Hormone receptor-positive,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6088,KP3,37775726,Shared decision-making#addresses#needs of patients eligible for combination therapy with CDK4/6 inhibitors plus aromatase inhibitors,Clinical Implementation,"CDK4, CDK6",-,Metastatic breast cancer,"CDK4/6 inhibitors, aromatase inhibitors",-,"Hormone receptor-positive, HER2-negative",-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
218,KP3,26689790,"Bortezomib, lenalidomide, temsirolimus, and ibrutinib#are approved for#use in refractory or relapsed MCL patients",Drug Development,-,-,Mantle cell lymphoma (MCL),"Bortezomib, lenalidomide, temsirolimus, ibrutinib",-,Refractory or relapsed,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4619,KP3,26689790,"CDK4/6, PI3K, BCL2, and PARP inhibitors#are being evaluated#for clinical use",Drug Development,"CDK4, CDK6, PI3K, BCL2, PARP",-,-,"CDK4/6 inhibitors, PI3K inhibitors, BCL2 inhibitors, PARP inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5495,KP3,26059247,Breast cancers#present#with ER-positive and HER2-negative features,Expression Patterns,"ER, HER2",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.1,-,基因表达谱
1168,KP3,37137501,Precision oncology#aims to translate#molecular features of cancer into predictive and prognostic tests,Clinical Implementation,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
3475,KP3,37137501,Trastuzumab#shows efficacy in#tumors overexpressing ERBB2,Cancer Association,ERBB2,-,Breast cancer,Trastuzumab,-,-,-,upregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2256,KP3,37137501,Endocrine therapy#is effective in#estrogen receptor-positive tumors,Cancer Association,ESR1,-,Breast cancer,Endocrine therapy,-,-,-,upregulated,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
3779,KP3,37137501,CDK4/6 inhibitors#are not associated with#strong predictive biomarkers,Therapeutic Response,"CDK4, CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,-,获得性耐药
2842,KP3,35785151,Alteration of genes and deregulation of proteins#play pivotal roles in#pathogenesis and progression of glioma,Cancer Pathways,"CDK4, CDK6, RTK, PI3K, AKT, PKC, RAS, RAF, MEK, HDAC, PARP, BCAT1, IDH",-,Glioma,-,"PI3K/AKT, PKC, RAS/RAF/MEK",-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
2538,KP3,34419955,Gene expression signatures#guide#adjuvant therapy in hormone receptor-positive tumors,Biomarker Analysis,-,-,Hormone receptor-positive tumors,-,-,-,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,-,细胞周期标志物
1236,KP3,34419955,Personalized strategies#represent#advances in systemic treatment of early-stage HER2-positive disease,Clinical Implementation,ERBB2,-,HER2-positive breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
1759,KP3,34419955,CDK4/6 inhibitors#are under exploration for#(neo)adjuvant treatment,Clinical Trial Data,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,治疗线别
5587,KP3,34419955,Unmet needs#include#development of predictive biomarkers and sequencing algorithms in metastatic BC,Translational Research,-,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
7157,KP3,32539467,CDK4/6 inhibitors#are used in#hormone receptor-positive breast cancer,Therapeutic Development,"CDK4, CDK6",-,Hormone receptor-positive breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7181,KP3,36751522,Cyclin-dependent kinase 4 inhibitors#remain under evaluation for#various cancers,Therapeutic Development,CDK4,-,Cancer,CDK4 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2253,KP3,31058077,CDK4/6 inhibitors#are approved for#cancer treatment,Therapeutic Development,"CDK4, CDK6",-,Cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7735,KP3,36139701,CDK4/6 inhibitors#target#intracellular signaling pathways in HER2+ cancers,Signaling Networks,"CDK4, CDK6",-,HER2-positive cancers,CDK4/6 inhibitors,PI3K/AKT/mTOR,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
5571,KP3,35580291,CDK4/6 inhibitors#are incorporated in#early-stage triple-negative breast cancer treatment,Therapeutic Development,"CDK4, CDK6",-,Triple-negative breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4598,KP3,32545895,CDK4/6 inhibitors#are evaluated in#anti-HER2 therapy combinations,Combination Optimization,"CDK4, CDK6",-,HER2-positive breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1214,KP3,30978559,"Palbociclib, Ribociclib, and Abemaciclib#are third-generation#CDK inhibitors",Drug Development,"CDK4, CDK6",-,Cancer,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6617,KP3,30978559,Cyclin-dependent kinases#regulate#cell cycle transitions,Cell Cycle Control,"CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
4942,KP3,30978559,Selective CDK4/6 inhibitors#show#limited toxicity and high in vivo activity,Therapeutic Development,"CDK4, CDK6",-,Cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2911,KP3,29743141,Ribociclib#is approved for#HR+/HER2- metastatic breast cancer,Drug Development,"CDK4,CDK6",-,HR+/HER2- metastatic breast cancer,Ribociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
6330,KP3,39796641,Tyrosine kinase inhibitors avapritinib and ripretinib#treat#gastrointestinal stromal tumours (GIST),Drug Development,NTRK,-,GIST,"avapritinib, ripretinib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
4336,KP3,39796641,Immune checkpoint inhibitor atezolizumab#treats#alveolar soft part tissue sarcoma,Drug Development,-,-,alveolar soft part tissue sarcoma,atezolizumab,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
2244,KP3,39796641,纬-secretase inhibitor nirogacestat#treats#desmoid tumours,Drug Development,-,-,desmoid tumours,nirogacestat,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
3646,KP3,39796641,NTRK inhibitors larotrectinib and entrectinib#target#tumours with NTRK fusions,Drug Development,NTRK,-,tumours with NTRK fusions,"larotrectinib, entrectinib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
2010,KP3,39796641,mTOR inhibitor nab-sirolimus#treats#PEComa,Drug Development,MTOR,-,PEComa,nab-sirolimus,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
3500,KP3,39796641,EZH-2 inhibitor tazemetostat#treats#epithelioid sarcoma,Drug Development,EZH2,-,epithelioid sarcoma,tazemetostat,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
465,KP3,39796641,Autologous T-cell therapy with afami-cel#is approved for#patients with HLA-A*02 and MAGE-A4-expressing synovial sarcoma,Clinical Implementation,MAGEA4,T cells,synovial sarcoma,afami-cel,-,-,HLA-A*02 expression,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
615,KP3,39796641,CDK4/6 inhibitors#are investigational for#well-/dedifferentiated liposarcoma,Drug Development,"CDK4,CDK6",-,well-/dedifferentiated liposarcoma,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
3912,KP3,39796641,Immune checkpoint inhibitors#are investigational for#head and neck angiosarcoma,Drug Development,-,-,head and neck angiosarcoma,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
2667,KP3,39796641,Immune checkpoint inhibitors#are investigational for#a subset of patients with undifferentiated pleomorphic sarcoma,Drug Development,-,-,undifferentiated pleomorphic sarcoma,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
2700,KP3,39796641,PARP inhibitors#are investigational for#leiomyosarcoma,Drug Development,PARP,-,leiomyosarcoma,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
2960,KP3,39318897,"Abemaciclib#is used for#hormone-receptor-positive, HER-2-negative breast cancer",Drug Development,"CDK4,CDK6",-,breast cancer,abemaciclib,-,-,"hormone-receptor-positive, HER-2-negative",-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5775,KP3,33227663,"First-line systemic treatment#includes#aromatase inhibitor and CDK4/6 inhibitor for metastatic hormone receptor-positive, HER-2-negative breast cancer",Clinical Implementation,"CDK4,CDK6",-,breast cancer,-,-,-,"metastatic hormone receptor-positive, HER-2-negative",-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
5572,KP3,30276363,"Signaling pathways#have#therapeutic targets in breast cancer, including CDK4/6",Signaling Networks,"CDK4,CDK6",-,breast cancer,-,"PI3K,AKT,VEGF,EGFR,HER2,mTOR,PARP,PD-1",-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,PI3K/AKT/mTOR通路
6145,KP3,36260177,Palbociclib#causes#grade 3/4 neutropenia in metastatic breast cancer patients,Safety Monitoring,"CDK4,CDK6",-,metastatic breast cancer,palbociclib,-,neutropenia,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
5246,KP3,36135712,Trilaciclib#induces#transient cell cycle arrest in hematopoietic stem and progenitor cells and immune cells,Cell Cycle Control,"CDK4,CDK6","hematopoietic stem cells, progenitor cells, immune cells",-,trilaciclib,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
2876,KP3,36135712,Trilaciclib#improved#overall survival in metastatic TNBC patients when administered prior to GCb,Therapeutic Response,"CDK4,CDK6",-,TNBC,"trilaciclib, gemcitabine, carboplatin",-,-,metastatic,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.2,-,协同增效作用
3807,KP3,37553297,Palbociclib#was evaluated with#standard four-drug re-induction chemotherapy in relapsed/refractory B- and T-cell lymphoblastic leukemia and lymphoma,Clinical Trial Data,"CDK4,CDK6","B cells, T cells","lymphoblastic leukemia, lymphoma",palbociclib,-,-,relapsed/refractory,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
5789,KP3,28059068,MEK inhibition#enhances#EGFR inhibitor-induced apoptosis and cell cycle arrest,Combination Therapies,EGFR,-,-,"MEK inhibitors, EGFR inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
5461,KP3,28059068,CDK4/6 and EGFR inhibitors#prevent#the emergence of resistance in vitro and in vivo,Combination Therapies,"CDK4,CDK6,EGFR",-,EGFR-amplified tumours,"CDK4/6 inhibitors, EGFR inhibitors",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
4697,KP3,39283299,Advanced breast cancer#is diagnosed as#HR-positive and HER2-negative,Clinical Description,HER2,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
55,KP3,35294522,MEK inhibitor binimetinib and CDK4/6 inhibitor ribociclib#is a rational combination for#NRAS-mutant melanoma,Combination Therapies,"CDK4,CDK6,NRAS",-,Melanoma,"Binimetinib, Ribociclib",MAPK,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
2956,KP3,35294522,Co-mutations of cell-cycle genes#may define#a population with greater likelihood of treatment benefit,Clinical Stratification,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,7,7.4,7.4.1,7.4.1.1,-,细胞周期基因集
7499,KP3,29793947,"Loss of CETN2, NEIL2, or ERCC1#induces#endocrine treatment resistance",Mechanisms of Resistance,"CETN2,NEIL2,ERCC1",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
2899,KP3,29793947,"Loss of CETN2, NEIL2, or ERCC1#increases sensitivity to#CDK4/6 inhibitors",Mechanisms of Resistance,"CETN2,NEIL2,ERCC1,CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
1474,KP3,29793947,DDR defects#are drivers of#endocrine treatment resistance,Mechanisms of Resistance,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.3,2.1.3.4,-,染色质状态改变
5345,KP3,34804958,Targeting specific mutations#acquired during the evolution of advanced breast cancer#enhances clinical efficacy,Therapeutic Strategies,-,-,Breast cancer,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
6655,KP3,34804958,ARID1A#plays a role in#maintaining luminal characteristics,Molecular Function,ARID1A,-,Breast cancer,"Endocrine therapies, HDAC inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
3915,KP3,33384227,"Targeted therapies#are directed at#HER2, VEGF, mTOR, EGFR, CDK4/6, PARP in breast cancer with brain metastases",Therapeutic Strategies,"HER2,VEGF,MTOR,EGFR,CDK4,CDK6,PARP",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3329,KP3,31477350,"CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib#demonstrate#significant clinical activity for metastatic breast cancer",Drug Development,"CDK4,CDK6",-,Metastatic breast cancer,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5318,KP3,39411551,Cyclin D1 expression#indicates use of#CDK4/6 inhibitor palbociclib,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,Cyclin D1表达
5646,KP3,36210566,CDK4/6 inhibitors#appear to have#a class thrombogenic effect in metastatic breast cancer,Adverse Effects,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,中性粒细胞减少
5725,KP3,36210566,Prothrombotic treatments#require#a personalized approach considering additive effects and pre-existing risk factors,Treatment Optimization,-,-,-,-,-,-,-,-,-,-,-,Inference,8,8.3,8.3.1,8.3.1.2,-,剂量减少
4465,KP3,36210562,"Anti-cancer treatments including surgery, radiotherapy, and certain chemotherapies#increase risk of#VTE and/or ATE",Adverse Effects,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,中性粒细胞减少
5915,KP3,36210562,Agents#target#pathways involved in tumor development and progression,Pathway Targeting,-,-,Cancer,-,"Angiogenesis, Growth factor receptor signaling, Anti-tumoral immune regulation",-,-,-,-,-,-,Fact,1,1.3,1.3.1,-,-,PI3K/AKT/mTOR通路
1734,KP3,36210562,Immune checkpoint inhibitors#are associated with#substantial rates of thrombotic complications,Adverse Effects,-,-,-,Immune checkpoint inhibitors,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,-,-,多药耐药
3298,KP3,30231371,"Checkpoint inhibitors (anti-PD-1/anti-CTLA-4)#are combined with#other immunotherapies (e.g., IDO inhibitors, anti-LAG-3, HDAC inhibitors, TLR-9 agonists, anti-GITR, pegylated IL-2)",Combination Therapies triples,-,-,-,"anti-PD-1, anti-CTLA-4, IDO inhibitors, anti-LAG-3, HDAC inhibitors, TLR-9 agonists, anti-GITR, pegylated IL-2",-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,-,-,化疗药物联合
860,KP3,30231371,"Combined targeted therapies (e.g., MEK and CDK4/6 coinhibition)#are investigated for#cancer treatment",Combination Therapies triples,"CDK4,CDK6",-,Cancer,-,MEK pathway,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
1798,KP3,30231371,The triplet combination of BRAF/MEK inhibition with anti-PD-1s#is explored for#cancer treatment,Combination Therapies triples,BRAF,-,Cancer,anti-PD-1,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
338,KP3,30186457,HER2-positive breast cancer#is characterized by#a high rate of metastasis and drug resistance,Clinical Correlation triples,ERBB2,-,Breast cancer,-,-,"Metastasis, Drug resistance",-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,7.2.1.2.2,MAPK通路活性
4155,KP3,30186457,Abemaciclib (CDK4/6 inhibitor)#has been demonstrated to#improve drug resistance,Drug Development triples,"CDK4,CDK6",-,Drug resistance,Abemaciclib,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
4776,KP3,27741402,Molecular targeted therapy#has potential to improve#clinical outcomes of patients with early-stage breast cancer as adjuvant therapy,Therapeutic Development triples,-,-,Breast cancer,-,-,-,Patients with early-stage breast cancer,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5903,KP3,27741402,Targeted agents#are used as#adjuvant treatment in BC to block key oncogenic drivers of micro-residual disease,Therapeutic Development triples,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7738,KP3,27741402,CDK4/6 inhibition#is presented as#a targeted adjuvant therapeutic strategy in BC,Therapeutic Development triples,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3897,KP3,38390865,Melanocytic and transitory cell subpopulation#is resistant to#iron-dependent oxidative stress,Resistance Mechanisms triples,-,"Melanocytic cells, Transitory cells",Melanoma,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.3,2.2.3.2,-,氧化还原失衡
6475,KP3,38390865,"Palbociclib#provoked#cell cycle arrest at the G(0)/G(1) phase, sensitizing auranofin-caused ferroptosis through senescence induction",Mechanism of Action triples,"CDK4,CDK6",-,-,"Palbociclib, Auranofin",-,-,-,Upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
2478,KP3,37603124,"Redundant combinations in hot targets (e.g., PD-1/PD-L1, PI3K, CDK4/6, PARP)#are included in#empirically driven strategies",Combination Therapies triples,"CDK4,CDK6,PI3K,PARP",-,-,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1915,KP3,36746338,Palbociclib (CDK4/6 inhibitor)#has shown promise in#phase I clinical trials of pediatric patients with progressive/refractory brain tumors,Clinical Trial Data triples,"CDK4,CDK6",-,Brain tumors,Palbociclib,-,-,Pediatric patients with progressive/refractory brain tumors,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
550,KP3,38555985,CDK4/6 inhibitors#have been shown to#prime anti-tumor immune cells and achieve impressive results in preclinical models,Therapeutic Development triples,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.3,3.3.1,3.3.1.1,-,免疫细胞浸润增加
3103,KP3,38555985,"Estrogen signaling#regulates#the immune microenvironment of normal breast, BCa, and immune disorders",Immune Cell Functions triples,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.3,-,免疫检查点表达
5914,KP3,38555985,"ER+ BCa#are described as#""immune-cold""",Cancer Association,ER,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.3,-,免疫检查点表达
5044,KP3,38555985,Research#is advocated for#therapies in combination with targeted therapies and/or immune checkpoint blockade,Therapeutic Development,-,-,Breast cancer,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5109,KP3,37190065,Development of targeted therapies and novel combination regimens#has improved#prognosis in breast cancer,Therapeutic Development,-,-,Breast cancer,"Endocrine therapies, Aromatase inhibitors, Her2-targeted therapies, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
470,KP3,29891002,CDK4/6 inhibitors#improve#progression-free survival,Therapeutic Response,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1933,KP3,29282688,"CDK4/6 inhibitors#are used in the treatment of#advanced, hormone receptor (HR)-positive postmenopausal breast cancer",Cancer Association,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,Postmenopausal,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4623,KP3,39410824,"Combination therapies with PI3K, mTOR, CDK4/6 inhibitors, and epigenetic modulators#are investigated for#synergistic effects in MPN patients",Combination Optimization,"PIK3CA,MTOR,CDK4,CDK6",-,Myeloproliferative neoplasms (MPN),"PI3K inhibitors, mTOR inhibitors, CDK4/6 inhibitors, Epigenetic modulators",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
1789,KP3,39410824,Dual or multiple inhibitors targeting JAK2 and MPN-related pathways#are urgent for#improving efficacy,Drug Development,JAK2,-,Myeloproliferative neoplasms (MPN),JAK2 inhibitors,-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
2947,KP3,38754225,Endocrine therapy plus CDK4/6 inhibitors#yielded#similar response rates and better quality of life in hormone receptor-positive breast cancer,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
3099,KP3,38754225,Combined chemotherapy (plus HER2-directed therapy for HER2-positive)#remains#the standard for HER2-positive and triple-negative breast cancer,Therapeutic Development,ERBB2,-,Breast cancer,"HER2-directed therapy, Chemotherapy",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
714,KP3,37457126,"CDK4/6 kinase inhibitor (e.g., palbociclib)#is explored for#overcoming resistance to FLT3 inhibitors",Strategies to Overcome Resistance,"CDK4,CDK6,FLT3",-,-,"FLT3 inhibitors, Palbociclib",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
5539,KP3,35484313,Trilaciclib#reduces#myelotoxicity in small-cell lung cancer patients treated with chemotherapy,Therapeutic Response,"CDK4,CDK6",-,Small-cell lung cancer,"Trilaciclib, Chemotherapy",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7460,KP3,29291023,Venetoclax combined with alvocidib#is synergistic in#AML models,Combination Optimization,"CDK4,CDK6",-,Acute myeloid leukemia (AML),"Venetoclax, Alvocidib",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
6137,KP3,34518211,Palbociclib combined with IACS-10759#demonstrates#antitumor efficacy in vitro and in vivo,Combination Optimization,"CDK4,CDK6",-,-,"Palbociclib, IACS-10759",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
3326,KP3,34103301,Biomarkers of response and resistance to FLT3 tyrosine kinase inhibitors (TKI)#are#emerging,Biomarker Analysis,FLT3,-,-,FLT3 tyrosine kinase inhibitors (TKI),-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,7.5.1.1.2,RB1丢失
3247,KP3,34103301,co-occurring mutations#influence#clinical response to FLT3 inhibitor pexidartinib (PLX3397),Mechanisms of Resistance,FLT3,-,-,pexidartinib (PLX3397),-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
3125,KP3,34103301,Mutations in CCND3#cause#primary resistance to FLT3 inhibitors in AML,Mechanisms of Resistance,"CCND3,FLT3",-,AML,FLT3 inhibitors,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
5075,KP3,34103301,Mutations in CCND3#may have sensitivity to#CDK4/6 inhibition,Mechanisms of Resistance,"CCND3,CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,2,2.4,2.4.1,2.4.1.1,-,激活性突变
2657,KP3,36158652,CDK4/6 inhibitors combined with endocrine therapy#treat#HR+/HER2- metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,HR+/HER2- metastatic breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
2803,KP3,39824712,"The SMILE study#evaluates#antiprogestin in combination with fulvestrant for ER+, PgR+/-, HER2- metastatic breast cancer",Clinical Trial Data,-,-,"ER+, PgR+/-, HER2- metastatic breast cancer","onapristone, fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.2,-,激素受体降解
2475,KP3,39824712,antiprogestins#may be evaluated with#various targeted therapies,Drug Development,-,-,-,antiprogestins,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7416,KP3,32914354,cyclin-dependent inhibitors#are a milestone in#therapeutics for ER+/HER2- metastatic breast cancer,Therapeutic Development,-,-,ER+/HER2- metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4903,KP3,32914354,Drug-related adverse events#are not yet fully characterized for#cyclin-dependent inhibitors,Safety Monitoring,-,-,-,cyclin-dependent inhibitors,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.3,-,剂量调整
1080,KP3,35008570,Mucosal melanoma#has#limited benefit from novel treatment approaches,Therapeutic Resistance,-,-,Mucosal melanoma,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
448,KP3,35008570,Mucosal melanoma#lacks#actionable driver mutations,Disease & Clinical Categories,-,-,Mucosal melanoma,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
6845,KP3,35008570,Mucosal melanoma#has#poor response to immunotherapy,Therapeutic Resistance,-,-,Mucosal melanoma,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
1609,KP3,35008570,Combo-immunotherapy#correlates with#higher rate of adverse events,Safety Monitoring,-,-,-,Combo-immunotherapy,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,血液学毒性
7817,KP3,35008570,Systemic treatment results#are updated for#mucosal melanoma,Clinical Implementation,-,-,Mucosal melanoma,-,-,-,-,-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.3,-,复发风险
7231,KP3,31401335,Concomitant genetic alterations#are associated with#worse clinical outcome in EGFR mutant NSCLC patients,Clinical Correlation triples,EGFR,-,NSCLC,-,-,-,-,-,-,-,-,Fact,2,2.3,2.3.1,2.3.1.3,-,基因融合事件
6844,KP3,31401335,EGFR-TKI#are recommended for#advanced NSCLC with sensitizing EGFR mutations,Therapeutic Development,EGFR,-,NSCLC,EGFR-TKI,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
7645,KP3,31401335,Progression-free survival#is shorter in#patients with concomitant FGFR3 mutation,Clinical Correlation triples,FGFR3,-,NSCLC,-,-,-,Patients with concomitant FGFR3 mutation,-,-,-,-,Fact,2,2.3,2.3.1,2.3.1.3,-,基因融合事件
2545,KP3,31209198,Lack of driver oncogenes#complicates#targeted treatments for HNSCC,Therapeutic Resistance,-,-,HNSCC,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
1075,KP3,31209198,LY2603618 (Rabusertib)#kills#HNSCC cells effectively,Drug Development,-,HNSCC cells,HNSCC,LY2603618 (Rabusertib),-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2189,KP3,31209198,Sensitivity to Chk1 inhibition#requires#functional CDK1 and CDK4/6,Mechanism of Action,"CDK1, CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
3873,KP3,31209198,Wee1 inhibitor Adavosertib#progresses#the cell cycle,Mechanism of Action,-,-,HNSCC,Adavosertib,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7109,KP3,31209198,Wee1 inhibitor Adavosertib#increases#lethality to Chk1 inhibition,Combination Therapies,-,-,HNSCC,"Adavosertib, Chk1 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
7822,KP3,38746158,APOBEC3 mutational signatures#are associated with#shorter progression-free survival on antiestrogen plus CDK4/6 inhibitor therapy,Clinical Correlation triples,"CDK4,CDK6",-,HR+ metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,7.5.1.1.4,耐药监测标志物：获得性耐药 - CDK6扩增
6372,KP3,39454516,Targeted therapies including CDK4/6#have not received#regulatory approval,Drug Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.4,单药治疗策略：治疗线别 - 维持治疗
2517,KP3,39454516,Immune checkpoint inhibitors (ICIs)#have shown#therapeutic efficacy,Therapeutic Response,-,-,Advanced esophageal SCC (ESCC),Immune checkpoint inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.2,3.1.3.2.1,细胞凋亡调控：死亡受体通路激活
4856,KP3,39454516,PD-L1 expression#is#the only clinically applicable biomarker for first-line therapy with ICIs in ESCC,Biomarker Analysis,-,-,ESCC,Immune checkpoint inhibitors,-,-,-,PD-L1,-,-,-,Fact,7,7.2,7.2.1,7.2.1.3,7.2.1.3.1,预后生物标志物：免疫标志物 - PD-L1表达
6753,KP3,38779868,Palbociclib or ribociclib#showed#limited efficacy in tumors with CDK4/6 pathway alterations,Therapeutic Response,"CDK4,CDK6",-,Tumors with CDK4/6 pathway alterations,"Palbociclib, Ribociclib",-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,获得性耐药的分子基础：替代性生存通路
414,KP3,38107071,Ribociclib#is#a potent CDK4/6 inhibitor administered for HR+/HER2- breast cancer,Drug Development,"CDK4,CDK6",-,HR+/HER2- breast cancer,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,CDK4/6抑制剂的作用机制：G1/S期转换抑制
6478,KP3,35485642,Early broad-spectrum CDK inhibitors#lack#a clinical therapeutic window due to toxicity,Drug Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,8,8.3,8.3.1,8.3.1.2,8.3.1.2.1,剂量优化：不良反应管理 - 剂量减少
3352,KP3,34978424,Endocrine therapy using ribociclib#is#an approach for treating HR+/HER2- MBC,Therapeutic Development,"CDK4,CDK6",-,HR+/HER2- MBC,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,3.2.1.3.3,联合治疗的机制基础：协同抗增殖作用
2067,KP3,33804398,CDK4/6 inhibitors#are studied in#combination with anti-HER2 agents in clinical trials,Combination Therapies,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,联合用药方案：联合芳香化酶抑制剂 - 来曲唑
2248,KP3,32431130,CDK4/6 inhibitors#have improved#response rates and time to progression in metastatic hormone-responsive breast cancer,Therapeutic Response,"CDK4,CDK6",-,Metastatic hormone-responsive breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,CDK4/6抑制剂的作用机制：增殖信号阻断
1066,KP3,37453150,Targeted agents including CDK4/6 inhibitors#might provide#new therapy options in the future,Drug Development,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.3,8.1.1.3.4,单药治疗策略：患者选择 - 耐受性评估
5702,KP3,34994597,Palbociclib#addressed#CDKN2A-inactivating alterations,Therapeutic Response,"CDK4,CDK6,CDKN2A",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,原发性耐药的机制：CDKN2A缺失
4851,KP3,33463941,CDK4/6 inhibitors#are combined with#PI3K/mTOR inhibitors and HER2 antibodies,Combination Therapies,"CDK4,CDK6",-,-,"CDK4/6 inhibitors, PI3K/mTOR inhibitors",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,8.2.1.2.2,联合用药方案：联合降雌激素药物 - 他莫昔芬
1602,KP3,38880927,Abemaciclib#showed#clinical efficacy in phase II trials,Therapeutic Response,"CDK4,CDK6",-,-,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.1,8.6.1.1.2,随访评估：随访计划 - 定期随访
3907,KP3,38645422,Palbociclib#was administered to#address CDKN2A/B alterations,Therapeutic Response,"CDK4,CDK6,CDKN2A,CDKN2B",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,原发性耐药的机制：CDKN2A缺失
3701,KP3,38645422,Tyrosine kinase inhibitors#serve as#viable alternatives for patients without access to pan-FGFR inhibitors,Drug Development,FGFR,-,-,Pazopanib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,单药治疗策略：肿瘤类型 - 晚期实体瘤
927,KP3,37876970,Treatment initiation#was defined as#dispensing during the last three months of life with a nine-month washout period,Treatment Monitoring,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,8.5.1.3.4,治疗监测：临床评估 - 长期预后
3720,KP3,37876970,Endocrine treatment#was continued by#39% of women during their last three months of life,Clinical Implementation,-,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,8.5.1.3.4,治疗监测：临床评估 - 长期预后
5913,KP3,37876970,Endocrine treatment continuation#was more likely among#older and less educated women,Patient Characteristics,-,-,Metastatic breast cancer,-,-,-,"Older women, less educated women",-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.2,8.6.1.2.3,随访评估：评估内容 - 生活质量
5149,KP3,37876970,Treatment-related factors#were associated with#treatment initiation,Treatment Monitoring,-,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,8.5.1.3.4,治疗监测：临床评估 - 长期预后
7256,KP3,37876970,More than a third of women with metastatic breast cancer#continue#endocrine treatments potentially past the point of benefit,Treatment Monitoring,-,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,8.5.1.2.2,生物标志物监测
4624,KP3,37876970,Further research#is warranted to determine#whether results reflect overtreatment at the end of life,Clinical Implementation,-,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Inference,8,8.5,8.5.1,8.5.1.2,8.5.1.2.2,生物标志物监测
7747,KP3,37504365,Most patients#had#hormone-receptor-positive and HER2-negative disease,Patient Characteristics,ERBB2,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.2,7.4.1.2.1,Luminal亚型
170,KP3,37504365,Forty toxicity events#were reported with#the majority being grade 1-2 events,Safety Monitoring,-,-,-,-,-,Toxicity,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
2202,KP3,37504365,37.5% of patients#experienced#grade 3-5 toxicities with SBRT and CDK4/6 inhibitor,Safety Monitoring,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitor,-,Toxicity,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
1548,KP3,37504365,"Progression-free and overall survival#ranged from#17 to 57% and 62 to 91%, respectively",Treatment Outcomes,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,8.5.1.1.1,CT扫描
6564,KP3,35693093,Metastatic melanoma#has#a five-year survival of ~10%,Disease Statistics,-,-,Metastatic melanoma,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,8.5.1.1.1,CT扫描
5295,KP3,35693093,Patients with melanoma or GBM and MDM2/4 amplifications and CDKN2A alterations#may benefit from#combinations of MDM2/4 and CDK4/6 inhibitors and immunotherapy,Combination Therapies,"MDM2, MDM4, CDKN2A, CDK4, CDK6",-,"Melanoma, GBM","MDM2/4 inhibitors, CDK4/6 inhibitors, immunotherapy",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,3.2.2.4.1,多靶点抑制策略
2704,KP3,35288936,One-third of patients with metastatic CRPC#exhibited#primary abiraterone resistance,Therapeutic Resistance,-,-,Metastatic CRPC,Abiraterone,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,2.2.1.4.1,关键基因突变
868,KP3,35288936,"Three drugs#were identified including#TOP2 inhibitor mitoxantrone, CDK4/6 inhibitor palbociclib, and pan-CDK inhibitor PHA-793887",Drug Development,"CDK4, CDK6, TOP2",-,-,"Mitoxantrone, Palbociclib, PHA-793887",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,3.1.1.4.1,增殖信号阻断
1239,KP3,35288936,These drugs#significantly suppressed#growth of abiraterone-resistant cell lines and PDX models,Drug Development,-,-,Metastatic CRPC,"Mitoxantrone, Palbociclib, PHA-793887",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,3.1.1.4.1,增殖信号阻断
7676,KP3,28114255,MEK and CDK4/6 inhibition#are burgeoning strategies for#NRAS-mutant melanoma,Therapeutic Development,"CDK4, CDK6, NRAS",-,NRAS-mutant melanoma,"MEK inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,3.2.2.3.1,MEK抑制剂组合
5306,KP3,34690920,A 60-year-old female#presented with#nausea and vomiting after treatment with abemaciclib and fulvestrant for bone metastasis of ILC,Patient Characteristics,"CDK4, CDK6",-,Bone metastasis of ILC,"Abemaciclib, Fulvestrant",-,"Nausea, vomiting",60-year-old female,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,8.4.1.2.1,胃肠道反应
3012,KP3,34690920,"Peritoneal metastatic lesions#acquired#ESR1 and PI3KCA mutations, explaining endocrine therapy resistance",Mechanisms of Resistance,"ESR1, PIK3CA",-,Peritoneal metastasis,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,2.1.1.4.1,ESR1突变
2965,KP3,34419350,Palbociclib#causes#myelosuppression due to cytostatic CDK6 inhibition on bone marrow,Drug Development,CDK6,-,Myelosuppression,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,3.1.1.4.1,增殖信号阻断
7352,KP3,31833955,MEK inhibition#is being developed as#a therapy in NRAS-mutated melanoma,Drug Development,NRAS,-,Melanoma,-,"MAPK, PI3K, CDK4/6",-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,3.2.2.3.1,MEK抑制剂组合
3690,KP3,31833955,CDK4/6 inhibitors#are used in combination with#MAPK and PI3K inhibitors,Combination Optimization,"CDK4, CDK6",-,Melanoma,-,"MAPK, PI3K",-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,3.2.2.1.1,PI3K抑制剂协同
2008,KP3,27409346,"Patients#are treated with#chemotherapy, radiotherapy, and surgery",Clinical Implementation,-,-,-,"Chemotherapy, Radiotherapy",-,-,General patients,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
697,KP3,37170613,CDK4/6 inhibitors#cause#hepatotoxicity,Safety Monitoring,"CDK4, CDK6",-,Metastatic breast cancer,-,-,Hepatotoxicity,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,8.4.1.2.2,肝功能异常
3443,KP3,35358627,Palbociclib#a CDK4/6 inhibitor#was evaluated in combination with sunitinib,Combination Optimization,"CDK4, CDK6",-,-,"Palbociclib, Sunitinib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,3.2.2.4.1,多靶点抑制策略
1523,KP3,31495008,Ribociclib#a CDK4/6 inhibitor#was used in combination with aromatase inhibitors,Combination Optimization,"CDK4,CDK6",-,-,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,联合芳香化酶抑制剂
2391,KP3,38280968,Abemaciclib#a CDK4/6 inhibitor#was used as adjuvant treatment in luminal-like breast cancer,Therapeutic Development,"CDK4,CDK6",-,Luminal-like breast cancer,Abemaciclib,-,-,High-risk patients,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5916,KP3,38280968,MonarchE trial#may affect#surgical practices,Clinical Implementation,-,-,High-risk breast cancer,Abemaciclib,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3543,KP3,39821032,RANK protein expression#is an independent biomarker of#poor prognosis in postmenopausal ER-negative breast cancer,Biomarker Analysis,TNFRSF11A,-,ER-negative breast cancer,-,-,-,Postmenopausal patients,Upregulated,RANK,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.4,RB蛋白表达
6216,KP3,39145854,Aromatase inhibitors#demonstrate#promising outcomes in luminal A tumors,Therapeutic Response,-,-,Luminal A tumors,Aromatase inhibitors,-,-,"Postmenopausal, low-grade patients",-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,联合芳香化酶抑制剂
7418,KP3,29404806,Ribociclib#improves#progression-free survival in HR+/HER2- advanced breast cancer,Therapeutic Development,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,Ribociclib,-,-,Hormone receptor-positive patients,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5383,KP3,30826934,"Triple-negative breast cancer#lacks#estrogen, progesterone, and HER2 receptors",Disease Characterization,-,-,Triple-negative breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
4652,KP3,19509251,CDK inhibition biomarkers#have not been identified for#predicting efficacy against cancers,Biomarker Analysis,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,-,获得性耐药
3815,KP3,33050633,Estrogen receptor expression#accounts for#70% of breast cancer cases,Expression Patterns,ESR1,-,Breast cancer,-,-,-,-,Expressed,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.3,ESR1突变
6368,KP3,33050633,CDK4/6 inhibitors#increase#overall survival of relapsing breast cancer patients,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,-,-,-,Relapsing patients,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7317,KP3,33050633,ATF3 expression#was elevated in#breast cancer patient datasets,Expression Patterns,ATF3,-,Breast cancer,-,-,-,-,Upregulated,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
5198,KP3,32883002,"CDK4/6 inhibitors#interact with#drug, gene, and pathophysiological conditions in breast cancer",Mechanism of Action,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
1976,KP3,32883002,Interindividual variability#has been reported in#therapeutic response of CDKis,Patient Stratification,"CDK4,CDK6",-,Breast cancer,CDKis,-,-,Interindividual variability,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,-,患者选择
4495,KP3,31261643,"Circulating tumor cells (CTCs)#hold promise for#prognosis, treatment optimization, and monitoring of breast cancer patients",Biomarker Analysis,-,Circulating tumor cells (CTCs),Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
542,KP3,31261643,ER-positive CTCs#exhibited#higher expression of Cyclin D1,Expression Patterns,CCND1,Circulating tumor cells (CTCs),Breast cancer,-,-,ER-positive,Upregulated,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
6714,KP3,38847486,"Cyclins, CDKs, CDK inhibitors, checkpoint kinases, and mitotic regulators#are therapeutic targets in#cancer",Drug Development,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,细胞周期阻滞
6912,KP3,38847486,"CDK4/6 inhibitors like palbociclib, ribociclib, and abemaciclib#are promising strategies for#breast cancer treatment",Therapeutic Development,"CDK4,CDK6",-,Breast cancer,"Palbociclib,Ribociclib,Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
952,KP3,38847486,"Future efforts#should focus on#combinatorial therapies, next-generation inhibitors, and biomarkers for patient selection",Translational Research,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,-,-,靶向药物联合
2546,KP3,28389808,Overcoming aromatase inhibitor resistance in breast cancer#focuses on#possible mechanisms and clinical applications,Mechanisms of Resistance,AR,-,Breast cancer,Aromatase inhibitors,-,Resistance,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
7616,KP3,28389808,Aromatase inhibitors (AIs)#inhibit#the growth of hormone-dependent breast cancers,Mechanism of Action,AR,-,Hormone-dependent breast cancer,Aromatase inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6663,KP3,28389808,AIs#block#the conversion of adrenal androgens to estrogen,Mechanism of Action,AR,-,-,Aromatase inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7491,KP3,28389808,Some breast cancer patients#relapse due to#acquisition of AI resistance,Mechanisms of Resistance,AR,-,Breast cancer,Aromatase inhibitors,-,Relapse,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
5608,KP3,28389808,This review#summarizes#several hypotheses of AI-resistance mechanisms,Mechanisms of Resistance,AR,-,Breast cancer,Aromatase inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
6402,KP3,27186656,The CDK4/6 inhibitor palbociclib#is successful in#combination with aromatase inhibitors in luminal breast cancer,Combination Optimization,"CDK4,CDK6",Luminal breast cancer,Breast cancer,"Palbociclib,Aromatase inhibitors",-,Combination therapy,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
5063,KP3,37500131,Estrogen receptor#was strongly positive in#breast cancer and focally positive in gastric cancer with bone metastasis,Biomarker Analysis,ESR1,-,"Breast cancer, gastric cancer with bone metastasis",-,-,-,Upregulated,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.4,ER/PR状态
2323,KP3,37500131,"The patient#was treated with#an aromatase inhibitor, a CDK4/6 inhibitor, and a RANKL monoclonal antibody",Combination Therapies,"CDK4,CDK6,RANKL",-,Breast cancer,"Aromatase inhibitors,CDK4/6 inhibitors,RANKL monoclonal antibody",-,Treatment,-,-,-,-,-,Fact,3,3.2,3.2.1,-,-,内分泌治疗联合
1616,KP3,37500131,The patient#showed#no symptoms or disease progression at 9-month follow-up,Treatment Monitoring,-,-,Breast cancer,-,-,No symptoms or progression,-,-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.1,-,随访时间点
701,KP3,34572780,In vitro analyses#determined efficacy of#the selective CDK4/6 inhibitor palbociclib on HPV(U) cancer cell lines,Preclinical Models,"CDK4,CDK6",-,HPV(U) cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5312,KP3,33762647,Patients#started receiving#chemotherapy or CDK4/6 inhibitor therapy in combination with endocrine therapy,Combination Therapies,"CDK4,CDK6",-,Breast cancer,"CDK4/6 inhibitors,Endocrine therapy",-,Baseline treatment,-,-,-,-,-,Fact,3,3.2,3.2.1,-,-,内分泌治疗联合
1394,KP3,35642432,Activating mutations in ER伪#confer#partial resistance to endocrine-based therapies,Mechanism of Resistance,ESR1,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
3317,KP3,36853016,Palbociclib#is approved for#advanced breast cancer in combination with endocrine therapy,Drug Development,"CDK4,CDK6",-,Advanced breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1665,KP3,32657779,CDK4/6 inhibitors#provide#efficacy in metastatic breast cancer,Drug Development,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
3164,KP3,39703168,Fatigue#is a#common nonhematologic toxicity of palbociclib in metastatic breast cancer patients,Side Effect Analysis,"CDK4,CDK6",-,Metastatic breast cancer,Palbociclib,-,Fatigue,Clinician-rated prevalence,"39.2% all-grade, 2.5% grade 3/4",-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,8.4.1.2.3,疲劳
4991,KP3,39316248,Alterations in CDK4/6#were most frequently investigated in#corresponding drugs abemaciclib and ribociclib,Biomarker Analysis,"CDK4,CDK6",-,-,"Abemaciclib, Ribociclib",-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
3942,KP3,29262551,CDK4/6 inhibitors#were effective in#Ewing's sarcoma PDOX,Drug Development,"CDK4,CDK6",-,Ewing's sarcoma,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.4,软组织肉瘤
6830,KP3,37380659,Clinical trials#provide#experience with CDK4/6 inhibitors in HR+/HER2- early breast cancer,Clinical Trial Data,"CDK4,CDK6",-,HR+/HER2- early breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3413,KP3,32755262,Real-world evidence#is limited for#HR+/HER2- metastatic breast cancer prior to CDK4/6 inhibitors,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
3791,KP3,38240964,Palbociclib and abemaciclib#are used to treat#breast cancer,Drug Development,"CDK4,CDK6",-,Breast cancer,"Palbociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
6636,KP3,37061333,Cyclins and CDKs#control#cell division,Cell Cycle Control,"CDK4,CDK6",-,-,-,-,Cell division,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
4008,KP3,37061333,"Ribociclib, Palbociclib, and Abemaciclib#have received#FDA approval for breast cancer treatment",Drug Development,"CDK4,CDK6",-,Breast cancer,"Ribociclib, Palbociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
7492,KP3,36778271,"Ki67(+) proliferative cells#respond to#palbociclib, a CDK4/6 inhibitor",Mechanism of Action,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4291,KP3,35767226,Abemaciclib#is a mainstay of treatment for#hormone receptor-positive breast cancer,Drug Development,"CDK4,CDK6",-,Hormone receptor-positive breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
6589,KP3,33348420,Trilaciclib#preserves#haematopoietic stem and progenitor cells during chemotherapy,Therapeutic Development,"CDK4,CDK6",Haematopoietic stem and progenitor cells,-,Trilaciclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.1,-,时序性联合
3288,KP3,33348420,Trilaciclib#was well tolerated with#fewer high-grade haematological toxicities than placebo,Side Effect Analysis,"CDK4,CDK6",-,-,Trilaciclib,-,Haematological toxicity,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
5800,KP3,33348420,Trilaciclib#generated#more newly expanded peripheral T-cell clones than placebo,Immune Cell Functions,"CDK4,CDK6",Peripheral T cells,-,Trilaciclib,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,6.1.1.1.3,记忆T细胞
589,KP3,25792301,Palbociclib#was approved for#postmenopausal women with ER+/HER2- advanced breast cancer,Clinical Implementation,"CDK4,CDK6",-,ER+/HER2- advanced breast cancer,Palbociclib,-,-,Postmenopausal women,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
680,KP3,39823755,Trilaciclib#reduces#chemotherapy-induced myelosuppression,Drug Development,"CDK4, CDK6",-,Myelosuppression,Trilaciclib,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.3,血小板减少
7924,KP3,39116089,Cell cycle disruption#causes#breast cancer,Cancer Association,CDK inhibitors,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7161,KP3,39116089,Palbociclib#is used for#treatment of ER+ metastatic cancers,Therapeutic Development,"CDK4, CDK6",-,Metastatic cancers,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
2523,KP3,35881485,Acquired mutations in ESR1#cause#endocrine therapy resistance in metastatic ER+ breast cancer,Mechanisms of Resistance,ESR1,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
4106,KP3,29954777,Matched therapy#extends#progression-free survival in patients with highly actionable biomarkers,Therapeutic Response,-,-,-,-,-,-,Patients with actionable biomarkers,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
6228,KP3,29247039,FGF19#activates#FGFR4 to drive hepatocellular carcinoma,Cancer Association,"FGFR4, FGF19",-,Hepatocellular carcinoma,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,MAPK通路激活
6605,KP3,29247039,Pan-FGFR inhibitors#are limited by#dose-limiting toxicities mediated by FGFR1-3 receptors,Drug Development,"FGFR1, FGFR2, FGFR3",-,-,Pan-FGFR inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
6506,KP3,29247039,FGF19 expression#is a predictive biomarker for#H3B-6527 response,Biomarker Analysis,FGF19,-,Hepatocellular carcinoma,H3B-6527,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
2083,KP3,29247039,Palbociclib in combination with H3B-6527#triggers#tumor regression in HCC xenograft models,Combination Therapies,"CDK4, CDK6, FGF19",-,Hepatocellular carcinoma,"Palbociclib, H3B-6527",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1373,KP3,21367843,Endocrine therapy#treats#ER-positive breast cancers,Therapeutic Development,ESR1,-,Breast cancer,Endocrine therapy,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
3464,KP3,21367843,Suppression of cyclin D-supported kinase activity#is viable for#tumors resistant to hormone therapies,Therapeutic Resistance,-,-,Tumors resistant to hormone therapies,-,-,-,-,-,-,-,-,Inference,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
3863,KP3,21367843,PD-0332991#suppresses#proliferation in hormone refractory models,Therapeutic Development,"CDK4, CDK6",-,Hormone refractory tumors,PD-0332991,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3097,KP3,38421520,Cutaneous adverse events#occur in#patients treated with antineoplastic treatments,Safety Monitoring,-,-,Cutaneous adverse events,Antineoplastic treatments,-,-,Patients treated with antineoplastic treatments,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
6816,KP3,38421520,CDK4/6 cyclin inhibitors#cause#skin toxicity in patients,Safety Monitoring,"CDK4, CDK6",-,Skin toxicity,CDK4/6 cyclin inhibitors,-,-,Patients treated with CDK4/6 inhibitors,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
4105,KP3,38255255,"WHO Classification#incorporates#histological, immunophenotypic, and molecular features for GBM diagnosis",Translational Research,-,-,Glioblastoma,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
5018,KP3,38255255,FGFR inhibitors#are evaluated for#GBM treatment,Drug Development,"FGFR1, FGFR2, FGFR3",-,Glioblastoma,FGFR inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6002,KP3,38255255,Clinicopathological information#is compared between#F3T3-positive and F3T3-negative GBMs,Translational Research,-,-,Glioblastoma,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
5747,KP3,38255255,TERT promoter mutation#is identified in#grade 4 GBMs,Biomarker Analysis,TERT,-,Glioblastoma,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
2233,KP3,38255255,Patients with follow-up periods exceeding 20 months#died of#disease,Long-Term Outcomes,-,-,Glioblastoma,-,-,-,Patients with >20-month follow-up,-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.3,-,预后评估
4230,KP3,38255255,F3T3-positive GBMs#harbor#TERT promoter mutations,Cancer Association,TERT,-,GBM,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
6041,KP3,38255255,F3T3-positive GBMs#exhibit#7+/10-,Cancer Association,-,-,GBM,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.2,5.2.2.3,-,染色体丢失
7768,KP3,38255255,"Amplifications of EGFR, PDGFRA, and KIT#were not detected in#F3T3-positive GBMs",Cancer Association,"EGFR,PDGFRA,KIT",-,GBM,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
6886,KP3,32532875,PAX3-FOXO1 fusion#is associated with#alveolar rhabdomyosarcoma,Cancer Association,"PAX3,FOXO1",-,Alveolar rhabdomyosarcoma,-,-,-,14-yr-old male,upregulated,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
7878,KP3,32532875,RET C634F mutation#is a driver of#MEN2A cancer,Cancer Association,RET,-,MEN2A cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,关键基因突变
5867,KP3,38653982,PD-1/PD-L1 checkpoint blockade#shows#some efficacy in metastatic breast cancer,Therapeutic Response,"CD274,PDCD1",-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.3,3.3.2,3.3.2.3,-,免疫逃逸抑制
7462,KP3,38653982,Mass cytometry analysis#was performed on#peripheral blood immune cells,Technical Methods,-,Immune cells,Metastatic breast cancer,-,-,-,"104 patients, 20 healthy donors",-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,-,生物标志物监测
6353,KP3,38653982,mBC patients#had#elevated monocyte levels,Immune Cell Functions,-,Monocytes,Metastatic breast cancer,-,-,-,-,upregulated,-,-,-,Fact,6,6.1,6.1.1,6.1.1.2,-,髓系细胞浸润
1116,KP3,38653982,mBC patients#had#reduced levels of CD4(+) T cells and plasmacytoid dendritic cells,Immune Cell Functions,-,"CD4(+) T cells,Plasmacytoid dendritic cells",Metastatic breast cancer,-,-,-,-,downregulated,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
5401,KP3,38653982,Previous chemotherapy and CDK4/6 inhibition#impacted#immune cell numbers and phenotype,Immune Cell Functions,"CDK4,CDK6",Immune cells,-,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
6147,KP3,38653982,A CD4(+) T cell cluster#was negatively associated with#tumor infiltration,Immune Cell Functions,-,CD4(+) T cells,Tumor,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
5545,KP3,36915147,BCSC secretome#potentiated#estrogen receptor activity in cancer cell population,Signaling Networks,ESR1,-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.1,1.2.1.2,-,激素信号通路
5639,KP3,36915147,BCSC secretome#renders#bulk cancer cell population resistant to anti-estrogen and CDK4/6 inhibitor therapy,Resistance Mechanisms,"CDK4,CDK6",Bulk cancer cells,Cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
4881,KP3,36915147,BCSC secretome#increases#metastatic burden attributable to bulk cancer cells,Metastasis Biology,"CDK4,CDK6",Bulk cancer cells,Cancer,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.3,6.1.1.3.1,PD-1/PD-L1表达
3339,KP3,36915147,Pharmacological inhibition of IL8#abrogates#metastatic burden,Metastasis Biology,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.3,6.1.1.3.1,PD-1/PD-L1表达
5011,KP3,31318440,Acquisition of ligand-independent ESR1 mutations#is#a common mechanism of hormonal therapy resistance,Resistance Mechanisms,ESR1,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
939,KP3,31318440,Patients with ESR1 mutations#derive#clinical benefit when treated with fulvestrant and CDK4/6-targeted therapies,Therapeutic Response,"ESR1,CDK4,CDK6",-,Breast cancer,Fulvestrant,-,-,-,-,-,-,-,Fact,-,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1
1888,KP3,31318440,Development of more potent selective ER degraders#is needed to overcome#endocrine-resistant phenotype of ESR1 mutant-bearing tumors,Therapeutic Development,ESR1,-,Breast cancer,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
1652,KP4,35304604,New insights into CDK4/6 mechanisms of action#trigger#identification of new therapeutic opportunities,Mechanism of Action,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
4389,KP4,35304604,Development of novel combination regimens#is triggered by#new insights into CDK4/6 mechanisms of action,Combination Therapies,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6405,KP4,35304604,CDK4/6 inhibitor resistance#is#an increasingly common challenge in clinical oncology,Resistance Mechanisms,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
4078,KP4,32289274,Inhibiting CDK4 and CDK6#results in#therapeutic effect in advanced hormone-positive breast cancer,Therapeutic Response,"CDK4,CDK6",-,Advanced hormone-positive breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4643,KP4,32289274,Efficacy of CDK4/6 inhibition#is limited by#innate or acquired resistance mechanisms,Resistance Mechanisms,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
633,KP4,32289274,"CDK4/6 inhibitors#are used in combination with#targeted therapies, immunotherapy, or chemotherapy",Combination Therapies,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
232,KP4,30537512,Loss-of-function mutations affecting FAT1 and RB1#are linked to#drug resistance in ER(+) breast cancers treated with CDK4/6 inhibitors,Resistance Mechanisms,"FAT1,RB1,CDK4,CDK6",-,ER(+) breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
4216,KP4,39136283,"SCLC mouse models, CDX models, and PDX models#reveal#potential effects of CDK4/6 inhibitors on SCLC chemoresistance",Preclinical Models,"CDK4,CDK6",-,Small cell lung cancer (SCLC),-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
7560,KP4,39437014,Subprotocol Z1C#was designed to evaluate#palbociclib in CDK4- or CDK6-amplified tumors,Clinical Trial Data,"CDK4,CDK6",-,Cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
6797,KP4,38403110,CD63(+) CAFs#are#highly enriched in CDK4/6i resistant tumor tissues,Expression Patterns,"CDK4,CDK6",Cancer-associated fibroblasts (CAFs),ER(+) breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.3,2.3.3,2.3.3.2,-,蛋白表达量
6773,KP4,35878668,Cyclin-dependent kinase 6#plays#significant roles in cell cycle events,Mechanism of Action,CDK6,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7689,KP4,35878668,CDK4/6 inhibitors#regulate#G1 to S transition by preventing Rb phosphorylation and E2F liberation,Mechanism of Action,"CDK4,CDK6",-,HR+/HER2- breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
812,KP4,35878668,Combination of CDK4/6 inhibitors with other drugs#is discussed for#therapeutic management of cancer,Combination Therapies,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4355,KP4,29408328,Ribociclib#enhances#glucocorticoid sensitivity in B-ALL,Therapeutic Development,"CDK4,CDK6",B cells,B-acute lymphoblastic leukemia (B-ALL),Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
6867,KP4,29408328,Pharmacologic inhibition of CDK4/CDK6#represents#a therapeutic strategy to control cell proliferation in B-ALL,Therapeutic Response,"CDK4,CDK6",B cells,B-acute lymphoblastic leukemia (B-ALL),-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6756,KP4,29408328,Pharmacologic inhibition of CDK4/CDK6#provides#insight into glucocorticoid resistance mechanisms,Resistance Mechanisms,"CDK4,CDK6",B cells,B-acute lymphoblastic leukemia (B-ALL),-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
3821,KP4,37451269,Intrinsic and acquired resistance#affects#long-term efficacy of CDK4/6 inhibitors,Resistance Mechanisms,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
2724,KP4,37451269,RANK pathway#is involved in#CDK4/6i resistance,Mechanisms of Resistance triples,"CDK4,CDK6",-,-,-,RANK,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
1052,KP4,26149830,Abemaciclib and palbociclib#are compared for#central nervous system exposure,Drug Development triples,"CDK4,CDK6",-,-,"Abemaciclib, Palbociclib",-,-,-,-,-,-,-,Fact,3,3.6,3.6.3,3.6.3.4,-,血脑屏障穿透
2898,KP4,38302240,Flow cytometry#assesses#cell cycle distribution and active DNA replication in MCF7 cells,Technical Methods triples,-,MCF7 cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7387,KP4,28479958,D-type cyclins and CDKs 4/6#play roles in#breast cancer,Cancer Association triples,"CDK4,CDK6,CCND1,CCND2,CCND3",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
193,KP4,28479958,Preclinical and clinical studies#explore#mechanisms of CDK4/6 inhibitor response and resistance in breast cancer,Mechanisms of Resistance triples,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
834,KP4,28479958,"Putative markers of response#include#ER-positivity, luminal patterns of gene expression, high cyclin D1 levels, and low p16 levels",Biomarker Analysis triples,"CCND1,CDKN2A,ESR1",-,Breast cancer,-,-,-,-,"Upregulated (Cyclin D1), Downregulated (p16)",ER-positivity,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
2746,KP4,29374415,Palbociclib and ribociclib#are registered for#first-line treatment in combination with letrozole,Drug Development triples,"CDK4,CDK6",-,Breast cancer,"Palbociclib, Ribociclib, Letrozole",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
1124,KP4,29374415,Palbociclib and abemaciclib#are approved for#second-line therapy in combination with fulvestrant,Drug Development triples,"CDK4,CDK6",-,Breast cancer,"Palbociclib, Abemaciclib, Fulvestrant",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,8.2.1.2.1,氟维司群
6095,KP4,27748766,ER/PR expression#is reduced after#CDK4/6 inhibitor resistance,Expression Patterns triples,"ESR1,PGR",-,Breast cancer,-,-,-,-,Downregulated,-,-,-,Fact,2,2.3,2.3.2,2.3.2.4,-,通路活性标志
2281,KP4,32885893,Cyclin genes and hormone genes#are analyzed for#alterations in CDK4/6 inhibitor resistance,Mechanisms of Resistance triples,"CDK4,CDK6,CCND1,CCND2,CCND3,CDKN2A,CDKN2B,ESR1,AR,RB1,CCNE1",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
1717,KP4,34948218,Pharmacophore model#is designed based on#FDA-approved CDK4/6 inhibitor structures,Drug Development triples,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,-,-,-,-,-,药物开发
3609,KP4,35075231,Variants of unknown significance (VUS)#remain#newly discovered mutations,Genomic Analysis,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,基因组稳定性
7165,KP4,35813283,"Abemaciclib#is approved for#HR+, HER2- advanced breast cancer",Clinical Implementation,"CDK4,CDK6",-,"HR+, HER2- advanced breast cancer",Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
535,KP4,35813283,"Abemaciclib#is used with#endocrine therapy for HR+, HER2- advanced breast cancer",Combination Therapies,"CDK4,CDK6",-,"HR+, HER2- advanced breast cancer",Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
5691,KP4,36806942,Polymorphic patients#experience#rapid failure in response to endocrine monotherapy,Patient Characteristics,-,-,Advanced cancer,-,-,-,Polymorphic,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
3561,KP4,36806942,Adding CDK4/6 inhibitors#eliminates#differences in progression-free survival for polymorphic patients,Therapeutic Response,"CDK4,CDK6",-,Advanced cancer,-,-,-,Polymorphic,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2910,KP4,39271490,Combination of CDK4/6 inhibitors and endocrine drugs#causes#dose reduction and discontinuation,Treatment Monitoring,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,8,8.3,8.3.1,8.3.1.2,-,不良反应管理
204,KP4,39271490,Comprehensive evaluation#is required for#avoiding dosage reductions and discontinuations in CDK4/6 inhibitor treatments,Clinical Implementation,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,8,8.5,8.5.1,8.5.1.2,-,生物标志物监测
3689,KP4,33663223,Palbociclib#demonstrates#improved outcomes in RWE studies,Clinical Trial Data,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
5094,KP4,33663223,Comparative data between CDK4/6i and endocrine monotherapy#are limited in#long-term studies,Clinical Trial Data,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
1809,KP4,39447792,"Virtual screening process#incorporated#drug-likeness filters, ADME, and toxicity predictions",Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,3,3.6,3.6.1,3.6.1.1,-,纳米载体设计
5042,KP4,34145036,Palbociclib in combination with ruxolitinib#may have#therapeutic potential for myelofibrosis,Combination Therapies,"CDK4,CDK6",-,Myelofibrosis,"Palbociclib, Ruxolitinib",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
780,KP4,34154797,"palbociclib, ribociclib, and abemaciclib#have been evaluated in#pivotal, randomized phase III trials",Clinical Trial Data,-,-,-,"palbociclib, ribociclib, abemaciclib",-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
1429,KP4,27336726,ribociclib plus letrozole#was assessed for#biological activity in the presurgical setting,Clinical Trial Data,"CDK4, CDK6",-,-,"ribociclib, letrozole",-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
6367,KP4,39392584,CDK4/6 inhibitors#were associated with#AEs reported in FAERS,Safety Monitoring,"CDK4, CDK6",-,-,"abemaciclib, ribociclib, palbociclib",-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,血液学毒性
1846,KP4,30837298,Direct CDKN2 modulation#alters#target engagement of CDK4 inhibitor drugs,Mechanism of Action,"CDK4, CDKN2",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7965,KP4,30837298,palbociclib#displays#cell type-specific target engagement,Expression Patterns,"CDK4, CDK6",-,-,palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5664,KP4,30837298,high levels of CDKN2A#predict#insensitivity to palbociclib,Biomarker Analysis,CDKN2A,-,-,palbociclib,-,-,high,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
6940,KP4,30837298,high CDKN2A#may provide#a useful biomarker to exclude patients from CDK4/6 inhibitor therapy,Biomarker Analysis,CDKN2A,-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
3847,KP4,39347707,MPNSTs#are characterized by#loss of NF1 and hyperactivation of MEK and CDK4/6 kinases,Cancer Pathways,"NF1, MEK, CDK4, CDK6",-,Malignant peripheral nerve sheath tumors (MPNSTs),-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
5683,KP4,39347707,dual CDK4/6-MEK inhibition#demonstrated#remarkable efficacy in de novo MPNSTs,Therapeutic Development,"CDK4, CDK6, MEK",-,Malignant peripheral nerve sheath tumors (MPNSTs),-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
4050,KP4,39347707,"future therapeutic strategies#target#oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1",Future Directions,"CDK4, CDK6, MEK, PD-L1, FOXM1",-,Malignant peripheral nerve sheath tumors (MPNSTs),-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
3091,KP4,38978241,CDK4/6 inhibitors#impact#erythrocyte mean corpuscular volume (MCV) change,Biomarker Analysis,"CDK4, CDK6",Erythrocytes,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,7,7.3,7.3.1,7.3.1.1,-,细胞周期标志物
3451,KP4,26988987,vemurafenib-resistant tumors#remain sensitive to#palbociclib,Therapeutic Resistance,"CDK4, CDK6",-,Vemurafenib-resistant metastatic disease,palbociclib,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
586,KP4,35021603,deucravacitinib#reduces#cell viability of TYK2 P760L-transformed models when combined with mTOR or CDK4/6 inhibitors,Combination Therapies,"CDK4, CDK6, TYK2, MTOR",-,-,"deucravacitinib, CDK4/6 inhibitors, mTOR inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
2158,KP4,31305131,"ribociclib plus letrozole#improved#progression-free survival in HR-positive, HER2-negative advanced breast cancer",Therapeutic Response,"CDK4, CDK6",-,"HR-positive, HER2-negative advanced breast cancer","ribociclib, letrozole",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
1177,KP4,31305131,ribociclib#improved#progression-free survival in combination with fulvestrant or tamoxifen,Therapeutic Response,"CDK4, CDK6",-,Advanced breast cancer,"ribociclib, fulvestrant, tamoxifen",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
6570,KP4,33522043,CDK4/6 amplification and CDKN2A/B loss#are associated with#therapeutic resistance in prostate cancer,Mechanisms of Resistance,"CDK4, CDK6, CDKN2A, CDKN2B",-,Prostate cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
3387,KP4,26183925,Pharmacological inhibitors of CDK4/6#target#chordoma cell systems,Therapeutic Development,"CDK4, CDK6",-,Chordoma,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5928,KP4,34699032,"cutaneous AEs#were associated with#CDK4/6 inhibitors (ribociclib, abemaciclib, palbociclib)",Safety Monitoring,"CDK4, CDK6",-,-,"ribociclib, abemaciclib, palbociclib",-,"Vitiligo, bullous dermatitis, erythema multiforme, onychoclasis, trichorrhexis",-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
7148,KP4,34460112,"CDK4/6 inhibitors#have been reimbursed for#HR-positive, HER2-negative advanced breast cancer in the Netherlands",Clinical Implementation,"CDK4, CDK6",-,"HR-positive, HER2-negative advanced breast cancer",CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
3070,KP4,35562811,CDK4/6 inhibitors#enhance#expression of MHC-I,Mechanism of Action,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,upregulated,-,-,-,-,Fact,3,3.3,3.3.1,3.3.1.2,-,抗原提呈增强
5348,KP4,35562811,Activation of interferons by endogenous retrovirus elements#is attributed to#CDK4/6 inhibitors,Mechanism of Action,"CDK4, CDK6",-,-,-,Interferons,-,-,-,-,-,-,Fact,3,3.3,3.3.2,3.3.2.4,-,协同免疫激活
6118,KP4,35562811,"Abemaciclib, palbociclib, and ribociclib#inhibit#cell growth in KSHV-induced PEL and EBV-positive BL cell lines",Mechanism of Action,"CDK4, CDK6",-,"Primary effusion lymphoma (PEL), Burkitt's lymphoma (BL)","Abemaciclib, Palbociclib, Ribociclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2216,KP4,35562811,"Abemaciclib, palbociclib, and ribociclib#inhibit#cell growth in KSHV-infected HUVECs",Mechanism of Action,"CDK4, CDK6",HUVECs,-,"Abemaciclib, Palbociclib, Ribociclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7229,KP4,35562811,CDK4/6 inhibitors#provide rationale for#clinical testing in KSHV- or EBV-induced tumors,Clinical Trial Data,"CDK4, CDK6",-,"KSHV-induced tumors, EBV-induced tumors",CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,8,8.5,8.5.1,8.5.1.2,-,生物标志物监测
7493,KP4,39499997,Fasting-mimicking diet (FMD)#restores#sensitivity of CDK4/6i-resistant cells to abemaciclib,Strategies to Overcome Resistance,"CDK4,CDK6",-,Triple-negative breast cancer (TNBC),Abemaciclib,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,联合用药方案
7313,KP4,39499997,Fasting-mimicking diet (FMD)#potentiates#anti-tumor activity of CDK4/6i,Strategies to Overcome Resistance,"CDK4,CDK6",-,Triple-negative breast cancer (TNBC),CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,联合用药方案
7454,KP4,38443662,Eight core assemblies#integrate#alterations across 90 genes to stratify palbociclib response,Biomarker Analysis,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
4181,KP4,38443662,Predictive assemblies#regulate#CDK4/6i response,Mechanism of Action,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
3619,KP4,30544932,FLT3 receptor tyrosine kinase#activates#AML through ITD or TKD mutations,Molecular Event,FLT3,-,Acute myeloid leukemia (AML),-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
6034,KP4,30544932,FLT3 inhibition#fails to induce#persistent response in patients due to resistance,Mechanisms of Resistance,FLT3,-,Acute myeloid leukemia (AML),FLT3 inhibitors,-,-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
1997,KP4,30544932,Combination of these drugs with palbociclib#induces#synergistic effects in AML with FLT3 mutations,Combination Therapies,"FLT3,CDK4,CDK6",-,Acute myeloid leukemia (AML),Palbociclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
3746,KP4,30544932,Targeting vulnerabilities with CDK6#may improve#AML patient responses,Therapeutic Development,CDK6,-,Acute myeloid leukemia (AML),-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2317,KP4,39745840,CDK4/6 inhibitors#transform#treatment landscape for HR+ HER2- MBC,Clinical Implementation,"CDK4,CDK6",-,Metastatic breast cancer (MBC),CDK4/6 inhibitors,-,-,"HR+, HER2-",-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
5128,KP4,39146623,NSCLC patients without targetable driver mutation#have#limited treatment options,Clinical Implementation,-,-,Non-small cell lung cancer (NSCLC),-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
4385,KP4,39146623,Gene mutations and copy number aberrations#are detected by#next-generation sequencing,Technical Methods,-,-,Non-small cell lung cancer (NSCLC),-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
256,KP4,39146623,NSCLC with EGFR amp and CDKN2A/2B homdel#are sensitive to#combined drugs,Mechanisms of Resistance,"EGFR,CDKN2A,CDKN2B",-,Non-small cell lung cancer (NSCLC),Combined drugs,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
6719,KP4,39146623,EGFR amp#is responsible for#osimertinib sensitivity,Mechanisms of Resistance,EGFR,-,Non-small cell lung cancer (NSCLC),Osimertinib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
4018,KP4,39603379,TFAP2C-DDR1 axis#regulates#resistance to CDK4/6 inhibitor in breast cancer,Mechanisms of Resistance,"CDK4,CDK6,TFAP2C,DDR1",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
6443,KP4,29437706,SCP3-cyclin D1-CDK4/6 axis#correlates negatively with#progression-free survival of cervical cancer patients,Prognostic Associations,"CDK4,CDK6,CCND1",-,Cervical cancer,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
5475,KP4,29437706,Targeting CDK4/6 with the inhibitor palbociclib#reversed#multiaggressive phenotypes of SCP3(high) immunoedited tumor cells,Therapeutic Response,"CDK4,CDK6",-,Immune-refractory cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4237,KP4,29437706,Palbociclib#led to#long-term control of the disease,Therapeutic Response,-,-,Immune-refractory cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
6406,KP4,29437706,CDK4/6 inhibitors#are identified as#actionable drugs for controlling SCP3(high) immune-refractory cancer,Drug Development,"CDK4,CDK6",-,Immune-refractory cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6573,KP4,29437706,Cyclin D1-CDK4/6 inhibition#is revealed as#an effective strategy for controlling SCP3(high) immune-refractory cancer,Therapeutic Response,"CDK4,CDK6,CCND1",-,Immune-refractory cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3138,KP4,39572000,A mass in her left breast#was found during#follow-up,Clinical Monitoring,-,-,Breast cancer,-,-,-,Female,-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.1,-,早期随访
5609,KP4,39572000,Multiple enlarged lymph nodes#were palpated in#ipsilateral axillary lymph nodes,Disease Progression,-,Lymph nodes,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
320,KP4,39572000,"A needle biopsy#revealed#invasive ductal carcinoma, ER positive, PgR positive, HER2 negative, Ki-67 12%",Biomarker Analysis,"ER,HER2,Ki-67",Ductal carcinoma,Breast cancer,-,-,-,-,-,Ki-67,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,Cyclin D1表达
6274,KP4,39572000,Fulvestrant and denosumab#were started due to#comorbidities preventing surgery,Clinical Implementation,-,-,Breast cancer,"Fulvestrant,Denosumab",-,-,Comorbidities,-,-,-,-,Fact,8,8.1,8.1.3,8.1.3.3,-,合并症评估
567,KP4,39572000,Abemaciclib#was added due to#elevated tumor markers,Therapeutic Response,-,-,Breast cancer,Abemaciclib,-,-,-,Upregulated,Tumor markers,-,-,Fact,7,7.3,7.3.1,7.3.1.1,-,细胞周期标志物
2950,KP4,39572000,Grade 3 neutropenia#was observed after#1 month of administration,Safety Monitoring,-,-,Breast cancer,Abemaciclib,-,Neutropenia,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,血液学毒性
6878,KP4,39572000,Increasing the dose of Abemaciclib#resulted in#a decrease in tumor markers and good tolerability,Therapeutic Response,-,-,Breast cancer,Abemaciclib,-,-,-,Downregulated,Tumor markers,-,-,Fact,8,8.3,8.3.1,8.3.1.2,-,不良反应管理
2776,KP4,39572000,Long SD#has continued for#36 months with no adverse events of grade 3 or higher,Clinical Monitoring,-,-,Breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.3,-,长期随访
5858,KP4,39278067,Cyclin-dependent kinase 4/6 inhibitors#have emerged as#a novel treatment strategy for breast cancer,Drug Development,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
990,KP4,33264486,Longitudinal biomarker measurements#may harbor#more dynamic predictive and prognostic information compared to single time point measurements,Biomarker Analysis,-,-,-,-,-,-,-,-,-,-,-,Inference,7,7.1,7.1.2,7.1.2.1,-,基因拷贝数
4030,KP4,39497720,Osimertinib#is designed to target#EGFR T790M mutation,Drug Development,EGFR,-,Lung cancer,Osimertinib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7476,KP4,39497720,NGS assay#achieves#a high concordance with FISH in MET amplification detection,Technical Methods,MET,-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.2,7.1.2.1,-,基因拷贝数
3997,KP4,39305463,CDK4/6 inhibitors#show#clinical efficacy in HR+/HER2- metastatic breast cancer,Therapeutic Response,"CDK4,CDK6,HER2",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2863,KP4,39305463,The combination of CDK4/6 inhibitors and letrozole/endocrine therapy#was not#cost-effective for postmenopausal advanced HR+/HER2- breast cancer,Economic & Access,"CDK4,CDK6,HER2",-,Advanced breast cancer,"CDK4/6 inhibitors,Letrozole",-,-,Postmenopausal,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.3,-,疗效监测
7675,KP4,37379778,PARP inhibition#is synthetic lethal with#defects in BRCA,Mechanism of Action,BRCA,-,TNBC,PARP inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.3,-,mTOR信号增强
7694,KP4,37379778,Approximately 80% of TNBC patients#do not have#BRCA mutations,Patient Stratification,BRCA,-,TNBC,-,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.2,-,原发性耐药
376,KP4,37379778,CDK4/6 inhibitors#can increase#sensitivity of wild-type BRCA cells to PARP inhibitors,Combination Optimization,"CDK4,CDK6,BRCA",-,TNBC,"CDK4/6 inhibitors,PARP inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
801,KP4,37379778,The inhibition capacity of BRCA wild-type cells#was higher compared to#Olaparib or its combination with Palbociclib,Therapeutic Response,BRCA,-,TNBC,"Olaparib,Palbociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1924,KP4,39083396,"CDK4/6 inhibitors#could lead to#pulmonary toxicity, myelosuppression, skin reactions",Adverse Effects,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,"pulmonary toxicity, myelosuppression, skin reactions",-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
6944,KP4,39083396,"Abemaciclib#is associated with#interstitial lung disease, erythema multiforme, and thrombosis risk",Adverse Effects,"CDK4,CDK6",-,-,Abemaciclib,-,"interstitial lung disease, erythema multiforme, thrombosis risk",-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
3936,KP4,39083396,"Ribociclib#is associated with#cardiac toxicity, hepatotoxicity, and musculoskeletal toxicity",Adverse Effects,"CDK4,CDK6",-,-,Ribociclib,-,"cardiac toxicity, hepatotoxicity, musculoskeletal toxicity",-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
3950,KP4,39083396,Palbociclib#is associated with#neurocognitive impairment and osteonecrosis of the jaw,Adverse Effects,"CDK4,CDK6",-,-,Palbociclib,-,"neurocognitive impairment, osteonecrosis of the jaw",-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
7573,KP4,28760782,High-dose Palbociclib#activates#endoplasmic reticulum stress response in beta cells,Mechanism of Action,"CDK4,CDK6",Beta cells,-,Palbociclib,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
4410,KP4,28760782,High-dose Palbociclib#causes#abnormal pancreatic islet histology in young rats,Adverse Effects,"CDK4,CDK6",-,-,Palbociclib,-,-,young rats,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
5263,KP4,31226848,Chemoresistance#is a major cause of#recurrence and death in T-cell acute lymphoblastic leukemia,Disease Mechanism,"CDK4,CDK6",-,T-cell acute lymphoblastic leukemia,-,-,"recurrence, death","adult, pediatric patients",-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
3820,KP4,31226848,Drug-resistant disease#is treated by#selecting a combination of other drugs,Therapeutic Strategy,"CDK4,CDK6",-,-,Combination of drugs,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
3025,KP4,31226848,"Resistance mechanisms to CDK4/CDK6 inhibitors#include#Cyclin D3:CDK4/CDK6, BCL2 inhibitors, and selective inhibitors of nuclear export",Mechanisms of Resistance,"CDK4,CDK6",Cyclin D3,-,"CDK4/CDK6 inhibitors, BCL2 inhibitors, selective inhibitors of nuclear export",-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
4842,KP4,28459468,"Combination of Palbociclib and PD0325901#was tested in#KRAS-mutant, BRAF-mutant CRC, normal colon epithelial lines, and xenograft models",Preclinical Models,"CDK4,CDK6",Colon epithelial cells,Colorectal cancer,"Palbociclib, PD0325901",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
4445,KP4,39352623,"Palbociclib#is used as#a standard of care in combination with endocrine therapy for HR-positive, HER2-negative advanced breast cancer",Clinical Implementation,"CDK4,CDK6",-,"HR-positive, HER2-negative advanced breast cancer","Palbociclib, endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
3715,KP4,28872469,CDK4/6 inhibitors#are being explored in#early breast cancer in combination with endocrine therapy,Therapeutic Development,"CDK4,CDK6",-,Early breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
6970,KP4,28872469,Biomarkers#are needed for#patients' selection in future research,Biomarker Analysis,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.1,-,基因突变
2646,KP4,25223380,RB pathway#plays#a critical role in breast cancer biology,Mechanism of Action,RB1,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
7771,KP4,25223380,RB pathway#is targeted through#CDK4/6 inhibition in estrogen receptor-positive and HER2-positive disease,Therapeutic Strategy,"CDK4,CDK6,RB1",-,"Estrogen receptor-positive, HER2-positive breast cancer",CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
14,KP4,23842682,F876L mutation#may serve as#a novel biomarker for drug sensitivity to CDK4/6 inhibitors,Biomarker Analysis,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,F876L,-,-,Inference,7,7.1,7.1.1,7.1.1.1,-,基因突变
6068,KP4,38961064,O-GlcNAcylation of MITF#regulates#CDK4/6 inhibitor resistance in breast cancer,Mechanism of Resistance,"CDK4,CDK6,MITF",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.3,2.1.3.2,-,组蛋白修饰异常
1400,KP4,38961064,Resistance to CDK4/6 inhibitors#remains#a substantial challenge in clinical settings,Therapeutic Resistance,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
4958,KP4,38961064,MITF#is activated via#O-GlcNAcylation by OGT in palbociclib-resistant breast cancer,Mechanism of Action,"CDK4,CDK6,MITF,OGT",-,Breast cancer,Palbociclib,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
7123,KP4,35121110,CDK4/6 inhibitor#strengthens#chromatin binding of the Rb-E2F repressor complex,Mechanism of Action,"CDK4,CDK6,RB1,E2F",-,CRPC,CDK4/6 inhibitor,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
1253,KP4,35121110,High-T treatment#is combined with#CDK4/6 inhibitors in treating CRPC,Therapeutic Development,"CDK4,CDK6",-,CRPC,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
7954,KP4,38175669,CDK4/6 inhibitors#are compared with#chemotherapy in HR+/HER2-negative MBC with aggressive characteristics,Clinical Trial Data,"CDK4,CDK6",-,HR+/HER2-negative metastatic breast cancer,"CDK4/6 inhibitors, chemotherapy",-,Aggressive characteristics,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
569,KP4,38175669,CDK4/6i+ET#mPFS is longer than#chemotherapy+ET in HR+/HER2-negative MBC,Therapeutic Response,"CDK4,CDK6",-,HR+/HER2-negative metastatic breast cancer,"CDK4/6 inhibitors, chemotherapy",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5036,KP4,34771669,Palbociclib#targets#ATP binding sites of CDK4 and CDK6,Mechanism of Action,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2909,KP4,34771669,CDK inhibitors#are part of#over 30 active clinical trials,Clinical Trial Data,"CDK4,CDK6",-,-,CDK inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
4965,KP4,34771669,CDK targeted PROTACs#exhibited#improved CDK selectivity in preclinical studies,Drug Development,"CDK4,CDK6",-,-,CDK targeted PROTACs,-,-,-,-,-,-,-,Fact,3,3.6,3.6.1,3.6.1.1,-,纳米载体设计
6027,KP4,38718141,Palbociclib and abemaciclib#affect#cell viability and proliferation in IDH-mutant glioma lines,Preclinical Models,"CDK4,CDK6",-,IDH-mutant glioma,"Palbociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4560,KP4,38718141,CDK4/6 inhibitor administration#improves#survival in IDH-mutant glioma models,Therapeutic Response,"CDK4,CDK6",-,IDH-mutant glioma,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4878,KP4,36040373,Genomic and proteomic data#help define#biomarkers of response to targeted therapies and immunotherapies,Biomarker Analysis,-,-,-,-,-,-,-,-,Biomarkers,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
3046,KP4,28417244,Ribociclib#is approved for#first-line treatment of advanced breast cancer,Clinical Implementation,"CDK4,CDK6",-,Advanced breast cancer,Ribociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,治疗线别
6129,KP4,28417244,Ribociclib#is used as#initial endocrine-based therapy for postmenopausal women with HR+/HER2-negative advanced breast cancer,Therapeutic Development,"CDK4,CDK6",-,HR+/HER2-negative advanced breast cancer,Ribociclib,-,Postmenopausal women,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
6439,KP4,30380421,CDK4 and CDK6 inhibitors#are pursued as#a therapeutic strategy for HNSCC patients,Therapeutic Development,"CDK4,CDK6",-,HNSCC,CDK4/6 inhibitors,-,Patients with poorest outcomes,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2154,KP4,37237509,Triple-negative breast cancer#lacks#a tumor-specific receptor or pathway to target,Cancer Pathways,-,-,Triple-negative breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
4693,KP4,37237509,Drugs#target#these molecules/pathways in clinical trials,Drug Development,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
3880,KP4,33403024,Patients with METex14 alterations#benefit from#MET inhibitors like crizotinib,Therapeutic Response,MET,-,-,Crizotinib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
4431,KP4,18462865,Enzastaurin#inhibits#PKCbeta and other isoforms,Mechanism of Action,PRKCB,-,-,Enzastaurin,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4654,KP4,18462865,Enzastaurin#is assessed in#malignant human glioma cell lines with diverse genomic alterations,Preclinical Models,PRKCB,-,Malignant glioma,Enzastaurin,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2882,KP4,18462865,Simultaneous exposure to both agents#increased#cytochrome c release and caspase 3 activation,Mechanism of Action,-,-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.3,-,线粒体通路调控
63,KP4,30355675,DNA sequencing#identified#driver mutations in metastatic breast cancer,Molecular Event triples,ESR1,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
136,KP4,30355675,ERBB2#is frequently amplified with#GRB7 and cell-cycle pathway members,Genomic Alteration triples,"ERBB2, GRB7, CCND1, CDK4, CDK6",-,-,-,Cell-cycle pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
4920,KP4,30355675,"CDKN2A, CDKN2B, CDKN1B#are mutually exclusive with#amplifications of CDK4/6",Genomic Alteration triples,"CDKN2A, CDKN2B, CDKN1B, CDK4, CDK6",-,-,-,Cell-cycle pathway,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3468,KP4,38781103,RP-6306 in combination with gemcitabine#is effective in#CDK4/6 inhibitor-resistant TP53 mutant ER+ breast cancer,Therapeutic Response triples,"TP53, CDK4, CDK6",-,ER+ breast cancer,"RP-6306, Gemcitabine",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
6313,KP4,31937617,Plasma Thymidine Kinase Activity#is a biomarker for#Luminal Metastatic Breast Cancer,Biomarker Analysis triples,-,-,Luminal Metastatic Breast Cancer,Palbociclib,-,-,Patients,-,Plasma Thymidine Kinase Activity,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
4281,KP4,39316555,ET plus CDK4/6 inhibitors#is a standard treatment for#HR-positive HER2-negative metastatic breast cancer,Clinical Implementation triples,"CDK4, CDK6",-,Metastatic breast cancer,ET,-,-,"HR-positive, HER2-negative",-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
2666,KP4,35780240,"Apigenin, chrysin, and fisetin#can inhibit#CDK6",Drug Development triples,CDK6,-,-,"Apigenin, Chrysin, Fisetin",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2760,KP4,27370397,CDK4/6 inhibitor palbociclib#inhibits#DNA damage repair,Mechanism of Action triples,"CDK4, CDK6",-,"Atypical teratoid rhabdoid tumor, glioblastoma",Palbociclib,-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.4,-,DNA合成修复
4521,KP4,27370397,CDK4/6 inhibitor palbociclib#delays#tumor regrowth,Therapeutic Response triples,"CDK4, CDK6",-,"Atypical teratoid rhabdoid tumor, glioblastoma",Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5395,KP4,27370397,Chemotherapeutics combined with radiation#are relevant for#malignant brain tumors,Therapeutic Development triples,-,-,Malignant brain tumors,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.3,8.2.3.2,-,协同增效作用
3532,KP4,27370397,Combination therapy regimens#outperformed#monotherapies,Therapeutic Response triples,-,-,Malignant brain tumors,-,-,-,RB-proficient,-,-,-,-,Fact,8,8.2,8.2.3,8.2.3.2,-,协同增效作用
4760,KP4,27370397,Palbociclib#is an adjuvant to#radiation therapy,Clinical Implementation triples,-,-,Malignant brain tumors,Palbociclib,-,-,RB expression retained,-,-,-,-,Fact,8,8.2,8.2.3,8.2.3.2,-,协同增效作用
5262,KP4,33462444,AR activation#exerts#antitumor activity in resistance to standard-of-care ER and CDK4/6 inhibitors,Therapeutic Response,"AR, CDK4, CDK6",-,Resistance to standard-of-care ER and CDK4/6 inhibitors,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
5740,KP4,33462444,AR agonists#enhanced#therapeutic responses when combined with standard-of-care agents,Combination Optimization,AR,-,-,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
3996,KP4,33797827,Combined therapy with CDK4/6 inhibitor and anti-melanoma chemotherapeutic agents#is a strategy for#clinical trials concerning metastatic OMM,Combination Optimization,"CDK4, CDK6",-,Metastatic ocular melanoma,"CDK4/6 inhibitor, anti-melanoma chemotherapeutic agents",-,-,-,-,-,-,-,Inference,8,8.2,8.2.3,8.2.3.2,-,协同增效作用
6955,KP4,24089445,Targeted therapies in melanoma#validate#the concept of targeting oncogenes,Cancer Pathways,BRAF,-,Melanoma,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2592,KP4,24089445,Selective CDK4/6 inhibitors#show#clinical benefit and are well tolerated in clinical trials,Drug Development,"CDK4, CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
2414,KP4,30405888,Targeted therapy#has become#a cornerstone for the treatment of melanoma patients,Clinical Implementation,-,-,Melanoma,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
547,KP4,30405888,Co-targeting of MEK and CDK4/6#has#antitumor activity,Combination Optimization,"CDK4, CDK6, MEK",-,NRAS mutant melanoma,"MEK inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
2663,KP4,30405888,"NRAS, BRAF mutant and wild type melanoma cells#respond to#MEK and CDK4/6 inhibitors in vitro and in vivo",Therapeutic Response,"NRAS, BRAF, CDK4, CDK6",-,Melanoma,"MEK inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
4173,KP4,30405888,In vitro growth response patterns#correspond to#in vivo efficacy of MEK/CDK4/6 co-targeting in melanoma xenograft models,Preclinical Models,"CDK4, CDK6, MEK",-,Melanoma,"MEK inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
8,KP4,35917168,Endocrine therapy combined with CDK4/6 inhibitors#improves#clinical outcomes in HR+ BCs,Combination Optimization,"CDK4, CDK6",-,Hormone receptor-positive breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
975,KP4,24795392,Efforts#are under way to develop#biomarkers of response and rational combinations of CDK4 inhibitors with chemotherapy,Biomarker Analysis,CDK4,-,Cancer,"CDK4 inhibitors, chemotherapy",-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,-,ESR1突变
7886,KP4,37917641,Drugs targeting CDK4/6#are promising treatments for#melanoma and other solid malignancies,Drug Development,"CDK4, CDK6",-,"Melanoma, solid malignancies",-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6502,KP4,37917641,CDK4/6 inhibitor palbociclib and PRMT5 inhibitor GSK3326595#induce#differential gene expression and pre-mRNA splicing in CHL1 and A375 melanoma cells,Mechanism of Action,"CDK4, CDK6, PRMT5","CHL1, A375 melanoma cells",Melanoma,"Palbociclib, GSK3326595",-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.4,-,DNA合成修复
5904,KP4,38464342,CDK4/6 inhibitors#are the mainstay of treatment for#HR+/HER2- advanced breast cancer,Therapeutic Development,"CDK4, CDK6",-,"Hormone receptor-positive, HER2-negative advanced breast cancer",-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
7875,KP4,36085411,CDK4/6 inhibitors in combination with endocrine therapy#have been approved for#breast cancer treatment,Clinical Implementation,"CDK4, CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.3,-,协同抗增殖作用
2277,KP4,36085411,CDK4/6 inhibitors#are combined with#endocrine therapy in hormone receptor-positive and HER2-negative breast cancer,Combination Therapies,"CDK4,CDK6",-,Breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,"Hormone receptor-positive, HER2-negative",-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,内分泌治疗联合
7961,KP4,37835528,Efficacy and resistance pathways#are evolving in response to#CDK4/6 inhibitors in breast cancer,Mechanisms of Resistance,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,2,2.1,2.1.2,-,-,信号通路激活
6219,KP4,28050067,Palbociclib#is the first#CDK4/6 inhibitor suitable for human use,Drug Development,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,-,-,-,CDK4/6抑制剂的作用机制
1071,KP4,37475713,"CDK4/6 inhibitors#show#variations in pharmacology, pharmacokinetics, and safety",Drug Development,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,-,-,-,CDK4/6抑制剂的作用机制
2336,KP4,37584881,"CDK4/6 inhibitors#improve#TTF, PFS, and OS compared to paclitaxel in breast cancer",Therapeutic Response,"CDK4,CDK6",-,Breast cancer,"CDK4/6 inhibitors, paclitaxel",-,-,-,-,-,-,-,Fact,3,3.1,-,-,-,CDK4/6抑制剂的作用机制
1595,KP4,33995631,CDK4/6 inhibitors#are developed as#anticancer drugs,Drug Development,"CDK4,CDK6",-,-,"Palbociclib, Abemaciclib, Ribociclib",-,-,-,-,-,-,-,Fact,3,3.1,-,-,-,CDK4/6抑制剂的作用机制
5871,KP4,33364954,Drug resistance#is an emerging cause of#breast cancer-related death,Mechanisms of Resistance,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,-,-,-,获得性耐药的分子基础
4109,KP4,33364954,Overcoming CDK4/6 resistance#is#an urgent problem,Mechanisms of Resistance,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.5,-,-,-,耐药克服策略
892,KP4,37109654,CDK4/6 inhibitors and endocrine therapy#are gold standards for#HR+/HER2- metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,Metastatic breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,"Hormone receptor-positive, HER2-negative",-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
274,KP4,36765648,CDK4/6 inhibitors#lead to#improvements in survival in advanced HR+/HER2- breast cancer,Therapeutic Response,"CDK4,CDK6",-,Advanced breast cancer,CDK4/6 inhibitors,-,-,"Hormone receptor-positive, HER2-negative",-,-,-,-,Fact,3,3.1,-,-,-,CDK4/6抑制剂的作用机制
3014,KP4,35920011,"CDK4/6 inhibitors#differ in#duration, sequence, and combinations based on clinical situations",Clinical Implementation,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,-,-,-,单药治疗策略
4,KP4,34882985,CDK4/6 inhibitors#may treat#SSc in combination with TGFβR inhibitors,Combination Therapies,"CDK4,CDK6",Fibroblasts?,SSc,"CDK4/6 inhibitors, TGFβR inhibitors",TGFβ,-,-,-,-,-,-,Inference,3,3.2,3.2.2,-,-,靶向药物联合
6986,KP4,36453028,CDK4 phosphorylation#predicts#high sensitivity of pleural mesotheliomas to CDK4/6 inhibition,Biomarker Analysis,CDK4,-,Pleural mesothelioma,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,-,获得性耐药
1206,KP4,36453028,Palbociclib#inhibits#MPM cell proliferation in preclinical studies,Preclinical Models,"CDK4,CDK6",MPM cell lines,Pleural mesothelioma,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,-,-,-,CDK4/6抑制剂的作用机制
7397,KP4,36453028,High p16 (CDKN2A) levels#accompany#RB1 defects or CCNE1 overexpression in MPM,Expression Patterns,"CDKN2A,RB1,CCNE1",-,Pleural mesothelioma,-,-,-,-,Upregulated,-,-,-,Fact,2,2.1,2.1.1,-,-,基因组改变
3877,KP4,36453028,Prolonged palbociclib treatment#irreversibly inhibits#cell proliferation in MPM,Preclinical Models,"CDK4,CDK6",MPM cell lines,Pleural mesothelioma,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,-,-,-,CDK4/6抑制剂的作用机制
5366,KP4,36453028,High p16 (CDKN2A) expression#is linked to#short survival in highly proliferative MPMs,Prognostic Biomarkers,CDKN2A,-,Pleural mesothelioma,-,-,-,-,Upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白表达
4428,KP4,36453028,CDK4/6 inhibitors#are supported for#MPM treatment in monotherapy or combination therapy,Therapeutic Development,"CDK4,CDK6",-,Pleural mesothelioma,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,-,-,-,单药治疗策略
5322,KP4,34556423,ET#is combined with#CDK4/6 inhibitors,Therapeutic Development,"CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
3273,KP4,34556423,"ET and CDK4/6 inhibitors#impact#cognition in pre-, peri-, and postmenopausal breast cancer patients",Clinical Implementation,"CDK4, CDK6",-,Breast cancer,-,-,-,"Pre-, peri-, postmenopausal",-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
3857,KP4,33815595,CDK4/6 inhibitors#improve#progression-free survival in HR+/HER2- breast cancer patients,Therapeutic Response,"CDK4, CDK6",-,Breast cancer,"CDK4/6 inhibitors, aromatase inhibitors, fulvestrant",-,-,"HR+/HER2-, metastatic, advanced",-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4864,KP4,37886470,MITF#is activated by#O-GlcNAcylation via OGT in palbociclib-resistant breast cancer cells,Mechanisms of Resistance,"MITF, OGT",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.3,2.1.3.2,-,组蛋白修饰异常
2655,KP4,37886470,MITF O-GlcNAcylation#promotes#nuclear translocation and senescence suppression,Mechanisms of Resistance,MITF,-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.3,2.1.3.4,-,染色质状态改变
5934,KP4,37886470,Inhibition of MITF or its O-GlcNAcylation#re-sensitizes#resistant cells to palbociclib,Strategies to Overcome Resistance,MITF,-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
702,KP4,29946797,"Postmenopausal HR+/HER2- mBC patients#are treated with#CDK4/6 inhibitors, ET, or chemotherapy",Patient Stratification,"CDK4, CDK6",-,Breast cancer,Palbociclib,-,-,"Postmenopausal, HR+/HER2-, metastatic",-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
929,KP4,35738597,CDK4/6 inhibitors#prolong#survival compared to chemotherapy or ET,Therapeutic Response,"CDK4, CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
220,KP4,31832106,CDK4/6 inhibitors#have an emerging role in#HER2-positive breast cancer,Cancer Pathways,"CDK4, CDK6",-,Breast cancer,-,-,-,HER2-positive,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
4768,KP4,31832106,HER2-directed therapies#improve#median survival in HER2+ metastatic breast cancer patients,Therapeutic Response,-,-,Breast cancer,HER2-directed therapies,-,-,"HER2-positive, metastatic",-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2699,KP4,33812267,ET plus CDK4/6 inhibitors#is the standard treatment for#luminal-metastatic breast cancer,Clinical Implementation,"CDK4, CDK6",-,Breast cancer,"ET, CDK4/6 inhibitors",-,-,Luminal-metastatic,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
3398,KP4,35936714,CDK4/6-cyclin D-Rb pathway alterations#occur frequently in#HCC,Cancer Pathways,"CDK4, CDK6, RB1, CCND1",-,Hepatocellular carcinoma (HCC),"Abemaciclib, Ribociclib, Lenvatinib",-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3400,KP4,35936714,Abemaciclib and Ribociclib#show efficacy in combination with#Lenvatinib in HCC Rb-expressing cell lines,Combination Optimization,"CDK4, CDK6, RB1",-,Hepatocellular carcinoma (HCC),"Abemaciclib, Ribociclib, Lenvatinib",-,-,Rb-expressing,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
2171,KP4,34830174,Targeted therapies#overcome#resistance to CDK4/6 inhibitors,Strategies to Overcome Resistance,"CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.2,2.5.2.1,-,新型抑制剂开发
574,KP4,34830174,Biomarkers#are needed for#predicting resistance to CDK4/6 inhibitors,Biomarker Analysis,"CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Inference,7,7.5,7.5.1,7.5.1.1,-,获得性耐药
6083,KP4,32560251,"CDK4/6 inhibitors#abemaciclib, palbociclib, and ribociclib#modulate AML resistance in PBMCs",Mechanisms of Resistance,"CDK4, CDK6",-,Acute myeloid leukemia (AML),"Abemaciclib, Palbociclib, Ribociclib",-,-,PBMCs,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
4935,KP4,32373071,CDK4/6 inhibitors#are promising candidates for#treatment of ACC patients,Therapeutic Development,"CDK4, CDK6",-,Adrenocortical carcinoma (ACC),CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1360,KP4,33085548,CDK4/6 inhibitors#improve#progression-free survival with ET in HR+/HER2- advanced breast cancer,Therapeutic Response,"CDK4, CDK6",-,Breast cancer,"CDK4/6 inhibitors, ET",-,-,"HR+/HER2-, advanced",-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3976,KP4,35008374,Acquired resistance to CDK4/6 inhibitors#occurs in#HR-positive breast cancer cases,Mechanisms of Resistance,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,HR-positive,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
3759,KP4,37833875,Cyclin-dependent kinase 4/6 inhibitors#are used in#first-line metastatic breast cancer,Clinical Implementation,"CDK4, CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
1057,KP4,37833875,Switching to other CDK4/6 inhibitors#is analyzed as#a potential therapeutic approach,Therapeutic Development,"CDK4, CDK6",-,-,CDK4/6 inhibitors,"PI3K, mTOR, AKT",-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.3,-,剂量优化
5940,KP4,31875862,CDK4/6 inhibitors#improve#progression-free survival when added to endocrine-based therapy,Therapeutic Response,"CDK4, CDK6",-,-,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
5241,KP4,39153367,CDK4/6 inhibitors combined with endocrine therapy#prolong#survival in HR-positive and HER2-negative advanced breast cancer,Therapeutic Response,"CDK4, CDK6",-,Advanced breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
3891,KP4,36609900,Eligible women#initiated#first-line therapy for breast cancer,Patient Characteristics,-,-,Breast cancer,-,-,-,Median age: 74 years,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
2255,KP4,29935901,"Palbociclib, Ribociclib and Abemaciclib#received#regulatory approval for metastatic breast cancer",Regulatory Documentation,"CDK4, CDK6",-,Metastatic breast cancer,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
2272,KP4,29935901,"Ribociclib and Abemaciclib#represent#""me-too"" therapies developed after Palbociclib",Drug Development,"CDK4, CDK6",-,-,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4764,KP4,37752406,"Aberrant activating mutations in CDK4 and CDK6#are common in#various cancers, including gastroesophageal malignancies",Cancer Association,"CDK4, CDK6",-,Gastroesophageal malignancies,-,-,-,-,Upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
1626,KP4,37752406,CDK4/6 inhibitors#are approved for#breast cancer treatment but limited as monotherapy for gastroesophageal tumors,Drug Development,"CDK4, CDK6",-,"Breast cancer, Gastroesophageal tumors","Abemaciclib, Palbociclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
862,KP4,38912058,"CDK4/6 inhibitors#represent#the gold standard for HR-positive, HER2-negative advanced breast cancer",Clinical Implementation,"CDK4, CDK6",-,Advanced breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
6662,KP4,33826903,Tumor metabolic vulnerabilities#link to#anti-tumor immunity,Signaling Networks,-,-,Tumor,-,-,-,-,-,-,-,-,Inference,6,6.1,6.1.1,6.1.1.3,-,免疫检查点表达
7162,KP4,37477144,Combined targeted therapy with PI3K and CDK4/6 inhibitors#is efficacious in#neuroblastoma cell lines,Combination Therapies,"CDK4, CDK6",-,Neuroblastoma,"PI3K inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7622,KP4,31690650,CDK4/6 inhibitors#advance#treatment for estrogen receptor-positive advanced breast cancer,Therapeutic Development,"CDK4, CDK6",-,Advanced estrogen receptor-positive breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
638,KP4,30559257,"Cdk4-targeting drugs#are approved for#metastatic ER/PR-positive, HER2-negative breast cancer",Regulatory Documentation,CDK4,-,Metastatic breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
893,KP4,30559257,Palbociclib#is assessed with#Ki67 as a marker of response in tumor explant cultures,Biomarker Analysis,CDK4,-,Tumor,Palbociclib,-,-,-,Ki67,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,7.3.1.1.1,Ki67指数
2551,KP4,30559257,pY88 biomarker#may identify#patients responsive to CDK4-targeting drugs,Biomarker Analysis,CDK4,-,-,CDK4-targeting drugs,-,-,-,pY88,-,-,-,Inference,7,7.3,7.3.1,7.3.1.1,7.3.1.1.2,pRB水平
7910,KP4,36070391,TTK inhibitor CFI-402257#is nominated as#a strategy for ER-positive breast cancer resistant to CDK4/6 inhibitors,Strategies to Overcome Resistance,"CDK4, CDK6",ER-positive cells,Breast cancer,CFI-402257,-,-,-,-,-,-,-,Inference,2,2.5,2.5.3,2.5.3.1,-,免疫检查点阻断
5321,KP4,38224427,CDK4/6 inhibitors#cause#cutaneous adverse effects,Adverse Effects,"CDK4, CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,Cutaneous adverse effects,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,8.4.1.2.4,皮肤反应
5597,KP4,38224427,CDK4/6 treatment#was discontinued due to#vitiligo-like lesions,Adverse Effects,"CDK4,CDK6",-,-,CDK4/6 treatment,-,Vitiligo-like lesions,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
4630,KP4,36373891,177 cases#received#palbociclib,Clinical Trial Data,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
3159,KP4,36373891,39 cases#received#abemaciclib,Clinical Trial Data,"CDK4,CDK6",-,-,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
7346,KP4,36373891,8 cases#received#both palbociclib and abemaciclib,Clinical Trial Data,"CDK4,CDK6",-,-,"Palbociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
6796,KP4,36373891,Palbociclib-treated cases#developed#interstitial lung disease,Adverse Effects,"CDK4,CDK6",-,Interstitial lung disease,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
462,KP4,36373891,Abemaciclib-treated cases#developed#interstitial lung disease,Adverse Effects,"CDK4,CDK6",-,Interstitial lung disease,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
6823,KP4,36373891,CDK4/6 inhibitors#induce#interstitial lung disease,Adverse Effects,"CDK4,CDK6",-,Interstitial lung disease,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
6602,KP4,39535168,Treatment for unresectable or metastatic disease#revolves around#palliative systemic therapy,Treatment Strategies,-,-,Unresectable or metastatic disease,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
6108,KP4,39535168,Search for novel agents#continues in#tyrosine kinase inhibitors for liposarcoma,Drug Development,-,-,Liposarcoma,Tyrosine kinase inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,新型抑制剂开发
855,KP4,39535168,Combination therapies#warrant#ongoing exploration for biomarker identification,Biomarker Analysis,-,-,Unspecified,-,-,-,-,-,Biomarkers,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
934,KP4,29644000,High grade serous ovarian cancer#is associated with#a high relapse rate and poor overall survival,Cancer Association,-,-,High grade serous ovarian cancer,-,-,"High relapse rate, poor overall survival",-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.4,RB蛋白表达
344,KP4,29644000,Targeted CDK4/6 inhibitors#show promise as#a maintenance therapy in cancer,Therapeutic Development,"CDK4,CDK6",-,Cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3094,KP4,29644000,CDK4/6 pathway genes#are commonly#mutated or dysregulated in ovarian cancer,Cancer Pathways,"CDK4,CDK6",-,Ovarian cancer,-,CDK4/6 pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
7380,KP4,29644000,"Ribociclib#was evaluated alone, in combination with chemotherapy, and as maintenance therapy#in ovarian cancer",Therapeutic Development,"CDK4,CDK6",-,Ovarian cancer,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
1184,KP4,29644000,Ribociclib-treated cells#express#markers of senescence,Expression Patterns,"CDK4,CDK6",-,-,Ribociclib,-,-,-,-,Markers of senescence,-,-,Fact,3,3.1,3.1.2,3.1.2.2,-,衰老相关分泌表型
7064,KP4,29644000,Ribociclib-treated cells#could re-enter#the cell cycle with discontinuation of therapy,Cell Cycle Control,"CDK4,CDK6",-,-,Ribociclib,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
2794,KP4,29644000,Clinical trials#are supported for#Ribociclib in combination with cisplatin and as maintenance therapy in ovarian cancer,Clinical Trial Data,"CDK4,CDK6",-,Ovarian cancer,"Ribociclib, Cisplatin",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
6559,KP4,34165265,CDK4/6 inhibitor therapies#improve#survival outcomes in metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7634,KP4,32847835,CDK4/6 inhibitors in combination with fulvestrant#are likely#the most effective treatment for PFS in endocrine-sensitive settings,Combination Therapies,"CDK4,CDK6",-,Endocrine-sensitive breast cancer,"CDK4/6 inhibitors, Fulvestrant",-,-,-,-,-,-,-,Inference,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
3333,KP4,39732370,Immunogenic cell death#reinforces#anti-PD-L1 blockade in triple-negative breast cancer,Therapeutic Development,-,-,Triple-negative breast cancer,Anti-PD-L1 blockade,-,-,-,-,-,-,-,Inference,3,3.3,3.3.2,3.3.2.3,-,免疫逃逸抑制
4522,KP4,39732370,Six self-assembled natural pentacyclic triterpenoid molecules#serve as#nanoplatforms for PAL delivery,Drug Delivery Innovation,-,-,-,PAL,-,-,-,-,-,-,-,Fact,3,3.6,3.6.1,3.6.1.1,-,纳米载体设计
2436,KP4,39732370,Study#offers#avenues for clinical applications of chemoimmunotherapy in TNBC,Therapeutic Development,"CDK4,CDK6",-,Triple-negative breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1608,KP4,36291780,FCN-437c#a novel CDK4/6 inhibitor#is studied in advanced solid tumors,Clinical Trial Data,"CDK4,CDK6",-,Advanced solid tumors,FCN-437c,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,晚期实体瘤
7274,KP4,36291780,FCN-437c#causes#adverse events,Adverse Events,-,-,-,FCN-437c,-,Adverse events,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
3504,KP4,36291780,Dose-limiting toxicities#occurred in#participants receiving 200-mg dose in dose-escalation phase,Adverse Events,-,Neutrophils,-,-,-,"Neutropenia, neutrophil count decreased",-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
5813,KP4,25494820,PD0332991#requires#efficacious combination with least toxicity for further development,Drug Development,"CDK4,CDK6",-,Multiple Myeloma (MM),PD0332991,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3072,KP4,35219113,Interstitial lung disease/pneumonitis#is associated with#rare adverse events,Adverse Events,-,Lung cells,-,-,-,"Interstitial lung disease (ILD), pneumonitis",-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
2142,KP4,39168715,Thrombosis#is associated with#breast cancer patients on CDK inhibitors,Adverse Events,"CDK4,CDK6",-,Breast cancer,-,-,Thrombosis,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.4,感染风险
870,KP4,39168715,Its significance#might be#greater than reported in randomized clinical trials,Clinical Trial Data,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Inference,8,8.5,8.5.1,8.5.1.3,-,生活质量
6449,KP4,39168715,CDK4/6 inhibitor treatment#is associated with#VTE/AT incidence of 5.48% during follow-up,Adverse Events,"CDK4,CDK6",-,Breast cancer,-,-,"Venous thromboembolism (VTE), arterial thrombosis (AT)",-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.4,感染风险
4921,KP4,39168715,CNS metastasis#is associated with#increased odds ratio for adverse outcomes in breast cancer,Disease Association,"CDK4,CDK6",-,Breast cancer,Abemaciclib,-,CNS metastasis,-,-,-,-,-,Fact,2,2.3,2.3.1,2.3.1.4,-,染色体异常
3973,KP4,29086897,PI3K/Akt/mTOR pathway#plays a role in#resistance to endocrine therapy in breast cancer,Mechanism of Action,"PIK3CA,AKT1,MTOR",-,Breast cancer,-,PI3K/Akt/mTOR,-,-,-,-,-,-,Inference,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
6877,KP4,29086897,PIK3CA#is frequently mutated in#ER+ HER2- breast cancers,Genetic Alteration,PIK3CA,-,Breast cancer,-,-,-,-,mutated,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.4,PIK3CA突变
2600,KP4,29086897,AKT1#is mutated in#1.4-8% of breast cancer patients,Genetic Alteration,AKT1,-,Breast cancer,-,-,-,-,mutated,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.4,PIK3CA突变
4221,KP4,29086897,Genetic alterations in PI3K/Akt/mTOR and CDK4/6/RB pathways#result in#deregulated kinase activity and malignant transformation,Mechanism of Action,"PIK3CA,AKT1,MTOR,CDK4,CDK6,RB1",-,Cancer,-,"PI3K/Akt/mTOR,CDK4/6/RB",-,-,-,-,-,-,Inference,2,2.1,2.1.2,2.1.2.1,-,PI3K/Akt通路异常
1807,KP4,29080858,Sensitivity to CDK4/6 inhibitor PD-0332991#is correlated with#protein and genomic data in PDA lines,Biomarker Analysis,"CDK4,CDK6",-,Pancreatic ductal adenocarcinoma (PDA),PD-0332991,-,-,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,-,细胞周期标志物
6312,KP4,37127652,Medulloblastoma (MB)#is classified into#four subgroups based on gene expression and genomic features,Disease Classification,"CDK4,CDK6",-,Medulloblastoma,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.2,-,分子亚型
3530,KP4,37127652,Spatially resolved transcriptomics#defines#cellular diversity within SHH patient-derived MB model,Experimental Technique,"CDK4,CDK6",-,Medulloblastoma,Palbociclib,-,Sonic hedgehog (SHH),-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.1,-,基因表达谱
996,KP4,37127652,Palbociclib treatment#induces#neuronal differentiation and reduces proliferation in treated tumors,Therapeutic Response,"CDK4,CDK6",Neuronal cells,Medulloblastoma,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7615,KP4,37127652,Spatial transcriptomics#provides#insights into response and resistance to CDK4/6 inhibitors in SHH MB,Experimental Technique,"CDK4,CDK6",-,Medulloblastoma,Palbociclib,-,Sonic hedgehog (SHH),-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,-,细胞周期标志物
7956,KP4,29090083,CDK4/6 inhibitors#are associated with#increased incidence of adverse events,Adverse Events,"CDK4, CDK6",-,-,-,-,Adverse events,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.3,-,不良反应管理
6926,KP4,29090083,Randomized trials#provide#safety profile on GI effects of CDK4/6 inhibitors,Clinical Trial Data,"CDK4, CDK6",-,Breast cancer,-,-,Gastrointestinal (GI) effects,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
5610,KP4,29090083,Selective CDK4/6 inhibitors#are not associated with#higher-grade GI toxicities,Safety Data,"CDK4, CDK6",-,Breast cancer,-,-,Gastrointestinal (GI) effects,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
7245,KP4,37378079,CDK4/6 inhibitors and endocrine therapy#are used in#advanced HR(+)/HER2(-) breast cancer treatment,Therapeutic Development,"CDK4, CDK6",-,Advanced HR(+)/HER2(-) breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
7482,KP4,37410426,"CDK4/6 and MEK inhibitors#showed#antitumor activity in MPNST cell lines, PDX, and de novo mouse MPNSTs",Therapeutic Development,"CDK4, CDK6",-,MPNST,"CDK4/6 inhibitors, MEK inhibitors",-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
2990,KP4,37410426,Low-dose combinations of CDK4/6 and MEK inhibitors#reactivated#retinoblastoma (RB1) tumor suppressor and induced cell death in MPNST cells,Mechanism of Action,"CDK4, CDK6, RB1",-,MPNST,"CDK4/6 inhibitors, MEK inhibitors",-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
4573,KP4,37410426,Combination therapy of de novo MPNSTs#caused#tumor regression and delayed resistant tumor outgrowth,Therapeutic Development,-,-,MPNST,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
494,KP4,37410426,Preclinical findings#provide rationale for#CDK4/6-MEK-ICB targeted therapies in MPNST,Therapeutic Development,"CDK4, CDK6",-,MPNST,"CDK4/6 inhibitors, MEK inhibitors, ICB",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5898,KP4,32623316,CDK4/6 inhibitors palbociclib and ribociclib#are used with#hormonal therapy for metastatic breast cancer management,Therapeutic Development,"CDK4, CDK6",-,Metastatic breast cancer,"Palbociclib, Ribociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
5102,KP4,34911915,Abemaciclib in combination with fulvestrant#improved#progression-free survival and overall survival in HR+/HER2- advanced breast cancer,Therapeutic Development,"CDK4, CDK6",-,HR+/HER2- advanced breast cancer,"Abemaciclib, Fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
7613,KP4,34911915,CDK4/6 inhibitors#abemaciclib#are used in the treatment of breast cancer,Therapeutic Development,"CDK4, CDK6",-,Breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1006,KP4,28454587,HER2 and CDK4/6#are#important biological targets for breast cancer,Molecular Target,"CDK4, CDK6, HER2",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
5488,KP4,28454587,Anti-HER2 treatments#enhance#progression-free survival and overall survival in breast cancer,Therapeutic Response,HER2,-,Breast cancer,Anti-HER2 treatments,-,-,-,-,-,-,-,Fact,8,8.2,8.2.2,8.2.2.4,-,多靶点抑制策略
2211,KP4,28454587,Three CDK4/6 inhibitors#improve#progression-free survival in breast cancer,Therapeutic Response,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7811,KP4,28454587,Checkpoint inhibitor-based immunotherapy#is promising for#triple-negative breast cancer,Therapeutic Development,-,-,Triple-negative breast cancer,Checkpoint inhibitors,-,-,-,-,-,-,-,Fact,3,3.3,3.3.2,3.3.2.3,-,免疫逃逸抑制
4458,KP4,30782616,FDA-approved CDK4/6 inhibitor palbociclib#was tested in#MM patient-derived xenograft (PDX) trial,Preclinical Models,"CDK4, CDK6",-,MM,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.6,3.6.2,3.6.2.1,-,持续缓释
3566,KP4,36497412,CDK4/6 inhibition#enhances#standard chemotherapy efficacy in malignant pleural mesothelioma cells,Combination Therapies,"CDK4, CDK6",-,Malignant pleural mesothelioma,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.2,-,协同增效作用
2470,KP4,36497412,Standard chemotherapy regimen and abemaciclib#combine to evaluate#antitumor potential,Combination Therapies triples,"CDK4,CDK6",-,MPM,abemaciclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4452,KP4,36497412,Combined treatment#induces#cellular senescence or autophagic cell death,Mechanism of Action,"CDK4,CDK6",-,-,-,-,Cell type dependent,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
4187,KP4,36497412,CDK4/6 inhibitors in combination with chemotherapy#demonstrate#therapeutic potential for MPM,Therapeutic Development,"CDK4,CDK6",-,MPM,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
2520,KP4,32640856,Checkpoint inhibitors and BRAF/MEK inhibitors#have#profound effects on survival in metastatic melanoma,Therapeutic Response,"BRAF,MEK",-,Metastatic melanoma,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
5841,KP4,36450591,"Canine lymphoma/leukemia cell lines#were treated with#CDK4/6 inhibitors (palbociclib, abemaciclib)",Preclinical Models,"CDK4,CDK6",-,"Canine lymphoma, leukemia","palbociclib, abemaciclib",-,-,"High, low",p16 protein,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3005,KP4,36450591,High p16 protein expression#may be used as#a biomarker for resistance to CDK4/6 inhibitors,Biomarker Analysis,"CDK4,CDK6",-,Canine lymphoma,-,-,-,-,p16 protein,-,-,-,Inference,7,7.5,7.5.1,7.5.1.2,-,p53功能缺失
3307,KP4,26857361,Broadly acting CDK inhibitors#were largely#disappointing in initial results,Therapeutic Development,CDK,-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
805,KP4,38715458,CDK4/6 inhibitors#are assessed for#real-world effectiveness in HR+/HER2- advanced breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,-,-,"Postmenopausal, younger (<45 years), older (>78 years)",-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
6541,KP4,34737452,Dalpiciclib plus fulvestrant#are tested in#DAWNA-1 phase 3 trial for HR+/HER2- ABC,Clinical Trial Data,"CDK4,CDK6",-,HR+/HER2- ABC,"dalpiciclib, fulvestrant",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
2483,KP4,34737452,361 patients#were randomized to receive#dalpiciclib plus fulvestrant or placebo plus fulvestrant,Clinical Trial Data,-,-,-,"dalpiciclib, fulvestrant",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,治疗线别
4716,KP4,34737452,Dalpiciclib plus fulvestrant#prolongs#progression-free survival compared to placebo plus fulvestrant,Therapeutic Response,"CDK4,CDK6",-,HR+/HER2- ABC,"dalpiciclib, fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
5941,KP4,34737452,Dalpiciclib plus fulvestrant#causes#grade 3 or 4 neutropenia and leukopenia,Adverse Events,-,-,-,"dalpiciclib, fulvestrant",-,"Neutropenia, leukopenia",-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,血液学毒性
7760,KP4,37524106,CDK4/6 inhibitors#have#differences in effects and adverse events,Adverse Events,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
4554,KP4,37234088,ER+ breast cancer#is responsive to#targeted therapies,Therapeutic Response,ESR1,-,ER+ breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7930,KP4,37234088,Cdk4/6 inhibitors and fulvestrant#show#significant synergism in clinical success,Combination Therapies triples,"CDK4,CDK6",-,ER+ breast cancer,fulvestrant,-,-,-,-,-,-,-,Inference,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
548,KP4,34440587,PDAC#has#oncogenic KRAS mutations and CDKN2A inactivation,Cancer Association,"KRAS,CDKN2A",-,PDAC,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
5756,KP4,34440587,Conventional immunotherapies#have been#less successful in PDAC patients compared to other tumors,Therapeutic Response,-,-,PDAC,-,-,-,-,-,-,-,-,Fact,3,3.3,3.3.2,3.3.2.3,-,免疫逃逸抑制
826,KP4,34440587,"Emerging strategies#target#PDAC with CDK4/6 inhibitors, RAS inhibitors, and immune checkpoint agents",Emerging Strategies,"CDK4,CDK6,RAS",-,PDAC,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4818,KP4,30078354,Acquired resistance to CDK4/6 inhibitors#necessitates#new therapeutic avenues for ER+ breast cancers,Therapeutic Resistance,"CDK4,CDK6",-,ER+ breast cancer,-,-,-,-,-,-,-,-,Inference,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
4267,KP4,38322413,"CDK4/6 inhibitors#demonstrate#efficacy in adjuvant, advanced and metastatic settings",Therapeutic Response,"CDK4, CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.2,晚期实体瘤
6207,KP4,36118250,Patients with advanced breast cancer#receive#endocrine therapy in combination with CDK4/6 inhibitors,Therapeutic Response,"CDK4, CDK6",-,Advanced breast cancer,-,-,-,Patients with advanced breast cancer,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,8.2.1.2.2,他莫昔芬
595,KP4,39006687,CDK4/6 inhibitors#cause#rare dermatologic side effects like palbociclib,Safety Monitoring,"CDK4, CDK6",-,-,Palbociclib,-,Dermatologic side effects,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,8.4.1.2.4,皮肤反应
2487,KP4,32529951,CDK4/6 inhibitors#are introduced for#treatment of hormone-positive breast cancer resistant to endocrine therapy,Cancer Association,"CDK4, CDK6",-,Hormone-positive breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
133,KP4,32529951,No treatment options#have been proposed for#CDK4/6 inhibitor-induced alopecia,Safety Monitoring,"CDK4, CDK6",-,-,-,-,Alopecia,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,8.4.1.2.4,皮肤反应
1298,KP4,32529951,Topical cetirizine#is used for#CDK4/6 inhibitor-induced alopecia,Therapeutic Development,"CDK4, CDK6",-,-,Cetirizine,-,Alopecia,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3631,KP4,35677682,ALK inhibitors#are used for#ALK-rearranged lung adenocarcinoma,Therapeutic Response,ALK,-,Lung adenocarcinoma,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
7065,KP4,35677682,Neuroendocrine transformation#is observed in#ALK-rearranged NSCLC after ALK inhibition,Cancer Pathways,ALK,-,NSCLC,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,1.3.2.1.2,RAS/RAF/MEK/ERK级联
5744,KP4,35677682,CDKN2A deletion and CDK4 amplification#are found in#ALK-rearranged lung adenocarcinoma,Genomic Alterations,"CDKN2A, CDK4",-,Lung adenocarcinoma,-,-,-,-,Amplified,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,2.1.1.1.1,CDK4/6基因扩增
91,KP4,38046373,Palbociclib#is introduced without#cross-toxicity and with excellent therapeutic response for more than 3 years,Therapeutic Response,"CDK4, CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
97,KP4,39508972,Patients#start#first-line treatment with CDK4/6 inhibitors combined with other therapies,Therapeutic Response,"CDK4, CDK6",-,-,-,-,-,Patients starting first-line treatment,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
7154,KP4,38870830,Compounds 18j and 24d#exhibit#remarkable MCF-7 inhibition in combination with ribociclib,Drug Development,"CDK4, CDK6",-,Breast cancer,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,3.2.2.1.1,PI3K抑制剂协同
6155,KP4,38849509,RNF43 mutations#are more frequent in#pediatric colorectal cancer cases,Genomic Alterations,RNF43,-,Colorectal cancer,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,5.5.1.1.1,错义突变
1244,KP4,38849509,CDK6 inhibitors#are proposed for#pediatric patients with colorectal cancer,Therapeutic Development,CDK6,-,Colorectal cancer,-,-,-,Pediatric patients with colorectal cancer,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
138,KP4,37519806,CDK4/6 inhibitors#improve#outcome of patients with hormone receptor-positive metastatic breast cancer,Therapeutic Response,"CDK4, CDK6",-,Metastatic breast cancer,-,-,-,Patients with hormone receptor-positive metastatic breast cancer,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5741,KP4,29995568,Primary acute lymphoblastic leukemia cells#are susceptible to#vincristine in G1 phase,Cell Cycle Control,ALL,-,Acute lymphoblastic leukemia,Vincristine,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,1.1.3.1.1,G1期阻滞
35,KP4,29995568,Palbociclib#inhibits#CDK4/6,Drug Development,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7732,KP4,29995568,Palbociclib#is combined with#VCR,Combination Therapies,-,-,-,"Palbociclib,VCR",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4499,KP4,29995568,ALL cells#arrest#in G1 phase,Cell Cycle Control,-,ALL cells,Acute lymphoblastic leukemia,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6860,KP4,29995568,CDK4/6 inhibitors#interfere with#microtubule targeting agents,Drug Development,"CDK4,CDK6",-,Acute lymphoblastic leukemia,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7326,KP4,36087253,CDK4/6 inhibitors#are used for#breast cancer treatment,Cancer Association,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
488,KP4,36087253,"CDK4/6 inhibitors#are potentially used for#liver cancer, lung cancer, sarcomas",Cancer Association,"CDK4,CDK6",-,"Liver cancer, Lung cancer, Sarcomas",-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5949,KP4,32641004,Genetic profiling#guides#cancer management,Clinical Implementation,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
132,KP4,35405009,Androgen receptor pathway inhibitors#treat#advanced prostate cancer,Drug Development,AR,-,Prostate cancer,Androgen receptor pathway inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
4711,KP4,35405009,Resistance#develops against#Androgen receptor pathway inhibitors,Therapeutic Resistance,AR,-,Prostate cancer,Androgen receptor pathway inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
6042,KP4,35405009,CRISPR activation screen#identifies#genes promoting resistance to AR inhibitors,Biomarker Analysis,AR,-,Prostate cancer,AR inhibitors,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,-,获得性耐药
4944,KP4,35405009,PRRX2 expression#is highest in#double-negative prostate cancer,Expression Patterns,PRRX2,-,Prostate cancer,-,-,-,-,Upregulated,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,斑块型银屑病
4010,KP4,35405009,PRRX2-related gene signature#identifies#patients with reduced survival in DNPC,Prognostic markers,PRRX2,-,Prostate cancer,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
481,KP4,28226315,LEE011 and 5-fluorouracil or everolimus#cooperatively downregulate#PI3K-Akt-mTOR and Ras-Raf-MEK-ERK pathways,Combination Therapies,-,-,-,"LEE011,5-fluorouracil,Everolimus","PI3K-Akt-mTOR,Ras-Raf-MEK-ERK",-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
1251,KP4,28226315,LEE011 and 5-fluorouracil or everolimus#enhance#inhibition of cell viability,Combination Therapies,-,-,-,"LEE011,5-fluorouracil,Everolimus",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
7547,KP4,39011477,DPM patients#have#poor prognosis,Disease-Specific Categories,-,-,DPM,-,-,-,2 years survival,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
3064,KP4,39011477,Abemaciclib#reduces#AKT phosphorylation,Mechanism of Action,AKT,-,DPM,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
4506,KP4,39011477,Abemaciclib#synergizes with#AKT inhibitor (AKTi VIII),Combination Therapies,AKT,-,DPM,"Abemaciclib,AKTi VIII",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
1037,KP4,36598514,Abemaciclib and talazoparib#are combined to treat#TNBC,Combination Therapies,-,-,Triple-negative breast cancer,"Abemaciclib,Talazoparib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1366,KP4,36598514,Abemaciclib#sensitizes#TAL-resistant HCC1937-R cells,Drug Development,-,-,Triple-negative breast cancer,"Abemaciclib,Talazoparib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7957,KP4,36722142,CDK4/6 inhibitors#show#limited clinical benefit as single agents in melanoma,Therapeutic Response,"CDK4,CDK6",-,Melanoma,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2561,KP4,35184131,Prosenescence therapies#act as#a barrier against tumor progression,Therapeutic Development,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
6738,KP4,35184131,F9 downregulation#prevents#cell cycle arrest and senescence in MCF7 cells,Regulation,F9,-,Breast cancer,-,-,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
5250,KP4,25082755,C481S mutation in BTK#develops#at progression following ibrutinib treatment,Mechanisms of Resistance,BTK,-,Mantle cell lymphoma,Ibrutinib,-,-,-,C481S,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
7103,KP4,25082755,PD 0332991#sensitizes#lymphoma cells to ibrutinib killing,Drug Development,"BTK,CDK4",-,Lymphoma,"PD 0332991,Ibrutinib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
5479,KP4,25082755,PD 0332991#induces#G1 arrest in lymphoma cells,Cell Cycle Control,CDK4,-,Lymphoma,PD 0332991,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
4526,KP4,33809148,Anti-EGFR therapy and CDK4/6 inhibitors#are investigated in#clinical trials,Clinical Trial Data,"EGFR,CDK4,CDK6",-,-,"Anti-EGFR therapy,CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
1782,KP4,36612312,Palbociclib#is administered#orally and cyclically,Drug Development,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.3,8.3.1,8.3.1.1,-,起始剂量选择
4370,KP4,36612312,Palbociclib#induces#neutropenia,Drug-induced Effects,"CDK4,CDK6",-,Neutropenia,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
486,KP4,36612312,Patients with metastatic breast cancer#received#palbociclib,Clinical Implementation,"CDK4,CDK6",-,Metastatic breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
3966,KP4,36612312,Education and monitoring#improve#CDK4/6i adherence and decrease toxicity,Therapeutic Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,8,8.5,8.5.1,8.5.1.3,-,临床评估
5659,KP4,35942220,Palbociclib and ribociclib#are used for#metastatic breast cancer,Drug Development,"CDK4,CDK6",-,Metastatic breast cancer,"Palbociclib,Ribociclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
1903,KP4,35989152,CDK4/6 inhibitors#are used in#HR+/HER2- metastatic breast cancer,Cancer Association,"CDK4,CDK6",-,HR+/HER2- metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
2739,KP4,35989152,CDK4/6 inhibitors#combined with#radiotherapy,Combination Optimization,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
7451,KP4,35989152,CDK4/6 inhibitors#show#synergistic effects with radiotherapy in cancer,Combination Optimization,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
2597,KP4,35989152,CDK4/6 inhibitors#should be discontinued before#irradiation,Therapeutic Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5317,KP4,35989152,Prospective clinical trials#assess#CDK4/6 inhibitor and radiotherapy combination,Clinical Trial Data,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.3,-,疗效监测
7172,KP4,33179425,Ribociclib#prolongs#cell differentiation in FGFR-dependent HCC,Mechanism of Action,"CDK4,CDK6,FGFR1,FGFR2,FGFR3",-,Hepatocellular carcinoma,Ribociclib,-,-,-,-,-,-,-,Inference,1,1.4,1.4.2,1.4.2.2,-,分化标志物表达
2741,KP4,33179425,Infigratinib#is combined with#ribociclib in FGFR-dependent HCC,Combination Optimization,"CDK4,CDK6,FGFR1,FGFR2,FGFR3",-,Hepatocellular carcinoma,"Infigratinib,Ribociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
7019,KP4,39059184,CDK4/6 inhibitors#benefit#adjuvant breast cancer treatment,Therapeutic Development,"CDK4,CDK6",-,Adjuvant breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
2902,KP4,31859178,CDK4/6 inhibitors#are commonly used with#PI3K inhibitors,Combination Optimization,"CDK4,CDK6,PIK3CA",-,-,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
5126,KP4,38997691,CDK4/6 inhibitors#are used in#breast cancer patients in Dubai,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
2885,KP4,38997691,CDK4/6 inhibitors#are prescribed with#aromatase inhibitors and estrogen receptor antagonists,Combination Optimization,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,内分泌治疗联合
1572,KP4,37070653,ESR1 mutation#causes#acquired resistance to CDK4/6 inhibitors,Mechanisms of Resistance,"CDK4,CDK6,ESR1",-,Advanced breast cancer,Aromatase inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
1009,KP4,37298520,Limited treatment options#exist for#well-differentiated/de-differentiated liposarcoma,Therapeutic Resistance,"CDK4,CDK6",-,Liposarcoma,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
7146,KP4,37298520,"DDLPS#responds to#doxorubicin, gemcitabine, trabectedin, eribulin, and pazopanib",Drug Response,"CDK4,CDK6",-,Various cancers,"doxorubicin, gemcitabine, trabectedin, eribulin, pazopanib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
3906,KP4,37298520,CDK4/6 inhibitors#are included in#clinical trials with developmental therapeutics,Clinical Trial Data,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
7280,KP4,32255704,HER2#was recognized as#a druggable target in the 1990s,Drug Development,ERBB2,-,Advanced breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1086,KP4,36031605,CDK4 and CCND2 amplifications#upregulate#CDK4/6,Mechanism of Action,"CDK4,CCND2",Osteosarcoma cells,Osteosarcoma,"palbociclib, lenvatinib",-,-,31-year-old woman,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.2,-,Cyclin D-CDK6复合物
6485,KP4,39002122,TCK-276#a novel CDK4/6 inhibitor#was evaluated for safety and efficacy in RA patients,Drug Development,"CDK4,CDK6",-,Rheumatoid arthritis,TCK-276,-,-,Patients with active RA,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3914,KP4,39002122,Safety and pharmacokinetic endpoints#were assessed in#RA patients,Clinical Trial Data,"CDK4,CDK6",-,Rheumatoid arthritis,-,-,-,Patients with active RA,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,-,生物标志物监测
7336,KP4,39002122,"No deaths, serious adverse events, or clinically meaningful changes#were observed in#RA patients",Safety Data,"CDK4,CDK6",-,Rheumatoid arthritis,-,-,-,Patients with active RA,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.3,-,预防和处理
1326,KP4,39002122,TCK-276#was rapidly absorbed with#a half-life of 6-12 hours,Pharmacokinetics,"CDK4,CDK6",-,-,TCK-276,-,-,-,-,-,-,-,Fact,3,3.6,3.6.2,3.6.2.1,-,持续缓释
5771,KP4,39002122,TCK-276#was well tolerated with#no clinically meaningful safety signals in RA patients,Safety Data,"CDK4,CDK6",-,Rheumatoid arthritis,TCK-276,-,-,Patients with active RA,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
1159,KP4,39002122,Preliminary efficacy data#warrant#further study of TCK-276 for RA treatment,Clinical Trial Data,"CDK4,CDK6",-,Rheumatoid arthritis,TCK-276,-,-,Patients with active RA,-,-,-,-,Inference,8,8.5,8.5.1,8.5.1.3,-,临床评估
4706,KP4,18855578,Specific mutations or aberrant expression#result in#many cancers,Cancer Biology,CDK4,-,Cancer,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6440,KP4,18855578,Cdk4#is targeted for#degradation via the ubiquitin-proteasome pathway,Protein Degradation,CDK4,-,-,-,Ubiquitin-proteasome pathway,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
6591,KP4,33193348,Estrogen receptor positive breast cancers (ERBC)#have#low TMB and are infiltrated with Tregs,Tumor Microenvironment,ERBB2,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
1033,KP4,33193348,CDK4/6 inhibitor (CDKi) treatment#suggests#a way forward via tumor antigen characterization in ERBC,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,CDKi,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.1,-,基因突变
5932,KP4,37079999,Palbociclib and dexamethasone combination#may target#leukemic cell growth,Drug Development,"CDK4, CDK6",-,Leukemia,"palbociclib, dexamethasone",-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6936,KP4,35962417,Choroidal metastasis#regressed following#systemic chemotherapy with palbociclib,Therapeutic Response,"CDK4, CDK6",-,Breast carcinoma,palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5352,KP4,28697311,CDK4/6 and mTOR inhibitors#are included in#therapeutic approaches,Drug Development,"CDK4, CDK6, MTOR",-,-,"CDK4/6 inhibitors, mTOR inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
3308,KP4,36643309,Chemotherapy-resistant bladder cancers#show#response to select kinase inhibitors on CAM-PDX,Drug Response,"CDK4, CDK6",-,Bladder cancer,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
5559,KP4,35298959,Ceritinib plus ribociclib therapy#was studied in#a phase Ib/II study for dose determination,Clinical Trial Data,"CDK4, CDK6",-,-,"ribociclib, ceritinib",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
1268,KP4,35298959,ALK-rearranged advanced NSCLC patients#receive#ceritinib and ribociclib,Drug Development,ALK,-,NSCLC,"ceritinib, ribociclib",-,-,ECOG PS ≤ 2,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
1979,KP4,37702298,Combination of PARP inhibitor and CDK4/6 inhibitor#modulates#cGAS/STING-dependent therapy-induced senescence,Mechanism of Action,"CDK4, CDK6",-,colorectal cancer,"PARP inhibitor, CDK4/6 inhibitor",cGAS/STING,-,-,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.2,-,衰老程序激活
2032,KP4,37702298,"Combination therapy#provides#""one-two punch"" opportunity with anti-PD-L1 therapy",Combination Optimization,"CDK4, CDK6",-,colorectal cancer,anti-PD-L1 therapy,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
7108,KP4,37702298,PARP inhibitor#provides#limited clinical benefit in colorectal cancer patients with low BRCA1/2 mutations,Therapeutic Response,"BRCA1, BRCA2",-,colorectal cancer,PARP inhibitor,-,-,-,low,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,晚期实体瘤
2108,KP4,35050937,Combination of cobimetinib and atezolizumab#was not superior to#pembrolizumab,Combination Optimization,-,-,-,"cobimetinib, atezolizumab, pembrolizumab",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
7466,KP4,39846287,"Palbociclib and ribociclib#interact with#analgesics, acid-reducing agents, and statins",Drug Development,"CDK4, CDK6",-,cancer,"palbociclib, ribociclib",-,-,-,-,-,-,-,Fact,3,3.6,3.6.1,3.6.1.2,-,靶向配体修饰
5713,KP4,33902205,"CDK4/6 inhibitors#are progressing in#HR-positive, HER2-negative advanced breast cancer",Therapeutic Development,"CDK4, CDK6",breast cells,advanced breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
404,KP4,39253474,Trametinib#exhibits#strong growth inhibition,Therapeutic Response,-,-,-,trametinib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6327,KP4,39253474,CDK4/6#may be overestimated in#driving the cell cycle,Mechanism of Action,"CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
3331,KP4,23647051,CDK inhibitors#exhibit#modest antitumor efficacy,Therapeutic Response,"CDK4, CDK6",-,cancer,CDK inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3437,KP4,39218392,Palbociclib#slows#disease progression in polycystic kidney disease,Therapeutic Response,"CDK4, CDK6",-,polycystic kidney disease,palbociclib,CDK4-dependent signaling,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
623,KP4,39218392,Palbociclib#potentiates#effects of mTORC1 deletion/inhibition,Combination Optimization,"CDK4, CDK6",kidney cells,polycystic kidney disease,palbociclib,mTORC1,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
5780,KP4,39429386,HER2-positive metastatic breast cancer#is treated with#CDK4/6 inhibitor for luminal type,Therapeutic Development,"CDK4, CDK6, ERBB2",-,metastatic breast cancer,CDK4/6 inhibitor,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5996,KP4,39429386,CDK4/6 inhibitor combination endocrine therapy#maintains#tumor shrinkage,Therapeutic Response,"CDK4, CDK6",-,tumor,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
6397,KP4,28135854,Systemic treatment options#were represented by#standard cytotoxic chemotherapy,Treatment Monitoring,-,-,metastatic disease,cytotoxic chemotherapy,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.2,二线治疗
1347,KP4,28135854,Innovative therapies#positively impact#disease control and patients' quality of life,Clinical Implementation,-,-,disease,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,生活质量
5537,KP4,28135854,Predictive biomarkers#need to be identified for#better target population selection,Biomarker Analysis,-,-,disease,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
4007,KP4,24961498,"Kinase inhibitor response#is predicted using#activity profiling, in vitro screening, and elastic net regression",AI Drug Discovery,-,-,cancer,kinase inhibitors,-,-,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,-,细胞周期标志物
946,KP4,24961498,Kinase inhibitors#are approved as#cancer therapies,Drug Development,-,-,cancer,kinase inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2504,KP4,24961498,libraries of kinase inhibitors#have been profiled#to provide a map of the strength of action on targets,Technical Methods,-,kinases,-,-,-,-,-,-,-,-,-,Fact,2,2.3,2.3.1,2.3.1.1,-,基因拷贝数变异
1046,KP4,24961498,drug effectiveness predictions#are difficult due to#partial knowledge of downstream biological processes,Mechanism of Action,-,cellular signaling,-,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7791,KP4,24961498,KIEN method#identifies#kinases statistically associated with drug sensitivity in cell lines,Biomarker Analysis,-,kinases,drug sensitivity,-,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,-,获得性耐药
6742,KP4,24961498,data from two-drug combinations#led to#predictive models,Combination Optimization,-,cell lines,-,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
2982,KP4,34953442,ribociclib#elicits#peripheral immune responses in metastatic HR+ breast cancer patients,Therapeutic Response,"CDK4,CDK6",immune cells,HR+ breast cancer,ribociclib,-,-,metastatic patients,-,-,-,-,Fact,3,3.3,3.3.1,3.3.1.1,-,免疫细胞浸润增加
954,KP4,24758225,clinically identifiable subtypes in BC#are addressed in#specific clinical trials,Clinical Trial Data,-,breast cancer,-,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
5643,KP4,24758225,combinations of targeted agents#have emerged as#strategies to overcome acquired resistance,Strategies to Overcome Resistance,-,cancer,-,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
4340,KP4,24758225,'Old' therapies#can be retargeted#to patient populations or reinvented as safer drug conjugates,Drug Development,-,cancer,-,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
4378,KP4,31379741,BRAF(V600E) mutation in PTC#can be targeted with#selective inhibitors like vemurafenib,Cancer Association,BRAF,-,papillary thyroid carcinoma,vemurafenib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
7143,KP4,31379741,clonal enrichments in thyroid tumor#implicate#tumor response to drug treatment and prognosis,Tumor Microenvironment,BRAF,-,thyroid tumor,-,-,-,-,-,-,-,-,Inference,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
2095,KP4,31379741,novel experimental models#enhance#understanding of tumor evolution during ultra-precision therapies,Preclinical Models,BRAF,-,thyroid tumor,-,-,-,-,-,-,-,-,Inference,5,5.5,5.5.3,5.5.3.3,-,驱动突变
5294,KP4,29508248,palbociclib and erlotinib#exert#synergistic anti-GBM activity,Combination Therapies,"CDK4,CDK6,EGFR",-,GBM,"palbociclib, erlotinib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3592,KP4,33595690,Trilaciclib#is a#first-in-class CDK4/6 inhibitor for myelopreservation,Drug Development,"CDK4,CDK6",HSPCs,extensive-stage small cell lung cancer,Trilaciclib,-,chemotherapy-induced damage,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2995,KP4,33595690,Trilaciclib#arrests#HSPCs in G1 phase to protect from chemotherapy damage,Mechanism of Action,"CDK4,CDK6",HSPCs,chemotherapy-induced damage,Trilaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1182,KP4,33595690,integrated analyses of preclinical and clinical data#informed#Phase II dose selection for trilaciclib trials,Clinical Trial Data,"CDK4,CDK6",HSPCs,extensive-stage small cell lung cancer,Trilaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.2,二线治疗
5547,KP4,33595690,Trilaciclib administration#demonstrated#100% G1 arrest in HSPCs and 40% decrease in bone marrow proliferation,Mechanism of Action,"CDK4,CDK6",HSPCs,chemotherapy-induced damage,Trilaciclib,-,-,downregulated,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6765,KP4,34554584,CDK4/6 inhibition-related biomarkers#are characterized by#relationship to progression-free survival in advanced breast cancer,Biomarker Analysis,"CDK4,CDK6",-,advanced breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
5838,KP4,32724874,"genomic profiling#provides#information on carcinogenesis, identification, and therapy for BTC",Genomic Profiling,BTC,-,biliary tract cancer,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.1,-,突变签名
7922,KP4,32724874,therapeutic options#are discussed based on#next-generation sequencing findings in BTC,Therapeutic Development,BTC,-,biliary tract cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
7392,KP4,31803359,HER2 alterations#point to#its pathogenic role in the disease,Molecular Event triples,ERBB2,-,Disease,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6069,KP4,31803359,Widespread metastasis#re-occurred after#10 cycles of trastuzumab and carboplatin,Clinical Outcome triples,-,-,Metastasis,"trastuzumab,carboplatin",-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,8.5.1.3.1,症状改善
6232,KP4,31803359,CDK6 amplification#provides#a potential mechanism of acquired treatment resistance,Mechanisms of Resistance triples,CDK6,-,Treatment resistance,-,-,-,upregulated,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
2848,KP4,31803359,ERBB3(A232V) and PIK3CA(G106V) mutations#are associated with#newly developing metastasis,Genetic Mutation triples,"ERBB3,PIK3CA",-,Metastasis,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
7832,KP4,31803359,Afatinib#was initiated#as an ERBB family inhibitor,Therapeutic Development triples,-,-,-,afatinib,-,-,-,-,-,-,-,Fact,8,8.2,8.2.2,8.2.2.3,-,MEK抑制剂组合
501,KP4,31803359,HER2#contributes to#the pathogenesis of metastatic extramammary Paget's disease,Disease Association triples,ERBB2,-,Metastatic extramammary Paget's disease,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
241,KP4,37675540,Endocrine therapy#has entered#an era of targeted combination therapy,Therapeutic Development triples,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
7286,KP4,32982644,Endocrine treatment#is effective for#estrogen receptor-positive breast cancer,Therapeutic Development triples,ESR1,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
2702,KP4,32982644,Alterations in the ESR1 gene and PIK3CA/mTOR pathway#have been identified as#molecular mechanisms of endocrine resistance,Mechanisms of Resistance triples,"ESR1,PIK3CA,MTOR",-,Endocrine resistance,-,PIK3CA/mTOR,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
3085,KP4,32982644,"CDK4/6, mTOR, and PI3K inhibition#improves#the efficacy of endocrine treatment",Therapeutic Strategy triples,"CDK4,CDK6,MTOR,PIK3CA",-,Endocrine resistance,-,PI3K/mTOR,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
3674,KP4,38390439,"Cyclin-dependent kinase 4/6 inhibitors#are widely used for#advanced-stage hormone receptor-positive, HER2-negative breast cancer",Therapeutic Strategy triples,"CDK4,CDK6,ERBB2",-,Advanced-stage breast cancer,"ribociclib,palbociclib,abemaciclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
1690,KP4,39871392,First-line use of CDK4/6 inhibitors#increased in#patients with CV comorbidities,Patient Usage Data triples,"CDK4,CDK6",-,Cardiovascular comorbidities,-,-,-,Patients with CV comorbidities,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,8.1.1.3.3,合并症评估
2217,KP4,28515242,Ribociclib#was recently approved by#the FDA,Drug Approval triples,-,-,-,ribociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3048,KP4,36913303,Cancer therapy#is limited by#toxicity in normal cells and drug-resistance in cancer cells,Therapeutic Limitation triples,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,2.6.1.1,-,药物外排增加
2832,KP4,36913303,Cancer resistance#can be exploited for#protection of normal cells and selective killing of resistant cancer cells,Therapeutic Strategy triples,-,-,Cancer,-,-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
6143,KP4,36913303,"Inhibitors of CDK4/6, caspases, Mdm2, mTOR, and mitogenic kinases#achieve#protection of normal cells",Therapeutic Strategy triples,"CDK4,CDK6,MTOR",-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
1157,KP4,36913303,Trilaciclib#may foster#similar approaches into clinical practice,Therapeutic Development triples,-,-,Brain tumors,trilaciclib,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
3809,KP4,30824486,Antiestrogen therapy#elicits and reinforces#cell-cycle arrest,Mechanism of Action triples,-,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4794,KP4,26826116,G1T28#is a#novel CDK4/6 inhibitor,Drug Development,"CDK4,CDK6",-,-,G1T28,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
637,KP4,26826116,"Chemotherapy-induced myelosuppression#manifests as#neutropenia, lymphopenia, anemia, and thrombocytopenia",Symptoms,"CDK4,CDK6",-,Myelosuppression,-,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,中性粒细胞减少
7100,KP4,26826116,"Myelosuppression#is the source of#adverse side effects of cancer treatment including infection, sepsis, bleeding, and fatigue",Symptoms,"CDK4,CDK6",-,Myelosuppression,-,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,中性粒细胞减少
4778,KP4,26826116,Myelosuppression#leads to#chemotherapy dose reductions,Clinical Implementation,"CDK4,CDK6",-,Myelosuppression,-,-,-,-,-,-,-,-,Fact,8,8.3,8.3.1,8.3.1.2,-,剂量减少
1288,KP4,26826116,The only course of treatment for myelosuppression#is#growth factor support,Clinical Implementation,"CDK4,CDK6",-,Myelosuppression,-,-,-,-,-,-,-,-,Fact,8,8.3,8.3.1,8.3.1.2,-,剂量减少
6518,KP4,26826116,Growth factor support treatments#do not protect#bone marrow from chemotherapy-inducing cytotoxic effects,Drug Development,"CDK4,CDK6",Bone marrow,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5543,KP4,26826116,G1T28#regulates#proliferation of murine and canine bone marrow hematopoietic stem and progenitor cells,Function triples,"CDK4,CDK6",Bone marrow hematopoietic stem and progenitor cells,-,G1T28,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
264,KP4,26826116,G1T28#provides#multilineage protection from hematologic toxicity of chemotherapy,Drug Development,"CDK4,CDK6",-,-,G1T28,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
985,KP4,24608573,Targeted next-generation sequencing#was performed on#formalin-fixed paraffin-embedded (FFPE) samples,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.2,5.5.2.3,-,基因组重排
3066,KP4,24608573,Alterations in CDK4#are detected in#cancer-related genes,Cancer Association,CDK4,-,Cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
1028,KP4,36184505,"CDK4/6 inhibitors, palbociclib and abemaciclib#have been approved in#Japan",Drug Development,"CDK4,CDK6",-,-,"Palbociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
1575,KP4,34488370,Targeted sequencing#was performed on#450 cancer-related genes for genomic alterations,Technical Methods,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.2,5.5.2.3,-,基因组重排
4796,KP4,34026637,"Ribociclib#is added to#endocrine therapy for HR+, HER2- advanced breast cancer",Combination Therapies,"CDK4,CDK6",-,Advanced breast cancer,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,内分泌治疗联合
735,KP4,29349755,CDK4/6 inhibitors#improve#outcome for early-stage hormone receptor-positive breast cancer,Therapeutic Response,"CDK4, CDK6",-,Hormone receptor-positive breast cancer,CDK4/6 inhibitors,-,-,Early-stage,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5378,KP4,39796647,CDK4/6 inhibitors#are in clinical use for#hormone receptor-positive and HER2-negative breast cancers,Drug Development,"CDK4, CDK6",-,"Hormone receptor-positive breast cancer, HER2-negative breast cancer",CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7377,KP4,34371379,Combined endocrine therapy plus CDK4/6 inhibitors#were entering#the market,Clinical Implementation,"CDK4, CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,内分泌治疗联合
5202,KP4,28699811,Phase 2 or 3 trials#recruit#patients with breast cancer for hormonal treatment plus CDK4/6 inhibitors,Clinical Trial Data,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
7125,KP4,33356996,CDK4/6 inhibitors#restore#retinoblastoma protein function in the ARC,Neural Cell Regulation,"CDK4, CDK6, RB1",Neuronal cells,Diet-induced obesity (DIO),CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2684,KP4,33356996,CDK4/6 inhibitor therapy#restores#Mc4r expression in PVN/PVH,Neural Cell Regulation,"CDK4, CDK6, MC4R",Neuronal cells,Obesity,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
5242,KP4,35982453,CDK4/6 inhibitors#are proposed for#other solid tumors,Drug Development,"CDK4, CDK6",-,Solid tumors,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
125,KP4,29146887,Molecular targeted therapy#encompasses#mTOR inhibitor everolimus and multi-tyrosinkinase inhibitor sunitinib,Drug Development,MTOR,-,Neuroendocrine tumors (NETs),"Everolimus, sunitinib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,3.2.2.2.1,mTOR抑制剂联用
2925,KP4,29146887,Tumor resistance#limits#clinical efficacy of molecular targeted therapy,Mechanisms of Resistance,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.2,2.5.2.4,-,生物标志物指导
6072,KP4,39640578,Nephrotoxic adverse events#are observed in#breast cancer patients receiving CDK4/6 inhibitors,Drug Safety,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,Nephrotoxicity,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
6230,KP4,39640578,Meta-analysis#evaluates#risk of nephrotoxicity associated with CDK4/6 inhibitors,Drug Safety,"CDK4, CDK6",-,-,CDK4/6 inhibitors,-,Nephrotoxicity,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
2387,KP4,39640578,Grade 3 or higher nephrotoxicity#is prevalent in#patients treated with CDK4/6 inhibitors,Drug Safety,"CDK4, CDK6",-,-,CDK4/6 inhibitors,-,Nephrotoxicity,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
7538,KP4,39640578,FDA Adverse Event Reporting System data#corroborated#nephrotoxicity findings,Safety Monitoring,"CDK4,CDK6",-,Nephrotoxicity,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,8.5.1.2.1,循环肿瘤DNA
7022,KP4,39640578,Clinicians#should monitor#renal function indicators when prescribing CDK4/6 inhibitors,Treatment Monitoring,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,8.5.1.2.1,循环肿瘤DNA
2074,KP4,30561760,Cancer genome knowledge#triggered#development of specific targeted inhibitors,Drug Development,-,-,Cancer,Targeted inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1852,KP4,30561760,60% of patients with metastases#exhibited#co-occurring activations of at least 2 pathways,Signaling Networks,-,-,Metastases,-,-,-,Patients with metastases,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
3784,KP4,38835797,Endocrine maintenance therapy#is explored for#higher estrogen receptor expression,Therapeutic Development,ESR1,-,-,Hormone therapy,-,-,-,Upregulated,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
384,KP4,38835797,"Novel therapeutic approaches#involve#CDK4/6 inhibitors, MEK inhibitors, and bevacizumab",Drug Development,"CDK4,CDK6,MEK1",-,-,"CDK4/6 inhibitors, MEK inhibitors, bevacizumab",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
1088,KP4,39171293,"FOXC1#has a conserved role in#TNBC, parallel to FOXA1 in ER+ breast cancer",Molecular Event,"FOXC1,FOXA1",-,"TNBC, ER+ breast cancer",-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
5757,KP4,39171293,"TNBC#is characterized by#lack of ER, PR, and HER2",Disease Characterization,"ER,PR,HER2",-,TNBC,-,-,Silenced,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
4408,KP4,39171293,"FOXC1#drives#growth, metastasis, and stem-cell-like properties in TNBC",Mechanism of Action,FOXC1,-,TNBC,-,-,Upregulated,-,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.3,-,凋亡阈值调节
2728,KP4,39171293,FOXC1 loss#leads to#differential response to CDK4/6 inhibitors in TNBC cell lines,Therapeutic Response,"FOXC1,CDK4,CDK6",-,TNBC,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
5542,KP4,38303227,Endocrine therapy#was switched from#tamoxifen to letrozole with a CDK4/6 inhibitor,Combination Optimization,"CDK4,CDK6",-,-,"Tamoxifen, letrozole, CDK4/6 inhibitor",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.2,-,激素受体降解
7113,KP4,34522451,Targeted therapy for hormone-resistant tumors#includes#PI3K/AKT/mTOR and CDK4/6 inhibitors,Combination Therapies,"CDK4,CDK6,PIK3CA,AKT1,MTOR",-,Hormone-resistant tumors,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
6575,KP4,34522451,Next-generation sequencing with ctDNA#has appeared as#a sensitive and minimally invasive tool,Technical Methods,-,-,Cancer,-,ctDNA,-,-,-,-,-,-,Fact,7,7.6,7.6.1,7.6.1.1,-,突变检测
6548,KP4,23174022,"Next-generation sequencing technologies#identify#point mutations, structural or copy number alterations, and gene expression changes in tumors",Technical Methods,-,-,Tumors,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
4831,KP4,23174022,Integrative sequencing#revealed#a new somatic point mutation in HRAS and rearrangement affecting CDKN2C,Genomic Alterations,"HRAS,CDKN2C",-,Cutaneous melanoma metastases,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
5468,KP4,23174022,Sequencing-based discoveries#may be used to motivate#inclusion of patients into clinical trials with pathway inhibitors,Clinical Trial Data,-,-,Cancer,Pathway inhibitors,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.3,8.1.1.3.1,生物标志物状态
712,KP4,34363593,CDK4/6 inhibitors with endocrine therapy#changed#treatment landscape of HR+ metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,HR+ metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,3.2.1.1.1,雌激素信号阻断
669,KP4,31091037,"CDK4/6, mTOR, and PI3K inhibitors#are associated with#endocrine therapy to increase effectiveness",Combination Therapies,"CDK4,CDK6,MTOR,PIK3CA",-,-,"CDK4/6 inhibitors, mTOR inhibitors, PI3K inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,3.2.2.1.1,PI3K抑制剂协同
4000,KP4,25206307,"Breast cancers expressing ER, PR, or HER2#account for#approximately 90% of cases",Disease Characterization,"ESR1,PR,HER2",-,Breast cancer,-,-,-,-,Upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
7039,KP4,28447036,Treatment for LPS#involves#surgical resection and radiation therapy,Clinical Implementation,-,LPS,-,-,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
2993,KP4,28447036,Use of conventional cytotoxic chemotherapy for unresectable or metastatic LPS#remains#controversial,Clinical Implementation,-,LPS,-,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
3785,KP4,28447036,Translational research and trials#target#various genetic and molecular aberrations in different subtypes of LPS,Clinical Trial Data,-,LPS,-,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,8.5.1.1.1,CT扫描
4432,KP4,28447036,"Tyrosine kinase inhibitors#target#MET, AXL, IGF1R, EGFR, VEGFR2, PDGFR-β, and Aurora kinase",Drug Development,"MET,AXL,IGF1R,EGFR,VEGFR2,PDGFRB",-,-,Tyrosine kinase inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,3.2.2.4.1,多靶点抑制策略
7277,KP4,28447036,Tyrosine kinase inhibitors#are effective in#certain types of LPS,Therapeutic Response,-,LPS,Tyrosine kinase inhibitors,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,3.1.1.4.1,增殖信号阻断
1735,KP4,37017995,"CDK4/6 inhibitor predictive biomarkers#include#CDKN2A loss, ATRX status, MDM2 levels, and Rb1 status",Biomarker Analysis,"CDK4,CDK6,CDKN2A,ATRX,MDM2,RB1",-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.3,CDKN2A缺失
3075,KP4,32477464,Liquid biopsies#provide#personalized options for targeted therapies in NEN patients,Clinical Implementation,-,NEN,-,-,-,-,-,-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.2,8.6.1.2.1,疾病状态
164,KP4,32393766,Emergence of resistance#necessitates#investigation of combination therapies and their effects on tumor evolution,Therapeutic Resistance,-,-,-,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.2,2.5.1.2.1,序贯治疗
7042,KP4,32393766,Palbociclib and paclitaxel#synergize with#BET inhibitor JQ1 in TNBC lines,Combination Therapies,"CDK4,CDK6",-,Triple-negative breast cancer,"Palbociclib, Paclitaxel, JQ1",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,3.2.2.4.1,多靶点抑制策略
4379,KP4,38751441,Genetic changes#are linked to#onset and development of HCC,Molecular Event,-,HCC,-,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.3,5.4.3.1,5.4.3.1.1,原癌基因激活
4857,KP4,38751441,"Genetic changes#include#dysregulated signaling pathways, somatic mutations, single-nucleotide polymorphisms, and genomic instability",Molecular Event,-,HCC,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,5.5.1.1.1,错义突变
2679,KP4,38751441,Efforts#are made to develop#treatments for HCC that are molecularly targeted,Therapeutic Development,-,HCC,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,3.1.1.4.1,增殖信号阻断
7660,KP4,38751441,Efforts#aim to unravel#genetic pathways facilitating early identification of HCC,Biomarker Analysis,-,HCC,-,-,-,-,-,-,-,-,-,Fact,7,7.6,7.6.1,7.6.1.1,7.6.1.1.1,驱动基因突变
6467,KP4,33009951,Responses to temozolomide and targeted treatments#are shown in#(epi)genetically defined subgroups,Therapeutic Response,"CDK4,CDK6,EGFR,MGMT",-,-,"Temozolomide, CDK4/6 inhibitors, EGFR inhibitors",-,-,-,-,-,-,-,Fact,2,2.1,2.1.3,2.1.3.3,2.1.3.3.1,非编码RNA表达变化
2759,KP4,35784572,Up to 80% of breast cancers#are#estrogen receptor positive,Expression Patterns,ESR1,-,Breast cancer,-,-,-,-,Upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
1112,KP4,33953185,Luminal B CINSARC high-risk tumors#are predicted to be#less sensitive to endocrine therapy and CDK4/6 inhibitors,Therapeutic Resistance,"CDK4,CDK6",-,Luminal B CINSARC high-risk tumors,-,-,-,-,-,-,-,-,Inference,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
993,KP4,33369581,Ongoing trials#use#immunotherapy and CDK4/6 inhibitors in advanced HER2-positive setting,Clinical Trial Data,"CDK4,CDK6,HER2",-,HER2-positive breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
7644,KP4,33369581,Therapies described in this review#have become#standard of care for HER2-positive breast cancer patients,Clinical Implementation,HER2,-,HER2-positive breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
6293,KP4,38001750,Most of these tumors#exhibit#estrogen receptor positivity and HER2 negativity,Expression Patterns,"ESR1,HER2",-,Breast cancer,-,-,-,-,"upregulated, silenced",-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,ER/PR状态
7089,KP4,38001750,Novel treatments like CDK4/6 inhibitors#have shown#importance for Her2 Low breast tumors,Therapeutic Development,"CDK4,CDK6,HER2",-,Her2 Low breast tumors,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7167,KP4,30372389,VEGF and mTOR inhibitors#showed#limited efficacy in non-clear cell RCCs compared with clear cell RCCs,Drug Development,MTOR,-,Non-clear cell RCC,"VEGF inhibitors, mTOR inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
2660,KP4,30372389,CDK4/6 inhibitors#are investigated in#tumors with cell cycle alterations,Therapeutic Development,"CDK4,CDK6",-,Tumors,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6410,KP4,30372389,EZH2 inhibitors#are investigated in#RCCs with INI1 loss,Therapeutic Development,"EZH2,INI1",-,RCC,EZH2 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.4,-,表观遗传改变
5785,KP4,30372389,Immune checkpoint inhibitors and combination strategies#enlarge#the spectrum of investigational treatments,Clinical Trial Data,-,-,Investigational treatments,Immune checkpoint inhibitors,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
5079,KP4,33498407,Several drugs that inhibit ER伪 functions#have been#in clinical use for decades,Drug Development,ESR1,-,-,ER伪 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
242,KP4,33498407,New classes of anti-estrogens#are being developed#continuously,Drug Development,ESR1,-,-,Anti-estrogens,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7952,KP4,33498407,Therapies combining anti-estrogens#target#ER伪+ breast cancers,Therapeutic Development,ESR1,-,ER伪+ breast cancer,"Anti-estrogens, PI3K/AKT/mTOR inhibitors, CDK4/6 inhibitors",PI3K/AKT/mTOR,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
2985,KP4,29807045,Androgen receptor targeted treatment#has shown#promising results in TNBC,Therapeutic Development,AR,-,Triple negative breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
1671,KP4,29807045,Combination therapy with androgen-blockade#demonstrated#promising benefit in preclinical studies,Therapeutic Development,AR,-,Aggressive tumors,Androgen-blockade,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4437,KP4,29807045,"Clinical trials#are ongoing for#combined strategies with CDK4/6 inhibitors, PI3K inhibition, chemotherapy, and immunotherapy",Clinical Trial Data,"CDK4,CDK6",-,Aggressive tumors,"CDK4/6 inhibitors, PI3K inhibitors, chemotherapy, immunotherapy",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
758,KP4,36563600,Intrinsic molecular subtypes#have#clinical implications in hormone receptor-positive and HER2-negative metastatic breast cancer,Cancer Association,HER2,-,"Hormone receptor-positive, HER2-negative metastatic breast cancer",-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.2,-,分子亚型
7876,KP4,36563600,Breast cancer classification#relies on#expression of IHC biomarkers,Biomarker Analysis,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
6251,KP4,36563600,Non-luminal biology in HoR+ tumors#has#prognostic value,Cancer Association,-,-,Hormone receptor-positive tumors,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
3291,KP4,36563600,Non-luminal biology in HoR+ tumors#identifies#reduced sensitivity to endocrine therapy,Therapeutic Response,-,-,Hormone receptor-positive tumors,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
3386,KP4,36563600,Non-luminal biology in HoR+ tumors#identifies#increased sensitivity to chemotherapy,Therapeutic Response,-,-,Hormone receptor-positive tumors,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.4,-,周期素表达失衡
4373,KP4,36563600,Intrinsic genomic instability and cell plasticity#represent#determinants of biological diversity in primary and metastatic disease,Cancer Pathways,-,-,Primary and metastatic disease,-,-,-,-,-,-,-,-,Inference,5,5.5,5.5.3,5.5.3.3,-,驱动突变
5783,KP4,36563600,Ongoing clinical trials#aim to validate#predictive and prognostic value of IS,Clinical Trial Data,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,-,生物标志物监测
1929,KP4,29576630,PARP inhibitors#treat#patients with BRCA mutations in breast and ovarian cancer,Drug Development,"BRCA1,BRCA2",-,"Breast cancer, ovarian cancer",PARP inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
5176,KP4,29576630,Supportive therapies#allow#treatment of alopecia or nausea and vomiting more effectively,Quality of Life,-,-,"Alopecia, nausea, vomiting",Supportive therapies,-,"Alopecia, nausea, vomiting",-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
1350,KP4,28059068,Upfront combination strategies targeting EGFR amplification#should be tested#clinically,Therapeutic Development,EGFR,-,Amplified tumors,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
197,KP4,39283299,Capivasertib plus fulvestrant#prolonged#progression-free survival compared to placebo plus fulvestrant,Therapeutic Response,"PIK3CA,AKT1,PTEN",-,Breast cancer,"Capivasertib, fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
5589,KP4,39283299,"Tumors with PIK3CA, AKT1, and/or PTEN alterations#had#better outcomes with capivasertib plus fulvestrant",Therapeutic Response,"PIK3CA,AKT1,PTEN",-,Breast cancer,"Capivasertib, fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
398,KP4,29528755,Patients#need#targeted therapies combined with conventional chemotherapy or new experimental agents,Personalized Medicine,-,-,Cancer,"Targeted therapies, chemotherapy, experimental agents",-,-,-,-,-,-,-,Inference,3,3.2,3.2.3,3.2.3.4,-,耐药预防
6822,KP4,36446866,elacestrant#is active after#acquired resistance to fulvestrant,Drug Development,ESR1,-,Breast cancer,"elacestrant, fulvestrant",-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
4501,KP4,36446866,elacestrant#enhances#antiproliferative effect of CDK4/6 inhibitors,Combination Optimization,"CDK4,CDK6",-,-,elacestrant,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
598,KP4,29282688,new selective CDK4/6 inhibitors#showed#potent efficacy with tolerable safety,Drug Development,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7701,KP4,38838928,CDK4/6 inhibitors#are used in#solid tumors,Clinical Implementation,"CDK4,CDK6",-,Solid tumors,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
3893,KP4,29291023,CDK4/6 inhibition with palbociclib#did not potentiate#venetoclax activity,Drug Development,"CDK4,CDK6",-,-,"palbociclib, venetoclax",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
410,KP4,38231045,palbociclib plus AI#extended#real-world progression-free survival,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,"palbociclib, AI",-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
6141,KP4,37459790,probiotics and trimebutine maleate#reduce#abemaciclib-induced diarrhea,Quality of Life,"CDK4,CDK6",-,Breast cancer,"probiotics, trimebutine maleate, abemaciclib",-,Diarrhea,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
3303,KP4,37459790,hormone receptor-positive advanced breast cancer patients#were randomized into#probiotic groups,Clinical Trial Data,-,-,Breast cancer,probiotic Bifidobacterium,-,-,"Hormone receptor-positive, HER2-negative",-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
7621,KP4,37459790,"endocrine therapy, abemaciclib, and probiotics#were administered for#28 days",Clinical Implementation,"CDK4,CDK6",-,Breast cancer,"abemaciclib, probiotics",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
4586,KP4,31209198,resistant cell lines#accumulate#chromosomal breaks,Mechanisms of Resistance,-,Cell lines,-,-,-,-,-,-,-,-,-,Fact,2,2.4,2.4.2,2.4.2.4,-,通路重编程
3243,KP4,39159705,CDKN2A loss#may respond to#CDK4/6 inhibitors,Cancer Association,"CDKN2A,CDK4,CDK6",-,PM,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.2,-,原发性耐药
483,KP4,39159705,Defects in MMR and HR#suggest#tailored approaches with ICI or PARP inhibitors,Therapeutic Development,-,-,-,"ICI,PARP inhibitors",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1964,KP4,39159705,Ongoing trials#explore#novel inhibitors and promising targets like mesothelin,Clinical Trial Data,-,-,-,novel inhibitors,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
6646,KP4,39159705,"Implementing these strategies#requires overcoming#challenges in patient selection, combination therapies, biomarker identification, and cost considerations",Clinical Implementation,-,-,-,-,-,-,Patient selection challenges,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,-,生物标志物监测
4390,KP4,38594722,The luminal androgen receptor (LAR) subtype#has attracted attention for#targeted treatment combining androgen receptor antagonists and CDK4/6 inhibitors,Cancer Association,"CDK4,CDK6",-,-,"CDK4/6 inhibitors, androgen receptor antagonists",-,-,-,-,-,-,-,Inference,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
2442,KP4,36125617,AM#has more frequent mutations in#KIT and CDK4/6,Cancer Association,"KIT,CDK4,CDK6",-,AM,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
7464,KP4,35485642,More than 50 cyclin-dependent kinase (CDK) inhibitors#have therapeutic applications in#multiple cancers,Therapeutic Development,"CDK4,CDK6",-,Multiple cancers,CDK inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
6446,KP4,35485642,"This review#discusses#design strategies, structure-activity relationships, and efficacy performances of selective or nonselective CDK inhibitors",Drug Development,"CDK4,CDK6",-,-,CDK inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1190,KP4,35485642,Selective CDK inhibitors#have#safer therapeutic potential than pan-CDK inhibitors,Drug Development,"CDK4,CDK6",-,-,"Selective CDK inhibitors, pan-CDK inhibitors",-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1611,KP4,35485642,Four CDK4/6 inhibitors#have been approved for#the treatment of breast cancer or for prophylactic administration during chemotherapy,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
7437,KP4,35485642,Emerging strategies in CDK inhibitors#are summarized as#anticancer drug targets for drug discovery,Drug Development,"CDK4,CDK6",-,-,CDK inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3580,KP4,34939467,Actionable mutations#were discovered in#36.9% of patients,Clinical Correlation triples,-,-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
5761,KP4,38542211,Case reports#show#immunotherapy efficacy in metastatic and neoadjuvant settings,Therapeutic Response,-,-,-,Immunotherapy,-,-,Metastatic and neoadjuvant settings,-,-,-,-,Fact,3,3.3,3.3.1,3.3.1.4,-,免疫抑制缓解
804,KP4,38542211,"Preclinical data#suggest#inhibiting pathways such as CDK4/6, AURKA, ATR, and EZH2 as promising for SMARCA4-UT",Pathway & Network Categories,"CDK4,CDK6,AURKA,ATR,EZH2",-,SMARCA4-UT,-,"CDK4/6 pathway, AURKA pathway, ATR pathway, EZH2 pathway",-,-,-,-,-,-,Inference,1,1.3,1.3.1,1.3.1.3,-,协同效应
4460,KP4,32042863,Biomarkers#allow#precision medicine approaches in ICBs,Biomarker Analysis,-,-,Triple-negative breast cancer,"nab-paclitaxel, anti-PD-L1, pembrolizumab",-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.3,-,药物外排
2962,KP4,32042863,Biomarker studies#guide#CDK4/6 inhibitor/fractionated radiotherapy/HDACi strategies in conjunction with ICBs,Combination Optimization,"CDK4,CDK6",-,-,"CDK4/6 inhibitors, HDACi",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3661,KP4,29226311,This article#reviews#the role of CDK4/6 inhibitors in ER-negative breast cancer patients,Therapeutic Development,"CDK4,CDK6",-,ER-negative breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3133,KP4,37893593,A patient#started treatment with#a CDK4/6-inhibitor and an aromatase inhibitor,Therapeutic Response,"CDK4,CDK6",-,-,"CDK4/6 inhibitors, aromatase inhibitor",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
721,KP4,37893593,NGS analysis#showed#PIK3CA and HER2 mutations,Molecular Event triples,"PIK3CA,HER2",-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
6512,KP4,32936368,FDA approval#exists for#17 different tumor entities and one agnostic indication,Regulatory Documentation,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
6536,KP4,32936368,immune checkpoint inhibitors#provide#clinical benefits for only a part of patients,Therapeutic Response,-,-,-,immune checkpoint inhibitors,-,-,part of patients,-,-,-,-,Fact,3,3.3,3.3.2,3.3.2.4,-,协同免疫激活
2284,KP4,32936368,CDK4/6 inhibitors#are under#clinical investigation to improve efficacy,Drug Development,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5045,KP4,32936368,predictive biomarkers#are urgently needed for#improved treatment strategies,Biomarker Analysis,-,-,-,-,-,-,-,-,-,-,-,Inference,7,7.5,7.5.1,7.5.1.3,-,药物外排
1527,KP4,27606939,dual CDK4/6 inhibitors#demonstrate#interesting results for personalized treatment,Therapeutic Development,"CDK4,CDK6",-,-,CDK inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3579,KP4,38450313,patients with androgen receptor (AR) GA only#have#better median OS compared to patients with AR GA plus at least one additional GA,Patient Stratification,AR,-,-,-,-,-,patients with AR GA only,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
4210,KP4,31480474,next-generation sequencing#identifies#unique aberrations in intimal sarcoma,Preclinical Models,-,-,intimal sarcoma,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.3,-,链侵入
4467,KP4,31480474,genetic alterations#were cataloged from#thirteen patients with intimal sarcoma using the AACR GENIE database,Genomic Profiling,-,-,intimal sarcoma,-,-,-,thirteen patients,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.3,-,沉默突变
2427,KP4,31480474,PDE4DIP-NOTCH2 and MRPS30-ARID2 fusions#were identified as#genomic rearrangement events,Cancer Association,"PDE4DIP,NOTCH2,MRPS30,ARID2",-,-,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
707,KP4,31480474,genomic profiling#is warranted in#management of intimal sarcoma and targeted therapy trials,Genomic Profiling,-,-,intimal sarcoma,-,-,-,-,-,-,-,-,Inference,5,5.5,5.5.1,5.5.1.3,-,沉默突变
1087,KP4,36986799,"LIV1 expression#correlates with#clinicopathological data including DFS, OS, pCR, and drug actionability in BC",Biomarker Analysis,LIV1,-,breast cancer,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
798,KP4,36986799,high LIV1 expression#is associated with#lower pCR rate after anthracycline-based chemotherapy,Therapeutic Response,LIV1,-,breast cancer,anthracycline-based chemotherapy,-,-,-,upregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2912,KP4,36986799,LIV1-high tumors#are associated with#higher sensitivity to hormone therapy and CDK4/6 inhibitors,Therapeutic Response,"LIV1,CDK4,CDK6",-,-,"hormone therapy, CDK4/6 inhibitors",-,-,-,upregulated,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
3335,KP4,34282751,Low PD-L1 expression levels#argue against#strong potential for novel immune checkpoint inhibitors,Therapeutic Resistance,CD274,-,-,-,-,low,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.3,6.1.1.3.1,PD-1/PD-L1表达
3499,KP4,30290287,Acquired resistance#often limits#the duration of ALK-TKI therapies,Therapeutic Resistance,ALK,-,non-small cell lung cancer,ALK-TKI inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
4087,KP4,30290287,Growth of MYC-overexpressing clones#was reduced by#Cdk4/6 inhibitors such as Palbociclib,Therapeutic Response,"MYC,CDK4,CDK6",-,-,palbociclib,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
4150,KP4,34684001,Palbociclib#is indicated in#HR+/HER2- advanced or metastatic breast cancer in combination with hormonotherapy,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- advanced or metastatic breast cancer,"palbociclib, hormonotherapy",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
2884,KP4,34684001,Palbociclib toxicity#is#neutropenia,Safety Monitoring,"CDK4,CDK6",-,-,palbociclib,-,neutropenia,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
357,KP4,28856074,"38-year-old female#is treated with#letrozole, everolimus, and palbociclib",Therapeutic Development,"CCND1,CDK4,CDK6",-,Breast cancer,"letrozole, everolimus, palbociclib",-,-,"38-year-old female, recurrent ER+ breast cancer",-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
2226,KP4,28856074,"The drugs#target#hormonal signaling pathway, PI3K-AKT pathway, and CCND1-CDK4/6 pathway",Mechanism of Action,"CCND1,CDK4,CDK6,PIK3CA",-,Breast cancer,"letrozole, everolimus, palbociclib","PI3K-AKT, CCND1-CDK4/6",-,"ER+ disease, PIK3CA mutation, CCND1 amplification",-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
4171,KP4,31160171,Ribociclib with letrozole#improved#progression-free survival versus letrozole alone,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,"ribociclib, letrozole",-,-,"Postmenopausal women, HR+/HER2- advanced breast cancer",-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
2439,KP4,39612621,Endocrine therapy#was prescribed in#97.3% of patients,Clinical Implementation,-,-,-,aromatase inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
6535,KP4,19509251,Expression levels of p18(INK4C)#showed#strong negative correlation to sensitivity,Biomarker Analysis,CDKN2C,-,-,-,-,-,-,downregulated,-,-,-,Fact,2,2.3,2.3.3,2.3.3.2,-,蛋白表达量
6828,KP4,32883002,"Concomitant medications, pharmacogenetic profile, and pathophysiological conditions#could influence#pharmacokinetics",Pharmacogenetics,-,-,-,-,-,-,-,-,-,-,metabolites,Fact,4,4.2,4.2.3,4.2.3.4,-,营养应激反应
3788,KP4,32883002,Personalized therapeutic approach#could better drive#safe and effective clinical use,Clinical Implementation,-,-,-,-,-,-,-,-,-,-,-,Inference,8,8.3,8.3.1,8.3.1.2,-,不良反应管理
4665,KP4,32234489,Resistance#may limit#long-term efficacy of KRAS inhibitors,Therapeutic Resistance,KRAS,-,-,KRAS inhibitors,-,-,-,-,-,-,-,Inference,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
1128,KP4,32234489,KRASi combinations#convert#cytostatic response to cytotoxic response,Combination Therapies,"KRAS,PIK3CA,HSP90,CDK4,CDK6,SHP2",-,-,"KRAS inhibitors, PI3K inhibitors, HSP90 inhibitors, CDK4/6 inhibitors, SHP2 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5689,KP4,27041411,"Tyrosine kinase inhibitors#target#BRAF/MEK, ALK, and CDK4/6 pathways",Drug Development,"CDK4,CDK6,BRAF,ALK,MAP2K1",-,-,Tyrosine kinase inhibitors,"BRAF/MEK, ALK, CDK4/6",-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4032,KP4,39025927,Genetic alterations#are associated with#immunotherapy prognosis in Chinese melanoma patients,Genomic Analysis,-,-,Melanoma,-,-,-,Chinese melanoma patients,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.1,-,RB1突变
5923,KP4,39025927,Immune checkpoint inhibitors#improve#clinical outcomes in melanoma patients,Therapeutic Response,-,-,Melanoma,Immune checkpoint inhibitors,-,-,Melanoma patients,-,-,-,-,Fact,3,3.3,3.3.2,3.3.2.1,-,PD-1/PD-L1表达调控
2533,KP4,39025927,Genetic profiling#evaluated#efficacy of ICI treatment in melanoma patients,Biomarker Analysis,-,-,Melanoma,Immune checkpoint inhibitors,-,-,Melanoma patients,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,-,Ki67指数
532,KP4,39025927,Genomic and pathological profiling#shed light on#molecular landscape of melanoma,Genomic Analysis,-,-,Melanoma,-,-,-,Chinese melanoma patients,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.3,-,驱动突变
6522,KP4,36165726,Selective CDK4/6 inhibition#is investigated as#a therapeutic strategy for HNSCC,Preclinical Models,"CDK4,CDK6",-,Head and neck squamous cell carcinoma,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5120,KP4,39605517,Differentiation therapy#provides#a potential alternative for medulloblastoma patients,Therapeutic Development,TP53,-,Medulloblastoma,-,-,-,Patients with TP53 mutations,-,-,-,-,Fact,3,3.4,3.4.1,3.4.1.2,-,DNA损伤应答
5856,KP4,39605517,Neuronal differentiation#could be induced by#UNC1999 combined with CDK4/6 inhibitor,Combination Therapies,"CDK4,CDK6,EZH2",-,Medulloblastoma,"UNC1999, palbociclib",-,-,MB cells,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
4827,KP4,38137564,CDKN2A mutations#lack#specific targeted therapies,Cancer Association,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
5093,KP4,38137564,CDK4/6 inhibitors#show#mixed results in clinical trials,Therapeutic Response,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
6319,KP4,36123435,Triple-negative breast cancer (TNBC)#has#high mortality rates and high risk of relapse,Cancer Association,-,-,Triple-negative breast cancer,-,-,"High mortality rates, high risk of relapse",-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
969,KP4,36123435,Palbociclib isethionate#a CDK4/6 inhibitor#is one of the drugs mentioned,Drug Development,"CDK4,CDK6",-,-,Palbociclib isethionate,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.3,-,E2F转录因子活性下调
5513,KP4,39295518,CDK4/6 inhibitors#improve#PFS and ORR compared to hormonal therapy alone,Therapeutic Response,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
5214,KP4,23979958,Fibroblast growth factor receptor pathway inhibitors#could be#a therapeutic option for a subset of patients,Pathway & Network Categories,FGFR,-,-,Fibroblast growth factor receptor pathway inhibitors,Fibroblast growth factor receptor pathway,-,-,-,-,-,-,Inference,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
2695,KP4,38470447,Dalpiciclib and abemaciclib#are approved for#HR+/HER2- advanced breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,"Dalpiciclib, Abemaciclib",-,-,Postmenopausal females,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
7222,KP4,28978144,PI3K/AKT/mTOR signaling pathway#is targeted by#candidate drugs for radiosensitization,Pathway & Network Categories,"PIK3CA,AKT1,MTOR",-,-,-,PI3K/AKT/mTOR signaling pathway,-,-,-,-,-,-,Inference,1,1.3,1.3.1,1.3.1.3,-,协同效应
4288,KP4,39043079,Tamoxifen with OFS#is received by#14% of patients,Therapeutic Development,-,-,-,Tamoxifen,-,-,Ovarian function suppression,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.2,-,激素受体降解
3564,KP4,39043079,Patients with AI and OFS#have#higher grade and more metastatic axillary nodes,Patient Characteristics,-,-,-,Aromatase inhibitor (AI),-,"Higher grade, metastatic axillary nodes",-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,症状改善
6493,KP4,30657954,BRAFV600E mutant acral melanomas#could benefit from#BRAF inhibitor therapy,Cancer Association,BRAF,-,Acral melanoma,BRAF inhibitors,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
6077,KP4,27825114,PD 0332991#could reverse#EGFR-TKI resistance in human lung cancer cells,Mechanisms of Resistance,"CDK4,CDK6,EGFR",-,Lung cancer,PD 0332991,EGFR-TKI pathway,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
5161,KP4,29262551,Patient-derived orthotopic xenograft (PDOX)#is used for#doxorubicin-resistant metastatic Ewing's sarcoma with FUS-ERG fusion and CDKN2A deletion,Preclinical Models,"FUS,ERG,CDKN2A",-,Ewing's sarcoma,Doxorubicin,-,-,-,-,-,-,-,Fact,2,2.3,2.3.1,2.3.1.3,-,基因融合事件
1318,KP4,37713138,Endocrine therapy combined with CDK4/6 inhibitor#is#the treatment of choice for 1L and 2L therapy,Therapeutic Development,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
1857,KP4,38240964,CDK4/6 inhibitors#affect#safe and favorable outcomes for breast cancer patients,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
5003,KP4,29801054,"TP53, MDM2, CDK4, RB1, ATRX, CDKN2A, PTEN, NF1, CDKN2B, KMT2D, GLI1, ATM, TERT, PI3KCA, NOTCH1, MAP2K4, ERBB4, ARID1A, TSC2, and TNFAIP3#are frequently altered in#genomic profiling studies",Expression Patterns,"TP53,MDM2,CDK4,RB1,ATRX,CDKN2A,PTEN,NF1,CDKN2B,KMT2D,GLI1,ATM,TERT,PI3KCA,NOTCH1,MAP2K4,ERBB4,ARID1A,TSC2,TNFAIP3",-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.3,-,驱动突变
6359,KP4,25792301,Palbociclib#was approved for#first-line treatment of advanced breast cancer,Drug Development,"CDK4,CDK6",-,Advanced breast cancer,"Palbociclib,Letrozole",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
1482,KP4,22090362,CDK4/6 inhibitor PD 0332991#was tested for#DLT and MTD in Rb-positive advanced solid tumors,Clinical Trial Data,"CDK4,CDK6",-,Rb-positive advanced solid tumors,PD 0332991,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
5157,KP4,22090362,10 out of 37 patients#had#stable disease for ≥4 cycles,Clinical Trial Data,-,-,Advanced solid tumors,-,-,Patients with stable disease,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,8.5.1.3.1,症状改善
7661,KP4,38499265,CDK4/6 inhibitors#might be effective for#N-LCNEC,Drug Development,"CDK4,CDK6",-,N-LCNEC,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,3.1.1.1.1,G1/S期转换抑制
3388,KP4,35023616,EGFR mutations#are frequently found with#genetic alterations in LUAD,Cancer Association,EGFR,-,Lung adenocarcinoma (LUAD),-,-,-,-,Upregulated,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,5.5.1.1.1,错义突变
5474,KP4,35023616,Next-generation sequencing (NGS)#detected#EGFR mutations in lung cancer-related genes,Biomarker Analysis,EGFR,-,Lung cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,基因突变
504,KP4,37284196,EGFR and ERBB2 exon 20 insertions/duplications#are associated with#advanced NSCLC,Cancer Association,"EGFR,ERBB2",-,Advanced non-small cell lung cancer (NSCLC),-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,2.1.1.3.1,CCNE1过表达
6544,KP4,37284196,Exon 20 insertions/duplications in EGFR and ERBB2#are detected in#1.5% of NSCLC cases,Cancer Association,"EGFR,ERBB2",-,Non-small cell lung cancer (NSCLC),-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,基因拷贝数
2140,KP4,37284196,EGFR exon 20 insertions/duplications#are associated with#de novo resistance to EGFR inhibitors,Mechanisms of Resistance,EGFR,-,Non-small cell lung cancer (NSCLC),EGFR inhibitors,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,2.2.1.4.1,关键基因突变
5681,KP4,37284196,EGFR/ERBB2 ex20 ins/dup variants#correlate with#response to targeted therapy,Cancer Association,"EGFR,ERBB2",-,-,-,-,-,-,-,-,-,-,Inference,7,7.3,7.3.1,7.3.1.1,7.3.1.1.1,细胞周期标志物
3552,KP4,37284196,Mobocertinib treatment#may lead to#resistant mutations,Mechanisms of Resistance,-,-,-,mobocertinib,-,-,-,-,-,-,-,Inference,2,2.5,2.5.2,2.5.2.1,2.5.2.1.1,新型抑制剂开发
3076,KP4,22374332,"Dose-limiting toxicities#were defined as#neutropenia, leukopenia, and febrile neutropenia",Safety Monitoring,-,-,-,-,-,"neutropenia, leukopenia, febrile neutropenia",-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
7171,KP4,38653982,Systemic immune signatures#indicate#an immune-suppressed environment in mBC patients,Immune Cell Functions,-,-,metastatic breast cancer,-,-,immune-suppressed,downregulated,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.3,6.1.1.3.1,免疫检查点表达
4141,KP4,36826463,"Abemaciclib#is approved in combination with#adjuvant endocrine therapy for HR+, HER2-, node-positive, early breast cancer with high recurrence risk",Therapeutic Development,-,-,early breast cancer,Abemaciclib,-,high recurrence risk,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3572,KP4,30847728,"Three CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib#are approved as#first-line therapy for HR+, HER2- metastatic breast cancer",Therapeutic Development,"CDK4,CDK6",-,metastatic breast cancer,"palbociclib, ribociclib, abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
4326,KP5,28368408,Cyclin D-CDK4/6 complexes#are activated by#mitogenic/oncogenic pathways,Cell Cycle Control,"CDK4,CDK6",-,-,-,"mitogenic, oncogenic",-,activated,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,1.1.2.3.1,复合物活性调节
5273,KP5,28368408,T172 phosphorylation of CDK4#determines#CDK4 activation,Regulation,CDK4,-,-,-,-,-,phosphorylated,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,1.2.3.1.1,翻译后修饰
416,KP5,28368408,T172 phosphorylation of CDK4#is conditioned by#adjacent proline (P173),Regulation,CDK4,-,-,-,-,-,-,phosphorylated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
1848,KP5,28368408,JNKs and ERK1/2#phosphorylate#p21 at S130 and T57,Post-translational Modifications,"JNK1,MAPK3,CDKN1A",-,-,-,-,-,-,phosphorylated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
2413,KP5,28368408,Phosphorylation of p21 by JNKs#facilitates#CDK7-dependent activation of p21-bound CDK4,Mechanism of Action,"CDKN1A,CDK7,CDK4",-,-,-,-,-,-,activated,-,-,-,Inference,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
6687,KP5,28368408,JNK inhibitors#inhibited#phosphorylation and activation of cyclin D1-CDK4-p21,Regulation,"CDK4,CDKN1A",-,-,-,-,-,-,inhibited,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
4615,KP5,28368408,JNK inhibitors#did not inhibit#activation of cyclin D3-CDK4 associated with p27,Regulation,"CDK4,CDKN1B",-,-,-,-,-,-,activated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
988,KP5,8891723,Cell proliferation control#is ensured by#cyclin-dependent kinases (CDKs),Cell Cycle Control,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3714,KP5,8891723,p16Ink4a#inhibits#G1 CDKs by competition with cyclin D,Regulation,"CDKN2A,CDK4,CDK6",-,-,-,-,-,-,inhibited,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
1444,KP5,8891723,p15Ink4b synthesis#is induced by#TGF beta,Regulation,CDKN2B,-,-,-,TGF beta,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.1,1.2.1.2,-,激素信号通路
7697,KP5,8891723,"p21Waf1#is up-regulated by#senescence, DNA damage, and cellular differentiation",Regulation,CDKN1A,-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.3,1.4.3.2,-,衰老程序激活
2686,KP5,8891723,Reduction of inhibitory activity#might favor#leukemogenesis,Cancer Association,-,-,leukemia,-,-,-,-,-,-,-,-,Inference,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
4011,KP5,36033522,CDK4 and CDK6#regulate#cell cycle,Cell Cycle Control,"CDK4,CDK6",-,-,-,-,-,-,essential,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
4195,KP5,36033522,Cell cycle regulation#is disrupted in#isocitrate dehydrogenase wild-type glioblastoma (GBM),Cancer Association,"CDK4,CDK6",-,glioblastoma,-,-,-,-,disrupted,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
2282,KP5,36033522,GLR2007#inhibits#CDK4/6 enzymatic activity,Drug Development,"CDK4,CDK6",-,-,GLR2007,-,-,-,inhibited,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7205,KP5,36033522,Radiolabeled GLR2007#was distributed in#rats through quantitative whole-body autoradiography,Preclinical Models,-,-,-,GLR2007,-,-,-,-,-,-,-,Fact,3,3.6,3.6.1,3.6.1.4,-,组织渗透增强
6894,KP5,36033522,GLR2007#inhibited#proliferation in tumor cell lines at lower concentrations than abemaciclib,Drug Development,"CDK4,CDK6",-,"glioblastoma, breast cancer, lung cancer, liver cancer","GLR2007, abemaciclib",-,-,-,inhibited,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
361,KP5,36033522,GLR2007#accumulates#in brains of rats at higher levels than in plasma,Pharmacokinetics,GLR2007,-,-,-,-,-,-,-,-,-,-,Fact,3,3.6,3.6.3,3.6.3.4,-,血脑屏障穿透
110,KP5,36033522,"GLR2007#induces#tumor growth inhibition in GBM, breast cancer, and colorectal cancer xenografts",Therapeutic Response,-,-,"GBM, breast cancer, colorectal cancer",GLR2007,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6060,KP5,31852484,Elacestrant#inhibits#growth of patient-derived xenografts resistant to CDK4/6 inhibitors,Therapeutic Response,"CDK4, CDK6",-,-,Elacestrant,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
4353,KP5,26840126,p53#regulates#expression of numerous genes encoding proteins and miRNAs,Mechanism of Action,TP53,-,-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
3900,KP5,26840126,p53#initiates#apoptotic cascades and activates cell cycle checkpoints,Mechanism of Action,TP53,-,-,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.3,1.3.3.3,-,细胞凋亡调控
6658,KP5,26840126,miRNAs#induce#G1 arrest by inhibiting expression of CDK4 and CDK6,Regulation,"CDK4, CDK6",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6458,KP5,18413728,G1-regulating genes#are involved in#neuronal differentiation processes,Neural Cell Regulation,"CDK4, CDK6, CCND1",Neuronal cells,-,-,-,-,-,-,-,-,-,Inference,1,1.4,1.4.2,1.4.2.1,-,谱系特异性分化
7199,KP5,18413728,Cyclin D1 and CDK4 knockdown#inhibits#pRb pathway by reducing pRb phosphorylation and E2F transcriptional activity,Mechanism of Action,"CDK4, CCND1",Neuroblastoma cells,-,-,pRb,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2305,KP5,18413728,Cyclin D1 and CDK4 knockdown#induces#G1-specific cell cycle arrest and neuronal differentiation,Phenotype Analysis,"CDK4, CCND1",Neuroblastoma cells,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
5323,KP5,28927034,Cyclin D3 ablation#results in#increased expression of cyclin D1 protein,Expression Patterns,"CCND3, CCND1",-,-,-,-,-,-,Upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
5615,KP5,28927034,Cyclin D3 ablation#elevates#CDK6/cyclin D1 and CDK4/cyclin D1 complexes,Protein Complex Dynamics,"CDK6, CDK4, CCND1",-,-,-,-,-,-,Upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
2071,KP5,27252418,Increased CDK6 expression#is observed in#fulvestrant-resistant cells,Expression Patterns,CDK6,-,Breast cancer,Fulvestrant,-,-,-,Upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
5001,KP5,27252418,Reduction of CDK6 expression#impairs#fulvestrant-resistant cell growth,Therapeutic Development,CDK6,-,Breast cancer,-,-,-,-,Downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7050,KP5,27252418,Palbociclib#resensitizes#fulvestrant-resistant cells to fulvestrant,Therapeutic Response,-,-,Breast cancer,"Palbociclib, Fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
3742,KP5,27252418,High CDK6 levels#correlate with#shorter progression-free survival in fulvestrant-treated breast cancer patients,Prognostic Associations,CDK6,-,Breast cancer,Fulvestrant,-,-,Breast cancer patients,Upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
1490,KP5,27252418,Upregulation of CDK6#overcomes#fulvestrant-mediated growth inhibition,Mechanisms of Resistance,CDK6,-,Breast cancer,Fulvestrant,-,-,-,Upregulated,-,-,-,Inference,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
3719,KP5,32934206,Non-TNBC subtypes#are more sensitive to#palbociclib,Therapeutic Response,-,Non-TNBC subtypes,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4728,KP5,32934206,Activation of c-myc#leads to#differential palbociclib sensitivities,Mechanisms of Resistance,MYC,-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
6198,KP5,32934206,c-myc activation#downregulates#miR-29b-3p and activates CDK6,Regulation,"MYC, CDK6",-,Breast cancer,-,-,-,-,Upregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
3772,KP5,32934206,Downregulated c-myc#increases#palbociclib efficacy in Xenograft and PDTX models,Therapeutic Development,MYC,-,Breast cancer,Palbociclib,-,-,-,Downregulated,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
4568,KP5,32934206,Combined blockade of CDK4/6 and c-myc signaling pathways#increases#palbociclib sensitivity,Combination Therapies,"CDK4, CDK6, MYC",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
334,KP5,27167191,Combination therapy#decreases#phosphorylated ribosomal protein S6 levels in vitro and in vivo,Mechanism of Action,-,-,-,-,-,-,-,Downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
663,KP5,12834607,Overexpression of cyclin D1#is found in#breast cancer and other types of human cancer,Cancer Association,CCND1,-,"Breast cancer, cancer",-,-,-,-,Upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
7323,KP5,12834607,Cyclin D1#activates#CDK4,Mechanism of Action,"CDK4,CCND1",-,Retinoblastoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
7862,KP5,12834607,CDK4#phosphorylates#Retinoblastoma protein,Mechanism of Action,CDK4,-,Retinoblastoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
727,KP5,20180048,GRN163L#holds#MSCs at G1 state of the cell cycle,Regulation,"CDK4,CDK6,CCND1",MSCs,-,GRN163L,Cell cycle,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
4055,KP5,34385584,Resistance to palbociclib and abemaciclib#is associated with#upregulation of CDK6 and CCND1,Mechanisms of Resistance,"CDK6,CCND1",-,-,"Palbociclib,Abemaciclib",-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
3520,KP5,34385584,ZEN-3694#reverses#upregulation of CDK6 and CCND1,Mechanisms of Resistance,"CDK6,CCND1",-,-,ZEN-3694,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5799,KP5,34385584,ZEN-3694#downregulates#multiple pathways involved in cell cycle regulation,Pathway & Network Categories,"CDK4,CDK6",-,-,ZEN-3694,Cell cycle,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
406,KP5,32418994,Adult GCTs#highly express#CDK4,Expression Patterns,CDK4,GCTs,Germ cell tumors,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
434,KP5,32418994,Pediatric GCTs#strongly express#CDK6,Expression Patterns,CDK6,GCTs,Germ cell tumors,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
2402,KP5,29160310,CDK4 and CDK6#increase#PD-L1 protein levels,Mechanism of Action,"CDK4,CDK6,CD274",-,-,-,Cyclin D-CDK4 pathway,-,-,upregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,MAPK通路激活
4702,KP5,9070222,cyclin D2 and D3#are expressed in#all cellular preparations,Expression Patterns,"CCND2, CCND3",-,-,-,-,-,-,expressed,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
6148,KP5,9070222,cyclin D1#is not expressed in#all cellular preparations,Expression Patterns,CCND1,-,-,-,-,-,-,not expressed,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
3695,KP5,9070222,CDK6#is detectable in#all populations investigated,Expression Patterns,CDK6,-,-,-,-,-,-,expressed,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
754,KP5,9070222,p15INK4B#is detectable in#granulocyte-monocyte precursors,Expression Patterns,CDKN2B,granulocyte-monocyte precursors,-,-,-,-,-,highly expressed,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.3,p16表达
1294,KP5,9070222,hematopoietic G1 phase machinery#is conserved during#different maturation processes,Cell Cycle Control,-,hematopoietic cells,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7210,KP5,33832512,olaparib#inhibits#cell viability in olaparib-sensitive MDA-MB-436 cells,Therapeutic Response,-,MDA-MB-436 cells,-,olaparib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7046,KP5,33832512,olaparib#affects#cell growth due to severe DNA damage,Mechanism of Action,-,MDA-MB-436 cells,-,olaparib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5015,KP5,10939591,inhibitors#form complexes with#CDK4 and CDK6,Protein Complex Dynamics,"CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
771,KP5,10939591,cells#showed#growth arrest and altered cellular morphology,Phenotype triples,-,-,-,-,-,"growth arrest, altered morphology",-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
546,KP5,10939591,cells#displayed#repression of telomerase activity,Phenotype triples,-,-,-,-,-,repressed telomerase activity,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.3,-,E2F转录因子活性下调
652,KP5,15138605,wild-type p16INK4a#inhibits#CDK4 and CDK6,Mechanism of Action,"CDKN2A, CDK4, CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
5993,KP5,15138605,"p16INK4a#is frequently deleted, methylated, or mutated in#many malignancies",Cancer Association,CDKN2A,-,Malignancies,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
5451,KP5,15138605,p16INK4a#controls#cellular senescence and other functions,Regulation,CDKN2A,-,-,-,-,-,-,-,-,-,-,Inference,3,3.4,3.4.1,3.4.1.1,-,细胞周期永久阻滞
2291,KP5,15138605,p16INK4a#suppresses#malignant phenotype in MCF-7 cells,Cancer Association,CDKN2A,MCF-7 cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3635,KP5,15138605,p16INK4a#restores#telomere shortening process in MCF-7 cells,Mechanism of Action,CDKN2A,MCF-7 cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.3,5.1.3.4,-,连接恢复
1480,KP5,15138605,p16INK4a#decreases#DNA repair ability in MCF-7 cells,Mechanism of Action,CDKN2A,MCF-7 cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.3,5.1.3.3,-,间隙填补
490,KP5,15138605,wild-type p16INK4a#inhibits#cell proliferation through cell cycle arrest,Cancer Pathways,CDKN2A,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5287,KP5,15138605,wild-type p16INK4a#inhibits#telomerase activity and DNA repair capacity,Cancer Pathways,CDKN2A,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.3,5.1.3.2,-,切除过程
5279,KP5,32130619,combination of CDK4/6 inhibitors and ER inhibitors#is a therapeutic strategy for#ER-positive breast cancer,Combination Optimization,"CDK4, CDK6",ER-positive breast cancer,-,"palbociclib, fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
7831,KP5,32130619,G1T48#inhibits#estrogen-mediated transcription and proliferation in ER-positive breast cancer cells,Mechanism of Action,-,ER-positive breast cancer,-,G1T48,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.3,-,E2F转录因子活性下调
5281,KP5,32130619,G1T48#suppresses#ER activity in models of endocrine therapy resistance,Mechanism of Action,-,Endocrine therapy-resistant breast cancer,-,G1T48,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
1743,KP5,32130619,G1T48#inhibits#growth of tamoxifen-resistant and LTED breast cancer models,Therapeutic Response,-,"Tamoxifen-resistant breast cancer, LTED breast cancer",-,G1T48,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
6246,KP5,32130619,combination of G1T48 and lerociclib#increases#antitumor response in breast cancer models,Combination Optimization,"CDK4, CDK6",Breast cancer,-,"G1T48, lerociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4398,KP5,32929370,Combination treatment#requires#CD8+ T cells and B cells,Cellular Mechanisms,"CD8, CD19","CD8+ T cells, B cells",-,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
7163,KP5,32929370,Abemaciclib#induces#a proinflammatory immune response in the tumor microenvironment,Immune Response,-,Tumor microenvironment,-,Abemaciclib,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
2854,KP5,32929370,Abemaciclib-treated ID8 tumors#exhibit#a Th1-polarized cytokine profile,Immune Response,-,Tumor,-,Abemaciclib,-,-,-,-,-,-,-,Inference,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
3316,KP5,32929370,Combination treatment#enhances#activities of CD8+ and CD4+ T cells,Immune Response,"CD8, CD4","CD8+ T cells, CD4+ T cells",-,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
4392,KP5,34376578,Combination of CDK4/6 and MEK inhibition#decreases#tumor growth in BRAF/MEK inhibitor-resistant patient-derived xenograft models,Therapeutic Response,"CDK4, CDK6, MAP2K1",Tumor cells,BRAF/MEK inhibitor-resistant tumor,"CDK4/6 inhibitors, MEK inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
6261,KP5,34376578,Combination of CDK4/6 and MEK inhibition#reduces#cellular growth and promotes cell-cycle arrest in BRAF inhibitor-resistant cell lines,Therapeutic Response,"CDK4, CDK6, MAP2K1",Cell lines,BRAF inhibitor-resistant tumor,"CDK4/6 inhibitors, MEK inhibitors","MAPK, Cell-cycle",-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
587,KP5,34376578,Knockdown of CDKN2A#increases#sensitivity to CDK4/6 inhibition in BRAF inhibitor-resistant cells,Mechanisms of Resistance,"CDKN2A, CDK4, CDK6",Cell lines,BRAF inhibitor-resistant tumor,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
5019,KP5,23238983,p16/INK4A/CDKN2A#arrests#cell cycle in G1 phase by inhibiting CDK4/6 binding with cyclin D1,Cell Cycle Regulation,"CDKN2A, CDK4, CDK6, CCND1",Tumor cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
1358,KP5,23238983,Parental CMT cell lines#lack#p16 expression at mRNA or protein levels,Expression Patterns,CDKN2A,CMT cells,Breast cancer,-,-,-,-,silenced,-,-,-,Fact,1,1.5,1.5.3,1.5.3.1,-,长链非编码RNA
6013,KP5,23238983,p16-transfected CMT27A and CMT27H cells#exit#cell cycle post-serum-starvation,Cell Cycle Regulation,CDKN2A,CMT cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
7440,KP5,23238983,p16#is upregulated#along with p27 during quiescence,Regulation,"CDKN2A, CDKN1B",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
3770,KP5,25216059,"IRG1 overexpression#increases#growth, invasion, and tumorigenesis in glioma cells",Cancer Association,IRG1,Glioma cells,Glioma,-,-,-,-,upregulated,-,-,-,Fact,4,4.1,4.1.2,4.1.2.1,-,氧化磷酸化改变
6176,KP5,25216059,"Suppression of IRG1#decreases#levels of cell cycle regulatory proteins E2F1, p21, CDK4, CDK6, and cyclin D1",Regulation,"IRG1, E2F1, CDKN1A, CDK4, CDK6, CCND1",Glioma cells,Glioma,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
6029,KP5,30084835,Pan-mTOR inhibitors#induce#apoptosis in ICC cells,Therapeutic Response,MTOR,-,ICC,MLN0128,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.3,-,线粒体通路调控
2864,KP5,30084835,Palbociclib#potentiates#MLN0128 mTOR inhibition activity,Drug Development,MTOR,Tumor cells,ICC,"Palbociclib, MLN0128",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5406,KP5,39769028,Combination of Alpelisib and Ribociclib#shows#synergistic effects in colorectal cancer models,Combination Therapies,"CDK4, CDK6, PIK3CA",Tumor cells,Colorectal cancer,"Alpelisib, Ribociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
3466,KP5,39769028,Ribociclib#presents#a viable strategy for treating CRC in combination with targeted therapies,Therapeutic Response,"CDK4, CDK6",Tumor cells,Colorectal cancer,Ribociclib,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
3835,KP5,39769028,Combination of Ribociclib and Alpelisib#is evaluated#across four cell lines with different mutational statuses,Combination Therapies,"CDK4, CDK6, PIK3CA, KRAS",Cell lines,Colorectal cancer,"Ribociclib, Alpelisib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
3391,KP5,39769028,"Drugs#impact#key proteins in PI3K pathway, cell cycle regulation, and apoptosis",Pathway Analysis,"PIK3CA, CDK4, CDK6",Tumor cells,Colorectal cancer,"Ribociclib, Alpelisib","PI3K, Cell-cycle, Apoptosis",-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
266,KP5,39769028,Alpelisib and Ribociclib#demonstrated#a synergistic anti-proliferative effect,Combination Therapies triples,-,All cell lines,-,"Alpelisib, Ribociclib",PI3K/AKT/mTOR,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
5159,KP5,39769028,"Combination therapy#led to#a decrease in pRB, pAKT, and p-S6 levels",Mechanism of Action,"RB1, AKT1, RPS6",-,-,"Alpelisib, Ribociclib",PI3K/AKT/mTOR,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
1922,KP5,39769028,Combination therapy#upregulated#p-BCL2,Markers,BCL2,-,-,"Alpelisib, Ribociclib",-,-,-,upregulated,p-BCL2,-,-,Fact,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
2245,KP5,39769028,Combination therapy#reduced#tumor growth in xenografts,Preclinical Models,-,"Caco-2, LS1034, SNUC4",Tumor,"Alpelisib, Ribociclib",-,-,-,-,-,-,-,Fact,3,3.4,3.4.2,3.4.2.3,-,凋亡执行
7793,KP5,26278998,CARF-induced signaling#caused#transcriptional repression of p21(WAF1),Regulation,CDKN1A,-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
7942,KP5,26278998,"Repression of p21(WAF1)#led to#increase in CDK4, CDK6, pRb, and E2F1",Regulation,"CDK4, CDK6, RB1, E2F1",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
1700,KP5,37348763,NEK2 overexpression#promoted#IL-22-induced alterations in cell viability,Regulation,NEK2,-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.1,1.4.1.1,-,增殖信号整合
4520,KP5,37348763,"NEK2#regulated#STAT3 phosphorylation, p-RB, cyclin D1, CDK4, and CDK6 protein levels",Mechanism of Action,"STAT3, RB1, CCND1, CDK4, CDK6",HaCaT cells,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
3360,KP5,33415002,CDK6 deficiency#reduced#collagen and MMP-2 levels,Markers,CDK6,-,-,-,-,-,-,downregulated,MMP-2,-,-,Fact,6,6.5,6.5.1,6.5.1.1,-,胶原蛋白
2968,KP5,30935694,UNC93B1 knockdown#decreased#cellular proliferation by G1 phase arrest,Mechanism of Action,"CDKN1A, CDK4, CDK6, CCND1, CCNE1",-,OSCC,-,-,-,-,upregulated/downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
1754,KP5,26137139,miR-218 expression#downregulated#CDK6 and cyclin D1,Regulation,"CDK6, CCND1",-,Glioma,-,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.3,-,非编码RNA调控
1078,KP5,26137139,miR-218 expression#upregulated#p21(Cip1/Waf1),Regulation,CDKN1A,-,Glioma,-,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.3,-,非编码RNA调控
3601,KP5,31358010,CDK4/6 inhibitors#inhibited#proliferation of mucosal melanoma cells,Preclinical Models,"CDK4, CCND1, CDKN2A",Mucosal melanoma,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4305,KP5,36825764,CPVL#affected#breast cancer cells under CDK4/6 inhibitor conditions,Mechanism of Action,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5582,KP5,36825764,CPVL#altered#PTEN-related pathways,Pathway & Network Categories,PTEN,-,Breast cancer,-,PTEN-related pathways,-,-,-,-,-,-,Inference,1,1.3,1.3.1,1.3.1.3,-,协同效应
2515,KP5,8988060,Cyclin D1 and Cdk4#were expressed in#normal and adenomatous intestinal epithelium,Expression Patterns,"CCND1, CDK4",-,Intestinal neoplasia,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
161,KP5,8988060,Cyclin D1 and Cdk4#overexpressed in#intestinal adenomas,Expression Patterns,"CCND1, CDK4",-,Intestinal adenomas,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
1522,KP5,8988060,Up-regulation of G1 cell cycle proteins#contributed to#intestinal carcinogenesis,Cancer Association,"CCND1, CDK4",-,Intestinal carcinogenesis,-,-,-,-,upregulated,-,-,-,Inference,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
753,KP5,35936714,Simultaneous drug combinations#exhibited#superior anti-proliferative activity,Combination Therapies triples,-,-,-,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
370,KP5,35936714,Abemaciclib with lenvatinib#reduced#3D cell growth and colony formation,Combination Therapies triples,-,-,-,"Abemaciclib, lenvatinib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4508,KP5,35936714,Drug combination#downregulated#c-myc protein expression,Regulation,MYC,-,-,"Abemaciclib, lenvatinib",-,-,downregulated,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
2279,KP5,35936714,"Drug combination#reduced#activation of MAPK, mTORC1/p70S6K or src/FAK signaling",Pathway & Network Categories,"MAPK, MTOR, FAK",-,HCC,"Abemaciclib, lenvatinib","MAPK, mTORC1/p70S6K, src/FAK",-,downregulated,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
31,KP5,35936714,Drug combination#arrested#cells in the G1 phase,Mechanism of Action,CDKN1A,-,HCC,"Abemaciclib, lenvatinib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7513,KP5,35936714,Drug combination#impaired#colony formation after withdrawal,Therapeutic Response,-,-,-,"Abemaciclib, lenvatinib",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.3,-,剂量优化
3392,KP5,29441600,"Berberine#inhibits#varicocele-induced cell cycle arrest by regulating cyclin D1, CDK4, and p21 expression",Mechanism of Action,"CDK4,CCND1,CDKN1A",Testicular cells,Varicocele,-,Cell cycle,Cell cycle arrest,-,Regulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
2459,KP5,38807144,CDK4/6 inhibitors#exhibit#anti-tumor effects in HNMM patient-derived xenograft models with CDK4 amplification,Cancer Association,"CDK4,CDK6",-,Head and neck MM,-,-,-,Amplified,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
6043,KP5,38807144,Dalpiciclib#was assessed for#anti-tumor efficacy in HNMM PDX and PDC models,Preclinical Models,"CDK4,CDK6",-,Head and neck MM,Dalpiciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2980,KP5,38807144,Dalpiciclib#suppressed#growth of HNMM-PDX and PDC with CDK4 amplification,Therapeutic Response,CDK4,-,Head and neck MM,Dalpiciclib,-,-,Amplified,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6466,KP5,37752406,Study#explored#mechanism of abemaciclib resistance,Therapeutic Resistance,"CDK4,CDK6",-,Gastric cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
5443,KP5,37752406,Abemaciclib-resistant gastric cancer cell lines#showed#increased p-eIF4E and eIF4E expression,Expression Patterns,EIF4E,-,Gastric cancer,Abemaciclib,-,-,Upregulated,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
917,KP5,37752406,eIF4E knockdown#was employed to analyze#role in resistance,Mechanism of Action,EIF4E,-,Gastric cancer,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
6908,KP5,37752406,Ribavirin#was evaluated for#effectiveness alone or with abemaciclib in gastric cancer xenograft models,Combination Therapies,EIF4E,-,Gastric cancer,"Ribavirin,Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5004,KP5,37752406,Prolonged abemaciclib treatment#upregulated#eIF4E in gastric cancer cells,Expression Patterns,EIF4E,-,Gastric cancer,Abemaciclib,-,-,Upregulated,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
6307,KP5,37752406,Gastric cancer cells with increased eIF4E levels#responded better to#eIF4E inhibition,Therapeutic Response,EIF4E,-,Gastric cancer,-,-,-,Upregulated,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
2242,KP5,37752406,Ribavirin#improved#efficacy of abemaciclib by inhibiting eIF4E,Combination Therapies,EIF4E,-,Gastric cancer,"Ribavirin,Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3763,KP5,37752406,Ribavirin#suppressed#abemaciclib-resistant gastric cancer growth without toxicity,Therapeutic Response,EIF4E,-,Gastric cancer,Ribavirin,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.4,-,时序调控
3602,KP5,28620137,CDK4/6 inhibitors#exhibit#dose-response relationships and composite response signatures,Mechanism of Action,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4334,KP5,28620137,Palbociclib#induces#cell cycle inhibition in an RB-dependent manner,Mechanism of Action,"CDK4,CDK6,RB1",-,-,Palbociclib,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6167,KP5,28620137,Abemaciclib#inhibits#cell cycle in an RB-dependent manner at clinical concentrations,Mechanism of Action,"CDK4,CDK6,RB1",-,-,Abemaciclib,-,Cell cycle,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1136,KP5,28620137,Abemaciclib#induces#cell death in RB-deficient cell lines at certain doses,Mechanism of Action,"CDK4,CDK6,RB1",-,-,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
4349,KP5,28620137,Abemaciclib#elicited#RB-dependent suppression of cell cycle regulatory genes,Mechanism of Action,"CDK4,CDK6,RB1",-,-,Abemaciclib,-,Cell cycle,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3965,KP5,28620137,Gene expression data#was used to develop#composite response signature to CDK4/6 inhibition,Biomarker Analysis,"CDK4,CDK6",-,-,"Abemaciclib,Palbociclib",-,-,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,-,细胞周期标志物
1786,KP5,28620137,Abemaciclib and palbociclib#exhibit#common gene expression features for CDK4/6 inhibition response,Expression Patterns,"CDK4,CDK6",-,-,"Abemaciclib,Palbociclib",-,-,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,-,细胞周期标志物
3890,KP5,10329038,Increased p21 and CDK4 levels#are associated with#pathogenesis of cervical carcinoma,Cancer Association,"CDK4,CDKN1A",-,Cervical carcinoma,-,-,-,-,Upregulated,-,-,-,Inference,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
619,KP5,37258566,genes involved in MAPK and EMT pathways#are upregulated in#FAR cells,Expression Patterns,MAPK,-,-,-,"MAPK, EMT",-,-,Upregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
2565,KP5,37258566,FAR cells#show#higher Pak1 expression and phosphorylation levels than parental cells,Expression Patterns,PAK1,FAR cells,-,-,-,-,-,Upregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
4836,KP5,36042494,S6K1 overexpression#increases#expression levels of G1/S transition-related proteins and phosphorylation of Rb,Expression Patterns,"S6K1,RB1",-,-,-,c-Myc,-,-,Upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
3913,KP5,36042494,S6K1 overexpression#activates#c-Myc pathway,Pathway & Network Categories,S6K1,-,-,-,c-Myc,-,-,Upregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
4490,KP5,36042494,mTOR inhibitor#blocks#upstream of S6K1,Drug Development,"MTOR,S6K1",-,-,mTOR inhibitor,-,-,-,-,-,-,-,Fact,2,2.5,2.5.2,2.5.2.1,-,新型抑制剂开发
3652,KP5,33330073,miR-3613-3p overexpression#inhibits#cell proliferation and induces G1 cell-cycle arrest in TNBC cells,Mechanism of Action,-,TNBC cells,TNBC,Palbociclib,-,-,-,Upregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7463,KP5,33330073,miR-3613-3p overexpression#enhances#sensitivity of TNBC cells to Palbociclib treatment,Therapeutic Response,-,TNBC cells,TNBC,Palbociclib,-,-,-,Upregulated,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
2145,KP5,33330073,miR-3613-3p overexpression#inhibits#TNBC tumorigenesis in vivo,Cancer Association,-,-,TNBC,Palbociclib,-,-,-,Upregulated,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
1471,KP5,33330073,miR-3613-3p overexpression#exerts#inhibitory effect of Palbociclib on MDA-MB-231 cells,Therapeutic Response,-,MDA-MB-231 cells,TNBC,Palbociclib,-,-,-,Upregulated,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
2816,KP5,38090281,"drugs#affect#cell proliferation, cell cycle, apoptosis, downstream protein expression, and gene expression in breast cancer cell lines",Drug Development,-,"T47D, MCF-7, BT474, MDA-MB-361",Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.2,-,协同增效作用
6769,KP5,38090281,TQB3616#induces#G1 stalling and reduces RB phosphorylation at Ser807/811,Mechanism of Action,RB1,-,-,TQB3616,-,-,-,Downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1943,KP5,38090281,TQB3616#promotes#cell apoptosis and enhances tumor killing effects,Mechanism of Action,-,-,-,TQB3616,-,-,-,Upregulated,-,-,-,Fact,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
688,KP5,29261702,Palbociclib#inhibits#RB-proficient TNBC cells,Therapeutic Response,RB1,-,TNBC,Palbociclib,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
4791,KP5,24269839,"CDK4 expression#is evaluated in#cells treated with 1α,25(OH)2D3 before and after VDR silencing",Expression Patterns,"CDK4,VDR",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
5876,KP5,24269839,"CDK4 activation#is reduced by#10 nM 1α,25(OH)2D3",Mechanism of Action,CDK4,-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
1694,KP5,23032699,PRMT6-mediated arginine methylation of p16 protein#suppresses#its ability to arrest A549 cell proliferation,Regulation,"PRMT6,CDKN2A",A549 cells,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
6184,KP5,23032699,p16 protein#blocks#cell cycle progression by inhibiting RB phosphorylation,Mechanism of Action,"CDKN2A,RB1",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
6144,KP5,23032699,mutated p16 protein#induces#a higher apoptosis ratio than wild-type p16 in A549 cells,Mechanism of Action,CDKN2A,-,-,-,-,-,-,upregulated,-,-,-,Fact,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
449,KP5,23032699,decrease of p16 arginine methylation level#promotes#association of p16 with CDK4,Protein Complex Dynamics,"CDKN2A,CDK4",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
4232,KP5,23032699,PRMT6#mediates#arginine methylation of p16 protein,Regulation,"PRMT6,CDKN2A",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
1063,KP5,23032699,PRMT6 overexpression#counteracts#cell cycle arrest at G1 phase induced by wild-type p16 in A549 cells,Cell Cycle Control,"PRMT6,CDKN2A",A549 cells,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
4475,KP5,32256815,ENO1#enhances#cell proliferation by accelerating G1 progression and upregulating CDK6,Cell Cycle Control,"ENO1,CDK6",-,Lung cancer,-,"MAPK, AKT",-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
5483,KP5,32256815,ENO1#improves#cell survival by upregulating p38 in MAPK cascade and increasing p-AKT in AKT cascade,Signaling Networks,ENO1,Lung cancer cells,Lung cancer,-,"MAPK, AKT",-,-,upregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.3,-,p38通路交互
1592,KP5,28226315,High expression of cyclin D1 and Rb#is associated with#treatment sensitivity towards LEE011,Therapeutic Response,"CCND1,RB1",-,-,LEE011,-,-,-,upregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5337,KP5,36722142,Palbociclib#induces#phosphorylation of eIF4E,Mechanism of Action,EIF4E,-,Tumor,Palbociclib,-,-,-,upregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4188,KP5,36722142,Cancer cells treated with palbociclib#use#upregulated phosphorylated eIF4E to escape antitumor benefits,Therapeutic Resistance,EIF4E,-,Cancer,Palbociclib,-,-,-,upregulated,-,-,-,Inference,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
6249,KP5,36722142,Disruption of MNK1/2 activity#enhances#ability of palbociclib to decrease clonogenic outgrowth,Strategies to Overcome Resistance,"MNK1,MNK2",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
6226,KP5,36722142,"Combined MNK1/2 and CDK4/6 inhibitors#downregulate#proteins critical for cell-cycle progression and mitosis, including AURKB, TPX2, and survivin",Cell Cycle Control,"MNK1,MNK2,CDK4,CDK6,AURKB,TPX2,BIRC5",-,Melanoma,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
4097,KP5,36722142,MNK1/2 inhibitors#sensitize#palbociclib-resistant breast cancer cells to CDK4/6 inhibition,Strategies to Overcome Resistance,"MNK1,MNK2,CDK4,CDK6",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.5,2.5.2,2.5.2.1,-,新型抑制剂开发
2722,KP5,36722142,Combination of MNK1/2 and CDK4/6 inhibition#increases#overall survival of mice compared with monotherapy,Combination Therapies,"MNK1,MNK2,CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4218,KP5,36722142,MNK1/2 inhibitors#potentiate#antineoplastic effects of palbociclib and overcome therapy-resistant disease,Strategies to Overcome Resistance,"MNK1,MNK2",-,Cancer,Palbociclib,-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
7728,KP5,38822363,METTL1 and WDR4#were downregulated in#BC tissues at mRNA and protein levels,Expression Patterns,"METTL1,WDR4",-,Breast cancer,-,-,-,-,downregulated,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,微小RNA
3545,KP5,38822363,METTL1#inhibited#BC cell proliferation and cell cycle progression relying on enzymatic activity,Cell Cycle Control,METTL1,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
2999,KP5,38822363,METTL1#increased#m(7)G levels of 19 tRNAs to modulate translation of GADD45A and RB1,RNA Regulation,"METTL1,GADD45A,RB1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,微小RNA
7459,KP5,38822363,Overexpression of METTL1#enhanced#anti-tumor effectiveness of abemaciclib,Combination Therapies,"METTL1,CDK4,CDK6",-,-,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
92,KP5,38822363,METTL1-mediated tRNA m(7)G modification#promotes#translation of GADD45A and RB1 mRNAs,Mechanism of Action,"METTL1,GADD45A,RB1",-,Breast cancer,-,-,G2/M phase arrest,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
5049,KP5,38822363,METTL1-mediated tRNA m(7)G modification#blocks#G2/M phase of the cell cycle,Cell Cycle Control,METTL1,-,Breast cancer,-,-,G2/M phase arrest,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
2591,KP5,37272756,HER2V777L; PIK3CAH1047R transgenes#drive#breast cancer formation in HP mice,Cancer Association,"HER2,PIK3CA",-,Breast cancer,-,-,-,HP mice,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
2185,KP5,37272756,HP breast cancers#showed#accelerated tumor formation in vivo,Cancer Association,-,-,Breast cancer,-,-,Increased invasion and migration,HP mice,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
1722,KP5,37272756,HP breast cancers#exhibited#increased invasion and migration in vitro assays,Cancer Association,-,-,Breast cancer,-,-,Increased invasion and migration,HP mice,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
684,KP5,37272756,HP breast cancer cells#were resistant to#neratinib,Therapeutic Resistance,-,-,Breast cancer,neratinib,-,-,HP mice,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
2169,KP5,37272756,HP breast cancer cells#were effectively treated with#neratinib plus trastuzumab deruxtecan,Combination Therapies,-,-,Breast cancer,"neratinib, trastuzumab deruxtecan",-,-,HP mice,-,-,-,-,Fact,8,8.2,8.2.2,8.2.2.4,-,多靶点抑制策略
2751,KP5,37272756,HP breast cancers#showed#increased gene expression of cyclin D1 and p21WAF1/Cip1,Expression Patterns,"CCND1,CDKN1A",-,Breast cancer,-,Cell-cycle markers,-,HP mice,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6289,KP5,37272756,PIK3CA mutation#activates#p21-CDK4/6-cyclin D1 signaling,Signaling Networks,"PIK3CA,CDK4,CDK6,CCND1",-,Breast cancer,-,-,-,-,-,-,-,-,Inference,1,1.2,1.2.1,1.2.1.1,-,生长因子信号
6584,KP5,37272756,p21-CDK4/6-cyclin D1 signaling#drives#resistance to HER2-targeted therapies,Therapeutic Resistance,"CDK4,CDK6,CCND1",-,Breast cancer,-,-,-,-,-,-,-,-,Inference,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
7139,KP5,37272756,CDK4/6 inhibitors#overcome#resistance to HER2-targeted therapies,Strategies to Overcome Resistance,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Inference,2,2.5,2.5.2,2.5.2.4,-,生物标志物指导
1202,KP5,34885226,CDK4/6 inhibitor-induced non-genetic changes#cause#treatment failure,Therapeutic Resistance,"CDK4,CDK6",-,Cancer,-,-,Autophagy activation,-,-,-,-,-,Inference,2,2.1,2.1.3,2.1.3.3,-,非编码RNA表达变化
4160,KP5,34885226,Abemaciclib#inhibited#cell proliferation via suppression of RB phosphorylation,Mechanism of Action,RB1,-,Glioblastoma,abemaciclib,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
5174,KP5,34885226,Abemaciclib#induced#autophagy activation in GBM cancer cells,Mechanism of Action,-,GBM cancer cells,Glioblastoma,abemaciclib,-,Autophagy activation,-,-,-,-,-,Fact,3,3.4,3.4.3,3.4.3.1,-,自噬启动
6994,KP5,34885226,MPT0L145 treatment#blocked#autophagy activation,Mechanism of Action,-,-,Glioblastoma,MPT0L145,-,Autophagy activation,-,-,-,-,-,Fact,3,3.4,3.4.3,3.4.3.2,-,自噬流变化
6407,KP5,34885226,MPT0L145 treatment#induced#generation of ROS and DNA damage in a concentration-dependent manner,Mechanism of Action,-,-,Glioblastoma,MPT0L145,-,-,-,-,-,-,-,Fact,5,5.1,5.1.3,5.1.3.1,-,DNA损伤修复
3834,KP5,34885226,MPT0L145 with abemaciclib#reduced#cell proliferation,Combination Therapies,-,-,Glioblastoma,"MPT0L145, abemaciclib",-,-,-,-,-,-,-,Fact,8,8.2,8.2.2,8.2.2.4,-,多靶点抑制策略
2437,KP5,34885226,MPT0L145 with abemaciclib#suppressed#RB phosphorylation,Combination Therapies,RB1,-,Glioblastoma,"MPT0L145, abemaciclib",-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2492,KP5,34885226,MPT0L145 with abemaciclib#increased#ROS production,Combination Therapies,-,-,Glioblastoma,"MPT0L145, abemaciclib",-,-,-,-,-,-,-,Fact,3,3.4,3.4.3,3.4.3.1,-,自噬启动
2089,KP5,34885226,Blocking autophagy by MPT0L145#sensitized#GBM cancer cells to abemaciclib,Strategies to Overcome Resistance,-,GBM cancer cells,Glioblastoma,"MPT0L145, abemaciclib",-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.3,-,剂量优化
4669,KP5,35383224,Albendazole (ABZ)#inhibits#proliferation of melanoma cells in vitro and in vivo,Mechanism of Action,-,Melanoma cells,Melanoma,Albendazole,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
1225,KP5,35383224,Albendazole (ABZ)#arrests#melanoma cells at the G2/M phase of the cell cycle,Cell Cycle Control,-,Melanoma cells,Melanoma,Albendazole,-,G2/M phase arrest,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
1067,KP5,35383224,Albendazole (ABZ)#induces#cell apoptosis,Mechanism of Action,-,Melanoma cells,Melanoma,Albendazole,-,Apoptosis,-,-,-,-,-,Fact,3,3.4,3.4.2,3.4.2.3,-,凋亡执行
1638,KP5,35383224,CDK4/6 inhibitor palbociclib#shows#synergistic effects with ABZ treatment in melanoma cells and mouse models,Combination Therapies,"CDK4,CDK6",-,Melanoma,"palbociclib, Albendazole",-,-,-,-,-,-,-,Fact,8,8.2,8.2.2,8.2.2.4,-,多靶点抑制策略
1661,KP5,35383224,ABZ plus CDK4/6 inhibitor treatment#induces#cell cycle arrest and apoptosis,Combination Therapies,"CDK4,CDK6",-,Melanoma,Albendazole,-,"Cell cycle arrest, Apoptosis",-,-,-,-,-,Fact,8,8.2,8.2.2,8.2.2.4,-,多靶点抑制策略
7436,KP5,30828336,CDK4/6 inhibition#reduces#FLS proliferation,Mechanism of Action,"CDK4,CDK6",FLS,Rheumatoid arthritis,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
5492,KP5,30828336,TNF inhibitor#suppresses#FLS activity,Mechanism of Action,-,FLS,Rheumatoid arthritis,TNF inhibitor,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
5652,KP5,30828336,CDK4/6 inhibitor#reduces#FLS proliferation,Mechanism of Action,"CDK4,CDK6",FLS,Rheumatoid arthritis,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5507,KP5,34611509,"NGS#revealed#amplifications in MDM2, CDK4, CCND3, RUNX2, GLI1, FRS2 in p-OS",Cancer Association,"MDM2,CDK4,CCND3,RUNX2,GLI1,FRS2",-,Osteosarcoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
3515,KP5,34611509,"NGS#revealed#amplifications in CDK4, CCND3, MDM2, RUNX2, GLI1, FRS2, CARD11, RAC1, SLC16A7, PMS2 in m-OS",Cancer Association,"CDK4,CCND3,MDM2,RUNX2,GLI1,FRS2,CARD11,RAC1,SLC16A7,PMS2",-,Osteosarcoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
5836,KP5,34611509,immunohistochemical staining#showed#increased GPC3 production in m-OS tissues,Expression Patterns,GPC3,-,Osteosarcoma,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.4,RB蛋白表达
6237,KP5,34611509,10 µM carboplatin#exerted#best inhibitory effects on p-OS spheroids,Drug Development,CDK4/6,-,Osteosarcoma,Carboplatin,-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.2,-,协同增效作用
1617,KP5,38381406,Selective CDK7 inhibition#suppresses#cell cycle progression and MYC signaling,Mechanism of Action,"CDK7,MYC",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
307,KP5,38381406,Selective CDK7 inhibition#enhances#apoptosis in therapy-resistant ER+ breast cancer,Therapeutic Response,CDK7,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
6968,KP5,38381406,CDK7 inhibition#involves#cell cycle inhibition and suppression of c-Myc,Mechanism of Action,"CDK7,MYC",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2931,KP5,38381406,CDK7 and MYC signaling#are#putative vulnerabilities in CDK4/6i resistance,Therapeutic Resistance,"CDK7,MYC,CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Inference,2,2.4,2.4.2,2.4.2.3,-,交叉激活
4879,KP5,38381406,CDK7 inhibition#effectively inhibited#CDK4/6i-resistant models,Therapeutic Response,"CDK7,CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
3037,KP5,10576656,EGFR gene amplification and enhanced expression#represent#major molecular genetic alterations in glioblastomas,Cancer Association,EGFR,-,Glioblastoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
2266,KP5,10576656,p53 and PML#were found to be#significantly increased in antisense-EGFR cells,Expression Patterns,"TP53,PML",-,Glioblastoma,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.4,RB蛋白表达
3502,KP5,10576656,"Expressions of CDK4, retinoblastoma, p16INK4a, and p21H-ras#were not altered#in antisense-EGFR cells",Expression Patterns,"CDK4,RB1,CDKN2A,HRAS",-,Glioblastoma,-,-,-,-,unchanged,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
6837,KP5,10576656,Inductions of PML and p53 proteins#may account for#G1 and growth arrest in antisense-EGFR treated cells,Mechanism of Action,"TP53,PML",-,Glioblastoma,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
425,KP5,37927012,PPP4C#is#highly expressed in gastric cancer,Expression Patterns,PPP4C,-,Gastric cancer,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
1141,KP5,37927012,PPP4C expression#promotes#malignant progression of gastric cancer,Cancer Association,PPP4C,-,Gastric cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
3634,KP5,37927012,PPP4C upregulation#increases#proportion of tumor cells in S phase and alleviates G2/M phase arrest,Cell Cycle Control,PPP4C,-,Gastric cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
6442,KP5,37927012,PPP4C downregulation#decreases#proportion of tumor cells in S phase and promotes G2/M phase arrest,Cell Cycle Control,PPP4C,-,Gastric cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
3151,KP5,9105418,Cyclin B1#is upregulated in#EL11 and EL12 phenotypes compared to control mammary gland,Expression Patterns,CCNB1,-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7987,KP5,9105418,Hormone exposure via pituitary isograft#stimulates synthesis of#Cyclin D1 and D2 associated with CDK4,Regulation,"CCND1,CCND2,CDK4",-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.1,1.2.1.2,-,激素信号通路
1414,KP5,9105418,BrdUrd labelling indices#show#increased cycling of epithelial cells in EL11 and EL12,Cell Cycle Control,-,Epithelial cells,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7972,KP5,9105418,EL11 outgrowths#are not#tumorigenic under hormone stimulation,Cancer Association,-,-,-,-,-,-,-,-,-,-,-,Inference,1,1.4,1.4.3,1.4.3.1,-,存活信号调控
661,KP5,29623577,p-AKT expression level#is upregulated in#RAD-R cells associated with everolimus resistance,Mechanisms of Resistance,AKT,-,-,Everolimus,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
6576,KP5,29623577,MLN0128#inhibits#AKT phosphorylation and suppresses RAD-R cell proliferation,Drug Development,AKT,-,-,MLN0128,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4756,KP5,18701644,miR-16 family#regulates#Cyclin D1 (CCND1) expression and induces G1 arrest in A549 cells,Regulation,CCND1,A549 cells,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
5627,KP5,18701644,"miR-16 family#regulates#Cyclin D3 (CCND3), Cyclin E1 (CCNE1), and CDK6",Regulation,"CCND3,CCNE1,CDK6",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.3,-,非编码RNA调控
576,KP5,18701644,miR-16 family#triggers#G0/G1 accumulation by silencing multiple cell cycle genes,Cell Cycle Control,-,-,-,-,-,-,-,silenced,-,-,-,Inference,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
4215,KP5,29119857,miR-638#inhibits#cell proliferation and cell cycle in porcine immature Sertoli cells,Cell Cycle Control,-,Sertoli cells,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
2113,KP5,29119857,"miR-638 overexpression#downregulates#CDK4, CCND1, and CCNE1 in PI3K/AKT pathway",Pathway & Network Categories,"CDK4,CCND1,CCNE1",-,-,-,PI3K/AKT,-,-,downregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.2,-,反馈调节
4780,KP5,29119857,SPAG1 siRNA#suppresses#mRNA levels of SOX2 and POU5F1 in ST cells,Regulation,"SOX2,POU5F1",ST cells,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.3,-,非编码RNA调控
3439,KP5,14654956,SFN#inhibits#CDK4 activity via induction of CDK inhibitor p21WAF-1/Cip-1,Regulation,"CDK4,CDKN1A",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3457,KP5,34564151,"3,10-Dibromofascaplysin (DBF)#induces#apoptosis in leukemia cells",Therapeutic Response,-,Leukemic cells,Leukemia,"3,10-Dibromofascaplysin",-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.3,-,线粒体通路调控
7911,KP5,34564151,Myeloid leukemia#is characterized by#clonal proliferation of hematopoietic stem cell progenitors,Disease & Clinical Categories,-,Hematopoietic stem cell progenitors,Myeloid leukemia,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
1320,KP5,34564151,"3,10-Dibromofascaplysin (DBF)#affects#myeloid leukemia cells",Therapeutic Response,-,Myeloid leukemia cells,Myeloid leukemia,"3,10-Dibromofascaplysin",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4904,KP5,34564151,Fascaplysin#inhibits#CDK4/6 to affect cell cycle,Mechanism of Action,"CDK4, CDK6",-,-,Fascaplysin,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4313,KP5,34564151,DBF#decreases#expression of genes responsible for cancer cell survival,Therapeutic Response,-,Cancer cells,Cancer,"3,10-Dibromofascaplysin",-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
5797,KP5,34564151,DBF#activates#E2F1,Mechanism of Action,E2F1,-,-,DBF,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
5504,KP5,34564151,DBF#synergistically increases#cytotoxic effect of cytarabine in myeloid leukemia cell lines,Combination Therapies,CYCS,-,Myeloid leukemia,Cytarabine,-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.2,-,协同增效作用
5700,KP5,26244501,p53#induces#PTEN- and p21-mediated downregulation of cyclin D1 and CDK4,Mechanism of Action,"TP53, PTEN, CDKN1A, CDK4, CCND1",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
4962,KP5,35843546,Extracellular adenosine#affects#tumor-associated macrophages,Function triples,-,Tumor-associated macrophages,-,-,-,-,-,-,-,Adenosine,-,Fact,6,6.1,6.1.1,6.1.1.2,-,髓系细胞浸润
4009,KP5,35843546,Extracellular adenosine#reduces#cyclin D1 (CCND1) in human macrophages,Regulation,CCND1,-,-,-,-,-,-,downregulated,-,Adenosine,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
1792,KP5,33243298,Palbociclib monotherapy#inhibits#NPC tumor growth and Ki-67 proliferation marker expression,Drug Development,"CDK4, CDK6",-,NPC tumor,Palbociclib,-,-,-,downregulated,Ki-67,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2416,KP5,35186754,SPOCK1 downregulation by siRNA#inhibits#cell proliferation and interferes with pAkt and CDK4 expression,Regulation,"SPOCK1, CDK4",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
287,KP5,35186754,SPOCK1 inhibition#alters#MAPK signaling in liver cancer cells,Pathway & Network Categories,SPOCK1,-,Liver cancer,-,MAPK,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
6203,KP5,23393200,FRS2 and FGFR proteins#are highly expressed in#high-grade liposarcoma cell lines,Expression Patterns,"FRS2, FGFR",-,Lipososarcoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
2269,KP5,23393200,NVP-BGJ-398#inhibits#growth of FU-DDLS-1 and LiSa-2 cells,Drug Development,FGFR,-,Lipososarcoma,NVP-BGJ-398,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
65,KP5,23393200,Attenuation of FRS2 protein#reduces#phosphorylated ERK1/2 and AKT in FU-DDLS-1 and LiSa-2 cell lines,Mechanism of Action,"FRS2, AKT, ERK1/2",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
5190,KP5,38356706,"CDKN3, CDC6, and CDK4#form#an interactive network to promote expression of each other",Protein Complex Dynamics,"CDKN3, CDC6, CDK4",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
4143,KP5,12853979,D-type cyclins#induce#alternative mammary oncogenic pathways,Cancer Pathways,"CCND1, CCND2, CCND3",-,Mammary carcinoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.1,1.4.1.1,-,增殖信号整合
3839,KP5,12853979,D-type cyclins#bind to and activate#CDK4 and CDK6,Mechanism of Action,"CCND1, CCND2, CCND3, CDK4, CDK6",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3962,KP5,12853979,MMTV-cyclin D1 mice#develop#adenocarcinoma,Cancer Association,CCND1,-,Adenocarcinoma,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.1,-,存活信号调控
7260,KP5,12853979,p16 expression#is abolished in#MMTV-cyclin D3 mice during involution,Regulation,CDKN2A,-,-,-,-,-,silenced,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6525,KP5,12853979,p27 expression#increases in#MMTV-cyclin D3 mice during involution,Regulation,CDKN1B,-,-,-,-,-,upregulated,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
5419,KP5,12853979,D-type cyclins#promote#distinct oncogenic pathways despite redundancy,Cancer Pathways,"CCND1, CCND2, CCND3",-,-,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6244,KP5,36059685,Selinexor#inhibits#growth of patient-derived chordomas in vivo,Drug Development,-,-,Chordoma,Selinexor,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
730,KP5,36059685,Selinexor in combination with abemaciclib#inhibits#growth of patient-derived chordomas through diverse mechanisms,Combination Therapies,-,-,Chordoma,"Selinexor, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4905,KP5,36059685,XPO1 inhibition#suppresses#oncogene translation and restores tumor suppressor protein activity in cancer,Mechanisms of Resistance,XPO1,-,Cancer,-,-,-,downregulated,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
5170,KP5,36059685,Selinexor and abemaciclib combination#showed#strongest activity (tumor growth inhibition of 78-92%),Combination Therapies triples,-,-,Chordoma,"Selinexor, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
2350,KP5,35491665,Alcohol treatment#increased#expression of p16,Regulation triples,CDKN2A,-,-,Alcohol,-,-,Upregulated,-,Alcohol,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
1378,KP5,35491665,"Alcohol treatment#decreased#expression of Bmi-1, CDK6, Cyclin D, E2F1, and BMP2",Regulation triples,"BMI1, CDK6, CCND1, E2F1, BMP2",-,-,Alcohol,-,-,Downregulated,-,Alcohol,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
2622,KP5,34108622,Combined inhibition of DDR1 and CDK4/6#induces#synergistic effects,Combination Therapies triples,"DDR1, CDK4, CDK6",-,"ER-positive, HER2-negative breast cancer","DDR1 inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5655,KP5,34108622,PIK3CA/AKT1 mutations#reduce#efficacy of palbociclib,Mechanisms of Resistance triples,"PIK3CA, AKT1",-,"ER-positive, HER2-negative metastatic breast cancer",Palbociclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
6105,KP5,34108622,Downregulation of DDR1#is#synthetically lethal with palbociclib,Mechanisms of Resistance triples,DDR1,-,-,Palbociclib,-,-,Downregulated,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
3556,KP5,34108622,DDR1 knockdown and DDR1 pharmacological inhibitor#decreased#cell growth,Function triples,DDR1,-,-,DDR1 inhibitors,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
6395,KP5,34108622,DDR1 knockdown and DDR1 pharmacological inhibitor#enhanced#sensitivity of PIK3CA/AKT1 mutant cells to palbociclib,Mechanisms of Resistance triples,"DDR1, PIK3CA, AKT1",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
1229,KP5,34108622,Combined treatment of palbociclib and 7rh#induced#cell cycle arrest in PIK3CA/AKT1 mutant cell lines,Combination Therapies triples,"PIK3CA, AKT1",-,-,"Palbociclib, 7rh",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1756,KP5,34108622,7rh#enhanced#palbociclib's antitumor efficacy in vivo,Combination Therapies triples,-,-,-,"7rh, Palbociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3765,KP5,34108622,DDR1 inhibition#augments#cell cycle suppressive effect of palbociclib,Mechanisms of Resistance triples,DDR1,-,"ER-positive, HER2-negative breast cancer",Palbociclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
1980,KP5,30826934,E6201#induced#G1 cell cycle arrest and apoptosis,Function triples,-,-,-,E6201,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
835,KP5,30826934,E6201#decreased#phosphorylated ERK expression in a dose-dependent manner,Regulation triples,ERK,-,-,E6201,-,-,-,Downregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
591,KP5,23919806,Silencing of YY1 expression#resulted in#increased proliferation by enhancing binding of P21 to Cyclin D1 and CDK4,Mechanism of Action triples,"YY1, CDKN1A, CCND1, CDK4",TE-1 cells,-,-,-,-,-,Upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
2818,KP5,38751701,EGFR family#influences#growth of human brain cancer cell lines,Signaling Networks triples,EGFR,-,Brain cancer,-,"MAPK, AKT, STAT3, Src, Abl",-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
748,KP5,28923602,Mannoprotein#promotes#transition of cell cycle from G1/G0 to S phase,Function triples,"CCND1, CDK4, RB, CDKN1A",-,-,Mannoprotein,-,-,-,"Upregulated (CCND1, CDK4, RB), Downregulated (CDKN1A)",-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
6649,KP5,28978144,Dual PI3K/mTOR inhibition#causes#G1 phase arrest associated with downregulation of cyclin D1/CDK4 activity,Mechanism of Action triples,"CCND1, CDK4",-,-,PI3K/mTOR inhibitors,AKT/mTOR,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
1195,KP5,29777202,"Knockdown of rpS6#downregulated#G1 phase-related proteins, including RB, cyclin D1, and CDK6",Regulation triples,"RB, CCND1, CDK6",-,-,-,-,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
348,KP5,29777202,Knockdown of rpS6#induced#cell cycle arrest and inhibited proliferation,Function triples,rpS6,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
6622,KP5,27825114,PD 0332991#potentiated#gefitinib-induced growth inhibition,Combination Therapies triples,-,-,EGFR-TKI-sensitive and EGFR-TKI-resistant cancers,"PD 0332991, Gefitinib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,-,-,靶向药物联合
2979,KP5,27825114,PD 0332991#induced#apoptosis and G0/G1 cell cycle arrest,Function triples,-,-,-,PD 0332991,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1956,KP5,27825114,Combination of PD 0332991 and gefitinib#had#fastest tumor regression and delayed relapse,Combination Therapies triples,-,-,-,"PD 0332991, Gefitinib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,-,-,靶向药物联合
2528,KP5,27825114,Combination treatment#downregulated#proliferation,Therapeutic Response,-,Tumor,-,-,-,-,-,downregulated,-,-,-,Fact,3,3.2,3.2.2,-,-,靶向药物联合
7503,KP5,27825114,Combination treatment#upregulated#apoptosis,Therapeutic Response,-,Tumor,-,-,-,-,-,upregulated,-,-,-,Fact,3,3.4,3.4.2,3.4.2.1,-,内源性途径激活
5959,KP5,27825114,Combination treatment#reduced#angiogenesis,Therapeutic Response,-,Tumor,-,-,-,-,-,-,-,-,-,Fact,3,3.5,3.5.1,3.5.1.1,-,血管密度降低
5952,KP5,17949234,Caspase-10#was downregulated in#CML cell lines,Expression Patterns,CASP10,-,Chronic myeloid leukemia (CML),-,-,-,-,downregulated,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
7273,KP5,17949234,SOD1#was downregulated in#CML cell lines,Expression Patterns,SOD1,-,Chronic myeloid leukemia (CML),-,-,-,-,downregulated,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
670,KP5,17949234,Notch4#was downregulated in#CML cell lines,Expression Patterns,NOTCH4,-,Chronic myeloid leukemia (CML),-,-,-,-,downregulated,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
1844,KP5,17949234,Caspase-2#was upregulated in#CML cell lines,Expression Patterns,CASP2,-,Chronic myeloid leukemia (CML),-,-,-,-,upregulated,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
7628,KP5,17949234,Caspase-3#was upregulated in#CML cell lines,Expression Patterns,CASP3,-,Chronic myeloid leukemia (CML),-,-,-,-,upregulated,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
2765,KP5,17949234,CDC2#was upregulated in#CML cell lines,Expression Patterns,CDC2,-,Chronic myeloid leukemia (CML),-,-,-,-,upregulated,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
1059,KP5,17949234,CDK4#was upregulated in#CML cell lines,Expression Patterns,CDK4,-,Chronic myeloid leukemia (CML),-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3610,KP5,10956386,Re-expression of myc#activated#cell cycle,Mechanism of Action,MYC,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
6098,KP5,10956386,"myc#triggered#expression of cyclin D2, cyclin E, and Cdk4",Mechanism of Action,"MYC,CCND2,CCNE,CDK4",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3910,KP5,10956386,Cyclin E-associated kinase#was activated by#myc,Mechanism of Action,CCNE,-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.2,-,Cyclin D-CDK6复合物
7588,KP5,10956386,myc#induced#hyper-phosphorylation of Rb,Mechanism of Action,"MYC,RB1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
1380,KP5,15309432,"Quercetin#downregulated#expression of cell cycle genes (CDC6, CDK4, and cyclin D1)",Regulation,"CDC6,CDK4,CCND1",-,-,Quercetin,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4910,KP5,15309432,Quercetin#downregulated#cell proliferation,Therapeutic Response,-,Caco-2 cells,-,Quercetin,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4198,KP5,15309432,Quercetin#induced#cell cycle arrest in Caco-2 cells,Therapeutic Response,-,Caco-2 cells,-,Quercetin,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1926,KP5,35042223,CCND1 overexpression#increased#cell viability,Expression Patterns,CCND1,-,-,Bortezomib (BTZ),-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.1,1.4.1.1,-,增殖信号整合
914,KP5,35042223,CCND1 overexpression#suppressed#cell apoptosis,Expression Patterns,CCND1,-,-,Bortezomib (BTZ),-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.3,1.4.3.1,-,存活信号调控
1920,KP5,35042223,CCND1 overexpression#decreased#p21,Expression Patterns,"CCND1,CDKN1A",-,-,Bortezomib (BTZ),-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
1930,KP5,35042223,"CCND1 overexpression#induced#N-cadherin, CCND2, and CDK4",Expression Patterns,"CCND1,CDK4,CDH2,CCND2",-,-,Bortezomib (BTZ),-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
6988,KP5,39116089,Palbociclib#was administered to#cells at varying doses,Drug Development,-,-,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
188,KP5,39116089,CDKN2A expression#increased significantly after#Palbociclib treatment,Expression Patterns,CDKN2A,-,-,Palbociclib,-,-,-,upregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2559,KP5,39116089,miR-141 expression#increased significantly after#Palbociclib treatment,Expression Patterns,MIR141,-,-,Palbociclib,-,-,-,upregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1841,KP5,29322514,YY1#stimulated#tumor suppressor BRCA1,Mechanism of Action,"YY1,BRCA1",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.3,1.3.3,1.3.3.2,-,DNA修复机制
2014,KP5,29322514,YY1#increased#Bax transcription,Regulation,"YY1,BAX",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.3,1.4.3.1,-,存活信号调控
2773,KP5,29322514,YY1#induced#apoptosis involving cytochrome c release and caspase-3/-7 cleavage,Mechanism of Action,"YY1,CASP3,CASP7",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
3985,KP5,29322514,YY1#inhibited#pRb phosphorylation,Mechanism of Action,"YY1,RB1",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
7333,KP5,29322514,YY1#reduced#expression of long noncoding RNA of SOX2 overlapping transcript,Regulation,"YY1,SOX2",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
1163,KP5,29322514,YY1#downregulated#MMP-10 via MUC4/ErbB2/p38/MEF2C pathway,Mechanism of Action,"YY1,MMP10,ERBB2,MAPK14,MEF2C",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,MAPK通路激活
285,KP5,12734434,drug#kills#different types of glioma cells by mitochondrial-dependent pathways,Mechanism of Action,-,glioma cells,glioma,-,-,-,-,-,-,-,-,Fact,4,4.1,4.1.2,4.1.2.3,-,线粒体动力学
2006,KP5,35212973,GA#upregulated#CDK4 and Cyclin D1 in diabetic treated rats,Regulation,"CDK4,CCND1",-,diabetes,-,-,-,diabetic treated rats,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
2649,KP6,33535617,cyclin-dependent kinases (CDKs)#are targeted for#development of therapies,Drug Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3982,KP6,33535617,CDK4/6 inhibitors#trigger#dephosphorylation of retinoblastoma tumor suppressor protein,Mechanism of Action,"CDK4,CDK6",retinoblastoma,tumor,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
601,KP6,33535617,CDK4/6 inhibitors#block#cell cycle transition from G1 to S phase,Cell Cycle Control,"CDK4,CDK6",-,-,-,G1/S transition,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
4656,KP6,10514479,Deregulated activity of cdk4 or cdk6#leads to#inappropriate cellular proliferation and tumorigenesis,Cancer Association,"CDK4,CDK6",-,tumor,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
2747,KP6,10514479,Certain tumor types#preferentially activate#either cdk4 or cdk6,Cancer Association,"CDK4,CDK6",-,tumor,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.1,1.2.1.3,-,应激反应通路
6035,KP6,10514479,cdk4#acts as#an oncogene by evading inhibition by p16(INK4a),Cancer Association,"CDK4,CDKN2A",-,tumor,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.2,-,共激活因子
4075,KP6,10514479,cdk6 overexpression#accelerates#progression through G1 phase in U2OS cells,Cell Cycle Control,CDK6,U2OS cells,-,-,G1 phase,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
1629,KP6,10514479,cdk6 overexpression#is dependent on#kinase activity,Mechanism of Action,CDK6,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
3843,KP6,10514479,cdk6R31C mutation#inactivates#proliferative effect of cdk6,Regulation,CDK6,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
6266,KP6,10514479,cdk6R31C mutation#increases#cytoplasmic localization,Regulation,CDK6,-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
7344,KP6,10514479,cdk6 INK4 interaction domain#is important for#functional nuclear cdk6 complexes,Structural Biology,CDK6,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
848,KP6,10514479,elevated cdk6 kinase activity#accelerates#G1 phase progression,Cell Cycle Control,CDK6,-,-,-,G1 phase,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
509,KP6,27748766,Acquired CDK6 amplification#promotes#breast cancer resistance to CDK4/6 inhibitors,Mechanisms of Resistance,CDK6,-,breast cancer,CDK4/6 inhibitors,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
4969,KP6,27748766,Acquired CDK6 amplification#causes#loss of ER signaling,Mechanisms of Resistance,"CDK6,ESR1",-,breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
7385,KP6,27748766,Dysregulated activation of CDK4/6 kinases#is#a hallmark of mammary-derived carcinomas,Cancer Association,"CDK4,CDK6",-,mammary-derived carcinomas,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3975,KP6,27748766,ATP-competitive inhibitors#showed#significant activity against ER-driven tumors,Therapeutic Response,ESR1,-,tumors,ATP-competitive inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
298,KP6,27748766,Prolonged exposure to CDK4/6 inhibitor LY2835219#caused#emergence of clones with CDK6 amplification,Mechanisms of Resistance,CDK6,-,tumor,LY2835219,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
6344,KP6,27748766,CDK6 amplification#increased#CDK6 expression,Expression Patterns,CDK6,-,-,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
3145,KP6,27748766,CDK6 amplification#reduced response of#CDK4/6 target phospho-Rb to inhibitors,Mechanisms of Resistance,"CDK6,RB1",-,tumor,CDK4/6 inhibitors,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
7241,KP6,27748766,Knockdown of CDK6#restored#drug sensitivity,Mechanisms of Resistance,CDK6,-,tumor,-,-,-,-,downregulated,-,-,-,Fact,2,2.5,2.5.1,2.5.1.3,-,剂量优化
4597,KP6,27748766,Overexpression of CDK6#mediated#drug resistance,Mechanisms of Resistance,CDK6,-,tumor,-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
3673,KP6,27748766,Loss of pRb and cyclin E1 overexpression#exhibited#decreased hormone responsiveness,Mechanisms of Resistance,"RB1,CCNE1",-,-,-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
7266,KP6,7651726,Mouse p16INK4a#binds specifically to#cdk4 and cdk6,Protein Complex Dynamics,"CDKN2A,CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
2303,KP6,31852484,elacestrant#inhibits#ER-dependent growth despite CDK4/6i resistance mechanisms,Therapeutic Response,"CDK4,CDK6,RB1,E2F1,CCNE1",-,Breast cancer,elacestrant,-,-,-,upregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4602,KP6,9418885,INK4 protein family#inhibits#CDK4 and CDK6-mediated phosphorylation of Rb,Mechanism of Action,"CDK4,CDK6,RB1,CDKN2A",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
6210,KP6,8741839,p19INK4d#inhibits#CDK6 and CDK4,Mechanism of Action,"CDK4,CDK6,CDKN2D",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6011,KP6,8741839,CDK4 and CDK6#are complexed with#small cellular proteins in vivo,Protein Complex Dynamics,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
34,KP6,8741839,p19 and p18#interaction hindered by#cyclin protein,Protein Complex Dynamics,"CDKN2D,CDKN2C,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
2563,KP6,8741839,p16 inhibitors and D cyclins#interact with#CDK4 and CDK6 in a competing manner,Protein Complex Dynamics,"CDKN2A,CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
5963,KP6,30343527,CDK4/6 inhibitor palbociclib and activin-SMAD2 signaling#inhibited#cell cycle progression,Therapeutic Response,"CDK4,CDK6,SMAD2",T47D (luminal-type breast cancer),Breast cancer,palbociclib,activin-SMAD2,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3660,KP6,30343527,palbociclib#augmented#different SMAD2-mediated functions based on cell type,Therapeutic Response,SMAD2,"T47D, Hs578T (triple-negative breast cancer cells)",Breast cancer,palbociclib,activin-SMAD2,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1173,KP6,8805225,p16#blocks#G1/S phase transition by inhibiting CDK4 and CDK6,Mechanism of Action,"CDKN2A,CDK4,CDK6,RB1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
1250,KP6,31530780,"Abemaciclib#is under development for#HR-positive, HER2-negative breast cancer",Drug Development,"CDK4,CDK6",-,Breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1660,KP6,31530780,CDK4 and CDK6 inhibitors#attenuate#Rb phosphorylation resulting in G1 arrest,Mechanism of Action,"CDK4,CDK6,RB1",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
6676,KP6,9324288,wt p16 protein#forms complexes with#CDK4 and CDK6,Protein Complex Dynamics,"CDKN2A,CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
2463,KP6,9324288,p16 mutants#inhibited#cell growth based on complex formation with CDK4 and CDK6,Mechanism of Action,"CDKN2A,CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
1254,KP6,8968104,"p16Ink4/CDKN2, D-type cyclins, CDK4/CDK6, and pRb#constitute#a G1 regulatory pathway",Cell Cycle Control,"CDKN2A,CDK4,CDK6,RB1",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
6788,KP6,8968104,p16Ink4/CDKN2 and pRb#lost in#melanoma due to genetic mechanisms,Cancer Association,"CDKN2A,RB1",-,Melanoma,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
7700,KP6,8968104,p16#prevented#S-phase entry in Rb+/p16- melanoma lines,Mechanism of Action,"CDKN2A,RB1",-,Melanoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
811,KP6,8968104,cyclin D1/Cdk4-R24C complex#required for#G1 progression and resistant to p16,Mechanism of Action,"CDK4,CCND1,CDKN2A",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
6464,KP6,8968104,Cdk4#is identified as#a novel proto-oncogene,Cancer Association,CDK4,-,Malignant melanoma,-,p16-cyclin D/Cdk-pRb,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.3,-,驱动突变
3949,KP6,8968104,p16-cyclin D/Cdk-pRb pathway#functions as#a functional unit,Pathway & Network Categories,"CDK4,CDK6",-,Malignant melanoma,-,p16-cyclin D/Cdk-pRb,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
2114,KP6,8968104,Deregulation of the p16-cyclin D/Cdk-pRb checkpoint#represents#a common step in sporadic malignant melanomas,Cancer Pathways,"CDK4,CDK6",-,Malignant melanoma,-,p16-cyclin D/Cdk-pRb,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
3068,KP6,12437373,p16(INK4a)#inhibits#Cdk4 and Cdk6,Regulation,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
4911,KP6,12437373,Cdk4/6/2#regulate#progression through the G1-S transition,Cell Cycle Control,"CDK4,CDK6,CDK2",-,-,-,G1-S transition,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
4701,KP6,12437373,p16(INK4a)#inhibits#phosphorylation of retinoblastoma protein,Regulation,"CDK4,CDK6",Retinoblastoma protein,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
5806,KP6,12437373,p16(INK4a)#forces#cells to remain in G1 phase,Cell Cycle Control,"CDK4,CDK6",-,-,-,G1 phase,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
7037,KP6,12437373,Cdk6-p16(INK4a) complex#is analyzed through#molecular dynamics simulations,Structural Biology,CDK6,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
4488,KP6,12437373,Cdk4-p16(INK4a) complex#is analyzed through#molecular dynamics simulations,Structural Biology,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
1339,KP6,12437373,Key interactions in Cdk6-p16(INK4a) complex#are anticipated from#crystal structure analysis,Structural Biology,CDK6,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
1469,KP6,12437373,Binding of p16(INK4a)#distorts#ATP binding-site of Cdks,Regulation,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
2271,KP6,27252418,Palbociclib#is approved for#treatment of ER(+) advanced breast cancer,Drug Development,"CDK4, CDK6",-,ER(+) advanced breast cancer,"Palbociclib, letrozole, fulvestrant",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3167,KP6,39196911,Ribociclib#affects#expression levels of CDK4/6-USP51 pathway genes,Pathway & Network Categories,"CDK4, CDK6",-,-,Ribociclib,CDK4/6-USP51,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
3169,KP6,39196911,miR-141#abnormally expresses in#many malignant tumors,Cancer Association,-,-,Malignant tumors,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
7744,KP6,39196911,Ribociclib#exhibits#cytotoxic effects on breast cancer cells,Drug Development,"CDK4, CDK6",-,Breast cancer,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
983,KP6,39196911,Ribociclib#inhibits#cell growth in dose- and time-dependent manner,Drug Development,"CDK4, CDK6",-,-,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3126,KP6,39196911,Ribociclib treatment#decreases#mRNA expression of CDK6 and MYH10,Expression Patterns,CDK6,-,-,Ribociclib,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
2574,KP6,11301189,CDK6#is expressed in#normal B-cell development and BLIN ALL cell lines,Expression Patterns,CDK6,B cells,Acute lymphoblastic leukemia (ALL),-,-,-,-,ubiquitously,-,-,-,Fact,1,1.1,1.1.2,1.1.2.2,-,Cyclin D-CDK6复合物
236,KP6,29844123,CDK4/6 inhibition#activates#c-Met and TrkA-B pathways,Signaling Networks,"CDK4, CDK6",Glioblastoma cells,Glioblastoma (GBM),-,"c-Met, TrkA-B",-,-,upregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
2933,KP6,29844123,CDK4/6 inhibition#is combined with#c-Met/TrkA-B inhibition,Combination Therapies,"CDK4, CDK6",-,Glioblastoma (GBM),-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5165,KP6,35562811,Abemaciclib#enhances#T-cell activation,Immune Cell Functions,-,T cells,-,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.3,3.3.2,3.3.2.2,-,T细胞活化增强
4405,KP6,25148008,Immunohistochemical staining#was performed on#cell-cycle regulatory proteins,Experimental & Technical Categories,"CDK4, CDK6, RB1, CDKN2A, CDKN2B, CDKN1A, CDKN1B, CCND1, TP53",-,-,-,-,-,"MIB-1, mitosis",-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
6036,KP6,25148008,"CDK4, CDK6, pRB protein, Cyclin D1#are overstained in#tissue samples",Biomarker Analysis,"CDK4, CDK6, RB1, CCND1",-,-,-,-,-,Upregulated,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
3734,KP6,25148008,"Overstaining of CDK6, pRB protein, p53#predicts#recurrence of atypical meningiomas",Prognostic markers,"CDK6, RB1, TP53",-,Atypical meningiomas,-,-,-,Upregulated,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
5950,KP6,38954773,Loss of CDKN2A and amplification of Cyclin D1 genes#occur in#HPV-negative HNSCC lesions,Cancer Pathways,"CDKN2A, CCND1",-,Head and neck squamous cell carcinoma (HNSCC),-,-,-,"Loss (CDKN2A), Amplified (Cyclin D1)",-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
2175,KP6,38954773,CDK4/6 inhibitors#show#modest effects in the clinic,Drug Development,"CDK4, CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7443,KP6,38954773,Combination of mTORi and palbociclib#shows#synergism in HNSCC-derived cells,Combination Therapies,"MTOR, CDK4, CDK6",-,Head and neck squamous cell carcinoma (HNSCC),Palbociclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
4726,KP6,30677445,Palbociclib#inhibits#cell cycle progression in ER+ breast cancers,Mechanism of Action,"CDK4, CDK6",-,ER+ breast cancers,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
734,KP6,30677445,Combination of pan-HER kinase inhibitors and CDK4/6 inhibitors#would show#synergistic antitumor activity,Combination Therapies,"CDK4, CDK6",-,-,"Palbociclib, Pyrotinib",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1579,KP6,30677445,Combination of palbociclib and pyrotinib#inhibits#cancer proliferation and colony formation,Combination Therapies,"CDK4, CDK6",-,-,"Palbociclib, Pyrotinib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1154,KP6,30677445,Combined treatment#induces#G0-G1 cell cycle arrest and increased apoptosis,Mechanism of Action,"CDK4, CDK6",-,-,"Palbociclib, Pyrotinib",-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
4126,KP6,27726394,"ASTs#increase#expression levels of p21(Cip1/Waf1), p27, and p53",Regulation triples,"CDKN1A,CDKN1B,TP53",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
500,KP6,27726394,ASTs#decrease#expression levels of CDK4 and CDK6,Regulation triples,"CDK4,CDK6",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
51,KP6,7592908,TGF-beta#upregulates#p15INK4B,Regulation triples,CDKN2B,-,-,-,TGF-beta,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
6710,KP6,7592908,p15INK4B#inhibits#enzymatic activities of CDK4 and CDK6,Mechanism of Action triples,"CDKN2B,CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7796,KP6,7592908,Cyclin D-CDK4/6 complex#is required for#pRb phosphorylation,Mechanism of Action triples,"CCND1,CDK4,CDK6,RB1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
6751,KP6,7592908,TGF-beta#induces#p15INK4B expression at transcription level,Regulation triples,"TGFB1,CDKN2B",-,-,-,TGF-beta,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
1255,KP6,34244855,Resistance mechanisms#change over#time in ER-positive breast cancer cells,Therapeutic Resistance triples,-,Breast cancer,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
6275,KP6,34244855,CDK4/6 inhibitors#are used for#treatment of advanced ER-positive breast cancer,Drug Development triples,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4967,KP6,34244855,Palbociclib-resistant sublines#were established to study#resistance mechanisms,Preclinical Models triples,-,-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.5,2.5.2,2.5.2.1,-,新型抑制剂开发
7967,KP6,34244855,Increase in CDK6 expression#was observed in#resistant sublines,Expression Patterns triples,CDK6,-,Breast cancer,-,-,-,-,upregulated,-,-,-,Fact,2,2.3,2.3.1,2.3.1.1,-,基因拷贝数变异
5367,KP6,34244855,Decrease in Rb expression/phosphorylation#was observed in#resistant sublines,Expression Patterns triples,RB1,-,Breast cancer,-,-,-,-,downregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
6920,KP6,34244855,Resistant sublines#exhibited#cross-resistance to abemaciclib,Therapeutic Resistance triples,-,-,Breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,2.6.1.1,-,药物外排增加
4500,KP6,34244855,Resistant sublines#responded similarly to#dinaciclib as wild-type cells,Therapeutic Response triples,-,-,Breast cancer,Dinaciclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
7537,KP6,34244855,Cell line with increased mTOR phosphorylation#showed#higher sensitivity to everolimus,Therapeutic Response triples,MTOR,-,Breast cancer,Everolimus,-,-,-,upregulated,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
6061,KP6,34244855,Palbociclib monotherapy#induces#mutations and copy number alterations in RB1 gene,Therapeutic Resistance triples,RB1,-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
5803,KP6,9001420,Cyclin D1#forms#abundant complexes with CDK4,Protein Complex Dynamics triples,"CCND1,CDK4",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
2047,KP6,9001420,Cyclin D1/CDK4 holoenzyme#is active as#a pRB kinase,Mechanism of Action triples,"CCND1,CDK4,RB1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
7254,KP6,30143714,D-type cyclins#are regulatory subunits of#CDK4 and CDK6,Mechanism of Action triples,"CCND1,CCND2,CCND3,CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
315,KP6,18760195,p16 gene#is involved in#pathogenesis of human skin BCC,Cancer Association triples,CDKN2A,-,BCC,-,-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
1836,KP6,16436672,Rap1GAP#regulates#proliferation,Regulation,RAP1GAP,-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,-,-,细胞增殖调控
2598,KP6,16436672,"Rap1GAP#down-regulated#active Rap1, ERK activation, and proliferation in oropharyngeal SCC",Regulation,"RAP1GAP,RAP1",-,Oropharyngeal squamous cell carcinoma,-,-,-,-,Downregulated,-,-,-,Fact,1,1.4,1.4.1,-,-,细胞增殖调控
2331,KP6,16436672,"Rap1GAP-transfected SCC cells#down-regulated#cyclin D1, cdk4, and cdk6",Regulation,"RAP1GAP,CDK4,CDK6",-,Squamous cell carcinoma,-,-,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7711,KP6,8855819,p16 and p15#inhibit#cyclin D1-associated kinases cdk4 and cdk6,Mechanism of Action,"CDKN2A,CDKN2B,CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
3670,KP6,20979106,Restored GPR43 expression and propionate treatment#induced#upregulation of p21,Regulation,CDKN1A,-,-,Propionate,-,-,-,Upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
1171,KP6,10594039,INK4 family proteins#bind to#CDK4 and CDK6,Protein Complex Dynamics,"CDKN2A,CDKN2B,CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,-,-,周期蛋白复合物形成
4004,KP6,10594039,INK4 proteins#prevent#phosphorylation of retinoblastoma protein,Mechanism of Action,"CDKN2A,CDKN2B",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2194,KP6,10594039,"INK4a#plays#a checkpoint function in response to stress, damage, or aging",Regulation,CDKN2A,-,-,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
692,KP6,33046519,"TNO155#combines with#EGFR inhibitors, BRAFi, KRAS(G12C)i, CDK4/6i, and anti-PD-1 antibody",Combination Therapies,"CDK4,CDK6",-,Cancer,"EGFR inhibitors, BRAFi, KRAS(G12C)i, CDK4/6i, anti-PD-1 antibody",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
144,KP6,33415002,Raf inhibitor sorafenib#displays#highest cytotoxicity in CDK6-depleted cells,Drug Development,CDK6,-,-,Sorafenib,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3105,KP6,8934552,p16INK4 family of CDK inhibitors#prevent#phosphorylation of pRb by CDK4 and CDK6,Cell Cycle Control,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2392,KP6,35418303,CHK1 and CHK2 inhibition#interferes with#E2:ER signaling,Signaling Networks,"CHK1,CHK2",-,ER-positive breast cancer,-,E2:ER,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
2109,KP6,35418303,ATR:CHK1 pathway inhibition#induces#DNA replication stress,Mechanism of Action,CHK1,-,-,-,ATR:CHK1,-,-,-,-,-,-,Fact,1,1.3,1.3.3,1.3.3.2,-,DNA修复机制
211,KP6,35418303,CHK1 inhibitors#exert#synergic effects with ET drugs and CDK4/CDK6 inhibitors,Combination Therapies,"CHK1,CDK4,CDK6",-,Primary and metastatic breast cancer,"AZD7762,MK8776,Prexasertib,Abemaciclib,Palbociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6495,KP6,26556739,"Dex#inhibits#BMSC proliferation by targeting CDK4, CDK6, and Cyclin D1",Cell Cycle Control,"CDK4,CDK6,Cyclin D1",BMSC,-,Dex,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
4816,KP6,34036394,CDK4 expression#is positively associated with#copy number gains,Expression Patterns,CDK4,-,-,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
4348,KP6,34036394,Higher expression and amplification of CDK4#is a predictive biomarker for#resistance to conventional chemotherapy in OS,Cancer Association,CDK4,-,OS,-,-,-,-,upregulated,Predictive biomarker,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
7762,KP6,34036394,Palbociclib#is a promising drug for#OS patients resistant to conventional chemotherapy,Drug Development,CDK4,-,OS,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4046,KP6,25255445,NF-魏B2#regulates#the expression of CDK4 and CDK6,Regulation,"CDK4,CDK6",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
253,KP6,25255445,RelB#regulates#the stability of p21 and p53,Regulation,"CDKN1A,TP53",-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
807,KP6,25255445,Activation of NF-魏B#induces#EZH2 expression in CD40L stimulated cells,Regulation,EZH2,-,Chronic Lymphocytic Leukemia,-,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
7425,KP6,28704762,Palbociclib#reduced#the phosphorylation levels of CDK6 and Rb,Mechanism of Action,"CDK6,RB1",-,-,Palbociclib,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
5224,KP6,28704762,Palbociclib#reduced#the expression of Myc,Mechanism of Action,MYC,-,-,Palbociclib,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1152,KP6,28704762,Palbociclib#increased#phosphorylation of AKT,Mechanism of Action,AKT1,-,-,Palbociclib,-,-,-,upregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
4885,KP6,28704762,AKT activation#was repressed while#p53 and p21 were up-regulated,Regulation,"AKT1,TP53,CDKN1A",-,-,-,-,-,-,"downregulated (AKT), upregulated (p53, p21)",-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
6670,KP6,29441600,BBR#up-regulated#cyclin-D1 and CDK4 expressions,Regulation,"CCND1,CDK4",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
4062,KP6,33072590,Simultaneous drug combination#inhibited#cell proliferation in Rb-proficient cells,Combination Optimization,RB1,-,-,-,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3607,KP6,7705923,p16Ink4/MTS1/CDKN2#is a cell-cycle regulatory inhibitor of#CDK4,Mechanism of Action,"CDKN2A,CDK4",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
2812,KP6,7705923,CDK4 in association with D-type cyclins and pRB#constitute#a G1-phase-controlling pathway,Cell Cycle Control,"CDK4,CCND1,RB1",-,-,-,G1-phase pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
1386,KP6,7705923,p16 expression#was preserved in#cancer cell lines with compromised RB function,Cancer Association,CDKN2A,-,Cancer,-,-,-,-,normal,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
2407,KP6,7705923,p16#operates upstream of#pRB along the same pathway in G1,Cell Cycle Control,"CDKN2A,RB1",-,-,-,G1-phase pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
5749,KP6,9388858,D-type cyclins#promote#progression of the cell through the G1 phase,Cell Cycle Control,CCND1,-,-,-,G1-phase pathway,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
3790,KP6,9388858,CDK4-mediated phosphorylation of Rb#promotes#G1-phase progression,Mechanism of Action,"CDK4,RB1",-,-,-,G1-phase pathway,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
920,KP6,9388858,CDK4#is constrained by#p16 in tumor cells,Regulation,"CDK4,CDKN2A",-,Tumor,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
6684,KP6,9388858,p16#acts as#a tumor suppressor,Cancer Association,CDKN2A,-,Tumor,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
5037,KP6,9388858,Cyclin D1#is overexpressed in#26/41 tumor samples,Expression Patterns,CCND1,-,Tumor,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
5183,KP6,9388858,Cyclin D1#is overexpressed in#mucosa adjacent to cancers,Expression Patterns,CCND1,-,Cancer,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
4053,KP6,9388858,Rb-positive cancers#are associated with#low or no p16 expression,Expression Patterns,"RB1,CDKN2A",-,Cancer,-,-,-,-,downregulated,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
5748,KP6,9388858,Rb-negative cancers#are associated with#high p16 expression,Expression Patterns,"RB1,CDKN2A",-,Cancer,-,-,-,-,upregulated,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
1583,KP6,9388858,"Abnormality in cyclin D1/CDK4, Rb, and p16 pathway#is involved in#molecular mechanism of esophageal cancer",Cancer Pathways,"CCND1,CDK4,RB1,CDKN2A",-,Esophageal cancer,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
800,KP6,32397800,SiNPs#activate#autophagy through CDK7-CDK4 cascade,Molecular Mechanism of Action,"CDK4,CDK7",-,-,-,Autophagy,-,-,-,-,-,-,Inference,1,1.3,1.3.3,1.3.3.2,-,DNA修复机制
2143,KP6,38271970,Tet1 knockdown#downregulates#CDK6 and Cyclin D1 expression,Regulation,"TET1,CDK6,CCND1",Chicken PGCs,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
1034,KP6,18459177,p16/INK4a#inhibits#CDK4,Regulation,"CDKN2A,CDK4",-,MHPC,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
2405,KP6,36497412,Abemaciclib#enhances#antiproliferative effect of cisplatin and pemetrexed,Combination Therapies,"CDK4,CDK6",-,MPM,"Abemaciclib,Cisplatin,Pemetrexed",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
250,KP6,36497412,AKT/mTOR signaling#is impaired in#autophagy induction,Signaling Networks,MTOR,-,-,-,AKT/mTOR,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.2,-,反馈调节
1636,KP6,36765430,CDK4/6 inhibitors#are enhanced with#focal radiation therapy when delivered prior,Therapeutic Development,"CDK4,CDK6",-,Cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.1,-,时序性联合
6122,KP6,8857999,"p16#is involved in#a cell-cycle regulatory cascade including CDK4, Cyclin D1, and pRb",Cell Cycle Control,"CDKN2A,CDK4,CCND1,RB1",-,Malignant astrocytomas,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6543,KP6,8857999,Alterations in CDK4 pathway components#are described in#GBM,Cancer Association,"CDK4,CCND1,CDKN2A,RB1",-,GBM,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6654,KP6,8857999,Homozygous deletions of CDKN2/p16 gene#are the most common#genetic alteration in GBM,Cancer Association,CDKN2A,-,GBM,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
4690,KP6,8857999,Homozygous CDKN2/p16 deletions#are associated with#cellular proliferation in astrocytomas,Cancer Association,"CDKN2,p16",-,Astrocytomas (Grade I-IV),-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
5654,KP6,8857999,Ki-67 proliferation indices#are higher in#tumors with CDKN2/p16 deletions,Expression Patterns,"CDKN2,p16",-,"Anaplastic astrocytomas, GBMs",-,-,-,-,upregulated,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
2772,KP6,29261702,Pharmacological CDK4/6 inhibition#induces#a cytostatic effect with doxorubicin in RB-proficient TNBC,Therapeutic Response,"CDK4,CDK6,RB",-,Triple-negative breast cancer (TNBC),Doxorubicin,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
772,KP6,29261702,Palbociclib-mediated G1 arrest#was attenuated by#RB knockdown in AR-positive/RB-proficient TNBC cells,Mechanisms of Resistance,RB,-,Triple-negative breast cancer (TNBC),Palbociclib,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
3264,KP6,24942317,EGCG treatment#modulated#multiple signaling pathways in WT-HuLM cells,Signaling Networks,COMT,-,-,EGCG,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
2524,KP6,24942317,EGCG effects#are mediated by#its modulation of COMT expression and enzyme activity,Mechanism of Action,COMT,-,-,EGCG,-,-,-,downregulated,-,-,-,Inference,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
7432,KP6,24269839,"Cell cycle arrest in G1#was observed after#10 nM 1伪,25(OH)鈧侱鈧?cell exposure",Cell Cycle Control,-,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
2105,KP6,12955883,Aberrant p16 RNA transcripts#encode#key peptides involved in binding CDK4,Molecular Event,"CDKN2,p16,CDK4",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
2100,KP6,12955883,GST-aberrant p16 fusion proteins#interact with#endogenous CDK4 in vitro,Protein Complex Dynamics,"CDKN2,p16,CDK4",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
4644,KP6,12955883,Overexpression of aberrant p16 RNA transcripts#results in#decreased cell proliferation rate and reduced hyperphosphorylated pRb levels,Regulation,"CDKN2,p16,pRB",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
6943,KP6,12006580,"pRb, p107, and p130#regulate#cell proliferation via phosphorylation-sensitive interactions with E2F transcription factors",Cell Cycle Control,"RB1,RBL1,RBL2,E2F",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
7456,KP6,12006580,Alanine substitution at Cdk4(6)-specific sites in p130#was assessed for#effects on phosphorylation,Structural Biology,"CDK4,CDK6,RBL2",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
3514,KP6,12006580,Triple p107(DeltaCdk4)* mutant#strongly inhibited#E2F-4 activity and imposed G1 arrest,Mechanism of Action,"RBL1,E2F4",-,-,-,G1 arrest,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
2394,KP6,32582803,"Targeted therapy#reduced#anti-apoptotic gene expression levels (BCL2, CMYC)",Therapeutic Response,"BCL2,CMYC",-,-,-,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
7968,KP6,36722142,Phosphorylated eIF4E#engenders#translation of mRNAs coding for cell survival proteins,RNA Regulation,EIF4E,-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
4255,KP6,25082755,Cell-cycle reprogramming for PI3K inhibition#overrides#a relapse-specific C481S BTK mutation in mantle cell lymphoma,Mechanisms of Resistance,"PI3K,BTK",-,Mantle cell lymphoma,-,-,-,-,-,-,-,-,Fact,2,2.4,2.4.2,2.4.2.4,-,通路重编程
7095,KP6,25082755,Resistance to BTK inhibitor ibrutinib#is common in#mantle cell lymphoma,Mechanisms of Resistance,BTK,-,Mantle cell lymphoma,Ibrutinib,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,2.6.1.4,-,细胞凋亡抑制
2732,KP6,25082755,BTK and AKT#are activated by#mutation and CDK4 activation,Mechanism of Action,"BTK,AKT,CDK4",MCL cells,Mantle cell lymphoma (MCL),-,Tissue-specific proliferation,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.1,1.2.1.3,-,应激反应通路
7943,KP6,25082755,Patients with primary resistance#lack#this mutation,Clinical Correlation,-,-,Primary resistance,-,-,-,Patients with primary resistance,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
4434,KP6,25082755,Relapse-specific BTK mutation#is discovered in#patients with MCL with acquired resistance,Clinical Correlation,BTK,-,Mantle cell lymphoma (MCL),ibrutinib,-,-,Patients with acquired resistance,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
1664,KP6,25082755,Targeting proliferative resistant MCL cells#is enabled by#inhibiting CDK4 and cell cycle in combination with ibrutinib,Therapeutic Response,CDK4,-,Mantle cell lymphoma (MCL),ibrutinib,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7996,KP6,25082755,Targeting proliferative resistant MCL cells#is enabled by#PI3K inhibitor independent of BTK mutation,Therapeutic Response,PI3K,-,Mantle cell lymphoma (MCL),PI3K inhibitor,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
4337,KP6,25082755,CDK4 and PI3K#are dysregulated in#human cancers,Cancer Association,"CDK4,PI3K",-,Human cancers,-,-,-,-,dysregulated,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
4364,KP6,25082755,Targeting CDK4#represents#a novel approach to lymphoma and cancer therapy,Therapeutic Development,CDK4,-,"Lymphoma, cancer",-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
584,KP6,34980892,ICF#upregulated#TGFB1 at mRNA and protein levels,Regulation,TGFB1,-,-,-,TGFβ,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
342,KP6,34980892,TGF-β inhibitor#abolished#ICF-induced CCND1 and CDK6 expression,Regulation,"CCND1,CDK6",-,-,SB431542,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
4375,KP6,23708653,The cyclin/CDK/RB-axis#is a critical modulator of#cell cycle entry,Molecular Event,"CDK,CCND1,RB1",-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7012,KP6,23708653,The cyclin/CDK/RB-axis#is aberrant in#many human cancers,Cancer Association,"CDK,CCND1,RB1",-,Human cancers,-,-,-,-,aberrant,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,RB1突变
2536,KP6,23708653,PD-0332991#is a#potent and selective CDK4/6 inhibitor,Drug Development,"CDK4,CDK6",-,Prostate cancer,PD-0332991,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3833,KP6,23708653,PD-0332991#was investigated in#human prostate cancer models and primary tumors,Preclinical Models,"CDK4,CDK6",-,Prostate cancer,PD-0332991,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
388,KP6,23708653,PD-0332991#impaired#PCa cell proliferation by promoting G1-arrest,Mechanism of Action,"CDK4,CDK6",-,Prostate cancer,PD-0332991,G1-S transition,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7633,KP6,23708653,Key regulators of G1-S cell cycle transition#were modulated by#PD-0332991,Mechanism of Action,"CCND1,CCNE1,CCNA2",-,Prostate cancer,PD-0332991,G1-S transition,-,-,modulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4292,KP6,23708653,CDK4/6 inhibition#revealed#anti-proliferative impact through reduced proliferation and delayed growth,Therapeutic Development,"CDK4,CDK6",-,Prostate cancer,PD-0332991,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2360,KP6,23708653,PD-0332991#showed#first-in-field effects on proliferation in primary prostatectomy tumor tissue explants,Preclinical Models,"CDK4,CDK6",-,Prostate cancer,PD-0332991,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1879,KP6,37272756,HER2V777L and PIK3CAH1047R mutations#activate#p21-CDK4/6-Cyclin D1 axis,Mechanism of Action,"ERBB2,PIK3CA,CDK4,CDK6,CCND1",-,Breast cancer,-,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.1,1.2.1.2,-,激素信号通路
1027,KP6,37272756,HER2 and PIK3CA mutations#are co-mutated in#40% of HER2-mutated breast cancers,Cancer Association,"ERBB2,PIK3CA",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.3,ESR1突变
1683,KP6,37272756,Combining neratinib with CDK4/6 inhibitors#was effective for#treating HP breast cancers,Combination Therapies,"CDK4,CDK6",-,Breast cancer,"Neratinib,Palbociclib",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
864,KP6,37272756,Neratinib plus trastuzumab deruxtecan and neratinib plus palbociclib combinations#were validated in#human breast cancer patient-derived xenografts,Preclinical Models,"ERBB2,PIK3CA",-,Breast cancer,"Neratinib,Trastuzumab deruxtecan,Palbociclib",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
6741,KP6,12566432,ZONAB#regulates#nuclear localization and transcriptional activity,Mechanism of Action,ZONAB,-,Cancer,-,ZO-1,-,-,modulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
2942,KP6,12566432,ZONAB#associates with#CDK4,Protein Complex Dynamics,"CDK4,ZONAB",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
2792,KP6,28123545,"S100A6 overexpression#increased#IL-8, CDK5, CDK4, MCM7, and BCL2 expression",Expression Patterns,"S100A6,IL8,CDK5,CDK4,MCM7,BCL2",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
7926,KP6,37702298,Talazoparib#induced#cellular senescence via inhibiting p53 ubiquitination and activating p21,Mechanism of Action,"TP53,CDKN1A",-,Cancer,Talazoparib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
156,KP6,37702298,Combination therapy#activated#T cell signatures and transformed TME into antitumor state,Immune Cell Functions,"CD8A,NK cells",-,Cancer,-,-,-,-,upregulated,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
5188,KP6,32647650,"PIC-treated cells#exhibited#altered protein levels of p53, p21, cyclin D1, and CDK4",Expression Patterns,"TP53, CDKN1A, CCND1, CDK4",-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
4341,KP6,38381406,CDK7#is#a candidate target in endocrine-resistant ER+ breast cancer models,Cancer Association,CDK7,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,-,ESR1突变
602,KP6,38381406,Selective CDK7 inhibitors (CDK7i)#are in clinical development for#treatment of ER+ breast cancer,Drug Development,CDK7,-,Breast cancer,CDK7 inhibitors (CDK7i),-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1738,KP6,38381406,CDK7 inhibition#exhibited#cytotoxic effects,Therapeutic Response,CDK7,-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
6780,KP6,38381406,CDK7 inhibition#is distinct from#cytostatic nature of ET and CDK4/6 inhibitors,Mechanism of Action,"CDK7, CDK4, CDK6",-,-,Endocrine therapy (ET),-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6612,KP6,38381406,CDK7 inhibition#resulted in#suppression of ER phosphorylation at S118,Mechanism of Action,"CDK7, ESR1",-,-,-,-,-,-,Downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
1557,KP6,38381406,Long-term CDK7 inhibition#resulted in#increased ER signaling,Mechanism of Action,"CDK7, ESR1",-,-,-,-,-,-,Upregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.3,-,E2F转录因子活性下调
7918,KP6,38381406,Selective CDK7 inhibition combined with ET#can overcome#treatment resistance in ER+ breast cancer,Therapeutic Response,CDK7,-,Breast cancer,Endocrine therapy (ET),-,-,-,-,-,-,-,Inference,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
3123,KP6,34276377,"PNO treatment#up-regulated#expression of PCNA, cyclin E, cyclin D1, and CDK4",Regulation,"PCNA, CCNE1, CCND1, CDK4",-,-,-,"MEK, p38, ERK1/2",-,-,Upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6832,KP6,33931882,CDK4/6 inhibitor combination therapy#was used for#Retinoblastoma 1-Intact hepatocellular carcinoma,Clinical Implementation,"CDK4, CDK6",-,Hepatocellular carcinoma,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
4413,KP6,33931882,Synthetic CDK4/6 inhibitors#exert#antitumor effects,Therapeutic Response,"CDK4, CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4773,KP6,33931882,"Re-expression of RB1#sensitized#liver tumors to CDK4/6 inhibitor, palbociclib",Therapeutic Response,"RB1, CDK4, CDK6",-,Liver tumor,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7696,KP6,33931882,Introduction of unphosphorylatable RB1#induced#effects similar to palbociclib,Mechanism of Action,RB1,-,-,Palbociclib,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
1337,KP6,33931882,RB7LP expression and palbociclib#enhanced#IKK伪/尾 phosphorylation and NF-魏B activation,Mechanism of Action,"RB1, CDK4, CDK6",-,-,Palbociclib,NF-魏B,-,-,-,-,-,-,Fact,1,1.3,1.3.3,1.3.3.3,-,细胞凋亡调控
3057,KP6,33931882,Combination therapy with palbociclib and Bay 11-7082#was more effective for#HCC treatment,Combination Therapies,"CDK4, CDK6",-,Hepatocellular carcinoma,"Palbociclib, Bay 11-7082",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
1868,KP6,33931882,Blockade of IKK-NF-魏B or AKT pathway#enhanced#effects of palbociclib on RB1-intact cancers,Strategies to Overcome Resistance,"RB1, CDK4, CDK6",-,"Lung cancer, Colon cancer",Palbociclib,"NF-魏B, AKT",-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
2670,KP6,34401529,"Extract treatment#decreased#CDK4, CCND1, and AP-1 subunits (c-Jun/c-Fos)",Regulation,"CDK4, CCND1, JUN, FOS",-,-,-,AP-1,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6050,KP6,33686114,Dinaciclib-triggered apoptosis#is mediated by#CDK9 inhibition and reduced RNA pol II phosphorylation,Mechanism of Action,CDK9,-,-,Dinaciclib,-,-,-,Downregulated,MYC,-,-,Fact,3,3.1,3.1.3,3.1.3.3,-,线粒体通路调控
3223,KP6,39765134,"3-carene#inhibits#cell cycle proteins CDKN2A, CCND1, CDK4",Mechanism of Action,"CDKN2A, CCND1, CDK4",-,-,3-carene,-,-,-,-,-,-,-,Inference,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
2710,KP6,29464035,Cyclin D1 and CDK4/6 levels#can serve as#biomarkers for erufosine intervention,Biomarker Analysis,"CCND1, CDK4, CDK6",-,Tumor,Erufosine,-,-,-,Downregulated,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
3731,KP6,28004111,COL11A1 suppression#led to#downregulation of cyclin D1 and upregulation of p21,Regulation,"COL11A1, CCND1, CDKN1A",-,-,-,-,-,-,Downregulated/Upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7979,KP6,35843546,palbociclib#increases#PD-L1 expression in tumors,Therapeutic Response,CD274,-,Tumors,palbociclib,-,-,-,upregulated,-,-,-,Fact,3,3.3,3.3.2,3.3.2.1,-,PD-1/PD-L1表达调控
4243,KP6,35843546,AB680#is a combinatory therapeutic option to overcome#side effects of palbociclib,Combination Therapies,CD274,-,Tumors,"AB680, palbociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
843,KP6,16863592,Cyclin D1#activates#CDK4 or CDK6,Mechanism of Action,"CCND1, CDK4, CDK6",-,-,-,G1 phase,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
6593,KP6,16863592,Cyclin D1#binds and modulates#transcription factors,Mechanism of Action,CCND1,-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
3760,KP6,16863592,"Cyclin D1 gene translocation, amplification, and/or overexpression#are frequent events in#selected tumor types",Cancer Association,CCND1,-,Tumors,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
7184,KP6,16863592,Cyclin D1 locus polymorphism#is implicated in#increased cancer risk or poor outcome,Cancer Association,CCND1,-,Cancer,-,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
7874,KP6,16863592,Cyclin D1b isoform#harbors#unique activities in cancer cells,Molecular Event,CCND1,-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
208,KP6,10534112,Cyclins and CDKs#are characterized as#catalytic partners,Structural Biology,"CCND1, CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7252,KP6,10534112,LPS#represses#cyclin D1 levels,Regulation,CCND1,-,-,LPS,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
4646,KP6,10534112,LPS#induces#cyclin D2 expression in macrophages,Expression Patterns,CCND2,Macrophages,-,LPS,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
2149,KP6,33243298,Dysregulated CDK4/6-cyclin D1 pathway signaling#is essential for#pathogenesis of NPC,Cancer Pathways,"CDK4, CDK6, CCND1",-,Nasopharyngeal carcinoma (NPC),-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
7749,KP6,33243298,Palbociclib monotherapy#induces#cell cycle arrest in G1 phase in NPC cells,Therapeutic Response,"CDK4, CDK6",NPC cells,Nasopharyngeal carcinoma (NPC),palbociclib,G1 phase,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3764,KP6,33243298,Combination therapy#inhibits#tumor growth by inducing autophagy-associated cell death,Therapeutic Response,"CDK4, CDK6",-,Tumors,-,-,-,-,-,-,-,-,Fact,3,3.4,3.4.3,3.4.3.1,-,自噬启动
6211,KP6,33243298,NPC cell lines with palbociclib or cisplatin resistance#remain sensitive to#cisplatin or palbociclib treatment,Mechanisms of Resistance,"CDK4, CDK6",NPC cells,Nasopharyngeal carcinoma (NPC),"palbociclib, cisplatin",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.4,-,生物标志物指导
3745,KP6,33243298,"Luteoloside#reduces#expression levels of cyclin D1, CDK4, and C-myc",Regulation,"CCND1, CDK4, MYC",-,-,Luteoloside,p38 MAPK,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
2077,KP6,11840272,p18#functions as#a tumor suppressor in myeloma cells,Cancer Association,CDKN2C,Myeloma cells,Myeloma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7724,KP6,11840272,Cyclin D1#is overexpressed in#KMS12 myeloma cells,Expression Patterns,CCND1,Myeloma cells,Myeloma,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
4118,KP6,11840272,p18 induction#results in#apoptosis by inhibiting cyclin D1/CDK/pRb pathway,Therapeutic Response,"CDKN2C, CCND1, CDK4, RB1",-,Tumors,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
2045,KP6,10825210,CDC37#functions as#an oncogene in mice,Cancer Association,CDC37,-,-,-,-,-,-,-,-,-,-,Fact,2,2.4,2.4.1,2.4.1.1,-,激活性突变
228,KP6,10825210,"CDC37#targets#Cdk4, Raf-1, and v-src to Hsp90",Protein Complex Dynamics,"CDC37,CDK4,RAF1,SRC",-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
7986,KP6,10825210,CDC37#is coexpressed with#cyclin D1 in proliferative zones during mouse development,Expression Patterns,"CDC37,CCND1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
7438,KP6,10825210,CDC37#is required for#proliferation in cells programmed or induced to proliferate,Cell Cycle Control,CDC37,-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.1,-,增殖信号整合
2659,KP6,10825210,MMTV-CDC37 transgenic mice#develop#mammary gland tumors,Cancer Association,CDC37,-,Mammary gland tumors,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
2205,KP6,10825210,CDC37#collaborates with#c-myc and cyclin D1 to transform mammary glands,Cancer Association,"CDC37, MYC, CCND1",-,Mammary gland tumors,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
7741,KP6,10825210,CDC37-Hsp90 complex#mediates#protein kinase pathway establishment,Signaling Networks,CDC37,-,-,-,-,-,-,-,-,-,-,Inference,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
5340,KP6,7677168,CDK4-cyclin D1 complex#phosphorylates#pRB to regulate cell cycle transitions,Cell Cycle Control,"CDK4, CCND1, RB1",-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
6445,KP6,30826934,E6201#exhibits#anti-tumor and anti-metastasis efficacy in TNBC,Drug Development,-,-,TNBC,E6201,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1938,KP6,30826934,E6201#demonstrates#anti-metastasis efficacy against TNBC in vivo,Drug Development,-,-,TNBC,E6201,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6476,KP6,35276236,CTL and ERA#induce#cell cycle arrest at G1/S phase in MCF-7 and MDA-MB-231 cells,Cell Cycle Control,"CDK4, CCND1","MCF-7, MDA-MB-231",-,"CTL, ERA",-,-,downregulated,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
1533,KP6,17949234,JNK2 and p38#are overexpressed in#chronic myeloid leukemia,Cancer Association,"MAPK9, MAPK14",-,Chronic myeloid leukemia,-,-,-,upregulated,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
2172,KP6,17949234,JNK2 depletion#causes#13 downregulated and 14 upregulated genes,Expression Patterns,MAPK9,-,Chronic myeloid leukemia,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
5922,KP6,17949234,p38 silencing#causes#7 downregulated and 13 overexpressed genes,Expression Patterns,MAPK14,-,Chronic myeloid leukemia,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
4580,KP6,17949234,JNK2 or p38 silencing#reveals#distinct sets of affected genes,Expression Patterns,"MAPK9, MAPK14",-,Chronic myeloid leukemia,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
1614,KP6,17949234,JNK2 or p38 silencing#does not lead to#significant changes in CML cell proliferation,Cancer Association,"MAPK9, MAPK14",-,Chronic myeloid leukemia,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
6905,KP6,17949234,JNK2 or p38 inhibition#is insufficient for#CML proliferation arrest,Mechanisms of Resistance,"MAPK9, MAPK14",-,Chronic myeloid leukemia,-,-,-,-,-,-,-,-,Inference,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
4987,KP6,34570813,Bergamottin#promotes#G0/G1 cell cycle block,Cell Cycle Control,-,-,-,Bergamottin,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
3299,KP6,34570813,"Cell cycle block#is accompanied by#reduction in cyclin D, cyclin B, CDK4, P-cdc2 (Y15), and P-wee1 (S642)",Cell Cycle Control,"CCND1, CCNB1, CDK4, CDC2, WEE1",-,-,-,-,-,downregulated,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
3395,KP6,32336043,Kinome multigenic panel#identified#EPHB4-V871I somatic variant in high-risk neuroblastoma,Molecular Event triples,EPHB4,-,Neuroblastoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
4471,KP6,32336043,Different kinases#are#potential therapeutic targets in various cancers including NB,Therapeutic Targets triples,"ALK, AURKA, RET",-,Neuroblastoma,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
2631,KP6,32336043,"EPHB4#regulates#vascularization in cancer-promoting angiogenesis, tumour growth and metastasis",Function triples,EPHB4,-,Cancer,-,-,-,-,-,-,-,-,Fact,6,6.2,6.2.1,6.2.1.1,6.2.1.1.4,血管生成反应
2642,KP6,32336043,"EPHB4-V871I#accounts for#increased proliferation, migration and invasion properties in NB cell lines",Function triples,"EPHB4,VEGF,RAF1,CDK4",NB cell lines,Neuroblastoma,-,ERK1/2,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
4297,KP6,34728571,Breast cancers expressing hormonal receptors (HR) and HER2#display#resistance to targeted therapy,Resistance Mechanisms triples,ERBB2,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
4989,KP6,34728571,Targeted triple combination approach#will be#clinically effective in drug-resistant tumors,Therapeutic Strategies triples,-,-,Drug-resistant tumors,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
238,KP6,23114123,"SBX#increases expression of#p-PKC, p-p38, Cdc25B, XIAP in HL-60 cells",Expression Patterns,"PRKCA,MAPK14,Cdc25B,XIAP",HL-60 cells,-,SBX,-,-,-,upregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
2397,KP6,23114123,"SBX#decreases expression of#p-AKT, p-SAPK/JNK, Notch4, Cdk4, Cdc2, cyclin E, Akt, Bcl-2, Bax, cdc42, TNF-α, p27, CaMKKa",Expression Patterns,"AKT1,MAPK8,NOTCH4,CDK4,CDK1,CCNE1,BCL2,BAX,CDC42,TNF,CDKN1B,CAMKK2",-,-,SBX,-,-,-,downregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
4328,KP6,35212973,"GA treatment#increases#E-cadherin, β-catenin, and PI3K/AKT expression in diabetic rats",Expression Patterns,"CDH1,CTNNB1,PIK3CA,AKT1",-,Diabetes,-,PI3K/AKT pathway,-,-,upregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
5315,KP7,28947133,Gastric cancer cells#are sensitive to#CDK4/6 inhibitor Palbociclib,Drug Development,"CDK4,CDK6",Gastric cancer cells,Gastric cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5616,KP7,28947133,Palbociclib#induces#senescence and autophagy in AGS gastric cancer cells,Mechanism of Action,"CDK4,CDK6",AGS gastric cancer cells,Gastric cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
7665,KP7,28947133,Simultaneous blockade of CDK4/6 and autophagy#exacerbates#senescence phenotype in AGS gastric cancer cells,Mechanism of Action,"CDK4,CDK6",AGS gastric cancer cells,Gastric cancer,-,Autophagy,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
5032,KP7,28947133,Knocking down p53#reduces#senescence and autophagy blockade,Regulation,TP53,-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.2,-,衰老程序激活
1607,KP7,30343527,Cyclin G2#plays essential roles in#SMAD2-dependent cytostatic response,Mechanism of Action,"CCNG2,SMAD2",-,-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
4835,KP7,32572774,"CDK4, CDK6, and cyclin D1#are involved in#cell cycle arrest and apoptosis",Cell Cycle Control,"CDK4,CDK6,CCND1",-,-,-,PI3K/AKT pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3225,KP7,27937072,PE-PDMSCs CM#induces#JunB downregulation and Cyclin D1 increase in placental explants,Expression Patterns,"JUNB,CCND1",Placental explants,-,-,-,-,"downregulated, upregulated",-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
4081,KP7,31530780,Abemaciclib#inhibits#growth of ER-positive breast cancer cells,Therapeutic Response,"CDK4,CDK6",ER-positive breast cancer cells,Breast cancer,Abemaciclib,-,-,"ER-positive, Rb-positive",-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1043,KP7,25667638,BZD#promotes#chondrocyte viability by stimulating cell cycle progression,Cell Cycle Control,-,Chondrocytes,-,BZD,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3744,KP7,25667638,"BZD#increases expression of#cyclin D1, CDK4, CDK6, and p21",Expression Patterns,"CCND1,CDK4,CDK6,CDKN1A",-,-,BZD,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
7514,KP7,36003783,GFI1#regulates#differentiation of myeloid and lymphoid cells,Immune Cell Functions,GFI1,"Myeloid cells, Lymphoid cells",-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.2,1.4.2.1,-,谱系特异性分化
3146,KP7,27571378,Resistant cells#show no inhibition of#CDK4 or CDK6,Therapeutic Resistance,"CDK4,CDK6",Resistant cells,-,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
5829,KP7,27571378,Prolonged incubation with compound#results in#downregulation of additional kinases critical for cell cycle progression,Therapeutic Resistance,-,Sensitive cells,-,-,-,-,-,downregulated,-,-,-,Fact,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
1334,KP7,27571378,Phosphorylation of retinoblastoma protein#was tracked as#a pharmacodynamic marker,Biomarker Analysis,RB1,-,Tumor,-,-,-,-,phosphorylation,-,-,-,Fact,7,7.3,7.3.1,7.3.1.2,-,pRB水平
7390,KP7,31207004,Palbociclib#resulted in#loss of phosphorylated retinoblastoma protein (pRb),Regulation,RB1,"P114,CF41 cells",-,Palbociclib,-,cell cycle machinery,-,phosphorylation,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
5650,KP7,10651629,p18INK4C#inhibits#cyclin-dependent kinase 4 (CDK4),Mechanism of Action,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
5372,KP7,10651629,p18#inhibits#CDK4 through specific residues and motifs,Mechanism of Action,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
5755,KP7,32157498,OIP5-AS1#is highly expressed in#pancreatic cancer tissues,Expression Patterns,-,-,Pancreatic cancer,-,-,-,-,upregulated,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,Expression patterns
2505,KP7,36174113,Letrozole and CDK4/6 inhibitor abemaciclib#demonstrate#promising activity in ER-positive endometrial cancer,Combination Therapies,"CDK4, CDK6",-,Endometrial cancer,"Letrozole, Abemaciclib",-,-,-,-,-,-,-,Inference,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
2837,KP7,36174113,Neutropenia and anemia#are#common grade 3 treatment-related adverse events,Quality of Life,-,-,-,-,-,"Neutropenia, anemia",-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,血液学毒性
3649,KP7,38462928,"STAT3 modulation#suppresses#expression of cyclin D1, cyclin E, CDK4, and CDK6",Regulation,"STAT3, CDK4, CDK6",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
4161,KP7,10880462,Cyclin D-dependent kinases Cdk4 and Cdk6#drive#entry of quiescent cells into the cell cycle,Cell Cycle Control,"CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
4865,KP7,9636670,P18#blocks#cell cycle progression by associating with CDK6 and CDK4,Cell Cycle Control,"CDKN2C, CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3519,KP7,30365726,"LIPUS#upregulates#cyclinD1, CDK6, CDK4, and VEGF",Regulation,"CDK4, CDK6, VEGFA",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
1890,KP7,18462865,Enzastaurin and 17-AAG#reduce#expression of CDK4 and CDK6,Drug Development,"CDK4, CDK6",-,-,"Enzastaurin, 17-AAG",-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
1483,KP7,9724636,P16(INK4a)#induces#G1 cell cycle arrest by inhibiting CDK4 and CDK6 phosphorylation of p-Rb,Cell Cycle Control,"CDKN2A, CDK4, CDK6, RB1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
4563,KP7,9774662,INK4a#binds to and inhibits#CDK4 and CDK6,Mechanism of Action,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
5122,KP7,9774662,ARF#increases#functional p53 via interaction with MDM2,Mechanism of Action,TP53,-,-,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.3,5.4.3.1,-,原癌基因激活
5772,KP7,29061795,Combination treatment of berberine and evodiamine#synergistically inhibited#MCF-7 cell proliferation,Drug Development,-,MCF-7 cells,-,"berberine, evodiamine",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4575,KP7,29061795,Combination treatment of berberine and evodiamine#resulted in#G(0)/G(1) phase accumulation of cells,Cell Cycle Control,-,MCF-7 cells,-,"berberine, evodiamine",-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
5362,KP7,29061795,Combination treatment of berberine and evodiamine#increased expression levels of#CDK inhibitors p21 and p27,Regulation,"CDKN1A,CDKN1B",-,-,"berberine, evodiamine",-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
2809,KP7,29061795,"Combination treatment of berberine and evodiamine#reduced expression levels of#cyclin D1, cyclin E, CDK4, and CDK6",Regulation,"CCND1,CDK4,CDK6",-,-,"berberine, evodiamine",-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
809,KP7,27499015,"Peridinin#reduced expression of#G1 cell cycle regulators including cyclin D1, cyclin D2, CDK4, and CDK6",Regulation,"CCND1,CCND2,CDK4,CDK6",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
6772,KP7,27499015,"Peridinin#reduced expression of#anti-apoptotic proteins including survivin, XIAP, and Bcl-2",Regulation,-,-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.3,1.3.3,1.3.3.3,-,细胞凋亡调控
7921,KP7,27922672,MCA#inhibited#TNF-α-induced cell proliferation,Therapeutic Response,-,-,-,MCA,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6651,KP7,27922672,"MCA#reduced levels of#cyclin D1, cyclin D3, CDK4, and CDK6",Regulation,"CCND1,CCND3,CDK4,CDK6",-,-,MCA,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
6872,KP7,27922672,MCA#increased levels of#CDK inhibitors p21 and p27,Regulation,"CDKN1A,CDKN1B",-,-,MCA,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
5301,KP7,26137139,High proliferative ability of glioma cells#is a cause of#poor prognosis in malignant gliomas,Cancer Association,-,glioma cells,Glioma,-,-,-,-,-,-,-,-,Inference,1,1.4,1.4.1,1.4.1.1,-,增殖信号整合
289,KP7,26137139,Expression level of miRNA-218#is downregulated in#glioma cell lines and human primary glioma tissues,Expression Patterns,-,glioma cells,Glioma,-,-,-,-,downregulated,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,微小RNA
3024,KP7,26137139,Upregulation of miR-218#inhibited#glioma U87 cell proliferation,Regulation,-,U87 glioma cells,Glioma,-,-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
2472,KP7,26137139,Upregulation of miR-218#induced#G(1)-S checkpoint arrest,Cell Cycle Control,-,U87 glioma cells,Glioma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
3182,KP7,26137139,miR-218#inactivated#CDK6/cyclin D1/p21(Cip1/Waf1) pathway,Pathway & Network Categories,"CDK6,CCND1,CDKN1A",-,Glioma,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
4821,KP7,26137139,miR-218#downregulated#CDK6 expression by targeting its 3'-untranslated region,Regulation,CDK6,-,Glioma,-,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.3,-,非编码RNA调控
7342,KP7,26137139,miR-218#plays a role in#prevention of glioma cell proliferation,Cancer Association,-,glioma cells,Glioma,-,-,-,-,-,-,-,-,Inference,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
3267,KP7,26137139,miR-218#suppresses#CDK6/cyclin D1/p21(Cip1/Waf1) pathway in glioma cells,Pathway & Network Categories,"CDK6,CCND1,CDKN1A",-,Glioma,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
5132,KP7,33575077,Low concentration of β-elemene#induced#senescence in glioma cells,Therapeutic Response,-,glioma cells,Glioma,β-elemene,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
5043,KP7,33575077,β-elemene#downregulated#Lamin B1 in glioma cells,Regulation,-,glioma cells,Glioma,β-elemene,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.2,3.1.2.4,-,表观遗传改变
5673,KP7,33575077,CDK6#was decreased in#glioma cells treated with β-elemene,Regulation,CDK6,-,Glioma,β-elemene,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
5251,KP7,39833962,METTL7B knockdown#induced#G1 phase arrest,Cell Cycle Control,-,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
4977,KP7,39833962,"METTL7B knockdown#reduced levels of#cyclin D1, CDK4, and CDK6",Regulation,"CCND1,CDK4,CDK6",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
627,KP7,39833962,METTL7B knockdown#elevated levels of#CDKN2D,Regulation,CDKN2D,-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
4423,KP7,38552377,"EGCG#regulated#cell cycle regulators cyclin D1, cyclin E1, CDK4, CDK6, cyclin B1, cyclin B2, p16, and p27",Regulation,"CCND1,CCNE1,CDK4,CDK6,CCNB1,CCNB2,CDKN2A,CDKN1B",-,-,EGCG,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6574,KP7,19145199,CDK6#drives#cell cycle progression from G1 to S phase through retinoblastoma 1 protein inactivation,Cell Cycle Control,"CDK6,RB1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
1542,KP7,19145199,Neoplastic B cells#expressed#CDK6 and cytoplasmic retinoblastoma 1 protein,Expression Patterns,"CDK6,RB1",B cells,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
2452,KP7,37044053,RAB7A#is upregulated in#most tumor types,Expression Patterns,RAB7A,-,Cancer,-,-,-,-,upregulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
166,KP7,37044053,RAB7A#is associated with#poorer prognosis in many cancers,Cancer Association,RAB7A,-,Cancer,-,-,-,-,-,-,-,-,Inference,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
4214,KP7,37044053,Knockdown of RAB7A#induced#G0/G1 arrest in HCC,Cell Cycle Control,RAB7A,-,Hepatocellular carcinoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
2196,KP7,34161670,"PB#downregulated#cyclin D1, cyclin D3, CDK4, CDK6, cyclin E, and p-Rb in HGC-27 cells in a dose-dependent manner",Regulation,"CCND1,CCND3,CDK4,CDK6,RB1",HGC-27 cells,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
3341,KP7,25655587,"Piperine#suppressed#Cdk1, Cdk4, Cdk6, cyclin B, cyclin D2, and Cdc25c protein phosphatase in IL-2-stimulated T lymphocytes",Regulation,"CDK1,CDK4,CDK6,CCNB1,CCND2,CDC25C",T lymphocytes,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
4604,KP7,35282060,Chemotherapy#modulates#CDK4/6 inhibitors resistance in metastatic breast cancer by Rb1 mutations,Therapeutic Resistance,"CDK4,CDK6,RB1",-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Inference,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
153,KP7,35282060,CDK4/6 inhibitors#prevent#cell cycle transition from G1 to S phase in breast cancer,Mechanism of Action,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2745,KP7,35282060,Retinoblastoma (Rb)#is#a negative regulator of cell cycle,Cell Cycle Control,RB1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6927,KP7,35282060,Rb#inhibits#cell cycle transition by binding to E2F transcription factors,Cell Cycle Control,"RB1,E2F",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
5464,KP7,35282060,Rb#is regulated by#phosphorylation,Regulation,RB1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2720,KP7,35282060,Decreasing estrogen signal#reduces#cyclin D-CDK4/6 complexing,Regulation,"CDK4,CDK6,CCND1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
5508,KP7,11756559,Mutations in CDK4 and p16(INK4a)#have been implicated in#genesis and progression of familial human melanoma,Cancer Association,"CDK4,CDKN2A",-,Familial human melanoma,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,RB1突变
391,KP7,11756559,Cdk4(R24C/R24C) mouse embryo fibroblasts#displayed#increased Cdk4 kinase activity resulting in hyperphosphorylation of Rb family members,Mechanism of Action,"CDK4,RB1,RBL1,RBL2",Mouse embryo fibroblasts,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
5343,KP7,11756559,"Tumors#were found in#pancreas, pituitary, brain, mammary tissue, and skin",Cancer Association,-,-,Tumors,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,RB1突变
7766,KP7,20505188,"CXCR2#promoted#cell cycle progression by modulating p21, cyclin D1, CDK6, CDK4, cyclin A, and cyclin B1",Cell Cycle Control,"CXCR2,CDKN1A,CCND1,CDK6,CDK4,CCNA1,CCNB1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6873,KP7,31358010,Genetic aberrations in cell cycle genes#indicate#potential for targeted therapy in mucosal melanoma,Cancer Association,"CDK4,CDK6",-,Mucosal melanoma,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,RB1突变
970,KP7,31358010,CDK4 inhibitors#may affect#tumor proliferation through multiple signaling pathways,Pathway & Network Categories,CDK4,-,Tumor,CDK4 inhibitors,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6521,KP7,8217195,Cyclin-dependent kinases (Cdk) and G1 cyclins#control#cell cycle progression through G1/S in a tissue-specific manner,Cell Cycle Control,"CDK4,CDK6,CCND1,CCND2",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
1093,KP7,29670090,Palbociclib#inhibits#CDK4/6-Rb signaling pathway,Mechanism of Action,"CDK4,CDK6",-,-,Palbociclib,CDK4/6-Rb,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
7651,KP7,29670090,Palbociclib#promotes#cell apoptosis,Mechanism of Action,-,-,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
5787,KP7,29670090,Palbociclib#does not change#CDK4/6 protein levels,Expression Patterns,"CDK4,CDK6",-,-,Palbociclib,-,-,-,unchanged,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7126,KP7,29670090,Palbociclib#induces#G1 cell-cycle arrest,Mechanism of Action,"CDK4,CDK6",-,-,Palbociclib,CDK4/6-Rb,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2498,KP7,29670090,Palbociclib#induces#apoptotic effects,Mechanism of Action,"CDK4,CDK6",-,-,Palbociclib,CDK4/6-Rb,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.2,-,死亡受体通路激活
7726,KP7,28050067,"Cell-cycle regulatory machinery#controls#cellular proliferation, growth, and division",Cell Cycle Control,-,-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,-,-,细胞增殖调控
7823,KP7,28050067,Cyclin-dependent kinases (CDKs)#regulate#cell cycle,Cell Cycle Control,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
2418,KP7,28050067,Cyclin-dependent kinases (CDKs)#control#transcriptional processes,Mechanism of Action,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,-,-,转录因子网络
5501,KP7,28050067,CDK family members#are commonly deregulated in#human cancer,Cancer Association,"CDK4,CDK6",-,Human cancer,-,-,-,-,deregulated,-,-,-,Fact,2,2.1,2.1.1,-,-,基因组改变
3467,KP7,28050067,Cyclin D-CDK4/6-Rb-INK4 axis#is affected in#many solid tumors,Cancer Pathways,"CDK4,CDK6,RB1,CDKN2A",-,Solid tumors,-,Cyclin D-CDK4/6-Rb-INK4,-,-,-,-,-,-,Fact,2,2.1,2.1.2,-,-,信号通路激活
3390,KP7,28050067,Cyclin D-CDK4/6-Rb-INK4 axis#leads to#cancer cell proliferation,Cancer Pathways,"CDK4,CDK6,RB1,CDKN2A",-,Cancer,-,Cyclin D-CDK4/6-Rb-INK4,-,-,-,-,-,-,Fact,2,2.1,2.1.2,-,-,信号通路激活
2801,KP7,28050067,CDK4/6 inhibitors#arrest#cells in G1 phase,Mechanism of Action,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7827,KP7,28050067,CDK4/6 inhibitors#block#RB phosphorylation at CDK4/6-specific sites,Mechanism of Action,"CDK4,CDK6,RB1",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
1252,KP7,32541838,Hyperphosphorylated RB#releases#E2F transcription factors,Mechanism of Action,"RB1,E2F1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
2417,KP7,32541838,E2F transcription factors#activate#a transcriptional program,Mechanism of Action,E2F1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
4363,KP7,32541838,"Senescence#is induced by#oncogenic activation, chemotherapy, irradiation, and targeted therapies",Regulation,-,-,-,CDK4/6 inhibitors,-,-,-,-,-,"Oncogenic activation, chemotherapy, irradiation",-,Fact,1,1.1,1.1.3,1.1.3.2,-,细胞衰老诱导
4227,KP7,9665476,Osteosarcomas#suffer#mutations of RB gene,Cancer Association,RB1,-,Osteosarcoma,-,-,-,-,mutated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
4056,KP7,9665476,RB gene mutations#inactivate#pRb protein,Mechanism of Action,RB1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
5985,KP7,9665476,pRb protein#is part of#a cell-cycle control pathway,Cell Cycle Control,RB1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
6977,KP7,9665476,High-grade osteosarcomas#showed loss of#p16 expression,Expression Patterns,CDKN2A,-,Osteosarcoma,-,-,-,-,downregulated,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,基因缺失
2023,KP7,9665476,High-grade osteosarcomas#had#homozygous CDKN2A deletions,Cancer Association,CDKN2A,-,Osteosarcoma,-,-,-,-,deleted,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,基因缺失
1802,KP7,9665476,Osteosarcomas with CDKN2A alterations#expressed#pRb,Expression Patterns,"CDKN2A,RB1",-,Osteosarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,基因缺失
4365,KP7,9665476,CDKN2A#is#a tumor suppressor,Cancer Association,CDKN2A,-,Osteosarcoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
3575,KP7,9665476,p16-pRb cell-cycle control pathway#is deregulated in#high-grade osteosarcomas,Cell Cycle Control,"CDKN2A,RB1",-,Osteosarcoma,-,-,-,deregulated,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
4888,KP7,15867383,Cdk4 R24C mutation#cooperates with#p27(Kip1) deficiency in tumor development,Cancer Association,"CDK4,CDKN1B",-,Tumor,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
921,KP7,19597485,CDK4-pRB-E2F1 cell-cycle regulators#are expressed in#non-proliferating beta cells,Expression Patterns,"CDK4,RB1,E2F1",Beta cells,-,-,-,-,expressed,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
2671,KP7,19597485,CDK4-pRB-E2F1 pathway#has a role in#beta-cell function,Mechanism of Action,"CDK4,RB1,E2F1",Beta cells,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
874,KP7,19597485,CDK4#is activated by#glucose through the insulin pathway,Regulation,CDK4,-,-,-,Insulin,-,activated,-,-,Glucose,-,Fact,1,1.2,1.2.1,1.2.1.1,-,生长因子信号
4906,KP7,19597485,CDK4 activation#results in#E2F1 activation,Mechanism of Action,"CDK4,E2F1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
2530,KP7,19597485,E2F1 activation#increases#Kir6.2 expression,Expression Patterns,E2F1,-,-,-,-,-,upregulated,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
2195,KP7,32958271,"Tumors with Rb-positivity, low p16 expression, and cyclin D1 overexpression#respond to#CDK4/6 inhibition",Markers,"RB1,CDKN2A,CCND1",-,Ovarian cancer,CDK4/6 inhibitors,-,-,"low, overexpressed",-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6224,KP7,18484097,Rb pathway#controls#G1-S checkpoint of the cell cycle,Cell Cycle Control,"RB1,CDKN2A,CDK4,CCND1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
116,KP7,18484097,Loss of p16/Rb protein#is associated with#gastric carcinomas,Cancer Association,"CDKN2A,RB1",-,Gastric carcinoma,-,-,-,downregulated,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
4894,KP7,18484097,Overexpression of cyclin D1/CDK4#is observed in#gastric carcinomas,Expression Patterns,"CDK4,CCND1",-,Gastric carcinoma,-,-,-,upregulated,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
2124,KP7,26133574,Lentivirus-mediated expression of microRNA let-7b#affects#cyclin D1 and CDK4 in epidermal stem cells,Regulation,"CCND1,CDK4",Epidermal stem cells,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.3,-,非编码RNA调控
1992,KP7,30613006,Fascin siRNA#reduces#expression of CDK4 and p21 in tumor xenograft,Regulation,"CDK4,CDKN1A",-,-,-,-,-,downregulated,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.3,-,非编码RNA调控
1376,KP7,8548755,Inactivation of the p16-CDK4/cyclin D1-pRb pathway#is observed in#glioblastomas,Cancer Pathways,"CDKN2A,CDK4,CCND1,RB1",-,Glioblastoma,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
5561,KP7,15809726,Vitamin K5 treatment#reduces#expression of CDK4 in HCC tumors,Regulation,CDK4,-,Hepatocellular carcinoma,Vitamin K5,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
3432,KP7,11515790,CDK4#is moderately upregulated in#SKMG-3 cell line,Expression Patterns,CDK4,-,Glioblastoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3562,KP7,11515790,Overexpressed CDK4 and loss of PTEN#confer#malignant phenotype in GBM cells,Cancer Pathways,"CDK4,PTEN",-,Glioblastoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
5365,KP7,20309622,Cyclin-dependent kinases CDK4 and Cdc2#are studied for#expression changes in cell cycle regulation,Expression Patterns,"CDK4,CDC2",-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
1749,KP7,7954407,p16Ink4#inhibits#CDK4 as a cell cycle regulator,Mechanism of Action,"CDKN2A,CDK4",-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
1174,KP7,10365910,Cdkn2a locus#encodes#p16INK4a and p19ARF as tumor suppressors,Gene Function,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
1424,KP7,10365910,p16INK4a variant#is diminished in#CDK6 binding and inhibition,Mechanism of Action,"CDKN2A,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.2,-,Cyclin D-CDK6复合物
2294,KP7,10365910,p16INK4a#is implicated in#lung cancer predisposition and development,Cancer Association,CDKN2A,-,Lung cancer,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
3611,KP7,28226315,Cyclin-dependent kinases (CDKs)#are crucial for#cell cycle regulation,Cell Cycle Control,"CDK4,CDK6",-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.2,-,-,周期蛋白复合物形成
7783,KP7,28226315,CDK4/6#orchestrates#G1 phase progression and G1/S transition,Cell Cycle Control,"CDK4,CDK6",-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
4115,KP7,28226315,LEE011#causes#dephosphorylation of Rb and G1 phase arrest,Drug Development,RB1,-,-,LEE011,Cell cycle,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
7534,KP7,28226315,CDK4/6 inhibitor LEE011#exhibits#anti-tumoral properties,Drug Development,"CDK4,CDK6",Neuroendocrine tumor cell lines,Neuroendocrine tumor,"LEE011,5-fluorouracil,everolimus",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
695,KP7,30176239,CDKN2A/2B/2BAS genes#play a role in#atherosclerosis and type 2 diabetes mellitus (T2DM),Disease Association,"CDKN2A,CDKN2B,CDKN2BAS",-,"Atherosclerosis, Type 2 diabetes mellitus (T2DM)",-,-,-,-,-,-,-,-,Inference,4,4.1,4.1.1,-,-,葡萄糖代谢改变
3840,KP7,30176239,"Reduced mRNA levels of CDKN2A, CDKN2B, and CDKN2BAS#were observed in#T2DM and T2DM-CAD subjects compared with controls",Expression Patterns,"CDKN2A,CDKN2B,CDKN2BAS",-,"T2DM, T2DM-CAD",-,-,-,T2DM and T2DM-CAD subjects,downregulated,-,-,-,Fact,4,4.1,4.1.1,-,-,葡萄糖代谢改变
5497,KP7,9598804,CDKN2A gene#is important in#the genesis of familial and sporadic melanoma,Cancer Association,CDKN2A,-,"Familial melanoma, Sporadic melanoma",-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
433,KP7,9598804,Alternative events#inactivate#CDKN2A in melanoma cell lines,Cancer Association,CDKN2A,Melanoma cell lines,Melanoma,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
135,KP7,9598804,Melanoma cell lines#were found to be#deleted/mutated/methylated for CDKN2A,Cancer Association,CDKN2A,Melanoma cell lines,Melanoma,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
44,KP7,9598804,CDKN2B#was homozygously deleted in#melanoma cell lines,Cancer Association,CDKN2B,Melanoma cell lines,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
571,KP7,9598804,CDK4#was mutated/amplified in#melanoma cell lines,Cancer Association,CDK4,Melanoma cell lines,Melanoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3232,KP7,9598804,CDKN2A#was homozygously deleted along with#a CDK4 mutation or amplification of CCND1,Cancer Association,"CDKN2A,CDK4,CCND1",-,Melanoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
6280,KP7,9598804,Homozygous deletions on 9p21#could target#tumor suppressor genes other than CDKN2A,Cancer Pathways,CDKN2A,-,Tumor,-,-,-,-,-,-,-,-,Inference,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
3641,KP7,21841792,Cell growth and proliferation#require#increased glycolytic and decreased oxidative metabolism levels,Metabolic Integration,-,-,-,-,-,-,-,-,-,-,-,Fact,4,4.1,4.1.1,4.1.1.1,-,有氧糖酵解增强
824,KP7,21613412,Resistance to endocrine therapies#includes#upregulation and/or activation of signal transduction pathways,Mechanisms of Resistance,-,-,Endocrine therapy resistance,-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
5206,KP7,21613412,Cyclin D1#serves as#a convergence point for multiple signaling pathways,Signaling Networks,CCND1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3403,KP7,21613412,Cyclin D1 expression and RB phosphorylation#were maintained in#endocrine therapy-resistant breast cancer cell lines,Mechanisms of Resistance,"CCND1,RB",Breast cancer cell lines,Endocrine therapy-resistant breast cancer,-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
5257,KP7,21613412,CDK4/6 inhibitor PD-0332991#induced#growth arrest through cellular senescence,Mechanism of Action,"CDK4,CDK6",-,-,PD-0332991,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
4745,KP7,24378856,"Blockade#caused#a strong decrease of G1 cyclins, cyclin D1, cyclin E, and CDK4",Regulation,"CCND1,CDK4,CCNE",-,-,-,-,-,downregulated,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
1022,KP7,20951943,MEP50#is#a CDK4 substrate and phosphorylation increases PRMT5/MEP50 activity,Protein Complex Dynamics,"CDK4,MEP50,PRMT5",-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
6149,KP7,33385409,HLCA#disrupts#G1 phase via downregulation of cyclin D1 and CDK4,Mechanism of Action,"CCND1,CDK4","OVCAR-3, Caov-4",Ovarian cancer,HLCA,-,-,downregulated,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
86,KP7,28877884,Upregulating c-Myc#through#JNK/CDK4-dependent pSmad3L pathway may be key to pathophysiology in cpk mice,Mechanism of Action triples,"MYC,JNK,CDK4",-,Polycystic kidney disease,-,JNK/CDK4-dependent pSmad3L,-,-,upregulated,-,-,-,Inference,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
3035,KP7,28877884,Qualitative abnormality of TGF-β/Smad3 pathway#is involved in#PKD,Pathway triples,SMAD3,-,Polycystic kidney disease,-,TGF-β/Smad3,-,-,-,-,-,-,Inference,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
1667,KP7,32647650,PIC treatment#caused#G0/G1 phase cell cycle arrest and induction of apoptosis,Mechanism of Action triples,-,-,-,Piceatannol,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
2043,KP7,32647650,PIC#is likely important in#p53 modulation and cell cycle arrest in androgen-dependent prostate cancer cells,Mechanism of Action triples,TP53,-,Prostate cancer,Piceatannol,-,-,-,-,-,-,-,Inference,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
7031,KP7,18520069,This compound#suppressed#activation of FAK-Akt and Erk1/2 pathways involved in cell proliferation,Pathway triples,"FAK,AKT,ERK1/2",-,-,-,"FAK-Akt,Erk1/2",-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
3776,KP7,24806290,"Blockade#was accompanied by#a strong decrease of G1 cyclins, especially cyclin D1, cyclin E, and CDK4",Expression Patterns triples,"CDK4,CCND1,CCNE1",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
1305,KP7,7936665,Cell cycle-dependent phosphorylation of RB tumor suppressor protein#is mediated by#activated CDK4:cyclin D complex,Mechanism of Action triples,"RB1,CDK4,CCND1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
6565,KP7,7936665,p16INK4#is a target for#mutations in tumor lines and primary tumors,Cancer Association,CDKN2A,-,Tumor,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,关键基因突变
4147,KP7,34361036,Hinokitiol#inhibits#expression of cyclin D1 and CDK4,Regulation,"CDK4,CCND1",-,Tumor,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
6520,KP7,34361036,Hinokitiol#induces#tumor suppressor protein p53,Regulation,TP53,-,Tumor,-,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
7907,KP7,27334220,Palbociclib#is a potential treatment for#Synovial Sarcoma patients,Therapeutic Development,"CDK4,CDK6",-,Synovial Sarcoma,Palbociclib,-,-,Patients,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6979,KP7,27334220,β-catenin#is overexpressed in#tumors,Expression Patterns,CTNNB1,-,Tumor,-,-,-,-,upregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
4531,KP7,27334220,t(X;18) translocation#influences#tumor behavior through cyclin D1 activation,Cancer Pathways,CCND1,-,Tumor,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3181,KP7,27334220,Alterations in the cyclin D1-CDK4/6-Rb axis#impact#prognosis,Cancer Association,"CDK4,CDK6,CCND1,RB1",-,Tumor,Palbociclib,-,-,-,-,-,-,-,Inference,7,7.2,7.2.1,7.2.1.1,7.2.1.1.4,RB蛋白表达
5420,KP7,27334220,Palbociclib#inhibits#Rb-phosphorylation in cell lines,Regulation,RB1,-,-,Palbociclib,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
6056,KP7,27334220,Palbociclib#induces#G1 arrest and proliferation block,Mechanism of Action,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5303,KP7,33228782,Roquin1#destabilizes#cell cycle-promoting genes via 3'UTR targeting,RNA Regulation,"CCND1,CDK6,CCNE1,MCM2",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.3,-,非编码RNA调控
152,KP7,24278101,"Resveratrol#dysregulates#cyclin D1, CDK4, CDK6, p21, and p16",Regulation,"CCND1,CDK4,CDK6,CDKN1A,CDKN2A",-,-,Resveratrol,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
2970,KP7,23650533,"LPLUNC1#inhibits#expression of cyclin D1, CDK4, and phosphorylated Rb",Regulation,"CCND1,CDK4,RB1",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
7067,KP7,23650533,LPLUNC1#delays#cell cycle progression from G1 to S phase,Cell Cycle Control,"CCND1,CDK4",-,-,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.3,1.3.3.2,-,DNA修复机制
3188,KP7,15703828,Vitamin K2 and K3#reduce#expression of cyclin D1 and CDK4 in tumors,Regulation,"CCND1,CDK4",-,Tumor,"Vitamin K2, Vitamin K3",-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7882,KP7,9721866,"EGF and TGF-alpha#overexpress#cyclin D1, Cdk4, and c-Myc during hepatocarcinogenesis",Cancer Pathways,"CCND1,CDK4,MYC",-,Hepatocarcinogenesis,-,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.1,1.2.1.1,-,生长因子信号
6966,KP7,9721866,Cyclin D1/CDK4 complex#increases#hyperphosphorylated:hypophosphorylated Rb ratio in tumors,Mechanism of Action,"CCND1,CDK4,RB1",-,Tumor,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
739,KP7,9721866,"Growth factors, cell cycle proteins, and transcription factors#cooperate in#development of H. hepaticus-associated liver tumors",Cancer Pathways,"CCND1,CDK4,MYC",-,Liver tumors,-,-,-,-,-,-,-,-,Inference,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
1622,KP7,32183020,CDKs#are regulated by#interactions with cyclins and CKIs,Regulation,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6298,KP7,32183020,CDKs#regulate#cell proliferation through cell-cycle checkpoints,Cell Cycle Control,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7002,KP7,32183020,CDKs#drive#cell-cycle progression,Mechanism of Action,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
541,KP7,23958495,PDGF-BB#induces#HSC-T6 cell proliferation,Mechanism of Action,-,HSC-T6 cells,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.1,1.2.1.1,-,生长因子信号
3441,KP7,23958495,2-APB#inhibits#PDGF-BB-induced HSC-T6 cell proliferation,Drug Development,-,HSC-T6 cells,-,2-APB,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
687,KP7,23958495,siRNA targeting TRPM7#inhibits#PDGF-BB-induced HSC-T6 cell proliferation,Drug Development,TRPM7,HSC-T6 cells,-,siRNA targeting TRPM7,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
2210,KP7,23958495,"PDGF-BB-induced HSC-T6 cell proliferation#is accompanied by#downregulation of cyclin D1, PCNA, and CDK4",Regulation,CDK4,-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3506,KP7,10660629,Cyclin D1 and Cdk4#stimulate#Brca1 promoter in an E2F-dependent manner,Mechanism of Action,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
1981,KP7,10660629,p16(INK4a)#inhibits#cyclin D1 and Cdk4 stimulation of Brca1 promoter,Mechanism of Action,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
5358,KP7,24742622,"Increase in p53, p21, p16, and cleaved PARP#is associated with#decrease in Cdk4",Regulation,CDK4,-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
4252,KP7,10470133,p16 protein#functions as#an inhibitor of CDK4 and CDK6,Mechanism of Action,"CDKN2A,CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
2866,KP7,10470133,CDK4/6#phosphorylates#retinoblastoma protein (pRb),Mechanism of Action,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
6770,KP7,10470133,Deregulated expression of p16#is involved in#multistage process of NSCL carcinogenesis,Cancer Association,CDKN2A,-,Non-small cell lung cancer,-,-,-,-,-,-,-,-,Inference,1,1.6,1.6.2,1.6.2.3,-,分化阻滞
5024,KP7,28599479,Downregulation of DNM3#promotes#cell proliferation by increasing CDK4,Regulation,CDK4,-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
4971,KP7,29464035,Erufosine#downregulates#cell cycle processes in OSCC cells,Drug Development,-,OSCC cells,Head and neck cancer,Erufosine,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
512,KP7,18310289,AMH/BMP and TGF-beta pathways#are deregulated in#Men1 LCTs,Signaling Networks,MEN1,-,Leydig cell tumors,-,"AMH/BMP, TGF-beta",-,-,-,-,-,-,Fact,1,1.2,1.2.1,1.2.1.3,-,应激反应通路
3101,KP7,11781230,TGF-beta#decreases#cyclin D2 protein levels in primary human CD34+ progenitors,Regulation,CCND2,CD34+ progenitors,-,-,TGF-beta,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
7097,KP7,11781230,TGF-beta#increases#p15 protein levels in primary human CD34+ progenitors,Regulation,CDKN2B,CD34+ progenitors,-,-,TGF-beta,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
4006,KP7,11781230,TGF-beta#prevents#pRb phosphorylation in CD34+ cells in the presence of cytokines,Cell Cycle Control,RB1,CD34+ cells,-,-,TGF-beta,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
5579,KP7,9286748,p18#is a candidate#tumor suppressor gene in parathyroid tumors,Cancer Association,CDKN2C,-,Parathyroid tumors,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
3971,KP7,9286748,p18#inhibits#cyclin D1-associated kinase CDK6,Mechanism of Action,"CDKN2C,CDK6,CCND1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7637,KP7,9286748,Cyclin D1#is#a parathyroid oncogene,Cancer Pathways,CCND1,-,Parathyroid tumors,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
3576,KP7,9286748,Inactivation of p18#might cause#excessive parathyroid growth,Cancer Association,CDKN2C,-,Parathyroid tumors,-,-,-,-,-,-,-,-,Inference,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
5909,KP7,9286748,Inactivating mutation of p18#occurs uncommonly in#parathyroid adenomas,Cancer Association,CDKN2C,-,Parathyroid adenomas,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
435,KP7,21597717,"Cyclin-dependent protein kinases (CDKs)#are regulated by#subunit composition, involving cyclins and negative effectors like p21, p16, and p27",Regulation,"CDK1,CDK2,CDK4,CDK6,CDKN1A,CDKN2A,CDKN1B",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
2309,KP7,22710759,Tob1#decreases#phosphorylation of Akt and GSK3β,Signaling Networks,"AKT1,GSK3B",-,-,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.2,-,反馈调节
3242,KP7,22710759,"Tob1#reduces#expression of cyclin D1, CDK4, uPAR, and PPARγ",Regulation,"CCND1,CDK4,PLAUR,PPARG",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
1415,KP7,20473331,G1 to S cell-cycle regulators#are decreased by#an unspecified effect,Cell Cycle Control,"CCND1,CDK4",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
2948,KP7,29705383,Endosulfan#induces#G1 cell cycle arrest,Cell Cycle Control,"CDK6,CDKN1A",-,-,Endosulfan,-,-,-,"downregulated (CDK6), upregulated (p21)",-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
2613,KP7,29705383,Endosulfan#downregulates#CDK6,Regulation,CDK6,-,-,Endosulfan,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.2,-,Cyclin D-CDK6复合物
1259,KP7,29705383,Endosulfan#upregulates#p21,Regulation,CDKN1A,-,-,Endosulfan,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6748,KP7,12203371,"KT#elevates#p53, p21, and p27 protein levels",Regulation,"TP53,CDKN1A,CDKN1B",-,-,KT,-,-,-,upregulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
3797,KP7,12203371,KT#inhibits#cyclin D3 and CDK4 protein expression,Regulation,"CCND3,CDK4",-,-,KT,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
7177,KP7,30235878,GAA#inhibits#myoblast proliferation,Cell Cycle Control,"CCND1,CDK4,CDKN1A",Myoblasts,-,GAA,-,-,-,"downregulated (CCND1, CDK4), upregulated (p21)",-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
7568,KP7,31477350,Cyclin-dependent kinase (CDK) inhibitors#are used as#anticancer drugs,Drug Development,"CDK1,CDK2,CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7329,KP7,31477350,Cyclin-dependent kinases (CDKs)#control#critical cell cycle checkpoints and transcriptional events,Cell Cycle Control,"CDK1,CDK2,CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7208,KP7,36838737,Luteoloside#induces#G0/G1 phase arrest in neuroblastoma cells,Cell Cycle Control,MAPK14,Neuroblastoma cells,Neuroblastoma,Luteoloside,p38 MAPK,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
3940,KP7,36838737,SB203580#inhibits#p38 MAPK,Drug Development,MAPK14,-,-,SB203580,p38 MAPK,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
6209,KP7,36838737,p38 MAPK#is targeted by#Luteoloside,Mechanism of Action,MAPK14,Neuroblastoma cells,Neuroblastoma,Luteoloside,p38 MAPK,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.3,-,p38通路交互
2675,KP7,36838737,Inhibition of p38 MAPK#reverses#the inhibitory effect of Luteoloside on neuroblastoma cells,Mechanism of Action,MAPK14,Neuroblastoma cells,Neuroblastoma,Luteoloside,p38 MAPK,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.3,-,p38通路交互
4712,KP7,36838737,Luteoloside#activates#p38 MAPK,Mechanism of Action,MAPK14,Neuroblastoma cells,Neuroblastoma,Luteoloside,p38 MAPK,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.3,-,p38通路交互
4455,KP7,7937935,HMBA#decreases#CDK4 expression,Regulation,CDK4,-,-,HMBA,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
5972,KP7,7937935,HMBA#inhibits#phosphorylation of retinoblastoma protein (pRB),Mechanism of Action,RB1,-,-,HMBA,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
1466,KP7,23992640,BKCa and IP3R3 silencing#decreases#cyclin D1 and CDK4 expression levels,Regulation,"CDK4,CCND1",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
6660,KP7,37456160,"Western blotting#assesses#protein expression levels of CDK4, CDK8, and cyclin D1",Expression Patterns,"CDK4,CDK8,CCND1",-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,Cyclin D1表达
290,KP7,20664182,"INK4 family genes (P15, P16, P18)#are upregulated in#cell cycle",Regulation,"CDKN2B,CDKN2A,CDKN2C",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
4200,KP7,20664182,Cyclin D1 and HDAC1#are downregulated in#cell cycle,Regulation,"CCND1,HDAC1",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3456,KP7,27878292,"BMI-1#enhances#cyclin D1, CDK4, and Bcl-2 expression",Regulation,"CCND1,CDK4,BCL2",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3404,KP7,27035431,Artemisinin#induces#p16 expression,Regulation,CDKN2A,-,-,Artemisinin,-,-,-,upregulated,-,-,-,Fact,1,1.1.3,1.1.3.3,-,-,增殖抑制
1801,KP7,27035431,"Artemisinin#downregulates#phosphorylated ERK1/2, CDK4, and cyclin D1 expression",Regulation,"CDK4,CCND1,MAPK3,MAPK1",-,-,Artemisinin,ERK1/2,-,-,downregulated,-,-,-,Fact,1,1.3.2,1.3.2.1,-,-,RAS/RAF/MEK/ERK级联
5152,KP7,25191523,Smurf2 siRNA#decreases#cyclin D1 and CDK4 expression,Regulation,"CCND1,CDK4",-,-,Smurf2 siRNA,-,-,-,downregulated,-,-,-,Fact,1,1.1.2,1.1.2.3,-,-,复合物活性调节
6707,KP7,25191523,Smurf2 siRNA#upregulates#p21 and p27 expression,Regulation,"CDKN1A,CDKN1B",-,-,Smurf2 siRNA,-,-,-,upregulated,-,-,-,Fact,1,1.1.3,1.1.3.3,-,-,增殖抑制
2055,KP7,12653665,CDK4#is found in#a complex containing free S6 ATPase,Protein Complex Dynamics,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1.2,1.1.2.1,-,-,Cyclin D-CDK4复合物
2180,KP7,12653665,Gankyrin overexpression#phosphorylates#retinoblastoma protein (pRb),Regulation,RB1,-,Hepatocellular carcinoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.1.1,1.1.1.1,-,-,RB蛋白磷酸化
1885,KP7,12653665,Gankyrin#releases#E2F transcription factor,Mechanism of Action,"RB1,E2F1",-,Hepatocellular carcinoma,-,-,-,-,-,-,-,-,Fact,1,1.1.1,1.1.1.2,-,-,E2F转录因子释放
1969,KP7,24033428,SAHA treatment#decreases#expression of CDKs and cyclins,Regulation,"CDK2,CDK4,CDK6,CCND1",-,Esophageal squamous cell carcinoma,SAHA,-,-,-,downregulated,-,-,-,Fact,1,1.1.2,1.1.2.3,-,-,复合物活性调节
2919,KP7,24033428,"SAHA treatment#increases#expression of p21, p27, and Rb",Regulation,"CDKN1A,CDKN1B,RB1",-,Esophageal squamous cell carcinoma,SAHA,-,-,-,upregulated,-,-,-,Fact,1,1.1.3,1.1.3.3,-,-,增殖抑制
2749,KP7,38385108,Rapamycin#exerted#antitumor effects by inhibiting mTOR/p70-S6k pathway,Cancer Pathways,"MTOR,RPS6KB1",-,Tumor,Rapamycin,mTOR/p70-S6k,-,-,-,-,-,-,Inference,1,1.3,1.3.1,1.3.1.3,-,协同效应
5611,KP7,12145988,Mutations in signal transduction molecules#are involved in#development of leukemia,Cancer Pathways,-,-,Leukemia,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
7325,KP7,12145988,RAS GTP-binding protein mutations#are found in#malignant tumors including hematopoietic tumors,Cancer Pathways,RAS,-,Hematopoietic tumors,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
1491,KP7,12145988,Mutations or deletions of tumor suppressor genes#are frequently found in#cell cycle regulators,Cancer Pathways,"TP53,RB1,CDKN2A",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.2,-,RB1缺失
6462,KP7,12145988,Mutations in signal transduction pathways#molecules contribute to#neoplastic transformation of hematopoietic cells,Cancer Pathways,-,-,Hematopoietic transformation,-,-,-,-,-,-,-,-,Inference,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
5014,KP7,34176404,Cyclin-dependent kinase inhibitors#are used in#treatment of cancer,Drug Development,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2137,KP7,34176404,CDKs#control#transition between cell cycle phases,Cell Cycle Control,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
22,KP7,34176404,Aberrant CDK activation#is common in#cancer,Cancer Association,"CDK4,CDK6",-,Cancer,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3350,KP7,34176404,CDK inhibitors#stem#proliferation of cancer cells,Therapeutic Response,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7203,KP7,34176404,Resistance to CDK inhibitors#remains#an issue,Therapeutic Resistance,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.2,2.5.2.3,-,个体化方案
2920,KP7,34176404,Biomarkers to predict CDK inhibitor therapy response#are#limited,Biomarker Analysis,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,-,ESR1突变
4219,KP7,24300090,Oncostatin M#inhibits#proliferation of solid tumor cell lines,Therapeutic Response,-,-,Solid tumors,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4684,KP7,24300090,IL-24 and OSM coexpression#induced#growth suppression and apoptosis,Therapeutic Response,"IL24,OSM",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
1977,KP7,24300090,"IL-24 and OSM coexpression#upregulated#p21, p53, Bax, and cleaved caspase-3",Expression Patterns,"CDKN1A,TP53,BAX,CASP3",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3425,KP7,24300090,Ad-IL-24-OSM treatment#reduced#expression of CDK4 and cyclin D1,Expression Patterns,"CDK4,CCND1",-,Melanoma,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
7526,KP7,24300090,Ad-IL-24-OSM treatment#reduced#expression of CD34 and Cox-2 in xenograft tumors,Expression Patterns,"CD34,PTGS2",-,Melanoma,-,-,-,-,downregulated,-,-,-,Fact,6,6.5,6.5.1,6.5.1.1,-,胶原蛋白
3093,KP7,24300090,Ad-IL-24-OSM#inhibited#tumor angiogenesis,Cancer Pathways,"IL24,OSM",-,Cancer,-,-,-,-,-,-,-,-,Fact,6,6.2,6.2.1,6.2.1.1,-,VEGF信号通路
7426,KP7,24300090,Cancer gene therapy combining IL-24 and OSM#constitutes#a novel therapeutic strategy,Therapeutic Development,"IL24,OSM",-,Cancer,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
6023,KP7,20210794,"Rosiglitazone#decreased#protein levels of Cdk4, cyclin D1, cyclin D2, and PCNA",Expression Patterns,"CDK4,CCND1,CCND2,PCNA",-,-,Rosiglitazone,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
4574,KP7,20210794,Rosiglitazone#increased#protein levels of p21 and p27,Expression Patterns,"CDKN1A,CDKN1B",-,-,Rosiglitazone,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
760,KP7,37894738,"Notopterol#inhibited#the expression of cyclin D1, cyclin E, CDK4, and E2F",Regulation,"CDK4,E2F,CCND1,CCNE",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7029,KP7,37061333,"Dysregulated cell division#is associated with#cancer and mutations in cyclins, CDKs, and tumor suppressor proteins",Cancer Association,CDK,-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
213,KP7,37061333,Cyclin-dependent kinases (CDKs)#are overexpressed in#many cancers,Expression Patterns,CDK,-,Cancer,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
3582,KP7,37061333,Oncogenesis#occurs by#overactivity of different CDKs impacting cell cycle progression and checkpoint dysregulation,Cancer Pathways,CDK,-,Tumor,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7176,KP7,9355981,"Progression through the mammalian cell cycle#is controlled by#a series of cyclins, cyclin-dependent kinases (CDKs), and CDK inhibitors",Cell Cycle Control,CDK,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
5524,KP7,19480713,"ChM1#decreased#the levels of cyclin D1, cyclin D3, and CDK6 and increased those of p21cip1",Regulation,"CDK6,CCND1,CCND3,CDKN1A",-,Hepatocellular carcinoma,-,-,-,-,"downregulated, upregulated",-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
6073,KP7,29048616,"RACK1#upregulates#the expression of NF-魏B, cyclin D1, and CDK4",Regulation,"CDK4,CCND1,NFKB1",-,Cervical cancer,-,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
1070,KP7,25168062,Decreased cyclin D1 and CDK4 expression#is associated with#reduced numbers of cells entering S phase,Expression Patterns,"CDK4,CCND1",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6045,KP7,24231788,"EESB treatment#suppresses#the activation of STAT3, Erk, and p38 signaling pathways and alters the expression of Cyclin D1, CDK4, and p21",Regulation,"CDK4,CCND1,CDKN1A",-,Colorectal cancer,EESB,"STAT3,Erk,p38",-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
2617,KP8,33535617,FGFR overexpression and/or hyperactivation#correlates with#CDK4/6 inhibitor resistance and shortened PFS in BC,Mechanisms of Resistance,"CDK4,CDK6,FGFR",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
4435,KP8,26500059,CDK6#is involved in#transcription in tumor cells and hematopoietic stem cells,Molecular Functions,CDK6,Hematopoietic stem cells,Tumor,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
6583,KP8,34654798,"Palbociclib-resistant RAS(MUT) colorectal cancer cells#showed increased#expression of p27(kip1), cyclin D, CDK4, and CDK6",Mechanisms of Resistance,"CDK4,CDK6,CDKN1B,CCND1",-,Colorectal cancer,Palbociclib,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
1796,KP8,34654798,Src inhibitors#re-sensitized#Palbociclib-resistant cells to Palbociclib,Therapeutic Response,SRC,-,Colorectal cancer,"Src inhibitors,Palbociclib",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
6085,KP8,28349562,PTEN#is one of#the most frequently mutated genes in human cancers,Cancer Association,PTEN,-,Cancer,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
2853,KP8,28349562,"Loss of PTEN#promotes#the accumulation of cyclin D1-CDK4/6 complexes, a feature of the tumor phenotype",Cancer Pathways,"PTEN,CDK4,CDK6,CCND1",-,Tumor,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7398,KP8,28349562,Palbociclib treatment#increased#survival of Pten-deficient mice,Therapeutic Response,"CDKN2A,PTEN",-,Tumor,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7298,KP8,28349562,Palbociclib treatment#reduced#tumor cell proliferation,Therapeutic Response,"CDKN2A,PTEN",-,Tumor,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3846,KP8,9328469,Germline mutations in CDKN2#underlie#susceptibility in melanoma families,Cancer Association,"CDKN2,CDK4",-,Melanoma,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
7594,KP8,10777219,CDKN2A#inhibits#CDK4 and CDK6,Regulation,"CDKN2A,CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
6222,KP8,31207004,Palbociclib#was analyzed in#CMT cell lines with CDK4/6 co-expression,Preclinical Models,"CDK4,CDK6",CMT cell lines,-,Palbociclib,-,-,co-expression,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6206,KP8,31207004,Palbociclib treatment#induced#cell cycle arrest in CMT cells,Therapeutic Response,"CDK4,CDK6",CMT cells,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2358,KP8,31207004,Palbociclib treatment#impaired#cell migration activity,Therapeutic Response,"CDK4,CDK6",CMT cells,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1167,KP8,31207004,CDK6#was consistently expressed in#canine mammary carcinoma types,Expression Patterns,CDK6,-,Canine mammary carcinoma,-,-,-,consistent,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
7265,KP8,31207004,Phosphorylated pRb#showed#tumor-specific expression pattern,Expression Patterns,RB1,-,Canine mammary carcinoma,-,-,-,tumor-specific,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.4,RB蛋白表达
3667,KP8,27099147,Mutations#are associated with#a poor prognosis,Cancer Association,-,-,-,-,-,Poor prognosis,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,7.2.1.2.4,炎症因子水平
1613,KP8,27099147,Mutations#are associated with#a high propensity to relapse,Cancer Association,-,-,-,-,-,High propensity to relapse,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,7.2.1.2.4,炎症因子水平
3209,KP8,27099147,CDK6#is found at#promoters of FLT3 and PIM1 genes,Regulation,"CDK6,FLT3,PIM1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
6107,KP8,27099147,CDK6#regulates#transcription in FLT3-mutant cells,Mechanism of Action,"CDK6,FLT3",-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
2087,KP8,27099147,CDK6#regulates#transcription in a kinase-dependent manner,Mechanism of Action,CDK6,-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
3988,KP8,22493355,CDK6#gains were associated with#biallelic 9p21 deletions,Cancer Association,CDK6,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3648,KP8,33732653,MAP kinase pathway#is activated in#cell cycle disturbances,Pathway & Network Categories,MAPK,-,-,-,MAP kinase pathway,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
4801,KP8,35373292,Inhibition of phosphorylation of p73#is a#key mechanism of action of these drugs,Mechanism of Action,TP73,-,-,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
7881,KP8,25876993,Therapeutic inhibition of CDKs#negates#evasion of growth suppressors in tumors,Cancer Pathways,"CDK4,CDK6",-,Tumor,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
4984,KP8,25876993,"Palbociclib, Ribociclib, and Abemaciclib#are#highly selective CDK4/6 inhibitors",Drug Development,"CDK4,CDK6",-,Breast cancer,"Palbociclib,Ribociclib,Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2731,KP8,10922411,CDKN2A and CDK4 mutations#confer#susceptibility to cutaneous malignant melanoma,Cancer Association,"CDKN2A,CDK4",-,Cutaneous malignant melanoma,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,RB1突变
6843,KP8,39667501,Downregulation of NSRP1#confers#resistance to CDK4/6 inhibitors,Mechanism of Action,"NSRP1,CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,IFN signaling,-,downregulated,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
5502,KP8,39667501,Activation of IFN signaling pathway#drives#intrinsic and acquired CDK4/6i resistance,Mechanism of Action,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,IFN signaling,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
2033,KP8,39667501,NSRP1#mediates#alternative splicing of NSD2 mRNA and activation of the IFN signaling pathway,Mechanism of Action,"NSRP1,NSD2",-,Breast cancer,-,IFN signaling,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
267,KP8,39667501,NSRP1 knockdown#reduces#palbociclib sensitivity in MCF7 cells,Drug Development,NSRP1,-,Breast cancer,Palbociclib,-,-,-,downregulated,-,-,-,Fact,2,2.5,2.5.2,2.5.2.2,-,给药策略改进
982,KP8,39667501,NSRP1 knockdown#activates#IFN signaling pathway and elevates expression of IRPS genes,Mechanism of Action,NSRP1,-,Breast cancer,Palbociclib,IFN signaling,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
1477,KP8,39667501,NSRP1#regulates#alternative splicing events in breast cancer cells,Mechanism of Action,NSRP1,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
1230,KP8,39667501,Inclusion of NSD2 exon 2#is elevated#upon NSRP1 knockdown,Mechanism of Action,"NSRP1,NSD2",-,Breast cancer,-,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
994,KP8,39667501,Inclusion of NSD2 exon 2#is associated with#poor prognosis in breast cancer,Cancer Association,NSD2,-,Breast cancer,-,-,Poor prognosis,upregulated,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
932,KP8,39667501,NSRP1#regulates#IFN signaling pathway and CDK4/6i resistance,Mechanism of Action,"NSRP1,CDK4,CDK6",-,Breast cancer,-,IFN signaling,-,-,Biomarker,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
1880,KP8,35149588,CDK4/6 inhibition#activates#DR5 and potentiates chemotherapy and immune checkpoint blockade,Therapeutic Response,"CDK4,CDK6,DR5",-,Breast cancer,-,Extrinsic apoptotic pathway,-,-,Biomarker,-,-,-,Fact,3,3.1,3.1.3,3.1.3.2,-,死亡受体通路激活
3312,KP8,35149588,Targeting CDK4 and CDK6#is#a successful therapeutic approach for breast and solid tumors,Drug Development,"CDK4,CDK6",-,"Breast cancer, Solid tumors",-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7887,KP8,35149588,CDK4/6 inhibition#halts#cell cycle progression and promotes antitumor immunity,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,-,-,-,downregulated,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1463,KP8,35149588,CDK4/6#bind and phosphorylate#p73 at threonine 86,Mechanism of Action,"CDK4,CDK6,TP73",-,Breast cancer,-,-,-,upregulated,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
113,KP8,35149588,CDK4/6 inhibition#induces#dephosphorylation and nuclear translocation of p73,Mechanism of Action,"CDK4,CDK6,TP73",-,Breast cancer,-,Extrinsic apoptotic pathway,-,downregulated,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.2,-,死亡受体通路激活
3590,KP8,35149588,"Deletion of DR5#abrogates#effects of CDK4/6 inhibitors on TRAIL, chemotherapy, and immunotherapy",Mechanism of Action,"DR5,CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.2,-,死亡受体通路激活
4058,KP8,35149588,CDK4/6 inhibition#potentiates#killing and immunogenic effects on cancer cells,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,-,-,-,downregulated,-,-,-,-,Inference,3,3.1,3.1.3,3.1.3.2,-,死亡受体通路激活
4807,KP8,36877344,Deregulation of CDKs and CKIs#is#a hallmark of cancer cells,Cancer Association,"CDK4,CDK6",-,Cancer,-,-,-,upregulated,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
187,KP8,36877344,Abemaciclib#inhibits#CDK4 and CDK6 in ATC cell lines,Drug Development,"CDK4,CDK6",-,Anaplastic thyroid cancer,Abemaciclib,-,-,downregulated,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
275,KP8,36877344,Abemaciclib#inhibits#cell proliferation and increases apoptosis in ATC cell lines,Therapeutic Response,"CDK4,CDK6",-,Anaplastic thyroid cancer,Abemaciclib,-,-,downregulated,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4915,KP8,27470964,CDK4 and CDK6 expression#is determined by#real-time PCR in PDGF-BB-treated VSMCs,Technical Methods,"CDK4,CDK6",-,-,-,MAPK signaling,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
6534,KP8,27470964,PDGF-BB#induces#VSMCs proliferation,Cell Cycle Control,PDGFB,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
1860,KP8,27470964,AST#reverses#PDGF-BB-induced VSMCs proliferation,Cell Cycle Control,PDGFB,-,-,AST,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
646,KP8,27470964,AST#reduces#percentages of cells in S phase in PDGF-BB-stimulated VSMCs,Cell Cycle Control,PDGFB,-,-,AST,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
5320,KP8,27470964,AST#increases#G0/G1 populations in PDGF-BB-stimulated VSMCs,Cell Cycle Control,PDGFB,-,-,AST,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
1970,KP8,27470964,"PDGF-BB#upregulates#mRNA expression of CDK6, CDK4, cyclin D1, cyclin E",Expression Patterns,"CDK6,CDK4,CCND1,CCNE1",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
1623,KP8,27470964,PDGF-BB#downregulates#p21 mRNA expression,Expression Patterns,CDKN1A,-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
1840,KP8,27470964,AST#reverses#PDGF-BB-induced changes in mRNA expression,Regulation,"CDK6,CDK4,CCND1,CCNE1,CDKN1A",-,-,AST,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
513,KP8,33072436,9za#arrests#cell cycle at G0/G1 phase,Cell Cycle Control,"CDK4,CDK6,CCND1",-,-,9za,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6747,KP8,33072436,"9za#downregulates#Cyclin D1, CDK4, and CDK6 protein expression",Expression Patterns,"CDK4,CDK6,CCND1",-,-,9za,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
4938,KP8,22888541,CDK6 gene#responds to#multiple environmental stresses,Environmental Factors,CDK6,-,-,-,-,-,-,-,-,multiple environmental stresses,-,Fact,6,6.4,6.4.1,6.4.1.1,6.4.1.1.4,IFN-γ
4304,KP8,22888541,CDKs#play#critical roles in cell cycle regulation,Cell Cycle Control,"CDK6,CDK4",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
3287,KP8,22888541,AccCDK6#participates in#intracellular reactions of ROS and development processes in honey-bees,Metabolic Integration,CDK6,-,-,-,-,-,-,-,-,-,ROS,Fact,4,4.3,4.3.1,4.3.1.1,-,线粒体ROS产生
5456,KP8,34388663,cis- or trans-nerolidol#inhibits#cell proliferation in a dose-dependent manner,Cell Cycle Control,"CDK4,CDK6,CCND1",-,-,"cis-nerolidol,trans-nerolidol",-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7756,KP8,34388663,cis- or trans-nerolidol#induces#cell cycle arrest in the G1 phase,Cell Cycle Control,"CDK4,CDK6,CCND1",-,-,"cis-nerolidol,trans-nerolidol",-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
2429,KP8,34388663,"cis- or trans-nerolidol#downregulates#Cyclin D1, CDK4, and CDK6 protein expression",Expression Patterns,"CDK4,CDK6,CCND1",-,-,"cis-nerolidol,trans-nerolidol",-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6978,KP8,8595411,"CDKN2A and CDKN2B#are frequently deleted in#primary human tumors, including esophageal carcinoma",Cancer Association,"CDKN2A,CDKN2B",-,Esophageal carcinoma,-,-,-,-,deleted,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
6355,KP8,8595411,CDKN2A and CDKN2B#inhibit#CDK4 and CDK6,Mechanism of Action,"CDKN2A,CDKN2B,CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
1053,KP8,8595411,CDKN2A and CDKN2B#prevent#entry into S phase of the cell cycle,Cell Cycle Control,"CDKN2A,CDKN2B",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
1656,KP8,12894891,p16 and p15#inhibit#Cyclin D-CDK4 and Cyclin D-CDK6 complexes,Mechanism of Action,"CDKN2A,CDKN2B,CDK4,CDK6,CCND1",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7354,KP8,12894891,"p16 and p15#are implicated in#variety of cancer types, including familial melanoma",Cancer Association,"CDKN2A,CDKN2B",-,Familial melanoma,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
6126,KP8,12894891,p16 and p15 gene deletions#are found in#a subset of retinoblastoma and osteosarcoma without Rb gene mutations,Cancer Association,"CDKN2A,CDKN2B,RB1",-,"Retinoblastoma, Osteosarcoma",-,-,-,deleted,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
7797,KP8,38462928,Pinocembrin#arrests#HCC cell cycle at G1 phase,Cell Cycle Control,"CDK4,CDK6,CCND1",-,Hepatocellular carcinoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
1497,KP8,38462928,Pinocembrin#suppresses#STAT3 phosphorylation at Tyr705 and Ser727,Mechanism of Action,STAT3,-,Hepatocellular carcinoma,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
6454,KP8,38462928,Pinocembrin#inhibits#HCC cell growth via suppressing STAT3 signaling pathways,Mechanism of Action,STAT3,-,Hepatocellular carcinoma,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
155,KP8,7585567,p16INK4a and p15INK4b#bind to and inhibit#Cyclin D-dependent kinases CDK4 and CDK6,Mechanism of Action,"CDKN2A,CDKN2B,CDK4,CDK6,CCND1",-,Skin tumors,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6582,KP8,32391377,High mutation load#is explained by#high frequency of mutations and expression of DNA double-strand break repair pathway genes,Genomic Instability,DNA repair genes,-,-,-,-,-,high,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.4,-,DNA合成修复
49,KP8,32071145,Transcription-associated CDKs#are targets and biomarkers for#cancer therapy,Biomarker Analysis,"CDK7,CDK8,CDK9,CDK12,CDK13",-,Cancer,-,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.4,-,PIK3CA突变
947,KP8,32071145,Drugs targeting CDK4 and CDK6#are approved for#treatment of hormone receptor-positive breast cancer,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
7072,KP8,32071145,Transcription-associated CDKs#regulate#gene expression,Mechanism of Action,"CDK7,CDK8,CDK9,CDK12,CDK13",-,-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
7919,KP8,32071145,"CDKs#regulate#epigenetic modifications, intronic polyadenylation, DNA-damage responses, and genomic stability",Function triples,"CDK4, CDK6",-,-,-,DNA-damage responses,-,-,-,-,-,-,Fact,5,5.6,5.6.3,5.6.3.4,-,转录调控
645,KP8,32071145,Transcriptional CDKs#serve as#biomarkers and therapeutic targets,Biomarker Analysis,-,-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.3,-,ESR1融合
5477,KP8,32071145,CDK inhibitors#target#CDK4 and CDK6 in hormone receptor-positive breast cancer,Drug Development,"CDK4, CDK6",-,Breast cancer,CDK inhibitors,Cell cycle control,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2711,KP8,32071145,Inhibiting transcription-associated CDKs#provides#therapeutic opportunities and vulnerabilities,Therapeutic Development,"CDK4, CDK6",-,Tumors,PARP inhibitors,Transcription regulation,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
4826,KP8,14645011,p18INK4c#is silenced by#promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas,Regulation,CDKN2C,Reed-Sternberg cells,Hodgkin lymphomas,-,Rb-kinase activity,-,Silenced,-,-,-,-,Fact,1,1.5,1.5.1,1.5.1.2,-,DNA甲基化
6396,KP8,14645011,p18INK4c#functions as#a tumor suppressor gene in HL,Cancer Association,CDKN2C,Reed-Sternberg cells,Hodgkin lymphomas,-,Cell cycle deregulation,-,-,-,-,-,-,Inference,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
1422,KP8,28092667,"MAPK, cell cycle, and PI3K-mTOR pathways#were frequently#mutated",Pathway Alterations,-,-,-,-,"MAPK, cell cycle, PI3K-mTOR",-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
7894,KP8,28092667,Combination of trametinib and BKM120 or LEE011#yielded#additive anti-tumor effects in BRAF fusion melanoma cells,Combination Therapies,BRAF,Melanoma cells,Melanoma,"Trametinib, BKM120, LEE011",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
1134,KP8,28586006,"Butein#downregulated#the protein expression of CDK4, CDK6, cyclin D1, cyclin D2, cyclin E, survivin, XIAP, c-IAP2, and phospho-pRb",Regulation,"CDK4, CDK6, CCND1, CCND2, CCNE1, XIAP",-,-,Butein,-,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
4236,KP8,30897301,MicroRNA-26a#inhibits#MM cell growth by suppressing CDK6 expression,Mechanism of Action,CDK6,MM cells,Multiple myeloma,-,-,-,-,Downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.3,-,非编码RNA调控
5863,KP8,30897301,Overexpression of miR-26a#induced#cell cycle arrest at G0/G1 phase in MM cells,Cell Cycle Control,-,MM cells,Multiple myeloma,-,-,-,-,Upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
5392,KP8,30897301,MiR-26a#regulated#CDK6 signaling pathway in MM,Pathway Regulation,CDK6,-,Multiple myeloma,-,CDK6 signaling pathway,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.3,-,非编码RNA调控
2209,KP8,32911343,SNHG17#regulates#CDK6 in ovarian cancer,Mechanism of Action,CDK6,-,Ovarian cancer,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.3,-,非编码RNA调控
333,KP8,32911343,SNHG17#is highly expressed in#multiple OC cohorts,Expression Patterns,-,-,Ovarian cancer,-,-,-,-,Upregulated,-,-,-,Fact,1,1.5,1.5.3,1.5.3.1,-,长链非编码RNA
7860,KP8,32911343,SNHG17#is overexpressed in#OC,Expression Patterns,SNHG17,-,OC,-,-,-,-,Upregulated,-,-,-,Fact,1,1.5,1.5.3,1.5.3.1,-,长链非编码RNA
1260,KP8,32911343,STAT3#promotes#SNHG17 expression,Regulation,STAT3,-,OC,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
2589,KP8,32911343,SNHG17#regulates#CDK6 expression,Cell Cycle Control,"SNHG17,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.3,-,非编码RNA调控
7836,KP8,32911343,SNHG17#acts as#a molecular sponge for miR-214-3p,RNA Regulation,"SNHG17,miR-214-3p",-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.3,-,非编码RNA调控
1573,KP8,32911343,SNHG17#acts as#an oncogene in OC,Cancer Association,SNHG17,-,OC,-,-,-,-,-,-,-,-,Inference,1,1.6,1.6.2,1.6.2.3,-,分化阻滞
1478,KP8,32911343,SNHG17#might serve as#a novel target for OC diagnosis and therapy,Clinical Implementation,SNHG17,-,OC,-,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
6806,KP8,19737942,MDM2 and HMGA2#are consistently amplified in#WDLPS/DDLPS,Cancer Association,"MDM2,HMGA2",-,"WDLPS,DDLPS",-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
6377,KP8,19737942,CDK4#is frequently amplified in#WDLPS/DDLPS,Cancer Association,CDK4,-,"WDLPS,DDLPS",-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1547,KP8,19737942,Genomic aberrations#compensate for#lack of CDK4 amplification,Cancer Pathways,"CDK4,RB1,CDKN2A,CCND1",-,"WDLPS,DDLPS",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.3,5.3.3.2,-,信号通路影响
4757,KP8,19737942,P16INK4a and CCND1#are overexpressed in#WDLPS/DDLPS,Expression Patterns,"CDKN2A,CCND1",-,"WDLPS,DDLPS",-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
7977,KP8,19737942,RB1#is downregulated in#WDLPS/DDLPS,Expression Patterns,RB1,-,"WDLPS,DDLPS",-,-,-,-,downregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.4,RB蛋白表达
7572,KP8,19737942,RB and p53 pathways#are regulated in#WDLPS/DDLPS,Regulation,"RB1,TP53",-,"WDLPS,DDLPS",-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
4704,KP8,19737942,"CDK4 amplification#acts as#a ""MDM2-HMGA2-helper"" in WDLPS/DDLPS tumorigenesis",Cancer Pathways,"CDK4,MDM2,HMGA2",-,"WDLPS,DDLPS",-,-,-,-,-,-,-,-,Inference,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7978,KP8,22932448,CDK4 and cyclin D1#govern#cell cycle progression through G1 phase,Cell Cycle Control,"CDK4,CCND1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
523,KP8,21528331,CDK4 and p16(INK4)#are frequently anomalous in#human gliomas and other cancers,Cancer Association,"CDK4,CDKN2A",-,"gliomas, cancers",-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5774,KP8,32541838,Inhibiting CDK4/6#is#an attractive therapeutic strategy,Therapeutic Development,"CDK4,CDK6",-,cancer,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2577,KP8,26252490,CDK4-cyclin D1 complex#plays a crucial role in#G1 to S phase transition,Cell Cycle Control,"CDK4,CCND1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
4901,KP8,26252490,CDK4#is frequently affected by#somatic genetic variations in cancer,Cancer Association,CDK4,-,cancer,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1331,KP8,9703873,"CDK4 amplification#is shown in#human neoplasms, including bone and soft tissue tumors",Cancer Association,CDK4,-,"neoplasms, bone tumor, soft tissue tumor",-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
6305,KP8,9703873,CDK4 amplification#is related to#RB gene mutations in osteosarcomas,Cancer Pathways,"CDK4,RB1",-,osteosarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5530,KP8,9703873,CDK4 amplification#coexists with#loss of RB protein expression in osteosarcomas,Cancer Pathways,"CDK4,RB1",-,osteosarcoma,-,-,-,-,downregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
4357,KP8,9703873,CDK4 amplification#may have#roles beyond RB inactivation in osteosarcomas,Cancer Pathways,"CDK4,RB1",-,osteosarcoma,-,-,-,-,-,-,-,-,Inference,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
4189,KP8,11606789,D-type cyclins#are overexpressed in#mutations,Expression Patterns,CCND1,-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
2604,KP8,11606789,INK4 inhibitors#are inactivated in#mutations,Expression Patterns,"CDKN2A,CDKN2B",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7843,KP8,27488531,Aberrant cell-cycle progression#is a hallmark feature of#cancer cells,Cancer Association,-,cancer cells,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7375,KP8,27488531,CDK4/6#drive#progression through the G1 stage of the cell cycle,Cell Cycle Control,"CDK4,CDK6",-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
5623,KP8,27488531,CDK4/6#inactivate#tumor suppressor retinoblastoma,Mechanism of Action,"CDK4,CDK6",Retinoblastoma,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
7379,KP8,27488531,NRAS and BRAF mutations#promote#CDK4/6 activation,Cancer Pathways,"NRAS,BRAF,CDK4,CDK6",-,Melanoma,"Palbociclib,BRAF inhibitors,MEK inhibitors",-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
6,KP8,27488531,Palbociclib#provides#therapeutic benefit in combination with BRAF inhibitors and/or MEK inhibitors,Combination Optimization,"CDK4,CDK6",-,Melanoma,"Palbociclib,BRAF inhibitors,MEK inhibitors",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
521,KP8,27488531,CDK4/6 inhibitors#affect#antiapoptotic protein expression,Therapeutic Response,"CDK4,CDK6",-,Melanoma,"CDK4/6 inhibitors,MEK inhibitors",-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
5177,KP8,27488531,CDK4/6 inhibitors#inhibit#melanoma xenograft growth,Preclinical Models,"CDK4,CDK6",-,Melanoma,"CDK4/6 inhibitors,MEK inhibitors",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
130,KP8,9600204,CDKN2A#is deleted in#48% of cases,Cancer Association,CDKN2A,-,Cancer,-,-,-,-,downregulated,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
52,KP8,36453028,Palbociclib#inhibits#proliferation of 23 cell lines,Preclinical Models,"CDK4,CDK6",-,MPM,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3859,KP8,36453028,CDK4/6 inhibition#induces#senescence-associated secretory phenotype,Cell Cycle Control,"CDK4,CDK6",-,MPM,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.2,-,衰老相关分泌表型
4371,KP8,36453028,Phosphorylated CDK4#indicates#sensitivity to CDK4/6 inhibitors,Biomarker Analysis,CDK4,-,MPM,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,7.3.1.1.2,pRB水平
1215,KP8,37886470,CDK4/6#play#pivotal role in cell cycle and cancer development,Cancer Association,"CDK4,CDK6",-,Cancer,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
7206,KP8,37886470,MITF#is activated in#tumors resistant to palbociclib,Mechanisms of Resistance,MITF,-,Cancer,Palbociclib,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
2632,KP8,37886470,Palbociclib resistance#requires#novel therapeutic approaches,Therapeutic Resistance,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
3313,KP8,9815774,CDK4#mRNA is overexpressed in#tumors,Expression Patterns,CDK4,-,Cancer,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
976,KP8,28704762,CDKN2A/ARF#is deleted in#70% of MPM cases,Cancer Association,"CDKN2A,CDKN2B",-,MPM,-,-,-,-,downregulated,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
7077,KP8,32373071,CDK4#is a therapeutic target for#selected adrenocortical carcinoma patients,Personalized Medicine,CDK4,-,Adrenocortical carcinoma,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2488,KP8,32373071,Adrenocortical carcinomas (ACC)#are#aggressive tumors with a heterogeneous prognosis and limited therapeutic options for advanced stages,Cancer Association,-,Adrenocortical carcinoma (ACC),Adrenocortical carcinoma (ACC),-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.2,5.2.2.2,-,非整倍体
7598,KP8,32373071,Cyclin-dependent kinase 4 (CDK4)#was investigated at protein level in#104 ACC samples,Expression Patterns,CDK4,-,Adrenocortical carcinoma (ACC),-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
5233,KP8,32373071,"TOP2A, IGF2, CDK1, CDK4, PLK4, and PLK1#were the most frequently overexpressed genes in#ACC samples",Expression Patterns,"TOP2A, IGF2, CDK1, CDK4, PLK4, PLK1",-,Adrenocortical carcinoma (ACC),-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
2430,KP8,32373071,Palbociclib#reduced#cell viability in NCI-H295R and MUC1 cell lines,Drug Development,CDK4,"NCI-H295R, MUC1",Adrenocortical carcinoma (ACC),Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2923,KP8,32958271,Cyclin-dependent kinases 4 and 6 (CDK4/6)#are#fundamental drivers of the cell cycle and involved in cancer progression,Cell Cycle Control,"CDK4, CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
7558,KP8,9394849,p16 and cyclin-dependent kinase 4#are expressed in#primary breast carcinomas,Expression Patterns,CDK4,-,Breast carcinoma,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
3463,KP8,9394849,p16 and CDK4#were immunolocalized in#pRB-positive and pRB-negative breast carcinomas,Biomarker Analysis,CDK4,-,Breast carcinoma,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
2915,KP8,9394849,p16 and CDK4#were expressed in#84.6% of pRB-positive and 100% of pRB-negative carcinomas,Expression Patterns,CDK4,-,Breast carcinoma,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
5062,KP8,9394849,p16 and CDK4 expression#was more heterogeneous in#larger tumors or higher-stage tumors,Expression Patterns,CDK4,-,Breast carcinoma,-,-,"Larger tumors, higher-stage tumors",-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
948,KP8,28477272,"Spindle cells#were positive for#CDK4, p16, cyclin D1, and alpha-smooth muscle actin",Biomarker Analysis,"CDK4, CCND1",-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
2337,KP8,23006472,"Spindle cells and glandular epithelium#expressed#CDK4, p53, and MDM2",Expression Patterns,"CDK4, TP53, MDM2",-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
3789,KP8,23006472,"TP53, MDM2, CDK4, and PTPN1#may be involved in#tumorigenesis",Cancer Pathways,"TP53, MDM2, CDK4, PTPN1",-,Tumor,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.1,-,-,G1/S期转换调控
4557,KP8,35779129,MDM2 and CDK4 genes#were not amplified and#RB1 locus was deleted,Genomic Alteration,"CDK4, MDM2, RB1",-,Atypical spindle cell/pleomorphic lipomatous tumor,-,-,-,Deleted,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.2,-,RB1缺失
986,KP8,25189115,"Cyclin D1, CDK4, Rb, and p16#mRNA and protein expression levels#were measured by reverse transcription PCR and western blotting",Expression Analysis,"CDK4, CCND1, RB1, CDKN2A",-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
6315,KP8,29086897,ER+ breast cancer patients#demonstrate#gain of CCND1 and CDK4,Cancer Association,"CCND1, CDK4",-,ER+ breast cancer,-,-,-,Upregulated,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
4138,KP8,29086897,CDK4#is gained in#luminal B breast cancer compared to luminal A,Cancer Association,CDK4,-,"Luminal B breast cancer, Luminal A breast cancer",-,-,-,Upregulated,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
1138,KP8,29086897,Loss of CDKN2A and CDKN2C#is correlated with#CDK4/6/RB pathway,Pathway Interaction,"CDKN2A, CDKN2C, CDK4, RB1",-,-,-,CDK4/6/RB pathway,-,Downregulated,-,-,-,-,Inference,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
3583,KP8,25550229,Constitutive activation of CDK4/6#results from#CDKN2A inactivation and CCND1 amplification,Regulation,"CDK4, CDKN2A, CCND1",-,Cancer,-,-,-,Upregulated,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
5377,KP8,25550229,Cyclin D1 overexpression#is a feature of#resistance to BRAF inhibitors,Drug Resistance,CCND1,-,Cancer,BRAF inhibitors,-,-,Upregulated,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
6208,KP8,38714024,"Expression of CDK4, Cyclin D3, and phosphorylated Rb#was analyzed by#western blotting",Expression Analysis,"CDK4, CCND3, RB1",-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
102,KP8,15951821,Rb bypass#occurs through#activating CDK4 mutations or CDK4 amplification,Cancer Pathways,"RB1, CDK4",-,-,-,-,-,Upregulated,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
7610,KP8,15951821,ARF deletion#results in#p53 pathway disruption,Pathway Interaction,"CDKN2A, TP53",-,-,-,p53 pathway,-,Deleted,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.3,-,p53功能缺失
4689,KP8,10666371,"Alterations in the Rb pathway#involve#p16 deletion, CDK4 amplification, or loss of pRb immunoreactivity",Cancer Pathways,"CDKN2A,CDK4,RB1",-,Cancer,-,-,-,-,Upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
6803,KP8,10666371,PTEN mutations#were found in#gliomatous and sarcomatous tumor components,Genomic Alteration,PTEN,-,Gliosarcoma,-,-,-,-,Mutated,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
7057,KP8,20309622,Salidroside#inhibits#cancer cell growth by modulating CDK4-cyclin D1 pathway,Mechanism of Action,"CDK4,CCND1",-,Cancer,Salidroside,CDK4-cyclin D1 pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
5834,KP8,18042149,Genomic analysis of melanoma specimens#reveals#recurrent DNA copy number aberrations and DNA methylation perturbations,Genomic Alteration,-,-,Melanoma,-,-,-,-,Aberrations,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
6931,KP8,25998154,"PDGFRA, MDM2, and CDK4 genes#are often simultaneously amplified in#IS",Cancer Association,"PDGFRA, MDM2, CDK4",-,IS,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
2645,KP8,25998154,MDM2 and CDK4 proteins#are frequently overexpressed in#IS tissue,Expression Patterns,"MDM2, CDK4",-,IS,-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
1581,KP8,12175345,Mutations of TP53 gene#were found in#one of 12 sPNETs and two of six GBMs,Cancer Association,TP53,-,"sPNET, GBM",-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
1744,KP8,12175345,Paediatric GBMs#differ from#sPNETs by higher incidence of allelic losses on 17p and TP53 mutations,Cancer Association,TP53,-,"GBM, sPNET",-,-,-,Paediatric,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
2116,KP8,23032699,Methylation at specific arginine residues of p16 protein by PRMT6#may be critical for#the activity of p16,Regulation,CDKN2A (p16),-,-,-,-,-,-,-,-,-,-,Inference,1,1.5,1.5.1,1.5.1.1,-,组蛋白修饰
5687,KP8,12234997,Corticosterone treatment#induces#KIP1/P27 expression,Regulation,CDKN1B,-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
3892,KP8,12234997,Corticosterone treatment#decreases#CDK4 and cyclin D1 protein levels,Regulation,"CDK4, CCND1",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
5423,KP8,28508842,IB-MECA treatment#induces#cell cycle arrest by affecting Cyclin D1 and CDK4 expression,Mechanism of Action,"CCND1, CDK4",-,-,IB-MECA,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7281,KP8,18558285,CDK4 and CCND2 genes#show#elevated copy number amplification on chromosome 12,Cancer Association,"CDK4, CCND2",-,-,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5171,KP8,38066633,BRAF::PTPRN2 fusion#affects#BRAF kinase domain,Molecular Event triples,BRAF,-,cancer,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.3,-,断裂点特征
4265,KP8,38066633,"Chromothripsis of chromosome 7q#results in#amplifications of CDK6, MET, and SMO",Cancer Association,"CDK6, MET, SMO",-,-,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK6扩增
2079,KP8,38066633,Elevated pERK staining#provides evidence of#activated MAPK signaling,Signaling Networks,MAPK,-,cancer,-,MAPK,-,-,upregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
6529,KP8,12484572,Genetic alterations in diffusely infiltrating cerebral gliomas#are rare or absent in#pleomorphic xanthoastrocytomas,Cancer Association,"TP53,CDKN2A,CDK4,MDM2,EGFR",-,"Diffuse cerebral glioma, pleomorphic xanthoastrocytoma",-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.2,-,缺失
1502,KP8,12484572,"Candidate genes TP53, CDKN2A, CDK4, MDM2, and EGFR#are frequently aberrant in#diffusely infiltrating astrocytic gliomas",Cancer Pathways,"TP53,CDKN2A,CDK4,MDM2,EGFR",-,Diffuse astrocytic glioma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6961,KP8,12484572,"Further analysis of PXAs#did not reveal#homozygous deletion, mutation, promoter hypermethylation, or complete loss of mRNA expression of CDKN2A, p14(ARF), and CDKN2B",Molecular Event,"CDKN2A,p14(ARF),CDKN2B",-,Pleomorphic xanthoastrocytoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
1732,KP8,12484572,Chromosomal and genetic aberrations in PXAs#are different from#those in diffusely infiltrating astrocytic and oligodendroglial gliomas,Cancer Association,"TP53,CDKN2A,CDK4,MDM2,EGFR",-,"Pleomorphic xanthoastrocytoma, diffuse astrocytic glioma, oligodendroglial glioma",-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.1,-,易位
7350,KP8,37272756,"HER2-activating mutations#frequently co-occur with#mutations in PIK3CA, TP53, or CDH1 in metastatic breast cancer",Cancer Pathways,"ERBB2,PIK3CA,TP53,CDH1",-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6191,KP8,18855578,Inhibition of Hsp90 function#has proven effective in#killing cancer cells resistant to targeted therapies,Mechanisms of Resistance,HSP90,-,Cancer,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
1828,KP8,33385409,Intracellular ROS accumulation#was found in#HLCA-treated cells,Mechanism of Action,-,-,-,HLCA,-,-,-,-,-,-,-,Fact,4,4.3,4.3.1,4.3.1.1,-,线粒体ROS产生
6572,KP8,32647650,"PFE treatments#affected#p21, cyclin D1, and CDK4, delaying disease progression in TRAMP",Therapeutic Response,"CDKN1A,CCND1,CDK4",-,-,PFE,-,-,-,Downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.3,-,E2F转录因子活性下调
1861,KP8,24258989,Mutations in CDK4#increase#melanoma risk by impairing interaction with p16INK4a,Cancer Association,"CDK4,CDKN2A",-,Melanoma,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
2320,KP8,24258989,Impaired SUMOylation of the E318K variant of MITF#results in#increased transcription of pro-malignant phenotype genes in melanocytes,Molecular Event,MITF,-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6778,KP8,24258989,Mutations in BAP1#enhance#metastatic potential of uveal melanoma and predispose to other malignancies,Cancer Association,BAP1,-,"Uveal melanoma, cutaneous melanoma, atypical melanocytic tumors, other malignancies",-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
2651,KP8,12112531,Gliosarcoma#is characterized by#gliomatous or sarcomatous differentiation,Cancer Association,-,"Gliomatous cells, sarcomatous cells",Gliosarcoma,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.1,-,易位
1379,KP8,12112531,"Amplification of PDGFRA, CCND3, EGFR, CDK4, MDM2, and AKT1#was identified in#gliosarcomas",Molecular Event,"PDGFRA,CCND3,EGFR,CDK4,MDM2,AKT1",-,Gliosarcoma,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7320,KP8,12112531,Genomic changes in gliosarcomas#resemble#those found in glioblastomas,Cancer Association,"PDGFRA,CCND3,EGFR,CDK4,MDM2,AKT1",-,"Gliosarcoma, glioblastoma",-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
5192,KP8,12112531,Gliosarcomas#exhibit#higher genomic stability compared to glioblastomas,Cancer Pathways,-,"Gliosarcoma, Glioblastoma",-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
1529,KP8,12112531,Gain/amplification of genes on proximal 12q#facilitates#development of sarcomatous phenotype,Cancer Pathways,-,Sarcomatous phenotype,-,-,-,-,-,-,-,-,-,Inference,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3452,KP8,12497626,CDKN2A#encodes#two unrelated proteins from alternately spliced transcripts,Molecular Event triples,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
7151,KP8,11741799,INK4a-ARF locus#encodes#p16INK4a and p14ARF tumor suppressor proteins,Molecular Event triples,CDKN2A,-,-,-,"CDK4-pRb, p53",-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
3658,KP8,11741799,CDK4#binds#pRB for phosphorylation,Mechanism of Action,"CDK4, RB1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
6626,KP8,27334220,CCND1#is amplified in#1 cell line but not in patient samples,Expression Patterns,CCND1,-,-,-,-,-,-,Upregulated (cell line),-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
7316,KP8,33228782,Roquin1#acts as#a novel breast tumor suppressor,Cancer Association,ROQUIN1,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.6,1.6.1,1.6.1.3,-,干性标志物表达
5080,KP8,28815764,PD-L1 expression#is studied in#early-stage squamous cell lung carcinomas,Expression Patterns,CD274,T lymphocytes,Squamous cell lung carcinoma,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.3,6.1.1.3.1,PD-1/PD-L1表达
2951,KP8,10022821,Malignant glial tumors#arise from#progression of low-grade precursor lesions or de novo formation,Cancer Pathways,-,-,"Anaplastic astrocytomas, Glioblastomas",-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.4,-,DNA合成修复
1074,KP8,10022821,Primary tumors#harbor#genetic aberrations associated with linear progression or de novo formation,Cancer Pathways,-,-,Glial tumor,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.4,-,DNA合成修复
2370,KP8,10022821,Recurrent tumors#sustain#specific abnormalities associated with linear progression or de novo formation,Cancer Pathways,-,-,Glial tumor,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.4,-,DNA合成修复
7131,KP8,28961193,Fascaplysin#inhibits#CDK4 to exert anti-cancer effects,Mechanism of Action,CDK4,-,Tumor,Fascaplysin,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6892,KP8,28961193,Fascaplysin#exhibits#stronger anti-cancer effects than other CDK4 inhibitors on lung cancer cells,Drug Development,CDK4,Lung cancer cells,Lung cancer,"Fascaplysin, PD0332991, LY2835219",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
492,KP8,28961193,Fascaplysin#inhibits#tumor growth through unknown target molecules,Mechanism of Action,CDK4,-,Tumor,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1387,KP8,18701644,MicroRNAs (miRNAs)#are involved in#regulating gene expression in diverse biological processes,RNA Regulation,miRNAs,-,-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,微小RNA
2286,KP8,18454140,Sustained cyclin-dependent kinase (CDK) activity#allows#abnormal centrosome duplication resulting in mitotic errors,Mechanism of Action,CDK,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
882,KP8,18454140,p53-driven apoptosis#occurs downstream of#NPM1 phosphorylation as a checkpoint mechanism,Cell Cycle Control,"TP53, NPM1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.3,1.3.3.3,-,细胞凋亡调控
2917,KP8,21523718,p16-INK4a and mcm-7#are expressed in#HPV-positive carcinoma cells,Expression Patterns,"CDKN2A, MCM7",Carcinoma cells,HPV-positive carcinoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6700,KP8,16293976,Loss of heterozygosity (LOH) at TP53#is examined in#primary human endometrial carcinomas,Cancer Association,TP53,-,Endometrial carcinomas,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6910,KP8,16293976,LOH#was found in#19% of informative endometrial carcinoma cases,Cancer Association,TP53,-,Endometrial carcinomas,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
2335,KP8,16293976,Tumors without hyperplasia#exhibited#30% LOH,Cancer Association,TP53,-,Endometrial carcinomas,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
2886,KP8,16293976,Cyclin D1/CDK4 complex#is overexpressed in#a case with TP53 LOH,Expression Patterns,"CCND1, CDK4, TP53",-,Endometrial carcinomas,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
1858,KP8,16293976,Allelic loss at TP53#arises independently of#LOH at the RB1 gene in endometrial carcinomas,Cancer Association,"TP53, RB1",-,Endometrial carcinomas,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
363,KP8,16293976,Disruptions at p16INK4A and/or CDK4/cyclin D1#occur concomitantly with#TP53 LOH in endometrioid-type ECs,Cancer Association,"CDKN2A, CDK4, CCND1, TP53",-,Endometrioid-type endometrial carcinomas,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
1805,KP8,11781230,Neutralization of TGF-beta#increases#colony-forming progenitors during culture with cytokines,Regulation,TGFB1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.1,1.2.1.3,-,应激反应通路
7720,KP8,9461560,"MEFs from mice lacking p53, p21, RB, or p16 genes#were used for#studying G1/S phase transition",Preclinical Models,"TP53, CDKN1A, RB1, CDKN2A",MEFs,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
6114,KP8,25568671,Cyclin D1 and CDK4 protein levels#are reduced by#G1 phase arrest enhancers,Regulation,"CCND1, CDK4",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
18,KP8,18332873,Cyclin D1#is overexpressed in#most tumors compared to surrounding glands,Expression Patterns,CCND1,-,Tumors,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
5108,KP8,27322250,Cypermethrin-induced G1 cell cycle arrest#is associated with#enhanced expression of p21 and...,Cell Cycle Control,"CDKN1A, TP53, CCND1, CCNE1, CDK4",-,-,-,-,-,-,"downregulated (CCND1, CCNE1, CDK4), upregulated (CDKN1A, TP53)",-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
759,KP8,30236142,CCND1#is amplified in#three NPC-PDXs,Cancer Association,CCND1,-,NPC,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
3281,KP8,30236142,CDKN2A#is deleted in#four NPC-PDXs,Cancer Association,CDKN2A,-,NPC,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
2714,KP8,30236142,CCND1 overexpression#is associated with#poor outcomes in metastatic NPC,Cancer Association,CCND1,-,Metastatic NPC,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
6537,KP8,30236142,Palbociclib#induces#G1 arrest,Mechanism of Action,-,-,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3337,KP8,10469453,Chromosome band 9p21#is frequently altered in#MPNST,Cancer Association,CDKN2A,-,MPNST,-,pRB,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.2,-,缺失
5134,KP8,10469453,CDKN2A#shows#aberrations in nine MPNSTs,Cancer Association,CDKN2A,-,MPNST,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
476,KP8,10469453,CDKN2A expression#is not detected in#four MPNSTs,Expression Patterns,CDKN2A,-,MPNST,-,-,-,-,silenced,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
2220,KP8,10469453,"DNA changes#are observed in#CDKN2A, CDKN2B, RB1, CDK4, MDM2, and CCND2 in MPNSTs",Cancer Association,"CDKN2A,CDKN2B,RB1,CDK4,MDM2,CCND2",-,MPNST,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
7110,KP8,10469453,pRB pathway disruption#is common in#MPNST,Cancer Pathways,RB1,-,MPNST,-,pRB,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2019,KP8,10469453,CDKN2A#dose reduction contributes to#MPNST development,Cancer Association,CDKN2A,-,MPNST,-,-,-,-,-,-,-,-,Inference,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
1687,KP8,12170781,"Translocations#alter#expression, function, and localization of fusion proteins",Mechanism of Action,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
2122,KP8,10599415,p16INK4a#elucidates#tumor suppressor mechanism,Cancer Pathways,CDKN2A,-,Bladder tumors,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
4547,KP8,9116295,p16 and p15#inhibit#CDK4/6,Mechanism of Action,"CDKN2A, CDKN2B, CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
149,KP8,27035431,artemisinin#inhibits#proliferation of gallbladder cancer cells,Cancer Association,-,-,Gallbladder cancer,artemisinin,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
227,KP8,29844131,ERG overexpression#is observed in#50% of prostate cancers with PTEN and TP53 alterations,Cancer Association,"ERG, PTEN, TP53",-,Prostate cancer,-,-,-,upregulated,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
3384,KP8,29844131,palbociclib#inhibits#CDK4/6 in prostate cancer,Drug Development,"CDK4, CDK6",-,Prostate cancer,palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5247,KP8,20196086,high-copy number amplifications#are observed in#GBMs,Cancer Association,CDK4,-,GBMs,-,-,-,upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7877,KP8,20196086,high-copy amplicons#result in#overexpression of CDK4,Expression Patterns,CDK4,-,-,-,-,-,upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
6496,KP8,20196086,allelic loss#results in#reduced expression of tumor suppressor genes,Cancer Pathways,-,-,"ODs, GBMs",-,-,-,downregulated,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.2,-,RB1缺失
590,KP8,20196086,homozygous deletion of Pragmin#is identified in#glioma samples,Cancer Pathways,-,-,Glioma,-,-,-,downregulated,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.4,-,肿瘤抑制子缺失
5577,KP8,16732325,ring chromosomes#are common in#mesenchymal tumors,Cancer Pathways,-,-,Mesenchymal tumors,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.3,-,重复
2118,KP8,16732325,CDK4#is amplified in#soft tissue and bone tumors,Cancer Association,CDK4,-,"Soft tissue tumor, Bone tumor",-,-,-,Upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1856,KP8,23851445,ATRA treatment#increases#p14(ARF) expression in primary human melanocytes,Regulation,CDKN2A,Primary human melanocytes,-,ATRA,-,-,Upregulated,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
1696,KP8,10517500,CDK4#is not amplified in#chordoid glioma,Cancer Association,CDK4,-,Chordoid glioma,-,-,-,Silenced,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.2,-,RB1缺失
5283,KP8,18006686,Mutant cyclin D1/CDK4 complexes#trigger#DNA rereplication and p53-dependent apoptosis in cancer cells,Mechanism of Action,"CDK4, TP53",-,Cancer,-,-,-,Upregulated,-,-,-,-,Fact,1,1.3,1.3.3,1.3.3.1,-,P53通路相互作用
1748,KP8,19158499,Cdk5#is important for#different cellular processes,Molecular Event,CDK5,-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.1,-,存活信号调控
7899,KP8,19158499,Cdk5#is involved in#abortive cell cycle triggered by amyloid-beta and prion peptides in cortical neurons,Neurological Conditions,CDK5,Cortical neurons,"Alzheimer's disease (AD), Prion disease (PRE)",-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.2,-,衰老程序激活
6691,KP8,8855976,p16 and p21#inhibit#cyclin D-CDK4 complexes to cause G1 checkpoint arrest,Cell Cycle Control,"CDKN2A, CDKN1A",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
3943,KP8,23151022,"Metformin treatment#decreases#cyclin D1, CDK4, and CDK6 protein levels in OSCC cells",Regulation,"CDK4, CDK6, CCND1",OSCC cells,Oral squamous cell carcinoma,Metformin,-,-,-,Downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
1672,KP8,14521217,"P16(INK4A)-CDK4/6-RB pathway#is implicated in#control of cellular proliferation, differentiation, and survival",Pathway & Network Categories,"CDKN2A, CDK4, CDK6",-,-,-,P16(INK4A)-CDK4/6-RB,-,-,-,-,-,-,Fact,1,1.4,1.4.1,-,-,细胞增殖调控
3654,KP8,23732836,Cyclin D1 and CDK4#regulate#cell cycle progression and apoptosis-related proteins in cancer cells,Cell Cycle Control,"CCND1, CDK4",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
3724,KP8,7887443,MTS1 gene encoding p16#is deleted or mutated in#a wide variety of human tumor cell lines,Cancer Association,CDKN2A,-,Human tumor cell lines,-,-,-,Silenced,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
1172,KP8,11025389,p16(INK4) and p15(INK4B)#are detected in#locally advanced prostate cancer,Cancer Association,"CDKN2A, CDKN2B",-,Prostate cancer,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
3203,KP8,11025389,p16(INK4)/MTS1 and p15(INK4B)/MTS2 genes#encode#proteins that inhibit CDK4/6,Mechanism of Action,"CDK4,CDK6,CDKN2A,CDKN2B",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6268,KP8,10469011,p16 gene#encodes#a physiological inhibitor of the cyclin D-CDK4 complex,Mechanism of Action,"CDKN2A,CDK4",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
7929,KP8,10469011,A marked reduction of p16 expression#has been reported to occur without#significant genetic alterations,Expression Patterns,CDKN2A,-,Pituitary adenomas,-,-,-,Downregulated,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
2299,KP8,10469011,p16 gene silencing#has been reported in#several human primary tumours,Regulation,CDKN2A,-,Tumours,-,-,-,Silenced,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
3573,KP8,10469011,A single A to G base substitution#leads to#a heterozygous Ala140Thr p16 polymorphism,Genetic Variations,CDKN2A,-,Pituitary adenomas,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
4731,KP8,10469011,Hypermethylation of the p16 gene#suggests#an early role in pituitary tumorigenesis,Regulation,CDKN2A,-,Pituitary tumours,-,-,-,Silenced,-,-,-,-,Inference,1,1.5,1.5.1,1.5.1.2,-,DNA甲基化
1446,KP8,32336043,"Somatic variants in ALK, EPHB4, LMTK3, and EPHB6 genes#were identified in#NB patients",Genetic Variations,"ALK,EPHB4,LMTK3,EPHB6",-,Neuroblastoma (NB),-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
7690,KP8,24231788,Scutellaria Barbata D Don#inhibits#Colorectal Cancer Growth,Therapeutic Development,SB,-,Colorectal Cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4439,KP8,24231788,Crosstalk between signaling pathways#generates#a robust signaling network regulated by compensatory mechanisms,Signaling Networks,-,-,-,-,-,-,-,-,-,-,-,Inference,1,1.3,1.3.1,1.3.1.3,-,协同效应
2296,KP8,24231788,Long-term use of agents#generates#drug resistance and toxicity against normal cells,Therapeutic Resistance,-,-,-,-,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,2.6.1.1,-,药物外排增加
6893,KP8,24231788,Scutellaria barbata D Don (SB)#has been used to treat#various types of cancer,Therapeutic Development,SB,-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6473,KP8,24231788,Ethanol extract of SB (EESB)#induces#colon cancer cell apoptosis,Mechanism of Action,-,Colon cancer cells,Colon Cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.3,-,线粒体通路调控
7505,KP8,24231788,Ethanol extract of SB (EESB)#inhibits#cell proliferation and tumor angiogenesis,Mechanism of Action,-,-,Colon Cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6048,KP8,24231788,"Ethanol extract of SB (EESB)#modulates#Hedgehog, Akt, and p53 pathways",Signaling Networks,TP53,-,Colon Cancer,-,"Hedgehog, Akt, p53",-,-,-,-,-,-,Fact,1,1.3,1.3.3,1.3.3.1,-,P53通路相互作用
5092,KP8,20444257,12q24 gain in neuroblastic tumors#has#prognostic implications,Cancer Association,-,-,Neuroblastic Tumors,-,-,-,-,-,-,-,-,Inference,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
2230,KP8,20444257,Few clinically useful prognostic markers#have been found#in neuroblastic tumors,Biomarker Analysis,-,-,Neuroblastic Tumors,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.3,-,免疫标志物
443,KP8,20444257,aCGH profiling#distinguished#genetic copy number alterations associated with transcriptional changes,Technical Methods,-,-,Neuroblastoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
3047,KP8,20444257,FISH analysis#evaluated#clinical significance and transcriptional consequences of detected alterations,Technical Methods,-,-,Neuroblastoma,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.4,-,融合蛋白功能
1189,KP8,20444257,"aCGH analysis#revealed#amplification and overexpression of MYCN, MEIS1, CDK4, and MDM2 oncogenes",Expression Patterns,"MYCN, MEIS1, CDK4, MDM2",-,Neuroblastoma,-,-,-,Upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5522,KP8,20444257,aCGH analysis#identified#microamplifications at 2p and 12q24.11,Genomic Alterations,-,-,Neuroblastoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
5053,KP8,20444257,Five genes at 12q24.31 amplicon#showed#elevated expression in neuroblastoma,Expression Patterns,"DIABLO, ZCCHC8, RSRC2, KNTC1, MPHOSPH9",-,Neuroblastoma,-,-,-,Upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
566,KP8,20444257,DIABLO#showed#strongest activation in neuroblastoma,Expression Patterns,DIABLO,-,Neuroblastoma,-,-,-,Upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
1703,KP9,34204543,Molecular alterations#result in#dysregulation of G1 to S phase transition,Cell Cycle Control,-,-,"Human Tumors, Ovarian Cancer",-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
2131,KP9,34204543,Alterations#have been identified as#therapeutic targets in several cancer types,Therapeutic Development,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2148,KP9,28042706,Cyclin D-CDK4/6-INK4-Rb pathway components#are altered in#squamous cell carcinomas (SCCs),Signaling Networks,"CDK4, CDK6, RB1",-,Squamous Cell Carcinomas,-,Cyclin D-CDK4/6-INK4-Rb,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3793,KP9,37686402,Malignant peripheral nerve sheath tumors (MPNSTs)#are deadly sarcomas#requiring effective therapies,Therapeutic Development,-,-,Malignant Peripheral Nerve Sheath Tumors,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
612,KP9,37686402,FOXM1#may regulate#MEK and CDK4/6 kinase pathways in MPNSTs,Signaling Networks,"FOXM1, CDK4, CDK6",-,Malignant Peripheral Nerve Sheath Tumors,-,"MEK, CDK4/6",-,-,-,-,-,-,Inference,1,1.3,1.3.1,-,-,PI3K/AKT/mTOR通路
4438,KP9,29408328,Cyclin D1-CDK4/CDK6 complex#is dysregulated in#almost all human cancer,Cancer Association,"CDK4,CDK6",-,Human cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
3758,KP9,29408328,Dysregulation of cyclin D1-CDK4/CDK6 complex#contributes to#aberrant cell proliferation and tumorigenesis,Cancer Pathways,"CDK4,CDK6",-,Tumorigenesis,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
3862,KP9,29408328,CDK4 and CDK6#are highly expressed in#B-acute lymphoblastic leukemia (B-ALL),Expression Patterns,"CDK4,CDK6",-,B-acute lymphoblastic leukemia,-,-,-,Childhood patients,Upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
4844,KP9,18413728,Potential downstream players#are identified in#CDK4/CDK6 signaling,Signaling Networks,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
2986,KP9,18413728,Neuroblastoma#depends on#overexpression of G(1)-regulating genes,Cancer Pathways,-,-,Neuroblastoma,-,-,-,-,Upregulated,-,-,-,Inference,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
4416,KP9,7647780,Deletion or mutation of CDK-inhibitors#leads to#unchecked cell growth,Cancer Pathways,-,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3874,KP9,7647780,Members of the p16INK4 family#may be#tumor suppressor genes,Cancer Association,CDKN2A,-,-,-,-,-,-,-,-,-,-,Inference,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
4622,KP9,9324288,Loss of p16INK4A gene#is attributed to#development of many types of cancers including leukemia,Cancer Association,CDKN2A,-,"Leukemia, many cancers",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
3598,KP9,17122635,Altered expression of Rb and p16 proteins#was identified in#67.8% and 65.1% of cases,Expression Patterns,"RB1,CDKN2A",-,-,-,-,-,Altered,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
436,KP9,17122635,"Overexpression of E2F1, cyclin D1, CDK4, and CDK6#was detected in#50.7%, 24.3%, 92.1%, and 10.5% of cases",Expression Patterns,"E2F1,CCND1,CDK4,CDK6",-,-,-,-,-,Upregulated,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
6130,KP9,38815172,ESR1 mutations#are a mechanism of#acquired resistance to aromatase inhibitors,Mechanisms of Resistance,ESR1,-,Metastatic breast cancer,Aromatase inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
956,KP9,38815172,Impact of ESR1 alterations#on#CDK4/6 inhibitor sensitivity,Mechanisms of Resistance,"ESR1,CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
5328,KP9,11301189,"CDK4, CDK6, p19(INK4d), and p57(KIP2)#are expressed in#normal B-cell precursors",Expression Patterns,"CDK4,CDK6,CDKN2D,CDKN1C",B-cell precursors,-,-,-,-,-,Expressed,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
1403,KP9,11301189,p16(INK4a)#is not detected in#normal B-cell precursors,Expression Patterns,CDKN2A,B-cell precursors,-,-,-,-,-,Silenced,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3953,KP9,11301189,Ubiquitous expression of p19(INK4d)#has not been previously described in#human or murine B-lineage cells,Expression Patterns,CDKN2D,B-lineage cells,-,-,-,-,-,Expressed,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.3,p16表达
6706,KP9,39524172,SAMD5 expression#negatively correlates with#PLK1 overexpression,Signaling Networks,"SAMD5, PLK1",-,"Breast cancer, TNBC",-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.2,-,共激活因子
64,KP9,39524172,PLK1 overexpression#counteracts#SAMD5's inhibitory effects,Mechanism of Action,"PLK1, SAMD5",-,"Breast cancer, TNBC",-,-,-,Upregulated,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
6900,KP9,35201661,Radiological imaging#has limitations in#treatment surveillance,Treatment Monitoring,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,8.5.1.1.1,CT扫描
1328,KP9,35201661,Serial ctDNA analysis#identified#disease progression with 75% sensitivity and 92% specificity,Biomarker Analysis,-,-,Disease progression,-,-,-,-,-,-,-,-,Fact,7,7.6,7.6.1,7.6.1.1,7.6.1.1.4,肿瘤负荷
7669,KP9,35201661,Biweekly sequencing#detected#sustained ctDNA levels in patients not responding to CDK4/6i,Biomarker Analysis,"CDK4, CDK6",-,Progressive disease,CDK4/6 inhibitors,-,-,Non-responding patients,Sustained,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,7.5.1.1.4,CDK6扩增
3994,KP9,35201661,Serial ctDNA analysis#tracked#RECIST response and acquired genetic alterations linked to CDK4/6i resistance,Mechanisms of Resistance,"CDK4, CDK6",-,Resistance,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
1967,KP9,35220309,Somatic evolution of cancer genome#is involved in#development of treatment resistance,Cancer Association,-,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Inference,2,2.4,2.4.1,2.4.1.1,-,激活性突变
5786,KP9,35220309,New mutations in ctDNA#were detected in#patients with progressive disease,Cancer Association,-,-,Progressive disease,-,-,-,-,-,-,-,-,Fact,7,7.6,7.6.1,7.6.1.1,7.6.1.1.2,耐药突变
7227,KP9,11029524,Genetic alteration involving p16/INK4a locus#is second only to#alteration of p53,Cancer Association,"CDKN2A, TP53",-,Human cancers,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
309,KP9,11029524,Homozygous p16/INK4a gene deletion#has been demonstrated in#glioblastoma tissues,Cancer Association,CDKN2A,Glioma cell lines,Glioblastoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
7196,KP9,37424386,"Amplifications of CDK4, CDK6, CCND1, CCND2, or CCND3#are associated with#therapy-refractory solid malignancies",Cancer Association,"CDK4, CDK6, CCND1, CCND2, CCND3",-,Therapy-refractory solid malignancies,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
2783,KP9,30093452,PI3K pathway alterations#have been identified in#over 50% of LUSC cases,Pathway & Network Categories,PIK3CA,-,Lung squamous cell carcinoma (LUSC),-,PI3K,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
724,KP9,30093452,PI3K pathway alterations#identified in#50% of LUSC PDX models,Pathway & Network Categories,PIK3CA,-,Lung squamous cell carcinoma (LUSC),-,PI3K,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
1962,KP9,30093452,PIK3CA mutations#predict#response to PI3K inhibitors,Cancer Association,PIK3CA,-,Lung squamous cell carcinoma (LUSC),PI3K inhibitors,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.4,PIK3CA突变
7916,KP9,35301407,Proteomic data#identified#cell cycle and DNA damage repair pathways,Pathway & Network Categories,-,-,-,-,"Cell cycle, DNA damage repair",-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7509,KP9,35301407,Targeting ATR pathway#re-sensitized#resistant cells to MTX,Strategies to Overcome Resistance,ATR,-,MTX-R tumors,MTX,ATR,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.3,-,剂量优化
383,KP9,30544932,CDK6 protein#regulates#oncogenic kinases mediating intrinsic drug resistance,Mechanism of Action,CDK6,-,-,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
963,KP9,38954773,mTOR inhibition#prevents#adaptive resistance to CDK4/CDK6 blockade,Strategies to Overcome Resistance,"MTOR, CDK4, CDK6",-,HNSCC,-,mTOR,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,2.5.1.1.1,多靶点抑制
957,KP9,38954773,Cyclin E1 (CCNE1) expression#underlies#acquired resistance to CDK4/6 inhibitor,Mechanism of Action,"CCNE1, CDK4, CDK6",-,-,Palbociclib,-,-,-,Upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
756,KP9,30397176,Resistance#emerges with#single-agent CDK4/6 inhibitors,Therapeutic Resistance Categories,"CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
3112,KP9,30397176,Elevated phospho-IGF1R levels#support#role of IGF1R signaling in acquired resistance,Mechanism of Action,IGF1R,-,Ewing sarcoma,-,IGF1R,-,-,Upregulated,-,-,-,Fact,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
2581,KP9,39352623,SEMA3F#is identified as#resistance gene for CDK4/6 inhibitors in breast cancer,Mechanism of Action,SEMA3F,-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
426,KP9,39352623,Loss of Rb gene and amplification of p16 gene#are known as#resistance mechanisms to CDK4/6 inhibitors,Mechanism of Action,"RB1,CDKN2A",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,2.2.1.1.1,RB通路缺陷
2373,KP9,39352623,SEMA3F-downregulated cells#maintained#p-Rb levels in palbociclib treatment,Mechanism of Action,"SEMA3F,RB1",-,Breast cancer,Palbociclib,-,-,-,downregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
114,KP9,9916806,CDKN2A#encodes#a CDK4/CDK6 kinase inhibitor,Mechanism of Action,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6616,KP9,36174113,"CTNNB1, KRAS, and CDKN2A mutations#are candidate predictors of#response to tumor profiling",Biomarker Analysis,"CTNNB1,KRAS,CDKN2A",-,-,-,-,-,-,Mutations,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,RB1突变
2495,KP9,27217383,Abemaciclib#inhibits#CDK4 and CDK6,Drug Development,"CDK4,CDK6",-,"Breast cancer, NSCLC, glioblastoma, melanoma, colorectal cancer",Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7969,KP9,9482902,Cdkn2a#encodes#p16INK4a and p19ARF,Mechanism of Action,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6253,KP9,23266667,"CCND2, CDK6 genes#showed#significant increase in mRNA expression level in AML group",Expression Patterns,"CCND2,CDK6",-,AML,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
5957,KP9,7585567,Cdk inhibitors#undergo#frequent deletions and/or mutations in human cancers,Cancer Association,"CDKN2A,CDKN2B",-,Human cancers,-,-,-,-,-,Mutations,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
2319,KP9,18760195,BCC patients#have#cell-cycle abnormalities,Cell Cycle Control,-,-,Basal cell carcinoma (BCC),-,-,-,Patients,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
832,KP9,29496665,MEK and CDK4/6 inhibition#has shown#promising clinical outcomes in patients with NRAS-mutant melanoma,Therapeutic Response,"CDK4,CDK6",-,NRAS-mutant melanoma,"MEK inhibitors, CDK4/6 inhibitors",-,-,Patients,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3332,KP9,29496665,MEKi + CDK4i therapy#initially led to#response but subsequently developed resistance,Therapeutic Resistance,"CDK4,CDK6",-,NRAS-mutant melanoma,"MEK inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
6631,KP9,29496665,Acquired PIK3CA(E545K) mutation#confers#drug resistance,Mechanisms of Resistance,PIK3CA,-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
7989,KP9,29496665,Preexisting PIK3CA(E545K) subpopulation#expands upon#MEKi + CDK4i therapy and exhibits drug resistance,Therapeutic Resistance,"PIK3CA,CDK4,CDK6",-,NRAS-mutant melanoma,"MEK inhibitors, CDK4/6 inhibitors","MAPK, PI3K, S6K1",-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
6777,KP9,30380421,Patient-derived xenografts (PDXs)#recapitulate#features of their corresponding clinical cancers,Preclinical Models,-,-,Clinical cancers,-,-,-,Patients,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
1847,KP9,30380421,CCND1 and CDKN2A genomic alterations#are predictive of#response to CDK4/6 inhibitor abemaciclib,Biomarker Analysis,"CCND1,CDKN2A",-,-,Abemaciclib,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
3359,KP9,10594039,p16(INK4a)#is#a potent tumor suppressor in humans,Cancer Association,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
4196,KP9,10594039,INK4c and INK4d#are expressed in#stereotypic tissue-specific patterns during mouse embryogenesis,Expression Patterns,"CDKN2C,CDKN2D",-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.2,1.4.2.2,-,分化标志物表达
3074,KP9,10594039,INK4d#was disrupted in#mice using targeted gene disruption,Preclinical Models,CDKN2D,-,-,-,-,-,-,-,-,-,-,Fact,3,3.4,3.4.2,3.4.2.1,-,内源性途径激活
5612,KP9,10594039,"Mouse embryo fibroblasts, bone marrow-derived macrophages, and lymphoid T and B cells#proliferated#normally in INK4d-deficient animals",Cell Cycle Control,CDKN2D,"Mouse embryo fibroblasts, bone marrow-derived macrophages, T cells, B cells",-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
4616,KP9,26278998,CARF expression#is associated with#cancer aggressiveness in epithelial and glial cancers,Cancer Association,CARF,"Epithelial cells, glial cells",Epithelial and glial cancers,-,-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.1,1.4.1.1,-,增殖信号整合
294,KP9,9774662,INK4a/ARF locus#encodes#two proteins involved in tumor suppression,Cancer Association,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
1114,KP9,9774662,ARF and INK4a#are coordinately expressed in#cells except when their promoter regions are methylated,Regulation,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.3,-,抑制复合物
6215,KP9,27146558,Next-generation sequencing#identifies#actionable alterations in cancer driver genes,Preclinical Models,"PIK3CA,AKT,FGFR,ERBB2",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
3781,KP9,33575077,尾-elemene#is associated with#glioma cell senescence in vitro and in vivo,Therapeutic Response,"CDK6,YAP",-,Glioma,尾-elemene,YAP-CDK6,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,细胞衰老诱导
1804,KP9,18438866,Amplification of 7q21#is detected in#various cancers,Cancer Association,CDK6,-,Cancer,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
7085,KP9,18438866,7q21.2 amplification#comprises#CDK6,Cancer Association,CDK6,-,Cancer,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
4735,KP9,33797827,CDK4 and TERT amplification#are frequent in#mucosal melanoma,Cancer Association,"CDK4,TERT",-,Mucosal melanoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
1674,KP9,33797827,CDK4 amplification#occurs in combination with#TERT amplification,Cancer Association,"CDK4,TERT",-,Mucosal melanoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
1131,KP9,24089445,Response to CDK4 inhibition#correlates with#genomic changes increasing CDK4 activity,Therapeutic Response,"CDK4,CDKN2A",-,Tumor,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,细胞周期阻滞
7955,KP9,24089445,CDKN2A deletion#increases#CDK4 activity,Mechanism of Action,"CDK4,CDKN2A",-,Tumor,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
1338,KP9,39464575,Genomic profiling#identifies#CDK4 and MDM2 amplification in UA,Cancer Association,"CDK4,MDM2",-,Undifferentiated sarcoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
3469,KP9,26252490,CDK4-cyclin D1 protein complex#abnormal function causes#cancer,Mechanism of Action,"CDK4,CCND1",-,Cancer,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
5220,KP9,26252490,CDK4#is considered as#a genetically validated therapeutic target,Drug Development,CDK4,-,Cancer,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,细胞周期阻滞
3931,KP9,26252490,"Five nsSNPs (R24C, Y180H, A205T, R210P, R246C)#are identified as#highly deleterious",Genetic Variation,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
5866,KP9,26252490,Deleterious nsSNPs#affect#CDK4-cyclin D1 and CDK4-flavopiridol interactions,Protein Interaction,CDK4,-,-,Flavopiridol,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
2219,KP9,26252490,5_7_DIHYDROXY_2_(3_4_5_TRI_HYDROXYPHENYL)_4H_CHROMEN_4_ONE#displays#good binding affinity for proteins with R24C or R246C mutations,Drug Binding,CDK4,-,-,5_7_DIHYDROXY_2_(3_4_5_TRI_HYDROXYPHENYL)_4H_CHROMEN_4_ONE,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,细胞周期阻滞
6182,KP9,26252490,Diosmin#displays#good binding affinity for protein with Y180H mutation,Drug Binding,CDK4,-,-,Diosmin,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,细胞周期阻滞
1103,KP9,26252490,Rutin#displays#good binding affinity for proteins with A205T and R210P mutations,Drug Binding,CDK4,-,-,Rutin,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,细胞周期阻滞
6644,KP9,26252490,CDK4 genetic variation#is linked to#biological phenomena in human cancer,Cancer Association,CDK4,-,Human cancer,-,-,-,-,-,-,-,-,Inference,5,5.5,5.5.1,5.5.1.1,-,错义突变
5835,KP9,26252490,CDK4 genetic variation#aids in#discovery of molecularly targeted therapies for personalized treatment,Therapeutic Development,CDK4,-,Human cancer,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,细胞周期阻滞
2312,KP9,27597521,Diagnosis#is guided by#MDM2 and CDK4 immunohistochemistry (IHC),Clinical Implementation,"MDM2,CDK4",-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
4696,KP9,27597521,Diagnosis#is confirmed by#amplification of MDM2 and CDK4 genes,Clinical Implementation,"MDM2,CDK4",-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
3697,KP9,27597521,p16 IHC#has been proposed as#a useful diagnostic biomarker,Biomarker Analysis,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.3,CDKN2A缺失
5945,KP9,27597521,101 tumors#were analyzed using#FISH for MDM2 and CDK4 amplification,Experimental Methods,"MDM2,CDK4",-,Tumors,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
2348,KP9,27508976,FISH for MDM2 amplification#is considered as#the gold standard for diagnosis,Experimental Methods,MDM2,-,ALT/WDL,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
362,KP9,27508976,Immunostaining for MDM2 and/or CDK4#has been adopted as#a surrogate method for diagnosis,Biomarker Analysis,"MDM2,CDK4",-,ALT/WDL,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
7307,KP9,27508976,Immunostaining for MDM2 and CDK4#was performed on#183 well-differentiated lipomatous tumors,Experimental Methods,"MDM2,CDK4",-,ALT/WDL,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
5760,KP9,27508976,"MDM2 and CDK4 staining#occurred in#2/125 and 10/117 benign lipomatous lesions, respectively",Biomarker Analysis,"MDM2,CDK4",-,Benign lipomatous lesions,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
1553,KP9,27508976,MDM2 and CDK4 staining#is restricted to#neoplastic cells with atypia,Biomarker Analysis,"MDM2,CDK4",-,ALT/WDL,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
1144,KP9,19574885,MDM2 and CDK4 gene amplification#was studied in#28 immunohistochemically positive cases,Experimental Methods,"MDM2,CDK4",-,"UHGPS,DDL",-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
2250,KP9,19574885,CDK4 and MDM2#can be used as#surrogate immunohistochemical markers for diagnosing malignant lipomatous tumors,Biomarker Analysis,"CDK4,MDM2",-,Malignant lipomatous tumors,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
1866,KP9,19574885,26% of UHGPS cases#showed#CDK4 and MDM2 gene amplification,Genetic Variation,"CDK4,MDM2",-,UHGPS,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
1102,KP9,24965044,MDM2 and CDK4 expression#was analyzed by#real-time PCR in lipoma and ALT/WDL cases,Experimental Methods,"MDM2,CDK4",-,"Lipoma, ALT/WDL",-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
5889,KP9,24965044,Karyotypes with rings and/or giant chromosomes#showed#higher MDM2 and CDK4 expression levels compared to other karyotypes,Expression Patterns,"MDM2,CDK4",-,-,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
3657,KP9,24227706,Six DDLPS tested#showed#ring or giant marker chromosomes and/or MDM...,Molecular Event,MDM2,-,DDLPS,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
6047,KP9,29266182,RNA-seq data from CTCs#identified#mutations associated with CRPC a...,Cancer Association,AR,-,CRPC,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
5141,KP9,28704762,Combined inhibition of CDK4/6 and PI3K/AKT/mTOR pathways#induces#a...,Combination Optimization,"CDK4,CDK6",-,Malignant pleural mesothelioma,-,PI3K/AKT/mTOR,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
7640,KP9,15221942,Most retroperitoneal pleomorphic MFHs#are accepted as#dedifferentia...,Cancer Association,"MDM2,CDK4",-,"Retroperitoneal pleomorphic MFH, dedifferentiated liposarcoma",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
2433,KP9,15221942,High-level amplification of MDM2 and CDK4 genes#was observed in#inf...,Molecular Event,"MDM2,CDK4",-,Inflammatory MFH,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
953,KP9,31634336,MDM2 and CDK4#are specifically amplified in#POS,Molecular Event,"MDM2,CDK4",-,POS,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
2151,KP9,31634336,POS tumors#had#a marked increase of MDM2 and CDK4 gene copies by M...,Molecular Event,"MDM2,CDK4",-,POS,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3354,KP9,37141549,CDK4/6i BP#impacts#genomic stratification factors,Mechanism of Action,"CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
657,KP9,37141549,Patients#were treated with#non-CDK4/6i-based treatment or CDK4/6i BP,Therapeutic Response,"CDK4, CDK6",-,HR-positive HER2-negative metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
38,KP9,37141549,CDK4/6i BP#impacts#progression-free survival (PFS) and overall sur...,Therapeutic Response,"CDK4, CDK6",-,HR-positive HER2-negative metastatic breast cancer,-,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
4896,KP9,37141549,ESR1 and RB1 mutations#are represented in#CDK4/6i BP subgroup,Expression Patterns,"ESR1, RB1",-,-,-,-,-,-,Upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
7188,KP9,39253462,Germline and somatic oncogenic alterations#co-occur in#breast cancer,Cancer Association,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.3,-,驱动突变
1098,KP9,34362013,CDK4#is amplified in#supernumerary ring and giant marker chromosomes,Structural Biology,CDK4,-,-,-,-,-,-,Amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7080,KP9,28794284,8p11-12 and 11q13 gene amplifications#correlate with#high Ki67,Expression Patterns,"FGFR1, CCND1",-,-,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
723,KP9,28794284,Letrozole-treated tumors#show#intrachromosomal ESR1 fusion transcripts and increased E2F-mediated transcription,Mechanism of Action,ESR1,-,Breast cancer,Letrozole,-,-,-,Upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
7319,KP9,29153098,CDK4#is amplified in#12q13-15 in DDLS,Structural Biology,CDK4,-,Dedifferentiated liposarcoma (DDLS),-,-,-,-,Amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1837,KP9,29153098,CDK4 amplification levels#predict#outcome in DDLS patients,Prognostic Associations,CDK4,-,Dedifferentiated liposarcoma (DDLS),-,-,-,-,Amplified,-,-,-,Inference,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
3870,KP9,39812054,G1/S transition pathways#are dysregulated in#breast cancer,Signaling Networks,-,-,Breast cancer,-,G1/S transition,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
7511,KP9,26336885,"HMGA2, CDK4, and JUN#are coamplified with#MDM2 in liposarcomas",Structural Biology,"HMGA2, CDK4, JUN, MDM2",-,"Atypical lipomatous tumor, well-differentiated liposarcoma, dedifferentiated liposarcoma",-,-,-,-,Amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
3664,KP9,11921282,CDK4#is amplified in#sarcomas,Structural Biology,CDK4,-,Sarcomas,-,-,-,-,Amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
564,KP9,11921282,PDGFRA amplification#is identified in#sarcomas,Structural Biology,PDGFRA,-,Sarcomas,-,-,-,-,Amplified,-,-,-,Fact,5,5.3,5.3.1,-,-,基因扩增
1563,KP9,38638737,CDK4#is upregulated in#tumor tissue,Expression Patterns,CDK4,-,Tumors,-,-,-,-,Upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
5145,KP9,15024701,CDK4#is amplified in#soft tissue sarcomas,Cancer Association,CDK4,-,"Soft tissue sarcomas, leiomyosarcomas (LMS), alveolar rhabdomyosarcomas (ARMS), embryonal rhabdomyosarcomas (ERMS)",-,12q13-15 region,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3382,KP9,15024701,MDM2#is amplified in#soft tissue sarcomas,Cancer Association,MDM2,-,"Soft tissue sarcomas, leiomyosarcomas (LMS), alveolar rhabdomyosarcomas (ARMS), embryonal rhabdomyosarcomas (ERMS)",-,12q13-15 region,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
4721,KP9,15024701,GLI#is amplified in#soft tissue sarcomas,Cancer Association,GLI,-,"Soft tissue sarcomas, leiomyosarcomas (LMS), alveolar rhabdomyosarcomas (ARMS), embryonal rhabdomyosarcomas (ERMS)",-,12q13-15 region,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
7447,KP9,36315915,"Immune checkpoint inhibitors#showed#clinical benefit in HR+ HER2-, APOBEC+, tumor mutational burden-high patients",Therapeutic Response,APOBEC,-,HR+ HER2- breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.3,3.3.2,3.3.2.4,-,协同免疫激活
1297,KP9,39535850,"NGS profiling#identified#GLI1, CDK4, and MDM2 co-amplification and TP53 mutations",Molecular Event triples,"GLI1, CDK4, MDM2, TP53",-,-,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
635,KP9,34725098,Resistance to CDK4/6i therapy#is driven by#alterations in cell-cycle mediators and oncogenic pathways,Therapeutic Resistance,CDK4,-,HR+ breast cancer,CDK4/6 inhibitors,"Cell-cycle mediators, oncogenic pathways",-,-,-,-,-,-,Inference,2,2.1,2.1.2,2.1.2.3,-,mTOR信号增强
6437,KP9,34725098,Aurora Kinase A#is a resistance node in#HR+ breast cancer,Therapeutic Resistance,AURKA,-,HR+ breast cancer,-,"AKT, MAPK pathways",-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
1016,KP9,33599863,Differentially expressed genes (DEGs)#are associated with#acquired resistance to palbociclib,Therapeutic Resistance,-,-,ER- breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
2420,KP9,33599863,"Pathway analysis#identified#PI3K/AKT, PTEN, and mTOR pathways in breast cancer",Signaling Networks,"PI3K, AKT, PTEN, MTOR",-,Breast cancer,-,"PI3K/AKT, PTEN, mTOR",-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
4629,KP9,7654823,"deletions of negative regulatory elements (TP53, CDKN2, MTS2)#include#TP53, CDKN2, MTS2",Cancer Association,"TP53, CDKN2, MTS2",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.2,-,RB1缺失
4368,KP9,7654823,"amplification of positive factors (MDM2, CDK4)#include#MDM2, CDK4",Cancer Association,"MDM2, CDK4",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
2208,KP9,36119484,amplification of MDM2 and CDK4#provides#rationale to explore targeting as a therapeutic approach,Drug Development,"MDM2, CDK4",-,"WDLPS, DDLPS",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
32,KP9,36119484,investigation of WD/DDLPS#reveals#potential targets such as receptor tyrosine kinases and Aurora A,Drug Development,AURKA,-,"WDLPS, DDLPS",-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6503,KP9,19454362,"amplification of 12q13-q15 region#contains#SAS, GLI, CDK4, and MDM2",Cancer Association,"SAS, GLI, CDK4, MDM2",-,Rhabdomyosarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
4955,KP9,25588041,review#highlights#therapeutic targeting of cell cycle control in melanoma,Drug Development,-,-,Melanoma,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
134,KP9,25588041,alterations in p16 INK4A:cyclinD-CDK4/6:RB pathway#are linked to#melanomagenesis,Cancer Pathways,"CDK4, CDK6",-,Melanoma,-,p16 INK4A:cyclinD-CDK4/6:RB,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.2,-,Cyclin D-CDK6复合物
6190,KP9,25588041,elevated CDK4 activity#correlates with#greater CDK4/6 inhibitor therapeutic activity,Therapeutic Response,"CDK4, CDK6",-,-,CDK4/6 inhibitors,-,-,-,Upregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2718,KP9,25588041,loss of RB1#is linked to#CDK inhibitor resistance,Therapeutic Resistance,RB1,-,-,CDK inhibitors,-,-,-,Silenced,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
2822,KP9,25588041,compounds targeting cell cycle control#reactivate#wild-type p53,Drug Development,TP53,-,Melanoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7649,KP9,37042132,CDK4 and DDIT3 gene amplification probe FISH tests#showed#CDK4 gene amplification,Cancer Association,"CDK4, DDIT3",-,"DDLPS, PLPS",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1484,KP9,37042132,co-amplification of CDK4 and DDIT3#was found in#2 of 10 cases,Cancer Association,"CDK4, DDIT3",-,"DDLPS, PLPS",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
2963,KP9,18459177,Rb pathway alterations#are associated with#low or negative Rb protein expression,Molecular Event,RB1,-,Meningeal hemangiopericytomas,-,Rb pathway,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
1291,KP9,18459177,Rb pathway alterations#are associated with#loss of p16/INK4a expression,Molecular Event,CDKN2A,-,Meningeal hemangiopericytomas,-,Rb pathway,-,-,Silenced,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
7985,KP9,18459177,Rb#does not act as#growth suppressor,Function triples,RB1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
2678,KP9,18459177,HDM2#activates#E2F1,Mechanism of Action,"HDM2,E2F1,RB1",-,Tumors,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
5975,KP9,18459177,HDM2#inactivates#Rb,Mechanism of Action,"HDM2,RB1",-,Tumors,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
1790,KP9,18459177,HDM2 colocalization with E2F1 and Rb#indicates#Rb suppressor pathway inactivation,Mechanism of Action,"HDM2,E2F1,RB1",-,MHPCs,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
5023,KP9,18459177,HDM2 colocalization with E2F1 and Rb#indicates#transactivation of DNA synthesis genes,Mechanism of Action,"HDM2,E2F1,RB1",-,MHPCs,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
5753,KP9,36316249,Mesenchymal neoplasms with GLI1 alterations#have been reported in#several anatomic locations,Disease Association,GLI1,-,Mesenchymal neoplasms,-,-,-,-,-,-,-,-,Fact,6,6.3,6.3.1,6.3.1.2,6.3.1.2.3,Wnt通路
5769,KP9,34280751,"UPSC sarcomas#frequently overexpress#MDM2, CDK4, and PDGFRA",Expression Patterns,"MDM2,CDK4,PDGFRA",-,UPSC sarcomas,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5243,KP9,24913233,CDK4#is associated with#gains of chromosome 12,Genetic Alterations,CDK4,-,Indolent follicular lymphoma (FL),-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
2774,KP9,19734852,Liposarcomas#demonstrate amplification of#MDM2 and CDK4 genes,Genetic Alterations,"MDM2,CDK4",-,Liposarcomas,-,-,-,-,Amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5209,KP9,32195970,Primary lesion#overexpresses#MDM2 and CDK4,Expression Patterns,"MDM2,CDK4",-,Primary lesion,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
6124,KP9,32195970,"Recurrent tumors#demonstrate amplification of#DDR2, SDHC, and TSHR",Genetic Alterations,"DDR2,SDHC,TSHR",-,Recurrent tumors,-,-,-,-,Amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
2022,KP9,37444415,Advanced breast cancer patients with BRCA1/2 mutations#are treated with#CDK4/6 inhibitors,Therapeutic Development,"BRCA1,BRCA2,CDK4",-,Advanced breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1316,KP9,37444415,Germline BRCA1/2 variants#are treated with#CDK4/6 inhibitors,Therapeutic Development,"BRCA1,BRCA2,CDK4",-,Endocrine-sensitive disease,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5555,KP9,38751483,HR(+)HER2(-) MBC patients#switch to#CDK4/6 inhibitors or targeted drugs,Therapeutic Development,CDK4,-,HR(+) HER2(-) metastatic breast cancer,"CDK4/6 inhibitors, targeted drugs",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7258,KP9,38751483,Abemaciclib-based therapy#is compared with#Tucidinostat-based therapy,Therapeutic Development,CDK4,-,HR(+) HER2(-) metastatic breast cancer,"Abemaciclib, Tucidinostat",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
2111,KP9,38751483,PIK3CA mutations#occurred in#44.20% of patients,Biomarker Analysis,PIK3CA,-,-,-,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,7.5.1.1.1,ESR1突变
3555,KP9,38751483,Abemaciclib-based therapy#is superior to#tucidinostat-based therapy in patients progressed on palbociclib,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,"Abemaciclib, Tucidinostat, Palbociclib",-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2578,KP9,28856628,"Immunohistochemical staining#was positive for#p16, CDK4, and MDM2 expression",Biomarker Analysis,"CDKN2A,CDK4,MDM2",-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.3,p16表达
4127,KP9,37046638,Loss of PTEN and CDKN2A#is associated with#poor prognoses in chordoma patients,Cancer Association,"PTEN,CDKN2A",-,Chordoma,-,-,-,-,-,-,-,-,Inference,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
5304,KP9,26642065,Cyclin-dependent kinase pathways#are targets for#women's cancer treatment,Therapeutic Development,"CDK4,CDK6",-,Women's cancer,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6852,KP9,26642065,"CDK4/6 inhibitors#are studied for#breast cancer, liposarcoma, mantle cell lymphoma, melanoma, germ cell tumors, glioblastoma, renal cancer, ovarian cancer",Drug Development,"CDK4,CDK6",-,"Breast cancer, Liposarcoma, Mantle cell lymphoma, Melanoma, Germ cell tumors, Glioblastoma, Renal cancer, Ovarian cancer",-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1543,KP9,26642065,These oral agents#offer#hope of clinical efficacy in many tumor types,Therapeutic Response,"CDK4,CDK6",-,Tumors,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3686,KP9,26642065,Amplification/overexpression of cyclin D#and#CDK4 are proposed biomarkers of improved response to CDK4/6 inhibition,Biomarker Analysis,"CDK4,CCND1",-,-,-,-,-,-,Upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
1,KP9,26642065,Research#is needed to understand#mechanisms of resistance and develop combination therapies,Mechanisms of Resistance,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
7075,KP9,37881487,"The tumor#harbored#CDK4, TSPAN31, and JUN amplification",Cancer Association,"CDK4,TSPAN31,JUN",-,Tumor,-,-,-,-,Amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
4104,KP9,33921435,"Markers#correlate with#gene amplifications (e.g., MDM2, CDK4), deletions (e.g., SMARCB1, SMARCA4), and increased expression (e.g., MUC4, DOG1, ETV4, NKX2.2, NKX3.1)",Biomarker Analysis,"MDM2,CDK4,SMARCB1,SMARCA4,MUC4,DOG1,ETV4,NKX2.2,NKX3.1",-,-,-,-,-,-,Upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
7302,KP9,30176239,CDK4#is augmented in#T2DM and T2DM-CAD subjects,Expression Patterns,CDK4,-,"T2DM, T2DM-CAD",-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
2743,KP9,30176239,p16(Ink4a) and p15(Ink4b)#are diminished in#T2DM-CAD patients,Expression Patterns,"CDKN2A, CDKN2B",-,T2DM-CAD,-,-,-,T2DM-CAD patients,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7506,KP9,30176239,Atherosclerosis complications in T2DM#associate with#altered immune cell homeostasis,Immune Cell Functions,"CDKN2A, CDKN2B",-,"Atherosclerosis, T2DM",-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.2,-,髓系细胞浸润
4929,KP9,30176239,CDKN2A/2B/2BAS expression#is diminished in#T2DM subjects,Regulation,"CDKN2A, CDKN2B, CDKN2BAS",-,T2DM,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
4596,KP9,33396985,"Tumor cells#express#PDGFRA, CDK4, and MDM2",Expression Patterns,"PDGFRA, CDK4, MDM2",Tumor cells,Tumor,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
1580,KP9,33396985,"MDM2, CDK4, and EGFR genes#show#co-amplification",Cancer Pathways,"MDM2, CDK4, EGFR",-,Tumor,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5896,KP9,11376805,Gains in the 12q region#are associated with#amplifications of MDM2 and CDK4,Cancer Pathways,"MDM2, CDK4",-,Soft tissue sarcomas,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5534,KP9,11376805,MDM2 and CDK4#are amplified in#soft tissue sarcomas,Cancer Pathways,"MDM2, CDK4",-,Soft tissue sarcomas,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
2000,KP9,37298520,DDLPS#exhibits#higher amplification ratios of chromosome region 1p32 and 6q23,Cancer Pathways,-,-,DDLPS,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
6010,KP9,37298520,Higher amplification of chromosome regions 1p32 and 6q23#may explain#the more aggressive biology of DDLPS,Cancer Pathways,-,-,DDLPS,-,-,-,-,-,-,-,-,Inference,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5150,KP9,37298520,WDLPS#does not respond to#systemic chemotherapy,Therapeutic Resistance,-,-,WDLPS,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
5640,KP9,37298520,"WDLPS#is managed with#local therapy, including multiple resections and debulking",Therapeutic Development,-,-,WDLPS,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3393,KP9,37298520,Biomarkers#are assessed for#identifying tumors sensitive to immune checkpoint inhibitors,Biomarker Analysis,-,-,Tumors,-,Immune checkpoint,-,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,-,细胞周期标志物
2128,KP9,10748295,Ring chromosomes#are found as#a primary cytogenetic anomaly in rare benign soft tissue chondroma,Cytogenetics,-,-,Soft tissue chondroma,-,-,-,3-year-old girl,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.4,-,倒位
1621,KP9,10748295,Ring chromosomes#are described as#the primary genetic anomaly in mesenchymal neoplasms,Cytogenetics,-,-,Mesenchymal neoplasms,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.4,-,倒位
3836,KP9,10748295,MDM2 and CDK4#are implicated in#mesenchymal tumorigenesis,Cancer Pathways,"MDM2, CDK4",-,Mesenchymal tumors,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3378,KP9,37264081,PI3K-mTOR pathway#is central to#breast cancer pathogenesis,Cancer Pathways,MTOR,-,Breast cancer,-,PI3K-mTOR,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
5112,KP9,37264081,"mTOR kinase#forms#two distinct complexes, mTORC1 and mTORC2",Signaling Networks,MTOR,-,-,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.2,-,反馈调节
4587,KP9,37264081,RMC-6272#causes#apoptosis in ER+/HER2- breast cancer cell lines,Therapeutic Response,"MTOR, MCL1",-,Breast cancer,RMC-6272,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.3,-,线粒体通路调控
4628,KP9,37264081,RMC-6272#inhibits#rapamycin-resistant mTORC1 substrate 4EBP1,Mechanism of Action,"MTOR, EIF4EBP1",-,-,RMC-6272,mTORC1,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.2,-,反馈调节
7198,KP9,37264081,"RMC-6272#reduces#translation of ribosomal mRNAs, MYC target genes, and CDK4/6 pathway components",Mechanism of Action,"MYC, CDK4",-,-,RMC-6272,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
5261,KP9,22160092,Non-retroperitoneal dedifferentiated liposarcoma (DDLS)#is characterized by#molecular genetic alterations,Cancer Pathways,-,-,DDLS,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.2,5.4.2.3,-,DNA修复错误
5354,KP9,22160092,Cytogenetic analysis#exhibits#a complex karyotype with numerical and structural alterations,Cytogenetics,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.4,-,倒位
5875,KP9,22160092,Comparative genomic hybridization analysis#shows#high-level amplifications of 1q21-q25 and 12q13-q21,Cytogenetics,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
1704,KP9,22160092,Interphase FISH analysis#reveals#MDM2 and CDK4 gene amplification,Cytogenetics,"MDM2, CDK4",-,Tumor,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
2633,KP9,37649981,WDLPS and DDLPS#share#similar somatic mutations and CNVs,Cancer Pathways,-,-,"WDLPS, DDLPS",-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.3,-,驱动突变
755,KP9,37649981,DDLPS#has#a higher and more concentrated amplification of chromosome 12q region,Cancer Pathways,-,-,DDLPS,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
5271,KP9,39650068,"Tumors#develop resistance through#acquisition of genetic alterations of ER, MAP kinase pathway components, or transcription factors",Mechanisms of Resistance,"ESR1, MAPK1",-,Tumors,-,MAP kinase pathway,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
5095,KP9,39650068,HER2-low subtype#intersects with#endocrine resistance signaling networks,Cancer Pathways,ERBB2,-,HER2-low tumors,-,-,-,-,-,-,-,-,Inference,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
223,KP9,39220649,Liposarcoma mural nodule#displays#copy number amplifications of CDK4 and DDR2,Molecular Event triples,"CDK4, DDR2",-,Liposarcoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1937,KP9,25822339,Deletion of PTEN and p53#cooperates in#formation of multiple subtypes of LPS,Cancer Pathways,"PTEN, TP53",-,Liposarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.3,-,TP53缺失
2329,KP9,25822339,Expression of D cyclins and CDK4/6#allows for#continued cell division,Cell Cycle Control,"CDK4, CDK6",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
1247,KP9,25822339,Microarray analysis#revealed#novel genes differentially expressed between LPS subtypes,Biomarker Analysis,"CDK4, CDK6",-,Liposarcoma,-,-,-,-,upregulated,-,-,-,Fact,7,7.4,7.4.1,7.4.1.1,-,细胞周期基因集
3230,KP9,17340131,HPVs and p16INK4A alterations#were investigated in#squamous cell carcinomas of the head and neck,Cancer Pathways,CDKN2A,-,Squamous cell carcinoma,-,-,-,-,-,-,-,-,Fact,5,5.6,5.6.3,5.6.3.4,-,转录调控
4238,KP9,29581135,Endocrine resistance in ER(+) breast cancers#was identified through#biomarkers of resistance to endocrine therapy,Biomarker Analysis,ESR1,-,Breast cancer,Letrozole,-,-,-,-,-,-,-,Fact,2,2.5,2.5.2,2.5.2.4,-,生物标志物指导
6982,KP9,29581135,CDK4/6 inhibitor palbociclib#decreased#expression of upregulated genes in letrozole-resistant tumors,Therapeutic Response,"CDK4, CDK6",-,Breast cancer,Palbociclib,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.3,-,E2F转录因子活性下调
5936,KP9,29581135,E2F4 activation signature#is associated with#resistance to aromatase inhibitors,Mechanisms of Resistance,E2F4,-,Breast cancer,-,-,-,-,-,-,-,-,Inference,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
6552,KP9,10778944,p16 and p15#are frequently inactivated in#T-cell acute lymphoblastic leukemia,Cancer Pathways,"CDKN2A, CDKN2B",T cells,T-cell acute lymphoblastic leukemia,-,-,-,silenced,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
1079,KP9,34979748,Amplification of 12q14-q15 region#contains#MDM2 and CDK4 genes,Molecular Event triples,"MDM2, CDK4",-,-,-,-,-,upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
6150,KP9,33782225,"Immunohistochemistry#was performed for#MDM2, CDK4, CD34, Rb, S100, and desmin",Biomarker Analysis,"MDM2, CDK4",-,APLT,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
6419,KP9,33782225,Rare cases#showed staining for#MDM2 or CDK4,Biomarker Analysis,"MDM2, CDK4",-,APLT,-,-,-,upregulated,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
6538,KP9,39361142,Several contributing factors#increase#risk of recurrence in early breast cancer,Disease Mechanism,-,-,Early breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.3,2.3.2,2.3.2.4,-,通路活性标志
1549,KP9,39361142,"Tumor features, individual biomarkers, and genomic risk#contribute to#increased recurrence risk",Disease Mechanism,-,-,Early breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.3,2.3.2,2.3.2.4,-,通路活性标志
393,KP9,39361142,CDK4/6 inhibitors#reduce#risk of recurrence in high-risk HR+ HER2- early breast cancer,Therapeutic Response,"CDK4,CDK6",-,High-risk early breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2575,KP9,39361142,PARP inhibitors#improve#overall survival in patients with BRCA1/BRCA2 mutations,Therapeutic Response,"BRCA1,BRCA2",-,-,PARP inhibitors,-,-,Germline BRCA1/BRCA2 mutations,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
3019,KP9,30420727,"MDM2, CDK4, and DDIT3#are involved in#liposarcoma pathogenesis",Disease Mechanism,"MDM2,CDK4,DDIT3",-,Liposarcoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7990,KP9,29307627,"MDM2, CDK4, pancytokeratin AE/1AE3, desmin, and myogenin#showed#expression in liposarcoma",Expression Patterns,"MDM2,CDK4",-,Liposarcoma,-,-,-,Upregulated,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
5638,KP9,34703440,Dedifferentiated osteosarcoma#bears#MDM2 and/or CDK4 gene amplifications,Genomic Alteration,"MDM2,CDK4",-,Dedifferentiated osteosarcoma,-,-,-,Amplified,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3603,KP9,39191167,"Several genes#are involved in#CRC pathogenesis and regulation of reactive oxygen species, metabolic reprogramming, cell cycle, and apoptosis",Disease Mechanism,-,-,Colorectal cancer,-,"Reactive oxygen species, metabolic reprogramming, cell cycle, apoptosis",-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
6317,KP9,39191167,"TP53, PCNA, CDK4, CCNEB1, CDKN1A, and LDHA#are#highly upregulated genes in the rutin network",Expression Patterns,"TP53,PCNA,CDK4,CCNEB1,CDKN1A,LDHA",-,-,-,-,-,-,Upregulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
7656,KP9,39191167,"KEGG pathway analysis#enriched#metabolic and ROS signaling pathways, HIF1a, and mTOR signaling",Pathway Analysis,"HIF1A,MTOR",-,-,-,"Metabolic pathway, ROS signaling pathway, HIF1a, mTOR signaling",-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
5696,KP9,39191167,Rutin-induced G1 phase arrest#leads to#cell death in HT-29 cells,Cell Cycle Regulation,-,HT-29 cells,-,Rutin,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
316,KP9,33947696,Cyclin D-CDK4/6-INK4-Rb pathway alterations#are involved in#resistance to MAPK inhibitors in metastatic melanoma,Mechanisms of Resistance,"CDK4,CDK6",-,Metastatic melanoma,-,Cyclin D-CDK4/6-INK4-Rb pathway,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
4068,KP9,27334220,Alterations in the cyclin D1-CDK4/6-Rb axis#have been described#in synovial sarcomas,Cancer Pathways,"CDK4,CDK6,CCND1,RB1",-,Synovial sarcoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
1222,KP9,27334220,FISH#showed#a sporadic translocation of CCND1 in a subset of tumors,Molecular Event,CCND1,-,Tumor,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
878,KP9,39553226,Compounds#were identified#to potentially target aberrations in CDK4/6,Drug Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
694,KP9,9551329,The gene CDKN2/MTS1#has been proposed as#a tumor-suppressor gene located on chromosome 9p21,Cancer Pathways,CDKN2A,-,"Human cancers, malignant melanoma",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
3163,KP9,39215191,Mutations in BRCA1 and/or BRCA2#increase#the risk of developing breast cancer,Cancer Association,"BRCA1,BRCA2",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
6481,KP9,21552124,Novel agents targeting chromosome 12 gene products CDK4 and MDM2#have shown#promise in preclinical studies,Drug Development,"CDK4,MDM2",-,"WDLS, DDLS",-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7677,KP9,21552124,"Additional targets including ZIC1, TOP2A, AURKA, and IGF-1R#could form#the basis of future therapies",Therapeutic Development,"ZIC1,TOP2A,AURKA,IGF1R",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6075,KP9,22790852,Consistent rearrangements of chromosomes 13q and 16q#have been identified#in spindle cell and pleomorphic lipomas,Cancer Pathways,RB1,-,"Spindle cell lipoma, pleomorphic lipoma",-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.3,-,重复
3361,KP9,22790852,"The tumor suppressor gene RB1#is located at#13q14, within a minimally deleted region in spindle cell lipoma",Cancer Pathways,RB1,-,Spindle cell lipoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.2,-,RB1缺失
7736,KP9,37043646,MEIS1::NCOA2 gene fusion and CDK4 amplification#were revealed#in a primary uterine sarcoma,Cancer Association,"MEIS1,NCOA2,CDK4",-,Uterine sarcoma,-,-,-,-,Amplification (CDK4),-,-,-,Fact,7,7.1,7.1.1,7.1.1.3,-,基因融合
949,KP9,37043646,HMGA2/CDK4/MDM2 region amplification#might be#a recurrent genetic event in this rare sarcoma subtype,Cancer Association,"HMGA2,CDK4,MDM2",-,Sarcoma,-,-,-,-,Amplification,-,-,-,Inference,7,7.1,7.1.1,7.1.1.3,-,基因融合
127,KP9,20228779,Well-differentiated spindle cell liposarcoma#has been regarded as#a variant of atypical lipomatous tumor,Cancer Association,-,-,"Well-differentiated spindle cell liposarcoma, atypical lipomatous tumor",-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.3,-,基因融合
1777,KP9,20228779,Well-differentiated spindle cell liposarcoma#lacks#amplification of MDM2 and/or CDK4 in most cases analyzed,Molecular Event,"MDM2,CDK4",-,Well-differentiated spindle cell liposarcoma,-,-,-,Lacks amplification,-,-,-,-,Fact,7,7.1,7.1.2,7.1.2.3,-,CDKN2A缺失
5090,KP9,20228779,Rb-1 gene#is deleted in#all six cases,Genetic alteration,RB1,-,Liposarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.2,-,RB1缺失
3778,KP9,20228779,MDM2/CDK4 amplification#is not identified in#all cases tested,Genetic alteration,"MDM2,CDK4",-,Liposarcoma,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.2,7.1.2.3,-,CDKN2A缺失
6236,KP9,20228779,well-differentiated spindle cell liposarcoma#may represent#the atypical/low-grade counterpart of spindle cell lipoma,Clinical correlation,-,Spindle cells,"Liposarcoma, Lipoma",-,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.3,-,基因融合
7869,KP9,16457759,germline mutations in CDKN2A and CDK4#play pivotal roles in#controlling cell cycle and division,Mechanism of Action,"CDKN2A,CDK4",-,Melanoma,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
3599,KP9,37511178,plasma samples from HR+/HER2- mBC patients#were interrogated using#digital PCR and SafeSEQ sequencing,Technical methods,-,Plasma,-,Endocrine therapy,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,-,生物标志物监测
4235,KP9,37511178,"mutations in ESR1, TP53, and KRAS#emerged as#putative drivers of acquired resistance",Mechanisms of Resistance,"ESR1,TP53,KRAS",-,HR+/HER2- metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
7717,KP9,37511178,longitudinal ctDNA characterization#supports#ongoing studies targeting actionable alterations,Biomarker analysis,-,ctDNA,HR+/HER2- metastatic breast cancer,-,-,-,-,-,-,-,-,Inference,7,7.6,7.6.1,7.6.1.1,7.6.1.1.1,循环肿瘤DNA检测
6332,KP9,10966854,germline mutations in CDKN2A#are identified in#hereditary melanoma,Genetic alteration,CDKN2A,-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,5.5.1.1.1,RB1突变
4183,KP9,10966854,changes in other genes at 9p21#may predispose to#melanoma,Genetic alteration,CDKN2A,-,Melanoma,-,-,-,-,-,-,-,-,Inference,5,5.3,5.3.1,5.3.1.1,-,基因扩增
6234,KP9,34135599,activating mutations in NRAS#are found in#20% of melanomas,Genetic alteration,NRAS,-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,激活性突变
5541,KP9,34135599,MEK inhibitors#have been#the most developed targeted therapy approach,Drug development,MAP2K1 (MEK1),-,Melanoma,MEK inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
397,KP9,34135599,greater comprehension of NRAS-mutant melanoma biology#will outline#novel impactful strategies to improve prognosis,Therapeutic development,NRAS,-,Melanoma,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4730,KP9,29489027,H3K27me3-deficient ESOS#showed#EED homozygous deletion,Genetic alteration,EED,-,ESOS,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.2,-,基因缺失
5550,KP9,29489027,"none of the three cases#showed alterations in#NF1, CDKN2A, or SUZ12 genes",Genetic alteration,"NF1,CDKN2A,SUZ12",-,ESOS,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.4,-,剪切位点突变
1355,KP9,26892441,HMGA2 expression#is associated with#a chromosomal rearrangement,Genetic alteration,HMGA2,-,Leiomyomatosis,-,-,-,Upregulated,-,-,-,-,Fact,5,5.4,5.4.2,5.4.2.3,-,DNA修复错误
3192,KP9,26892441,loss of hybridization signal at 7q22 region#is not detected in#uterine leiomyomata,Genetic alteration,-,Smooth muscle cells,Leiomyomata,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.4,-,肿瘤抑制子缺失
1935,KP9,26892441,intravenous leiomyomatosis case#revealed#complex copy number variations,Genetic alteration,-,Smooth muscle cells,Leiomyomatosis,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
2223,KP9,22699518,tumor cells#harbor#high-level MDM2 amplification,Genetic alteration,MDM2,-,Tumor,-,-,-,Upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
4953,KP9,22699518,MDM2 amplification#was detected when#one tumor recurred,Genetic alteration,MDM2,-,Tumor,-,-,-,Upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
4125,KP9,22699518,CDK4#is amplified in#atypical lipomatous tumors and dedifferentiated liposarcomas,Molecular Event triples,CDK4,-,"Atypical lipomatous tumors, Dedifferentiated liposarcomas",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5937,KP9,37982827,TP53#is mutated in#57% of cases,Molecular Event triples,TP53,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
5574,KP9,37982827,GNAQ#is mutated in#35% of cases,Molecular Event triples,GNAQ,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
2988,KP9,37982827,PIK3CA#is mutated in#17% of cases,Molecular Event triples,PIK3CA,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6401,KP9,28463841,"CDKN2A, CDK4, MITF#are associated with#increased melanoma penetrance when coincident with MC1R variants",Molecular Event triples,"CDKN2A, CDK4, MITF",-,Melanoma,-,Pigmentation pathway,-,-,-,-,-,-,Fact,1,1.2,1.2.1,1.2.1.1,-,生长因子信号
6903,KP9,25059573,CDK4#amplification levels#are explored as tumor behavior markers,Biomarker Analysis,CDK4,-,Tumor,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
3371,KP9,37406274,CDK6#is included in#the molecular expression panel,Molecular Event triples,CDK6,-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
3071,KP9,39137473,"CDKN2A, CDK4, BAP1, POT1#are linked to#high melanoma risk",Molecular Event triples,"CDKN2A, CDK4, BAP1, POT1",-,Melanoma,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,RB1突变
1688,KP9,31505115,"CDKN2A, CDK4, MITF, BAP1#are associated with#hereditary predisposition to melanoma",Molecular Event triples,"CDKN2A, CDK4, MITF, BAP1",-,Melanoma,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,RB1突变
7308,KP9,7656201,CDK4#is amplified in#human soft tissue tumors,Molecular Event triples,CDK4,-,Soft tissue tumors,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,5.3.1.1.1,CDK4扩增
2053,KP9,34853632,"CDKN2A, CDK4#are clinically tested for#familial melanoma",Clinical Implementation,"CDKN2A, CDK4",-,Familial melanoma,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,RB1突变
1845,KP9,15721476,Heritable mutations in CDKN2A and CDK4#increase#melanoma susceptibility more than tenfold,Cancer Association,"CDKN2A, CDK4",-,Melanoma,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,RB1突变
2635,KP9,15721476,Molecular pathways#are identified as being central to#melanoma growth and apoptosis,Cancer Pathways,-,-,Melanoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
2691,KP9,12036902,Genes#were found differentially expressed in#dedifferentiated and pleomorphic liposarcomas,Expression Patterns,-,-,"Dedifferentiated liposarcoma, Pleomorphic liposarcoma",-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
2085,KP9,12036902,Genomic profiling#appears to be more advantageous than#RNA expression analysis for distinguishing liposarcoma types,Technical Methods,-,-,Liposarcoma,-,-,-,-,-,-,-,-,Inference,7,7.4,7.4.1,7.4.1.1,7.4.1.1.1,细胞周期基因集
1711,KP9,32359372,Clinical features and follow-up information#were summarized for#patients with LPD during pregnancy,Clinical Implementation,-,-,LPD (lymphoproliferative disorder),-,Pregnancy,-,Pregnancy,-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.2,8.6.1.2.1,疾病状态
6337,KP9,38427931,"ESR1, PIK3CA, AR, FGFR2, and TP53#are frequently mutated in#T0",Expression Patterns,"ESR1, PIK3CA, AR, FGFR2, TP53",-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.3,ESR1突变
16,KP9,33190190,"Genomic biomarkers#are used for#managing HR+, HER2- MBC",Biomarker Analysis,"BRCA1, BRCA2, ESR1, HER2, PIK3CA",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.3,ESR1突变
6152,KP9,16631473,HLA of 8q24#is related to#MYC,Genomic Alterations,MYC,-,-,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.1,-,易位
1781,KP9,16631473,HLA of 17q12#is related to#ERBB2,Genomic Alterations,ERBB2,-,-,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.1,-,易位
1745,KP9,21274402,"Amplification of 12q13-15#involves#MDM2, CDK4, and CPM genes in liposarcomas",Genomic Alterations,"MDM2, CDK4, CPM",-,Liposarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1590,KP9,25600792,"CDKN2A, CDK4, and BAP1#are identified as#high-risk susceptibility genes",Cancer Association,"CDKN2A,CDK4,BAP1",-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
4036,KP9,34159748,Long-term disease control and survival#are observed after#stereotactic ablative body radiotherapy for oligometastatic breast cancer,Therapeutic Response,-,-,Oligometastatic breast cancer,-,-,-,Long-term,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
5536,KP9,34159748,"Alterations in CEBPB, RB1, TBX3, PTEN, and CDK4#are associated with#worse survival outcomes",Cancer Association,"CEBPB,RB1,TBX3,PTEN,CDK4",-,-,-,-,-,-,-,-,-,-,Inference,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
329,KP9,33738541,MDM2/CDK4 amplification#is identified in#all WDL/DDL cases,Cancer Association,"MDM2,CDK4",-,"WDL,DDL",-,-,-,-,amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
2744,KP9,33738541,DDIT3 rearrangement#is identified in#all ML cases,Structural Biology,DDIT3,-,ML,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
4748,KP9,11734312,Supernumerary markers of WDLPS#share#12q amplified sequences with centromere alterations,Structural Biology,-,-,WDLPS,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.3,-,重复
6457,KP9,19691106,Ring chromosomes in ALT#contain#amplified material from 12q12-->15 and segments from other chromosomes,Structural Biology,-,-,ALT,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.2,5.4.2.2,-,基因组重排
6254,KP9,19691106,Recurrent amplicons in ALT#harbor#TSPAN31 and CDK4,Structural Biology,"TSPAN31,CDK4",-,ALT,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1058,KP9,19691106,Breakpoints in ALT#are enriched in#repeated elements important for ring chromosome formation,Structural Biology,-,-,ALT,-,-,-,-,-,-,-,-,Inference,5,5.5,5.5.2,5.5.2.3,-,基因组重排
6269,KP9,36898668,Childhood retinoblastoma#is associated with#AC/DL,Disease Association,RB1,-,Childhood retinoblastoma,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,RB1突变
3136,KP9,36898668,Germline RB1 gene deletion#is associated with#bilateral RB in infancy,Disease Association,RB1,-,Bilateral retinoblastoma,-,-,-,30-year-old male,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.2,-,RB1缺失
7195,KP9,38981345,"Mutations of CDC73, ATM, TP53, ALK, ERBB2, MAP3K4, TSC1, CCND1#overlap between#metastatic lesions and primary lesions",Genomic Alterations,"CDC73,ATM,TP53,ALK,ERBB2,MAP3K4,TSC1,CCND1",-,Cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
4275,KP9,38981345,"CNV of CDK4, MCL1, SMARCB1#overlap between#metastatic lesions and primary lesions",Genomic Alterations,"CDK4,MCL1,SMARCB1",-,Cancer,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7066,KP9,37444470,Sarcoma oncology#lacks#targeted therapeutic interventions,Clinical Research,CDK4,-,Sarcoma,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
837,KP9,37444470,Differential pathways#contribute to#dedifferentiation process in liposarcoma,Pathway & Network,CDK4,-,Liposarcoma,-,-,-,-,-,-,-,-,Inference,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
6888,KP9,37444470,Gli2#is differentially expressed between#WDLPS and DDLPS,Expression Patterns,Gli2,-,"WDLPS, DDLPS",-,ECM remodeling,-,Differentially expressed,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.3,细胞周期蛋白
3375,KP9,36618786,Mutation and copy number changes#were input into#a computational model,Genomic Alterations,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.3,-,-,剂量效应
3537,KP9,36618786,Treatment#achieved#a prompt and clinically meaningful remission lasting 6 months,Therapeutic Response,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1149,KP9,36618786,Combination of abemaciclib and nelfinavir#appear promising for#GBM and other cancers harboring chromosome 12q amplification,Combination Therapies,CDK4,-,"GBM, other cancers","Abemaciclib, Nelfinavir",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6059,KP9,10825007,Genes at 13q31#are significant in#development or progression of alveolar rhabdomyosarcoma,Genomic Alterations,-,-,Alveolar rhabdomyosarcoma,-,-,-,-,-,-,-,-,Inference,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
2674,KP9,35294522,"NRAS mutation with concurrent alterations of CDKN2A, CDK4, or CCND1#has a response rate of#32.5% in patients",Therapeutic Response,"NRAS,CDKN2A,CDK4,CCND1",-,Cancer,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
5886,KP9,23393200,FRS2#is located on#chromosome 12q13-15,Genomic Alterations,FRS2,-,Liposarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
6558,KP9,23393200,"Amplification and expression of FRS2, CDK4, and MDM2#were observed in#55%-48%-44% of UHGPS",Expression Patterns,"FRS2,CDK4,MDM2",-,UHGPS,-,-,-,Amplified,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
7889,KP9,23393200,Amplification and expression of genes#suggest that#UHGPS may represent DDLS,Disease Association,"FRS2,CDK4,MDM2",-,"UHGPS, DDLS",-,-,-,-,-,-,-,-,Inference,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
6328,KP9,39411551,NGS analyses#revealed#five class 4 or 5 sequence variants,Genomic Alterations,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.4,-,乘客突变
978,KP9,39411551,OncoScan and targeted analyses#identified#genomic gains of CCND1 in two cases,Genomic Alterations,CCND1,-,-,-,-,-,Upregulated,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
7664,KP9,24771630,IMP3#is targeted by#differentially expressed miRNAs,Regulation,IMP3,-,-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,微小RNA
4453,KP9,24771630,ROR2#is targeted by#differentially expressed miRNAs,Regulation,ROR2,-,-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,微小RNA
1760,KP9,24771630,MDM2#is targeted by#differentially expressed miRNAs,Regulation,MDM2,-,-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,微小RNA
7841,KP9,24771630,CDK4#is targeted by#differentially expressed miRNAs,Regulation,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,微小RNA
5237,KP9,24771630,UPA#is targeted by#differentially expressed miRNAs,Regulation,PLAU,-,-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,微小RNA
5180,KP9,24771630,miRNA expression patterns#are linked to#tumor development/progression of LMS and UPS,Expression Patterns,CDK4,-,"LMS, UPS",-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,微小RNA
1101,KP9,38926909,PTEN gene#contains#a nonsense mutation,Cancer Association,PTEN,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.2,-,无义突变
6761,KP9,38926909,CDK4#undergoes#focal amplification,Cancer Association,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
4792,KP9,38926909,MDM2#undergoes#focal amplification,Cancer Association,MDM2,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
1878,KP9,18403636,CDK4#is overexpressed in#amplified regions,Expression Patterns,CDK4,-,-,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1118,KP9,18403636,MDM2#is overexpressed in#amplified regions,Expression Patterns,MDM2,-,-,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
7393,KP9,15041220,MDM2#is amplified in#12q regions,Cancer Association,MDM2,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
5882,KP9,15041220,CDK4#is amplified in#12q regions,Cancer Association,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
4683,KP9,31807008,MDM2#is amplified in#inflammatory myofibroblastic tumor,Cancer Association,MDM2,-,Inflammatory myofibroblastic tumor,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.4,MDM2扩增
1630,KP9,31334109,Clinically relevant inhibitors#sensitize#MCL cell line,Therapeutic Response,CDK4,-,Mantle cell lymphoma,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2467,KP9,22804906,CDKN2A#contains#germline mutations,Cancer Association,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
5264,KP9,22804906,CDK4#contains#germline mutations,Cancer Association,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
4985,KP9,11840272,Cyclin D1#is overexpressed in#20-25% of primary tumors,Expression Patterns,CCND1,-,-,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
794,KP9,11840272,CDKN2B#is deleted in#cyclin D1-expressing MM cell lines,Cancer Association,CDKN2B,-,Multiple myeloma,-,-,-,-,downregulated,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
6205,KP9,11840272,CDKN2A#is deleted in#cyclin D1-expressing MM cell lines,Cancer Association,CDKN2A,-,Multiple myeloma,-,-,-,-,downregulated,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
5440,KP9,11840272,CDKN2C#is deleted in#38% of MM cell lines,Cancer Association,CDKN2C,-,Multiple myeloma,-,-,-,-,downregulated,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
1468,KP9,34518211,Sensitive models#display#a basal-like 1 TNBC subtype,Expression Patterns,CDK4,-,Triple-negative breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.2,7.4.1.2.2,Basal样亚型
5277,KP9,34518211,Mitochondrial genes#showed#higher expression in sensitive PDXs,Expression Patterns,-,PDXs,-,-,-,-,-,upregulated,-,-,-,Fact,4,4.1,4.1.2,4.1.2.1,-,氧化磷酸化改变
3219,KP9,34518211,Functional genomics screen#identified#CDK4 as a synthetic lethal target in tumors treated with IACS-10759,Mechanism of Action,CDK4,-,Tumors,IACS-10759,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
336,KP9,34518211,Triple-negative breast cancer#is reliant on#OXPHOS,Cancer Pathways,-,-,Triple-negative breast cancer,-,OXPHOS,-,-,-,-,-,-,Inference,4,4.1,4.1.2,4.1.2.1,-,氧化磷酸化改变
3844,KP9,34714275,CDKN2A gene#is associated with#pancreatic cancer and melanoma susceptibility,Cancer Association,CDKN2A,-,"Pancreatic cancer, melanoma",-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.2,-,RB1缺失
6387,KP9,31401335,"TP53 mutation#is most common in#genetic alterations, followed by CDK4 and CDKN2A CNV",Cancer Association,"TP53,CDK4,CDKN2A",-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6876,KP9,22034077,Pharmacological inhibition of cell cycle genes#might provide#therapeutic promises for high-risk neuroblastoma patients,Therapeutic Development,-,-,Neuroblastoma,-,-,-,High-risk,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3077,KP9,16547504,Keratoacanthomas and squamous cell carcinomas#are frequent in#immune-suppressed transplant patients,Cancer Association,-,-,"Keratoacanthomas, squamous cell carcinomas",-,-,-,Immune-suppressed,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
7401,KP9,16547504,Gain of chromosome 11q#is frequent in#keratoacanthomas,Genetic Alterations,-,-,Keratoacanthomas,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.3,-,重复
2834,KP9,16547504,A clone#additionally upregulated#CDK4 and p21,Expression Patterns,"CDK4,CDKN1A",-,-,-,-,-,-,upregulated,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6923,KP9,12447651,OSCC#develops along#a multistep pathway involving loss of tumor suppressor genes and amplification of oncogenes,Cancer Pathways,-,-,Oral squamous cell carcinoma (OSCC),-,Multistep pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
3319,KP9,35725578,"A tumor#showed#a BRAF V600E mutation and homozygous deletion in PTEN, without changes in EGFR, CDKN2A, TP53, NFKBIA, CDK4, MDM2, and PDGFRA",Genetic Alterations,"BRAF,PTEN,EGFR,CDKN2A,TP53,NFKBIA,CDK4,MDM2,PDGFRA",-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
5808,KP9,36811835,MEIS1-NCOA1/2 fusions#are found in#rare sarcomas mainly involving genitourinary and gynecologic tracts,Genetic Alterations,"MEIS1,NCOA1,NCOA2",-,Sarcomas,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
2012,KP9,25762475,Resistance to ET#is observed in#intrinsic or acquired settings,Therapeutic Resistance,-,-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
7680,KP9,25762475,CDK4/6 inhibitors#show promise in#targeting mechanisms of resistance to ET,Drug Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3226,KP9,25762475,ER signaling#remains#a therapeutic target in resistance settings,Therapeutic Development,ESR1,-,-,-,-,-,-,-,-,-,-,Inference,2,2.5,2.5.2,2.5.2.1,-,新型抑制剂开发
3036,KP9,25762475,Recurrent mutations in ESR1#are identified in#metastatic ER+ breast cancer,Genetic Alterations,ESR1,-,Metastatic ER+ breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
2777,KP9,25284789,Cancer development#is driven by#genetic mutations and epigenetic alterations,Cancer Pathways,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.1,1.5.1.2,-,DNA甲基化
5460,KP9,25284789,"CHTOP#methylates#H4R3 in genes involved in glioblastomagenesis, including EGFR, AKT3, CDK6, CCND2, and BRAF",Molecular Mechanisms,"EGFR,AKT3,CDK6,CCND2,BRAF",-,Glioblastoma,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.1,1.5.1.1,-,组蛋白修饰
6925,KP9,39592485,TERT promoter mutation#was detected in#2 cases,Mutation frequencies,TERT,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.2,-,无义突变
7239,KP9,39592485,RNA NGS sequencing#identified#differences in mRNA expression between DICER1(MUT) and DICER1(WT) tumors,Expression Patterns,DICER1,-,Tumor,-,-,-,-,-,-,-,-,Fact,5,5.6,5.6.3,5.6.3.2,-,非编码RNA
6007,KP9,31995237,Tumor#was diffusely positive for#MDM2 and CDK4,Molecular Event triples,"MDM2,CDK4",-,Tumor,-,-,-,upregulated,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
368,KP9,29859466,Anticancer drugs#are designed to act on#specific targets by altering the activity of involved transporters and genes,Drug Development,-,-,Cancer,Anticancer drugs,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3293,KP9,29859466,Cancer cells#exhibit#complex cellular machinery leading to chemo resistance and tissue regeneration,Therapeutic Resistance,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,2.6.1.3,-,靶点修饰
3254,KP9,29859466,"78 pathways, genes, and natural compounds#were included in#multitargeted cancer treatment approach",Pathway & Network Categories,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
2215,KP9,29859466,"Selected genes#include#CDKN2A, FH, VHL, STK11, SUFU, RB1, MEN1, HRPT2, EXT1, EXT2, CDK4, p14, p16, TSC1, TSC2, AXIN2, SDHB, SDHC, SDHD, NF1, NF2, BHD, PTCH, GPC3, CYLD, WT1",Gene List,"CDKN2A,FH,VHL,STK11,SUFU,RB1,MEN1,HRPT2,EXT1,EXT2,CDK4,CDKN2A,TSC1,TSC2,AXIN2,SDHB,SDHC,SDHD,NF1,NF2,BHD,PTCH,GPC3,CYLD,WT1",-,Cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,RB1突变
4333,KP9,24405942,"Immunohistochemistry#showed no expression of#p16(INK4a), VEGFR1, KDR (VEGFR2), VEGFR3, cKIT, MDM2, CDK4",Expression Patterns,"CDKN2A,FLT1,KDR,FLT4,KIT,MDM2,CDK4",-,Tumor,-,-,-,silenced,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
37,KP9,38306361,"Stem-like glioma cells (SLGCs)#are involved in#tumor initiation, ...",Neural Cell Regulation,-,Stem-like glioma cells,Glioma,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.1,-,细胞增殖调控
4404,KP9,31442826,Clinico-radiological findings and pathological features#are often#...,Clinical Implementation,-,-,Intimal sarcoma,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
5288,KP9,31442826,MDM2 amplification#was reported to be#a characteristic genetic eve...,Cancer Association,MDM2,-,Intimal sarcoma,-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
6514,KP9,31442826,MDM2 and CDK4#were immunopositive in#all 10 intimal sarcoma tumors,Expression Patterns,"MDM2,CDK4",-,Intimal sarcoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6580,KP9,31442826,High-level amplification of MDM2#was detected in#eight tumors by b...,Mutation frequencies,MDM2,-,Intimal sarcoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
4808,KP9,31442826,MDM2 aberrations#were observed in#three p-SCs (two with amplificati...,Mutation frequencies,MDM2,-,p-SCs,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
7861,KP9,31442826,MDM2 amplification#strongly supports#the diagnosis of intimal sarc...,Prognostic associations,MDM2,-,Intimal sarcoma,-,-,-,-,upregulated,-,-,-,Inference,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
5369,KP9,25554652,NAB2-STAT6#is#a specific diagnostic marker for solitary fibrous t...,Biomarker Analysis,"NAB2, STAT6",-,Solitary fibrous tumors (SFTs),-,-,-,-,-,Diagnostic marker,-,-,Fact,7,7.6,7.6.1,7.6.1.1,-,循环肿瘤DNA
3013,KP9,25554652,NAB2-STAT6 fusion gene-negative tumors#showed#amplification of MDM...,Expression Patterns,"MDM2, CDK4",-,Tumors,-,-,-,-,Amplified,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
3501,KP9,24070870,Sarcomas with MDM2-negative rings#show#complete loss of CDKN2A or RB1,Disease Mechanisms,"MDM2, CDKN2A, RB1",-,Sarcomas,-,-,-,-,Loss,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
7324,KP9,34636747,Strategies to increase response rates#are being investigated#by co...,Drug Development,"CDK4, CDK6",-,Low-grade serous ovarian cancer (LGSC),CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
1183,KP9,34636747,LGSC#has#a high prevalence of activating somatic mutations in mito...,Pathway & Network Categories,"KRAS, BRAF, NRAS",-,Low-grade serous ovarian cancer (LGSC),-,Mitogen-activated protein kinase pathway,Mutated,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
4850,KP9,36307579,Advanced treatment strategies#such as#targeted therapy and immunotherapy are yet to be explored,Therapeutic Development,-,-,Pituitary neuroendocrine tumors (PitNET),"Targeted therapy, immunotherapy",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7251,KP9,36307579,"Potential therapeutic targets#identified#including CDK6, TWIST1, EGFR, and VEGFR2 for different clusters",Therapeutic Development,"CDK6, TWIST1, EGFR, VEGFR2",-,Pituitary neuroendocrine tumors (PitNET),-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7782,KP9,36307579,Immune subtyping#identified#an association between JAK1-STAT1-PDL1 axis alterations and immune exhaustion,Immune Cell Functions,"JAK1, STAT1, CD274",-,Immune exhaustion,-,JAK1-STAT1-PDL1 axis,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.3,6.1.1.3.1,PD-1/PD-L1表达
352,KP9,36307579,Changes in JAK3-STAT6-FOS/JUN axis#are associated with#immune infiltration,Immune Cell Functions,"JAK3, STAT6, FOS, JUN",-,Immune infiltration,-,JAK3-STAT6-FOS/JUN axis,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,6.1.1.1.4,细胞毒性活性
565,KP9,28807343,MDM2/CDK4#were#negative by immunohistochemistry in all cases,Biomarker Analysis,"MDM2, CDK4",-,Lipomatous neoplasms,-,-,-,Negative,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
6483,KP9,28807343,Rb1 FISH analysis#revealed#copy number aberrations in 3 of 4 cases,Molecular Event,RB1,-,-,-,-,-,Aberrations,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
7121,KP9,19820690,"Abnormal chromosomes#contain#amplified genomic sequences including MDM2, CDK4, TSPAN31, and HMGA2",Molecular Event,"MDM2, CDK4, TSPAN31, HMGA2",-,-,-,-,-,Amplified,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
6341,KP9,19820690,CPM#is consistently amplified in#well-differentiated liposarcomas/atypical lipomatous tumors,Cancer Association,CPM,-,"Well-differentiated liposarcomas, atypical lipomatous tumors",-,-,-,Amplified,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
1091,KP9,38137564,"CDKN2A mutations#are associated with#recurrent alterations such as c.307_308del, c.159G>C and c.71G>C",Mutation triples,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
1604,KP9,34572780,"TP53, ARID1A, PTEN, ARID5B, CTNNB1, CTCF, and CCND1#are enriched in#HPV(U) tumors",Mutation triples,"TP53, ARID1A, PTEN, ARID5B, CTNNB1, CTCF, CCND1",-,HPV(U) tumors,-,Cell cycle progression,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.4,-,剪切位点突变
4031,KP9,39759323,"CSF#exhibited#genetic variations such as EGFR mutations/amplifications and alterations in TP53, CDKN2A, MET, and CDK6",Mutation triples,"EGFR, TP53, CDKN2A, MET, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
7421,KP9,21117066,"Liposarcomas#had#12q13-q15 amplifications with peaks at CDK4, HMGA2, and MDM2",Mutation triples,"CDK4, HMGA2, MDM2",-,Liposarcoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
4474,KP9,24457460,CDK4 expression#was observed in#dedifferentiated liposarcoma cases,Expression Patterns,CDK4,-,Dedifferentiated liposarcoma,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
3813,KP9,33671468,CDK4/6 inhibitors#are approved for use in combination with#endocrine therapies in HR+ breast cancer,Drug Development,"CDK4, CDK6",-,HR+ breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
2858,KP9,33671468,Targeted therapies#have changed#the natural history of HR+ breast cancers,Therapeutic Response,-,-,HR+ breast cancer,-,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3179,KP9,33671468,Genomic tests#guide#the addition of chemotherapy to endocrine therapy,Clinical Implementation,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.3,8.2.1.3.2,生物标志物监测
3302,KP9,20305534,Atypical lipomatous tumor-like areas#were negative for#MDM2 and CDK4,Expression Patterns,"MDM2, CDK4",-,Atypical lipomatous tumor,-,-,-,-,silenced,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
4863,KP9,17213017,"JUN, CDK4, and SLUG protooncogenes#are implicated in#cancer development",Cancer Association,"JUN, CDK4, SLUG",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2375,KP9,35398754,"Over 50% of breast tumors#harbor#alterations in PI3K pathway genes including PIK3CA, PTEN, and AKT1",Pathway & Network Categories,"PIK3CA, PTEN, AKT1",-,Breast tumors,-,PI3K pathway,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
6412,KP9,35398754,PI3K and mTOR inhibitors#are approved for use in#advanced breast cancer,Drug Development,MTOR,-,Advanced breast cancer,"PI3K inhibitors, mTOR inhibitors",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
951,KP9,35398754,"Toxicity profile#includes#hyperglycemia, diarrhea, and maculopapular rash",Safety Monitoring,-,-,-,-,-,"Hyperglycemia, Diarrhea, Maculopapular rash",-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,8.4.1.2.1,胃肠道反应
1129,KP9,16738322,Rb-mediated G1 control pathway inactivation#is a common event in#many human tumors,Pathway & Network Categories,RB1,-,Human tumors,-,G1 control pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
3522,KP9,16738322,"Double mutant mice#develop#a wider spectrum of tumors, including prostate cancer",Disease & Clinical Categories,-,mice,Prostate cancer,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,7.2.1.2.4,ER/PR状态
2062,KP9,25168062,Macrophage migration inhibitory factor (MIF)#is involved in#cell cycle regulation and the control of proliferation,Molecular & Cellular Categories,MIF,-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
991,KP9,25168062,Overexpression of MIF#is upregulated in#melanocytic tumors with the highest expression levels in malignant melanoma,Expression Patterns,MIF,-,Malignant melanoma,-,-,-,-,Upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.3,p16表达
5892,KP9,25168062,High MIF levels in metastatic melanoma#are associated with#faster disease recurrence,Disease & Clinical Categories,MIF,-,Metastatic melanoma,-,-,Disease recurrence,-,High,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.4,RB蛋白表达
5353,KP9,38148576,PIK3CA gene#is mutated in#approximately 40% of HER2-negative/HR-positive breast cancer tumors,Cancer Association,PIK3CA,-,HER2-negative/HR-positive breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
6392,KP9,33072577,Endocrine therapy (ET)#is the mainstay of treatment for#hormone receptor-positive HER2-negative metastatic breast cancer,Clinical Implementation,-,-,Metastatic breast cancer,Endocrine therapy,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5160,KP9,33072577,Epigenetic-mediated events#are potentially involved in#alternative mechanisms of resistance,Mechanisms of Resistance,-,-,-,-,Epigenetic mechanisms,-,-,-,-,-,-,Inference,2,2.1,2.1.3,2.1.3.2,-,组蛋白修饰异常
2258,KP9,33072577,ESR1 and PIK3CA mutations#are associated with#ET resistance,Mechanisms of Resistance,"ESR1,PIK3CA",-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
822,KP9,31848929,"Pembrolizumab#is FDA-approved for#PD-L1 positive, locally advanced or metastatic ESCC",Drug Development,CD274,-,Metastatic ESCC,Pembrolizumab,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1194,KP9,24231788,Cancer development#involves#multiple cellular signaling transduction pathways,Pathway & Network Categories,-,-,Cancer,-,Signaling pathways,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
4116,KP10,26658964,Selective inhibitors of CDK4/6#validate#these cell-cycle kinases as anticancer drug targets,Drug Development,"CDK4,CDK6",-,Cancer,CDK4/6 inhibitors,Cell cycle,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7223,KP10,8891723,"p16Ink4a and p15Ink4b genes#present#frequent homozygous deletions in ALL T, ATL, and lymphoblastic acutisation of CML",Cancer Association,"CDKN2A,CDKN2B",-,"ALL T, ATL, CML",-,-,-,-,Deleted,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
4034,KP10,11407596,Aberrations#drive#astrocytoma cells into relentless proliferation,Mechanism of Action triples,-,Astrocytoma cells,Astrocytoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
1830,KP10,26840126,p53-downregulated mRNAs#were identified through#parallel microarray analysis,Regulation triples,TP53,-,-,-,-,-,-,downregulated,-,-,-,Fact,5,5.5,5.5.1,5.5.1.4,-,剪切位点突变
6672,KP10,23010077,Low DLC1 expression#occurred frequently with#downregulation of p15(Ink4b) or p16(Ink4a) or upregulation of CDK4 or CDK6,Expression Patterns,"DLC1,CDKN2B,CDKN2A,CDK4,CDK6",-,"Lung cancer, Colon cancer",-,-,-,-,"downregulated, upregulated",-,-,-,Fact,1,1.5,1.5.2,1.5.2.3,-,抑制复合物
597,KP10,23010077,Several genes and biochemical activities#collaborate with#inactivation of DLC1 to give rise to cell transformation,Mechanism of Action triples,DLC1,-,Human tumors,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7682,KP10,24848372,G1-phase cyclin-dependent kinases 6 and 4#modulate#expression of genes encoding estrogen metabolizing enzymes,Regulation triples,"CDK6,CDK4",-,Breast cancer,-,-,-,-,modulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
6776,KP10,24848372,Alterations in cdk6 or cdk4 levels#differentially influence#levels of numerous steroid metabolic enzymes,Regulation triples,"CDK6,CDK4",-,Breast tumor,-,-,-,-,altered,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
5430,KP10,24848372,"Cdk6 and cdk4#interact with#the promoter region of a cdk-regulated gene, 17尾-HSD2",Protein-DNA Interaction triples,"CDK6,CDK4",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
8000,KP10,17122635,CDK6 and p27#showed#correlation with the histologic grade of the sarcomas,Clinical Correlation triples,"CDK6,CDKN1B",-,Sarcomas,-,-,-,-,-,Prognostic marker,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
7189,KP10,28573225,Cell-cycle disruption#is#the major characteristic feature of neoplastic transformation,Mechanism of Action triples,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
6733,KP10,28573225,Topical application of DMBA#developed#well-differentiated squamous cell carcinoma in hamsters' buccal pouches,Experimental Model triples,-,-,Squamous cell carcinoma,DMBA,-,-,-,-,-,-,-,Fact,3,3.4,3.4.2,3.4.2.2,-,外源性途径激活
2827,KP10,10939591,The role of p16#has been#well documented as a tumor suppressor,Functional Role triples,CDKN2A,-,Tumor,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
4633,KP10,10939591,Wild-type p16 and p15#were compared in#glioma cell lines using adenoviruses,Experimental Model triples,"CDKN2A,CDKN2B",-,Glioma,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
4695,KP10,17654117,INK4 family members#are#differentially expressed during mouse development,Expression Patterns,"CDKN2A,CDKN2B,CDKN2C,CDKN2D",-,-,-,-,-,-,differentially expressed,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
6590,KP10,17654117,INK4 genes#might have#cell lineage-specific or tissue-specific functions,Functional Role triples,"CDKN2A,CDKN2B,CDKN2C,CDKN2D",-,-,-,-,-,-,-,-,-,-,Inference,1,1.4,1.4.2,1.4.2.1,-,谱系特异性分化
5490,KP10,39232581,"GABAergic neuronal lineage development#determines#clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant",Therapeutic Target triples,-,GABAergic neuronal lineage,Diffuse hemispheric glioma,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
4900,KP10,39232581,"Interneuronal precursors#originate#diffuse hemispheric glioma, H3G34-mutant",Developmental Biology triples,-,Interneuronal precursors,Diffuse hemispheric glioma,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.2,1.4.2.1,-,谱系特异性分化
1369,KP10,39232581,DHG-H3G34#mirror#spatial patterns of progenitor streams surrounding interneuron nests,Developmental Biology triples,-,Interneuron progenitors,Diffuse hemispheric glioma,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.2,1.4.2.1,-,谱系特异性分化
6260,KP10,39232581,genes#are upregulated in#interneuron lineage progenitors,Expression Patterns,CDK6,-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
2396,KP10,39232581,CDK6#emerges as#a targetable vulnerability,Cancer Association,CDK6,tumor cells,DHG-H3G34,"CDK4/6 inhibitors, CDK6-specific degrader",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5966,KP10,39232581,CDK4/6 inhibitors#promote#a shift toward more mature interneuron-like states,Therapeutic Response,"CDK4, CDK6",tumor cells,DHG-H3G34,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
4538,KP10,39232581,CDK4/6 inhibitors#reduce#tumor growth,Therapeutic Response,"CDK4, CDK6",tumor cells,DHG-H3G34,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
145,KP10,39232581,CDK4/6 inhibitors#prolong#xenograft survival,Therapeutic Response,"CDK4, CDK6",tumor cells,DHG-H3G34,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5984,KP10,39232581,CDK6#is highlighted as#a promising clinically actionable target,Cancer Association,CDK6,interneuronal progenitor-like states,DHG-H3G34,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5768,KP10,9001420,cyclin D1 overexpression#is associated with#mantle cell NHL,Cancer Association,CCND1,-,Mantle cell NHL,-,-,-,-,upregulated,-,-,-,Inference,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
5270,KP10,9001420,p16CDKN2 deletion#is associated with#mantle cell NHL,Cancer Association,CDKN2A,-,Mantle cell NHL,-,-,-,-,silenced,-,-,-,Inference,7,7.1,7.1.1,7.1.1.2,7.1.1.2.3,CDKN2A缺失
3726,KP10,9001420,cyclin D1 overexpression#accelerates#G1 phase in breast cancer cells lacking p16CDKN2,Cell Cycle Control,"CCND1, CDKN2A",breast cancer cells,Breast cancer,-,-,-,-,"upregulated, silenced",-,-,-,Inference,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
6324,KP10,9001420,ectopic expression of p16CDKN2#prevents#G1 acceleration,Cell Cycle Control,CDKN2A,breast cancer cells,Breast cancer,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
3171,KP10,31854063,"TP53, BRCA2, and NOTCH pathways#are more frequently altered in#IBC",Cancer Pathways,"TP53, BRCA2",IBC cells,IBC,-,NOTCH,-,-,altered,-,-,-,Fact,5,5.1,5.1.1,5.1.1.4,-,DNA合成修复
4840,KP10,31854063,PIK3CA#is more frequently altered in#non-IBC,Cancer Pathways,PIK3CA,non-IBC cells,non-IBC,-,-,-,-,altered,-,-,-,Fact,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
4137,KP10,30143714,genes encoding contractile function proteins#are upregulated in#cyclin D3-/- muscle,Expression Patterns,CCND3,muscle,-,-,"MEF2, NFAT",-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
4771,KP10,31703248,tissue development genes#are upregulated in#HNSCC patients,Expression Patterns,-,tissue,-,HNSCC,-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.2,1.4.2.2,-,分化标志物表达
2762,KP10,31703248,cell differentiation genes#are downregulated in#HNSCC patients,Expression Patterns,-,tissue,-,HNSCC,-,-,-,downregulated,-,-,-,Fact,1,1.4,1.4.2,1.4.2.1,-,谱系特异性分化
575,KP10,31703248,CDK6 overexpression#is associated with#poorer prognosis tumors,Cancer Association,CDK6,-,Tumors,-,-,-,-,upregulated,-,-,-,Inference,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
3238,KP10,31703248,CDK4 overexpression#is associated with#poorer prognosis tumors,Cancer Association,CDK4,-,Tumors,-,-,-,-,upregulated,-,-,-,Inference,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
747,KP10,38811726,CDKs and their cyclins#are redeployed in#the multiciliation cycle,Cell Cycle Control,"CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
1785,KP10,38811726,E2F7#is expressed at#high levels during the multiciliation cycle,Expression Patterns,E2F7,multiciliated cells,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
5029,KP10,38811726,E2F7#dampens#expression of DNA replication machinery genes,Regulation,E2F7,-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
143,KP10,37348763,NEK2#plays#a hub role in psoriasis initiation and development,Disease Association,NEK2,-,Psoriasis,-,-,-,-,-,-,-,-,Fact,6,6.4,6.4.1,6.4.1.1,-,促炎因子
6838,KP10,31784493,CDK4#is altered in#a low frequency of cancers,Cancer Association,CDK4,-,Cancers,-,-,-,-,altered,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
6952,KP10,31784493,CDK6#is altered in#a low frequency of cancers,Cancer Association,CDK6,-,Cancers,-,-,-,-,altered,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.4,CDK6扩增
6469,KP10,27864121,"CCNE1, CCND1, and CDK6#are frequently amplified in#gastric cancer",Cancer Association,"CCNE1, CCND1, CDK6",-,Gastric cancer,-,G1-S regulatory pathway,-,Upregulated,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
769,KP10,27864121,"CCNE1, CCND1, and CDK6 amplification#may influence#molecularly targeted therapies against ERBB2 or EGFR",Cancer Pathways,"CCNE1, CCND1, CDK6",-,Gastric cancer,-,-,-,-,-,-,-,-,Inference,2,2.4,2.4.2,2.4.2.1,-,旁路激活
1191,KP10,27864121,"Amplified CCNE1, CCND1, and CDK6#are potentially useful as#direct targets for molecular therapy",Drug Development,"CCNE1, CCND1, CDK6",-,Advanced gastric cancer,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5026,KP10,27864121,"Amplified CCNE1, CCND1, and CDK6#are potentially useful for#combination therapy with ERBB2 or EGFR inhibitors",Combination Therapies,"CCNE1, CCND1, CDK6",-,Advanced gastric cancer,"ERBB2 inhibitors, EGFR inhibitors",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4347,KP10,38633610,CDK4/6 inhibitors#are associated with#drug-induced liver injury,Drug Safety,"CDK4, CDK6",-,Drug-induced liver injury,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
5791,KP10,38633610,Palbociclib#causes#ascites as an unlisted hepatic adverse effect,Drug Safety,-,-,Ascites,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
7233,KP10,38633610,"STAT3, HSP90AA1, and EP300#play#central roles within the network",Protein Complex Dynamics,"STAT3, HSP90AA1, EP300",-,-,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
905,KP10,38633610,KEGG pathway enrichment#highlights#multiple pathways,Pathway Analysis,-,-,-,-,Multiple pathways,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
3406,KP10,36825764,Bioinformatics screening#identifies#differentially expressed genes between cells susceptible and resistant to CDK4/6 inhibitors,Expression Patterns,"CDK4, CDK6",-,-,CDK4/6 inhibitors,-,-,Differentially expressed,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7226,KP10,36825764,Gene set enrichment analysis#suggests#potential regulatory pathway of CPVL in breast cancer,Cancer Pathways,CPVL,-,Breast cancer,-,-,-,-,-,-,-,-,Inference,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
216,KP10,36825764,CPVL#is more abundant in#cells resistant to CDK4/6 inhibitors,Expression Patterns,CPVL,-,-,CDK4/6 inhibitors,-,-,Upregulated,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
2780,KP10,35082402,Erk1/2i-CDK4/6i treatment#is associated with#a five-gene signature including SNRPB and SLC25A5,Biomarker Analysis,"SNRPB, SLC25A5",-,-,"Erk1/2i, CDK4/6i",-,-,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,-,细胞周期标志物
21,KP10,9667525,Alterations in cell cycle regulation genes#are common in#many tumor types,Cell Cycle Control,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
1050,KP10,9667525,Inactivating mutations in CDKN2#are frequently observed in#pancreatic adenocarcinomas,Cancer Association,CDKN2,-,Pancreatic adenocarcinomas,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.2,-,无义突变
3124,KP10,9667525,CDKN2 mutations#are identified in#the germline of 50% of hereditary melanoma patients,Cancer Association,CDKN2,-,Hereditary melanoma,-,-,-,Hereditary,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
4035,KP10,9667525,A mutation in CDK4#abolishes#p16 inhibition in melanoma-prone kindreds with CDKN2 wild-type status,Mechanism of Action,CDK4,-,Melanoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
7890,KP10,9667525,CDK4 mutation#is not supported as#an oncogenic mechanism in pancreatic head tumorigenesis,Cancer Pathways,CDK4,-,Pancreatic head tumorigenesis,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.3,-,沉默突变
7271,KP10,36985460,CDK4/6 and aromatase#are targets for#breast cancer drug discovery,Drug Development,"CDK4, CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3282,KP10,36985460,CDK4/6 and aromatase#are involved in#abnormal cell proliferation and growth,Cell Cycle Control,"CDK4, CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
1425,KP10,39239747,Cul3 knockdown#induces#G0/G1 cell cycle arrest,Cell Cycle Control,CUL3,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
7679,KP10,39239747,"Cul3 knockdown#suppresses#key cell cycle regulatory proteins, cyclin D, CDK4, and CDK6",Regulation,"CUL3, CDK4, CDK6",-,-,-,-,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6682,KP10,21499307,CSN5#is elevated in#early HCC compared with dysplastic stage,Expression Patterns,CSN5,-,HCC,-,-,-,-,Upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
7292,KP10,21499307,CSN5 knockdown#downregulates#CDK6 and ITGB1,Regulation,"CSN5, CDK6, ITGB1",-,HCC,-,-,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
5598,KP10,21499307,CDK6 and ITGB1#are functionally interconnected with#MYC and TGFB1,Signaling Networks,"CDK6, ITGB1, MYC, TGFB1",-,HCC,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
7933,KP10,21499307,"MYC and TGFB1#control#proliferation, apoptotic cell death, and HCC progression",Cancer Pathways,"MYC, TGFB1",-,HCC,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
122,KP10,36980794,Palbociclib#downregulates#immune-related gene sets and gene expression related to leukocyte migration,Regulation,CDKN2A,-,-,Palbociclib,-,-,-,Downregulated,-,-,-,Fact,3,3.3,3.3.1,3.3.1.1,-,免疫细胞浸润
7224,KP10,36980794,Concomitant senolysis#reverses#a portion of pathway-level enrichment of TGF-β- and senescence-related signaling,Signaling Networks,TGFB1,-,-,-,"TGF-β, senescence",-,-,-,-,-,-,Fact,1,1.2,1.2.1,1.2.1.3,-,应激反应通路
6935,KP10,36980794,Palbociclib-treated endothelial cells#exhibit#hallmark senescent features in vitro,Cellular Phenotypes,-,Endothelial cells,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
6418,KP10,36980794,"Palbociclib-treated endothelial cells#upregulate#genes involved with SASP, leukocyte migration, and TGF-β-mediated paracrine senescence",Regulation,TGFB1,-,-,Palbociclib,SASP,-,-,Upregulated,-,-,-,Fact,3,3.1,3.1.2,3.1.2.2,-,衰老相关分泌表型
5978,KP10,36980794,Palbociclib-treated endothelial cells#induce#tumor cell migration and monocyte trans-endothelial invasion in co-culture,Cancer Pathways,-,"Endothelial cells, monocytes",Tumor,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.2,-,协同增效作用
2263,KP10,36739402,"Clinical characteristics, mutational landscapes, and tumor immune microenvironment of AM patients#were profiled for#insights into disease characteristics and potential treatment strategies",Clinical Implementation,-,-,AM,-,-,AM patients,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
4278,KP10,36739402,"BRAF, KIT, NRAS, NF1, APC, and ARID2#are frequently altered in#AM",Cancer Association,"BRAF, KIT, NRAS, NF1, APC, ARID2",-,AM,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
4562,KP10,36739402,CD8+ T cells and M1 macrophages#are more enriched in#the invasive margin than in the tumor center,Immune Cell Functions,-,"CD8+ T cells, M1 macrophages",Tumor,-,-,-,-,Upregulated,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
7953,KP10,35677682,Genes associated with Notch signaling and PI3K/AKT pathway#are upregulated in#tumor immune microenvironment,Pathway & Network Categories,"NOTCH, PIK3CA, AKT",-,Tumor,-,"Notch, PI3K/AKT",-,-,Upregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
101,KP10,35677682,Genes related to lymphocyte activation and NF-kB signaling#are downregulated in#tumor immune microenvironment,Pathway & Network Categories,NFKB1,-,Tumor,-,NF-kB,-,-,Downregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
5961,KP10,35677682,Macrophages M2#have higher abundance in#tumor immune microenvironment after NE transformation,Immune Cell Functions,-,M2 macrophages,Tumor,-,-,-,-,Upregulated,-,-,-,Fact,6,6.1,6.1.1,6.1.1.2,-,髓系细胞浸润
5767,KP10,22740238,Aberrant methylation#is detected in#neuroendocrine component involving APC and DAPK1,Epigenetic Regulation,"APC,DAPK1",-,Neuroendocrine tumor,-,-,-,-,-,-,-,-,Fact,1.5,1.5.1,1.5.1.1,-,-,组蛋白修饰
6998,KP10,32256815,Enolase 1 (ENO1)#differentially contributes to#cell transformation in lung cancer but not in esophageal cancer,Cancer Pathways,ENO1,-,"Lung cancer, esophageal cancer",-,-,-,-,-,-,-,-,Fact,1.4,1.4.1,1.4.1.2,-,-,细胞周期进程
7693,KP10,32256815,ENO1#is expressed in#almost all tissues,Expression Patterns,ENO1,-,-,-,-,-,-,upregulated,-,-,-,Fact,1.5,1.5.2,1.5.2.1,-,-,关键转录因子
4810,KP10,32256815,Exogenous ENO1#is overexpressed in#cell lines derived from various tissues,Expression Patterns,ENO1,-,-,-,-,-,-,upregulated,-,-,-,Fact,1.5,1.5.2,1.5.2.1,-,-,关键转录因子
2548,KP10,32256815,"ENO1#regulates#cell proliferation, cell transformation, cell cycle progression, and survival factors MAPK and AKT",Regulation,"ENO1,MAPK,AKT",-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1.4,1.4.1,1.4.1.2,-,-,细胞周期进程
87,KP10,27255164,"Chromosomal 12q gains#are associated with#cancer-associated genes CDK4, MDM2, CPM, YEATS4, DDIT3, GLI1, HMGA2, and STAT6",Cancer Association,"CDK4,MDM2,CPM,YEATS4,DDIT3,GLI1,HMGA2,STAT6",-,Cancer,-,-,-,-,-,-,-,-,Fact,2.1,2.1.1,2.1.1.1,-,-,CDK4/6基因扩增
7013,KP10,27255164,Chromothripsis-like copy number profiles#are observed in#fatal cases with sarcomatous overgrowth,Genomic Alterations,-,-,Sarcomatous overgrowth,-,-,-,-,-,-,-,-,Fact,5.3,5.3.1,5.3.1.4,-,-,基因组不稳定性
520,KP10,15526363,17 targets#exhibited#tumor-associated changes,Cancer Association,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,1.1,1.1.3,1.1.3.3,-,-,增殖抑制
2092,KP10,15526363,Methylation profile of 31 genes#provides#insights into DNA methylation mechanisms underlying carcinogenesis,Mechanism of Action,-,-,"Colon cancer, Colorectal adenomas",-,-,-,-,-,-,-,-,Fact,2.1,2.1.3,2.1.3.1,-,-,DNA甲基化模式改变
6688,KP10,30322893,Transcriptomic data#enabled#identification of gene overexpression and expressed DNA alterations,Expression Patterns,-,-,-,-,-,-,Upregulated,-,-,-,-,Fact,1.5,1.5.2,1.5.2.1,-,-,关键转录因子
5302,KP10,25231023,Sarcomatous overgrowth#is associated with#higher stage and shorter survival,Patient Outcomes,-,-,Sarcomatous overgrowth,-,-,-,-,-,-,-,-,Fact,5.2,5.2.1,5.2.1.2,-,-,缺失
181,KP10,25231023,CDK4 and MDM2 amplifications#are accompanied by#focal CDK4 and MDM2 and diffuse HMGA2 expression,Expression Patterns,"CDK4,MDM2,HMGA2",-,-,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5382,KP10,30420727,DDIT3 amplification#was evaluated in#48 cases of dedifferentiated liposarcoma,Genomic Alterations,DDIT3,-,Dedifferentiated liposarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
3156,KP10,30420727,DDIT3 amplification#was analyzed for#relationship with prognostic outcomes,Prognostic Associations,DDIT3,-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
6146,KP10,30420727,Myxoid liposarcoma-like features#were identified in#cases with DDIT3 amplification,Disease-Specific Categories,DDIT3,-,Myxoid liposarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
4279,KP10,19304958,Cancer-associated genes#may serve as#prognostic markers or therapeutic targets,Biomarker Analysis,-,-,Cancer,-,-,-,-,-,-,-,-,Inference,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
3567,KP10,36676955,"WA treatment#up-regulates#miR-181c-5p, miR-15a-5p, miR-500b-5p, miR-191-3p, and miR-34a-5p",RNA Regulation,-,-,Cancer,-,-,-,-,Upregulated,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,微小RNA
3030,KP10,36676955,"WA treatment#down-regulates#miR-1275, miR-326, miR-1908-5p, and miR-3940-3p",RNA Regulation,-,-,Cancer,-,-,-,-,Downregulated,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,微小RNA
7312,KP10,36676955,Predicted target genes of DEMs#showed enrichment in#cancer-associated gene ontology terms and KEGG pathways,Pathway Analysis,-,-,Cancer,-,KEGG,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
6679,KP10,15221937,"DNA sequence copy number gains#were detected for#SNRPN, GNLY, NME1, DDX15, ABCB1, ATM, LAMA3, MYBL2, ZNF217, TNFRSF6B, MSH2, TERC, SERPINE1, AFM137XA11, IGF1R, PTPN1",Expression Patterns,"SNRPN, GNLY, NME1, DDX15, ABCB1, ATM, LAMA3, MYBL2, ZNF217, TNFRSF6B, MSH2, TERC, SERPINE1, IGF1R, PTPN1",-,-,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
202,KP10,33863325,SHMT2 expression#correlates with#the cell cycle,Expression Patterns,SHMT2,-,-,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
6973,KP10,33863325,SHMT2 expression#is upregulated in#TSCC tissues and cell lines,Expression Patterns,SHMT2,-,TSCC,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
1983,KP10,33863325,SHMT2#is involved in#cell cycle regulation of TSCC cells,Cell Cycle Control,SHMT2,-,TSCC,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7908,KP10,33863325,SHMT2#may serve as#a novel prognostic indicator of TSCC,Prognostic Associations,SHMT2,-,TSCC,-,-,-,-,-,-,-,-,Inference,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
676,KP10,25903125,RB tumor suppressor and related proteins#play#critical roles in development through regulation of genes involved in cell fate,Cell Fate Regulation,RB1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.3,-,凋亡阈值调节
6422,KP10,28463841,Genes#are involved in#regulation and distribution of melanin pigmentation or melanogenesis in melanocytes,Molecular Mechanisms,-,Melanocytes,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
5758,KP10,28463841,"SNPs and haplotypes within or surrounding these genes#have been identified as#risk factors for skin cancer, in particular melanoma",Cancer Association,-,Melanocytes,"Skin cancer, melanoma",-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
594,KP10,28463841,Predictive value and utility#are increased when considering#gene polymorphism interactions,Biomarker Analysis,-,-,Skin cancer,-,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.1,-,基因突变
3114,KP10,28463841,Clinical phenotypes associated with germline changes in pigmentation and naevogenic genes#must be understood by#clinicians,Clinical Implementation,-,Melanocytes,Skin cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
609,KP10,11960918,CDKN2A (p16INK4a and p14ARF) and p53 genes#are#major targets for inactivation in OSCC,Cancer Association,"CDKN2A, TP53",-,OSCC,-,-,inactivated,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
7554,KP10,11960918,Tumors#were analyzed for#mutations in exons 5-8 and allelic losses in the p53 gene,Biomarker Analysis,TP53,-,OSCC,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
2410,KP10,11960918,CDKN2A/p16INK4a inactivation#is inversely related to#frequency of loss of heterozygosity at the p53 locus,Cancer Association,"CDKN2A, TP53",-,OSCC,-,-,inactivated,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
4675,KP10,11960918,CDKN2A (p16INK4a and p14ARF) and p53 genes#are involved in#two independent cell cycle pathways,Cell Cycle Control,"CDKN2A, TP53",-,OSCC,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
1269,KP10,12812137,Loss of p16INK4A#coincided with#transformation of neurofibromas to malignant peripheral nerve sheath tumors in NF1 patients,Cancer Association,CDKN2A,-,"Neurofibromas, malignant peripheral nerve sheath tumors",-,-,NF1 patients,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
3009,KP10,12812137,Cell cycle regulators#carried#independent prognostic value in lymphomas,Prognostic Associations,-,Lymphocytes,Lymphomas,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
1615,KP10,12812137,"MDM2 overexpression#identified#patients with poor prognosis in follicle center lymphomas, extranodal marginal zone lymphomas, and mantle cell lymphomas",Prognostic Associations,MDM2,-,"Follicle center lymphomas, extranodal marginal zone lymphomas, mantle cell lymphomas",-,-,Poor prognosis,upregulated,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
4182,KP10,35489737,"MB#is classified into#three subgroups: WNT, SHH, and non-WNT/non-SHH",Cancer Pathways,"WNT, SHH",-,Medulloblastoma,-,-,Discrete patient profiles and prognoses,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.2,-,分子亚型
5390,KP10,35489737,"SHH tumors#contain#mutations and alterations in GLI1, GLI2, SUFU, and PTCH1 genes",Molecular Event triples,"GLI1,GLI2,SUFU,PTCH1",-,SHH tumors,-,SHH pathway,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
2624,KP10,35489737,Presence of TP53 gene alterations and/or MYC amplifications#was considered as#the most reliable prognostic factor,Prognostic Factors,"TP53,MYC",-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
768,KP10,35489737,"Group3/4 MB subgroup#displays#several molecular patterns, including MYC and OTX2 amplification, GFI1B activation, KBTBD4 mutation, GFI1 rearrangement, PRDM6 enhancer hijacking, KDM6A mutation, LCA histology, chromosome 10 loss, isochromosome 17q, SNCAIP duplication, and CDK6 amplification",Genetic Alterations,"MYC,OTX2,GFI1B,KBTBD4,GFI1,PRDM6,KDM6A,SNCAIP,CDK6",-,Medulloblastoma (Group3/4),-,-,-,upregulated,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
3800,KP10,38890447,Chromosomal translocations of the NUP98 gene#are found in#acute myeloid leukemia (AML) patients,Genetic Alterations,NUP98,-,Acute myeloid leukemia (AML),-,-,poor outcomes,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
1810,KP10,38890447,Oncogenic activity of NUP98 fusion proteins#is dependent on#interaction between Mixed Lineage Leukemia 1 and menin,Mechanism of Action,"NUP98,MLL1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.3,1.3.3.1,-,P53通路相互作用
4421,KP10,38890447,"Palbociclib or Gilteritinib combined with menin inhibitor#affects#pathways relevant to leukemogenesis, including cell cycle regulation, cell proliferation, and differentiation",Combination Therapies triples,-,-,Leukemogenesis,"Palbociclib,Gilteritinib,Menin inhibitor",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1025,KP10,38890447,Study#provides#strong rationale for clinical translation of menin and kinase inhibitors as novel treatments for NUP98-r leukemia,Therapeutic Development,NUP98,-,NUP98-r leukemia,"Menin inhibitors,Kinase inhibitors",-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2260,KP10,26310374,"CDK6, MET, EZH2, EGFR, and NOTCH1#were over-expressed#in chromosomes 7 and 9",Expression Patterns,"CDK6,MET,EZH2,EGFR,NOTCH1",-,-,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
6870,KP10,26310374,CDKN2A/2B#were minimally expressed#in chromosomes 7 and 9,Expression Patterns,"CDKN2A,CDKN2B",-,-,-,-,-,-,downregulated,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,基因缺失
7731,KP10,26310374,"Fusion gene analysis#showed#14 candidate genes, including TWIST2 and UPK3BL, functionally involved in R-GBM",Genetic Alterations,"TWIST2,UPK3BL",-,R-GBM,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
7758,KP10,38751441,ctDNA#demonstrates#significance as a polyvalent biomarker for cancer,Biomarker Analysis,ctDNA,-,Cancer,-,-,-,-,Polyvalent biomarker,-,-,-,Fact,7,7.6,7.6.1,7.6.1.1,-,突变检测
6091,KP10,38356706,HCS in neuroblastoma BE(2)-C cells#identified#cell cycle regulators that control cell differentiation,Experimental Methods,-,Neuroblastoma BE(2)-C cells,Neuroblastoma,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.2,1.4.2.2,-,分化标志物表达
233,KP10,38356706,High tumor CDKN3 mRNA levels#correlate with#poor patient survival in neuroblastoma,Prognostic Factors,CDKN3,-,Neuroblastoma,-,-,poor patient survival,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
3512,KP10,38356706,miR-506-3p and retinoic acid#down-regulated#CDKN3 expression,Regulation,CDKN3,-,-,"miR-506-3p,Retinoic acid",-,-,-,downregulated,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,微小RNA
3568,KP10,36838737,"Luteoloside#has shown#anti-inflammatory, antiviral, and antitumor properties",Drug Properties,-,-,-,Luteoloside,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.2,-,死亡受体通路激活
5765,KP10,36838737,"Bioinformatics, molecular docking, and cellular thermal shift assays#were utilized to predict#potential targets of luteoloside in neuroblastoma",Experimental Methods,-,-,Neuroblastoma,Luteoloside,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.3,-,抑制复合物
7635,KP10,38113031,SMARCA4 gene#encodes#BRG1,Molecular Event triples,SMARCA4,-,-,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.3,5.4.3.1,-,原癌基因激活
1826,KP10,38113031,SMARCA4/BRG1-deficient uterine tumor#fulfills#clinicopathologic features of undifferentiated uterine sarcoma,Disease triples,SMARCA4,-,Uterine sarcoma,-,-,34-year-old Asian woman,-,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.2,-,衰老程序激活
1702,KP10,38113031,"Frameshift mutations in SMARCA4 gene#occurred with#mutations in KMT2C, ARID1B, KAT6A, NCOR1, APC, and CTNNB1",Mutation triples,"SMARCA4, KMT2C, ARID1B, KAT6A, NCOR1, APC, CTNNB1",-,-,-,Wnt signaling,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
2190,KP10,38113031,Copy number gain#identified in#MDM2 and CDK4,Mutation triples,"MDM2, CDK4",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
4479,KP10,37114614,Knowledge about SCAs#comes from#intracranial glioma,Disease triples,-,-,Intracranial glioma,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
2059,KP10,37114614,Genome-sequencing analyses of primary SCAs#aim to characterize#mutational landscape,Experimental Methods triples,-,-,Primary SCAs,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.2,-,热点区域
3016,KP10,37114614,Recurrently mutated pathways#were#summarized,Pathway triples,-,-,-,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.3,1.3.3.2,-,DNA修复机制
6451,KP10,37114614,Molecular profiling of primary SCAs#might represent#candidate drug targets,Disease triples,-,-,Primary SCAs,-,-,-,-,-,-,-,-,Inference,7,7.4,7.4.1,7.4.1.3,-,通路活性
4551,KP10,37671310,Proto-oncogenes#regulate#critical intra- or intercellular functions,Function triples,-,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
5680,KP10,25191523,Smurf2 E3 ubiquitin ligase#modulates#proliferation and invasiveness of breast cancer cells,Function triples,SMURF2,Breast cancer cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
6461,KP10,25191523,Smurf2#regulates#TGF-β/BMP pathway and other signaling pathways,Pathway triples,SMURF2,-,-,-,"TGF-β, BMP",-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.3,-,p38通路交互
5844,KP10,25191523,Silencing of Smurf2#downregulated#proliferation of breast cancer cells by modulating PI3K-PTEN-AKT-FoxO3a pathway via CNKSR2,Regulation triples,"SMURF2, PTEN, AKT, FOXO3A, CNKSR2",Breast cancer cells,Breast cancer,-,PI3K-PTEN-AKT-FoxO3a,-,-,Downregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
6932,KP10,25191523,Silencing Smurf2 using siRNAs#regulates#tumorigenic properties of human breast cancer cells,Regulation triples,SMURF2,Breast cancer cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
1295,KP10,25191523,Smurf2#may serve as#potential molecule for targeted cancer therapy,Therapeutic Development triples,SMURF2,-,Breast cancer,-,PI3K-AKT,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2496,KP10,31261643,CTC subpopulations#exhibit#different expressions of transcripts regarding differential phenotypes and endocrine signaling pathways,Expression Patterns triples,"EPCAM, CD44, CD24, MYC, MUC1, FOXO, PTEN",Circulating tumor cells,-,-,Endocrine signaling,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
4309,KP10,14521217,Mutated gatekeeper genes#implicated in#five specific signaling pathways in skin carcinogenesis,Pathway triples,-,-,Skin carcinogenesis,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
1515,KP10,14521217,"70-80% of XP skin cancers#exhibit#mutations in P53, PTCH1, SMO, or CDKN2A genes",Mutation triples,"TP53, PTCH1, SMO, CDKN2A",-,"Skin cancer, SCCs, BCCs",-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
2644,KP10,14521217,Acquired activation of pathways#alters#proliferation and differentiation of keratinocytes,Cell Cycle Control,CDKN2A,keratinocytes,Carcinogenesis,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
6106,KP10,37138505,Key regulators and related signaling pathways#are involved in#functional defects of MMD ECFCs,Signaling Networks,CDKN2A,ECFCs,Moyamoya disease (MMD),-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
1668,KP10,37138505,Cell cycle pathway#is enriched in#functional analysis of ECFCs,Pathway Enrichment,CDKN2A,ECFCs,Moyamoya disease (MMD),-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7539,KP10,37138505,CDKN2A#shows#highest expression in MMD ECFCs,Expression Patterns,CDKN2A,ECFCs,Moyamoya disease (MMD),-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
2539,KP10,21151896,"MCRs of gain or loss#contain#MOCS2, NSUN3, KHDRBS2, SNTG1, and ST18",Genetic Alterations,"MOCS2, NSUN3, KHDRBS2, SNTG1, ST18",-,Lung adenocarcinoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
6428,KP10,21151896,"Genetic pathways#involve#gains of MYC, deletions of RB1 and WRN in lung adenocarcinoma",Cancer Pathways,"MYC, RB1, WRN",-,Lung adenocarcinoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1312,KP10,37420093,iCell-based integration#identifies#biological processes perturbed during senescence,Systems Biology,TP53,-,Senescence,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.2,-,衰老程序激活
7646,KP10,17457042,Prognostic significance of TP53 loss of function#has been#controversial in astrocytomas,Cancer Association,TP53,-,Astrocytomas,-,-,-,-,-,-,-,-,Inference,5,5.5,5.5.1,5.5.1.2,-,无义突变
770,KP10,17457042,Mutant erbB2#can inhibit#EGFR-mediated oncogenic transformation irrespective of p53 status,Mechanism of Action,"ERBB2, EGFR, TP53",Glioblastoma cells,Glioblastoma,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
5722,KP10,17457042,T691S-expressing cells#show#reduced Akt and GSK-3 alpha/beta phosphorylation,Signaling Networks,"AKT1, GSK3A, GSK3B",-,Glial cell transformation,-,PI3K,-,-,Downregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.2,-,反馈调节
467,KP10,32532875,PI3K and HSP90 inhibitors#are validated in#drug combination synergy experiments,Drug Development,"PIK3CA, HSP90AA1",-,Cancer,"PI3K inhibitors, HSP90 inhibitors",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,联合用药方案
2579,KP10,32532875,Study of tumor#generates#insights into RET and other targets in rhabdomyosarcoma,Cancer Association,RET,-,Rhabdomyosarcoma,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
154,KP10,31553483,Driver genes and signaling pathways#are relevant to#GIST progression,Cancer Pathways,"KIT, PDGFRA",-,Gastrointestinal stromal tumor (GIST),-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
7087,KP10,31553483,"Genetic profiles#include#mutations, gene fusions, copy number alterations in driver genes",Genetic Alterations,"KIT, PDGFRA",-,Gastrointestinal stromal tumor (GIST),-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6821,KP10,31553483,Genetic alterations#include#oncogenic mutations and amplification-dependent expression of oncogenes,Genetic Alterations,"KIT, PDGFRA",-,Cancer,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
6435,KP10,31553483,PI3K-related genes#are upregulated in#malignant GIST,Expression Patterns,"SNAI1, TPX2",-,Gastrointestinal stromal tumor (GIST),-,PI3K,-,-,Upregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
1117,KP11,8891723,CDKs#are negatively controlled by#cyclin-dependent kinase inhibitors (CKIs),Regulation,"CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7216,KP11,7651726,p16INK4a#is not expressed in#many normal tissues,Expression Patterns,CDKN2A,-,-,-,-,-,-,Silenced,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
7681,KP11,7651726,p16INK4a#causes#G1 phase arrest in NIH3T3 fibroblasts,Cell Cycle Control,CDKN2A,NIH3T3 fibroblasts,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
4781,KP11,8805225,Synthetic peptide from p16#interacts with#CDK4 and CDK6,Protein Interaction,"CDKN2A, CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7670,KP11,7647780,"p16INK4 mutations#are detected in#familial melanoma kindreds, human tumour cell lines, and primary tumours",Cancer Association,CDKN2A,-,"Familial melanoma, Tumours",-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
3255,KP11,9324288,Growth suppression#involves#pRb pathway,Cell Cycle Control,RB1,T-ALL cell line,-,-,pRb pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
3806,KP11,21224071,CDK4 expression#induces#epidermal hyperplasia and increased malignant progression to squamous cell carcinoma,Cancer Association,CDK4,-,Squamous cell carcinoma,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
4925,KP11,21224071,CDK6 and cyclin D3#form#preferential complexes in K5CDK6 epidermis,Protein Complex Dynamics,"CDK6, CCND3",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.2,-,Cyclin D-CDK6复合物
3056,KP11,8633069,Alterations in cell cycle regulatory machinery#contribute to#development of many human cancers,Cancer Pathways,-,-,Human cancers,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
3918,KP11,8633069,Deregulated expression of G1 cyclins#includes#loss of function of p16INK4a and RB,Regulation,"CDKN2A, RB1",-,-,-,G1 cyclin-dependent kinase,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
124,KP11,8633069,p16INK4a expression#shows#inverse relationship with functional RB in many cell lines,Expression Patterns,"CDKN2A, RB1",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
4093,KP11,8633069,p16INK4a#is expressed in#cervical cancer cell lines with non-functional RB,Expression Patterns,"CDKN2A, RB1",Cervical cancer cell lines,Cervical cancer,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
7519,KP11,8633069,p16INK4a levels#are increased in#primary cells with inactivated RB by DNA tumor virus proteins,Expression Patterns,"CDKN2A, RB1",Primary cells,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
5556,KP11,8633069,RB#controls#E2F transcription factor activity,Cell Cycle Control,"RB1, E2F",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
7500,KP11,8633069,E2F1 overexpression#leads to#inhibition of cyclin D1-dependent kinase activity and induces p16-related transcript expression,Regulation,"E2F1,CDKN2A,CCND1",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
7742,KP11,17122635,CDK6 expression#correlates with#histologic grade of sarcoma,Cancer Association,CDK6,-,Sarcoma,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
2461,KP11,17122635,p27 expression#is inversely correlated with#sarcoma grade,Cancer Association,CDKN1B,-,Sarcoma,-,-,-,-,downregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.3,p16表达
2443,KP11,31207004,Palbociclib#is#an effective anticancer drug for breast cancer in women,Drug Development,"CDK4,CDK6",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4139,KP11,31207004,Palbociclib#represents#a candidate drug to combat CMT,Drug Development,-,-,CMT,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5586,KP11,31207004,Palbociclib#inhibited#growth of P114 and CF41 cell spheroids,Therapeutic Response,-,"P114, CF41 cell spheroids",-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2107,KP11,20180048,"GRN163L#alters#expression of cyclin D1, cdk4, and cdk6",Regulation,"CCND1,CDK4,CDK6",Mesenchymal stem cells,-,GRN163L,-,-,-,altered,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
3249,KP11,20180048,Telomerase activity#is essential for#growth and survival of malignant cells,Cancer Pathways,-,Malignant cells,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
1303,KP11,20180048,GRN163L removal#restores#mRNA and protein expression of genes and MSC phenotype,Therapeutic Development,"CCND1,CDK4,CDK6",Mesenchymal stem cells,-,GRN163L,-,-,-,normalized,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
5776,KP11,20180048,GRN163L#does not interfere with#self-renewal and differentiation of MSCs under short-term culture,Stem Cell Biology,-,Mesenchymal stem cells,-,GRN163L,-,-,-,-,-,-,-,Fact,1,1.6,1.6.1,1.6.1.1,-,自我更新
171,KP11,20180048,GRN163L#supports#cancer treatment without depleting stem cell pools,Therapeutic Development,-,Stem cells,Cancer,GRN163L,-,-,-,-,-,-,-,Fact,1,1.6,1.6.1,1.6.1.1,-,自我更新
167,KP11,9655257,cyclin D1#declines significantly#in treated versus untreated cells,Expression Patterns,CCND1,-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3527,KP11,9655257,cyclin D2 and D3#remain higher#in treated versus untreated cells,Expression Patterns,"CCND2,CCND3",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3617,KP11,30397176,IGF1R overexpression#promoted#drug escape,Mechanism of Action,IGF1R,-,-,-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
427,KP11,30397176,CDK4/6 inhibitors and IGF1R inhibitors#were synergistic#in vitro and active in mouse models,Combination Therapies,"CDK4,CDK6,IGF1R",-,-,"CDK4/6 inhibitors, IGF1R inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
4535,KP11,30397176,CDK4/6 inhibitors and IGF1R inhibitors#repressed#cell cycle and PI3K/mTOR signaling,Pathway & Network Categories,"CDK4,CDK6,IGF1R",-,-,"CDK4/6 inhibitors, IGF1R inhibitors",PI3K/mTOR,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
3823,KP11,30397176,IGF1R inhibitors activation#is an escape mechanism#to CDK4/6 inhibitors in Ewing sarcoma,Mechanisms of Resistance,"IGF1R,CDK4,CDK6",-,Ewing sarcoma,"CDK4/6 inhibitors, IGF1R inhibitors",-,-,-,-,-,-,-,Inference,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
5564,KP11,30397176,Dual targeting of CDK4/6 inhibitors and IGF1R inhibitors#provides#a candidate synergistic combination for clinical application,Combination Therapies,"CDK4,CDK6,IGF1R",-,Ewing sarcoma,"CDK4/6 inhibitors, IGF1R inhibitors",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
2026,KP11,9001420,Genetic abnormalities#affect#G1 control of Granta 519 cells,Regulation,-,Granta 519 cells,-,-,G1 control,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
4952,KP11,9001420,Overexpression of cyclin D1 and elimination of p16CDKN2 and p15CDKN2B#characterize#certain cases of mantle cell NHL,Cancer Association,"CCND1,CDKN2A,CDKN2B",-,Mantle cell NHL,-,-,-,-,"upregulated,silenced",-,-,-,Inference,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
1238,KP11,9001420,Cooperation of cyclin D1 overexpression and p16CDKN2/p15CDKN2B elimination#provides#a growth advantage to tumor cells,Cancer Pathways,"CCND1,CDKN2A,CDKN2B",-,Mantle cell NHL,-,-,-,-,"upregulated,silenced",-,-,-,Inference,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
2031,KP11,8855819,Rearrangement and overexpression of PRAD1/cyclin D1#are implicated in#pathogenesis of a subset of parathyroid adenomas,Cancer Association,CCND1,-,Parathyroid adenomas,-,-,-,-,upregulated,-,-,-,Inference,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
5820,KP11,33046519,TNO155#inhibited#RAS activation by CSF1R,Mechanism of Action,"CSF1R,RAS",-,-,TNO155,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
4159,KP11,33046519,TNO155#showed#combination activity with anti-PD-1 antibody,Combination Therapies,-,-,-,"TNO155,anti-PD-1 antibody",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
6284,KP11,33046519,TNO155#blocks#tumor-promoting and immune-suppressive RTK signaling,Therapeutic Response,RTK,-,RTK- and MAPK-driven cancers,TNO155,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7515,KP11,35082402,Translocation t(11;14) involving IgH/CCND1#enhances#uncontrolled MM cell growth,Cancer Pathways,CCND1,-,Multiple myeloma,-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,基因扩增
3743,KP11,35082402,Targeting RAS/MAPK pathway molecules and cyclin-Ds#enhances#MM cytotoxicity,Therapeutic Development,"CCND1,CCND2,CCND3,MAPK",-,Multiple myeloma,-,RAS/MAPK,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3415,KP11,35082402,Erk1/2i-CDK4/6i treatment#arrested#MM cells in G0/G1 phase,Therapeutic Response,"CDK4,CDK6,ERK1,ERK2",-,Multiple myeloma,"Erk1/2 inhibitors,CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1343,KP11,35082402,Erk1/2i-CDK4/6i treatment#inhibited#key target molecules in Erk1/2 and CDK4/6 signaling,Mechanism of Action,"CDK4,CDK6,ERK1,ERK2,c-MYC,RPS6KA1,RPS6,RB1,E2F1",-,Multiple myeloma,"Erk1/2 inhibitors,CDK4/6 inhibitors","CDK4/6,Erk1/2",-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
4497,KP11,8988060,Cyclin D1 and Cdk4#are increased in#intestinal adenomas from FAP patients,Expression Patterns,"CCND1,CDK4",-,FAP (Familial Adenomatous Polyposis),-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
1188,KP11,29441600,BBR#promotes#cell cycle through cellular DNA content protection,Mechanism of Action,-,-,-,BBR,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
5633,KP11,29441600,BBR#downregulates#p21 expression,Regulation,CDKN1A,-,-,BBR,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
6933,KP11,29441600,BBR#maintains#cyclin-D1 and CDK4 expressions,Regulation,"CDK4,CCND1",-,-,BBR,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
2943,KP11,35917055,CDK4/6 inhibitors#downregulate#UBE2C/S/T,Regulation,"CDK4,CDK6,UBE2C,UBE2S,UBE2T",-,Breast cancer,CDK4/6 inhibitors,Ubiquitin-proteasome pathway,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
1761,KP11,35917055,Ubiquitin-proteasome pathway (UPP)#maintains#homeostasis and turnover of proteins,Mechanism of Action,-,-,-,-,Ubiquitin-proteasome pathway,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
2339,KP11,35917055,Palbociclib#treats#HR(+) breast cancer cell lines MCF7 and T47D,Preclinical Models,-,"MCF7,T47D",Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7915,KP11,35917055,Palbociclib and ribociclib#decrease#UBE2C at mRNA and protein levels,Regulation,UBE2C,-,-,"Palbociclib, ribociclib",-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
1176,KP11,35917055,Abemaciclib#does not share#decrease in UBE2C levels with Palbociclib and ribociclib,Regulation,UBE2C,-,-,Abemaciclib,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
1258,KP11,35917055,UBE2C/UBE2S/UBE2T#modulate#E3 ubiquitin ligases including APC/C complex,Protein Complex Dynamics,"UBE2C,UBE2S,UBE2T",-,-,-,Ubiquitin-proteasome pathway,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
3233,KP11,35917055,UBE2C/UBE2T expression levels#are associated with#breast cancer survival,Cancer Association,"UBE2C,UBE2T",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
6533,KP11,35917055,HR(+) breast cancer cells#demonstrate#dependence on UBE2C,Cancer Association,UBE2C,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
4446,KP11,35917055,CDK4/6 inhibitors#link to#UPP pathway,Signaling Networks,"CDK4,CDK6",-,Cancer,CDK4/6 inhibitors,Ubiquitin-proteasome pathway,-,-,-,-,-,-,Inference,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
4298,KP11,38854937,"Abemaciclib#impacts#cell cycle, cell viability, and apoptosis in SCLC cell lines",Mechanism of Action,-,SCLC cell lines,Small cell lung cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
6610,KP11,38854937,Abemaciclib#induces#double-strand DNA damage,Mechanism of Action,-,-,-,Abemaciclib,-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.1,-,DSB识别
3433,KP11,38854937,Abemaciclib coupled with radiotherapy (RT)#enhances#double-strand DNA damage,Combination Optimization,-,-,-,"Abemaciclib, RT",-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.1,-,DSB识别
651,KP11,29080858,p16-cyclin D-CDK4/6-RB protein pathway#regulates#cell proliferation,Cell Cycle Control,"CDK4,CDK6,RB1,CDKN2A,CCND1",-,Pancreatic ductal adenocarcinoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
6009,KP11,29080858,Targeting CDK4#forms#novel personalized treatment strategy for PDA,Therapeutic Development,CDK4,-,Pancreatic ductal adenocarcinoma,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
372,KP11,29080858,Monotherapy and combination therapy#interact with#tumor cell and ECM signaling,Combination Optimization,-,-,Tumor,-,ECM signaling,-,-,-,-,-,-,Fact,6,6.3,6.3.1,6.3.1.2,-,信号通路激活
4022,KP11,29080858,RB protein#is evaluated as#a prognostic biomarker in PDA,Biomarker Analysis,RB1,-,Pancreatic ductal adenocarcinoma,-,-,-,-,RB protein,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
5822,KP11,29080858,PD-0332991#disrupts#ECM organization in PDA,Mechanism of Action,-,-,Pancreatic ductal adenocarcinoma,PD-0332991,-,-,-,-,-,-,-,Fact,6,6.3,6.3.1,6.3.1.2,-,信号通路激活
2583,KP11,29080858,"PD-0332991#leads to#quiescence, apoptosis, improved chemosensitivity, and reduced invasion in PDA",Therapeutic Response,-,-,Pancreatic ductal adenocarcinoma,PD-0332991,-,"Quiescence, apoptosis",-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.3,-,代谢重编程
6409,KP11,29080858,RB protein#is prevalent in#primary operable and metastatic PDA,Cancer Association,RB1,-,Pancreatic ductal adenocarcinoma,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
5955,KP11,29080858,RB protein#presents#a predictive biomarker for PDA therapy,Biomarker Analysis,RB1,-,Pancreatic ductal adenocarcinoma,-,-,-,-,RB protein,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
2471,KP11,24942317,EGCG#decreases#COMT expression and enzyme activity in WT-HuLM cells,Regulation,COMT,WT-HuLM cells,-,EGCG,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
5432,KP11,12955883,Aberrant p16 RNA transcripts#play functional roles in#HCC cells,Molecular Event triples,CDKN2A,HCC cells,Hepatocellular carcinoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7951,KP11,12006580,Cyclin D-Cdk4(6) kinases#target#22 in vivo phosphorylation sites in human p130,Mechanism of Action,"CDK4,CDK6",Human cells,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
3237,KP11,12006580,p130(DeltaCdk4) mutant#responds to#cyclin D1,Mechanism of Action,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
7104,KP11,12006580,Six residues in p130#are necessary and sufficient for#regulation of E2F-4 and the cell cycle,Mechanism of Action,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
6879,KP11,12006580,12 phosphorylation sites in p130#modulate#other functions of p130,Mechanism of Action,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
174,KP11,12006580,Regulation of p130#explains#differential control of p107 and p130 by cyclin-dependent kinases,Mechanism of Action,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
5864,KP11,21777578,Gallbladder cancer cases#are associated with#gallstones,Disease Association,-,Gallbladder cells,Gallbladder cancer,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.3,2.2.3.4,-,葡萄糖代谢改变
4732,KP11,21777578,p16#decreases to#the lowest level in gallbladder cancer,Expression Patterns,CDKN2A,Gallbladder cells,Gallbladder cancer,-,-,-,-,downregulated,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
4324,KP11,21777578,Apoptotic index#rises to#the highest level in undifferentiated carcinoma,Disease & Clinical Categories,-,Carcinoma cells,Undifferentiated carcinoma,-,-,-,-,upregulated,-,-,-,Fact,3,3.4,3.4.2,3.4.2.3,-,凋亡执行
5097,KP11,37529698,Cuproptosis-related lncRNAs#regulate#biological functions of various cancers,Mechanism of Action,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
5590,KP11,37529698,Cuproptosis-related lncRNAs#have clinical applications in#breast cancer,Clinical Implementation,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4682,KP11,37529698,Cuproptosis-related lncRNAs#regulate#proliferation and metastasis in breast cancer,Mechanism of Action,-,Breast cancer cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.1,-,增殖信号整合
1335,KP11,37529698,Cuproptosis-related lncRNAs#play essential roles in#regulating proliferation and metastasis of breast cancer cells,Mechanism of Action,-,Breast cancer cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
3855,KP11,37529698,"Low-risk patients#exhibit#lower expression of CDK4/6 inhibitor-resistant biomarkers (CCNE1, E2F1, E2F2) and PARP inhibitor-resistant biomarkers (BRCA1, BRCA2)",Markers,"CDK4,CCNE1,E2F1,E2F2,BRCA1,BRCA2",-,-,-,-,-,Low-risk,downregulated,"CDK4/6 inhibitor resistance, PARP inhibitor resistance",-,-,Fact,7,7.5,7.5.1,7.5.1.1,7.5.1.1.3,CCNE1扩增
5309,KP11,30447641,Bortezomib#suppresses#tumor growth in liposarcoma,Therapeutic Response,-,-,Liposarcoma,Bortezomib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
235,KP11,30447641,PDX model#is used for#studying tumorigenesis and differentiation in carcinomas,Preclinical Models,-,-,Carcinomas,-,-,-,-,-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.2,8.6.1.2.1,疾病状态
7818,KP11,30447641,Immunohistochemistry for MDM2 and CDK4#showed#overexpression patterns of both proteins in PDX models and PDCs,Expression Patterns,"MDM2,CDK4","PDX models, PDCs",-,-,-,-,-,overexpressed,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
1454,KP11,30447641,MDM2 amplification#was observed to be correlated with#successful establishment of PDX mouse models,Cancer Association,MDM2,PDX mouse models,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
3356,KP11,30447641,CDK4 expression#did not show#correlation with successful establishment of PDX mouse models,Expression Patterns,CDK4,PDX mouse models,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
4832,KP11,30447641,Bortezomib#suppressed#MDM2 expression in a dose-dependent manner,Regulation,MDM2,-,-,Bortezomib,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
5175,KP11,30447641,p21#elicited#an increase in PDC expression,Regulation,CDKN1A,PDCs,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
6162,KP11,30447641,Treatment with bortezomib#resulted in#anticancer effect similar to that seen in PDCs,Therapeutic Response,MDM2,-,-,Bortezomib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6195,KP11,23708653,PD#cooperates with#hormone-based regimens and ionizing radiation to suppress cellular growth,Therapeutic Development,-,-,-,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
5967,KP11,23708653,PD#is#a critical mediator of PD action,Mechanism of Action,-,-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.1,1.2.1.2,-,激素信号通路
4824,KP11,23708653,Selective CDK4/6 inhibition#hinders#key proliferative pathways necessary for disease progression,Mechanism of Action,"CDK4,CDK6",-,-,-,Proliferative pathways,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3682,KP11,23708653,RB status#is#a critical prognostic determinant for therapeutic efficacy,Cancer Association,RB1,-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.4,RB蛋白表达
7234,KP11,23708653,Selective targeting of CDK4/6#is#a bona fide therapeutic target in early stage and advanced PCa,Cancer Association,"CDK4,CDK6",-,Prostate cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
889,KP11,12566432,Reduction of ZONAB expression#reduced#proliferation of MDCK cells,Mechanism of Action,ZONAB,MDCK cells,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
2791,KP11,12566432,Overexpression of ZONAB#resulted in#increased cell density in mature monolayers,Mechanism of Action,ZONAB,-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
4417,KP11,12566432,Depletion of ZONAB or overexpression of ZO-1#reduced#cell density,Mechanism of Action,"ZONAB,ZO1",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
6628,KP11,12566432,ZONAB and ZO-1#influence#proliferation by regulating nuclear accumulation of CDK4,Mechanism of Action,"ZONAB,ZO1,CDK4",-,-,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
1349,KP11,39574120,Overexpression of RERE-AS1#promoted#anti-tumor activity of ribociclib in BC cells,Therapeutic Development,RERE-AS1,BC cells,Breast cancer,Ribociclib,-,-,-,upregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4360,KP11,15526363,Methylation profile of promoter CpG islands#was established for#31 genes in colon carcinogenesis,Regulation,-,-,Colon cancer,-,-,-,-,-,-,-,-,Fact,5,5.6,5.6.3,5.6.3.1,-,DNA甲基化
966,KP11,15526363,Cyclin-dependent kinase inhibitor 2B (p15)#inhibits#CDK4,Mechanism of Action,"CDKN2B,CDK4",-,Colorectal cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
2431,KP11,18520069,Glycolipids#participate in#signal transduction and regulation of melanoma cell growth and apoptosis,Mechanism of Action,-,Melanoma cells,Melanoma,-,Signal transduction,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
2102,KP11,10576656,PML and p53#play#critical roles in cancer development and cell growth suppression,Cancer Association,"PML,TP53",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
2554,KP11,29508248,Combination treatment#synergistically suppressed#GBM cell proliferation,Therapeutic Response,-,GBM cells,Glioblastoma,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
944,KP11,38173098,MED8#is highly expressed in#gastric cancer,Expression Patterns,MED8,-,Gastric cancer,-,-,-,-,upregulated,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,染色质重塑
7290,KP11,10361135,Mantle cell lymphomas#are characterized by#11q13 translocations and cyclin D1 overexpression,Cancer Association,CCND1,-,Mantle cell lymphoma,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
3130,KP11,10361135,Loss of 17p#correlated with#P53 gene deletions and mutations,Cancer Association,TP53,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.3,-,TP53缺失
7267,KP11,10361135,8q24 amplification#showed#C-MYC amplification by Southern blot,Cancer Association,MYC,-,-,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
6322,KP11,10361135,"Alterations in 2p, 3q, 13, and 18q#were not associated with#N-MYC, BCL6, RB, or BCL2 alterations",Cancer Association,"MYCN,BCL6,RB1,BCL2",-,Mantle cell lymphoma,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.3,-,染色体重复
1855,KP11,10361135,Increased chromosome imbalances#are associated with#blastoid variants of MCLs,Cancer Association,-,-,Mantle cell lymphoma,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.2,5.2.2.2,-,非整倍体
5119,KP11,16863592,Cyclin D1b splice variant#learns#new oncogenic functions,Cancer Association,CCND1,-,-,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
3756,KP11,16863592,Cyclin D1#is a positive regulator of#cell cycle and proto-oncogene,Cell Cycle Control,CCND1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
6017,KP11,16863592,Cyclin D1#impinges on#several pathways governing cancer cell proliferation,Cancer Pathways,CCND1,-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
1374,KP11,16863592,Cyclin D1 and Cyclin D1b splice variant#have#differential roles in prostate cancer,Cancer Association,CCND1,-,Prostate cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
5649,KP11,35546399,CDK4/6 inhibition using palbociclib#showed#modest or conflicting results in HPV(neg) HNSCC,Therapeutic Response,"CDK4, CDK6",-,Head and neck squamous cell carcinoma,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
577,KP11,35546399,Palbociclib-based drug combination#was evaluated and compared with#palbociclib plus cetuximab or cisplatin,Combination Therapies triples,-,"HPV(neg) HNSCC cell lines, xenograft models",HPV(neg) HNSCC,"Palbociclib, cetuximab, cisplatin",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,-,-,靶向药物联合
2457,KP11,35546399,"Significant synergistic effects#were observed when combining#palbociclib with PI3K, EGFR, and MEK inhibitors",Combination Therapies triples,-,-,-,"Palbociclib, PI3K inhibitors, EGFR inhibitors, MEK inhibitors","PI3K, EGFR, MEK",-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7917,KP11,35546399,PI3K pathway inhibitors#reduced#cell proliferation and induced cell-cycle arrest in HPV(neg) HNSCC cell lines,Mechanism of Action,PIK3CA,HPV(neg) HNSCC cell lines,HPV(neg) HNSCC,Alpelisib,PI3K,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
3679,KP11,35546399,RRM2-dependent EMT induced by palbociclib#was attenuated by#alpelisib and cetuximab,Mechanism of Action,RRM2,-,-,"Palbociclib, alpelisib, cetuximab",EMT,-,-,-,-,-,-,Fact,1,1.3,1.3.2,-,-,MAPK信号通路
2204,KP11,16547504,Control vector-transfected cells#formed#a well-stratified and orderly differentiated epidermis-like epithelium,Cellular Differentiation,-,Epidermis-like epithelium,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.2,1.4.2.2,-,分化标志物表达
6598,KP11,35491665,Conditioned medium of HUVEC cells#induced differentiation of#BM-MSCs into osteoblasts,Stem Cell Biology,-,"HUVEC cells, BM-MSCs",-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.2,-,-,分化过程调控
5118,KP11,34108622,Molecular alterations in PI3K/AKT pathway#occur frequently in#hormone receptor-positive breast tumors,Cancer Pathways,"PIK3CA, AKT1",-,Breast cancer,-,PI3K/AKT,-,Hormone receptor-positive,-,-,-,-,Fact,1,1.3,1.3.1,-,-,PI3K/AKT/mTOR通路
2511,KP11,22678079,"Amplification#was observed at#12q14.3 for GNS, WIF1, and HMGA2",Genomic Alterations,"GNS, WIF1, HMGA2",-,-,-,-,-,-,Amplified,-,-,-,Fact,5,5.3,5.3.1,-,-,基因扩增
2967,KP11,22678079,"mRNA overexpression#was correlated with#genomic amplification for CDK4, HMGA2, and others",Expression Patterns,"CDK4, HMGA2",-,-,-,-,-,-,Upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
2344,KP11,28978144,Dual PI3K/mTOR signaling pathway#regulated#radiosensitization in patient-derived cells,Mechanism of Action,-,Patient-derived cells,-,-,PI3K/mTOR,-,Radiation-resistant,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
7964,KP11,12960127,p27#was expressed in#40 of 74 HCCs,Expression Patterns,CDKN1B,-,HCC,-,-,-,-,High levels,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7586,KP11,34570813,Bergamottin#a CYP3A inhibitor#inhibits prostate cancer cell growth,Drug Development,-,Prostate cancer cells,Prostate cancer,Bergamottin,CYP3A,-,-,Downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6366,KP11,34570813,Therapies#have been developed to treat#advanced prostate cancer,Cancer Association,-,-,Prostate cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
3396,KP11,34570813,Bergamottin#reduces#AR activation,Mechanism of Action,-,-,Prostate cancer,-,-,-,-,-,PSA,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4729,KP11,34570813,PSA levels#are markers for#Prostate cancer,Markers,-,-,Prostate cancer,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
28,KP11,34570813,Bergamottin#triggers#apoptosis in prostate cancer cell lines,Mechanism of Action,-,Prostate cancer cell lines,Prostate cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
6323,KP11,10956386,"p16, p21, p27, and p57#are expressed at#low or not detectable levels in proliferating cells",Expression Patterns,"CDKN2A,CDKN1A,CDKN1B,CDKN1C",Proliferating cells,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7901,KP11,38653982,mBC patients#had#more effector T cells and regulatory T cells,Immune Cell Functions,-,"Effector T cells, regulatory T cells",Metastatic breast cancer,-,-,-,mBC patients,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
5445,KP11,38653982,mBC patients#showed#increased expression of immune checkpoints and activation/exhaustion markers,Immune Cell Functions,-,-,Metastatic breast cancer,-,-,-,mBC patients,upregulated,-,-,-,Fact,6,6.1,6.1.1,6.1.1.3,-,免疫检查点表达
7374,KP11,38653982,mBC patients#had#a shift to a Th2/Th17 phenotype,Immune Cell Functions,-,"Th2 cells, Th17 cells",Metastatic breast cancer,-,-,-,mBC patients,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
5424,KP12,7651726,Mouse p16INK4a and p15INK4b#are induced by#SV40T-antigen and TGF-beta,Regulation,"CDKN2A,CDKN2B",-,-,-,TGFB,-,-,-,-,-,-,Fact,1,1.2,1.2.1,1.2.1.2,-,激素信号通路
6037,KP12,7651726,p16INK4a#associates with#CDK6 in mouse MEL erythroleukemia cells,Protein Complex Dynamics,"CDKN2A,CDK6",Mouse MEL erythroleukemia cells,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.2,-,Cyclin D-CDK6复合物
5447,KP12,31852484,CDK4/6 inhibitors#increase#progression-free survival in metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6183,KP12,21224071,CDK6 overexpression#results in#decreased skin tumor development,Cancer Association,CDK6,-,Skin tumor,-,-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
7674,KP12,21224071,CDK4 and CDK6#mediate#keratinocyte proliferation,Cell Cycle Control,"CDK4,CDK6",Keratinocytes,Skin tumor,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
5458,KP12,21224071,CDK4 and CDK6#differ in#apoptosis activation and skin tumor development,Molecular Event,"CDK4,CDK6",-,Skin tumor,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.3,-,凋亡阈值调节
1998,KP12,12834607,Cyclin D1 expression#was investigated in#pre-cancerous and cancerous lesions of the canine mammary gland,Expression Patterns,CCND1,-,Canine mammary gland cancer,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
7709,KP12,34385584,CDK4/6 inhibitors#prolong#progression-free survival in HR+ HER2-negative breast cancer,Therapeutic Response,"CDK4,CDK6",-,HR+ HER2-negative breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6028,KP12,29344143,"p16, cyclin D1, and pRb#are associated with#SPA progression",Cancer Pathways,"CDKN2A,CCND1,RB1",-,SPA,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
5944,KP12,10939591,p15 overexpression#inhibits#cell proliferation in glioma cells,Therapeutic Response,CDKN2B,Glioma cells,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
3663,KP12,10939591,p15 overexpression#causes#replicative senescence in glioma cells,Cell Cycle Control,CDKN2B,Glioma cells,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.2,-,细胞衰老诱导
2503,KP12,10939591,p15 overexpression#inhibits#telomerase activity in glioma cells,Cell Cycle Control,CDKN2B,Glioma cells,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3082,KP12,21047732,OTX2#inhibits#proliferation in cell lines,Therapeutic Response,OTX2,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
962,KP12,21047732,OTX2#induces#a senescence-like phenotype in cell lines,Cell Cycle Control,OTX2,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.2,-,细胞衰老诱导
750,KP12,30143714,Myofiber remodeling#is accompanied by#enhanced running endurance and increased energy expenditure,Phenotype triples,-,Myofibers,-,-,-,-,-,-,-,-,-,Fact,4,4.1,4.1.2,4.1.2.1,-,氧化磷酸化改变
7017,KP12,30143714,Myofiber remodeling#is accompanied by#fatty acid oxidation,Metabolic Integration,-,Myofibers,-,-,Fatty acid oxidation,-,-,-,-,-,-,Fact,4,4.4,4.4.1,4.4.1.2,-,脂肪酸氧化
6969,KP12,30143714,Cyclin D3#represses#calcineurin- or MEF2-dependent activation in muscle cells,Regulation,CCND3,Muscle cells,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
1274,KP12,26278998,Knockdown of CARF#causes#apoptosis,Therapeutic Response,CARF,-,Cancer,-,-,-,-,downregulated,-,-,-,Fact,3,3.4,3.4.2,3.4.2.3,-,凋亡执行
845,KP12,26278998,Overexpression of CARF#causes#senescence and increases malignant properties of cancer cells,Cancer Association,CARF,-,Cancer,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.2,-,细胞衰老诱导
2497,KP12,26278998,CARF overexpression#is linked to#increase and decrease in p53 activity,Regulation,"CARF,TP53",-,Cancer,-,-,-,-,upregulated,-,-,-,Fact,1,1.3,1.3.3,1.3.3.1,-,P53通路相互作用
1447,KP12,26278998,CARF#induces#growth arrest in p53 wild-type cancer cells,Therapeutic Response,"CARF,TP53",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
2199,KP12,26278998,CARF#promotes#carcinogenesis in p53-absent cancer cells,Cancer Association,"CARF,TP53",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3542,KP12,26278998,CARF#increases#migration and invasion of cancer cells,Cancer Association,CARF,-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
1041,KP12,26278998,"CARF upregulation#is marked by#increased expression of MMP2, MMP3, MMP9, uPA, interleukins, and VEGF",Markers,"CARF,MMP2,MMP3,MMP9,VEGF",-,Cancer,-,-,-,-,upregulated,-,-,-,Fact,6,6.5,6.5.1,6.5.1.3,-,蛋白多糖
3531,KP12,26278998,CARF#is considered#diagnostic marker and therapeutic target in p53-compromised malignancies,Biomarker Analysis,TP53,-,Malignancies,-,-,-,-,-,-,-,-,Inference,7,7.5,7.5.1,7.5.1.1,-,ESR1突变
6505,KP12,9101469,p16#mRNA expression level is elevated in#ovarian tumors compared with normal ovaries,Expression Patterns,CDKN2A,-,Ovarian tumors,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
279,KP12,26398286,Mps1#is upregulated in#basal-a subset of triple-negative breast cancer,Expression Patterns,MPS1,-,Triple-negative breast cancer,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
2878,KP12,26398286,Depletion of Mps1#reduces#tumor cell viability relative to normal cells,Mechanism of Action,MPS1,-,Tumor,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
2453,KP12,26398286,"PF-7006#modulates#Mps1-dependent biology (reduced pHH3-Ser10 levels, shorter mitosis...)",Mechanism of Action,MPS1,-,Tumor,PF-7006,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7169,KP12,26398286,Palbociclib#induces#G1 cell cycle arrest in Rb1-competent cells to mitigate Mps1...,Regulation,"CDK4,CDK6,RB1",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
5143,KP12,26398286,CDK4/6 drugs#may improve#tolerance of Mps1 inhibitors in combination therapies,Combination Therapies,"CDK4,CDK6,MPS1",-,-,CDK4/6 drugs,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4966,KP12,36825764,CPVL#negatively regulates#PTEN to impact anticancer effects of CDK4/6 inhibitors,Mechanism of Action,"PTEN,CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
879,KP12,38017459,PEG10-targeting siRNA or ASOs combined with palbociclib#inhibits#proliferation of...,Combination Therapies,"PEG10,CDK4,CDK6",-,Palbociclib-resistant tumor,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
330,KP12,34277427,Targeting WEE1#inhibits#growth of breast cancer cells resistant to endocrine therapy...,Therapeutic Resistance,"WEE1,CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.1,-,G1/S检查点失控
3412,KP12,34277427,ER+ tumors progressing on antiestrogens#are treated with#antiestrogens and CDK4/6...,Clinical Implementation,"CDK4,CDK6",-,ER+ tumors,"Antiestrogens,CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
6760,KP12,34277427,Defective G1 checkpoint#allows#resistant cells to escape arrest and depend on...,Mechanism of Action,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,2,2.2,2.2.2,2.2.2.1,-,G1/S检查点失控
471,KP12,34277427,AZD1775#inhibits#WEE1 to decrease cell proliferation and increase G2/M arrest...,Mechanism of Action,WEE1,-,Resistant cells,AZD1775,-,-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.1,-,G1/S检查点失控
7806,KP12,34277427,Targeting WEE1#is#anti-cancer therapeutic strategy in resistant ER+ breast cancer,Therapeutic Development,WEE1,-,ER+ breast cancer,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4037,KP12,28418845,Current treatment regimens#require#a dosing holiday due to severe neutropenia...,Safety Monitoring,-,-,"Neutropenia, infections",-,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,中性粒细胞减少
3987,KP12,28418845,G1T38#decreases#RB1 phosphorylation and inhibits proliferation in CDK4/6-dependent...,Mechanism of Action,"RB1,CDK4,CDK6",-,"Breast cancer, melanoma, leukemia, lymphoma",G1T38,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
1919,KP12,14597415,TGFbeta#inhibits#pRb-kinase activity,Mechanism of Action,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.1,1.2.1.2,-,激素信号通路
2477,KP12,14597415,TGFbeta#prevents#nuclear import of cyclin D3-CDK4,Mechanism of Action,"CDK4,CCND3",-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
6310,KP12,14597415,TGFbeta#inhibits#CDK4 phosphorylation within residual p27-bound cyclin D3-CDK4...,Mechanism of Action,"CDK4,CCND3",-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
2576,KP12,38807144,Dalpiciclib#reduces#expression levels of Ki-67 and phosphorylated Rb,Mechanism of Action,RB1,-,-,Dalpiciclib,-,-,-,downregulated,Ki-67,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
620,KP12,19369901,Immunohistochemical analysis#identifies#expression of cell-cycle-related and apoptosis-related proteins in melanomas,Biomarker Analysis,-,-,Melanoma,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
1898,KP12,19369901,"Thick melanomas#showed#increased expression of nuclear Cdk4, tumor suppressor protein p53, and p21",Expression Patterns,"CDK4,TP53,CDKN1A",-,Thick melanoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2544,KP12,19369901,Thin melanomas#showed#higher expression of cyclin D1 and cytoplasmic Cdk4,Expression Patterns,"CDK4,CCND1",-,Thin melanoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
5269,KP12,19369901,Cyclin D1 expression#is related to#initial phases of melanoma development,Expression Patterns,CCND1,-,Melanoma,-,-,-,-,upregulated,-,-,-,Inference,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
1301,KP12,19369901,Increased p21 expression#represents#cell cycle control in cells with reduced p16 and/or increased nuclear Cdk4 expression,Cell Cycle Control,"CDKN1A,CDKN2A,CDK4",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
6671,KP12,10329038,Cdk4#is expressed in#5-50% of normal cervical epithelial cells,Expression Patterns,CDK4,Cervical epithelial cells,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
5006,KP12,37258566,This study#aims to identify#resistance mechanisms to ER antagonists in combination with CDK4/6 inhibitors,Mechanisms of Resistance,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
4930,KP12,37258566,T47D and MCF7 cell lines#are resistant to#ER antagonist fulvestrant and CDK4/6i abemaciclib,Mechanisms of Resistance,"CDK4,CDK6","T47D,MCF7",Breast cancer,"Fulvestrant,Abemaciclib",-,-,-,resistant,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
3334,KP12,37258566,PAK1 knockdown#re-sensitizes#T47D-FAR and MCF7-FAR cells to fulvestrant and abemaciclib,Mechanisms of Resistance,PAK1,"T47D-FAR,MCF7-FAR",Breast cancer,"Fulvestrant,Abemaciclib",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
1731,KP12,37258566,Pak1 inhibitors#restore#cell sensitivity to fulvestrant and abemaciclib,Mechanisms of Resistance,PAK1,-,Breast cancer,"PF-3758309,NVS-PAK1-1",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
283,KP12,36042494,Predictive biomarkers and mechanisms#remain unknown for#innate resistance to CDK4/6 inhibitors,Biomarker Analysis,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,7,7.5,7.5.1,7.5.1.2,-,原发性耐药
2044,KP12,36042494,Resistance#is verified in#MCF-7 and T47D cells and their derivatives,Mechanisms of Resistance,-,"MCF-7,T47D",-,-,-,-,-,resistant,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
7282,KP12,33330073,CDK4/6 inhibitor Palbociclib#is approved as#anti-cancer agent for breast cancer,Drug Development,"CDK4,CDK6",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7516,KP12,33330073,miR-3613-3p#is downregulated in#TNBC tumors and cells,Expression Patterns,-,-,TNBC,-,-,-,-,downregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.3,-,免疫标志物
423,KP12,33330073,miR-3613-3p overexpression#is correlated with#favorable prognosis in patients,Biomarker Analysis,-,-,TNBC,-,-,-,"Smaller tumor size, lower Ki-67",upregulated,-,-,-,Inference,7,7.2,7.2.1,7.2.1.3,-,免疫标志物
4956,KP12,33330073,SMAD2 and EZH2#mediate#proliferation of TNBC cells and sensitivity to Palbociclib,Mechanism of Action,"SMAD2,EZH2",-,TNBC,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3814,KP12,33330073,miR-3613-3p#acts as#cancer-suppressor miRNA in TNBC,Mechanism of Action,-,-,TNBC,-,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1720,KP12,33330073,miR-3613-3p#might be used as#a predictive biomarker for TNBC response to Palbociclib,Biomarker Analysis,MIR3613,-,TNBC,Palbociclib,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.1,-,基因突变
5310,KP12,8857999,Homozygous deletions of CDKN2/p16#were detected in#5 anaplastic astrocytomas and 6 GBMs,Cancer Association,CDKN2A,-,"Anaplastic astrocytomas, GBMs",-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
5280,KP12,33213401,The cotreatment#reduced#percentage of cells in S and G2/M phases,Cell Cycle Control,-,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3905,KP12,33213401,The cotreatment#induced#apoptosis,Cell Cycle Control,-,-,-,-,-,-,-,-,-,-,-,Fact,3,3.4,3.4.2,3.4.2.3,-,凋亡执行
1986,KP12,33213401,Rib#showed#Rb-independent effects in Rb knock-down MCF-7,Regulation,RB1,MCF-7,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
6471,KP12,36087253,Abnormal CDK4/6-Rb-E2F signal transduction#is#a driving factor for excessive proliferation of tumor cells,Cancer Pathways,"CDK4,CDK6,RB1,E2F",-,Tumor,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
4567,KP12,36087253,Tumor cells with senescence induced by PD-0332991#are used as#screening tools for cytolytic drugs,Preclinical Models,"CDK4,CDK6",-,Tumor,PD-0332991,-,-,-,-,-,-,-,Inference,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
4426,KP12,17060721,p53#plays#a central role in sensing and signaling for growth arrest and apoptosis in DNA-damaged cells,Mechanism of Action,TP53,-,-,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.3,1.3.3.1,-,P53通路相互作用
81,KP12,17060721,"Cyclin D1 expression#was not significantly different among#ESCC, esophageal dysplasia, and normal mucosa",Expression Patterns,CCND1,-,"ESCC, esophageal dysplasia",-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
2341,KP12,17060721,p53 mutation and loss of p16#might play#a central role in ESCC pathogenesis,Cancer Association,"TP53,CDKN2A",-,ESCC,-,-,-,-,-,-,-,-,Inference,5,5.5,5.5.1,5.5.1.1,-,错义突变
5284,KP12,39456616,PAM inhibitors#selectively target#single PAM pathway nodes,Drug Development,-,-,-,PAM inhibitors,PAM,-,-,-,-,-,-,Fact,2,2.5,2.5.2,2.5.2.1,-,新型抑制剂开发
5533,KP12,39456616,"Gedatolisib and other PAM inhibitors#were tested in#endometrial, ovarian, and cervical cancer cell lines",Preclinical Models,-,"Endometrial, ovarian, cervical cancer cells","Endometrial cancer, ovarian cancer, cervical cancer","Gedatolisib, alpelisib, capivasertib, everolimus",PAM,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
7778,KP12,39456616,Gedatolisib#was evaluated in combination with#CDK4/6 inhibitor (palbociclib) or anti-estrogen (fulvestrant),Combination Therapies,"CDK4,CDK6",-,-,"Gedatolisib, palbociclib, fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
3002,KP12,39456616,Gedatolisib#induced#a substantial decrease in PAM pathway activity,Pathway & Network Categories,-,-,-,Gedatolisib,PAM,-,Downregulated,-,-,-,-,Fact,4,4.1,4.1.2,4.1.2.1,-,氧化磷酸化改变
3165,KP12,39456616,Gedatolisib#exhibited#greater growth-inhibitory effects in cell lines regardless of PAM pathway mutations,Drug Development,-,-,-,Gedatolisib,PAM,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
5290,KP12,39191167,RT-PCR#demonstrated#reduced expression levels of target biomolecules in HT-29 cells treated with rutin,Expression Patterns,-,HT-29,-,Rutin,-,-,Downregulated,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.2,-,共激活因子
7369,KP12,36847915,FOXM1 inhibitors#were combined with#drugs used in breast and other cancers,Combination Therapies,FOXM1,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
4766,KP12,36847915,FOXM1 inhibitors#were assessed for#suppression of cell viability and cell cycle progression,Preclinical Models,FOXM1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3740,KP12,36847915,FOXM1 inhibitors#enhance#effectiveness in combination with proteasome inhibitors and CDK4/6 inhibitors,Drug Development,"FOXM1,CDK4,CDK6",-,Breast cancer,"Palbociclib, Abemaciclib, Ribociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6585,KP12,28961193,Fascaplysin treatment#increases#cleaved-caspase-3 in xenografted tumor tissues,Mechanism of Action,-,-,Tumor,-,-,-,-,Upregulated,-,-,-,Fact,3,3.1,3.1.3,3.1.3.3,-,线粒体通路调控
1832,KP12,29623577,CDK4/6 inhibitor palbociclib#establishes#resistance mechanisms of RAD-R,Resistance Management,"CDK4,CDK6",-,-,Palbociclib,mTORC1/2,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.4,-,生物标志物指导
1991,KP12,26244501,ARV p17#stabilizes#PTEN by stimulating phosphorylation and elevating Rak-PTEN association,Regulation,PTEN,-,-,-,-,-,-,Upregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
3680,KP12,26244501,CDK4 knockdown#increases#virus production,Function triples,CDK4,-,-,-,-,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
2455,KP12,26244501,p53 knockdown#reduces#virus yield,Function triples,TP53,-,-,-,-,-,-,Downregulated,-,-,-,Fact,5,5.5,5.5.1,5.5.1.2,-,无义突变
4044,KP12,38992220,Palbociclib and ribociclib#exhibit#biological effects in HR+ breast cancer,Clinical Trial Data,"CDK4,CDK6",-,Breast cancer,"Palbociclib, Ribociclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
6882,KP12,38992220,Palbociclib or ribociclib#modulate#HR+ breast cancer cell lines with fulvestrant,Drug Development,"CDK4,CDK6",-,Breast cancer,"Palbociclib, Ribociclib, Fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
7005,KP12,38992220,"PAM50 gene expression#is assessed by#RB1 phosphorylation, Lamin-B1 protein levels, and senescence-associated β-galactosidase activity",Biomarker Analysis,RB1,-,Breast cancer,-,-,-,-,Upregulated,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,7.3.1.1.2,pRB水平
5788,KP12,38992220,CDK4/6 inhibitors#inhibit#proliferation across HR+ cell lines,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
455,KP12,38992220,CDK4/6 inhibitors#reduce#p-RB1 at higher doses over time,Mechanism of Action,"RB1,CDK4,CDK6",-,Breast cancer,-,-,-,-,Downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
3623,KP12,38992220,Treatment#reduces#Lamin-B1 expression and increases senescence-associated β-galactosidase activity,Mechanism of Action,"CDK4,CDK6",-,Breast cancer,-,-,-,-,Downregulated,-,-,-,Fact,3,3.1,3.1.2,3.1.2.2,-,衰老相关分泌表型
4169,KP12,38992220,CDK4/6 inhibitors#enhance#Luminal A and reduce Luminal B proliferation signatures,Molecular Event triples,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.2,7.4.1.2.1,Luminal亚型
5388,KP12,38992220,CDK4/6 inhibitors#modulate#HER2-enriched signatures dose-dependently with fulvestrant,Therapeutic Response,"CDK4,CDK6,HER2",-,Breast cancer,Fulvestrant,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
6479,KP12,35843546,Combination of AB680 and palbociclib#improves#anti-tumor efficacy in CRC models,Combination Therapies triples,CDK4,-,CRC,"Palbociclib, AB680",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
6097,KP12,20473331,Downregulation of cell-cycle control genes#includes#cyclin D and CDK4,Regulation,"CDK4,CCND1",-,-,-,-,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
5086,KP12,11212250,Increased tumor formation#is associated with#altered cell maturation in intestinal mucosa of p21-deficient mice,Cancer Association,CDKN1A,-,Tumor,-,-,-,p21-deficient,-,-,-,-,Fact,1,1.4,1.4.2,1.4.2.2,-,分化标志物表达
5706,KP12,11212250,c-myc upregulation#up-regulates#cdk4 through altered beta-catenin-Tcf signaling,Pathway & Network Categories,"CDK4, MYC",-,Tumor,-,Beta-catenin-Tcf,-,-,Upregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
3586,KP12,38751701,Neratinib in combination with palbociclib or miransertib#exhibits#synergistic effects in brain cancer cells,Combination Therapies triples,"CDK4, CDK6",-,Brain cancer,"Palbociclib, Miransertib, Neratinib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6750,KP12,23077401,HMGA2 gene silencing#deregulates#molecular mechanisms in retinoblastoma cells,Molecular Event triples,HMGA2,-,Retinoblastoma,-,-,-,-,Downregulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.3,-,抑制复合物
1436,KP12,23077401,"HMGA2 silencing#upregulates#1,132 genes in Y79 cells",Expression Patterns,HMGA2,Y79 RB cells,Retinoblastoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
6783,KP12,23077401,"HMGA2 silencing#downregulates#1,562 genes in Y79 cells",Expression Patterns,HMGA2,Y79 RB cells,Retinoblastoma,-,-,-,-,downregulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.3,-,抑制复合物
6389,KP12,23077401,"Deregulated genes#are involved in#MAPK, JAK/STAT, Ras, ERK1/2, and p53 pathways",Pathway & Network Categories,"ELK1, CDK6, E2F4, GTSE1, DRAM, CDH1, SNAI1, MMP2, MMP9",-,Retinoblastoma,-,"MAPK, JAK/STAT, Ras, ERK1/2, p53",-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
314,KP12,23077401,HMGA2 silencing#induces#molecular regulatory changes in RB cancer cells,Mechanism of Action,HMGA2,Y79 RB cells,Retinoblastoma,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.3,-,抑制复合物
2106,KP13,7651726,Progression through G1 phase#is regulated by#Cdk4 and Cdk6,Cell Cycle Control,"CDK4, CDK6",-,-,-,G1 phase,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
4949,KP13,9324288,Wild-type p16INK4A#inhibits#growth of human leukemia cell lines,Cancer Association,CDKN2A,-,Leukemia,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.3,-,E2F转录因子活性下调
6627,KP13,9324288,COOH-terminal tail of wt p16 protein#enhances#growth suppressive capability of p16,Mechanism of Action,CDKN2A,-,Leukemia,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.3,-,E2F转录因子活性下调
4655,KP13,9324288,Amino acid substitutions in p16 mutants#disrupt#CDK4 and CDK6 binding,Structural Biology,"CDKN2A, CDK4, CDK6",-,Leukemia,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
168,KP13,9324288,Amino acid substitutions in p16 mutants#decrease#protein half-lives,Structural Biology,CDKN2A,-,Leukemia,-,-,-,-,downregulated,-,-,-,Fact,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
1657,KP13,9324288,Restoration of wt p16 expression#reverts#transformed phenotype in p16-deficient leukemias,Therapeutic Development,CDKN2A,-,Leukemia,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.3,-,E2F转录因子活性下调
6278,KP13,35562811,CDK4/6 inhibitors#enhance#gammaherpesvirus and ERV3-1 gene expression in PEL and BL lines,Regulation,"CDK4, CDK6","PEL cells, BL cells",Lymphoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
6326,KP13,35562811,Gammaherpesvirus gene enhancement#is associated with#gamma interferon-induced gene expression including MHC-I,Regulation,"CDK4, CDK6",-,Lymphoma,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.3,-,非编码RNA调控
7481,KP13,22728232,Methyl nomilinate#induces#G0/G1 cell cycle arrest,Cell Cycle Control,"CDK4, CDK6",-,Colon adenocarcinoma,Methyl nomilinate,G0/G1 phase,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
3612,KP13,22728232,Methyl nomilinate#suppresses#CDK4/6 and cyclin D3 expression,Regulation,"CDK4, CDK6, CCND3",-,Colon adenocarcinoma,Methyl nomilinate,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
2117,KP13,22728232,Methyl nomilinate#inhibits#cell proliferation by inducing G1 cell cycle arrest,Cancer Prevention,"CDK4, CDK6",-,Colon adenocarcinoma,Methyl nomilinate,G1 phase,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
1341,KP13,34388663,Nerolidol#correlated with#generation of intracellular ROS,Mechanism of Action,-,-,-,Nerolidol,-,-,-,-,-,-,ROS,Fact,4,4.3,4.3.1,4.3.1.1,-,线粒体ROS产生
5728,KP13,34388663,Nerolidol#induced#p-γH2AX(ser139) expression,Mechanism of Action,H2AX,-,-,Nerolidol,-,-,-,Upregulated,-,-,-,Fact,5,5.1,5.1.1,5.1.1.1,-,DSB识别
1264,KP13,34388663,Nerolidol#induced#DNA damage,Mechanism of Action,-,-,-,Nerolidol,-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.1,-,DSB识别
4999,KP13,34388663,Nerolidol#downregulated#ATM and its phosphorylation,Regulation,ATM,-,-,Nerolidol,-,-,-,Downregulated,-,-,-,Fact,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
6286,KP13,34388663,KU-55933#mimicked#inhibitory effects of nerolidol on cell proliferation and Akt phosphorylation,Mechanism of Action,"ATM, AKT",-,-,KU-55933,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6618,KP13,14559232,"PI3K signaling#is involved in#proliferation, differentiation, anti-apoptosis, tumorigenesis, and angiogenesis",Mechanism of Action,PIK3CA,-,Tumor,-,PI3K,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
6826,KP13,38266771,Targeting mutant receptor levels#shows promise for#inhibiting growth in metastatic BC expressing ERα variants,Therapeutic Development,ESR1,-,Breast cancer,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7055,KP13,38266771,PMM2#emerged as#a significant target,Biomarker Analysis,PMM2,-,Breast cancer,-,-,-,-,Upregulated,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
4146,KP13,38266771,Depletion of PMM2#induces#degradation of ERα Y537S,Mechanism of Action,"PMM2, ESR1",-,Breast cancer,-,-,-,-,Downregulated,-,-,-,Fact,3,3.4,3.4.2,3.4.2.4,-,死亡信号放大
7279,KP13,38266771,Depletion of PMM2#leads to#reduction in ESR1 mRNA levels,Mechanism of Action,"PMM2, ESR1",-,Breast cancer,-,-,-,-,Downregulated,-,-,-,Fact,3,3.4,3.4.2,3.4.2.4,-,死亡信号放大
1676,KP13,38266771,Reduction of PMM2#decreases#FOXA1 levels,Mechanism of Action,"PMM2, FOXA1",-,Breast cancer,-,-,-,-,Downregulated,-,-,-,Fact,3,3.4,3.4.2,3.4.2.4,-,死亡信号放大
2681,KP13,18760195,Protein and mRNA expression#is significant in#BCC cells compared to normal skin tissue,Expression Patterns,-,BCC cells,Basal cell carcinoma,-,-,-,-,Upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
1396,KP13,16436672,Active GTP-bound rap1#is upregulated in#SCC compared to normal or immortalized keratinocytes,Expression Patterns,RAP1,"SCC cells, keratinocytes",Squamous cell carcinoma,-,-,-,-,Upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
6021,KP13,16436672,"Rap1GAP#inactivates#rap1 isoforms (rap1A, rap1B)",Mechanism of Action,"RAP1GAP, RAP1A, RAP1B",-,Squamous cell carcinoma,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
1705,KP13,18462865,Enzastaurin#produced#dose-dependent inhibition of cellular proliferation,Drug Development,-,Glioma cells,Glioma,Enzastaurin,-,-,-,Downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3747,KP13,9774662,ARF promoter#is silenced by#DNA methylation,Regulation,CDKN2A,-,-,-,-,-,Silenced,-,-,-,-,Fact,2,2.1,2.1.3,2.1.3.1,-,DNA甲基化模式改变
422,KP13,9774662,Wild-type p53#downregulates#transcription from ARF promoter,Regulation,"TP53, CDKN2A",-,-,-,-,-,-,Downregulated,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
41,KP13,9774662,"Feedback loop between p53, MDM2, and ARF#keeps#p53 levels in check",Regulation,"TP53, MDM2, CDKN2A",-,-,-,-,-,-,-,-,-,-,Inference,5,5.5,5.5.3,5.5.3.4,-,转录调控网络
3741,KP13,35418303,ATR:CHK1 pathway#controls#ERα stability and cell proliferation in luminal A BC cells,Pathway,"ATR, CHEK1, ESR1",Luminal A BC cells,Breast cancer,-,ATR:CHK1,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
5894,KP13,25655587,Piperine#inhibits#immune cell-mediated inflammation,Anti-inflammatory Mechanism,-,Immune cells,-,Piperine,-,-,-,-,-,-,-,Fact,6,6.4,6.4.1,6.4.1.1,-,促炎因子
572,KP13,25655587,Piperine#inhibited#IL-2-driven T lymphocyte proliferation,Function triples,IL2,-,-,Piperine,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
2007,KP13,25655587,Piperine#did not cause#T lymphocytes to die,Function triples,-,T lymphocytes,-,Piperine,-,-,-,-,-,-,-,Fact,3,3.4,3.4.2,3.4.2.3,-,凋亡执行
534,KP13,25655587,Piperine#did not decrease#expression of high-affinity IL-2 receptor,Function triples,IL2RA,-,T lymphocytes,Piperine,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
1576,KP13,23897809,Cdk4#interacts with#NDR1/2,Protein Interaction triples,"CDK4, NDR1, NDR2",-,-,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
7966,KP13,23897809,Cyclin D1 K112E#enhanced#NDR1/2 kinase activity,Mechanism of Action triples,"CCND1, NDR1, NDR2",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7984,KP13,23897809,Cyclin D1#promotes#G1/S transition,Cell Cycle Control triples,CCND1,-,-,-,G1/S transition,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
3945,KP13,23897809,Knockdown of NDR1/2#abolished#Cyclin D1 K112E function in promoting G1/S transition,Mechanism of Action triples,"CCND1, NDR1, NDR2",-,-,-,G1/S transition,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
2388,KP13,23897809,Cyclin D1 K112E overexpression#reduced#p21 protein levels,Regulation triples,"CCND1, CDKN1A",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
306,KP13,23897809,Cyclin D1#promotes#cell cycle progression by enhancing NDR kinase activity independent of Cdk4,Mechanism of Action triples,"CCND1, NDR1, NDR2, CDK4",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
150,KP13,25255445,Canonical pathway#induces#RelA or c-Rel containing complexes,Pathway triples,"RELA, REL",-,-,-,Canonical pathway,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
2468,KP13,25255445,Canonical pathway#involves#degradation of I魏B伪 in an IKK尾-dependent manner,Pathway triples,"NFKBIA, IKBKB, NEMO",-,-,-,Canonical pathway,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
6846,KP13,25255445,Non-canonical pathway#induces#NF-魏B2(p52)/RelB containing complexes,Pathway triples,"NFKB2, RELB",-,-,-,Non-canonical pathway,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
6304,KP13,25255445,Non-canonical pathway#depends on#IKK伪 and NIK,Pathway triples,"IKBKE, NIK",-,-,-,Non-canonical pathway,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
3324,KP13,25255445,"Alternative NF-魏B pathway subunits#affect#expression of key cell cycle regulators, ROS generation, and protein stability",Pathway triples,"NFKB2, RELB",-,-,-,Alternative NF-魏B pathway,-,-,-,-,-,-,Fact,1,1.3,1.3.3,1.3.3.1,-,P53通路相互作用
7780,KP13,25255445,EZH2#antagonizes#p53 target genes associated with senescence,Gene Regulation triples,"EZH2, TP53",-,-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.1,1.5.1.1,-,组蛋白修饰
4290,KP13,25255445,Microenvironment-induced NF-魏B pathway#inhibits#tumor suppressor function,Cancer Pathways triples,NFKB,-,Tumor,-,-,-,-,-,-,-,-,Inference,6,6.1,6.1.1,6.1.1.1,-,CD8+效应T细胞
2786,KP13,25255445,Microenvironment-induced NF-魏B pathway#promotes#tumorigenesis,Cancer Pathways triples,NFKB,-,Tumor,-,-,-,-,-,-,-,-,Inference,6,6.1,6.1.1,6.1.1.3,6.1.1.3.1,免疫检查点表达
1020,KP13,32373071,Nuclear immunostaining of CDK4#correlated with#mRNA expression,Expression Patterns triples,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
224,KP13,7652161,Overexpression of G1-phase regulatory transgenes#decreased#proportion of cells at G1/S-phase border after irradiation,Regulation triples,-,-,-,-,G1/S-phase border,downregulated,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
7798,KP13,32958271,CDDD2-94#arrested#G1/G0 cell cycle,Cell Cycle Control triples,CDK4,-,Ovarian cancer,CDDD2-94,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6960,KP13,32958271,CDDD2-94#induced#senescence,Cell Cycle Control triples,CDK4,-,Ovarian cancer,CDDD2-94,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
26,KP13,32958271,CDDD2-94#inhibited#proliferation of Rb-proficient ovarian cancer cells,Cell Cycle Control triples,CDK4,Rb-proficient cells,Ovarian cancer,CDDD2-94,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7667,KP13,39153367,"CDK4/6 inhibitors#combined with#radiotherapy in HR-positive, HER2-negative breast cancer models",Combination Therapies triples,"CDK4,CDK6","MCF-7, T-47D",Breast cancer,"Ribociclib, Palbociclib",RT,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
4310,KP13,10329038,CDK4#overexpressed in#69% of cervical carcinoma tumors,Cancer Association triples,CDK4,-,Cervical carcinoma,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
2653,KP13,10329038,Cyclin D1#overexpressed in#3% of cervical carcinoma tumors,Cancer Association triples,CCND1,-,Cervical carcinoma,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
6555,KP13,10329038,p21#overexpressed in#96% of cervical carcinoma tumors,Cancer Association triples,CDKN1A,-,Cervical carcinoma,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
1097,KP13,10329038,MDM2#overexpressed in#35% of cervical carcinoma tumors,Cancer Association triples,MDM2,-,Cervical carcinoma,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
5387,KP13,10329038,EGFR#overexpressed in#20% of cervical carcinoma tumors,Cancer Association triples,EGFR,-,Cervical carcinoma,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
7995,KP13,10329038,Aberrant expression of MDM2#is involved in#development of cancers,Cancer Association,MDM2,-,Cancers,-,-,-,-,-,-,-,-,Inference,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
2870,KP13,39241517,Pirfenidone#inhibits#CCL2-mediated Treg chemotaxis in HR+/HER2- breast cancer,Therapeutic Response,CCL2,-,HR+/HER2- breast cancer,Pirfenidone,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
6362,KP13,39241517,Neoadjuvant chemotherapy#results in#pCR rate of less than 18% in HR+/HER2- breast cancer,Clinical Implementation,-,-,HR+/HER2- breast cancer,-,-,-,Advanced-stage disease,Downregulated,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,-,生物标志物监测
331,KP13,39241517,These therapeutics#alter#tumor immune microenvironment in HR+/HER2- breast cancer,Immune Cell Functions,-,-,HR+/HER2- breast cancer,-,-,-,-,-,-,-,-,Inference,6,6.1,6.1.1,6.1.1.3,-,免疫检查点表达
1752,KP13,39241517,Combination of palbociclib and fulvestrant#upregulated#CCL2 in tumor cells,Expression Patterns,CCL2,-,Tumors,"Palbociclib, Fulvestrant",MAPK,-,-,Upregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
3676,KP13,39241517,Pirfenidone#enhanced#antitumor efficacy of Pal + Ful,Combination Therapies,-,-,Tumors,"Pirfenidone, Palbociclib, Fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
1357,KP13,39241517,CCL2 inhibitors#may treat#advanced HR+/HER2- breast cancer,Therapeutic Development,CCL2,-,HR+/HER2- breast cancer,-,-,-,-,-,-,-,-,Inference,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
3933,KP13,32397800,CDK7-CDK4 signaling axis#activates#autophagy by phosphorylating RB1,Mechanism of Action,"CDK7,CDK4,RB1,E2F1,FOXO3",Autophagy regulators,-,-,-,-,-,Upregulated,-,-,-,Inference,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
7088,KP13,38090281,Inhibition of CDK4/6-RB pathway#prevents#spread and metastasis of breast cancer,Cancer Pathways,"CDK4,CDK6,RB",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6560,KP13,29261702,Triple negative breast cancer#lacks#specific drug targets,Disease-Specific Categories,-,-,Triple negative breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
3708,KP13,29261702,CDK4/6 inhibitors#combine with#AR antagonists for therapeutic benefit,Combination Optimization,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1370,KP13,20309622,Salidroside#affects#proliferation of human cancer cell lines,Function triples,-,Human cancer cell lines,Cancer,Salidroside,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
2016,KP13,20309622,Salidroside#induces#change in cell cycle distribution,Cell Cycle Control,-,-,-,Salidroside,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
6390,KP13,23032699,Posttranslational control#affects#functionality of p16 protein,Regulation,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
5068,KP13,12234997,"Corticosterone#affects#cell growth, cell cycle machinery, and apoptosis",Regulation,-,-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.1,-,增殖信号整合
1544,KP13,12234997,Energy restriction#increases#secretion of adrenal cortical steroids,Metabolic Integration,-,-,Mammary carcinogenesis,-,-,-,-,-,-,-,-,Fact,4,4.1,4.1.3,4.1.3.2,-,代谢酶基因转录
6774,KP13,12234997,Energy restriction#reduces#circulating levels of insulin-like growth factor-1,Metabolic Integration,IGF1,-,Carcinogenesis,-,-,-,-,Downregulated,-,-,-,Fact,4,4.2,4.2.1,4.2.1.3,-,ATP消耗过程
5296,KP13,12234997,KIP1/P27 antisense oligonucleotides#reversed#growth inhibitory effects of corticosterone,Mechanism of Action,CDKN1B,-,Mammary cells,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
1456,KP13,12234997,Corticosterone#exerts#reversible growth inhibitory effects,Mechanism of Action,-,-,-,Corticosterone,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
2973,KP13,12234997,Corticosterone#limits#apoptotic cell death,Mechanism of Action,-,-,-,Corticosterone,-,-,-,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.1,-,存活信号调控
3222,KP13,29483214,CyclinD:CDK4/6:Rb axis#is dysregulated in#a variety of human cancers,Cancer Association,"CDK4,CDK6,RB1",-,Human cancers,-,-,-,-,Dysregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
2757,KP13,29483214,Subset of TNBC cell lines with intact Rb signaling#were found to be#responsive,Expression Patterns,RB1,TNBC cell lines,Triple-negative breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
5178,KP13,29483214,"Equivalent levels of tumor growth inhibition#were observed in#ER(+)/HER2(-), ER(+)/HER2(+) and biomarker-selected TNBC xenografts in response to abemaciclib",Therapeutic Response,-,"ER(+)/HER2(-), ER(+)/HER2(+), TNBC xenografts",Breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1945,KP13,29483214,Abemaciclib combined with hormonal blockade and/or HER2-targeted therapy#induced#significantly improved antitumor activity,Combination Optimization,-,-,Breast cancer,"Abemaciclib, HER2-targeted therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
7809,KP13,29483214,Rb/E2F-regulated genes#constitute#potential pharmacodynamic biomarkers of response to abemaciclib,Biomarker Analysis,"RB1,E2F",-,-,Abemaciclib,-,-,-,-,Pharmacodynamic biomarkers,-,-,Fact,7,7.3,7.3.1,7.3.1.1,-,细胞周期标志物
5548,KP13,29483214,Subtypes most likely to respond to abemaciclib-based therapies#can be identified by#measurement of specific biomarkers,Personalized Medicine,-,-,-,Abemaciclib,-,-,-,-,Specific biomarkers,-,-,Fact,7,7.5,7.5.1,7.5.1.1,-,耐药基因标志物
2048,KP13,28508842,A3 adenosine receptor agonist#induces#G1 cell cycle arrest via Cyclin D and CDK4 pathways,Cell Cycle Control,"CDK4,CCND1","OVCAR-3, Caov-4 cell lines",Ovarian cancer,-,Cyclin D/CDK4,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
5087,KP13,28508842,IB-MECA#inhibits#proliferation of cancer cells by inducing cell cycle arrest,Mechanism of Action,-,Cancer cells,Cancer,IB-MECA,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3589,KP13,28508842,IB-MECA#significantly reduced#cell viability in a dose-dependent manner,Mechanism of Action,-,-,Cancer,IB-MECA,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
5883,KP13,28508842,Low concentration of IB-MECA#induced#G1 cell cycle arrest,Cell Cycle Control,-,-,Cancer,IB-MECA,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
151,KP13,28508842,Reduction of Cyclin D1 and CDK4 protein levels#was observed after#treating cancer cells with IB-MECA,Regulation,"CDK4,CCND1",Cancer cells,Cancer,IB-MECA,-,-,Downregulated,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7614,KP13,28508842,IB-MECA#induces#G1 phase cell cycle arrest through Cyclin D1/CDK4-mediated pathway,Cell Cycle Control,"CDK4,CCND1",Ovarian cancer cells,Ovarian cancer,IB-MECA,Cyclin D1/CDK4,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
4157,KP13,29581135,47 upregulated genes#showed#significant overlap with 20 E2F4-regulated genes,Expression Patterns,E2F4,-,Letrozole-resistant tumors,-,-,-,-,Upregulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
4941,KP13,29581135,Palbociclib#downregulated#20 E2F4 target genes and P-RB levels,Regulation,"E2F4,RB1",-,Breast cancer,Palbociclib,-,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
5433,KP13,36127291,Findings#demonstrated#novel mechanism underlying resistance to palbociclib in ER(+) BC cells,Mechanisms of Resistance,-,-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
2028,KP13,34611509,GPC3 mutation and upregulation#identified in#multidrug-resistant osteosarcoma and its spheroids,Cancer Association,GPC3,-,Osteosarcoma,-,-,-,-,Upregulated,-,-,-,Fact,2,2.6,2.6.1,2.6.1.1,-,药物外排增加
7428,KP13,34611509,Mutant GPC3#is upregulated in#metastatic osteosarcoma and its spheroids,Cancer Association,GPC3,-,Osteosarcoma,-,-,-,-,Upregulated,-,-,-,Fact,2,2.6,2.6.1,2.6.1.1,-,药物外排增加
4234,KP13,19513537,GP#inhibited#cell proliferation and colony formation by upregulation of TGFbeta1 and downregulation of Akt and phospho-Akt,Mechanism of Action,"TGFB1,AKT",-,-,GP,-,-,-,"Upregulated (TGFbeta1), Downregulated (Akt, phospho-Akt)",-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
5219,KP13,39456616,Gedatolisib#represents#an effective treatment option for patients with gynecologic cancers,Therapeutic Development,-,-,Gynecologic cancers,Gedatolisib,-,-,Patients with gynecologic cancers,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
7045,KP13,39456616,Gedatolisib in combination with other therapies#has shown#promising preliminary efficacy in clinical studies with various solid tumor types,Combination Therapies,-,-,Solid tumors,Gedatolisib,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
3435,KP13,34276377,PNO treatment#promoted#cell vitality in replicative senescent NIH-3T3 fibroblasts,Stem Cell Biology,-,Fibroblasts,-,-,-,-,-,Upregulated,-,-,-,Fact,1,1.4,1.4.2,1.4.2.3,-,干细胞维持
5648,KP13,34276377,PNO treatment#inhibited#SA-β-galactosidase activity in replicative senescent NIH-3T3 fibroblasts,Stem Cell Biology,-,Fibroblasts,-,-,-,-,-,Downregulated,-,-,-,Fact,1,1.4,1.4.3,1.4.3.2,-,衰老程序激活
6117,KP13,34276377,PNO treatment#reduced#p16 and p21 protein-level expression in replicative senescent NIH-3T3 fibroblasts,Regulation,"CDKN2A,CDKN1A",Fibroblasts,-,-,-,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.2,-,细胞衰老诱导
7142,KP13,34276377,Oligosaccharides from P. notoginseng#reverse#fibroblast replicative senescence,Stem Cell Biology,-,Fibroblasts,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.2,-,衰老程序激活
2173,KP13,34276377,"Oligosaccharides from P. notoginseng#promote#fibroblast cell proliferation, migration, and CoL-I production",Stem Cell Biology,-,Fibroblasts,-,-,-,-,-,Upregulated,-,-,-,Fact,6,6.3,6.3.1,6.3.1.1,6.3.1.1.4,细胞外基质产生
84,KP13,12616621,MY and MG#promote#development of hepatic preneoplastic lesions induced by DEN,Cancer Pathways,-,-,Hepatic preneoplastic lesions,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
6109,KP13,12616621,Cell cycle controls#ensure#integrity of the genome and arrest of cells at G1/S or G2/M checkpoints,Cell Cycle Control,-,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
4418,KP13,12616621,"PCNA, cyclin D1, cdk4, cyclin B1, and cdc2#regulate#cell proliferation and cell cycle",Cell Cycle Control,"PCNA,CCND1,CDK4,CCNB1,CDC2",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
2001,KP13,12616621,Increased mRNA levels#result from#increased transcription rate of these genes,Regulation,-,-,-,-,-,-,Upregulated,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
6674,KP13,12616621,Dysregulation of G1/S and G2/M checkpoints#links to#tumor promotion by MY and MG,Cancer Pathways,-,-,Tumor,-,-,-,-,-,-,-,-,Inference,2,2.2,2.2.2,2.2.2.1,-,G1/S检查点失控
7043,KP13,9546285,CDKN2A mRNA expression#shows#no or weak signals in 11 tumors,Expression Patterns,CDKN2A,-,Tumors,-,-,-,-,Downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
828,KP13,9546285,CDKN2A gene product (p16)#shows#expression restricted to single tumor cells,Expression Patterns,CDKN2A,-,Tumors,-,-,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7557,KP13,9546285,"CCND1#reveals#no amplification, rearrangement, or overexpression",Expression Patterns,CCND1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
7388,KP13,9546285,"None of the 20 PCNSL#demonstrated#gene amplification of MDM2, MYC, or REL",Cancer Association,"MDM2,MYC,REL",-,PCNSL,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
7548,KP13,39765134,Structural isomers of carene#induce#apoptotic cell death by inhibiting cell cycle in breast cancer cells,Cancer Pathways,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
5891,KP13,39765134,Structural isomers of carene#exhibit#anti-cancer effects in breast cancer cells,Cancer Pathways,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2957,KP13,39765134,3-carene#hinders#cell cycle and promotes apoptosis in MCF-7 cells,Cancer Pathways,-,MCF-7 cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.3,-,线粒体通路调控
5009,KP13,23958495,TRPM7 mRNA and protein#are measured in#rat model of liver fibrosis and PDGF-BB-activated HSC-T6 cells,Expression Patterns,TRPM7,HSC-T6 cells,Liver fibrosis,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
2201,KP13,14654956,Phosphorylation of Rb proteins#decreases#transition from G1- to S-phase,Cell Cycle Control,RB1,-,-,-,-,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
3349,KP13,14654956,Cell cycle progression#is retarded by#decreased phosphorylation of Rb proteins,Cell Cycle Control,RB1,-,-,-,-,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
4079,KP13,14654956,SFN#down-regulates#bcl-2 expression in prostate cancer cells,Cancer Pathways,BCL2,-,Prostate cancer,-,-,-,-,Downregulated,-,-,-,Fact,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
704,KP13,14654956,SFN#activates#caspases to execute apoptosis in prostate cancer cells,Cancer Pathways,-,-,Prostate cancer,-,-,-,-,Upregulated,-,-,-,Fact,3,3.1,3.1.3,3.1.3.2,-,死亡受体通路激活
4264,KP13,35843546,CD73 inhibitor#has additive effect with#CDK4/6 inhibitor in colorectal cancer treatment,Combination Therapies triples,"CDK4,CDK6",-,Colorectal cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
2952,KP13,35843546,Extracellular adenosine-mediated signaling#is considered#promising target for advanced-stage cancers,Signaling Networks,-,Advanced-stage cancers,-,-,"PD-1, PD-L1",-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.3,6.1.1.3.1,免疫检查点表达
419,KP13,35843546,AB680#reversed#effects of adenosine on CCND1 and PD-L1,Regulation,CCND1,-,-,AB680,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
428,KP13,35843546,Combination therapy of AB680 and palbociclib#may be advantageous for#treatment of CRC,Combination Therapies triples,"CDK4, CDK6",-,Colorectal cancer,"AB680, palbociclib",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7545,KP13,25568671,Doxazosin#suppresses#JAK/STAT phosphorylation and enhances IFN-伪/纬-induced apoptosis,Mechanism of Action,"JAK, STAT",-,-,Doxazosin,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.3,-,线粒体通路调控
5136,KP13,25568671,Doxazosin#suppressed#tumor growth in ovarian cancer xenograft mouse model,Preclinical Models,"TP53, MYC",-,Ovarian cancer,Doxazosin,-,Apoptosis,-,"Upregulated, downregulated",-,-,-,Fact,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
7880,KP13,27322250,Cypermethrin#induces#macrophages death through cell cycle arrest and oxidative stress-mediated JNK/ERK signaling,Signaling Networks,-,Macrophages,-,Cypermethrin,"JNK, ERK",-,-,-,-,-,-,Fact,4,4.3,4.3.1,4.3.1.4,-,氧化应激反应
1561,KP13,27322250,Cypermethrin#reduced#cell viability and induced apoptosis in RAW 264.7 cells,Cell Cycle Control,-,RAW 264.7 cells,-,Cypermethrin,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
1800,KP13,27322250,Cypermethrin#caused#immune cell death via cell cycle arrest and apoptosis regulated by ROS-mediated JNK/ERK pathway,Signaling Networks,-,Immune cells,-,Cypermethrin,"JNK, ERK",-,-,-,-,-,-,Fact,4,4.3,4.3.1,4.3.1.4,-,氧化应激反应
431,KP13,20664182,Downregulation of NS#decreased#S stage and increased G1 stage in cell cycle,Cell Cycle Control,NS,-,-,-,-,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
731,KP13,22678079,Hypertriploid karyotype#showed#multiple structural anomalies,Structural Biology,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.1,-,易位
5521,KP13,30826934,E6201#inhibited#TNBC xenograft growth and lung metastasis,Preclinical Models,-,-,TNBC,E6201,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7174,KP13,30826934,Combination of E6201 with CDK4/6 or mTOR inhibitor#enhanced#anti-tumor efficacy,Combination Therapies triples,"CDK4, CDK6, MTOR",-,-,E6201,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5641,KP13,38751701,Aberrant expression and activation of EGFR#resulted in#approval of EGFR inhibitors for epithelial cancers,Drug Development,EGFR,-,Epithelial cancers,EGFR inhibitors,-,-,-,Aberrant,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
2519,KP13,38751701,No EGFR inhibitor#has been approved for#treatment of brain cancer,Drug Development,EGFR,-,Brain cancer,EGFR inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
4802,KP13,38751701,"Neratinib, dinaciclib, dasatinib, stattic, and trametinib#inhibited#migration of A172 brain tumor cells",Drug Development,-,A172 brain tumor cells,Brain tumor,"Neratinib, dinaciclib, dasatinib, stattic, trametinib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6643,KP13,28923602,Mannoprotein#inhibits#apoptosis of HaCaT cells,Molecular Event triples,BCL2,HaCaT cells,-,-,-,-,-,Upregulated,-,-,-,Fact,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
5523,KP13,28923602,Mannoprotein#increases#phosphorylation levels of RELA and NFKBIA in HaCaT cells,Pathway triples,"RELA,NFKBIA",HaCaT cells,-,-,NF-κB signal pathway,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
6306,KP13,28923602,Mannoprotein#activates#NF-κB signal pathway to mediate cell cycle alternation and inhibit apoptosis,Pathway triples,-,HaCaT cells,-,PDTC,NF-κB signal pathway,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
6329,KP13,35276236,10 euphorbiaceous plants of Pakistan#have#anti-breast cancer potential,Disease & Clinical Categories,-,-,Breast cancer,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
7412,KP13,35276236,Further studies#are suggested to find#clinical implications of these plants in breast cancer therapy,Disease & Clinical Categories,-,-,Breast cancer,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
2623,KP13,10956386,Myc#is transcriptionally activated by#chromosomal translocation in Burkitt lymphoma,Cancer Association,MYC,B-cells,Burkitt lymphoma,-,-,-,-,upregulated,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
5266,KP13,26643872,"SNP array analysis#indicated#amplified genes MDM2, CDK4, HMGA2",Molecular Event triples,"MDM2, CDK4, HMGA2",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5801,KP13,26643872,"Recurrent mutations#signaled through#MAPK, JAK-STAT, Wnt, ErbB, axon guidance, apoptosis, DNA damage repair, cell cycle pathways",Pathway triples,-,-,Liposarcomagenesis,-,"MAPK, JAK-STAT, Wnt, ErbB, axon guidance, apoptosis, DNA damage repair, cell cycle",-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
823,KP14,30537512,CDK4/6 inhibitors#are effective in#breast cancer,Therapeutic Response triples,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2419,KP14,30537512,FAT1 loss#is a mechanism of resistance to#CDK4/6 inhibitors,Mechanisms of Resistance triples,FAT1,-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
5402,KP14,38409585,Aberrant activation of CDK4/6 pathway#engenders#uncontrolled breast cancer cell proliferation,Mechanism of Action triples,"CDK4, CDK6",Breast cancer cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6824,KP14,35053461,CDKs#regulate#cell cycle progression,Cell Cycle Control triples,"CDK4, CDK6",-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
1441,KP14,35053461,Targeted inhibition of CDKs#has shown#therapeutic benefit in tumors,Therapeutic Response triples,"CDK4, CDK6",-,Tumor,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7495,KP14,35053461,CDK4/6 inhibitors#approved for#breast cancer,Clinical Implementation triples,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1693,KP14,35053461,Combination therapies with CDK inhibitors#may provide#promising results in tumor therapy,Combination Therapies triples,"CDK4, CDK6",-,Tumor,CDK inhibitors,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3541,KP14,32805138,"Palbociclib, ribociclib, abemaciclib#approved for#HR+/HER2- metastatic breast cancer",Clinical Implementation triples,"CDK4, CDK6",-,HR+/HER2- metastatic breast cancer,"Palbociclib, ribociclib, abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1601,KP14,32805138,Active investigations#include#predictive biomarkers for CDK4/6 inhibitors,Biomarker Analysis triples,"CDK4, CDK6",-,HR+/HER2- metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,Predictive biomarkers,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
7347,KP14,38670537,TQB3616#is#a novel CDK4-biased inhibitor,Drug Development triples,CDK4,-,-,TQB3616,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1524,KP14,29374415,Addition of CDK inhibitors#doubled#progression-free survival,Therapeutic Response triples,"CDK4, CDK6",-,-,CDK inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7799,KP14,11407596,Targeting of Ras or PKC#may show#efficacy in astrocytoma therapy,Therapeutic Development triples,"RAS, PKC",-,Astrocytoma,-,Growth factor receptor signaling,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1686,KP14,35535675,CDK4/6 inhibitors#are used for#HR+/HER2- metastatic breast cancer treatment,Clinical Implementation,"CDK4, CDK6",-,Metastatic breast cancer,"Palbociclib, Abemaciclib, Ribociclib",-,-,Female,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3923,KP14,38540112,CDK4/6 inhibitors#target#cell cycle machinery to overcome endocrine resistance,Mechanism of Action,"CDK4, CDK6",-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
6186,KP14,32799335,Abemaciclib#is recommended for#brain cancer treatment,Therapeutic Development,"CDK4, CDK6",-,Brain cancer,Abemaciclib,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
526,KP14,32799335,Palbociclib#is not recommended for#brain cancer treatment,Therapeutic Development,"CDK4, CDK6",-,Brain cancer,Palbociclib,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5217,KP14,24848372,Cyclin D1 or CDK level alterations#are seen in#most tumors,Expression Patterns,"CDK4,CDK6",-,Tumors,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
1849,KP14,24848372,CDK6 and CDK4#regulate#pre-receptor control of steroid hormone action,Mechanism of Action,"CDK6,CDK4",-,Steroid hormone-dependent cancers,-,-,-,-,-,-,-,-,Inference,1,1.2,1.2.1,1.2.1.2,1.2.1.2.2,激素信号通路
1498,KP14,39754579,CDK4/6 inhibitors#are effective for#HR+/HER2- breast cancer treatment,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
6399,KP14,39754579,CDK6 inhibition#causes#hematological toxicity,Safety Monitoring,CDK6,-,Hematological toxicity,-,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.4,感染风险
897,KP14,29700711,CDK4/6 inhibitors#are used in#HR+ early breast cancer,Clinical Implementation,"CDK4,CDK6",-,Early breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
726,KP14,30685576,Understanding DDIs#helps in#treatment personalization for CDK4/6 inhibitors,Clinical Implementation,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,8,8.6,8.6.1,8.6.1.2,8.6.1.2.4,治疗依从性
6825,KP14,36562909,CDK4/6 inhibitors#improved#overall survival for HR+/HER2- metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,Metastatic breast cancer,-,-,Racial disparities,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
2076,KP14,34588615,CDK4/6 inhibitors#show efficacy in#malignant pleural mesothelioma models,Preclinical Models,"CDK4,CDK6",-,Malignant pleural mesothelioma,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
6038,KP14,34588615,There is no effective therapy#for#progressed malignant pleural mesothelioma,Clinical Implementation,-,-,Malignant pleural mesothelioma,"Platinum-based chemotherapy, immunotherapy",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
786,KP14,34588615,Palbociclib#reduces#tumor growth in malignant pleural mesothelioma models,Preclinical Models,"CDK4,CDK6",-,Malignant pleural mesothelioma,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
979,KP14,38404005,Ribociclib#is indicated for#pre/perimenopausal patients,Patient Stratification,"CDK4,CDK6",-,-,Ribociclib,-,-,Pre/perimenopausal,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.3,8.1.1.3.1,生物标志物状态
1417,KP14,38404005,Abemaciclib#is recommended for#endocrine-resistant or visceral disease,Patient Stratification,"CDK4,CDK6",-,Endocrine-resistant or visceral disease,Abemaciclib,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.3,8.1.1.3.1,生物标志物状态
7419,KP14,35223478,CDK4/6 inhibitors#improved#outcome for HR+/HER2- advanced breast cancer,Therapeutic Response,"CDK4,CDK6",-,Advanced breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
2921,KP14,38600865,CDK4/6 inhibitors#are#cornerstones in the treatment of HR-positive and HER2-negative metastatic breast cancer,Cancer Association,"CDK4,CDK6",-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4395,KP14,30061045,Pharmacologic inhibitors of CDK4/6#show#promising activity in patients with breast and other cancers,Therapeutic Development,"CDK4,CDK6",-,"Breast cancer, other cancers",-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3593,KP14,30061045,CDK4/6 inhibitors#inhibit#RB protein phosphorylation,Mechanism of Action,"CDK4,CDK6,RB",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,1.1.1.1.1,RB蛋白磷酸化
2535,KP14,30061045,CDK4/6 inhibitors#induce#cell cycle arrest,Mechanism of Action,"CDK4,CDK6",-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,1.1.3.1.1,G1期阻滞
3577,KP14,30061045,CDK4/6 inhibitors#modulate#mitogenic kinase signaling,Signaling Networks,"CDK4,CDK6",-,-,-,Mitogenic kinase,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
5072,KP14,30061045,CDK4/6 inhibitors#induce#a senescence-like phenotype,Cancer Pathways,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
5851,KP14,30061045,CDK4/6 inhibitors#enhance#cancer cell immunogenicity,Therapeutic Response,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.3,3.3.1,3.3.1.1,-,免疫细胞浸润增加
7745,KP14,30061045,CDK4/6 inhibitors#alter#cancer cell biology,Cancer Pathways,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7070,KP14,36191999,Endocrine therapy with or without CDK4/6 inhibitors#is#the primary treatment for ER-positive and HER2-negative metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,Endocrine therapy,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5567,KP14,35220309,New mutations#significantly differ#between patients treated with chemo and those treated with chemo followed by CE therapy,Resistance Mechanisms,-,-,-,"Chemo,CE therapy",-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
998,KP14,39732088,"CDK4/6 inhibitors#influence#crucial signaling pathways, including TP53 and EGFR",Signaling Networks,"CDK4,CDK6,TP53,EGFR",-,-,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
2046,KP14,39392584,CDK4/6 inhibitors#are associated with#neurological and psychiatric adverse events in breast cancer patients,Safety Monitoring,"CDK4,CDK6",-,Breast cancer,-,-,Neurological and psychiatric adverse events,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
2934,KP14,39392584,This study#investigates#neurological and psychiatric AEs associated with CDK4/6 inhibitors,Safety Monitoring,"CDK4,CDK6",-,-,-,-,Neurological and psychiatric adverse events,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
3,KP14,39392584,Onset times for AEs associated with CDK4/6 inhibitors#tend to be#early in drug therapy,Safety Monitoring,"CDK4,CDK6",-,-,-,-,Adverse events,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
545,KP14,38959677,CDK4/6 inhibitors with endocrine therapy#are#effective treatment for ER-positive and HER2-negative metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,Endocrine therapy,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4581,KP14,32694159,Abemaciclib#was administered#as monotherapy or with endocrine therapy,Drug Development,CDK4,-,-,"Abemaciclib,Endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
5987,KP14,32694159,Unbound brain metastases concentrations of abemaciclib analytes#were#96-fold (CDK4) and 19-fold (CDK6) above in vitro IC(50),Drug Development,"CDK4,CDK6",-,Brain metastases,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
4026,KP14,26324739,"Palbociclib#was approved#for use with letrozole for ER-positive, HER2-negative advanced breast cancer",Drug Development,"CDK4,CDK6",-,Advanced breast cancer,"Palbociclib,Letrozole",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
5164,KP14,35149588,CDK4/6 inhibition#sensitizes#cancer cells to chemotherapy and immune checkpoint blockade,Combination Optimization,"CDK4,CDK6",-,Cancer,Chemotherapy,-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.1,-,时序性联合
6819,KP14,36877344,CDK4/6-blockade therapies#are#promising strategies in ATC,Therapeutic Development,"CDK4,CDK6",-,ATC,-,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
6179,KP14,38668064,CDK4/6 inhibitors#are used#in HR-positive/HER2-negative advanced/metastatic breast cancer in first-line settings,Therapeutic Development,"CDK4,CDK6",-,Advanced/metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
1296,KP14,33522043,Cyclin pathway#contains#genomic alterations in prostate cancers,Molecular Event triples,-,-,Prostate cancer,-,Cyclin pathway,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
1918,KP14,33522043,Cyclin pathway#confers#resistance to standard treatments in prostate cancer,Cancer Pathways,-,-,Prostate cancer,-,Cyclin pathway,-,-,-,-,-,-,Inference,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
2068,KP14,39881422,CDK4/6 inhibitors#improve#outcomes in several cancers,Therapeutic Development,"CDK4,CDK6",-,Cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6526,KP14,39881422,"CDK4/6 inhibitors#induce#organ system toxicities, including musculoskeletal disorders",Safety Monitoring,"CDK4,CDK6",-,Musculoskeletal disorders,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
175,KP14,35817775,Prolonged CDK4/6 inhibition#engages#a senescence-like state in Triple Negative Breast Cancers (TNBCs),Cell Cycle Control,"CDK4,CDK6",-,Triple Negative Breast Cancer (TNBC),CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
126,KP14,34699032,"CDK4/6 inhibitors#are associated with#dermatologic reactions, especially alopecia",Safety Monitoring,"CDK4,CDK6",-,Alopecia,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
5847,KP14,38684839,CDK4/6 inhibitors#are#standard agents for treating ER+/HER2- advanced breast cancer,Clinical Implementation,"CDK4,CDK6",-,Advanced breast cancer,CDK4/6 inhibitors,-,-,"ER+, HER2-",-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
4799,KP14,34230123,Combination of palbociclib and everolimus#was evaluated in#osteosarcoma PDOX mouse model,Preclinical Models,"CDK4,CDK6,MTOR",-,Osteosarcoma,"Palbociclib, Everolimus",mTOR,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
1685,KP14,28801307,Endocrine therapy-resistant tumor proliferation#is associated with#disease recurrence and death,Cancer Association,-,-,Primary breast cancer,Endocrine therapy,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
5324,KP14,33233970,CDK4/6 inhibitors#differ in#toxicity profiles,Safety Monitoring,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
6630,KP14,33233970,CDK4/6 inhibitors#changed#therapeutic algorithms for hormone-responsive breast tumors,Therapeutic Development,"CDK4,CDK6",-,Hormone-responsive breast tumors,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
4544,KP14,39589751,CDK4/6 inhibitors plus endocrine therapy#improved#outcomes in HR+/HER2- metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,"HR+, HER2-",-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
2186,KP14,39487364,CDK6#drives#endothelial cell cycle acceleration in hereditary hemorrhagic telangiectasia,Cell Cycle Control,CDK6,Endothelial cells,Hereditary hemorrhagic telangiectasia,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
3065,KP14,39487364,Endothelial cells in HHT mice#bypassed#G1/S checkpoint,Cell Cycle Control,-,Endothelial cells,Hereditary hemorrhagic telangiectasia,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
6272,KP14,33743330,CDK4/6 inhibitors#are used as#adjuvant treatment for HR+/HER2- early breast cancer,Clinical Implementation,"CDK4,CDK6",-,Early breast cancer,CDK4/6 inhibitors,-,-,"HR+, HER2-",-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
5735,KP14,39146623,Osimertinib plus palbociclib#showed#antitumor activity in NSCLC PDX/2D/3D models,Combination Therapies,"EGFR,CDKN2A,CDKN2B",-,Non-small cell lung cancer,"Osimertinib, Palbociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
5298,KP14,39146623,Osimertinib plus palbociclib#effectively treat#NSCLC with wildtype EGFR and CDK6 amp and CDKN2A/2B homdel in the absence of oncogenic KRAS mutation,Combination Therapies,"EGFR,CDK6,CDKN2A,CDKN2B,KRAS",-,NSCLC,"Osimertinib, palbociclib",-,-,-,"amplified, homozygous deletion",-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
4570,KP14,29437706,Immunoediting caused by antitumor immunity#drives#tumor cells to acquire refractory phenotypes,Immune Cell Functions,-,Tumor cells,Cancer,-,-,-,-,-,-,-,-,Inference,6,6.1,6.1.1,6.1.1.3,-,免疫检查点表达
1757,KP14,29437706,Tumor antigen-specific T cells#edit#tumor cells to become resistant to CTL killing and enrich NANOG(high) cancer stem cell-like cells,Immune Cell Functions,NANOG,-,Cancer,CTL,-,-,-,upregulated,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
56,KP14,29437706,SCP3#is overexpressed in#immunoedited cells and upregulates NANOG by hyperactivating the cyclin D1-CDK4/6 axis,Regulation,"SCP3,NANOG,CDK4,CDK6,Cyclin D1",-,-,-,Cyclin D1-CDK4/6 axis,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7318,KP14,39278067,CDK4/6 inhibitors#are studied in#patients with breast cancer via meta-analysis of RCTs and real-world studies,Clinical Trial Data,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
6288,KP14,39278067,Abemaciclib and palbociclib#significantly increased#the risk of VTE in patients with breast cancer compared to placebo,Safety Monitoring,"CDK4,CDK6",-,Breast cancer,"Abemaciclib, palbociclib",-,-,Patients with risk of VTE,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,血液学毒性
7356,KP14,39278067,"Abemaciclib#enhanced#agonist-induced platelet activation, especially with collagen as the inducer",Mechanism of Action,"CDK4,CDK6",-,-,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7707,KP14,34864350,CDK4/6 inhibitors and endocrine therapy#transformed#the treatment landscape of HR+/HER2- advanced breast cancer,Therapeutic Development,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
4746,KP14,31399935,CDK4/6 inhibitors#are increasingly utilized in#advanced HR+ breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR+ breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
4271,KP14,39727671,Timing of dose reductions and survival outcomes#are studied in#metastatic breast cancer patients treated with CDK4/6 inhibitors,Clinical Trial Data,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.3,8.3.1,8.3.1.2,-,不良反应管理
5580,KP14,39727671,"ECOG performance status, line of therapy, and CDK4/6 inhibitor type#were significant predictors of#PFS and OS",Clinical Implementation,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
6376,KP14,39497720,EGFR and TP53#are the most frequently mutated genes in#NSCLC patients with osimertinib resistance,Cancer Pathways,"EGFR,TP53,NRG1,PIK3CA,ATM",-,NSCLC,Osimertinib,-,-,-,mutated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
5494,KP14,39254653,QTc prolongation#across#CDK4/6 inhibitors is studied in a systematic review,Safety Monitoring,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
1039,KP14,39254653,CDK4/6 inhibitors#improved outcomes for#ER+/HER2- breast cancer patients,Therapeutic Development,"CDK4,CDK6",-,ER+/HER2- breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4588,KP14,38879437,Different sensitivities to CDK4/6 inhibitors#indicate#the need for biomarkers in HR+/HER2- metastatic breast cancer,Biomarker Analysis,"CDK4,CDK6",-,HR+/HER2- metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,-,耐药基因标志物
305,KP14,39177933,CDK4/6 inhibitors#have improved#patient survival in HR+/HER2- metastatic breast cancer,Clinical Trial Data,"CDK4,CDK6",-,HR+/HER2- metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
4625,KP14,39413680,CDK4/6 inhibitors combined with endocrine therapy#are compared to#endocrine therapy alone in adjuvant treatment of high-risk HR+/HER2- early breast cancer,Clinical Trial Data,"CDK4,CDK6",-,HR+/HER2- early breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,High-risk patients,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.3,-,疗效监测
5229,KP14,30054831,Eight RCTs#were eligible for#4578 breast cancer patients,Clinical Trial Data,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
1628,KP14,39656925,CDK4/6 inhibitors#block#cell cycle progression,Mechanism of Action,"CDK4,CDK6",-,"Breast cancer (hormone receptor-positive), Triple-negative breast cancer (TNBC)",CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
215,KP14,39656925,CDK4/6 inhibitors#are effective in treating#hormone receptor-positive breast cancer,Therapeutic Response,"CDK4,CDK6",-,Hormone receptor-positive breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
4917,KP14,39656925,Triple-negative breast cancer#remains#resistant to CDK4/6 inhibitors,Cancer Association,"CDK4,CDK6",-,Triple-negative breast cancer (TNBC),CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
2029,KP14,39425174,CDK4/6 inhibitors#are combined with#endocrine therapy (ET),Combination Therapies,"CDK4,CDK6",-,Metastatic breast cancer (MBC),"CDK4/6 inhibitors, Endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
775,KP14,39425174,Patients with metastatic breast cancer#receive#CDK4/6 inhibitors plus ET or ET alone,Treatment Monitoring,"CDK4,CDK6",-,Metastatic breast cancer,"CDK4/6 inhibitors, Endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
2815,KP14,39278979,Peripheral blood biomarkers#are evaluated at#end of treatment with CDK4/6 inhibitors abemaciclib and palbociclib,Biomarker Analysis,"CDK4,CDK6",-,Advanced breast cancer,"Abemaciclib, Palbociclib",-,-,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,-,细胞周期标志物
1273,KP14,39278979,Absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR)#are#peripheral blood biomarkers,Biomarker Analysis,-,-,Advanced breast cancer,-,-,-,-,-,"ALC, NLR",-,-,Fact,7,7.3,7.3.1,7.3.1.1,-,细胞周期标志物
3174,KP14,33970738,Abemaciclib#is used in#different treatment lines,Treatment Monitoring,"CDK4,CDK6",-,Breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,治疗线别
409,KP14,33970738,"Abemaciclib#is combined with#endocrine therapy (fulvestrant, aromatase inhibitor)",Combination Therapies,"CDK4,CDK6",-,Breast cancer,"Abemaciclib, Fulvestrant, Aromatase inhibitor",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,内分泌治疗联合
7721,KP14,33970738,Abemaciclib#shows#utilization and outcomes post-FDA approval,Clinical Trial Data,"CDK4,CDK6",-,Breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,治疗线别
1104,KP14,33970738,Patients#benefit from#abemaciclib treatment in real-world settings,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
5924,KP14,38554981,"New compounds#are developed for#different pathologies, including breast cancer",Drug Development,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2013,KP14,38554981,Antiprogestins#are used for#breast cancer prevention in women with BRCA1 mutations,Drug Development,BRCA1,-,Breast cancer,Antiprogestins,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.2,-,衰老相关分泌表型
711,KP14,38554981,"Antiprogestins#are combined with#tamoxifen, CDK4/CDK6 inhibitors, pembrolizumab",Combination Therapies,"CDK4,CDK6",-,Breast cancer,"Antiprogestins, Tamoxifen, Pembrolizumab",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
2177,KP14,38554981,Antiprogestin therapy#decreases#proliferative pathways,Regulation,BRCA1,-,Breast cancer,Antiprogestins,Proliferative pathways,-,downregulated,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
6599,KP14,38783218,CDK4/6 inhibitors#are recommended by#NCCN and ESMO guidelines,Clinical Implementation,"CDK4,CDK6",-,Locally advanced/metastatic breast cancer (HR+/HER2-),CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
1965,KP14,39232581,CDK4/6 inhibitor#achieved#17 months of stable disease in a DHG-H3G34 patient,Therapeutic Response,"CDK4,CDK6",-,"Diffuse hemispheric gliomas, H3G34R/V-mutant (DHG-H3G34)",CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
3148,KP14,39169295,CDK4/6 inhibitors#enhance#survival outcomes in HR+/HER2- advanced breast cancer,Therapeutic Response,"CDK4,CDK6",-,Advanced breast cancer (HR+/HER2-),CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
394,KP14,38175669,"PAM50 IS, genomic, and immunological features#are#promising biomarkers",Biomarker Analysis,-,-,-,-,-,-,-,"PAM50 IS, genomic, immunological features",-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
4686,KP14,29147869,CDK4/6 inhibitors#cause#hematological adverse effects,Adverse Effects,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,Hematological adverse effects,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,血液学毒性
1248,KP14,29147869,CDK4/6 inhibitors#improve#progression-free survival in hormone receptor-positive metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
1106,KP14,29147869,Randomized trials#provide#safety data on hematological adverse effects of CDK4/6 inhibitors,Safety Monitoring,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,Hematological adverse effects,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,血液学毒性
5656,KP14,39500869,CDK4/6 and ER inhibition#create#vulnerability to ferroptosis induction,Mechanism of Action,"CDK4,CDK6,ESR1",-,Breast cancer,GPX4 inhibitors,-,-,-,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.3,-,凋亡阈值调节
4525,KP14,39195280,CDK4/6 inhibitors in combination with ET#are#standard-of-care for ER+/HER2- advanced/metastatic breast cancer,Clinical Implementation,"CDK4,CDK6,ESR1,ERBB2",-,Advanced/metastatic breast cancer,"CDK4/6 inhibitors, Endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
4277,KP14,39851968,CDK4/6 inhibitors in combination with AIs#are#first-line treatment for HR+/HER2- metastatic breast cancer,Therapeutic Development,"CDK4,CDK6,ERBB2",-,Metastatic breast cancer,"CDK4/6 inhibitors, Aromatase inhibitors",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,治疗线别
485,KP14,39020297,PR status#affects#prognosis of ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitors,Prognostic Associations,"PGR,ESR1,ERBB2",-,Breast cancer,"CDK4/6 inhibitors, Endocrine therapy",-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
191,KP14,39020297,Patients with advanced ER-high HER2-negative breast cancer#received#CDK4/6 inhibitors combined with endocrine therapy,Clinical Implementation,"CDK4,CDK6,ESR1,ERBB2",-,Advanced breast cancer,"CDK4/6 inhibitors, Endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
76,KP14,39604725,Early use of CDK4/6 inhibitors#improves#outcomes in advanced breast cancer,Therapeutic Response,"CDK4,CDK6",-,Advanced breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,8,8.5,8.5.1,8.5.1.3,-,临床评估
6766,KP14,39604725,"CDK4/6 inhibitors in combination with ET#improve#outcomes in HR-positive, HER2-negative advanced breast cancer",Therapeutic Response,"CDK4,CDK6,ERBB2",-,Advanced breast cancer,"CDK4/6 inhibitors, Endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
2602,KP14,39604725,Patients#received#aromatase inhibitors for first-line treatment and fulvestrant for second-line treatment,Clinical Implementation,-,-,Breast cancer,"Aromatase inhibitors, Fulvestrant",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
7358,KP14,38922642,Expression of six genes#provides#patient-specific response score,Biomarker Analysis,"CCND1,CCNE1,ESR1,RB1,MYC,CDKN1A",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,-,细胞周期标志物
7609,KP14,38922642,Response#measured by#Ki67 levels and PAM50 risk of relapse,Treatment Monitoring,MKI67,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,8.5.1.2.2,肿瘤标志物
7580,KP14,38922642,Mathematical modeling#predicts#outcome following CDK4/6i plus endocrine therapy,Personalized Medicine,"CDK4,CDK6",-,Luminal B breast cancer,"CDK4/6 inhibitors, Endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
3389,KP14,39779447,Efficacy of CDK4/6 inhibitors in combination with ET#evaluated in#HR-positive/HER2-negative advanced breast cancer,Therapeutic Response,"CDK4,CDK6,ERBB2",-,Advanced breast cancer,"CDK4/6 inhibitors, Endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
1778,KP14,32407488,CDK4/6 inhibitors plus ET#prolong#progression-free survival as first- or second-line therapy,Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,"CDK4/6 inhibitors, Endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
48,KP14,30899002,Combined treatment with CB-839 plus metformin/phenformin#increases#sensitivity of ESCC cells,Combination Therapies,"CDK4,CDK6",-,Esophageal squamous cell carcinoma,"CB-839, Metformin, Phenformin",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6601,KP14,30899002,Combined treatment#shows#efficacy in ESCC cells with acquired resistance to CDK4/6 inhibitors,Resistance Management,"CDK4,CDK6",-,Esophageal squamous cell carcinoma,"CB-839, Metformin, Phenformin",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
1505,KP14,30899002,Fbxo4-cyclin D1 axis#is dysregulated in#ESCC and cancers resistant to CDK4/6 inhibitors,Cancer Association,"FBXO4,CDK4,CDK6",ESCC,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
2680,KP14,36539670,CDK4/6 inhibitors#are used for#HR+/HER2- MBC treatment,Therapeutic Development,"CDK4,CDK6",-,HR+/HER2- MBC,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
7230,KP14,37237509,CDK4 and CDK6#are emerging therapeutic targets for#metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,-,PI3K/AKT/mTOR,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
2828,KP14,33812473,"ER, PR, HER2, and Ki-67#are immunohistochemical markers for#breast cancer",Biomarker Analysis,"ERBB2,MKI67,BRCA1,BRCA2,PIK3CA",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
6019,KP14,32619077,Ribociclib#a CDK4/6 inhibitor#is used in combination with endocrine therapy for advanced breast cancer,Drug Development,"CDK4,CDK6",-,Advanced breast cancer,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6784,KP14,32619077,MONALEESASIA study#evaluates#Ribociclib plus endocrine therapy efficacy in HR+/HER2- advanced breast cancer,Clinical Trial Data,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,Ribociclib,-,-,Asian patients,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
1906,KP14,32619077,Ribociclib combined with endocrine therapy#inhibits#target genes by suppressing pharmacodynamic biomarker gene expression,Mechanism of Action,"CDK4,CDK6",-,-,Ribociclib,-,-,-,Downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.3,-,E2F转录因子活性下调
1556,KP14,39303197,Optimal treatment sequence after progression on CDK4/6 inhibitors#is unclear for#HR+/HER2- advanced breast cancer,Therapeutic Development,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
7625,KP14,33415002,TNBC#is characterized by#angiogenic and fibrotic microenvironment,Tumor Microenvironment,-,-,TNBC,-,-,-,-,-,-,-,-,Fact,6,6.5,6.5.1,6.5.1.1,-,基质蛋白合成
3340,KP14,33415002,CDK6#mediates#recruitment of c-Jun and Sp1 to the MMP2 promoter,Regulation,CDK6,-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
1875,KP14,33415002,CDK6 inhibitor combined with sorafenib#leads to#a synthetic therapeutic effect for TNBC patients,Combination Optimization,CDK6,-,TNBC,Sorafenib,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6142,KP14,31649043,Palbociclib#is approved for#HR+/HER2- advanced breast cancer in men and women,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3245,KP14,31649043,Palbociclib#was first approved for#HR+/HER2- advanced breast cancer with letrozole or fulvestrant,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,"Palbociclib,Letrozole,Fulvestrant",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
7583,KP14,8934552,p15INK4b and p16INK4a#are deleted or mutated in#human tumor-derived cell lines and primary tumors,Cancer Association,"CDKN2B,CDKN2A",-,Human tumors,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
4212,KP14,31351869,HNSCCs#are driven by#p16(INK4A) inactivation and cyclin D1 overexpression,Cancer Pathways,"CDKN2A,CCND1",-,HNSCC,-,-,-,-,Upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
265,KP14,31351869,Palbociclib#a selective CDK4/6 inhibitor#is given with cetuximab for HNSCC,Combination Therapies,"CDK4,CDK6",-,HNSCC,"Palbociclib,Cetuximab",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
3304,KP14,31351869,Palbociclib and cetuximab#achieve#objective response in recurrent or metastatic HNSCC,Therapeutic Response,"CDK4,CDK6",-,Recurrent/metastatic HNSCC,"Palbociclib,Cetuximab",-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
6287,KP14,31351869,Eligibility criteria#required#measurable disease according to RECIST 1.1,Clinical Implementation,-,-,Disease progression,-,-,-,"ECOG performance status 0-2, age ≥18 years",-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,8.5.1.1.4,RECIST标准
4176,KP14,29487225,ctDNA analysis#can identify#somatic alterations in HCC,Biomarker Analysis,-,Blood-derived circulating tumor cells,HCC,-,-,-,-,-,-,-,-,Fact,7,7.6,7.6.1,7.6.1.1,-,突变检测
4661,KP14,29487225,"Mutations#were identified in#TP53 (57%), CTNNB1 (29%), PTEN (7%), CDKN2A (7%), ARID1A (7%), MET (7%)",Genomic Alterations,"TP53,CTNNB1,PTEN,CDKN2A,ARID1A,MET",-,HCC,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
901,KP14,29487225,"Amplifications#were found in#CDK6 (14%), EGFR (14%), MYC (14%), BRAF (7%), RAF1 (7%), FGFR1 (7%), CCNE1 (7%), PIK3CA (7%), ERBB2/HER2 (7%)",Genomic Alterations,"CDK6,EGFR,MYC,BRAF,RAF1,FGFR1,CCNE1,PIK3CA,ERBB2",-,HCC,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1936,KP14,29487225,A patient#received#palbociclib (CDK4/6 inhibitor) and celecoxib (COX-2/Wnt inhibitor),Therapeutic Development,"CDK4,CDKN2A,CTNNB1",-,HCC,"palbociclib,celecoxib",COX-2/Wnt,-,-,low AFP at baseline,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
4970,KP14,28586006,Butein#inhibited#tumor growth in HTLV-1-infected T-cell lines and SCID mice,Therapeutic Response,"NF-κB,AP-1,AKT",-,ATLL,butein,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.3,-,线粒体通路调控
890,KP14,28586006,Caspase inhibitor#partially blocked#butein-induced inhibition of cell viability,Mechanism of Action,Caspase,-,ATLL,butein,-,-,-,-,-,-,-,Fact,3,3.4,3.4.2,3.4.2.1,-,内源性途径激活
4595,KP14,28586006,Butein#reduced#serum levels of soluble interleukin-2 receptor α chain and soluble CD30,Biomarker Analysis,"IL2RA,CD30",-,ATLL,butein,-,-,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.2,-,细胞死亡标志物
836,KP14,28586006,"Butein#suppressed#NF-κB, AP-1, and Akt signaling in HTLV-1-infected T cells",Mechanism of Action,"NF-κB,AP-1,AKT",T cells,ATLL,butein,"NF-κB, AP-1, Akt",-,-,downregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
2639,KP14,27864121,"Cyclins E and D1#form a complex with#CDK2, CDK4, or CDK6 to regulate G1-S transition",Cell Cycle Control,"CDK2,CDK4,CDK6,CCNE1,CCND1",-,-,-,G1-S transition,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
345,KP14,38526689,Ribociclib and palbociclib#were used in#HR-positive and HER2-negative metastatic breast cancer patients,Drug Development,"CDK4, CDK6",-,Breast cancer,"Ribociclib, Palbociclib",-,-,HR-positive and HER2-negative patients,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1842,KP14,30405888,"Combined MEK/CDK4,6 inhibition#could offer#therapeutic modality in BRAF and NRAS mutant melanoma",Combination Optimization,"CDK4, CDK6, NRAS, BRAF",-,Melanoma,-,-,-,BRAF and NRAS mutant patients,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
4852,KP14,37314645,CDK4/6 inhibitors#can be harnessed in#novel combinations at progression,Therapeutic Development,"CDK4, CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,-,-,靶向药物联合
4790,KP14,31396487,Resistance to CDK4/6 inhibitors#is considered#near-inevitable in most patients,Therapeutic Resistance,"CDK4, CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,-,-,信号通路激活
4070,KP14,31396487,Biomarkers#are needed to#identify resistance to CDK4/6 inhibitors,Biomarker Analysis,"CDK4, CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Inference,7,7.5,7.5.1,-,-,耐药基因标志物
4443,KP14,39199665,Chemotherapy following CDK4/6 inhibitors#was studied in#a real-world cohort of breast cancer patients,Clinical Implementation,"CDK4, CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,-,-,内分泌治疗联合
2359,KP14,39199665,Cyclin-dependent kinase 4/6 inhibitors#are used with#endocrine therapy for advanced breast cancer,Therapeutic Development,"CDK4, CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,-,-,内分泌治疗联合
5327,KP14,35633421,CDK4/6 inhibitors#are approved for#HR-positive/HER2-negative metastatic breast cancer,Clinical Implementation,"CDK4, CDK6",-,Metastatic breast cancer,"Palbociclib, Ribociclib, Abemaciclib",-,Neutropenia,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1698,KP14,39677112,study#aims to determine#efficacy of maintaining CDK4/6 inhibition and switching ET versus ET alone,Therapeutic Development,"CDK4, CDK6",-,"Hormone-receptor-positive, HER2-negative breast cancer",CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1160,KP14,38961854,CDK4/6 inhibitors#are the cornerstone of#systemic therapy for HR+/HER2- metastatic breast cancer,Clinical Implementation,"CDK4, CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
7130,KP14,37381597,CDK4/6 inhibitor and locoregional radiotherapy#were used for#de novo metastatic breast cancer,Combination Optimization,"CDK4, CDK6",-,De novo metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,-,-,靶向药物联合
7803,KP14,37381597,patients#were treated with#CDK4/6 inhibitors and locoregional radiation therapy,Combination Optimization,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,-,-,靶向药物联合
6024,KP14,37381597,data#were analyzed from#patients treated with CDK4/6 inhibitors and locoregional RT,Clinical Trial Data,"CDK4, CDK6",-,De novo metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,-,-,治疗监测
2479,KP14,28819400,disease progression#occurred following#CDK4/6 inhibitor discontinuation,Therapeutic Resistance,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,-,-,信号通路激活
1207,KP14,28819400,CDK4/6 inhibitors#arrest#unregulated cancer cell proliferation,Mechanism of Action,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,细胞周期阻滞
5824,KP14,28819400,patient#developed#rapid disease progression after CDK4/6i discontinuation,Therapeutic Resistance,"CDK4, CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,Rapid disease progression,-,-,-,-,-,Fact,2,2.1,2.1.2,-,-,信号通路激活
745,KP14,28819400,patients#were treated on#randomized trial of endocrine therapy +/- CDK4/6i,Clinical Trial Data,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,-,-,治疗监测
2460,KP14,39329126,combination of CDK4/6 inhibitors and endocrine therapy#is standard treatment for#HR+/HER2- advanced breast cancer,Clinical Implementation,"CDK4,CDK6",-,Advanced breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
0,KP14,39386840,CDK4/6 inhibitors and everolimus#are effective for#HR+/HER2- metastatic breast cancer,Combination Optimization,"CDK4,CDK6",-,Metastatic breast cancer,"CDK4/6 inhibitors,Everolimus",-,-,-,-,-,-,-,Fact,8,8.2,8.2.2,8.2.2.2,-,mTOR抑制剂联用
210,KP14,35552450,endocrine therapy with CDK4/6 inhibitors#has become#standard systemic therapy,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
3345,KP14,31695840,CDK4/6 inhibitors#demonstrated#progression-free survival and overall survival benefit,Clinical Trial Data,"CDK4,CDK6",-,Advanced HR+/HER2- breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
549,KP14,36528759,study#analyzed#non-hematologic toxicity with combined RT and CDK4/6 inhibitors,Toxicity Analysis,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,2.6.1.2,-,代谢酶变化
6874,KP14,36528759,data#are lacking on#RT and CDK4/6 inhibitor risk factors and toxicity,Toxicity Analysis,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,2.6.1.2,-,代谢酶变化
3476,KP14,37366898,CDK4/6 inhibitors#significantly improve#progression-free survival and overall survival,Clinical Trial Data,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
2998,KP14,37366898,CDK4/6 inhibitor and RT target#were assessed for#toxicities,Toxicity Analysis,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,2.6.1.2,-,代谢酶变化
4841,KP14,39267829,"Combination of CDK4/6 inhibitors and endocrine therapy#is#standard first-line treatment for HR+, HER2- metastatic breast cancer",Clinical Implementation,"CDK4,CDK6",-,"Metastatic hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer","CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,一线治疗
2512,KP14,38927874,CDK4/6 inhibitors#have replaced#endocrine therapy alone as standard of care in HR+/HER2- metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,Hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
1234,KP14,34350900,"Elective discontinuation of CDK4/6 inhibitors#occurred in#HR-positive, HER2-negative metastatic breast cancer patients",Clinical Implementation,"CDK4,CDK6",-,"HR-positive, HER2-negative metastatic breast cancer",CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.3,-,复发风险
4002,KP14,34350900,"CDK4/6 inhibitors with endocrine therapy#are#standard of care for advanced HR-positive, HER2-negative breast cancer",Clinical Implementation,"CDK4,CDK6",-,"Advanced HR-positive, HER2-negative breast cancer","CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
1205,KP14,30574210,CDK4/6 inhibitors#are part of#evolving therapeutic landscape for HER2-negative metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,HER2-negative metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3086,KP14,31798393,"Selective CDK4/6 inhibitors#target#a variety of tumors, mainly HR-positive, HER2-negative breast cancer",Cancer Association,"CDK4,CDK6",-,"HR-positive, HER2-negative breast cancer",CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.1,-,增殖信号整合
4957,KP14,37994878,CDK4/6 inhibitors#have changed#treatment paradigm for metastatic and high-risk early-stage HR-positive breast cancer,Therapeutic Development,"CDK4,CDK6",-,Metastatic and early-stage high-risk HR-positive breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6444,KP14,37994878,"CDK4/6 inhibitors#are associated with#ILD incidence, mechanism, and treatment",Therapeutic Resistance,"CDK4,CDK6",-,Interstitial lung disease (ILD),CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.5,2.5.2,2.5.2.4,-,生物标志物指导
2974,KP14,37994878,"CDK4/6 inhibitors with endocrine therapy#are#standard treatment for HR-positive, HER2-negative metastatic and early-stage breast cancer",Clinical Implementation,"CDK4,CDK6",-,"HR-positive, HER2-negative metastatic and early-stage breast cancer","CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
53,KP14,37994878,"Individualized risk#should be considered for#patients with lung disease, thrombosis risk, or drug-drug interactions",Patient Stratification,-,-,"Lung disease, thrombosis risk",-,-,-,Patients with underlying conditions,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.3,-,合并症评估
7111,KP14,32642630,RAS-mediated activation of alternative pathways#renders#CDK4/6 inhibitor monotherapy ineffective,Mechanisms of Resistance,"CDK4,CDK6",RAS,-,CDK4/6 inhibitors,PI3K-mTOR,-,-,-,-,-,-,Fact,2,2.4,2.4.2,2.4.2.1,-,旁路激活
5557,KP14,32642630,CDK4/6 inhibitors#pharmacologically target#CDK4/6 in mPC,Mechanism of Action,"CDK4,CDK6",-,Metastatic pancreatic cancer (mPC),CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6163,KP14,36547170,CDK4/6 inhibitors#have limited data on#use in life-threatening conditions or visceral crisis,Clinical Implementation,"CDK4,CDK6",-,"Life-threatening conditions, visceral crisis",CDK4/6 inhibitors,-,-,-,Excluded population,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
5684,KP14,36547170,Data#is lacking for#direct comparison between chemotherapy and CDK4/6 inhibitors,Clinical Implementation,"CDK4,CDK6",-,-,"CDK4/6 inhibitors, chemotherapy",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.4,剂量调整策略
6759,KP14,36547170,Patient#achieved#rapid partial response with Abemaciclib plus letrozole,Therapeutic Response,"CDK4,CDK6",-,-,"Abemaciclib, letrozole",-,Rapid clinical stabilization,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
924,KP14,33319074,"CDK4/6 inhibitors#are prescribed with#hormone therapy for HR-positive, HER2-negative metastatic or locally advanced breast cancer",Clinical Implementation,"CDK4,CDK6",-,"HR-positive, HER2-negative metastatic or locally advanced breast cancer","CDK4/6 inhibitors, hormone therapy",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,8.2.1.2.2,他莫昔芬
3353,KP14,38206533,"CDK4/6 inhibitors with aromatase inhibitor or fulvestrant#are used in#first-line treatment of HR+, HER2- metastatic breast cancer",Clinical Implementation,"CDK4,CDK6",-,"HR+, HER2- metastatic breast cancer","CDK4/6 inhibitors, aromatase inhibitor, fulvestrant",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
7471,KP14,34422318,Radiological and pathological assessments#evaluate#response to neoadjuvant CDK4/6 inhibitor and endocrine treatments,Clinical Implementation,"CDK4,CDK6",-,-,"CDK4/6 inhibitors, endocrine treatments",-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,8.5.1.1.1,CT扫描
4640,KP14,36091147,CDK4/6 inhibitors#are compared with#PI3K/AKT/mTOR inhibitors for HR-positive/HER2-negative metastatic breast cancer,Treatment Monitoring,"CDK4,CDK6,PIK3CA,AKT1,MTOR",-,Metastatic breast cancer,-,PI3K/AKT/mTOR,-,"HR-positive, HER2-negative",-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
4774,KP14,38791919,CDK4/6 inhibitors#have emerged as#promising treatments for HR-positive/HER2-negative advanced and early breast cancer,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,-,-,-,"HR-positive, HER2-negative",-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5877,KP14,32882980,CDK4/6 inhibitors#transformed#treatment paradigms in advanced HR-positive breast cancer,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,-,-,-,HR-positive,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
552,KP14,32882980,CDK4/6 inhibitors#are used in#clinical practice for advanced HR-positive metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,Metastatic breast cancer,-,-,-,HR-positive,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5614,KP14,35248122,CDK4/6 inhibitors#are#standard of care for advanced hormone receptor-positive breast cancer,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,-,-,-,HR-positive,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1418,KP14,35248122,CDK4/6 inhibitors#suppress#phosphorylation of the retinoblastoma tumor suppressor protein,Mechanism of Action,"CDK4,CDK6,RB1",-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
1345,KP14,34556423,Studies#are needed to evaluate#cognitive effects of combined ET-CDK4/6 inhibitors,Clinical Trial Data,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
6675,KP14,34556423,"Studies#should include#cognitive assessments and account for ET, CDK4/6 inhibition, menopausal status, and symptoms like fatigue and distress",Clinical Trial Data,"CDK4,CDK6",-,-,-,-,-,Menopausal status,"Fatigue, distress",-,-,-,Inference,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
129,KP14,39011505,CDK4/6 inhibitors#are#first-line treatments for HR-positive/HER2-negative breast cancer,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,-,-,-,"HR-positive, HER2-negative",-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
7931,KP14,34985783,CDK4/6 inhibition#reveals#a p53-dependent senescent state with restricted toxicity,Mechanism of Action,"CDK4,CDK6,TP53",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
7834,KP14,34985783,CDK4/6 inhibitors#restrain#tumor growth by activating a senescence-like program,Mechanism of Action,"CDK4,CDK6",-,Tumor,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
6917,KP14,34985783,CDK4/6i-induced senescent program#activates#a partial SASP enriched in p53 targets but lacking NF-κB-driven components,Mechanism of Action,"CDK4,CDK6,TP53,NFKB1",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
3460,KP14,39373732,Low HER2 expression#impacts#response to CDK4/6 inhibitors in HR-positive/HER2-negative advanced breast cancer,Therapeutic Response,"CDK4,CDK6,ERBB2",-,Breast cancer,-,-,-,"HR-positive, HER2-negative",-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
941,KP14,39373732,CDK4/6 inhibitors#represent#first-line therapy for HR-positive/HER2-negative advanced breast cancer,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,-,-,-,"HR-positive, HER2-negative",-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
1105,KP14,39373732,Trastuzumab deruxtecan (T-DXd)#demonstrated#efficacy in patients with low HER2 expression in the DESTINY-Breast04 trial,Clinical Trial Data,ERBB2,-,Breast cancer,Trastuzumab deruxtecan,-,-,Low HER2 expression,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,8.1.1.3.1,生物标志物状态
3865,KP14,35137602,"CDK4/6 inhibitors#improve#outcome of patients with HR-positive, HER2-negative MBC",Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,-,Cell cycle machinery,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3227,KP14,35477069,CDK4/6 inhibitors#are employed in#treatment of HR(+)/HER2(-) metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5278,KP14,37865915,Upregulation or activating mutations in mitogenic or hormone signaling#stabilize#c-Myc levels,Mechanism of Action,MYC,-,-,-,-,-,-,upregulated,-,-,-,Inference,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
1397,KP14,37536378,CDK4/6 inhibitors#are combined with#radiotherapy for HR-positive/HER2-negative breast cancer,Combination Therapies,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3630,KP14,37536378,CDK4/6 inhibitors#improve#overall survival in HR-positive/HER2-negative breast cancer,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6165,KP14,26649278,Patient-derived glioblastoma cell lines#showed#sensitivity to PD0332991,Preclinical Models,"CDK4,CDK6",Glioblastoma cell lines,Glioblastoma,PD0332991,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
489,KP14,26649278,CDK4/6 inhibitors#may be#beneficial in glioblastoma treatment,Therapeutic Development,"CDK4,CDK6",-,Glioblastoma,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7150,KP14,34072070,Genomic alterations on circulating tumor DNA#are tested as#markers of CDK4/6i treatment response,Biomarker Analysis,"CDK4,CDK6",-,-,-,-,-,-,-,Genomic alterations,-,-,Fact,7,7.6,7.6.1,7.6.1.1,-,突变检测
4110,KP14,38894920,Breast cancer#exhibits#amplification and overexpression of CDK4/6,Cancer Association,"CDK4,CDK6",-,Breast cancer,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7200,KP14,38894920,Ribociclib#acts as#a selective CDK4/6 inhibitor for ER+/HER2- breast cancer,Drug Development,"CDK4,CDK6",-,Breast cancer,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
3637,KP14,36985460,Activation of alternative signaling pathways#evades#antiproliferative effects of aromatase inhibitors,Mechanisms of Resistance,-,-,-,Aromatase inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
206,KP14,36985460,Abemaciclib and exemestane#are selected as#reference drugs for virtual screening,Drug Development,"CDK4,CDK6",-,-,"Abemaciclib,Exemestane",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
7340,KP14,36985460,Computational approaches#provide#therapeutic potential for CDK4/6-aromatase dual inhibitors,Drug Development,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7947,KP14,38240835,CDK4/6 inhibitors#change#challenge of ET resistance in HR+/HER2- breast cancer,Mechanisms of Resistance,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
865,KP14,37701962,CDK4/6 inhibitors#yield#conflicting results in adjuvant treatment of HR+/HER2- breast cancer,Clinical Trial Data,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,晚期实体瘤
7807,KP14,15867383,Cdk4(R/R) knock-in mice#develop#pituitary tumors in p27Kip1-/- or p27Kip1+/- background,Preclinical Models,CDK4,-,Pituitary tumors,-,-,-,p27Kip1-/- or p27Kip1+/-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.2,-,细胞衰老诱导
6197,KP14,39697620,CDK4/6 inhibitors#emerged as#standard first-line treatment for HR+/HER2- metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3525,KP14,39478692,Combined chemotherapy#is preferred for#HR+/HER2- metastatic breast cancer with visceral crisis,Clinical Implementation,-,-,Metastatic breast cancer,Combined chemotherapy,-,Visceral crisis,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
2400,KP14,39478692,CDK4/6 inhibitors#introduce#a potential alternative to combined chemotherapy,Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2587,KP14,36765923,Pancreaticobiliary cancers#are associated with#poor prognosis and resistance to therapies,Cancer Association,"CDK4,CDK6",-,Pancreaticobiliary cancers,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
7214,KP14,36765923,CDK4/6 inhibitors#are approved for#ER+/HER2- breast cancer treatment,Clinical Implementation,"CDK4,CDK6",-,ER+/HER2- breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
2932,KP14,34885105,CDK4/6 inhibitors#improve#progression-free survival and overall survival in HR+/HER2- MBC,Therapeutic Response,"CDK4,CDK6",-,HR+/HER2- metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
965,KP14,28580882,Abemaciclib#is compared with#fulvestrant alone in advanced breast cancer treatment,Clinical Trial Data,"CDK4,CDK6",-,Advanced breast cancer,"Abemaciclib,Fulvestrant",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,8.2.1.2.1,氟维司群
6086,KP14,34098827,CDK4/6 inhibitors#increase#healthcare resource utilization and costs in HR+/HER2- advanced breast cancer,Economic & Access,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.3,8.4.1.3.3,剂量调整
844,KP14,38326452,"Three CDK4/6 inhibitors#are evaluated for#overall survival, safety, and tolerability",Drug Development,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
7345,KP14,38326452,4415 patients#met#inclusion criteria for CDK4/6 inhibitor studies,Clinical Trial Data,"CDK4,CDK6",-,-,-,-,-,4415 patients,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,8.1.1.3.1,生物标志物状态
4872,KP14,37198053,CDK4/6 inhibitors#radically changed#first-line treatment for metastatic hormone-sensitive breast cancer,Therapeutic Development,"CDK4,CDK6",-,Metastatic hormone-sensitive breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
4734,KP14,35666660,Palbociclib#is used with#letrozole or fulvestrant in real-world HR+/HER2- breast cancer patients,Combination Optimization,"CDK4,CDK6",-,HR+/HER2- breast cancer,"Palbociclib,Letrozole,Fulvestrant",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,8.2.1.2.1,氟维司群
4510,KP14,39648753,CDK4/6 inhibitors#improve#efficacy of endocrine therapy in HR+/HER2- breast cancer,Therapeutic Development,"CDK4,CDK6",-,HR+/HER2- breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
2183,KP14,33527479,Venous thromboembolic events#occurred in#1%-5% of patients treated with CDK4/6 inhibitors,Safety Monitoring,"CDK4,CDK6",-,Venous thromboembolic events,-,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
7207,KP14,33527479,Thrombosis#is assessed within#30 days of CDK4/6 inhibitor discontinuation,Safety Monitoring,"CDK4,CDK6",-,Thrombosis,-,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
7033,KP14,28303264,Cell cycle targeting#represents#a core attack on cancer,Mechanism of Action,"CDK4,CDK6",-,Cancer,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
2307,KP14,28303264,CDK4/6 targeted agents#act through#mechanisms with few parallels in cancer treatment,Mechanism of Action,"CDK4,CDK6",-,Cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
918,KP14,28303264,CDK4/6 inhibitors#act downstream of#mitogenic signaling cascades,Signaling Networks,"CDK4,CDK6",-,-,CDK4/6 inhibitors,Mitogenic signaling,-,-,-,-,-,-,Fact,1,1.2,1.2.1,1.2.1.1,-,生长因子信号
3377,KP14,28303264,Mechanism of action and biomarkers#direct#precision use of CDK4/6 inhibitors,Biomarker Analysis,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,RB1突变
1145,KP14,34930649,CDK4/6 inhibitors#are integrated into#early breast cancer treatment,Clinical Implementation,"CDK4,CDK6",-,Early breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1223,KP14,34930649,CDK4/6 inhibitors#have an established role in#HR+/HER2- advanced breast cancer treatment,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
7597,KP14,34930649,CDK4/6 inhibitors#demonstrated#benefit in overall survival,Therapeutic Response,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2730,KP14,34930649,MonarchE study#improved#invasive disease-free survival with abemaciclib in early breast cancer,Clinical Trial Data,"CDK4,CDK6",-,Early breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
7579,KP14,34237967,CDK inhibitors#improve#survival outcomes in HR+ breast cancer,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,CDK inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1237,KP14,32560251,CDK4/6 inhibitors#target#pharmacokinetic drug resistance in AML cells,Therapeutic Resistance,"CDK4,CDK6",-,Acute Myeloid Leukemia,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
450,KP14,34006717,Abemaciclib and Fulvestrant#treat#HR+/HER2- advanced/recurrent breast cancer,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,"Abemaciclib,Fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
1911,KP14,34006717,Withdrawal of CDK4/6 inhibitors#restores#susceptibility to the inhibitory signal,Resistance Management,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
5218,KP14,36349599,CDK4/6 inhibitors#are safe with#concomitant radiation therapy in metastatic breast cancer,Safety Monitoring,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.3,-,剂量调整
4564,KP14,36349599,CDK4/6 inhibitors#are#standard of care for HR+/HER2- metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
6084,KP14,36349599,Concurrent RT#does not increase#severe toxicity in systemic treatment,Safety Monitoring,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.3,-,剂量调整
7618,KP14,37760527,CDK4/6 inhibitors#are#effective first-line endocrine treatment for HR+/HER2- metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
3157,KP14,37760527,Phase III trials#compare#first-line aromatase inhibitors with/without CDK4/6 inhibitors in HR+/HER2- MBC,Clinical Trial Data,"CDK4,CDK6",-,Breast cancer,"Aromatase inhibitors,CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.4,剂量调整策略
7384,KP14,37775349,Adjuvant endocrine therapy (AET)#is changing in#HR+ early breast cancer,Clinical Implementation,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
1023,KP14,37775349,Aromatase inhibitors (AIs)#are added to#Tamoxifen in HR+ EBC,Combination Optimization,-,-,Breast cancer,"Aromatase inhibitors,Tamoxifen",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,8.2.1.2.4,时序优化
4578,KP14,37775349,AIs#show#reduced TE rate compared to Tamoxifen,Safety Monitoring,-,-,Breast cancer,"Aromatase inhibitors,Tamoxifen",-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
5416,KP14,37775349,CDK4/6 inhibitors#increase#TE rate when added to AIs,Safety Monitoring,"CDK4,CDK6",-,Breast cancer,"CDK4/6 inhibitors,Aromatase inhibitors",-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
6731,KP14,36257536,CDK4/6 inhibitors combined with ET#are#backbone of treatment for HR+/HER2- advanced breast cancer,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,"CDK4/6 inhibitors,Endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5529,KP14,37578747,Abemaciclib#causes#severe hepatotoxicity,Safety Monitoring,"CDK4,CDK6",-,Breast cancer,Abemaciclib,-,Hepatotoxicity,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
7523,KP14,37578747,"A 73-year-old woman with bone metastatic breast cancer#was treated with#abemaciclib, fulvestrant, denosumab, and pCCCM",Patient Treatment,"CDK4,CDK6",-,Breast cancer,"Abemaciclib,Fulvestrant,Denosumab,pCCCM",-,-,73-year-old female,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,8.1.1.3.3,合并症评估
738,KP14,37578747,Fulvestrant and Denosumab#were suspended#as causes of severe hepatotoxicity,Safety Monitoring,-,-,Breast cancer,"Fulvestrant,Denosumab",-,Hepatotoxicity,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
4478,KP14,37578747,Rechallenge with Palbociclib#may allow for#continued treatment after severe liver injury with Abemaciclib,Resistance Management,"CDK4,CDK6",-,Breast cancer,"Palbociclib,Abemaciclib",-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
846,KP14,30288930,"CDK4/6 inhibitors in combination with endocrine therapy#improve#progression-free survival, overall response rate, and clinical benefit rate in women with HR+ HER2- metastatic breast cancer",Therapeutic Response,"CDK4,CDK6",-,HR+ HER2- metastatic breast cancer,Endocrine therapy,-,-,Women,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
5989,KP14,39021492,CDK4/6 inhibitors and aromatase inhibitors#are used as#first-line treatment in metastatic high-grade neuroendocrine carcinoma of the breast,Therapeutic Development,"CDK4,CDK6",-,Metastatic high-grade neuroendocrine carcinoma of the breast,Aromatase inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
4090,KP14,37833875,Progression after first-line CDK4/6 inhibitor treatment#is analyzed for#molecular mechanisms and clinical data,Clinical Trial Data,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
4759,KP14,37833875,There#is currently no#standard treatment recommended at the category 1 level in international guidelines for progression under CDK4/6 inhibitors,Clinical Implementation,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,治疗线别
1228,KP14,37833875,This article#reviews#cellular mechanisms underlying resistance to CDK4/6 inhibitors and treatment strategies,Mechanism of Action,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
6664,KP14,37038927,CDK4/6 inhibitors plus endocrine therapy#are approved as#upfront treatment in HR+/HER2- metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- metastatic breast cancer,Endocrine therapy,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
2130,KP14,37038927,CDK4/6 inhibitors#have a clinical role in#HER2+ and triple-negative breast cancer and therapeutic sequences in resistant tumors,Therapeutic Development,"CDK4,CDK6",-,"HER2+, triple-negative breast cancer",-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
1213,KP14,37038927,Further evidence regarding the best treatment strategy in HR+ HER2- metastatic breast cancer#will be necessary in#early stage efficacy of CDK4/6 inhibitors,Therapeutic Development,"CDK4,CDK6",-,HR+ HER2- metastatic breast cancer,-,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
4314,KP14,37038927,Predictive biomarkers of response or resistance#need to be#validated,Biomarker Analysis,-,-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
6263,KP14,33514405,There#is no#clinical trial data regarding the efficacy of everolimus exemestane following prior treatment with CDK4/6 inhibitors,Clinical Trial Data,"CDK4,CDK6",-,-,"Everolimus, exemestane",-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,-,生物标志物监测
6460,KP14,37267715,The optimal treatment following endocrine therapy plus CDK4/6 inhibitor#has not been#established,Therapeutic Development,"CDK4,CDK6",-,-,Endocrine therapy,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,治疗线别
2750,KP14,35859155,Additional alterations#can function as#prognostic or predictive markers,Biomarker Analysis,-,-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
2987,KP14,35859155,A group of neuroblastoma patients#showed#amplification of one or multiple 12q loci,Genomic & Genetic Analysis,-,Neuroblastoma,Neuroblastoma,-,12q loci,-,Neuroblastoma patients,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
7359,KP14,35859155,Pharmacological inhibition of CDK4/6 with ribociclib or abemaciclib#decreased#proliferation in neuroblastoma cell lines,Therapeutic Development,"CDK4,CDK6",-,Neuroblastoma,"Ribociclib, abemaciclib",-,-,-,Downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
466,KP14,35859155,Combined CDK4/MDM2 targeting#had#additive effects in p53(wild-type) cell lines,Combination Optimization,"CDK4,MDM2",p53(wild-type),-,-,-,-,-,-,-,-,-,Fact,2,2.4,2.4.1,2.4.1.2,-,失活性突变
5373,KP14,35859155,Most 12q-amplified primary tumors#were of#abdominal origin,Cancer Pathways,-,-,Primary tumors,-,12q loci,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.2,-,缺失
6350,KP14,35859155,"An atypical metastatic pattern#was observed with#low degree of bone marrow involvement, favoring lungs",Cancer Pathways,-,-,-,-,-,-,-,-,-,-,-,Fact,6,6.6,6.6.1,6.6.1.1,-,微环境因子
5158,KP14,29935901,The identification of novel therapeutic strategies for breast cancer#cannot be#ignored,Therapeutic Development,-,-,Breast cancer,-,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
4914,KP14,27493616,Two significant clinical trials#have been#fully published to date,Clinical Trial Data,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
7399,KP14,34271289,The benefit of adjuvant CDK4/6 inhibitors with endocrine therapy#is#uncertain in HR+/HER2- early breast cancer,Therapeutic Development,"CDK4,CDK6",-,HR+/HER2- early breast cancer,Endocrine therapy,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,治疗线别
3204,KP14,37293258,"CDK4/6 inhibitors#are combined with#nonsteroidal AIs in ER-positive, HER2-negative advanced breast cancer",Therapeutic Development,"CDK4,CDK6",-,Advanced breast cancer,"ribociclib,palbociclib,abemaciclib",-,-,"ER-positive, HER2-negative",-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
5426,KP14,39461947,Palbociclib#affects#bladder cancer cells over a 48-hour time course,Preclinical Models,"CDK4,CDK6",-,Bladder cancer,palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4995,KP14,37886029,Radiotherapy#is timed with#CDK4/6 inhibitor therapy in bone-only metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,Bone-only metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5602,KP14,37886029,Existing publications#focus on#safety and toxicity profiles of CDK4/6 inhibitors,Safety Monitoring,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.3,-,剂量调整
4736,KP14,36575782,"CDK4/6 inhibitors#cause#bone marrow suppression, gastrointestinal toxicities, liver dysfunction...",Safety Monitoring,"CDK4,CDK6",-,-,-,-,"Bone marrow suppression, gastrointestinal toxicities, liver dysfunction, skin or subcutaneous tissue adv...",-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,血液学毒性
6561,KP14,36575782,Expert consensus#guides#management of adverse events from CDK4/6 inhibitors in clinical practice,Clinical Implementation,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.3,-,剂量调整
1610,KP14,37942358,Premenopausal patients with HR+/HER2- early breast cancer#are treated with#tamoxifen +/- ovarian...,Therapeutic Development,-,-,Early breast cancer,"tamoxifen,AI,GnRH",-,-,Premenopausal,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
2595,KP14,37942358,CDK4/6 inhibitors#shift#endocrine treatment landscape in early-stage breast cancer with higher...,Clinical Implementation,"CDK4,CDK6",-,Early-stage breast cancer,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
80,KP14,37942358,Potential candidates#are classified into#risk cohorts using NATALEE and monarchE trial criteria,Patient Stratification,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.2,-,分子亚型
7079,KP14,36902831,CDK4/6 inhibitors#are combined with#endocrine therapy for HR-positive/HER2-negative advanced b...,Therapeutic Development,"CDK4,CDK6",-,Advanced breast cancer,-,-,-,"HR-positive, HER2-negative",-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
6571,KP14,34145976,CDK4/6 inhibitors#are approved for#hormone receptor-positive and HER2-negative metastatic breas...,Clinical Implementation,"CDK4,CDK6",-,Metastatic breast cancer,-,-,-,Postmenopausal,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
3984,KP14,35957944,"CDK4/6 inhibitors#become#standard of care for HR-positive, HER2-negative metastatic breast can...",Clinical Implementation,"CDK4,CDK6",-,Metastatic breast cancer,-,-,-,"HR-positive, HER2-negative",-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
6794,KP14,39229634,"CDK4/6 inhibitors#are used in#first-line therapy for HR-positive, HER2-negative locally advance...",Therapeutic Development,"CDK4,CDK6",-,Locally advanced or metastatic breast cancer,-,-,-,"HR-positive, HER2-negative",-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,晚期实体瘤
2073,KP14,38130467,Peripheral blood lymphocytes#predict#clinical outcomes in HR-positive HER2-negative advanced br...,Biomarker Analysis,"CDK4,CDK6",Peripheral blood lymphocytes,Advanced breast cancer,-,-,-,"HR-positive, HER2-negative",-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,-,细胞周期标志物
6349,KP14,38130467,Progression-free survival#is associated with#ETs plus CDK4/6 inhibitors in HR-positive/HER2-ne...,Therapeutic Response,"CDK4,CDK6",-,Advanced breast cancer,-,-,-,"HR-positive, HER2-negative",-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
4457,KP14,38130467,Clinical strategies#boost#antitumor immunity in HR-positive/HER2-negative advanced breast cance...,Therapeutic Development,"CDK4,CDK6",-,Advanced breast cancer,-,-,-,"HR-positive, HER2-negative",-,-,-,-,Inference,3,3.3,3.3.2,3.3.2.3,-,免疫逃逸抑制
6363,KP14,37995303,Palbociclib#is received by#HR-positive HER2-negative metastatic breast cancer patients in Taiwan,Clinical Implementation,"CDK4,CDK6",-,Metastatic breast cancer,palbociclib,-,-,"HR-positive, HER2-negative",-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
7011,KP14,37995303,CDK4/6 inhibitors#are associated with#neutropenia,Adverse Effect,"CDK4,CDK6",-,Neutropenia,-,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,血液学毒性
2793,KP14,37343321,CDK4/6 inhibitors#improve#treatment outcomes for HR+ metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,Metastatic hormone receptor-positive breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
6291,KP14,32669921,Trials#are evaluating#CDK4/6 inhibitors with adjuvant endocrine therapy,Clinical Trial Data,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
3852,KP14,39685899,CDK4/6 inhibitors#are the standard of care for#HR+/HER2- metastatic breast cancer,Clinical Implementation triples,"CDK4,CDK6",-,HR+/HER2- metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1635,KP14,29644000,Ribociclib#restricted#cellular proliferation in ovarian cancer cell lines,Mechanism of Action triples,"CDK4,CDK6",-,Ovarian cancer,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7612,KP14,29644000,Ribociclib and cisplatin therapy#was synergistic in#ovarian cancer,Combination Therapies triples,"CDK4,CDK6",-,Ovarian cancer,"Ribociclib, cisplatin",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3102,KP14,29644000,Ribociclib#demonstrated#activity in platinum-resistant and platinum-sensitive tumor models,Therapeutic Response triples,"CDK4,CDK6",-,"Platinum-resistant tumor, Platinum-sensitive tumor",Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2206,KP14,36097254,Abemaciclib#is FDA approved for#HR+/HER2- advanced or metastatic breast cancer,Regulatory Documentation triples,"CDK4,CDK6",-,HR+/HER2- advanced or metastatic breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
838,KP14,33776424,CDK4/6 inhibitors#are being evaluated in#HR+/HER2- early-stage breast cancer with endocrine therapy,Clinical Trial Data triples,"CDK4,CDK6",-,HR+/HER2- early-stage breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
1721,KP14,35100715,Ribociclib#is effective in#cyclin D-CDK4/6 pathway-aberrant tumors,Therapeutic Response triples,"CDK4,CDK6",-,Cyclin D-CDK4/6 pathway-aberrant tumors,Ribociclib,Cyclin D-CDK4/6,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
1948,KP14,32783667,CDK4/6 inhibitors#show#survival gains in metastatic breast cancer,Therapeutic Response triples,"CDK4,CDK6",-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5682,KP14,37958338,CDK4/6 inhibitors#impact#ER+/HER2- advanced breast cancer in elderly women,Clinical Implementation triples,"CDK4,CDK6",-,ER+/HER2- advanced breast cancer,-,-,-,Elderly women,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5162,KP14,37958338,Ribociclib and abemaciclib#improve#overall survival in clinical trials,Clinical Trial Data triples,"CDK4,CDK6",-,-,"Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
6635,KP14,37958338,De novo disease#is associated with#prolonged PFS and OS compared with recurrence disease,Clinical Correlation triples,-,-,"De novo disease, Recurrence disease",-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
4577,KP14,37958338,PR+/de novo disease#obtains#maximum survival benefit,Clinical Correlation triples,-,-,PR+/de novo disease,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
3728,KP14,37266562,CDK4/6 inhibition#protects#normal gut epithelia against gemcitabine and irinotecan metabolite,Therapeutic Response triples,"CDK4,CDK6",Gut epithelia,-,"Gemcitabine, irinotecan",-,-,-,-,-,-,-,Fact,3,3.4,3.4.1,3.4.1.4,-,表观遗传重编程
1047,KP14,37266562,Cancer chemotherapy#relies on#toxicity toward cancer cells vs. nonmalignant cells,Mechanism of Action triples,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6057,KP14,37266562,Murine intestinal organoid model#is used for#assessing protection of epithelia against chemotherapy,Preclinical Models triples,-,Intestinal organoid,-,-,-,-,-,-,-,-,-,Fact,6,6.3,6.3.1,6.3.1.2,-,信号通路激活
5754,KP14,37266562,Palbociclib#stalls#cell cycle progression in gut organoids,Mechanism of Action triples,"CDK4,CDK6",Gut organoids,-,Palbociclib,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
5739,KP14,37266562,Washout of Palbociclib#allows#subsequent outgrowth of gut organoids,Mechanism of Action triples,"CDK4,CDK6",Gut organoids,-,Palbociclib,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
3864,KP14,37266562,transient cell cycle arrest#conferred#protection toward gemcitabine,Therapeutic Response,"CDK4,CDK6",-,-,gemcitabine,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5701,KP14,37266562,pre-treatment with palbociclib#protected#organoids against SN-38,Therapeutic Response,"CDK4,CDK6",-,-,"palbociclib,SN-38",-,gastrointestinal toxicities,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
201,KP14,37266562,RB1-deficient tumors#fail to arrest#cell cycle in response to CDK4/6 inhibitors,Cancer Pathways,"RB1,CDK4,CDK6",-,RB1-deficient tumors,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
7449,KP14,32985794,CDK4/6 inhibitors#treat#HR+/HER2- metastatic breast cancer,Cancer Association,"CDK4,CDK6",-,HR+/HER2- metastatic breast cancer,"palbociclib,ribociclib,abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1399,KP14,37567880,"CDK4/6 inhibitors + endocrine therapy#are standard of care for#HR-positive, HER2-negative metastatic breast cancer",Standard of Care,"CDK4,CDK6",-,"HR-positive, HER2-negative metastatic breast cancer","CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4064,KP14,39749028,"CDK4/6 inhibitors#are combined with#endocrine therapy for HR-positive, HER2-negative metastatic breast cancer",Drug Combination,"CDK4,CDK6",-,"HR-positive, HER2-negative metastatic breast cancer","Abemaciclib, Ribociclib, Palbociclib, endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
7658,KP14,34911915,Abemaciclib#induces#G1 cell cycle arrest and tumor growth inhibition,Mechanism of Action,"CDK4,CDK6",-,Tumor,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
1891,KP14,38730711,Prognostic and predictive markers#are assessed with#Kaplan-Meier and multivariate regression analyses,Biomarker Analysis,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
4084,KP14,38730711,Progesterone receptor expression#predicts#progression-free survival,Prognostic Marker,PGR,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,7.2.1.2.4,ER/PR状态
7725,KP14,25177151,Cyclin-dependent kinases#complex with#cyclin partners to allow cell cycle progression,Mechanism of Action,"CDK4,CDK6",-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.2,-,-,周期蛋白复合物形成
1833,KP14,31285369,CDK4/6 and PI3K/mTOR inhibitors#may be explored for#treating recurrent glioblastoma,Combination Therapies,"CDK4,CDK6,PIK3CA,MTOR",-,Recurrent glioblastoma,"CDK4/6 inhibitors, PI3K/mTOR inhibitors",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
2369,KP14,39013131,Patients with soft tissue sarcoma with CDK4 amplification#were treated with#palbociclib,Clinical Trial Data,CDK4,-,Soft tissue sarcoma,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
3170,KP14,29719410,Gastrointestinal stromal tumors (GISTs)#exhibit#a high frequency of KIT or PDGFRA mutations,Cancer Association,"KIT,PDGFRA",-,Gastrointestinal stromal tumors,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
2833,KP14,29719410,TKIs#have been used in#the treatment of GISTs with KIT/PDGFRA mutations,Drug Development,"KIT,PDGFRA",-,Gastrointestinal stromal tumors,TKIs,-,-,-,-,-,-,-,Fact,2,2.5,2.5.2,2.5.2.1,-,新型抑制剂开发
2735,KP14,29719410,Other mutation profiles#affect#the sensitivity to TKIs in GIST treatment,Mechanisms of Resistance,"KIT,PDGFRA",-,Gastrointestinal stromal tumors,TKIs,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
6103,KP14,29719410,Mutations in a small fraction of Chinese GIST#need further investigation for#targeted therapeutics,Biomarker Analysis,"KIT,PDGFRA",-,Gastrointestinal stromal tumors,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
1869,KP14,35135362,Abemaciclib#is approved for#adjuvant treatment of HR+/HER2- early breast cancer at high risk of recurrence,Clinical Implementation,"CDK4,CDK6",-,Early breast cancer,Abemaciclib,-,-,High risk of recurrence,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,-,患者选择
7695,KP14,36450591,Cyclin-dependent kinase 4/6 inhibitors#show decreased sensitivity to#canine lymphoma cells with high p16 expression and low retinoblastoma protein phosphorylation,Mechanisms of Resistance,"CDK4,CDK6",-,Canine lymphoma,"Palbociclib,Abemaciclib",-,-,"High p16 expression, Low phosphorylation",-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
5710,KP14,38244190,Ribociclib#is#a selective CDK4/6 inhibitor,Drug Development,"CDK4,CDK6",-,-,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6511,KP14,35349366,EAC SCC models#are useful for#testing agents targeting cell cycle regulation,Preclinical Models,"CDK4,CDK6",-,Esophageal adenocarcinoma squamous cell carcinoma,-,Cell cycle regulation,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
477,KP14,37454444,CDK4/6 inhibitors with endocrine therapy#represent#the standard treatment for HR+/HER2- metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,"CDK4/6 inhibitors,Endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
2422,KP14,35941421,Novel variants#may affect#vaccination efficacy,Mechanisms of Resistance,-,-,-,-,-,-,-,-,-,-,-,Inference,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
1710,KP14,30151703,"Alterations in the CDK4/6-RB signaling pathway#are common in#many cancers, including glioblastoma",Signaling Networks,"CDK4,CDK6,RB1",-,Glioblastoma,-,CDK4/6-RB pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
643,KP14,36704980,CDK4/6 inhibitors combined with endocrine therapy#are evaluated for#HR+/HER2- breast cancer,Clinical Trial Data,"CDK4,CDK6",-,Breast cancer,"CDK4/6 inhibitors,Endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
1427,KP14,38322413,HR+/HER2- breast cancer#constitutes#a considerable proportion of cases,Cancer Association,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
2754,KP14,38322413,Tumor nuclei expressing estrogen receptors (ER+)#are positive for#GATA3 and CK7 markers,Expression Patterns,-,-,Breast cancer,-,-,-,-,-,"GATA3,CK7",-,-,Fact,-,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1
7981,KP14,31451564,Palbociclib treatment#inhibited#malignant progression of MCFDCIS tumors,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3986,KP14,39539943,Endocrine therapy plus CDK4/6 inhibitors#is the standard of care for#HR+/HER2- metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,Metastatic breast cancer,"CDK4/6 inhibitors,Endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
3206,KP14,29527939,The aim#is to determine the optimal CDK4/6 inhibitor for#metastatic luminal breast cancer,Therapeutic Development,"CDK4,CDK6",-,Metastatic luminal breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3529,KP14,29527939,Palbociclib-based regimen#is associated with#lower treatment discontinuation rates,Therapeutic Response,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
912,KP14,38395242,CDK4/6 inhibitors#have advanced#hormone-dependent breast cancer treatment paradigm,Cancer Association,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5431,KP14,24505496,Androgen receptor expression#has#prognostic impact in non-basal triple-negative breast cancers,Biomarker Analysis,-,-,Triple-negative breast cancer,-,Androgen receptor-related pathways,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,7.2.1.2.4,ER/PR状态
4380,KP14,36698435,Clinical research on targeted therapy#has brought#new strategies for biliary duct tumors treatment,Therapeutic Development,-,-,Biliary duct tumors,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
1401,KP14,29792845,"CDK4/6 inhibitors, like palbociclib, abemaciclib, and ribociclib#have resulted in#improvement in treatment outcomes",Therapeutic Response,"CDK4,CDK6",-,-,"Palbociclib,Abemaciclib,Ribociclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4828,KP14,38046373,DRESS#is#a severe side effect of drugs,Safety Monitoring,-,-,-,-,-,DRESS,-,-,-,-,-,Fact,-,8,8.4,8.4.1,8.4.1.2,8.4.1.2.4
6281,KP14,36200010,"Three CDK4/6 inhibitor drugs#are approved and available#including Palbociclib, Ribociclib, and Abemaciclib",Drug Development,"CDK4,CDK6",-,-,"Palbociclib,Ribociclib,Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4449,KP14,32424005,Dual signaling pathways#are targeted with#immune checkpoints for pancreatic cancer treatment,Cancer Pathways,-,-,Pancreatic cancer,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.3,6.1.3.1,6.1.3.1.1,PD-1/PD-L1表达
7569,KP14,32424005,Patient-derived cell lines and xenograft models#were used to define#response to CDK4/6 and MEK inhibition,Preclinical Models,"CDK4,CDK6,MEK",-,Tumor,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
343,KP14,33830080,Cotargeting p16-CDK4/6-RB and AREG/EGFR signaling#produces#enhanced antitumor responses,Combination Therapies,"CDK4,CDK6,RB1,EGFR",-,-,"Palbociclib,Erlotinib","p16-CDK4/6-RB,AREG/EGFR",-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4256,KP14,37306107,CDK4#is#a genomic vulnerability in EWS synergistic with IGF-1R inhibition,Cancer Pathways,CDK4,EWS,-,-,IGF-1R,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
6652,KP14,32843618,Nanocarriers targeting CDK4/6 and autophagy pathways#are used for#pancreatic cancer treatment,Drug Delivery Innovation,"CDK4,CDK6",-,Pancreatic cancer,-,Autophagy,-,-,-,-,-,-,Fact,3,3.6,3.6.1,3.6.1.1,-,纳米载体设计
6744,KP14,32788596,A retrospective safety analysis#evaluates#CDK4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients,Clinical Trial Data,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
1817,KP14,32788596,CDK4/6 inhibitors#gained#an essential role in the treatment of metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6482,KP14,32788596,Toxicities#were measured according to#CTCAE 4.0,Safety Monitoring,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.3,-,预防和处理
7903,KP14,32788596,"Patients#received#palbociclib, ribociclib, or abemaciclib",Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6847,KP14,35534752,CDK4/6 inhibitors plus fulvestrant#are evaluated for#cost and outcomes as second-line therapy for HR+/HER2- metastatic breast cancer,Economic & Access,"CDK4,CDK6",-,Metastatic breast cancer,"CDK4/6 inhibitors, Fulvestrant",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
4447,KP14,29522364,Clinical trials of CDK4/6 inhibitors#have been performed on#various carcinomas including breast cancer,Clinical Trial Data,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
2346,KP14,34178122,Endocrine therapy and CDK4/6 inhibitors#are#standard treatment options for HR+/HER2- metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
244,KP14,33353132,CDK4/6 inhibitors in combination with endocrine therapy#show#meaningful efficacy and tolerability in metastatic breast cancer,Combination Optimization,"CDK4,CDK6",-,Metastatic breast cancer,"CDK4/6 inhibitors, Endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
4283,KP14,39345487,Continuous application of CDK4/6 inhibitors#results in#resistance in ER+ breast cancer,Therapeutic Resistance,"CDK4,CDK6",-,ER+ breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
6790,KP14,21670085,BRAF and KIT mutations#provided#basis for molecular classification of cutaneous melanoma,Cancer Pathways,"BRAF,KIT",-,Cutaneous melanoma,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.1,-,基因表达谱
2343,KP14,21670085,BRAF-targeted therapy#moves toward#regulatory approval and incorporation as standard therapy for metastatic disease,Clinical Implementation,BRAF,-,Metastatic melanoma,-,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
774,KP14,21670085,Targeting mutated KIT#established#proof of concept in melanoma,Cancer Pathways,KIT,-,Melanoma,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.1,-,基因表达谱
5476,KP14,21670085,NRAS mutations#are present in#a subset of melanomas,Cancer Association,NRAS,-,Melanoma,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
2826,KP14,21670085,Patient subgroups with genetic aberrations in phosphoinositide 3-kinase and CDK4 pathways#have not yet been matched with#appropriate targeted therapies,Therapeutic Resistance,CDK4,-,Melanoma,-,"Phosphoinositide 3-kinase, CDK4",-,-,-,-,-,-,Inference,2,2.4,2.4.1,2.4.1.1,-,关键驱动基因变异
6380,KP14,21670085,Understanding of MITF role#provides#another axis to approach melanoma therapies,Mechanism of Action,MITF,-,Melanoma,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.1,-,细胞增殖调控
2123,KP14,21670085,Melanoma field#stands poised to lead#advancing combination therapy strategies,Combination Optimization,-,-,Melanoma,-,-,-,-,-,-,-,-,Inference,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
189,KP14,29804650,CDK4/6 inhibitors#are assessed for#efficacy and toxicity in advanced breast cancer with HR(+) and HER2(-) disease,Clinical Trial Data,"CDK4,CDK6",-,Advanced breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
2082,KP14,37329428,Addition of CDK4/6 inhibitors to standard endocrine therapy#is cost-effective for#first-line treatment of advanced HR+/HER2- breast cancer in Mexico,Economic & Access,"CDK4,CDK6",-,Advanced HR+/HER2- breast cancer,CDK4/6 inhibitors,-,-,Women,-,-,-,-,Inference,8,8.1,8.1.2,8.1.2.1,-,一线治疗
234,KP14,37329428,CDK4/6 inhibitor addition to endocrine therapy#is cost-effective for#postmenopausal and premenopausal women with advanced HR+/HER2- breast cancer,Economic & Access,"CDK4,CDK6",-,Advanced HR+/HER2- breast cancer,CDK4/6 inhibitors,-,-,"Postmenopausal, Premenopausal women",-,-,-,-,Inference,8,8.1,8.1.2,8.1.2.1,-,一线治疗
172,KP14,37329428,Partitioned survival model#was used to simulate#health outcomes in breast cancer patients,Preclinical Models,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,-,耐药基因标志物
7363,KP14,37329428,"Palbociclib, ribociclib, and abemaciclib#led to#life year increases compared to letrozole alone",Clinical Trial Data,-,-,Breast cancer,"Palbociclib, Ribociclib, Abemaciclib, Letrozole",-,-,Postmenopausal patients,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1552,KP14,37329428,Differences between therapies for postmenopausal patients#were not#statistically significant,Clinical Trial Data,-,-,Breast cancer,"Palbociclib, Ribociclib, Abemaciclib, Letrozole",-,-,Postmenopausal patients,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5125,KP14,38601755,Primary CDK4/6 inhibitor and endocrine therapy#affects#gut and intratumoral microbiota in locally advanced breast cancer,Mechanisms of Resistance,"CDK4,CDK6",-,Locally advanced breast cancer,"CDK4/6 inhibitors, Endocrine therapy",-,-,-,-,-,Gut microbiota,-,Fact,2,2.6,2.6.3,2.6.3.3,-,代谢适应
7983,KP14,38601755,Locally advanced breast cancer#poses#significant challenges for lower pathological complete responses with chemotherapy,Therapeutic Resistance,-,-,Locally advanced breast cancer,-,-,-,HR(+) HER2(-) tumors,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
5110,KP14,38601755,CDK4/6 inhibitors plus endocrine therapy#are increasingly used in#different breast cancer settings,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,"CDK4/6 inhibitors, Endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3524,KP14,31859178,Molecular profiling of CNS tumors#is used for#treatment and management of disease,Personalized Medicine,-,-,CNS tumors,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.1,-,基因表达谱
3490,KP14,31859178,Correlation of molecular signatures of glioblastoma#with clinical significance for#precision medicine is not well-known,Clinical Implementation,-,-,Glioblastoma,-,-,-,-,-,-,-,-,Inference,7,7.4,7.4.1,7.4.1.1,-,基因表达谱
4101,KP14,31859178,48 glioblastomas#were evaluated using#JAX ActionSeq NGS panel,Technical Methods,-,-,Glioblastoma,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.1,-,基因表达谱
7581,KP14,31859178,131 clinically significant variants#were identified across#30 of the 212 genes,Biomarker Analysis,-,-,Glioblastoma,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
6160,KP14,31859178,Molecular profiles of glioblastoma#are established based on#2017 joint consensus guidelines by AMP/ASCO/CAP,Clinical Implementation,GLI1,-,Glioblastoma,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.1,-,基因表达谱
5486,KP14,38562645,Luminal phenotype#is associated with#a worse prognosis,Cancer Association,-,-,Cancer,-,-,-,-,-,-,-,-,Inference,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
7963,KP14,38562645,Complete radiological response#was achieved in#metastatic disease,Therapeutic Response,-,-,Metastatic disease,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6508,KP14,38562645,Patient#was submitted to#radical breast surgery and bilateral oophorectomy,Clinical Implementation,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
7870,KP14,38327739,CDKN2A mutation and PD-L1 positivity#are associated with#partial response and progression-free survival of 9.5 months,Clinical Correlation triples,"CDKN2A,CD274",-,Cancer,"CDK4/6 inhibitors, immunotherapy",-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
1056,KP14,38327739,Thromboembolism rates#are higher in#real-world patients treated with CDK4/6 inhibitors,Safety Monitoring,"CDK4,CDK6",-,Thromboembolism,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,血液学毒性
1877,KP14,37319380,Targeting estrogen receptor#remains#the single most effective way of targeting cancer,Therapeutic Development,ESR1,-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
5069,KP14,37319380,New oral selective ER degraders#are becoming#a standard of care in cancers with ESR1 mutations,Therapeutic Development,ESR1,-,Cancer,Selective ER degraders,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
5938,KP14,37070653,Camizestrant#significantly improved#progression-free survival over fulvestrant in ER+/HER2- ABC,Therapeutic Response,"ESR1,ERBB2",-,Advanced breast cancer,"Camizestrant, Fulvestrant",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6067,KP14,34665067,CDK4/6 inhibitors#have become#part of the standard of care in HR+/HER2- metastatic breast cancer,Therapeutic Development,"CDK4,CDK6,ERBB2",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5210,KP14,29250202,Carboplatin addition#increases#pathologic complete remission rate in triple-negative breast cancer,Therapeutic Response,-,-,Triple-negative breast cancer,Carboplatin,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6842,KP14,29250202,Olaparib#is superior to#conventional chemotherapy in BRCA germ-line mutation metastatic breast cancer,Therapeutic Development,"BRCA1,BRCA2",-,Metastatic breast cancer,Olaparib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
987,KP14,34731655,FMD#lowers#glucose-dependent protein kinase A signaling and stemness markers in CSCs,Stem Cell Biology,-,CSCs,-,FMD,PKA,-,-,downregulated,Stemness markers,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
1506,KP14,34731655,Lower glycemia#is associated with#longer survival in metastatic TNBC patients,Patient Characteristics,-,-,Metastatic triple-negative breast cancer,-,-,Lower glycemia,-,-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.3,-,长期随访
6695,KP14,34731655,"FMD#activates#PI3K-AKT, mTOR, and CDK4/6 pathways in differentiated cancer cells",Signaling Networks,"CDK4,CDK6,MTOR,PIK3CA",-,Cancer,FMD,"PI3K-AKT, mTOR, CDK4/6",-,-,upregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
2994,KP14,34731655,FMD#provides#a method for targeting starvation escape pathways in cancer and CSCs,Signaling Networks,-,"Cancer, CSCs",-,FMD,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
5332,KP14,31176618,RB1 gene#was identified as#the first tumor suppressor in the 80s,Cancer Association,RB1,-,Cancer,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.2,-,RB1缺失
1123,KP14,31176618,RB1 loss of function#occurs in#most human cancers,Cancer Association,RB1,-,Cancer,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.2,-,RB1缺失
5235,KP14,31176618,RB1 status#is a crucial determinant of#cell response to antitumoral therapies,Therapeutic Response,RB1,-,Cancer,-,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.3,-,剂量调整
1051,KP14,31176618,RB1#impacts#outcome of traditional and modern anti-cancer strategies,Therapeutic Development,RB1,-,Cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
4829,KP14,31176618,RB1#has#predictive value in response to CDK4/6 inhibitors,Predictive Biomarkers,RB1,-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,RB1突变
162,KP14,31176618,RB1#impacts#response to antitumoral treatments,Therapeutic Response,RB1,-,-,-,-,-,-,-,-,-,-,Inference,8,8.4,8.4.1,8.4.1.3,-,剂量调整
4228,KP14,33677841,Breast cancer patients receiving CDK4/6 inhibitors#have#COVID-19 risk,Clinical Correlation,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,6,6.4,6.4.1,6.4.1.1,-,促炎因子
7435,KP14,37653397,Ribociclib#demonstrates#overall survival benefit in HR+/HER2- advanced breast cancer,Therapeutic Response,"CDK4,CDK6",-,Advanced breast cancer,"Ribociclib,Fulvestrant",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4163,KP14,37653397,CDK4/6 inhibitors with endocrine therapy#are#preferred option for HR+/HER2- advanced breast cancer,Therapeutic Development,"CDK4,CDK6",-,Advanced breast cancer,"CDK4/6 inhibitors,Endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
6667,KP14,37509319,CDK4/6 inhibitors#represent#advances in therapeutics for estrogen receptor+/HER2 breast cancer,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
2489,KP14,35462410,Pathogenic mutations in CDK4/6#were observed in#patients with therapeutically relevant genes,Mutation Frequencies,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
6891,KP14,35462410,Personalized treatment options#might be informed by#mutations in relevant genes,Personalized Medicine,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,8,8.3,8.3.1,8.3.1.2,-,不良反应管理
7489,KP14,29236940,Cyclin D1-CDK4/6-retinoblastoma pathway#is deregulated in#HR+ breast cancer,Signaling Networks,"CDK4,CDK6,RB1",-,Breast cancer,-,Cyclin D1-CDK4/6-retinoblastoma pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
3904,KP14,31174843,RB1#regulates#cell cycle progression as a downstream target of CDK4/6 inhibitors,Cell Cycle Control,"RB1,CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
3494,KP14,31174843,CDK4/6 inhibitor combinations#target#tumors that have lost RB1,Targeted Therapy,"RB1,CDK4,CDK6",-,Tumors,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
7124,KP14,36959160,Cyclin-dependent kinases#control#progression of the cell cycle,Cell Cycle Control,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
4645,KP14,36959160,First-generation pan-CDKIs#target#cancer in clinical trials,Drug Development,"CDK4,CDK6",-,Cancer,"Flavopiridol,Roscovitine",-,-,-,-,-,-,-,Fact,8,8.1,8.1.2,-,-,临床试验
7753,KP14,36959160,CDK inhibitors with PD1/PDL1 antibodies#could lead to#viable cancer treatment strategies,Combination Optimization,"CDK4,CDK6",-,Cancer,PD1/PDL1 antibodies,-,-,-,-,-,-,-,Inference,3,3.2,3.2.3,3.2.3.4,-,耐药预防
2713,KP14,33193348,Identifying these antigens#supports#development of multi-antigen-based immunotherapy,Therapeutic Development,-,-,Metastatic disease,-,-,-,-,-,-,-,-,Inference,3,3.3,3.3.1,-,-,免疫微环境重塑
400,KP14,33193348,Multi-antigen-based immunotherapy#targets#metastatic disease with minimal autoimmune toxicity against normal tissues,Therapeutic Development,-,-,Metastatic disease,-,-,-,-,-,-,-,-,Inference,3,3.3,3.3.2,-,-,免疫检查点调节
4001,KP14,35962417,The choroidal tumor#showed regression after#introduction of palbociclib,Therapeutic Response,"CDK4,CDK6",-,Choroidal tumor,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
7341,KP14,35269621,"CDK inhibitors Ribociclib, Palbociclib, and Abemaciclib#affect#breast cancer bone microenvironment",Therapeutic Development,"CDK4,CDK6",-,Breast cancer,"Ribociclib,Palbociclib,Abemaciclib",-,-,-,-,-,-,-,Fact,6,6.6,6.6.1,6.6.1.2,-,肿瘤干细胞微环境中的调控信号
2285,KP14,38497444,"MONALEESA-7 study#evaluates#effectiveness of CDK4/6 inhibitors in premenopausal patients with HR-positive, HER2-negative metastatic breast cancer",Clinical Trial Data,"CDK4,CDK6",Premenopausal patients,Metastatic breast cancer,Palbociclib,-,-,Premenopausal,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌的单药治疗策略
1146,KP14,30828336,TNF and CDK4/6 inhibitors#showed#therapeutic effects in FLSs stimulated with 2GF+TNF in RA,Therapeutic Development,"CDK4,CDK6",FLSs,Rheumatoid arthritis,"TNF inhibitors,CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4330,KP14,34157782,CDK4/6 inhibitors including palbociclib#treat#HR-positive/HER2-negative advanced breast cancer,Therapeutic Development,"CDK4,CDK6",-,Advanced breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5584,KP14,31875860,PARP inhibitors#are being investigated with#chemotherapy combinations in breast and ovarian cancer,Combination Optimization,-,-,"Breast cancer,Ovarian cancer",PARP inhibitors,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6701,KP14,31980996,Genetic profiling of advanced melanoma#identifies#candidate mutations for predicting sensitivity and resistance to targeted therapy,Biomarker Analysis,-,-,Melanoma,-,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.1,-,基因突变
1882,KP14,31980996,A majority of patients#experience#relapse within 1 year of treatment due to acquired resistance,Therapeutic Resistance,-,Patients,Melanoma,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
3485,KP14,31980996,Approximately 10-25% of patients#gain no benefit from#targeted therapy due to intrinsic resistance,Therapeutic Resistance,-,Patients,Melanoma,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
3964,KP14,37275963,Ribociclib#demonstrates#statistically significant overall survival benefit,Clinical Trial Data,"CDK4,CDK6",-,Advanced breast cancer,Ribociclib,-,-,"Premenopausal, postmenopausal",Upregulated,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
1323,KP14,37275963,36-month treatment duration of ribociclib#is intended to maximize#efficacy of CDK4/6 inhibition,Therapeutic Development,"CDK4,CDK6",-,-,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6497,KP14,30322893,CHEK2 and ATM mutations#predispose#patients to developing chordoma,Cancer Association,"CHEK2,ATM",-,Chordoma,-,-,-,Young age,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
4128,KP14,30322893,CHEK2 and ATM mutations#are associated with#sensitivity to PARP inhibitors,Mechanism of Action,"CHEK2,ATM",-,Chordoma,PARP inhibitors,Homologous recombination repair deficiency,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.2,-,末端切除
1140,KP14,30322893,Targeting the IGF1R/FGFR/EGFR and CDK4/6 pathways#provides#treatment strategies for chordoma patients,Pathway & Network Categories,"CDK4,CDK6,IGF1R,FGFR,EGFR",-,Chordoma,-,"CDK4/6,IGF1R/FGFR/EGFR",-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
514,KP14,29497091,CDK4/6 inhibition#improves#progression-free survival in advanced estrogen receptor-positive breast cancer,Therapeutic Response,"CDK4,CDK6",-,Advanced estrogen receptor-positive breast cancer,-,-,-,Women,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5397,KP14,29497091,Change in PIK3CA ctDNA level#predicts#progression-free survival on palbociclib and fulvestrant,Biomarker Analysis,PIK3CA,-,Advanced breast cancer,"Palbociclib, Fulvestrant",-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.4,-,PIK3CA突变
7650,KP14,29059492,Japanese patients with solid tumors#received#escalating doses of ribociclib,Clinical Trial Data,"CDK4,CDK6",-,Solid tumors,Ribociclib,-,-,Japanese patients,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
3315,KP14,36267663,ribociclib#is combined with#letrozole to investigate safety and efficacy,Drug Development,"CDK4,CDK6",-,-,"ribociclib, letrozole",-,-,Men and women,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,3.2.1.1.1,来曲唑
7204,KP14,35540707,Ribociclib plus endocrine therapy#demonstrated#a great OS benefit as first-line treatment,Therapeutic Response,"CDK4, CDK6",-,"Hormone receptor-positive, Her2-negative breast cancer","Ribociclib, endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
1673,KP14,33568653,Somatic structural variants (SSVs)#impact#gene expression in pediatric brain tumors,Regulation,-,-,Pediatric brain tumors,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.3,5.2.3.3,-,染色体桥
3516,KP14,33568653,SSV breakpoints#are associated with#altered expression of hundreds of genes,Regulation,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.3,5.2.3.3,-,染色体桥
2922,KP14,33568653,High SSV burden#associates with#TP53 mutations and H3F3C mutations,Cancer Association,"TP53, H3F3C",-,-,-,DNA damage response,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.1,-,DSB识别
6192,KP14,33568653,Pediatric brain tumors#would involve#a different set of genes with SSV-altered cis-regulation compared to adult cancers,Regulation,-,-,Pediatric brain tumors,-,-,-,-,-,-,-,-,Inference,5,5.2,5.2.3,5.2.3.3,-,染色体桥
1315,KP14,33568653,SSVs#play#a major role in shaping the transcriptome of pediatric brain tumors,Regulation,-,-,Pediatric brain tumors,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.3,5.2.3.3,-,染色体桥
1893,KP14,36901951,Combining MEK1 and CDK4/6 inhibitors#is challenging#in resistance to MEK inhibitor monotherapy,Drug Development,"CDK4, CDK6, MEK1",-,-,MEK inhibitor monotherapy,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.4,-,生物标志物指导
2652,KP14,29383146,20-30% of patients#demonstrate#intrinsic resistance to multi-targeted TKIs,Mechanisms of Resistance,-,-,-,Multi-targeted TKIs,-,Progressive disease,-,-,-,-,-,Fact,2,2.2,2.2.3,2.2.3.4,-,葡萄糖代谢改变
7468,KP14,29383146,Tumor next-generation sequencing#is associated with#resistant and non-resistant outcomes,Biomarker Analysis,-,Tumor,-,-,-,-,-,-,-,-,-,Fact,7,7.6,7.6.1,7.6.1.1,-,突变检测
2727,KP14,29383146,Results replication#has potential to inform#personalized prescribing,Personalized Medicine,-,Independent patient cohort,-,-,-,-,-,-,-,-,-,Inference,7,7.4,7.4.1,7.4.1.1,-,基因表达谱
1900,KP14,36859416,Machine learning multi-gene signatures#identify#complex biological features,AI Drug Discovery,-,-,Tumor,-,Proliferation,-,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,-,细胞周期标志物
3638,KP14,39152401,AI plus CDK4/6 inhibitors#is the standard first-line treatment for#HR+/HER2- advanced breast cancer,Clinical Implementation,"CDK4, CDK6",-,Advanced breast cancer,"Aromatase inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
4184,KP14,37914699,Resistance to endocrine therapy and CDK4/6 inhibitors#reduces#patient survival,Therapeutic Resistance,"CDK4, CDK6",-,ER+ breast cancer,"Endocrine therapy, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.4,-,生物标志物指导
7510,KP14,37914699,Elucidating mechanisms of sensitivity and resistance#is urgently needed for#SOC therapy,Mechanisms of Resistance,"CDK4, CDK6",-,ER+ breast cancer,SOC therapy,-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.4,-,生物标志物指导
3252,KP14,34953442,CDK4/6 inhibitors#enhance#adaptive immune response in HR+ breast cancer,Combination Optimization,"CDK4,CDK6",-,HR+ breast cancer,"CDK4/6 inhibitors, immunotherapies",-,-,-,-,-,-,-,Inference,3,3.3,3.3.1,3.3.1.1,-,免疫细胞浸润增加
7364,KP14,36493359,ESR1 point mutations#cause#acquired resistance to aromatase inhibition,Mechanisms of Resistance,ESR1,-,HR+ metastatic breast cancer,Aromatase inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
6096,KP14,36493359,CDK4/6 inhibition#may be effective against#ESR1-FUS with functional ligand-binding domain swaps,Therapeutic Development,"CDK4,CDK6,ESR1",-,HR+ metastatic breast cancer,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3079,KP14,35949590,Heritable mutation in PTCH1#causes#constitutive activation of the Hedgehog pathway,Molecular Event,PTCH1,-,-,-,Hedgehog,-,-,-,-,-,-,Fact,1,1.2,1.2.1,1.2.1.3,-,应激反应通路
6316,KP14,33683521,Cutaneous toxicities#occur during#palbociclib and endocrine therapy,Safety Monitoring,"CDK4,CDK6",-,Advanced breast cancer,"Palbociclib, Endocrine therapy",-,Cutaneous toxicities,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
5796,KP14,37734262,ADME gene polymorphisms#are associated with#toxicity to CDK4/6 inhibitors,Mechanisms of Resistance,"CDK4,CDK6",-,HR+ HER2- metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,2.6.1.2,-,代谢酶变化
869,KP14,37734262,Therapeutic response to CDK4/6 inhibitors#varies among#patients with HR+/HER2- metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,HR+/HER2- metastatic breast cancer,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,-,生物标志物监测
5688,KP14,29783894,Fulvestrant#is used in#management of HR+ metastatic breast cancer,Clinical Implementation,-,-,HR+ metastatic breast cancer,Fulvestrant,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
3932,KP14,29783894,Fulvestrant#is approved for#ER-positive metastatic breast cancer (ER+ MBC),Drug Development,ESR1,-,Metastatic breast cancer,Fulvestrant,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
3854,KP14,29783894,Fulvestrant label#was updated to include#endocrine therapy naive ER+ MBC,Clinical Implementation,ESR1,-,Metastatic breast cancer,Fulvestrant,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
1235,KP14,29783894,Postmarketing trials#challenged#the equivalence of fulvestrant to aromatase inhibitors,Clinical Trial Data,ESR1,-,Metastatic breast cancer,"Fulvestrant, aromatase inhibitors",-,-,-,-,-,-,-,Fact,8,8.3,8.3.1,8.3.1.2,-,不良反应管理
2289,KP14,29783894,Fulvestrant#was proven superior to#anastrozole in efficacy,Drug Development,ESR1,-,Metastatic breast cancer,"Fulvestrant, anastrozole",-,-,-,-,-,-,-,Fact,8,8.3,8.3.1,8.3.1.2,-,不良反应管理
4876,KP14,36292649,PIK3CA/mTOR inhibitors#warrant examination in#PIK3CA-mutant luminal ABC,Drug Development,"PIK3CA, MTOR",-,Luminal ABC,PIK3CA/mTOR inhibitors,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.4,-,PIK3CA突变
6657,KP14,31147264,Genomic profiling#can guide#therapeutic opportunities for testicular cancers,Biomarker Analysis,-,-,Testicular cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
5674,KP14,37805496,CDK4/6 inhibitors#show#synergistic effects with anti-HER2 therapy,Combination Optimization,"CDK4, CDK6, ERBB2",-,Breast cancer,"CDK4/6 inhibitors, anti-HER2",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
511,KP14,37805496,Dalpiciclib#is combined with#pyrotinib as front-line treatment for HER2-positive advanced BC,Drug Development,"CDK4, CDK6, ERBB2",-,Breast cancer,"Dalpiciclib, pyrotinib",-,-,-,-,-,-,-,Fact,-,8,8.1,8.1.2,8.1.2.1,8.1.2.1.1
73,KP14,36539444,CDK4/6 inhibitors#improve#benefit in HR+/HER2- mBC with ET,Therapeutic Response,"CDK4, CDK6, MTOR, PIK3CA",-,Metastatic breast cancer,"CDK4/6 inhibitors, mTOR inhibitors, PI3K inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
1099,KP14,35303782,"CDK4/6 inhibitors#abemaciclib, palbociclib, and ribociclib#modified treatment of HR+/HER2- advanced BC",Drug Development,"CDK4, CDK6",-,Advanced breast cancer,"Abemaciclib, palbociclib, ribociclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6980,KP14,37982827,Palbociclib#shows#radiosensitizing effects in preclinical studies,Preclinical Models,CDK4,-,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7788,KP14,35337692,CDK4/6 inhibitors#represent#less toxic alternatives to chemotherapy in HR+/HER2- BC,Drug Development,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,Postmenopausal women,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2975,KP14,32582373,"CDK4/6 inhibitors#improve#PFS, ORR, and CB in HR+/HER2- advanced BC",Therapeutic Response,"CDK4, CDK6",-,Advanced breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2239,KP14,38414945,CDK inhibitors#improve#progression-free and overall survival in HR+/HER2- ABC,Therapeutic Response,"CDK4, CDK6",-,Advanced breast cancer,CDK inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2698,KP14,38414945,63% of patients#received#palbociclib with ET as first line treatment,Patient Characteristics,"CDK4, CDK6",-,Advanced breast cancer,Palbociclib,-,-,"49 years (19-86), de novo stage IV",-,-,-,-,Fact,8,8.1,8.1.2,8.1.2.1,8.1.2.1.1,一线治疗
4614,KP14,39544292,Targeted therapy and immunotherapy#have benefited#LSCC patients,Therapeutic Development,-,-,LSCC,-,-,-,-,-,-,-,-,Fact,3,3.3,3.3.1,3.3.1.4,-,免疫抑制缓解
373,KP14,39544292,PI3K signaling pathway#is discussed as#a classical pathway,Pathway & Network Categories,PIK3CA,-,-,-,PI3K,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
1208,KP14,39544292,CDK4/6 pathway#is discussed as#a therapeutic target,Pathway & Network Categories,"CDK4,CDK6",-,-,-,CDK4/6,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
2080,KP14,39544292,EGFR pathway#is discussed as#a therapeutic target,Pathway & Network Categories,EGFR,-,-,-,EGFR,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
6218,KP14,24266804,Novel compounds#have been assessed in#clinical trials,Clinical Trial Data,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.3,-,疗效监测
833,KP14,24266804,Studies#should improve#prognosis of sarcoma patients,Clinical Implementation,-,-,Sarcoma,-,-,-,-,-,-,-,-,Inference,8,8.5,8.5.1,8.5.1.3,-,临床评估
2844,KP14,26670561,Expression of HPV#was detectable in#12% of patients,Expression Patterns,HPV,-,-,-,-,-,12% of patients,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
5199,KP14,26670561,Expression of p16#was detectable in#28% of patients,Expression Patterns,CDKN2A,-,-,-,-,-,28% of patients,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
4113,KP14,26670561,PeSCCA analysis#offers#new insight into precision medicine approaches,Translational Research Categories,-,-,PeSCCA,-,-,-,-,-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.2,-,评估内容
5349,KP14,26670561,Strategies targeting EGFR#are suggested for#precision medicine approaches,Clinical Trial Data,EGFR,-,PeSCCA,-,-,-,-,-,-,-,-,Inference,8,8.6,8.6.1,8.6.1.2,-,评估内容
2456,KP14,10470133,p16INK4A inactivation#is caused by#point mutations and aberrant methylation,Molecular & Cellular Categories,CDKN2A,-,Non-small cell lung carcinoma,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.3,2.1.3.2,-,组蛋白修饰异常
6119,KP14,34371379,CDK4/6 inhibitors#were being introduced for#HR+/HER2- ABC patients,Therapeutic Development,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2603,KP14,34049239,Cancer drugs#have well-known#cell cycle specificities,Drug Development,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3796,KP14,38472501,CDK4/6 inhibitors#abemaciclib and ribociclib#were introduced for high-risk eBC,Therapeutic Development,"CDK4,CDK6",-,Early breast cancer,"Abemaciclib,Ribociclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6689,KP14,38201285,Recurrent mutations in SMARCA4#may serve as#a target for therapies,Therapeutic Development,SMARCA4,-,-,"EZH1/2 inhibitors,CDK4/6 inhibitors",-,-,-,-,-,-,-,Inference,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
3768,KP14,38201285,Mutated SMARCA4#showed a strong response to#CDK4/6 inhibitor palbociclib,Therapeutic Response,SMARCA4,-,-,Palbociclib,CDK4/6,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3006,KP14,29162134,Patients in NeoPalAna trial#received#anastrozole and palbociclib,Clinical Trial Data,"CDK4,CDK6",-,ER+/HER2- breast cancer,"Anastrozole,Palbociclib",-,-,Clinical stage II/III,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1.1,-,HR+/HER2-乳腺癌
3899,KP14,37060423,Patients with high-risk eBC#should participate in#clinical trials of novel agents,Clinical Trial Data,-,-,Early breast cancer,-,-,-,High-risk,-,-,-,-,Inference,8,8.6,8.6.1,8.6.1.1.2,-,定期随访
6782,KP14,31117035,Immunotherapeutic agent#is included as#an option in triple-negative breast cancer,Therapeutic Development,-,-,Triple-negative breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.3,3.3.2,3.3.2.3,-,免疫逃逸抑制
3215,KP14,35350768,Resistance to palbociclib#is mediated by#ABCB1 transporter,Mechanisms of Resistance,"CDK4,CDK6,ABCB1",-,Cancer,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
7804,KP14,34026622,DDR pathways inhibitors#are suggested for#combination with ICIs,Combination Therapies,"CDK4,CDK6,PARP,ATR",-,-,"PARP inhibitors,CDK4/6 inhibitors,ATR inhibitors",DDR,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
1570,KP14,35614407,Gene alterations#are identified in#CSF,Molecular & Cellular Categories,"CDK4,CDKN2A,MET,SOX2,JAK2,BRAF,PIK3CG",-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6283,KP14,39419769,Patients with brain metastases#were treated with#CDK4/6 inhibitors,Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,-,-,-,Brain metastases,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.3.1,-,影像学评估
7082,KP14,39419769,"Hormone receptor-positive, HER2-negative MBC#is associated with#brain metastases",Cancer Association,"HR,Hormone receptor 2",-,"MBC, brain metastases",-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1.3,-,记忆T细胞
2264,KP14,38427931,Circulating tumor DNA#was analyzed for#mutational analysis to identify biomarkers for CDK4/6 inhibitors,Biomarker Analysis,"CDK4,CDK6",-,MBC,-,-,-,-,-,-,-,-,Fact,7,7.6,7.6.1,7.6.1.1.1,-,驱动基因突变
6199,KP14,38107828,CDK4/6 inhibitor plus endocrine therapy#is the standard-of-care for#HR+/HER2- advanced breast cancer,Therapeutic Development,"CDK4,CDK6",-,Advanced breast cancer,Endocrine therapy,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
58,KP14,34471951,Cell-free DNA comparative analysis#revealed#genomic landscape differences in HR+ metastatic breast cancer between US and China,Genomic Profiling,HR,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,-,-,基因组不稳定性
6620,KP14,34471951,NGS-based liquid biopsy assay#explored#genomic landscape in HR+ HER2- MBC patients,Preclinical Models,"HR,Hormone receptor 2",-,MBC,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,-,-,基因组不稳定性
1769,KP14,34471951,Genomic alterations#were correlated with#progression-free survival in HR+ HER2- MBC patients,Biomarker Analysis,"HR,Hormone receptor 2",-,MBC,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,-,-,预后生物标志物
6550,KP14,34471951,US cohort patients#received#hormonal therapy plus CDK4/6 inhibitors,Clinical Implementation,"CDK4,CDK6",-,MBC,Hormonal therapy,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,-,-,内分泌治疗联合
1270,KP14,34471951,Mutations#were detected in#85% of US patients and 83% of CN patients,Genomic Profiling,-,-,MBC,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,-,-,基因组不稳定性
7160,KP14,34471951,PTEN deletions#were associated with#shorter progression-free survival in CN cohort,Cancer Association,PTEN,-,MBC,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,-,-,获得性耐药的分子基础
2435,KP14,34471951,PTEN deletion#had reduced association with#PFS in patients receiving CDK4/6 inhibitors,Mechanisms of Resistance,"PTEN,CDK4,CDK6",-,MBC,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.2,-,-,耐药克服策略
5805,KP14,33085843,Ribociclib#was evaluated for#cost-effectiveness in HR+ HER2- ABC treatment,Economic & Access,"CDK4,CDK6",-,Advanced breast cancer,"Ribociclib,Goserelin",-,-,Premenopausal women,-,-,-,-,Fact,8,8.4,8.4.1,-,-,不良反应管理
1406,KP14,12812137,p16INK4A inactivation#was associated with#increased expression of CDK4,Regulation,"CDK4,p16INK4A",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.3,-,-,蛋白水平调控
6530,KP14,38170552,CDK4/6 inhibitors#demonstrated#promising results in curative settings,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,细胞周期阻滞
7475,KP14,39171293,Core FOXC1 targets in TNBC#are regulated by#FOXA1 and NR2F2 in ER+ breast cancer,Transcriptional Control,"FOXC1,FOXA1,NR2F2",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,-,-,转录因子网络
7657,KP14,23174022,RNA-Seq analysis#identified#11 novel melanoma gene fusions in cell lines,Genomic Profiling,-,Melanoma cell lines,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,-,-,基因融合和重排
6624,KP14,35093912,CDK4/6 inhibitors#were continued in#ER+ HER2- MBC after disease progression,Therapeutic Development,"CDK4,CDK6",-,MBC,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,细胞周期阻滞
6993,KP14,31091037,Targeted therapies#modified#strategies for advanced stage breast and tubo-ovarian cancers,Therapeutic Development,-,-,"Breast cancer, tubo-ovarian cancer",-,-,-,-,-,-,-,-,Fact,3,3.2,-,-,-,联合治疗的机制基础
1909,KP14,31091037,Immunotherapy#integrated into#treatment of triple-negative cancers,Therapeutic Development,-,-,Triple-negative cancers,-,-,-,-,-,-,-,-,Fact,3,3.3,-,-,-,抗肿瘤免疫反应的调控
1747,KP14,31091037,Antiangiogenic treatment and PARP inhibitors#prolong#disease control in patients with BRCA1/2 mutation,Therapeutic Development,"BRCA1, BRCA2",-,Tubo-ovarian cancers,"Antiangiogenic treatment, PARP inhibitors",-,-,-,-,-,-,-,Fact,3,3.5,-,-,-,肿瘤微环境的调节
103,KP14,39687977,Molecular genetics and targeted therapeutics#enable#biomarker analysis and molecular applications,Biomarker Analysis,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,-,-,-,预测性生物标志物
3116,KP14,39610055,CDK4/6 inhibitors in combination with ET#improve#progression-free survival and overall survival,Therapeutic Development,"CDK4, CDK6",-,Breast cancer,"CDK4/6 inhibitors, Endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
4559,KP14,38497887,CDK4/6 inhibitors#evolve#HR-positive/HER2-negative metastatic breast cancer treatment,Therapeutic Development,"CDK4, CDK6, HER2",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6690,KP14,38497887,Palbociclib#was introduced into#clinical practice based on progression-free survival benefit,Drug Development,"CDK4, CDK6",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.2,8.1.2.3,-,维持治疗
588,KP14,39463748,Abemaciclib#was approved for#HR-positive/HER2-negative early breast cancer in the adjuvant setting,Drug Development,"CDK4, CDK6, HER2",-,Early breast cancer,Abemaciclib,-,-,High-risk patients,-,-,-,-,Fact,8,8.1,8.1.2,8.1.2.1,-,一线治疗
2166,KP14,38872062,ESR1 mutation#is associated with#less favorable rwPFS and rwOS in HR-positive/HER2-negative breast cancer,Biomarker Analysis,ESR1,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,-,ESR1突变
6938,KP14,34297598,CDK4/6 inhibitors#are approved for#HR-positive/HER2-negative advanced or metastatic breast cancer,Drug Development,"CDK4, CDK6, HER2",-,Advanced breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
2507,KP14,30532569,Ribociclib and Palbociclib#are compared for#cost-effectiveness in HR-positive/HER2-negative breast cancer,Economic & Access,HER2,-,Breast cancer,"Ribociclib, Palbociclib",-,-,Postmenopausal women,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
6854,KP14,30532569,Survival model#was developed from#clinical trials with Ribociclib or Palbociclib,Clinical Trial Data,HER2,-,Breast cancer,"Ribociclib, Palbociclib",-,-,Postmenopausal women,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
190,KP14,30532569,Disease progression#was modeled with#a survival model including subsequent treatments,Clinical Trial Data,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
6897,KP14,30532569,Ribociclib+letrozole#showed#a greater benefit compared to Palbociclib+letrozole,Economic & Access,-,-,Breast cancer,"Ribociclib, Palbociclib, Letrozole",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
4051,KP14,30532569,Ribociclib+letrozole#would represent#a cost-effective option for HR+/HER2- ABC in postmenopausal women,Economic & Access,HER2,-,Advanced breast cancer,"Ribociclib, Letrozole",-,-,Postmenopausal women,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
1243,KP14,30340505,Ribociclib#is approved for#HR-positive/HER2-negative advanced breast cancer in combination with aromatase inhibitor,Drug Development,"CDK4, CDK6, HER2",-,Advanced breast cancer,"Ribociclib, Aromatase inhibitors",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
7868,KP14,35631440,"Palbociclib, Ribociclib, and Abemaciclib#are in#post-marketing surveillance phase",Drug Development,"CDK4, CDK6",-,Breast cancer,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.3,8.1.3.1,-,影像学评估
7472,KP14,34739192,Ribociclib in combination with endocrine therapies#is approved for#HR-positive/HER2-negative metastatic breast cancer,Drug Development,"CDK4, CDK6, HER2",-,Metastatic breast cancer,"Ribociclib, Endocrine therapies",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
5051,KP14,39076888,Such agents#prolong#patients' survival,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
4963,KP14,39076888,CDK4/6 inhibitors#play a role in#clinical use,Drug Development,"CDK4,CDK6",-,Cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
7577,KP14,38001750,Invasive lobular carcinomas (ILCs)#have#different regulating genetic pathways,Cancer Pathways,-,-,Invasive lobular carcinomas,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
4511,KP14,37775726,Shared decision-making#involves#using a CDK4/6 inhibitor plus an aromatase inhibitor for HR+/HER2- metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,联合芳香化酶抑制剂
4860,KP14,30372389,Advances in molecular biology#helped to define#oncogenic mechanisms in RCC subtypes,Cancer Pathways,-,-,Renal cell carcinoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
4263,KP14,39139449,"Efforts#target#critical dependencies including NTRK3, EGFR, and CDK4/6",Drug Development,"NTRK3,EGFR,CDK4,CDK6",-,Desmoplastic small round cell tumor (DSRCT),B7-H3,-,-,-,-,B7-H3,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4737,KP14,34875670,Therapy sequence#is unclear after#disease progression on CDK4/6 inhibitors,Therapeutic Resistance,"CDK4,CDK6",-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.4,-,时序调控
5921,KP14,33227663,CDK4/6 inhibition#may exacerbate#acute radiation and radiation recall toxicities,Therapeutic Resistance,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Inference,2,2.6,2.6.1,2.6.1.4,-,细胞凋亡抑制
2894,KP14,32195331,In silico analysis#includes#gene expression data from ER+/HER2- breast cancers,Expression Patterns,ERBB2,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
3208,KP14,32195331,Basal subtype#is associated with#better chemosensitivity,Cancer Association,-,-,-,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.2,7.4.1.2.2,Basal样亚型
1944,KP14,32195331,Basal subtype#is associated with#lesser benefit from adjuvant hormone therapy,Cancer Association,-,-,-,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.2,7.4.1.2.2,Basal样亚型
5852,KP14,32195331,"Basal subtype#is associated with#better sensitivity to PARP inhibitors, platinum salts, and immune therapy",Drug Development,-,-,-,"PARP inhibitors, platinum salts, immune therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4678,KP14,32195331,Luminal subtype#displays#potential better sensitivity to CDK4/6 inhibitors,Cancer Association,"CDK4, CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1187,KP14,32195331,"Luminal subtype#is vulnerable to#PIK3CA, AR and Bcl-2 inhibitors",Cancer Association,"PIK3CA, AR, BCL2",-,-,"PIK3CA inhibitors, AR inhibitors, BCL2 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3039,KP14,37585491,Phase I trial#studied#safety and efficacy of PLX51107 (BETi) and azacitidine combination therapy,Clinical Trial Data,-,-,"Relapsed/Refractory AML, HR MDS","PLX51107, azacitidine",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,8.2.1.2.1,氟维司群
304,KP14,37585491,Thirty-seven patients with HR R/R MDS and R/R AML#were treated with#PLX51107 + azacitidine,Clinical Trial Data,-,-,"HR R/R MDS, R/R AML","PLX51107, azacitidine",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,8.2.1.2.1,氟维司群
4257,KP14,37585491,"Immunoblot analyses#confirmed#reduction in protein levels of c-Myc, CDK6, BCL2, and BCL-xL",Molecular Event,"MYC, CDK6, BCL2, BCL2L1",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
4224,KP14,37585491,Immunoblot analyses#confirmed#induction of BRD4 and HEXIM1 protein levels in responders,Molecular Event,"BRD4, HEXIM1",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
6336,KP14,37363965,TLP combination#was proposed for#treatment of HR+/HER2+ metastatic breast cancer,Combination Therapies,"CDK4, CDK6, ESR1, ERBB2",-,HR+/HER2+ metastatic breast cancer,"Tucatinib, letrozole, palbociclib",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
1095,KP14,39662069,Palbociclib#is associated with#a high incidence of neutropenia,Safety Monitoring,"CDK4, CDK6",-,-,Palbociclib,-,Neutropenia,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
4454,KP14,37967116,Ribociclib and everolimus#have shown#synergistic growth inhibition in multiple tumor models,Combination Therapies,"CDK4, MTOR",-,-,"Ribociclib, everolimus",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
4753,KP14,37967116,Targeting CDK4/6 in DDL and mTOR in LMS#is of#biologic interest,Cancer Pathways,"CDK4, CDK6, MTOR",-,"Dedifferentiated liposarcoma (DDL), leiomyosarcoma (LMS)",-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5911,KP14,37205634,CDK4/6 inhibitors#are employed for#treatment of several cancers,Cancer Association,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6099,KP14,37205634,Idasanutlin and carfilzomib combination#demonstrated#effects on liposarcoma growth in vivo,Combination Therapies,"CDK4,CDK6",-,Liposarcoma,"Idasanutlin,Carfilzomib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6320,KP14,33955129,Palbociclib#is associated with#neutropenia,Safety Monitoring,"CDK4,CDK6",-,Neutropenia,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
5552,KP14,33955129,Palbociclib plus endocrine therapy#improves#advanced breast cancer outcomes,Therapeutic Response,"CDK4,CDK6",-,Advanced breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
4758,KP14,39379782,Patients with HR-positive/HER2-negative advanced breast cancer#were assigned to#capivasertib or placebo plus fulvestrant,Clinical Trial Data,"CDK4,CDK6",-,Advanced breast cancer,"Capivasertib,Fulvestrant",-,-,HR-positive/HER2-negative,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
622,KP14,35002243,Combination of CDK4/6 inhibitors and endocrine therapy#is#standard treatment for HR-positive and HER2-negative MBC,Clinical Implementation,"CDK4,CDK6",-,MBC (metastatic breast cancer),CDK4/6 inhibitors,-,-,HR-positive/HER2-negative,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
6798,KP14,33402826,Endocrine therapy with or without CDK4/6 inhibitors#is used for#metastatic hormone receptor-positive breast cancer,Clinical Implementation,"CDK4,CDK6",-,Metastatic hormone receptor-positive breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
225,KP14,29951582,CDK4/6 inhibitors#are associated with#overall survival in metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
186,KP14,29951582,"Palbociclib, ribociclib, and abemaciclib#are investigated in#first-line therapy for metastatic hormone receptor-positive breast cancer",Clinical Trial Data,"CDK4,CDK6",-,Metastatic hormone receptor-positive breast cancer,"Palbociclib,Ribociclib,Abemaciclib",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
3977,KP14,38838928,Drug-drug interaction (DDI)#is associated with#reduced anti-tumor effects or severe toxicities,Safety Monitoring,"CDK4,CDK6",-,Tumor,-,-,-,-,-,-,-,-,Inference,2,2.6,2.6.1,2.6.1.1,-,药物外排增加
6157,KP14,35484313,Reducing myelotoxicity#increases#efficacy of chemotherapy,Therapeutic Development,"CDK4,CDK6",-,Cancer,-,-,Frailer patients,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,血液学毒性
3402,KP14,30459450,MET-mutant patients with advanced-stage tumors#showed#better prognosis at 12 months,Clinical Correlation,MET,-,Advanced-stage tumors,-,-,Older age,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
5265,KP14,28432176,Ribociclib#displayed#preclinical activity in neuroblastoma and MRT models,Preclinical Models,"CDK4,CDK6",-,"Neuroblastoma, Malignant rhabdoid tumor",Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,细胞周期阻滞
1865,KP14,28432176,Ribociclib#is combined with#other agents in neuroblastoma and MRT,Combination Therapies triples,-,-,"Neuroblastoma, MRT",Ribociclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
6202,KP14,37916184,CDK4/6 inhibitor treatment#is compared with#chemotherapy in the first line of therapy,Clinical Trial Data triples,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,治疗线别
5821,KP14,39352477,MEK and CDK4/6 pathway targeting#suggests#a synergistic role in pancreatic cancer,Pathway & Network Categories,"CDK4,CDK6",-,Pancreatic cancer,-,"MEK,CDK4/6",-,-,-,-,-,-,Inference,1,1.3,1.3.1,1.3.1.3,-,协同效应
4217,KP14,34745997,Palbociclib in combination with Letrozole#is evaluated for#primary resistance in HR+/HER2- advanced breast cancer,Therapeutic Resistance triples,"CDK4,CDK6",-,Advanced breast cancer,"Palbociclib, Letrozole",-,"HR+, HER2-",upregulated,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
54,KP14,34745997,Primary resistance to adjuvant endocrine therapy#is associated with#liver metastasis and elevated serum CA-15-3,Therapeutic Resistance triples,-,-,Breast cancer,-,-,"Liver metastasis, elevated serum CA-15-3",-,CA-15-3,-,-,-,Fact,2,2.2,2.2.2,2.2.2.1,-,G1/S检查点失控
1886,KP14,33138346,Cyclin-dependent kinase 4/6 inhibitors#improved#survival outcome in HR+ metastatic breast cancer patients,Therapeutic Response triples,"CDK4,CDK6",-,Metastatic breast cancer,-,-,HR+,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,细胞周期阻滞
923,KP14,39229468,Dalpiciclib#showed#tolerability and preliminary efficacy as monotherapy for advanced breast cancer,Drug Development triples,"CDK4,CDK6",-,Advanced breast cancer,Dalpiciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,细胞周期阻滞
3261,KP14,34930650,Preoperative endocrine therapy#is combined with#a CDK4/6 inhibitor in clinical situations,Combination Therapies triples,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
3197,KP14,34930650,HER2 positive LABCs#are targeted with#anti-HER2 agents combined with chemotherapy,Combination Therapies triples,-,-,HER2 positive LABCs,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
3998,KP14,39118946,Endocrine-based therapies#are preferred over#chemotherapy in HR+/HER2- metastatic breast cancer,Clinical Implementation triples,-,-,Metastatic breast cancer,-,-,"HR+, HER2-",-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,-,患者选择
2015,KP14,36125617,Patients with AM#have#worse overall survival rates,Patient Outcome triples,-,-,Melanoma,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
5167,KP14,36125617,"Anti-angiogenic drugs, albumin paclitaxel, or interferons#enhance#the effectiveness of immune checkpoint inhibitors",Combination Therapies triples,-,-,-,"Anti-angiogenic drugs, albumin paclitaxel, interferons",-,-,-,-,-,-,-,Inference,3,3.2,3.2.3,3.2.3.1,-,免疫检查点阻断
2521,KP14,38841159,58% of patients#had#actionable mutations for targeted therapies,Biomarker Analysis triples,-,-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
4354,KP14,38841159,CDK4/6 inhibitor mutations#are common in#adults with osteosarcoma,Therapeutic Resistance triples,"CDK4,CDK6",-,Osteosarcoma,-,-,Adults,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
6371,KP14,34978424,Ribociclib-loaded transfersomes#eradicate#breast cancer via CD44 targeting,Therapeutic Development triples,"CDK4,CDK6",-,Breast cancer,Ribociclib,-,-,-,-,CD44,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
107,KP14,34978424,HR+/HER2- metastatic breast cancer#is diagnosed as#a life-threatening condition in women,Clinical Correlation triples,-,-,Metastatic breast cancer,-,-,"HR+, HER2-",-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1566,KP14,34978424,"Repeated cycles of RB#led to#severe neutropenia, hepatobiliary, gastrointestinal, and renal toxicities, and QT interval prolongation",Safety Monitoring triples,-,-,Breast cancer,Ribociclib,-,"Neutropenia, hepatobiliary, gastrointestinal, renal toxicities, QT interval prolongation",-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
4119,KP14,34978424,HA-RB-Ts#internalize into#tumor cells,Drug Delivery Innovation,-,tumor cells,cancer,-,-,-,-,-,-,-,-,Fact,3,3.6,3.6.1,3.6.1.4,-,组织渗透增强
128,KP14,34978424,HA-RB-Ts#interact with#CD44,Interaction triples,CD44,-,-,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,6.1.1.1.1,CD8+效应T细胞
6939,KP14,34978424,Drug concentrations#remain within#therapeutic window for 48 hours,Pharmacokinetics,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,8.5.1.2.4,药物浓度
2865,KP14,34978424,RB concentration#is reduced by#8.3-fold in vital organs,Safety Monitoring,-,-,-,RB,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
3259,KP14,34978424,MN system#offers#self-administrable and biodegradable treatment option,Therapeutic Development,-,-,cancer,-,-,-,-,-,-,-,-,Fact,3,3.6,3.6.1,3.6.1.4,-,组织渗透增强
1654,KP14,35450470,Alpelisib + fulvestrant#demonstrate#efficacy as a first-line treatment for metastatic breast cancer,Clinical Trial Data,-,-,metastatic breast cancer,"alpelisib, fulvestrant",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
7713,KP14,35450470,Alpelisib + fulvestrant#are used as#treatment after CDK4/6 inhibitors,Clinical Implementation,"CDK4,CDK6",-,metastatic breast cancer,"alpelisib, fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
3755,KP14,30626916,Recurrent mutations#involve#RAS-MAPK signaling pathway,Cancer Pathways,"MAP2K1,KRAS,NRAS,BRAF,PTPN11,NF1,CBL",-,histiocytic sarcoma,-,RAS-MAPK,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
3794,KP14,30626916,MEK inhibitor Cobimetinib#shows#clinical response in NF1-mutated histiocytic sarcoma,Drug Development,NF1,-,histiocytic sarcoma,Cobimetinib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
459,KP14,30626916,Mutations#result in#activation of PI3K signaling pathway,Cancer Pathways,"PTEN,MTOR,PIK3R1,PIK3CA",-,histiocytic sarcoma,-,PI3K,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
2887,KP14,30626916,CDKN2A#is#most frequently altered gene,Cancer Association,CDKN2A,-,histiocytic sarcoma,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
4861,KP14,30626916,"MAPK, PI3K, and cyclin-CDK4/6-INK4 signaling#cooperate in#pathogenesis of histiocytic sarcoma",Signaling Networks,"MAPK,PI3K,CDK4,CDK6",-,histiocytic sarcoma,-,-,-,-,-,-,-,-,Inference,1,1.3,1.3.1,1.3.1.3,-,协同效应
4407,KP14,37893593,Breast cancer#switches from#Luminal-Androgen-Receptor-Positive to Hormone-Receptor-Positive,Molecular Event triples,-,-,breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.2,7.4.1.2.1,Luminal亚型
7276,KP14,37893593,Triple-negative breast cancer (TNBC)#represents#15% of all breast cancers,Epidemiology,-,-,triple-negative breast cancer (TNBC),-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.3,黑色素瘤
4282,KP14,37893593,TNBC#is characterized by#aggressive clinical behavior and poor prognosis,Disease Characteristics,-,-,triple-negative breast cancer (TNBC),-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.3,黑色素瘤
4517,KP14,37893593,TNBC#is divided into#four subgroups with different molecular profiles,Molecular Subtypes,-,-,triple-negative breast cancer (TNBC),-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.2,7.4.1.2.2,Basal样亚型
599,KP14,37893593,Patient#experiences#local recurrence with strong estrogen receptor expression,Clinical Outcome,ESR1,-,luminal androgen receptor (LAR) breast cancer,-,-,-,-,upregulated,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.3,ESR1突变
7081,KP14,37893593,Everolimus and exemestane#determine#temporary disease stabilization,Therapeutic Response,-,-,breast cancer,"everolimus, exemestane",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
2540,KP14,37893593,Re-biopsy and molecular testing#are emphasized for#rare breast cancer subtypes,Clinical Implementation,-,-,breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,8.5.1.2.1,循环肿瘤DNA
1169,KP14,37626854,Cyclins and CDKs#are studied and targeted in#cancer treatment,Therapeutic Development,"CDK4,CDK6",-,cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6513,KP14,37626854,Four CDK4/6 inhibitors#are approved by#FDA,Regulatory Documentation,"CDK4,CDK6",-,cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
395,KP14,34605036,Cyclin-dependent kinases (CDK)#are#extensively studied drug targets,Drug Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4639,KP14,34605036,FDA#approves#three CDK inhibitors for therapeutic use,Regulatory Documentation,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
6934,KP14,34605036,27 CDK inhibitors#are under#active clinical development,Drug Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1089,KP14,34605036,amino-pyrimidine#is#a well-represented scaffold among CDK inhibitors,Molecular & Cellular Categories,CDK,-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6092,KP14,34605036,selectivity aspects among CDKs#are discussed in#relation to clinical trial toxicities,Clinical Trial Data,CDK,-,-,-,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.3,-,剂量调整
5481,KP14,34605036,changing paradigm towards selective inhibitors#is discussed with#an overview of ATP-binding pockets of druggable CDKs,Drug Development,CDK,-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7826,KP14,34605036,"dual CDK4/6 inhibitors#exist alongside#selective CDK7, CDK9, and CDK8/19 inhibitors in the clinical pipeline",Drug Development,"CDK4,CDK6,CDK7,CDK9,CDK8,CDK19",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5088,KP14,32936368,humanized antibodies#target#immune checkpoints CTLA-4 and PD1/PD-L1,Immune Cell Functions,"CTLA4,PDCD1,CD274",-,-,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.3,6.1.1.3.1,PD-1/PD-L1表达
553,KP14,32936368,long-term remission#can be achieved in#two-thirds of patients with tumor response,Clinical Implementation,-,-,Tumor,-,-,-,two-thirds of patients,-,-,-,-,Inference,8,8.5,8.5.1,8.5.1.3,-,症状改善
3026,KP14,32936368,mechanisms of resistance to immune checkpoint inhibitors#are evolving#in primary and secondary contexts,Mechanisms of Resistance,"CTLA4,PDCD1,CD274",-,Tumor,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
7003,KP14,37690320,ribociclib#is used as#a CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer,Drug Development,"CDK4,CDK6",-,Metastatic breast cancer,ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
761,KP14,37690320,ribociclib#is added to#maintenance endocrine therapy in HR+/HER2- metastatic breast cancer,Combination Optimization,"CDK4,CDK6",-,Metastatic breast cancer,ribociclib,-,-,pre- and post-menopausal women,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
2252,KP14,37690320,maintenance treatment with ribociclib#shows#promising efficacy and safety in HR+/HER2- metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,Metastatic breast cancer,ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4289,KP14,31166679,CDK4/6 inhibitor#provides#greater progression-free survival benefit in HR+/HER2- advanced breast cancer,Therapeutic Response,"CDK4,CDK6",-,Advanced breast cancer,-,-,-,premenopausal or perimenopausal patients,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2775,KP14,38537957,25% of patients#had received#prior therapy with CDK4/6 inhibitors,Patient Characteristics,"CDK4,CDK6",-,Advanced breast cancer,-,-,-,25% of patients,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,-,患者选择
411,KP14,28281842,one in three patients#respond to#hormonal or antihormonal therapy in breast cancer,Therapeutic Response,ESR1,-,Breast cancer,-,-,-,one in three patients,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,-,患者选择
4094,KP14,36605432,"metastatic breast cancer subtype#includes#HR-positive/HER2-negative, HER2 overexpression, and triple-negative",Cancer Association,HER2,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
2197,KP14,36605432,CDK4/6 inhibitors combined with ET#control#disease progression in HR(+)/HER2(-) patients,Therapeutic Response,"CDK4,CDK6",-,Metastatic breast cancer,"CDK4/6 inhibitors, ET",-,-,Good physical status,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
4909,KP14,37899576,ribociclib#causes#liver toxicity in metastatic HR-positive postmenopausal breast cancer,Safety Monitoring,"CDK4,CDK6",-,Metastatic HR-positive breast cancer,Ribociclib,-,Liver toxicity,Postmenopausal,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
7185,KP14,30220928,elderly women treated with CDK4/6 inhibitors and aromatase inhibitors#experience#higher toxicity grades compared to younger patients,Safety Monitoring,"CDK4,CDK6",-,-,"CDK4/6 inhibitors, Aromatase inhibitors",-,-,Elderly women,Higher,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
3560,KP14,36430703,mutations in patient tumors#are#amenable to targeted therapies or clinical trial drugs,Clinical Implementation,-,-,Cancer,Targeted therapies,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
3276,KP14,35117951,"CDK4/6 inhibitors#are combined with#PI3K inhibitors, immune checkpoint inhibitors, and atezolizumab",Combination Optimization,"CDK4,CDK6,PI3K,PD1,PDL1,CTLA4",-,-,"CDK4/6 inhibitors, PI3K inhibitors, Atezolizumab",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4383,KP14,34884204,radiation therapy#causes#radiation-induced hypothyroidism in multimodally treated breast cancer patients,Safety Monitoring,-,-,Breast cancer,Radiation therapy,-,Hypothyroidism,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
795,KP14,34884204,therapeutic advances#prolong#survival in metastatic breast cancer patients,Therapeutic Response,-,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7774,KP14,34884204,multimodal treatment for breast cancer#leads to#primary hypothyroidism as a late effect,Safety Monitoring,-,-,Breast cancer,-,-,Hypothyroidism,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
2374,KP14,33989019,lower-risk patients#are treated with#tamoxifen alone,Clinical Implementation,-,-,Breast cancer,Tamoxifen,-,-,Lower risk,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,-,患者选择
6971,KP14,33989019,role of CDK4/6 inhibitors#in adjuvant endocrine therapy#is unclear,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,8,8.2,8.2.1,8.2.1.3,-,疗效监测
3202,KP14,32429381,CDK4/6 and PI3K/mTOR inhibitors#are debated in#neoadjuvant breast cancer therapy,Therapeutic Development,"CDK4,CDK6,PI3K,MTOR",-,Breast cancer,"CDK4/6 inhibitors, PI3K/mTOR inhibitors",-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6817,KP14,37580773,ribociclib plus endocrine therapy#was evaluated for#efficacy and safety in Asian patients with HR+/HER2- advanced breast cancer,Clinical Trial Data,ERBB2,-,Advanced breast cancer,Ribociclib,-,-,Asian patients,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
7007,KP14,39313156,data#may support#studies on acquired resistance mechanisms in post-CDK4/6 inhibitor setting,Therapeutic Resistance,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
4843,KP14,36717797,Palbociclib plus endocrine therapy#was studied in#HR+/HER2- metastatic breast cancer in northwest China,Clinical Implementation,ERBB2,-,Metastatic HR+/HER2- breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
3107,KP14,36717797,real-world outcomes#were investigated in#HR+/HER2- metastatic breast cancer patients treated with Palbociclib,Real-world Evidence,ERBB2,-,Metastatic HR+/HER2- breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
493,KP14,36717797,"real-world objective response rate (ORR), progression-free survival (PFS), and safety profiles#were analyzed in#HR+/HER2- metastatic breast cancer",Clinical Implementation,ERBB2,-,Metastatic HR+/HER2- breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,-,生物标志物监测
6074,KP14,36717797,early Palbociclib initiation#was associated with#prolonged PFS in HR+/HER2- MBC,Therapeutic Response,ERBB2,-,Metastatic HR+/HER2- breast cancer,Palbociclib,-,-,"Estrogen receptor and progesterone receptor double positivity, less than 3 metastatic sites, without visceral metastasis, bone metastasis only, without prior chemotherapy or endocrine therapy",-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4672,KP14,36717797,Palbociclib plus endocrine therapy#exhibited#favorable effectiveness and manageable toxicities in HR+/HER2- metastatic breast cancer,Therapeutic Response,ERBB2,-,Metastatic HR+/HER2- breast cancer,Palbociclib,-,-,Chinese patients,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1907,KP14,37256976,a phase 3 trial#enrolled#patients with HR+/HER2- advanced breast cancer who had relapse or progression after aromatase inhibitor treatment,Clinical Trial Data,ERBB2,-,Advanced breast cancer,Aromatase inhibitors,-,-,"Pre-, peri-, and postmenopausal women and men",-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,影像学评估
5435,KP14,32954927,many patients with HR+/HER2- early breast cancer#will not experience#recurrence with standard therapies,Therapeutic Response,ERBB2,-,Early breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,8.5.1.1.4,RECIST标准
5204,KP14,32954927,superior treatment options#are needed to prevent#early recurrence and metastases in HR+/HER2- early breast cancer,Therapeutic Development,ERBB2,-,Early breast cancer,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
1593,KP14,32954927,Abemaciclib#is approved for#HR+/HER2- advanced breast cancer,Drug Development,"CDK4, CDK6",-,Advanced breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5291,KP14,36165726,selective CDK4/6 inhibition#has potential in#therapy for head and neck squamous cell carcinoma,Therapeutic Development,"CDK4, CDK6",-,Head and neck squamous cell carcinoma,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7789,KP14,36165726,CDKN2A mutations#correlated with#better overall survival with palbociclib and cetuximab in certain subsets,Biomarker Analysis,CDKN2A,-,Head and neck squamous cell carcinoma,"Palbociclib, Cetuximab",-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.2,7.5.1.2.1,CDKN2A缺失
7349,KP14,36123435,four drugs#were evaluated for#synergy with doxorubicin and paclitaxel,Combination Optimization,-,-,-,"Doxorubicin, Paclitaxel",-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.2,-,协同增效作用
1827,KP14,35158866,OlympiAD and EMBRACA trials#demonstrated#favorable efficacy/toxicity ratio of PARPi in HER2-negative metastatic breast cancer with BRCA mutation,Clinical Trial Data,"BRCA1, BRCA2",-,Metastatic breast cancer,PARPi,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,8.5.1.2.1,循环肿瘤DNA
7457,KP14,35158866,PARPi#are largely adopted in#triple-negative metastatic breast cancer,Therapeutic Implementation,-,-,Triple-negative metastatic breast cancer,PARPi,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4653,KP14,35158866,patients with ER+/HER2- BRCA-mutated mBC#have#higher risk of early disease progression on CDK4/6 inhibitors,Therapeutic Resistance,"BRCA1, BRCA2, CDK4, CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
4815,KP14,33762647,ctDNA#evaluates#impact of cancer-driven mutations on the prognosis of MBC,Biomarker Analysis,CTCFL,-,Metastatic breast cancer (MBC),-,-,-,-,-,-,-,-,Fact,7,7.6,7.6.1,7.6.1.1,7.6.1.1.1,驱动基因突变
2465,KP14,33762647,59 ER+ HER2-negative MBC patients#were included in#the study,Patient Stratification,ERBB2,-,Metastatic breast cancer (MBC),-,-,-,ER+ HER2-negative,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.2,7.4.1.2.1,Luminal亚型
7752,KP14,39520520,clinical trials#evaluate#role of other targets in HER2-positive cancers,Clinical Trial Data,"PI3KCA, CD274, CDK4, CDK6",-,HER2-positive cancers,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,8.5.1.1.1,CT扫描
5880,KP14,38961527,ribociclib#improves#PFS in ER+ HER2-negative locally advanced or metastatic breast cancer,Therapeutic Response,"CDK4, CDK6",-,ER+ HER2-negative breast cancer,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6076,KP14,23979958,hot spot gene sequencing#screens for#mutations and copy number abnormalities in stage III-IV ACC,Biomarker Analysis,ACC,-,Adrenocortical carcinoma (ACC),-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,RB1突变
4892,KP14,23979958,Drugs targeting the cell cycle#could be#relevant for advanced ACC treatment,Drug Development,"CDK4, CDK6",-,Adrenocortical carcinoma (ACC),-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1461,KP14,39759323,NGS#explores#mechanisms of LM after EGFR-TKIs resistance,Mechanisms of Resistance,EGFR,-,Lung metastases (LM),EGFR-TKIs,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
7866,KP14,39534582,HER2-low breast cancer#is identified as#a targetable subset of breast tumors,Cancer Association,ERBB2,-,HER2-low breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.2,7.4.1.2.4,正常样亚型
5429,KP14,39534582,T-Dxd#provides#long-term disease response after CDK4/6 inhibitor failure,Therapeutic Response,"CDK4, CDK6",-,Breast cancer,T-Dxd,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3596,KP14,30595753,ribociclib#increases#median PFS in HR+ HER2-negative advanced breast cancer,Therapeutic Response,"CDK4, CDK6",-,HR+ HER2-negative advanced breast cancer,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6071,KP14,38838498,Palbociclib#combines with#endocrine treatment in HR+ HER2-negative breast cancer,Combination Therapies,"CDK4,CDK6",-,HR+ HER2-negative breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
6855,KP14,38729566,abemaciclib#improves#PFS and OS in HR+ HER2-negative ABC,Therapeutic Response,"CDK4,CDK6",-,HR+ HER2-negative ABC,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4122,KP14,38729566,abemaciclib#improves#chemotherapy-free survival in HR+ HER2-negative ABC,Therapeutic Response,"CDK4,CDK6",-,HR+ HER2-negative ABC,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6333,KP14,38729566,abemaciclib#results in#clinically meaningful OS improvement in HR+ HER2-negative ABC,Therapeutic Response,"CDK4,CDK6",-,HR+ HER2-negative ABC,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2972,KP14,27717303,CDK4/6 inhibition#delays#resistance to endocrine therapy in HR+ HER2-negative advanced breast cancer,Mechanisms of Resistance,"CDK4,CDK6",-,HR+ HER2-negative advanced breast cancer,-,-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.4,-,耐药机制克服
4871,KP14,27717303,ribociclib#is combined with#letrozole for HR+ HER2-negative breast cancer,Combination Therapies,"CDK4,CDK6",-,HR+ HER2-negative breast cancer,"Ribociclib,Letrozole",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
7367,KP14,36853016,palbociclib#is explored in#nonbreast solid tumors with CCND1/2/3 amplification,Drug Development,"CDK4,CDK6,CCND1,CCND2,CCND3",-,Nonbreast solid tumors,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4663,KP14,36853016,"Palbociclib#was not effective at treating#nonbreast solid tumors with CCND1, CCND2, or CCND3 amplification",Drug Development,"CCND1,CCND2,CCND3",-,Nonbreast solid tumors,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6685,KP14,30657954,"BRAF, NRAS, and KIT mutations#were identified in#a broad array of MAPK pathway activating alterations",Signaling Networks,"BRAF,NRAS,KIT",-,-,-,MAPK,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
5074,KP14,30657954,"BRAF, NTRK3, ALK, and PRKCA fusions#can be targeted by#available inhibitors",Drug Development,"BRAF,NTRK3,ALK,PRKCA",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7601,KP14,30657954,Inactivation of SPRED1#occurred in#eight cases as an alternative mechanism of disrupting negative regulation of RAS,Regulation,SPRED1,-,-,-,RAS,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
7497,KP14,30657954,Acral melanomas with BRAFV600E mutations#harbored#fewer genomic amplifications,Cancer Association,BRAF,-,Acral melanomas,-,-,-,Patients with European ancestry,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
6621,KP14,30657954,Acral melanomas with BRAFV600E mutations#were more common in#patients with European ancestry,Cancer Association,BRAF,-,Acral melanomas,-,-,-,Patients with European ancestry,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
7149,KP14,30083595,ESR1 mutations#were found to be#an important mechanism of endocrine resistance in ER-positive metastatic breast cancer,Mechanisms of Resistance,ESR1,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
3442,KP14,30083595,There were no associations between pathological features of primary disease#and#emergence of ESR1 mutations in metastatic disease,Mechanisms of Resistance,ESR1,-,Metastatic disease,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
7867,KP14,30083595,The prevalence of ESR1 mutations#was positively associated with#prior fulvestrant treatment,Mechanisms of Resistance,ESR1,-,-,Fulvestrant,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
3104,KP14,30083595,Prevalence of ESR1 mutations#was lower after treatment with#CDK4/6 inhibitors,Mechanisms of Resistance,ESR1,-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
3882,KP14,30083595,There were no significant associations between systemic treatments#and#prevalence of PIK3CA mutations,Mechanisms of Resistance,PIK3CA,-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
2883,KP14,30083595,ESR1 mutations#evolved under#selective pressure of aromatase inhibitors in adjuvant and metastatic settings,Mechanisms of Resistance,ESR1,-,-,Aromatase inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
7544,KP14,26247885,"Cyclin pathway abnormalities#involved#CCND1, CDK4/6, or CDKN2A/B in 26.5% of patients",Cancer Pathways,"CCND1,CDK4,CDK6,CDKN2A,CDKN2B",-,Salivary gland tumors,-,Cyclin pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
3322,KP14,26247885,"PI3K pathway abnormalities#involved#PIK3CA, PIK3R1, PTEN, or AKT1/3 in 23.9% of patients",Cancer Pathways,"PIK3CA,PIK3R1,PTEN,AKT1,AKT3",-,Salivary gland tumors,-,PI3K pathway,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
7759,KP14,39409937,"20% of patients with ER-positive, HER2-negative breast cancer#will experience#disease recurrence",Disease Progression,-,-,"ER-positive, HER2-negative breast cancer",-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
6185,KP14,39409937,"CDK4/6 inhibitors#improve#survival in high-risk ER-positive, HER2-negative BC patients",Therapeutic Response,"CDK4,CDK6",High-risk patients,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2618,KP14,36010842,Mutagenesis mechanisms in HAS#are associated with#spontaneous or enzymatic deamination of 5-methylcytosine and defective homologous recombination-related DNA damage repair,Mechanism of Action,-,-,HAS,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.2,-,末端切除
5153,KP14,33847193,HR+ subtype#constitutes#75% of diagnosed breast cancers,Disease & Clinical Categories,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
1620,KP14,33847193,Cyclin D-CDK4/6 inhibitor and endocrine therapy#significantly improve#overall survival and progression-free survival,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1940,KP14,33847193,Ribociclib-letrozole combination therapy#may cause#elevation of creatinine in 20% of patients,Safety Monitoring,"CDK4,CDK6",-,Breast cancer,"Ribociclib,Letrozole",-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,肝功能异常
3285,KP14,35986800,Treatment utilization patterns#are reported for#HR+/HER2- breast cancer in urban mainland China,Clinical Implementation,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
5033,KP14,35986800,No standard of care regimens#were established for#fourth or greater lines of treatment,Clinical Implementation,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.3,三线及以上
4754,KP14,35986800,HR+/HER2- breast cancer patients in urban mainland China#were prescribed#chemotherapy regimens more frequently than CDK4/6 inhibitors,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
1598,KP14,33177814,Preferences for CDK4/6 inhibitor regimens#were studied for#advanced/metastatic HR+/HER2- breast cancer,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
2064,KP14,33177814,Preferences for dosing and toxicity attributes#were compared among#US oncologists and patients,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,8.1.1.3.4,耐受性评估
3688,KP14,33177814,Palbociclib + aromatase inhibitor profile#is preferred due to#lower risk of diarrhea and no ECG monitoring compared to abemaciclib + AI and ribociclib + AI,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,"Palbociclib,Abemaciclib,Ribociclib",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.4,剂量调整策略
563,KP14,27277747,Palbociclib combined with letrozole#significantly improves#progression-free survival,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,"Palbociclib,Letrozole",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4670,KP14,38764430,Adding CDK4/6 inhibitors#has improved#progression-free survival,Therapeutic Response,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2138,KP14,25792301,Palbociclib#is developed as#a selective CDK4/6 inhibitor for cancer treatment,Drug Development,"CDK4,CDK6",-,Cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1322,KP14,34414532,CompLEEment-1 trial#is conducted in#HR+/HER2- advanced breast cancer patients,Clinical Trial Data,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
6335,KP14,34414532,Patients#received#ribociclib with letrozole and goserelin/leuprolide in CompLEEment-1 trial,Clinical Trial Data,"CDK4,CDK6",-,Breast cancer,"Ribociclib,Letrozole,Goserelin,Leuprolide",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.4,剂量调整策略
4916,KP14,34414532,ribociclib plus letrozole#is used for#first-line treatment in HR+/HER2- advanced breast cancer,Therapeutic Development,"CDK4,CDK6",-,Advanced breast cancer,"Ribociclib,Letrozole",-,-,"HR+,HER2-",upregulated,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
4148,KP14,33332933,Tamoxifen resistance#affects#Palbociclib efficacy in HR+/HER2- metastatic breast cancer,Mechanisms of Resistance,"CDK4,CDK6",-,Metastatic breast cancer,"Palbociclib,Tamoxifen",-,-,"HR+,HER2-",variable,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
1488,KP14,33332933,Palbociclib plus exemestane with ovarian function suppression#prolongs#progression-free survival in HR+/HER2- metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,Metastatic breast cancer,"Palbociclib,Exemestane",-,-,"HR+,HER2-",upregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3127,KP14,33332933,Tamoxifen-sensitive patients#show#limited data due to early recurrence during adjuvant endocrine therapy,Patient Characteristics,-,-,Breast cancer,Tamoxifen,-,Early recurrence,Premenopausal,variable,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,8.5.1.3.1,症状改善
5885,KP14,33332933,Patients#were randomized to receive#Palbociclib+ET or chemotherapy,Clinical Trial Data,"CDK4,CDK6",-,Breast cancer,"Palbociclib,Exemestane,Leuprolide,Capecitabine",-,-,Premenopausal,variable,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.4,剂量调整策略
5346,KP14,33332933,Palbociclib+ET#prolongs#median progression-free survival compared to Capecitabine in tamoxifen-sensitive patients,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,"Palbociclib,Exemestane,Capecitabine",-,-,Tamoxifen-sensitive,upregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7533,KP14,39823755,Trilaciclib#demonstrates#myeloprotection and antitumor efficacy in ES-SCLC,Therapeutic Development,"CDK4,CDK6",-,Small-cell lung cancer,Trilaciclib,-,-,Extensive-stage,variable,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1811,KP14,39823755,"Myeloprotection effect#is explored in#1L, 2L/3L populations by risk category",Therapeutic Development,"CDK4,CDK6",-,Small-cell lung cancer,Trilaciclib,-,-,"1L, 2L/3L",variable,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7837,KP14,39823755,Trilaciclib#reduces#duration and incidence of severe neutropenia in cycle 1,Therapeutic Development,"CDK4,CDK6",-,Severe neutropenia,Trilaciclib,-,Severe neutropenia,"1L, 2L/3L",variable,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5437,KP14,39823755,Median progression-free survival#is#5.3 months for Trilaciclib and 4.9 months for placebo,Therapeutic Response,"CDK4,CDK6",-,Small-cell lung cancer,Trilaciclib,-,-,-,variable,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5857,KP14,39823755,Consistent efficacy of Trilaciclib#is observed in#pooled data across treatment lines,Therapeutic Response,"CDK4,CDK6",-,Small-cell lung cancer,Trilaciclib,-,-,-,variable,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6721,KP14,39172305,Patients with low HER2 expression#may benefit from#novel HER2-directed agents post-chemotherapy,Therapeutic Development,ERBB2,-,Breast cancer,-,-,Low HER2 expression,variable,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3621,KP14,36797664,Combination of CDK4/6 inhibitor and aromatase inhibitor#is#standard first-line treatment for HR+/HER2- advanced breast cancer,Therapeutic Development,"CDK4,CDK6",-,Advanced breast cancer,-,-,"HR+,HER2-",upregulated,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
1838,KP14,36624321,Further studies#are justified for#combination of CDK4/6 inhibitors with other active agents,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,-,-,"HR+,HER2-",variable,-,-,-,-,Inference,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
2325,KP14,35378469,CDK4/6 inhibitors#yield#propitious results with hormone therapy in HR+/HER2- metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,Metastatic breast cancer,-,-,"HR+,HER2-",upregulated,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
7480,KP14,35378469,Response to CDK4/6 inhibitors#is#variable,Therapeutic Response,"CDK4,CDK6",-,-,-,-,-,variable,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2616,KP14,38148576,67.1% of patients#received#ET plus CDK4/6 inhibitor as first-line therapy,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,-,-,-,upregulated,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
5503,KP14,38148576,PIK3CA mutational status#has no bearing on#ET efficacy in first-line setting,Mechanisms of Resistance,PIK3CA,-,Breast cancer,-,-,-,variable,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
5065,KP14,37935631,Abemaciclib#inhibits#CDK4/6,Drug Development,"CDK4,CDK6",-,Metastatic breast cancer,Abemaciclib,CDK4/6 pathway,-,"Hormone receptor-positive, HER2-negative",-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4618,KP14,37866161,Cancer cells#exhibit#aberrant redox homeostasis,Molecular Event,-,Cancer cells,Cancer,-,Redox homeostasis,-,-,-,-,-,-,Fact,4,4.3,4.3.1,4.3.1.1,-,线粒体ROS产生
3436,KP14,37866161,SGK3 inhibition#potentiates#Palbociclib-mediated cytotoxicity,Mechanisms of Resistance,SGK3,Cancer cells,Cancer,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
506,KP14,37866161,SGK3 inhibition#overcomes#Cisplatin resistance,Mechanisms of Resistance,SGK3,-,Cancer,Cisplatin,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
7391,KP14,37866161,SGK3-catalase antioxidant signaling axis#may be targeted to improve#treatment efficacy for cervical cancers,Therapeutic Development,SGK3,-,Cervical cancer,-,Antioxidant signaling,-,PIK3CA helical domain mutations,-,-,-,-,Inference,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
6420,KP14,31853266,Endocrine therapy#is combined with#CDK4/6 inhibitor,Combination Therapies,"CDK4,CDK6",-,Tumors,CDK4/6 inhibitor,-,-,-,-,-,-,-,Inference,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
2293,KP14,29247442,Palbociclib#is combined with#Endocrine therapy,Combination Therapies,"CDK4,CDK6",-,Metastatic breast cancer,Palbociclib,-,-,Hormone receptor-positive,-,-,-,-,Fact,-,3,3.2,3.2.1,3.2.1.1,3.2.1.1.1
5154,KP14,21725359,RB1 alterations#are mutually exclusive with#p16(INK4A) loss,Genetic Interaction,"RB1,CDKN2A",-,Tumors,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
6356,KP14,21725359,Tumors with RB1 loss#exhibit#diminished dependence on BRAF signaling,Molecular Event,"RB1,BRAF",-,Tumors,-,BRAF pathway,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
6178,KP14,21725359,Targeted inhibitors of MAPK pathway#result in#heterogeneous clinical outcomes,Clinical Trial Data,MAPK,-,Cancer,-,MAPK pathway,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
2938,KP14,38653982,PBMC-tumor analysis#shows correlation between#CD4(+) T cells and NK cells,Cell Interaction,-,"CD4(+) T cells, NK cells",Tumors,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
3842,KP14,35972817,Ribociclib#demonstrates#synergistic effect with platinum chemotherapy,Combination Therapies,"CDK4,CDK6",-,Cancer,"Ribociclib, platinum chemotherapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5884,KP14,35972817,Ribociclib#is effective as#maintenance therapy after chemotherapy,Therapeutic Development,"CDK4,CDK6",-,Cancer,Ribociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.4,维持治疗
4927,KP15,35304604,CDK4/6 inhibitors#arrest#tumor cells in G1 phase,Cell Cycle Control,"CDK4,CDK6",-,Tumors,CDK4/6 inhibitors,G1 phase,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6724,KP15,38943828,Sensitivity and resistance to CDK4/6 inhibitors#occur in#HR-positive breast cancer treatment,Therapeutic Resistance,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,Hormone receptor-positive,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
6459,KP15,38943828,CDK4/6 inhibitors#block#phosphorylation of tumor suppressor Rb,Mechanism of Action,"CDK4,CDK6,RB1",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2557,KP15,28706010,FDA#approved#CDK4/6 inhibitors for HR-positive metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,Hormone receptor-positive,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4343,KP15,28706010,Abemaciclib#received#Breakthrough Therapy designation from FDA,Drug Development,"CDK4,CDK6",-,Breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5837,KP15,28706010,Modern CDK inhibitors#have changed#treatment paradigm for metastatic HR-positive breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR-positive breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
7016,KP15,34573335,PROTAC YX-2-107#degrades#CDK6 by recruiting Cereblon ubiquitin ligase,Drug Development,CDK6,-,Ph+ ALL,PROTAC YX-2-107,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.3,-,线粒体通路调控
4739,KP15,34573335,CDK6-selective PROTACs#exploit#CDK6 dependence of Ph+ ALL cells,Drug Development,CDK6,-,Ph+ ALL,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3122,KP15,29236235,Cyclin D/CDK4/6 complex inhibitors#are proven effective in#combination with endocrine therapy,Combination Optimization,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
2093,KP15,29236235,Combination therapeutics#are optimized for#ER-positive breast cancer,Combination Optimization,-,-,ER-positive breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
4931,KP15,29236235,Antiestrogen agents combined with CDK4/6 inhibitors#are reviewed in#ER-positive breast cancer,Combination Optimization,"CDK4,CDK6",-,ER-positive breast cancer,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
7576,KP15,29236235,CDK4/6 inhibitors combined with endocrine therapy#increase#toxicity and financial burden,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.3,-,剂量调整
614,KP15,28042706,CDK4/6 inhibitors#are predicted to be ineffective in#HPV-induced SCCs,Mechanisms of Resistance,"CDK4,CDK6",-,SCCs,-,Cell cycle pathway,-,-,Low levels,-,-,-,Inference,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
7754,KP15,34654798,CDK4/6 inhibitors#are tested as#therapeutic strategy in combination with other drugs,Combination Optimization,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5520,KP15,34654798,Identifying sensitive patients and overcoming resistance to CDK4/6 inhibitors#represent#open challenges,Therapeutic Resistance,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.2,2.5.2.4,-,生物标志物指导
259,KP15,34654798,p27(kip1) expression#inversely correlates with#Palbociclib response,Markers,-,-,-,Palbociclib,-,-,-,Variable,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,-,Ki67指数
354,KP15,34654798,p27(kip1)#could serve as#biomarker to stratify patients for CDK4/6 inhibition,Markers,-,-,Colorectal cancer,"Palbociclib, Src inhibitors",-,-,-,Variable,-,-,-,Inference,7,7.3,7.3.1,7.3.1.1,-,Ki67指数
2981,KP15,32426848,Resistance mechanisms#are described in#CDK4/6/cyclin D complex or pRb,Mechanisms of Resistance,"CDK4,CDK6,RB1",-,-,-,PI3K/mTOR,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
5971,KP15,30986809,HPV-negative SCCHN#is driven by#genetic aberrations in CDK4 and CDK6 activation,Cancer Pathways,"CDK4,CDK6",-,HPV-negative SCCHN,-,Cell cycle pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
4424,KP15,30986809,CDK4/6 inhibitors#demonstrate#cytostatic activity in HPV-negative SCCHN,Therapeutic Response,"CDK4,CDK6",-,SCCHN,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3687,KP15,30986809,Combination with EGFR inhibitors or PI3K/mTOR inhibitors#shows#promising preclinical efficacy,Combination Optimization,"CDK4,CDK6",-,SCCHN,"EGFR inhibitors, PI3K/mTOR inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7250,KP15,30986809,Palbociclib or Ribociclib in combination with cetuximab#is well tolerated in#Phase I clinical trials,Clinical Trial Data,"CDK4,CDK6",-,SCCHN,"Palbociclib, Ribociclib, Cetuximab",-,-,-,-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.1,-,早期随访
7096,KP15,30986809,Molecular profile#is required to predict#CDK4/6 inhibitor activity,Biomarker Analysis,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,RB1突变
3668,KP15,26149830,Both inhibitors#are substrates for#xenobiotic efflux transporters P-glycoprotein and breast cancer resistant protein,Drug Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.6,3.6.1,3.6.1.1,-,纳米载体设计
6638,KP15,26149830,Abemaciclib#crosses#the blood-brain barrier,Drug Development,"CDK4,CDK6",-,-,"Abemaciclib, Palbociclib",-,-,-,-,-,-,-,Fact,3,3.6,3.6.3,3.6.3.4,-,血脑屏障穿透
7801,KP15,26149830,CDK4 and CDK6 inhibitors#reach#unbound brain levels in rodents,Drug Development,"CDK4,CDK6",-,-,"Abemaciclib, Palbociclib",-,-,-,-,-,-,-,Fact,3,3.6,3.6.3,3.6.3.4,-,血脑屏障穿透
4698,KP15,31448056,CDK6#is overexpressed in#MCF7-C6 cells,Expression Patterns,CDK6,MCF7-C6 cells,-,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,Cyclin D1表达
4981,KP15,24369047,Cyclin D-CDK4/6-Rb pathway#governs#the cell cycle restriction point,Cell Cycle Control,"CDK4,CDK6",Rb-positive cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7764,KP15,24369047,Cyclin D-CDK4/6-Rb pathway#is frequently altered in#breast cancer,Cancer Association,"CDK4,CDK6",Rb-positive cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
1594,KP15,24369047,Palbociclib#inhibits#proliferation of Rb-positive cancer cell lines,Drug Development,"CDK4,CDK6",Rb-positive cancer cells,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3096,KP15,24369047,Palbociclib#inhibits#xenograft models,Preclinical Models,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7083,KP15,24369047,Combination of palbociclib with endocrine agents#is promising for#treatment,Combination Optimization,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Inference,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
7407,KP15,24369047,Combinations with HER2- and PI3K-inhibitors#target#mitogenic signaling pathways,Combination Optimization,"CDK4,CDK6",-,-,"HER2-inhibitors, PI3K-inhibitors",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
3957,KP15,38302240,CDK4/6 inhibitors#induce#cytostatic effects leading to cell cycle arrest,Cell Cycle Control,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6342,KP15,38302240,CDK4/6 inhibitors#induce#a state of cellular senescence,Cell Cycle Control,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
6415,KP15,38302240,Senescence#is associated with#metabolic modifications and SASP,Metabolic Integration,"CDK4,CDK6",Cancer cells,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.3,-,代谢重编程
5205,KP15,38302240,SASP#can promote or limit#antitumor immunity,Immune Cell Functions,"CDK4,CDK6",Cancer cells,-,-,-,-,-,-,-,-,-,Fact,3,3.3,3.3.1,3.3.1.4,-,免疫抑制缓解
2057,KP15,38302240,Anti-cancer effects of CDK4/6 inhibitors#depend on#promotion of antitumor immune responses,Immune Cell Functions,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,3,3.3,3.3.1,3.3.1.4,-,免疫抑制缓解
6716,KP15,38302240,Assessing cell cycle arrest#is key for#investigating efficacy of CDK4/6 inhibitors,Experimental Methods,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
625,KP15,28349562,Palbociclib#was tested on#endometrial carcinoma xenografts,Preclinical Models,"CDK4,CDK6",Endometrial cancer cells,Endometrial carcinoma,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6640,KP15,28349562,Cyclin D-CDK4/6 activity#plays a role in#development of PTEN-deficient endometrial malignancies,Cancer Pathways,"CDK4,CDK6",PTEN-deficient cells,Endometrial malignancies,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
40,KP15,25776104,Fucoidan#affects#AMPK and downstream molecules in HLF cells,Metabolic Integration,AMPK,HLF cells,Hepatocellular carcinoma,Fucoidan,AMPK,-,-,-,-,-,-,Fact,4,4.1,4.1.2,4.1.2.1,-,氧化磷酸化改变
1862,KP15,25776104,Fucoidan#modulated expression of#CDK4 and CDK6 in HLF cells,Regulation,"CDK4,CDK6",HLF cells,Hepatocellular carcinoma,Fucoidan,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
1434,KP15,25776104,Fucoidan#suppressed#HLF cell proliferation in a dose- and time-dependent manner,Drug Development,-,HLF cells,Hepatocellular carcinoma,Fucoidan,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
749,KP15,25776104,Fucoidan#induced#ACC phosphorylation on Ser79,Post-translational Modifications,ACC,-,Hepatocellular carcinoma,Fucoidan,-,-,-,-,-,-,-,Fact,4,4.1,4.1.3,4.1.3.3,-,翻译后修饰
257,KP15,25776104,Fucoidan#suppressed#HLF cell proliferation,Function triples,-,HLF cells,-,Fucoidan,AMPK,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
803,KP15,25776104,Fucoidan#activated#AMPK phosphorylation,Mechanism of Action,-,HLF cells,-,Fucoidan,AMPK,-,-,Upregulated,-,-,-,Fact,4,4.2,4.2.2,4.2.2.3,-,下游效应器激活
2607,KP15,25776104,Fucoidan#inhibits#proliferation through AMPK-associated suppression of fatty acid synthesis and G1/S transition,Mechanism of Action,-,HLF cells,-,Fucoidan,AMPK,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
1530,KP15,29109039,"PL#altered#expression of CDK4, CDK6, cyclin D1, and Rb",Expression Patterns,"CDK4,CDK6,RB1",-,-,PL,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
3423,KP15,29109039,"PL#altered#expression of ERK1/2, Akt, p38, and NF-κB",Expression Patterns,"ERK1,ERK2,AKT1,MAPK14,NFKB1",-,-,PL,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
1064,KP15,29109039,PL treatment#increased#number of cells in G1 phase,Cell Cycle Control,-,-,-,PL,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
873,KP15,29109039,PL#suppressed#phosphorylation of Akt,Mechanism of Action,AKT1,-,-,PL,-,-,-,Downregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.2,-,反馈调节
6200,KP15,29109039,PL#increased#ERK1/2 phosphorylation,Mechanism of Action,"ERK1,ERK2",-,-,PL,-,-,-,Upregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
6006,KP15,27099147,Targeting two critical signaling nodes in leukemogenesis#could represent#a therapeutic breakthrough,Therapeutic Development,-,-,Leukemogenesis,FLT3 inhibitors,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
2218,KP15,20534551,CDK6#is identified as#a GBM oncogene,Cancer Association,CDK6,-,GBM,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.2,-,Cyclin D-CDK6复合物
4606,KP15,20534551,CDK6#is required for#proliferation and viability in GBM cell lines and tumors,Cancer Association,CDK6,GBM cell lines,GBM,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
4403,KP15,20534551,Small molecule targeting CDK4 and CDK6#determined#response to CDK4/6 inhibitor therapy,Drug Development,"CDK4,CDK6",-,Retinoblastoma,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7786,KP15,35813283,Abemaciclib#preferentially inhibited#CDK4 kinase activity versus CDK6,Mechanism of Action,"CDK4,CDK6",-,Breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3675,KP15,35813283,Abemaciclib#inhibited#cell proliferation in BC cell lines,Mechanism of Action,-,BC cell lines,Breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6781,KP15,35813283,Abemaciclib#had higher potency than#Palbociclib or Ribociclib,Drug Development,-,-,Breast cancer,"Abemaciclib,Palbociclib,Ribociclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4516,KP15,32145796,CDK4/6 inhibitors#were developed and approved for#hormone receptor-positive and HER2-negative metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5705,KP15,32145796,Emerging data#shed light on#resistance mechanisms associated with CDK4/6 inhibitors,Mechanisms of Resistance,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
6592,KP15,27087139,Cyclin and CDK complexes#regulate#cell cycle progression,Cell Cycle Control,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
1788,KP15,27087139,Inhibition of CDKs#represents#an important target for novel agents,Drug Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2349,KP15,27087139,Ribociclib and Abemaciclib#are under investigation as#monotherapy and in combination therapies for MBC,Drug Development,"CDK4,CDK6",-,Metastatic breast cancer,"Ribociclib,Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
200,KP15,34588615,CDK4/6 inhibitors#showed#antitumor activity in preclinical models of MPM,Preclinical Models,"CDK4,CDK6",-,MPM,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6231,KP15,34588615,CDK4 or CDK6 overexpression#is associated with#shorter overall survival in MPM patients,Cancer Association,"CDK4,CDK6",-,MPM,-,-,-,Upregulated,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,7.2.1.2.1,PI3K/AKT活性
2570,KP15,34588615,CDK4/6 inhibitors#induce#G1 cell cycle arrest,Cell Cycle Control,"CDK4,CDK6",-,MPM,-,"Interferon signaling pathway, tumor antigen presentation process",-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6914,KP15,34588615,CDK4/6 inhibitors#increase#cell senescence,Cell Cycle Control,"CDK4,CDK6",-,MPM,-,"Interferon signaling pathway, tumor antigen presentation process",-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
2949,KP15,34145036,CDK6#expression is elevated in#hematopoietic progenitor cells,Expression Patterns,CDK6,hematopoietic progenitor cells,"MPN, myelofibrosis",-,-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
1916,KP15,34145036,palbociclib and ruxolitinib#normalize#peripheral blood leukocyte counts,Therapeutic Response,-,-,myelofibrosis,"palbociclib, ruxolitinib",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.3,-,疗效监测
3808,KP15,34145036,palbociclib and ruxolitinib#reduce#spleen size,Therapeutic Response,-,-,myelofibrosis,"palbociclib, ruxolitinib",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.3,-,疗效监测
4229,KP15,34145036,palbociclib and ruxolitinib#abrogate#bone marrow fibrosis,Therapeutic Response,-,bone marrow cells,myelofibrosis,"palbociclib, ruxolitinib",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.3,-,疗效监测
3373,KP15,34145036,"palbociclib or CDK6 depletion#inhibits#Aurora kinase, NF-κB, and TGF-β signaling pathways",Regulation,CDK6,-,myelofibrosis,palbociclib,"Aurora kinase, NF-κB, TGF-β",-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
6987,KP15,34145036,palbociclib or CDK6 depletion#attenuates#fibrotic markers in bone marrow,Biomarker Analysis,CDK6,bone marrow cells,myelofibrosis,palbociclib,-,fibrotic markers,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.2,-,细胞死亡标志物
5585,KP15,28649895,Palbociclib#is introduced for#ER+ HER2- metastatic breast cancer,Drug Development,"CDK4,CDK6",-,ER+ HER2- metastatic breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
6424,KP15,28649895,Palbociclib#selectively inhibits#CDK4 and CDK6,Mechanism of Action,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5974,KP15,28649895,Palbociclib#enhances#antiproliferative effects of letrozole and fulvestrant,Combination Optimization,"CDK4,CDK6",-,-,"Palbociclib, letrozole, fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
6694,KP15,28649895,Palbociclib#doubles#treatment efficacy of letrozole and fulvestrant,Therapeutic Response,"CDK4,CDK6",-,-,"Palbociclib, letrozole, fulvestrant",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.3,-,疗效监测
502,KP15,28649895,CDK4/6 inhibitors#influence#treatment landscape in ER+ HER2- MBC,Clinical Implementation,"CDK4,CDK6",-,ER+ HER2- metastatic breast cancer,-,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5980,KP15,28395543,Cyclin D-CDK4/6-Rb pathway#is hyperactivated in#HR+ breast cancer,Cancer Pathways,"CDK4,CDK6,RB1",-,HR+ breast cancer,-,Cyclin D-CDK4/6-Rb pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
4798,KP15,28395543,Ribociclib#induces#G1 arrest in pRb-positive cancer cells,Cell Cycle Control,"CDK4,CDK6",pRb-positive cancer cells,-,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1706,KP15,28395543,Ribociclib#improves#progression-free survival in advanced HR+ breast cancer,Therapeutic Response,"CDK4,CDK6",-,advanced HR+ breast cancer,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
6468,KP15,30360668,Dysregulation of CDK-Rb pathway#causes#aberrant cellular proliferation in cancers,Cancer Pathways,"CDK4,CDK6,RB1",-,cancers,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
2234,KP15,30360668,"Palbociclib, ribociclib, and abemaciclib#are approved for#HR+ HER2- MBC",Drug Development,"CDK4,CDK6",-,HR+ HER2- metastatic breast cancer,"Palbociclib, ribociclib, abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3816,KP15,30401694,CDK4/6 inhibitors#offer#comparable therapeutic benefits for breast cancer,Therapeutic Response,"CDK4,CDK6",-,breast cancer,"Palbociclib, ribociclib, abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1532,KP15,30401694,Neutropenia#is observed in#patients treated with palbociclib and ribociclib,Safety Monitoring,-,-,neutropenia,"Palbociclib, ribociclib",-,neutropenia,patients,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
6159,KP15,30401694,Diarrhea#is observed in#patients treated with abemaciclib,Safety Monitoring,-,-,diarrhea,Abemaciclib,-,diarrhea,patients,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,8.4.1.2.1,胃肠道反应
6169,KP15,30401694,"Palbociclib, ribociclib, and abemaciclib#affect#the gastrointestinal tract in rats",Preclinical Models,"CDK4,CDK6",gastrointestinal tract,-,"Palbociclib, ribociclib, abemaciclib",-,-,rats,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,8.4.1.2.1,胃肠道反应
7688,KP15,30401694,Abemaciclib#causes#fecal alterations,Drug Development,"CDK4,CDK6",-,-,abemaciclib,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,8.4.1.2.1,胃肠道反应
5519,KP15,30401694,Morphologic changes in the intestine#are characterized by#mucosal inflammation,Symptoms,-,-,-,-,-,mucosal inflammation,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,8.4.1.2.1,胃肠道反应
3730,KP15,30401694,Wnt pathway#activates#downstream transcriptional regulation,Signaling Networks,-,-,-,-,Wnt,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
7937,KP15,30401694,Intestinal toxicity#is unique to#abemaciclib-treated rats,Therapeutic Response,-,-,-,abemaciclib,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,8.4.1.2.1,胃肠道反应
5101,KP15,30401694,Abemaciclib#targets#secondary pharmacologic targets,Mechanism of Action,"CDK4,CDK6",-,-,abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
3817,KP15,39153252,CDK4/6 inhibitors#enhance#sensitivity to targeted cell death inducers,Therapeutic Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
59,KP15,39153252,SP1 or SLC7A11 inhibition#enhances#sensitivity to CDK4/6 inhibitors,Mechanisms of Resistance,"SP1,SLC7A11",luminal A breast cancer cells,Luminal A breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
3049,KP15,39153252,SP1 or SLC7A11 inhibition#synergistically inhibits#luminal A breast cancer growth,Therapeutic Response,"SP1,SLC7A11",luminal A breast cancer cells,Luminal A breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
33,KP15,30130984,CDK4/6#regulate#transition from G0/G1-phase to S-phase of the cell cycle,Cell Cycle Control,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
5827,KP15,30130984,CDK4/6#drive#proliferation in HR-positive breast cancer,Cancer Pathways,"CDK4,CDK6",-,HR-positive breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.1,-,增殖信号整合
4797,KP15,30130984,Palbociclib#is approved for#HR-positive/HER2-negative breast cancer treatment,Clinical Implementation,"CDK4,CDK6",-,HR-positive/HER2-negative breast cancer,palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
6734,KP15,30130984,Clinical trials#explore#combinations of palbociclib with targeted agents or immunotherapy,Clinical Trial Data,"CDK4,CDK6",-,Breast cancer,palbociclib,-,-,-,-,-,-,-,Fact,8,8.2,-,-,-,联合用药方案
1568,KP15,36548336,Ribociclib#combines with#AR inhibitor enzalutamide in AR-positive TNBC,Combination Optimization,"CDK4,CDK6",-,AR-positive TNBC,"ribociclib, enzalutamide",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,-,-,靶向药物联合
1600,KP15,36548336,Ribociclib#inhibits#TNBC cells,Therapeutic Response,"CDK4,CDK6",-,Triple-negative breast cancer,ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,细胞周期阻滞
3925,KP15,36548336,Enzalutamide therapy#increases#cytostatic impact of ribociclib in AR+ TNBC cells,Combination Optimization,"CDK4,CDK6",-,AR-positive TNBC,"enzalutamide, ribociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,-,-,靶向药物联合
1675,KP15,36548336,Dual inhibition of AR and CDK4/6#demonstrates#synergy in AR+ TNBC model,Combination Optimization,"CDK4,CDK6",-,AR-positive TNBC,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,-,-,靶向药物联合
3961,KP15,32297248,Abemaciclib-resistant cell lines#show#low sensitivity to other CDK4/6 inhibitors,Mechanisms of Resistance,"CDK4,CDK6",-,-,abemaciclib,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,-,-,多药耐药
3751,KP15,32297248,Abemaciclib-resistant cell lines#maintain#sensitivity to PI3K and mTOR inhibitors,Mechanisms of Resistance,"CDK4,CDK6",resistant cells,-,"PI3K inhibitor, mTOR inhibitor",-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,-,-,信号通路激活
5593,KP15,32297248,CDK4/6 inhibitor-resistant cells#acquire#cross-resistance to other CDK4/6 inhibitors,Mechanisms of Resistance,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,-,-,多药耐药
3175,KP15,32297248,PI3K/Akt/mTOR inhibitor therapy#might serve as#optimal treatment for resistant breast cancers,Therapeutic Development,"CDK4,CDK6",-,Resistant breast cancer,PI3K/Akt/mTOR inhibitors,-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,-,-,联合用药方案
2207,KP15,32068118,CDK4/6 inhibitors#transform#treatment paradigm of ER-positive breast cancer,Clinical Implementation,"CDK4,CDK6",-,ER-positive breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,-,-,适应症选择
3919,KP15,32068118,CDK4/6 inhibitors#improve#survival outcomes in ER-positive breast cancer,Therapeutic Response,"CDK4,CDK6",-,ER-positive breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,细胞周期阻滞
4335,KP15,33477469,CDK4/6 inhibitors#improve#outcome in HR+ advanced breast cancer,Therapeutic Response,"CDK4,CDK6",-,Advanced breast cancer,"Palbociclib,Ribociclib,Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,细胞周期阻滞
2526,KP15,33477469,CDK4/6 inhibitors#target#cell-cycle machinery,Mechanism of Action,"CDK4,CDK6",-,-,"Palbociclib,Ribociclib,Abemaciclib",Cell-cycle machinery,-,-,-,-,-,-,Fact,1,1.1,1.1.2,-,-,周期蛋白复合物形成
806,KP15,29243224,CDK4/6 inhibitors#show#efficacy as single agents and in combination,Therapeutic Response,"CDK4,CDK6",-,BRAF mutant cancer,"BRAF inhibitors, MEK inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,-,-,靶向药物联合策略
1219,KP15,29243224,CDK4/6 inhibitors#are effective in#BRAF inhibitor-tolerant or resistant cell lines,Mechanisms of Resistance,"CDK4,CDK6",-,BRAF mutant cancer,BRAF inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
7928,KP15,29243224,CDK4/6 inhibitors#enhance#in vivo efficacy in combination with BRAF inhibitors,Combination Therapies,"CDK4,CDK6",-,BRAF mutant cancer,BRAF inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,-,-,靶向药物联合策略
950,KP15,29243224,Dual targeting of CDK4/6 and BRAF#enables#tumor cells to evade resistance,Mechanisms of Resistance,"CDK4,CDK6,BRAF",-,Cancer,BRAF inhibitors,-,-,-,-,-,-,-,Inference,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
6962,KP15,29243224,Dual targeting of CDK4/6 and BRAF#is required for#sustained tumor regression,Therapeutic Response,"CDK4,CDK6,BRAF",-,Cancer,BRAF inhibitors,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5549,KP15,26896604,CDK4/6 inhibitors#inhibit#proliferation of Rb-positive tumor cells,Mechanism of Action,"CDK4,CDK6",-,Rb-positive tumors,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3944,KP15,26896604,CDK4/6 inhibitors#demonstrate#dose-dependent growth inhibition in ER+ breast cancer models,Therapeutic Response,"CDK4,CDK6",-,ER+ breast cancer,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
653,KP15,29496664,CDK4/6 inhibitors#represent#a therapeutic option in melanoma,Cancer Association,"CDK4,CDK6",-,Melanoma,"BRAF inhibitors, MEK inhibitors",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4937,KP15,29496664,Continuous dosing of CDK4/6 inhibitors#elicits#toxicities in patients,Safety Monitoring,"CDK4,CDK6",-,-,-,-,Toxicities,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
3916,KP15,31369120,CDK4/6#control#entry into the cell cycle,Cell Cycle Control,"CDK4,CDK6",-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
6181,KP15,31369120,CDK4/6 inhibitors#are available for#women with HR+/HER2- advanced breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
7642,KP15,31369120,CDK4/6 inhibitors#are used with#an aromatase inhibitor as initial therapy in postmenopausal women,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,Aromatase inhibitors,-,-,Postmenopausal women,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,-,患者选择
2904,KP15,31369120,CDK4/6 inhibitors#are used with#fulvestrant in women with disease progression during endocrine therapy,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,Fulvestrant,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,-,患者选择
992,KP15,31369120,Abemaciclib#is indicated for#monotherapy in women with progression after endocrine therapy and prior chemotherapy,Clinical Implementation,CDK6,-,HR+/HER2- advanced breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,-,患者选择
7427,KP15,31369120,CDK4/6 inhibitors#increase#progression-free survival with AI in controlled trials,Therapeutic Response,"CDK4,CDK6",-,-,Aromatase inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1692,KP15,31369120,Neutropenia#is#a dose-limiting adverse effect of palbociclib and ribociclib,Safety Monitoring,"CDK4,CDK6",-,-,"Palbociclib, Ribociclib",-,Neutropenia,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,血液学毒性
4658,KP15,31369120,Fatigue#is more common with#palbociclib and abemaciclib use,Safety Monitoring,"CDK4,CDK6",-,-,"Palbociclib, Abemaciclib",-,Fatigue,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
1988,KP15,31369120,Gastrointestinal effects#are more common with#abemaciclib use,Safety Monitoring,CDK6,-,-,Abemaciclib,-,Gastrointestinal effects,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
1192,KP15,31369120,CDK4/6 inhibitors#demonstrate#clinical activity in HR+/HER2- advanced or metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,HR+/HER2- advanced or metastatic breast cancer,"Aromatase inhibitors, Fulvestrant",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1910,KP15,33004541,Trilaciclib#preserves#hematopoietic stem and progenitor cells during chemotherapy,Mechanism of Action,"CDK4,CDK6","Hematopoietic stem cells, progenitor cells",-,Trilaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3486,KP15,33004541,Trilaciclib#preserves#immune system function during chemotherapy,Mechanism of Action,"CDK4,CDK6",-,-,Trilaciclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
673,KP15,22728232,Methyl nomilinate#induces#cytotoxicity in human colon cancer cells,Mechanism of Action,-,Colon cancer cells,Colon cancer,Methyl nomilinate,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
3739,KP15,22728232,Methyl nomilinate#inhibits#cell metabolic activity in vitro,Mechanism of Action,-,-,-,Methyl nomilinate,-,-,-,-,-,-,-,Fact,4,4.1,4.1.3,4.1.3.1,-,关键酶活性调节
5798,KP15,38788968,Breast cancer cells#develop#resistance to fulvestrant and abemaciclib,Mechanisms of Resistance,"CDK4,CDK6","MCF7,T47D",Breast cancer,"Fulvestrant,Abemaciclib",-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
3190,KP15,38788968,"RNA-seq-based Gene Set Enrichment Analysis (GSEA)#revealed#hyper-activation of EGFR, HER2, and AKT signaling",Expression Patterns,"EGFR, ERBB2, AKT1","MCF7, T47D",-,-,"EGFR, HER2, AKT",-,-,upregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
6491,KP15,38788968,Patient-derived organoids (PDOs) from individuals with ER+ mBC#exhibited#up-regulation of EGFR and HER2 pathways,Pathway & Network Categories,"EGFR, ERBB2",-,Metastatic breast cancer (mBC),Palbociclib,"EGFR, HER2",-,ER+ patients,upregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
1691,KP15,39449657,Treating a sensitive luminal BC PDX with the CDK4/6i palbociclib#revealed#tumors might eventually regrow under drug treatment,Therapeutic Resistance Categories,"CDK4, CDK6",-,Luminal breast cancer,Palbociclib,-,-,-,-,-,-,-,Inference,2,2.2,2.2.2,2.2.2.1,-,G1/S检查点失控
1503,KP15,39449657,"RNA sequencing#unveiled#significant enrichment in proliferation pathways, such as MTORC1, E2F and MYC",Pathway & Network Categories,"MTOR, E2F, MYC",-,-,CDK4/6 inhibitors,"MTORC1, E2F, MYC",-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
271,KP15,33072436,High concentrations of 9za#induced#cell apoptosis,Molecular & Cellular Categories,-,-,-,9za,-,-,-,-,-,-,-,Fact,3,3.4,3.4.2,3.4.2.3,-,凋亡执行
5568,KP15,33072436,9za#was verified as#a dual MEK/PDK1 inhibitor,Drug Development,"MAP2K1, PDPK1",-,-,9za,"MEK, PDK1",-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6850,KP15,26369631,Combination therapy#cotargets#MEK and CDK4/6,Combination Optimization,"MAP2K1, CDK4, CDK6",-,Colorectal cancer,-,MEK,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6321,KP15,26369631,Cotargeting MEK and CDK4/6#proves#efficacious in KRAS-mutant colorectal cancers,Therapeutic Development Categories,"MAP2K1, CDK4, CDK6, KRAS",-,KRAS-mutant colorectal cancer,-,MEK,-,-,upregulated,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3493,KP15,26369631,"RB(+) patient-derived colorectal xenograft models#are#genomically diverse with respect to KRAS, BRAF, and PIK3CA mutational status",Preclinical Models,"KRAS, BRAF, PIK3CA",-,Colorectal cancer,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.2,-,热点区域
4859,KP15,26369631,Synergy#was observed in#HCT-116 cells treated with trametinib and palbociclib,Combination Therapies,"MAP2K1, CDK4, CDK6",HCT-116,-,"Trametinib, Palbociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
2072,KP15,26369631,Combination therapy#showed#a higher degree of antitumor activity compared to single-agent treatment,Combination Optimization,-,-,-,"Trametinib, Palbociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
2805,KP15,26369631,Combination of trametinib and palbociclib#resulted in#objective responses in all KRAS(mt) models tested,Therapeutic Development Categories,"MAP2K1, CDK4, CDK6, KRAS",-,KRAS-mutant colorectal cancer,"Trametinib, Palbociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6408,KP15,29669860,Palbociclib#is#a CDK4/6 inhibitor approved for metastatic estrogen receptor-positive breast cancer,Drug Development,"CDK4, CDK6",-,Metastatic estrogen receptor-positive breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5405,KP15,29669860,Proteasome inhibitors#counteract#cellular senescence,Molecular & Cellular Categories,-,-,-,Proteasome inhibitors,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.2,-,细胞衰老诱导
2669,KP15,29669860,"Loss of ECM29#activates#the proteasome, blocks cell proliferation, and induces a senescence-like phenotype",Molecular & Cellular Categories,-,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.2,-,细胞衰老诱导
3201,KP15,34388663,Nerolidol#displayed#anti-UF activity in a leiomyoma cell model,Therapeutic Development Categories,-,Leiomyoma cells,Uterine fibroids (UF),Nerolidol,"ATM, AKT",-,-,-,-,-,-,Fact,3,3.4,3.4.2,3.4.2.3,-,凋亡执行
3271,KP15,30692100,[(18)F]FLT and [(18)F]ISO-1 PET#evaluated#tumor-proliferation after combined CDK4/6 inhibitor and endocrine therapy,Biomarker Analysis,"CDK4, CDK6",-,Breast cancer,"[(18)F]FLT, [(18)F]ISO-1",-,-,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,7.3.1.1.4,细胞周期分布
3200,KP15,30692100,[(18)F]FLT and [(18)F]ISO-1 PET#suggest#complementary roles in evaluating tumor-proliferation,Biomarker Analysis,-,-,Breast cancer,"[(18)F]FLT, [(18)F]ISO-1",-,-,-,-,-,-,-,Inference,7,7.3,7.3.1,7.3.1.1,7.3.1.1.4,细胞周期分布
2243,KP15,25991817,Inhibition of ESR1 and CDK4/6#increased#progression-free survival in advanced patients,Clinical Implementation,"ESR1, CDK4, CDK6",-,Endocrine therapy-resistant ESR1(+) breast cancer,"SERD, SSH-CDK4/6 inhibitors",-,-,Advanced patients,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
1684,KP15,39617889,absence of actionable genetic alterations#challenges#generation of molecular-driven treatment concepts,Clinical Implementation,-,-,ATRT,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.4,-,乘客突变
2332,KP15,39617889,functional genomics approach#identifies#genetic dependencies in ATRT,Preclinical Models,-,ATRT cells,ATRT,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.3,-,驱动突变
3992,KP15,39617889,small molecule drug library#shows#preferential activity in ATRT cells,Drug Development,-,ATRT cells,ATRT,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
7599,KP15,39617889,G1 phase cell cycle regulators#modulate#response to CDK4/6 inhibition in ATRT cells,Cell Cycle Control,"CDK4,CDK6",ATRT cells,ATRT,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
5906,KP15,32629666,tumors at thoracic vertebrae T1 and T3#shrink#from 35.2 and 12.0 μm to 28.1 and 9.9 μm after adjuvant therapy,Therapeutic Response,-,thoracic vertebrae tumors,MBC,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3902,KP15,32629666,AC#ad shows#better anti-tumor efficacy on active tumor cells than PAL plus FUL,Therapeutic Response,-,circulating tumor cells,MBC,"AC,PAL,FUL",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4571,KP15,32629666,AC#is#effective complementary medicine for HR-positive/HER2-negative MBC,Therapeutic Development,-,-,HR-positive/HER2-negative MBC,AC,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
7698,KP15,32629666,elevation of carcinoma antigen 15-3 and lactate dehydrogenase levels#indicates#potent efficacy of treatment resulting in massive tumor cell death,Monitoring Markers,-,-,Carcinoma,-,-,-,-,upregulated,"carcinoma antigen 15-3, lactate dehydrogenase",-,-,Fact,7,7.3,7.3.1,7.3.1.2,7.3.1.2.1,凋亡标志物
902,KP15,26633733,palbociclib#is#a potent and specific oral CDK4/6 inhibitor,Drug Development,"CDK4,CDK6",-,-,palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3422,KP15,26633733,palbociclib#has#activity in retinoblastoma protein-expressing tumors,Cancer Pathways,"CDK4,CDK6",-,retinoblastoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
6779,KP15,26633733,palbociclib#demonstrates#efficacy for multiple cancers alone and in combination with endocrine therapy,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,palbociclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
479,KP15,29061795,combination of berberine and evodiamine#shows#synergistic effects against human breast cancer MCF-7 cells,Combination Optimization,-,MCF-7 cells,Breast cancer,"berberine, evodiamine",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4822,KP15,31235998,miR-34a overexpression#enhances#inhibitory effect of doxorubicin on HepG2 cells,Therapeutic Response,-,HepG2 cells,HCC,doxorubicin,-,-,-,upregulated,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6532,KP15,31235998,Hepatocellular carcinoma (HCC)#is#the third leading cause of death from malignant tumors worldwide,Disease Statistics,-,-,HCC,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.3,-,驱动突变
3732,KP15,31235998,prognosis of HCC#remains#poor,Clinical Correlation,-,-,HCC,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.4,-,乘客突变
2770,KP15,31235998,specific mechanisms of progression of HCC#are#partially established,Mechanism of Action,-,-,HCC,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.3,-,驱动突变
1459,KP15,31235998,"expression levels of p-p53, SIRT1, cyclin D1, CDK4, CDK6, BCL-2, MDR1/P-gp, and AXL#are detected by#Western blotting",Expression Patterns,"TP53,SIRT1,CDK4,CDK6,BCL2,ABCB1,AXL",-,HCC,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.1,1.5.1.1,-,组蛋白修饰
6295,KP15,31235998,growth of HepG2 cells#is inhibited by#upregulation of miR-34a,Therapeutic Response,-,HepG2 cells,HCC,-,-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
1031,KP15,31235998,doxorubicin#induces#G1 phase arrest in HepG2 cells,Cell Cycle Control,-,HepG2 cells,HCC,doxorubicin,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2959,KP15,31235998,"miR-34a combined with doxorubicin#causes#changes in expression levels of p-p53, SIRT1, cyclin D1, CDK4, CDK6, BCL-2, MDR1/P-gp, and AXL proteins",Combination Optimization,"TP53,SIRT1,CDK4,CDK6,BCL2,ABCB1,AXL",-,HCC,doxorubicin,-,-,-,upregulated,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
785,KP15,24469340,LKB1/AMPK signaling#induces#G1 arrest in cells with endogenous LKB1 expression,Cell Cycle Control,STK11,-,-,-,AMPK,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
3927,KP15,24469340,LKB1#plays a critical role in#cell proliferation,Mechanism of Action,LKB1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
3106,KP15,24469340,LKB1 inactivation#has been linked to#tumorigenesis in various cancer types,Cancer Association,LKB1,-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.2,-,衰老程序激活
2127,KP15,24469340,Current understanding of LKB1 function#is largely restricted to#LKB1-deficient cancer cells,Experimental & Technical Categories,LKB1,-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.1,-,存活信号调控
6918,KP15,24469340,LKB1 knockdown#accelerates#cell cycle progression through the G1/S checkpoint,Cell Cycle Control,LKB1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
4480,KP15,24469340,LKB1 knockdown#inhibits#p53 and p16 pathways,Regulation,"LKB1,TP53,CDKN2A",-,-,-,"p53, p16",-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
6032,KP15,24469340,Exogenous LKB1#activates#LKB1/AMPK signaling,Signaling Networks,LKB1,-,-,-,AMPK,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
3872,KP15,24469340,Exogenous LKB1#arrests#the cell cycle at the G1 phase,Cell Cycle Control,LKB1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
1511,KP15,24469340,Exogenous activation of LKB1/AMPK signaling#inhibits#G1/S cell cycle transition,Cell Cycle Control,LKB1,-,-,-,AMPK,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7483,KP15,24469340,Findings of the present study#provide#novel insights into the growth-inhibitory effects of LKB1,Mechanism of Action,LKB1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
6472,KP15,38781103,High PKMYT1 mRNA levels#associate with#resistance to ET and CDK4/6 inhibition,Mechanisms of Resistance,"PKMYT1,CDK4,CDK6",-,-,-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
6577,KP15,38781103,PKMYT1 inhibitor lunresertib (RP-6306)#reduces#viability of ET and palbociclib-resistant ER+ breast cancer cells,Drug Development,PKMYT1,-,ER+ breast cancer,"lunresertib (RP-6306), palbociclib",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
2135,KP15,38781103,Combination of RP-6306 with gemcitabine#synergistically reduces#viability of ET and palbociclib-resistant ER+ breast cancer cells,Combination Therapies,PKMYT1,-,ER+ breast cancer,"RP-6306, gemcitabine",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
2641,KP15,38781103,Combination of RP-6306 and gemcitabine#increases#DNA damage and apoptosis,Mechanism of Action,PKMYT1,-,-,"RP-6306, gemcitabine",-,-,-,-,-,-,-,Fact,1,1.3,1.3.3,1.3.3.3,-,细胞凋亡调控
961,KP15,38781103,"RP-6306 with low-dose gemcitabine#induces#greater tumor volume reduction in palbociclib-resistant, TP53 mutant PDX-derived organoids and PDXs",Therapeutic Response,"PKMYT1,TP53",-,Tumor,"RP-6306, gemcitabine",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1450,KP15,32259210,Osalmide and pterostilbene#induce#cytotoxicity and cell cycle arrest in diffuse large B-cell lymphoma cells,Drug Development,-,B-cell lymphoma,Diffuse large B-cell lymphoma,"osalmide, pterostilbene",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2682,KP15,32259210,DCZ0801 treatment#inhibits#cell viability in a dose- and time-dependent manner,Drug Development,-,-,-,DCZ0801,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2274,KP15,32259210,Intraperitoneal injection of DCZ0801#suppresses#tumor development in xenograft mouse models,Preclinical Models,-,-,Tumor,DCZ0801,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
263,KP15,28652278,Fulvestrant and goserelin with palbociclib#were assessed in#premenopausal women with advanced breast cancer,Clinical Trial Data,-,-,Advanced breast cancer,"palbociclib, fulvestrant, goserelin",-,-,Premenopausal women,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,8.2.1.2.4,时序优化
4441,KP15,28652278,Inclusion of premenopausal and postmenopausal women#facilitates access to#novel drugs for young women,Clinical Implementation,-,-,-,-,-,-,Premenopausal and postmenopausal women,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,8.1.1.3.4,耐受性评估
4063,KP15,28652278,PALOMA-3 study#included#premenopausal women in a trial investigating CDK4/6 inhibitors,Clinical Trial Data,"CDK4,CDK6",-,Endocrine-resistant breast cancer,-,-,-,Premenopausal women,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,8.1.1.3.1,生物标志物状态
764,KP15,28652278,Palbociclib plus fulvestrant and goserelin#almost doubled#median progression-free survival in pretreated premenopausal women,Therapeutic Response,-,-,Advanced breast cancer,"Palbociclib, Fulvestrant, Goserelin",-,-,Premenopausal women,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,8.2.1.2.4,时序优化
1198,KP15,28652278,The regimen#supports use in#premenopausal women with endocrine-resistant disease,Therapeutic Development,-,-,Endocrine-resistant disease,-,-,-,Premenopausal women,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.3,8.1.1.3.1,生物标志物状态
415,KP15,39026843,"Synergy#is associated with#increased DNA damage, interrupted cell-cycle checkpoints, and enhanced apoptotic cell death",Mechanism of Action,-,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
2088,KP15,39225211,Myrtleciclib#induces#cell death and apoptosis selectively in cancer cell lines,Drug Development,-,Cancer cell lines,-,Myrtleciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.3,-,线粒体通路调控
11,KP15,37434680,"CDK4/6 inhibitors#improve#prognosis of HR(+), HER2-negative advanced breast cancer when combined with endocrine therapy",Therapeutic Response,"CDK4,CDK6",-,Advanced breast cancer,Endocrine therapy,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
1371,KP15,38293701,CDK4/6 inhibitors#block#the G1 cell cycle via the cyclinD-CDK4/6-INK4-RB pathway,Cell Cycle Control,"CDK4,CDK6",-,Breast cancer,-,CyclinD-CDK4/6-INK4-RB,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
5115,KP15,38293701,"Palbociclib, abemaciclib, and ribociclib#are effective in#managing advanced HR(+) BC",Therapeutic Response,-,-,Advanced HR(+) breast cancer,"Palbociclib, Abemaciclib, Ribociclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3449,KP15,39593745,Abnormal activations of CDKs#drive#cell proliferation and tumorigenesis,Cancer Pathways,"CDK4,CDK6",-,Tumorigenesis,-,-,-,-,Upregulated,-,-,-,Inference,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
335,KP15,39376495,CDK4/6 inhibitors#selectively block#CDK4/6 regulators of the cell cycle,Mechanism of Action,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
6606,KP15,39376495,The analysis#examined#adverse effects of CDK4/6 inhibitors using the FAERS database,Biomarker Analysis,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.3,7.5.1.3.3,药物外排
3824,KP15,36876172,CDK4/6i treatment#supports#efficacy and safety for HR+/HER2- advanced breast cancer,Therapeutic Response,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5375,KP15,26726315,Dysregulation of cyclin D-CDK pathway#inhibits#senescence,Cell Cycle Control,"CDK4,CDK6",-,Cancer,-,Cyclin D-CDK pathway,-,-,-,-,-,-,Inference,1,1.1,1.1.3,1.1.3.2,-,细胞衰老诱导
2571,KP15,26726315,Dysregulation of cyclin D-CDK pathway#promotes#cellular proliferation,Cell Cycle Control,"CDK4,CDK6",-,Cancer,-,Cyclin D-CDK pathway,-,-,-,-,-,-,Inference,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
4338,KP15,26726315,"Three selective CDK4/6 inhibitors#are in development#(palbociclib, ribociclib, abemaciclib)",Drug Development,"CDK4,CDK6",-,-,"palbociclib, ribociclib, abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5526,KP15,39355786,Combination of abemaciclib and bazedoxifene#exerts#greater effect than monotherapy,Combination Therapies,"CDK4,CDK6",-,-,"abemaciclib, bazedoxifene",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
2141,KP15,29963233,ERα-mediated cell cycle progression#is requisite for#CDK4/6 inhibitor response,Mechanism of Action,"CDK4,CDK6",Breast cancer cells,HR+ breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
229,KP15,29963233,ER-cyclin D1-CDK4/6-RB pathway#is critical for#estrogen action on cell cycle,Pathway & Network Categories,"CDK4,CDK6,CCND1,RB1",-,Breast cancer,-,ER-cyclin D1-CDK4/6-RB pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
4164,KP15,29963233,CDK4/6 inhibitors#target#phosphorylation of RB tumor suppressor,Mechanism of Action,"CDK4,CDK6,RB1",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
3594,KP15,29963233,CDK4/6 inhibitors combined with endocrine therapies#improve#progression-free survival,Therapeutic Response,"CDK4,CDK6",-,ER+/HER2- breast cancer,"CDK4/6 inhibitors, endocrine therapies",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
5743,KP15,29963233,Palbociclib#was used on#estrogen-dependent PDX tumor model,Preclinical Models,"CDK4,CDK6",-,Hormone receptor-positive breast cancer,palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4960,KP15,34277427,Endocrine-resistant cells#are resistant to#CDK4/6 inhibitors,Therapeutic Resistance,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,Endocrine-resistant cells,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
6110,KP15,34433817,CDK4/6 inhibitors combined with endocrine therapy#show#efficacy in ER+ advanced breast cancer,Therapeutic Response,"CDK4,CDK6",-,ER+ advanced breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
4838,KP15,34433817,Patients#experience#disease progression on CDK4/6i-endocrine therapy,Therapeutic Resistance,"CDK4,CDK6",-,Advanced breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
4722,KP15,34433817,"Triple inhibition with fulvestrant, CDK4/6i, and AKTi#prevents#progression in resistant tumors",Combination Therapies,"CDK4,CDK6",-,Breast cancer,"CDK4/6 inhibitors, fulvestrant, AKTi",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4384,KP15,34433817,Triple combination with AKTi#inhibits#growth of resistant PDX tumors,Combination Therapies,"CDK4,CDK6",-,Breast cancer,"CDK4/6 inhibitors, fulvestrant, AKTi",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
36,KP15,34433817,High phospho-AKT levels#correlate with#shorter PFS in breast cancer patients,Biomarker Analysis,AKT,-,Breast cancer,-,-,-,-,phospho-AKT,-,-,-,Fact,2,2.3,2.3.3,2.3.3.1,-,磷酸化水平
5146,KP15,37886470,Targeting CDK4/6#demonstrates#promising effects against breast cancer,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3627,KP15,38751527,Estrogen#affects#cyclin signaling for breast cancer proliferation,Pathway & Network Categories,"CDK4,CDK6,CCND1",-,Breast cancer,-,Cyclin signaling,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
7086,KP15,38751527,HR+ breast cancers#are characterized by#dysregulation of CDK4/6 activity,Cancer Association,"CDK4,CDK6",-,HR+ breast cancer,-,Cell cycle,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7763,KP15,30631751,"CDK4/6 inhibitors#are under evaluation in#phase I, II, and III trials for solid tumors",Clinical Trial Data,"CDK4,CDK6",-,Solid tumors,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
2811,KP15,39239747,Chemotherapy#is the primary treatment for#advanced CCA,Treatment Monitoring,-,-,Advanced CCA,Chemotherapy,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
4884,KP15,39239747,Drug-resistant phenotypes#hinder#the efficacy of chemotherapy,Mechanisms of Resistance,-,-,Advanced CCA,Chemotherapy,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,2.6.1.1,-,多药耐药
4308,KP15,39239747,Cul3 knockdown#sensitized#cells to 5-fluorouracil and gemcitabine,Mechanisms of Resistance,CUL3,-,-,"5-fluorouracil,gemcitabine",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,联合用药方案
6294,KP15,39239747,"Cul3 knockdown#inhibited#cell proliferation, colony formation, migration, and invasion",Mechanisms of Resistance,CUL3,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
6736,KP15,31375512,CDK4/6 inhibitors combined with anti-PD-1 antibody monotherapy#were evaluated in#PD-1-humanized mouse and HIS patient-derived xenograft models,Preclinical Models,"CDK4,CDK6","PD-1-humanized mouse, HIS patient-derived xenograft",-,Anti-PD-1 antibody,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
5979,KP15,36530984,CDK4/6 inhibitors#are used in#HR+/HER2- breast cancer in combination with endocrine therapy,Cancer Association,"CDK4,CDK6",-,HR+/HER2- breast cancer,Endocrine therapy,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
1923,KP15,28629371,Combined MDM2/CDK4 targeting#is associated with#higher antitumor activity than a single agent in DDLPS,Combination Therapies,"CDK4,MDM2",-,DDLPS,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6666,KP15,28629371,RG7388 and palbociclib#exerted#a greater antitumor effect than either drug alone,Combination Therapies,CDK4,-,DDLPS,"RG7388,palbociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5326,KP15,28629371,Combination treatment#increased#apoptosis compared to single agents,Mechanisms of Resistance,-,-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
5213,KP15,28629371,RG7388 and palbociclib#were analyzed for#antitumor activity in a xenograft model of DDLPS,Preclinical Models,CDK4,-,DDLPS,"RG7388,palbociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1433,KP15,30359883,CDK4/6 pathways#are targeted in#breast cancer,Cancer Pathways,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4867,KP15,30359883,Metastatic or advanced breast cancer#mBC/ABC#remains incurable despite systemic treatment options,Clinical Implementation,-,-,"Metastatic breast cancer,Advanced breast cancer",-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,晚期实体瘤
2734,KP15,30359883,Hormone receptor positive disease#represents#the most common subtype in early and advanced breast cancer,Cancer Association,-,-,"Early breast cancer,Advanced breast cancer",-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.2,-,分子亚型
3032,KP15,30359883,Understanding the biology of HR+ breast cancer#led to#the development of CDK4/6 inhibitors,Therapeutic Development,"CDK4,CDK6",-,HR+ breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1797,KP15,30359883,Selective CDK4/6 inhibitors#improve#progression-free survival when combined with endocrine therapy in HR+/HER2- ABC,Therapeutic Response,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,"Palbociclib,Ribociclib,Abemaciclib,Endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
773,KP15,30359883,Overall survival#did not reach#statistical significance in 2 out of 7 trials as first-line therapy,Clinical Trial Data,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,治疗线别
782,KP15,30359883,"This article#reviews#CDK signaling pathway, inhibitors, preclinical/clinical data, and toxicity",Scientific Review,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,-,生物标志物监测
5058,KP15,30359883,CDK4/6 inhibitors#are included in#international guidelines for breast cancer,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
7429,KP15,29027483,Dysregulated cellular proliferation#is mediated by#aberrant activation of the cell cycle machinery through CDKs,Mechanism of Action,CDKs,-,Cancer,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7289,KP15,39579620,Combination of CDK4/6 inhibitors with ET#is the standard of care for#HR+/HER2- advanced breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,"CDK4/6 inhibitors, Endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
5455,KP15,39579620,Combination of CDK4/6i and ET#significantly improves#PFS and OS in HR+/HER2- aBC,Therapeutic Response,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,"CDK4/6 inhibitors, Endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
7512,KP15,31600301,CDK4/6#play critical roles in#G1 to S checkpoint of the cell cycle,Mechanism of Action,"CDK4,CDK6",-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
7729,KP15,31600301,Highly selective CDK4/6 inhibitors#were tested with#cytotoxic drugs in cancer cell lines,Combination Optimization,"CDK4,CDK6","Lung cancer cells, Breast cancer cells, Brain cancer cells","Lung cancer, Breast cancer, Brain cancer","Highly selective CDK4/6 inhibitors, Cytotoxic drugs",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6964,KP15,31600301,Pre-treatment with CDK4/6 inhibitors#reduced#cytotoxicity of cytotoxic agents,Combination Optimization,"CDK4,CDK6",-,-,"CDK4/6 inhibitors, Cytotoxic agents",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6382,KP15,38832268,Combination of CDK4/6 inhibitors with ET#has emerged as#new focus in HR+ HER2- breast cancer treatment,Therapeutic Development,"CDK4,CDK6",-,HR+/HER2- breast cancer,"CDK4/6 inhibitors, Endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
7524,KP15,39145064,Encorafenib-cetuximab combination with CDK4/6 inhibitors#was tested for#inherent resistance in BRAF-mutated CRC,Therapeutic Development,"CDK4,CDK6,BRAF",-,Colorectal cancer,"Encorafenib, Cetuximab, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
7296,KP15,30287548,"Palbociclib, ribociclib, and abemaciclib#are#ATP-competitive inhibitors of CDK4/6",Drug Development,"CDK4, CDK6",-,-,"Palbociclib, ribociclib, abemaciclib",G1 phase cell cycle,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7507,KP15,28741274,CDK4/6 inhibitors#trigger#cell cycle arrest in pRb-competent cells,Mechanism of Action,"CDK4, CDK6, RB1",pRb-competent cells,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
3258,KP15,27313785,Activation of CDK4/6-cyclin D1 signaling#correlates with#resistance to standard therapies,Mechanisms of Resistance,"CDK4, CDK6, CCND1",-,HR-positive breast cancer,-,CDK4/6-cyclin D1,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
5409,KP15,29483206,CDK-Rb-E2F pathway#plays#a critical role in cell cycle control in ER-positive breast cancer,Cell Cycle Control,"CDK4, CDK6, RB1, E2F",-,Breast cancer,-,CDK-Rb-E2F,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
3523,KP15,29483206,PI3K/mTOR pathway and CDK4/6 inhibition#cooperate in#preventing early adaptation and eliciting growth arrest,Pathway Cross-talk,"CDK4, CDK6, MTOR",-,Breast cancer,"CDK4/6 inhibitors, mTOR inhibitors","PI3K/mTOR, CDK4/6",-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
424,KP15,29483206,Combination of mTORC1/2 inhibitor with CDK4/6 inhibitor#results in#more profound effects on E2F-dependent transcription,Combination Therapies,"CDK4,CDK6,E2F1",-,-,-,"mTORC1/2,CDK4/6",-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.3,-,E2F转录因子活性下调
5050,KP15,29483206,"Combined inhibition of mTORC1/2, CDK4/6, and ER#delivers#more profound and durable regressions in breast cancer cell lines and xenografts",Combination Therapies,"CDK4,CDK6,ESR1",-,Breast cancer,-,"mTORC1/2,CDK4/6,ER",-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
2971,KP15,29483206,CDK4/6 inhibitor-resistant cell lines#remain sensitive to#mTORC1/2 inhibition,Resistance Mechanisms,"CDK4,CDK6",-,-,-,mTORC1/2,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.3,-,mTOR信号增强
3704,KP15,30745839,AR inhibition#is identified as#a novel therapeutic strategy to treat CDK4/6 inhibitor resistance in cancer,Therapeutic Development,"CDK4,CDK6,AR",-,Cancer,-,-,-,-,-,-,-,-,Inference,2,2.5,2.5.2,2.5.2.4,-,生物标志物指导
2829,KP15,32026050,CDK4 inhibitor abemaciclib#is supported by#recent clinical trials for dedifferentiated liposarcoma (DDLPS),Clinical Trial Data,CDK4,-,Dedifferentiated liposarcoma,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
6453,KP15,32026050,Anti-MDM2 therapies#are limited by#bone marrow toxicity and thrombocytopenia,Drug Development,MDM2,-,-,Anti-MDM2 therapies,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,血液学毒性
2502,KP15,31709685,In vitro inhibition of CDK4/6 activity#has#potent antiproliferative properties against luminal breast cancer cell lines,Mechanism of Action,"CDK4,CDK6",-,Luminal breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
4814,KP15,31709685,Inhibition of CDK4/6 activity#is enhanced by#combination with traditional ET,Combination Therapies,"CDK4,CDK6",-,Luminal breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
1460,KP15,31709685,Three selective CDK4/6 inhibitors#are approved as#first-line therapy in ER+/HER2- ABC,Drug Development,"CDK4,CDK6",-,ER+/HER2- ABC,"Palbociclib,Ribociclib,Abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,治疗线别
3644,KP15,24065146,Cyclin-dependent kinase 4 (CDK4) and insulin-like growth factor 1 receptor (IGF1R)#are identified as#synergistic drug targets in DDLS-derived cell lines,Drug Development,"CDK4,IGF1R",-,Dedifferentiated liposarcoma,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4710,KP15,39732370,Chemoresistance and clinical adverse effects#restrict#efficiency of PAL and combination strategies,Resistance Mechanisms,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
3084,KP15,39732370,PAL nanoassemblies#ensure#efficient synergistic anti-PD-L1 chemoimmunotherapy by facilitating T-cell immune response,Combination Therapies,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.3,3.3.2,3.3.2.4,-,协同免疫激活
668,KP15,25494820,PD0332991 (Palbociclib)#induces#cell cycle arrest in the G1 phase by inhibiting CDK4/6-cyclin complex and RB activation pathway,Mechanism of Action,"CDK4,CDK6,RB1",-,Multiple myeloma,Palbociclib,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
4456,KP15,36817127,Palbociclib#inhibited#proliferation of activated T cells,Therapeutic Response,"CDK4,CDK6",T cells,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6492,KP15,37129951,Inhibition of ACAA1#restrained#TNBC proliferation,Cancer Association,ACAA1,-,Triple-negative breast cancer (TNBC),Abemaciclib,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
1863,KP15,37129951,Inhibition of ACAA1#potentiated#response to CDK4/6 inhibitor abemaciclib,Therapeutic Response,"ACAA1,CDK4,CDK6",-,Triple-negative breast cancer (TNBC),Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
6948,KP15,37129951,ACAA1#interacted with#CDK4,Protein Complex Dynamics,"ACAA1,CDK4",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
3115,KP15,37129951,Inhibition of ACAA1#blocked#RB1 phosphorylation,Mechanism of Action,"ACAA1,RB1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
960,KP15,37129951,Inhibition of ACAA1#resulted in#G1-S cell-cycle arrest,Cell Cycle Control,ACAA1,-,-,-,G1-S cell cycle arrest,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
7335,KP15,37129951,Trimetazidine#caused#decrease in ACAA1 protein levels,Regulation,ACAA1,-,Triple-negative breast cancer (TNBC),Trimetazidine,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
997,KP15,37129951,Trimetazidine#enhanced#efficacy of abemaciclib in TNBC models,Combination Optimization,ACAA1,-,Triple-negative breast cancer (TNBC),"Trimetazidine,Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1899,KP15,37129951,ACAA1#is highly expressed in#TNBC,Expression Patterns,ACAA1,-,Triple-negative breast cancer (TNBC),-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
3410,KP15,37129951,ACAA1#serves as#a potential therapeutic target in ACAA1-high tumors,Cancer Association,ACAA1,-,Triple-negative breast cancer (TNBC),-,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
6595,KP15,39224861,"CDK4/6 inhibitors#revolutionized#treatment of HR-positive, HER2-negative metastatic breast cancer",Therapeutic Development,"CDK6,CDK4",-,"HR-positive, HER2-negative breast cancer","Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6082,KP15,39224861,CDK4/6 inhibitors#are combined with#ET as standard first-line treatment for metastatic disease,Clinical Implementation,"CDK6,CDK4",-,"HR-positive, HER2-negative breast cancer","Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
3671,KP15,39224861,"CDK4/6 inhibitors and ET combination#is associated with#longer overall survival, progression-free survival, and better objective response rates",Therapeutic Response,"CDK6,CDK4",-,"HR-positive, HER2-negative metastatic breast cancer",-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
6423,KP15,39224861,"CDK4/6 inhibitors#are investigated in combination with#ET in early-stage HR-positive, HER2-negative breast cancer",Preclinical Models,"CDK6,CDK4",-,"HR-positive, HER2-negative breast cancer",-,-,-,High-risk patients,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
1641,KP15,39224861,"Practical guidance#is provided for#abemaciclib in combination with ET for early HR-positive, HER2-negative breast cancer",Clinical Implementation,"CDK6,CDK4",-,"HR-positive, HER2-negative breast cancer",Abemaciclib,-,-,High-risk patients,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.3,-,疗效监测
3886,KP15,36660646,HR+ subtype in PPBC#increased#risk of death two-fold,Patient Outcomes,-,-,"PPBC, HR-positive breast cancer",-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
420,KP15,36660646,TNBC subtype in PPBC#modestly increased#risk of death,Patient Outcomes,-,-,"PPBC, triple-negative breast cancer",-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
2736,KP15,36660646,HER2+ subtype in PPBC#did not significantly increase#risk of death,Patient Outcomes,-,-,"PPBC, HER2-positive breast cancer",-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
5828,KP15,31450618,Endocrine-based treatments#are#standard-of-care for HR-positive/HER2-negative metastatic breast cancer,Clinical Implementation,-,-,"HR-positive, HER2-negative metastatic breast cancer",-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,适应症选择
6039,KP15,31450618,50% of women#develop#endocrine resistance and disease progression,Therapeutic Resistance,-,-,"HR-positive, HER2-negative metastatic breast cancer",-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
743,KP15,31450618,CDK4/6 and PI3K/AKT/mTOR inhibitors#changed#prognosis of endocrine treatment-resistant patients,Therapeutic Development,"CDK6,CDK4,PIK3CA,AKT1,MTOR",-,Endocrine-resistant breast cancer,-,"PI3K, AKT, mTOR",-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
7409,KP15,32164162,Breast cancers#express#estrogen receptor and depend on estrogen for growth and survival,Expression Patterns,ESR1,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
5734,KP15,32164162,Endocrine therapy#is#standard of care for ER-positive tumors,Clinical Implementation,ESR1,-,ER-positive breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,适应症选择
2324,KP15,32164162,ET in combination with CDK4/6 inhibitors#achieves#superior outcomes in ER-positive/HER2-negative metastatic breast cancer,Therapeutic Response,"CDK6,CDK4,ESR1",-,"ER-positive, HER2-negative metastatic breast cancer",Palbociclib,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
82,KP15,32164162,ER(+)/HER2(-) breast cancer cells#are characterized by#enhanced aerobic glycolysis during palbociclib sensitivity,Metabolic Integration,"ESR1,HER2",-,"ER-positive, HER2-negative breast cancer",Palbociclib,-,-,-,-,-,-,Glycolysis,Fact,4,4.1,4.1.1,4.1.1.1,-,有氧糖酵解增强
3752,KP15,32164162,ER(+)/HER2(+) breast cancer cells#enhance#glycolytic catabolism at resistance,Metabolic Integration,"ESR1,HER2",-,"ER-positive, HER2-positive breast cancer",-,-,-,-,-,-,-,Glycolysis,Fact,4,4.1,4.1.1,4.1.1.1,-,有氧糖酵解增强
732,KP15,32164162,Metabolic phenotype#has#prognostic value and clinical relevance,Biomarker Analysis,-,-,Breast cancer,-,-,-,-,-,-,-,-,Inference,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
4546,KP15,31285369,CDK4/6-dependent cell-cycle regulation#is disrupted in#most glioblastomas,Cell Cycle Control,"CDK6,CDK4",-,Glioblastoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
5551,KP15,31285369,Patients with recurrent glioblastoma#are treated with#ribociclib,Clinical Implementation,"CDK6,CDK4",Glioblastoma cells,Glioblastoma,Ribociclib,-,-,Recurrent glioblastoma,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,适应症选择
7209,KP15,31285369,Ribociclib concentrations#exceed#5-fold the in vitro IC(50) for CDK4/6 inhibition,Drug Development,"CDK6,CDK4",-,Glioblastoma,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
5147,KP15,31285369,G(1)-to-S phase suppression#is inferred from#decreases in RB phosphorylation and cellular proliferation,Cell Cycle Control,RB1,-,Glioblastoma,-,-,-,-,downregulated,-,-,-,Inference,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
7905,KP15,31285369,recurrent tumors following monotherapy#indicated#upregulation of the PI3K/mTOR pathway,Pathway & Network Categories,"PIK3CA,MTOR",-,Recurrent tumors,-,PI3K/mTOR,-,-,upregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
1245,KP15,31285369,Ribociclib#indicated#inhibition of RB phosphorylation and tumor proliferation,Mechanism of Action,RB1,-,Tumor,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
5795,KP15,39731909,Combined HCQ with high-dose CDK4/6i palbociclib#showed#tolerable toxicity and promising efficacy,Combination Optimization,"CDK4,CDK6",-,HR+/HER2- breast cancer,"Hydroxychloroquine,Palbociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1170,KP15,33990344,CDK4/6 inhibitors#are approved for#hormone receptor-positive breast cancer,Drug Development,"CDK4,CDK6",-,Hormone receptor-positive breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1281,KP15,34944934,endocrine therapy#is effective for#ERα-positive breast cancer,Therapeutic Response,ESR1,-,ERα-positive breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
4707,KP15,34944934,"patients#develop#treatment-resistant, metastatic cancer",Therapeutic Resistance,-,-,Metastatic cancer,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.4,-,周期素表达失衡
6916,KP15,34944934,resistant tumors#remain dependent on#ERα action,Therapeutic Resistance,ESR1,-,Resistant tumors,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
1299,KP15,34944934,activating ESR1 gene mutations#occur in#15-40% of advanced cancers,Cancer Association,ESR1,-,Advanced cancers,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.3,ESR1突变
3574,KP15,34944934,novel effective therapies#are needed to eradicate#cancer cells with aberrant ERα,Therapeutic Development,ESR1,-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
5900,KP15,34944934,CDK4/6 inhibitor ribociclib#is#a standard-of-care therapy for metastatic ERα-positive breast cancer,Drug Development,"CDK4,CDK6",-,Metastatic ERα-positive breast cancer,Ribociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
2424,KP15,34944934,CDK4/6 inhibitor ribociclib#is under evaluation in#neoadjuvant setting,Clinical Trial Data,"CDK4,CDK6",-,-,Ribociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.4,维持治疗
2005,KP15,37406085,CDK4/6 inhibitor abemaciclib and ERK1/2 inhibitor LY3214996#were evaluated for#reducing PNF tumor burden,Combination Optimization,"CDK4,CDK6,ERK1,ERK2",-,PNF,"Abemaciclib,LY3214996",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
4536,KP15,37406085,CDK4/6 inhibitor abemaciclib in combination with ERK1/2 inhibitor LY3214996#showed#robust additivity in NF1 mutant Schwann cells,Combination Optimization,"CDK4,CDK6,ERK1,ERK2",Schwann cells,NF1 mutant,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
4866,KP15,37406085,combination of abemaciclib and LY3214996#synergized to suppress#molecular signatures of MAPK activation,Signaling Networks,"CDK4,CDK6,ERK1,ERK2",-,-,"Abemaciclib,LY3214996",MAPK,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,MAPK通路激活
4671,KP15,37406085,combination of abemaciclib and LY3214996#exhibited#enhanced antitumor activity in vivo,Combination Optimization,"CDK4,CDK6,ERK1,ERK2",-,PNF,"Abemaciclib,LY3214996",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
1634,KP15,37406085,CDK4/6 inhibitors#target#RAS/MAPK pathway,Mechanism of Action,"CDK4,CDK6",-,"Peripheral nerve sheath tumors, NF1",-,RAS/MAPK,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
7835,KP15,25852058,CDK4/6 inhibitors PD-0332991 and LEE011#inhibit#RB1 phosphorylation,Mechanism of Action,"CDK4,CDK6,RB1",-,-,"PD-0332991, LEE011",-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
4943,KP15,25852058,CDK4/6 inhibitors PD-0332991 and LEE011#inhibit#proliferation,Mechanism of Action,"CDK4,CDK6",-,-,"PD-0332991, LEE011",-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
2996,KP15,38212842,CDK4/6 inhibitors#improve#therapeutic efficacy in first-line treatment,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4924,KP15,38212842,Avelumab#enhances#PFS and OS with CDK4/6 inhibitors and SERDs,Combination Optimization,"CDK4,CDK6",-,-,Avelumab,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
903,KP15,34937317,Cyclin D3#is essential for#T-ALL initiation and progression,Mechanism of Action,CCND3,-,T-ALL,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
3269,KP15,34937317,Targeting CDK4/6-cyclin D complex#suppresses#T-ALL proliferation,Therapeutic Response,"CDK4,CDK6,CCND3",-,T-ALL,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5350,KP15,34937317,CDKi#cause#cell cycle arrest,Mechanism of Action,"CDK4,CDK6",-,-,CDKi,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6902,KP15,34937317,CDKi#decrease#S phase entry,Mechanism of Action,"CDK4,CDK6",-,-,CDKi,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
3448,KP15,29352052,"CDK4/6 pathway#is targeted in#women with HR-positive, HER2-negative BC",Therapeutic Development,"CDK4,CDK6",-,Breast cancer,-,CDK4/6 cell cycle pathway,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1465,KP15,38066089,MAPK signaling hyperactivation#serves as#a mechanism of CDK4/6i resistance,Mechanisms of Resistance,"CDK4,CDK6",-,ALM,-,MAPK,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
5635,KP15,38066089,Cyclin D1#is elevated in#CDK4/6i-resistant ALM,Mechanisms of Resistance,CCND1,-,ALM,-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
6477,KP15,38066089,MEK and/or ERK inhibition#increases#CDK4/6i efficacy,Combination Optimization,"CDK4,CDK6",-,ALM,-,MAPK,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
7566,KP15,38066089,MEK and/or ERK inhibition#promotes#defective DNA repair and apoptosis,Mechanism of Action,"CDK4,CDK6",-,ALM,-,MAPK,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
617,KP15,38066089,Targeting MAPK pathway and CDK4/6#improves#outcomes in metastatic ALM,Therapeutic Development,"CDK4,CDK6",-,ALM,-,MAPK,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
5169,KP15,29995568,PCB#causes#G1 arrest in ALL cells,Mechanism of Action,-,ALL cells,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6455,KP15,29995568,PCB pretreatment#renders#ALL cells refractory to VCR-induced death,Mechanisms of Resistance,-,ALL cells,-,"PCB,VCR",-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,2.6.1.1,-,药物外排增加
2896,KP15,29995568,PCB pretreatment#retains#susceptibility to ABT-263 in ALL cells,Mechanism of Action,-,ALL cells,-,"PCB,ABT-263",-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7719,KP15,39649909,Ribociclib#disrupts#cell cycle progression,Mechanism of Action,"CDK4,CDK6",-,Tumor,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2726,KP15,39649909,Ribociclib with endocrine therapy#targets#HR-positive breast cancers,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
2564,KP15,39649909,Pharmacokinetic studies#underscore#efficacy and tolerability of ribociclib,Clinical Trial Data,-,-,-,Ribociclib,-,-,Renal and hepatic impairments,-,-,-,-,Fact,8,8.3,8.3.1,8.3.1.1,-,起始剂量选择
5333,KP15,39649909,Ribociclib#improves#quality of life and patient-reported outcomes,Quality of Life,-,-,-,Ribociclib,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,生活质量
4332,KP15,39649909,"Ribociclib#is associated with#hematologic toxicity, hepatotoxicity, and thromboembolism",Safety Monitoring,-,-,-,Ribociclib,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,-,血液学毒性
7532,KP15,39649909,"Ribociclib resistance mechanisms#comprise#genetic variations, compensatory signaling pathways, and epigenomic changes",Mechanisms of Resistance,"CDK4,CDK6",-,Breast cancer,Ribociclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
3584,KP15,39649909,Ribociclib combined with endocrine therapy#represents#advancement in breast cancer treatment,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
2104,KP15,37576607,Anti-HER2 monoclonal antibodies plus chemotherapy#are effective for#HER2+ advanced disease,Therapeutic Response,ERBB2,-,HER2+ advanced breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
3766,KP15,37576607,Treatments#attenuate#other signaling pathways involved in receptor crosstalk,Signaling Networks,-,-,HER2+ advanced breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
239,KP15,37576607,CDK4/6 inhibitors#play a role in#resistance to HER2-directed therapies,Mechanisms of Resistance,"CDK4,CDK6",-,HER2+ breast cancer,-,"PI3K,AKT,MTOR",-,-,-,-,-,-,Inference,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
6374,KP15,27785059,Hormone treatment#is the mainstay of therapy for#HR+/HER2- breast cancer,Therapeutic Development,-,-,Hormone receptor-positive/HER2-negative breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
1111,KP15,27785059,Progress#has been slow in#enhancing the efficacy of treatment options for HR+ breast cancer,Therapeutic Development,-,-,Hormone receptor-positive breast cancer,-,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
4179,KP15,27785059,Everolimus in combination with exemestane#increases#progression-free survival in ER+ advanced breast cancer,Therapeutic Response,-,-,Estrogen receptor-positive advanced breast cancer,"Everolimus,Exemestane",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
4107,KP15,27785059,Palbociclib#received#FDA approval for ER+/HER2- advanced breast cancer,Drug Development,"CDK4,CDK6",-,Estrogen receptor-positive/HER2-negative advanced breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
1689,KP15,27785059,Adding palbociclib to fulvestrant#increases#median progression-free survival,Combination Therapies,"CDK4,CDK6",-,Advanced breast cancer,"Palbociclib,Fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
7424,KP15,27785059,Palbociclib with endocrine agents#represents#important addition for ER+/HER2- advanced breast cancer,Therapeutic Development,"CDK4,CDK6",-,Estrogen receptor-positive/HER2-negative advanced breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
6623,KP15,38751535,CDK4/6 inhibitors#are#targeted therapies for ER+/PR+ breast cancers,Therapeutic Development,"CDK4,CDK6",-,Estrogen receptor-positive/Progesterone receptor-positive breast cancer,"Palbociclib,Ribociclib,Abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
4130,KP15,38751535,Selective inhibition of CDK4/6#causes#cell cycle arrest in G1 phase,Cell Cycle Control,"CDK4,CDK6",-,-,-,G1 phase arrest,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
2790,KP15,39345487,Inhibiting WEE1#delays#resistance to palbociclib and fulvestrant,Strategies to Overcome Resistance,"CDK4,CDK6",-,Breast cancer,"Palbociclib,Fulvestrant",-,-,-,-,-,-,-,Fact,2,2.5,2.5.2,2.5.2.4,-,生物标志物指导
6515,KP15,39345487,Alternating treatment#prevents#drug resistance to palbociclib and fulvestrant,Strategies to Overcome Resistance,"CDK4,CDK6",-,Breast cancer,"Palbociclib,Fulvestrant",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.4,-,时序调控
496,KP15,28653662,Breast cancer cells#activate#autophagy in response to palbociclib,Mechanisms of Action,"CDK4,CDK6",-,Breast cancer,Palbociclib,-,Autophagy,-,-,-,-,-,Fact,3,3.4,3.4.3,3.4.3.1,-,自噬启动
6849,KP15,28653662,Inhibition of CDK4/6 and autophagy#is synergistic in#solid cancers with intact G1/S checkpoint,Combination Therapies triples,"CDK4,CDK6",-,"Breast cancer, solid tumors",-,G1/S checkpoint,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
5008,KP15,37330596,ACK1 activation#is increased in#most breast cancer subtypes,Expression Patterns,TNK2,-,Breast cancer,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
5843,KP15,24378856,"The antitumor mechanism of metformin#is not elucidated in#several types of cancers, including hepatocellular carcinoma",Mechanism of Action,MTOR,-,Hepatocellular carcinoma,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.4,-,表观遗传改变
2689,KP15,24378856,miRNAs induced by metformin#contribute to#tumor growth suppression,RNA Regulation,-,-,Tumor,Metformin,-,-,-,-,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,微小RNA
5738,KP15,37264081,RMC-6272#maintained efficacy in#CDK4/6 inhibitor-resistant cell lines and PDX,Mechanisms of Resistance,"CDK4,CDK6",-,Hormone therapy-resistant tumors,RMC-6272,CDK4/6,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
980,KP15,38393465,ERBC cells with fibroblasts crosstalk#activates#ERK/MAPK signaling pathway,Signaling Networks,-,Fibroblasts,-,-,ERK/MAPK,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
6113,KP15,38393465,Reparixin#inhibits#ERBC cell growth,Drug Development,-,ERBC cells,-,Reparixin,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3538,KP15,38393465,Combination of reparixin and CDK4/6 inhibitors#increases#inhibitory effect on ERBC cell growth,Combination Therapies triples,"CDK4,CDK6",-,ERBC cells,"Reparixin, palbociclib, ribociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1242,KP15,30948930,Radiation#improves#survival and decreases cell proliferation through enhanced G1 cell cycle arrest,Cell Cycle Control,-,-,-,-,G1 cell cycle arrest,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
675,KP15,35269621,"Palbociclib, ribociclib, and abemaciclib#affect#breast cancer bone microenvironment",Tumor Microenvironment,"CDK4,CDK6",-,Breast cancer,"Palbociclib, ribociclib, abemaciclib",-,-,-,-,-,-,-,Fact,6,6.6,6.6.1,6.6.1.1,6.6.1.1.2,细胞外基质
6678,KP15,35269621,"Ribociclib, palbociclib, and abemaciclib#inhibit#osteoclast differentiation and bone resorption markers",Bone Biology,"CDK4,CDK6",Osteoclasts,-,"Ribociclib, palbociclib, abemaciclib",-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3650,KP15,35269621,Palbociclib#has lower anti-tumor effect than#ribociclib and abemaciclib in OB/MCF-7 co-culture models,Therapeutic Response,"CDK4,CDK6","Osteoblasts, MCF-7 cells",Breast cancer,"Palbociclib, ribociclib, abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7247,KP15,35269621,CDKi#affect#tumor bone microenvironment,Tumor Microenvironment,"CDK4,CDK6",-,Tumor,-,-,-,-,-,-,-,-,Fact,6,6.6,6.6.1,6.6.1.1,6.6.1.1.2,细胞外基质
7699,KP15,36643309,Clinical problem of resistance mechanisms#requires#reliable pre-clinical models,Mechanisms of Resistance,-,-,Bladder cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
2181,KP15,19351720,Cyclin D1#induces#Runx2 protein phosphorylation and degradation,Post-translational Modifications,"CCND1,RUNX2",-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
85,KP15,19351720,cyclin D1#affects#Runx3 protein stability and function,Mechanism of Action,"CCND1,RUNX3","COS cells, osteoprogenitor C3H10T1/2 cells, chondrogenic RCJ3.1C5.18 cells",-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
7288,KP15,19351720,cyclin D1#induces#Runx3 degradation,Mechanism of Action,"CCND1,RUNX3","COS cells, RCJ3.1C5.18 cells",-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
778,KP15,19351720,Myc-tagged Runx3 and endogenous Runx3#interact with#CDK4,Protein Complex Dynamics,"RUNX3,CDK4","COS cells, RCJ3.1C5.18 cells",-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
4177,KP15,19351720,CDK recognition site#is identified in#C-terminal region of Runx3,Structural Biology,"CDK4,RUNX3",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
2550,KP15,19351720,mutation of Runx3 at Ser356 to alanine (SA-Runx3)#increases#half-life of Runx3,Regulation,RUNX3,-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.2,-,蛋白稳定性
1407,KP15,19351720,CDK4#phosphorylates#GST-Runx3 in vitro,Mechanism of Action,"CDK4,RUNX3",-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
2872,KP15,19351720,proteasome inhibitor PS1#blocks#Runx3 degradation by cyclin D1,Regulation,"CCND1,RUNX3",-,-,PS1,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
1550,KP15,19351720,cyclin D1#affects#chondrocyte proliferation and hypertrophy,Cell Cycle Control,CCND1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
1895,KP15,23647051,CDKs#represent#attractive targets for anticancer drug development,Drug Development,"CDK4,CDK6",-,diverse malignancies,-,-,-,-,aberrant expression,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2229,KP15,23647051,CDK inhibitors#target#CDK4/6,Drug Development,"CDK4,CDK6",-,-,"flavopiridol (alvocidib), PD0332991",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3143,KP15,30522347,ribociclib#is approved for#HR+/HER2- advanced or metastatic breast cancer treatment,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- advanced or metastatic breast cancer,ribociclib,-,-,premenopausal/perimenopausal and postmenopausal women,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5720,KP15,28403773,CDK4/6#are related to#oncogenesis,Cancer Association,"CDK4,CDK6",-,oncogenesis,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
887,KP15,28403773,CDK inhibitors#suppress#tumor cell proliferation,Therapeutic Response,"CDK4,CDK6",-,tumors,-,-,suppressed,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2567,KP15,28403773,Palbociclib#demonstrates#antitumor potential,Drug Development,"CDK4,CDK6",-,tumors,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7197,KP15,17452903,rapamycin (RAPA)#inhibits#proliferation of EBV-infected B lymphoblastoid cell lines (SLCL),Therapeutic Response,-,B lymphoblastoid cell lines,EBV-infected SLCL,rapamycin,-,arresting cells in G1 phase,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1627,KP15,17452903,RAPA#decreases#Rb hyperphosphorylation by CDK complexes,Regulation,"CDK4,CDK6,RB1",-,-,rapamycin,-,-,-,decreased,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
4803,KP15,17452903,RAPA#provides#therapeutic potential for PTLD and EBV+ lymphomas,Therapeutic Development,-,B-cell lymphomas,"PTLD, EBV+ lymphomas",rapamycin,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2097,KP15,34712959,CDK inhibitors with endocrine therapy#improve#outcomes for metastatic ER+ breast cancer patients,Combination Optimization,"CDK4,CDK6",-,metastatic ER+ breast cancer,"CDK inhibitors, endocrine therapy",-,-,metastatic patients,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
1487,KP15,34712959,ribociclib#is combined with#letrozole in FELINE clinical trial,Clinical Trial Data,"CDK4,CDK6",-,early-stage breast cancer,"ribociclib, letrozole",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
6463,KP15,34712959,Cancer cells#potentiate#CDK4/6 activation and ERK upregulation through ERBB4 signaling,Signaling Networks,"CDK4,CDK6,ERBB4",-,Cancer,-,ERK,-,-,Upregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
7550,KP15,37141550,"Endocrine therapy plus CDK4/6 inhibition#is#first-line treatment for HR+, HER2- metastatic breast cancer",Clinical Implementation,"CDK4,CDK6",-,"HR+, HER2- metastatic breast cancer",CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3952,KP15,37141550,Abemaciclib#has#distinct pharmacokinetic and pharmacodynamic properties compared to palbociclib and ribociclib,Drug Development,"CDK4,CDK6",-,-,"Abemaciclib, palbociclib, ribociclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5878,KP15,37141550,ESR1-MUT and CDKi-R mutations#affect#abemaciclib sensitivity of immortalized breast cancer cells and circulating tumor cell lines,Mechanisms of Resistance,ESR1,-,Breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
3547,KP15,37141550,CDKi-R alterations#induced#abemaciclib resistance in immortalized breast cancer cells,Mechanisms of Resistance,-,-,Breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
4886,KP15,33509944,Triple-negative breast cancers (TNBC)#are#resistant to standard-of-care chemotherapy,Therapeutic Resistance,-,-,Triple-negative breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
231,KP15,33509944,Functional genomics screening#identified#CREBBP as a novel tumor suppressor in TNBC,Biomarker Analysis,CREBBP,-,Triple-negative breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
4306,KP15,33509944,CREBBP protein expression#was absent in#8% of TNBCs and frequently in squamous lung cancer,Expression Patterns,CREBBP,-,"Triple-negative breast cancer, squamous lung cancer",-,-,-,-,Silenced,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
4699,KP15,33509944,CREBBP alterations#resulted in#higher genomic heterogeneity and poorer patient survival in TNBC,Cancer Association,CREBBP,-,Triple-negative breast cancer,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.1,-,突变签名
4694,KP15,33509944,CREBBP alterations#upregulated#FOXM1 proliferative program in TNBC,Signaling Networks,"CREBBP,FOXM1",-,Triple-negative breast cancer,-,-,-,-,Upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
4637,KP15,33509944,Clinical CDK4/6 inhibitors#impaired#growth in CREBBP-mutated tumor models,Therapeutic Development,"CDK4,CDK6,CREBBP",-,Tumor,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2406,KP15,33509944,CREBBP alterations#may serve as#a biomarker of CDK4/6i response,Biomarker Analysis,CREBBP,-,Tumor,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.1,-,基因突变
1589,KP15,33509944,"CREBBP genomic alterations#drive#aggressive TNBC, lung cancer, and lymphomas",Cancer Association,CREBBP,-,"Triple-negative breast cancer, lung cancer, lymphomas",-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.1,-,突变签名
4325,KP15,33154823,Fulvestrant plus palbociclib#had#the best safety record among co-treatment options,Clinical Trial Data,"CDK4,CDK6",-,Cancer,"Fulvestrant, Palbociclib",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
3417,KP15,33154823,Fulvestrant plus capecitabine#demonstrated#palpable toxic effects despite superior efficacy,Clinical Trial Data,-,-,Cancer,"Fulvestrant, Capecitabine",-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
7366,KP15,33154823,Fulvestrant plus CDK4/6 inhibitors#was#slightly better than AI plus CDK4/6 inhibitors in efficacy,Clinical Trial Data,"CDK4,CDK6",-,Cancer,"Fulvestrant, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
7116,KP15,28961193,Survivin and HIF-1伪#were downregulated by#suppressing 4EBP1-p70S6K1 axis-mediated de novo protein synthesis,Regulation,HIF1A,-,-,-,4EBP1-p70S6K1,-,-,Downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
199,KP15,28961193,Fascaplysin#inhibited#VEGFR2 and TRKA via DFG-out non-competitive inhibition,Drug Development,"VEGFR2,NTRK1",-,-,Fascaplysin,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6989,KP15,36358625,Resistance mechanisms#involve#mutations of direct targets of anti-estrogen therapies,Mechanisms of Resistance triples,-,-,-,anti-estrogen therapies,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
4786,KP15,36358625,Resistance mechanisms#involve#compensatory survival pathways,Mechanisms of Resistance triples,-,-,-,-,-,-,-,-,-,-,-,Fact,2,2.4,2.4.2,2.4.2.2,-,反馈环路
7014,KP15,36358625,Resistance mechanisms#involve#alterations in non-coding RNA expression,Mechanisms of Resistance triples,-,-,-,-,-,-,-,altered,-,-,-,Fact,2,2.1,2.1.3,2.1.3.3,-,非编码RNA表达变化
2327,KP15,32183020,"Dual CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib#were approved for#treatment of HR+ advanced/metastatic breast cancer",Drug Development triples,"CDK4,CDK6",-,Hormone receptor-positive (HR+) advanced/metastatic breast cancer,"palbociclib, ribociclib, abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
4345,KP15,32183020,CDK4/6 inhibitors#are used for#treatment of ER+/HER2- metastatic breast cancer,Drug Development triples,"CDK4,CDK6",-,ER+/HER2- metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
4029,KP15,32183020,Emerging strategies#involve#combination therapies and microRNA therapy,Therapeutic Development triples,-,-,-,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3924,KP15,27729458,MYCN amplification status#is associated with#ribociclib sensitivity,Biomarker Analysis triples,MYCN,-,-,ribociclib,-,-,-,-,-,-,-,Fact,7,7.1,7.1.2,7.1.2.1,-,基因拷贝数
2901,KP15,27729458,Increased MAPK signaling#determines#binimetinib sensitivity,Mechanisms of Resistance triples,MAPK,-,-,binimetinib,-,MAPK,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
5667,KP15,27729458,MYCN amplification status#is associated with#binimetinib resistance,Mechanisms of Resistance triples,MYCN,-,-,binimetinib,-,-,-,altered,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,基因组改变
2707,KP15,30568462,Fulvestrant in combination with CDK4/6 inhibitors#is associated with#superior efficacy,Combination Therapies triples,"CDK4,CDK6",-,-,fulvestrant,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,协同抗增殖作用
3669,KP15,30568462,Fulvestrant in combination with PI3K/mTOR inhibitors#is associated with#superior efficacy,Combination Therapies triples,"PI3K,MTOR",-,-,fulvestrant,-,"PI3K,MTOR",-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
2977,KP15,30568462,Combination of fulvestrant with CDK4/6 or PI3K/mTOR inhibitors#may open#new avenues for therapies in HR+ breast cancer,Therapeutic Development triples,"CDK4,CDK6,PI3K,MTOR",-,Hormone receptor-positive (HR+) breast cancer,fulvestrant,-,"PI3K,MTOR",-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
2672,KP15,39090086,Resistance#arises through#upregulation of MDR proteins like ABCB1,Mechanisms of Resistance triples,ABCB1,-,-,-,-,-,-,upregulated,-,-,-,Fact,2,2.6,2.6.1,2.6.1.1,-,多药耐药
6044,KP15,39090086,ABCB1#is upregulated in#RC4-2B cells,Expression Patterns triples,ABCB1,-,-,-,-,-,-,upregulated,-,-,-,Fact,2,2.6,2.6.1,2.6.1.1,-,多药耐药
5662,KP15,39090086,CDK4/6 inhibitors#potentiated#cytotoxic effect of CPT or Ara-C,Combination Therapies triples,"CDK4,CDK6",-,-,"CDK4/6 inhibitors, Camptothecin (CPT), Cytarabine (Ara-C)",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
2665,KP15,39090086,CPT and Ara-C alone or with CDK4/6 inhibitors#can be suggested as#new treatment for CRPC patients,Therapeutic Development triples,"CDK4,CDK6",-,Castration-resistant prostate cancer (CRPC),"Camptothecin (CPT), Cytarabine (Ara-C), CDK4/6 inhibitors",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5868,KP15,31371343,"ER(+)/FGFR1-amplified CAMA1 cells#are partially sensitive to#fulvestrant, palbociclib, and alpelisib",Mechanisms of Resistance triples,FGFR1,-,Breast cancer,"fulvestrant, palbociclib, alpelisib",-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
6434,KP15,31371343,FGFR1 expression vector transduction#induces#resistance to fulvestrant,Mechanisms of Resistance triples,FGFR1,-,Breast cancer,fulvestrant,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
1410,KP15,31371343,"FGFR1 amplification#confers#broad resistance to ER, PI3K, and CDK4/6 inhibitors",Mechanisms of Resistance triples,FGFR1,-,Breast cancer,"ER inhibitors, PI3K inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,基因组改变
3007,KP15,31371343,mTOR inhibitors#have#unique therapeutic role in ER(+)/FGFR1(+) MBC,Therapeutic Development triples,MTOR,-,ER(+)/FGFR1(+) metastatic breast cancer,mTOR inhibitors,-,-,-,-,-,-,-,Fact,3,3.6,3.6.2,3.6.2.1,-,持续缓释
3381,KP15,28599479,DNM3 expression#is decreased in#human HCC tissues and cell lines,Expression Patterns triples,DNM3,-,Hepatocellular carcinoma (HCC),-,-,-,-,downregulated,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,表达水平减少
1127,KP15,28599479,DNM3#induces#HCC cell apoptosis,Mechanism of Action,DNM3,HCC cells,Hepatocellular carcinoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.3,1.3.3,1.3.3.3,-,细胞凋亡调控
1126,KP15,28599479,DNM3#inhibits#tumor growth,Mechanism of Action,DNM3,-,Hepatocellular carcinoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制
853,KP15,28599479,DNM3 overexpression#increases#iNOS protein expression level,Expression Patterns,DNM3,HCC cells,Hepatocellular carcinoma,-,-,-,-,upregulated,-,-,-,Fact,4,4.3,4.3.1,4.3.1.3,-,抗氧化系统激活
6563,KP15,28599479,DNM3 overexpression#increases#iNOS protein expression level in subcutaneous HCC tumor xenografts,Expression Patterns,DNM3,-,Hepatocellular carcinoma,-,-,-,-,upregulated,-,-,-,Fact,4,4.3,4.3.1,4.3.1.3,-,抗氧化系统激活
2231,KP15,28599479,DNM3 overexpression#activates#iNOS production,Mechanism of Action,DNM3,-,Hepatocellular carcinoma,-,NO-ROS,-,-,-,-,-,-,Inference,4,4.3,4.3.1,4.3.1.3,-,抗氧化系统激活
3161,KP15,28599479,DNM3 overexpression#induces#HCC cell apoptosis,Mechanism of Action,DNM3,HCC cells,Hepatocellular carcinoma,-,NO-ROS,-,-,-,-,-,-,Inference,3,3.4,3.4.2,3.4.2.1,-,内源性途径激活
728,KP15,28599479,DNM3 overexpression#inhibits#tumor growth,Mechanism of Action,DNM3,-,Hepatocellular carcinoma,-,NO-ROS,-,-,-,-,-,-,Inference,1,1.4,1.4.1,1.4.1.3,-,增殖抑制
4254,KP15,29464035,TCGA database analysis#identifies#deregulation of cell cycle genes across 24 cancer types,Expression Patterns,-,-,Multiple cancers,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
5498,KP15,29464035,Deregulated cell cycle genes#affect#patient survival,Clinical Correlation,-,-,Multiple cancers,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
605,KP15,29464035,HNSCC#ranks amongst#top four cancers with deregulated cell cycle genes,Cancer Association,-,-,Head and neck squamous cell carcinoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3472,KP15,29464035,Increased CCND1/CDK6 levels#negatively impact#patient survival,Clinical Correlation,"CCND1,CDK6",-,Multiple cancers,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
765,KP15,29464035,Cyclins and CDKs#are downregulated#upon exposure to erufosine,Regulation,"CCND1,CDK6",-,-,Erufosine,Cell cycle,-,downregulated,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
922,KP15,29464035,Cyclins and CDKs#participate in#negative enrichment of cell cycle processes,Pathway,"CCND1,CDK6",-,-,Erufosine,Cell cycle,-,downregulated,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2354,KP15,29464035,Erufosine#causes#G2/M block,Mechanism of Action,-,-,-,Erufosine,Cell cycle,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6607,KP15,29464035,Erufosine#is a potential#cell cycle inhibitor in HNSCC treatment,Drug Development,-,-,Head and neck squamous cell carcinoma,Erufosine,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
177,KP15,32366234,FAT4#has#a tumor suppressor function,Cancer Association,FAT4,-,Multiple cancers,-,-,-,-,downregulated,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制
4477,KP15,32366234,FAT4#regulates#epithelial-to-mesenchymal transition,Mechanism of Action,FAT4,-,Multiple cancers,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.2,1.4.2.1,-,谱系特异性分化
3262,KP15,32366234,FAT4#regulates#proliferation and metastasis,Mechanism of Action,FAT4,-,Multiple cancers,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,-,-,细胞增殖调控
7705,KP15,32366234,"FAT4 knockdown#reduces#cell viability, colony formation, and invasion",Mechanism of Action,FAT4,-,Ovarian cancer,-,-,-,downregulated,-,-,-,-,Fact,1,1.4,1.4.1,-,-,细胞增殖调控
4890,KP15,32366234,"FAT4#regulates#proteins in apoptotic, Wnt, Hippo, and retinoblastoma pathways",Pathway,FAT4,-,Ovarian cancer,-,"Apoptotic, Wnt, Hippo, Retinoblastoma",-,downregulated,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
973,KP15,32366234,FAT4 expression#is lower in#ovarian cancer cell lines and samples,Expression Patterns,FAT4,-,Ovarian cancer,-,-,-,downregulated,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
2781,KP15,32366234,"FAT4 silencing#upregulates#E2F5, vimentin, YAP, β-catenin, cyclin D1, cdk4, and Bcl2",Regulation,"FAT4,E2F5,VIM,YAP,CTNNB1,CCND1,CDK4,BCL2",-,Ovarian cancer,-,"Wnt, Hippo",-,upregulated,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
4295,KP15,32366234,FAT4 silencing#downregulates#GSK-3-β and caspase 9,Regulation,"FAT4,GSK3B,CASP9",-,Ovarian cancer,-,"Wnt, Hippo",-,downregulated,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
4261,KP15,32366234,FAT4 downregulation#promotes#increased growth and invasion,Mechanism of Action,FAT4,-,Ovarian cancer,-,"Hippo, Wnt-β-catenin",-,downregulated,-,-,-,-,Inference,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
1971,KP15,32366234,FAT4 downregulation#activates#Hippo and Wnt-β-catenin pathways,Pathway,FAT4,-,Ovarian cancer,-,"Hippo, Wnt-β-catenin",-,downregulated,-,-,-,-,Inference,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
6641,KP15,32393766,High-complexity DNA barcoding#indicates#a high rate of de novo acquired resistance to drugs,Mechanisms of Resistance,-,-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
6193,KP15,32393766,JQ1 and palbociclib#induce#cell division errors,Mechanism of Action,"CDK4,CDK6",-,Aneuploidy,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5442,KP15,32393766,Combination treatment#acquires resistance through#activation of G1-S and senescence pathways,Mechanism of Action,"CDK4,CDK6",-,-,-,"G1-S pathway, senescence pathway",-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
6102,KP15,32393766,Combined BET and CDK4/6 inhibition#establishes#novel mechanisms of action in TNBC,Mechanism of Action,"CDK4,CDK6",-,TNBC,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1018,KP15,22710759,Tob1#inhibits#gastric cancer progression,Mechanism of Action,TOB1,-,Gastric cancer,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,-,-,细胞增殖调控
3710,KP15,28619757,Rb-positive cell lines treated with palbociclib#arrest in#G1 phase of the cell cycle,Cell Cycle Control,RB1,-,-,palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5173,KP15,28619757,Palbociclib-induced cell-cycle arrest#poises#Rb-positive sarcoma cells to be more sensitive to doxorubicin and Wee1 kinase inhibitors,Therapeutic Response,RB1,-,Sarcoma,"palbociclib, doxorubicin, AZD1775",-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.2,-,协同增效作用
7034,KP15,34625531,Alpelisib#inhibits#p-ERK and p-AKT in HCC progression,Mechanism of Action,"PIK3CA, MET",-,HCC,alpelisib,"MAPK, AKT",-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
2249,KP15,34625531,Alpelisib#does not affect#mTOR pathway in HCC progression,Mechanism of Action,"PIK3CA, MET",-,HCC,alpelisib,mTOR pathway,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
6378,KP15,34625531,Alpelisib#is effective for treating#PIK3CA-mutated HCC,Therapeutic Response,PIK3CA,-,HCC,alpelisib,"MAPK, AKT",-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
1148,KP15,33542852,CDK4/6 inhibitors#are approved for#HR+/HER2- breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- breast cancer,"palbociclib, ribociclib, abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
7327,KP15,33542852,CDK4/6 inhibitors#demonstrated#success in clinical trials,Clinical Trial Data,"CDK4,CDK6",-,-,"palbociclib, ribociclib, abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
1897,KP15,33542852,CDK4/6 inhibitors#are given#orally,Clinical Implementation,"CDK4,CDK6",-,-,"palbociclib, ribociclib, abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
6267,KP15,38800404,Fulvestrant#is used in combination with#CDK4/6 inhibitors for advanced-stage disease,Combination Therapies,"CDK4,CDK6",-,Advanced-stage disease,"palbociclib, abemaciclib, ribociclib, fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,3.2.1.1.1,联合芳香化酶抑制剂
2321,KP15,32545895,HER2 targeted therapies#are developed for#HER2-positive advanced breast cancer,Therapeutic Development,ERBB2,-,HER2-positive advanced breast cancer,"trastuzumab, lapatinib, pertuzumab, ado-trastuzumab emtansine",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,3.1.1.1.1,G1/S期转换抑制
6276,KP15,32545895,Novel anti-HER2 antibodies#are developed with#increased affinity,Therapeutic Development,ERBB2,-,HER2-positive advanced breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,3.1.1.1.1,G1/S期转换抑制
6587,KP15,32545895,Bispecific monoclonal antibodies#are emerging for#dual targeting of HER2 epitopes,Therapeutic Development,ERBB2,-,HER2-positive advanced breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,3.1.1.1.1,G1/S期转换抑制
5496,KP15,32545895,More potent HER2 tyrosine kinase inhibitors#are under development for#HER2-positive advanced breast cancer,Therapeutic Development,ERBB2,-,HER2-positive advanced breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,3.1.1.1.1,G1/S期转换抑制
1354,KP15,32545895,Predictive biomarkers#are needed to define#populations benefiting from HER2-positive/HR-positive therapies,Biomarker Analysis,ERBB2,-,HER2-positive/HR-positive advanced breast cancer,-,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,RB1突变
2302,KP15,12203371,Ketoconazole#induces#apoptosis and G0/G1 phase cell cycle arrest in human cancer cell lines,Mechanism of Action,"CDK4,CDK6",Human cancer cell lines,Cancer,Ketoconazole,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,1.1.3.1.1,G1期阻滞
440,KP15,37205634,Targeting of the proteasome#could improve#efficacy of MDM2 inhibitors in liposarcoma,Combination Therapies,MDM2,-,Liposarcoma,MDM2 inhibitors,-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.1,2.5.1.1.1,多靶点抑制
851,KP15,27322250,Cypermethrin treatment#activated#MAPK signaling pathways by inducing JNK and ERK1/2 phosphorylation,Signaling Networks,"MAPK, JNK, ERK1, ERK2",-,-,Cypermethrin,MAPK,-,-,Upregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,1.3.2.1.1,RAS/RAF/MEK/ERK级联
6702,KP15,30236142,Plasma CCND1/CDKN2A ratio#is correlated with#EBV DNA load in NPC patients' plasma,Biomarker Analysis,"CCND1, CDKN2A",-,Nasopharyngeal carcinoma,-,-,-,NPC patients,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,7.5.1.1.1,ESR1突变
7099,KP15,30236142,Plasma CCND1/CDKN2A ratio#could serve as#a screening test to select potential CDK4/6 inhibitor treatment candidates,Biomarker Analysis,"CCND1, CDKN2A, CDK4, CDK6",-,Cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,7,7.5,7.5.1,7.5.1.1,7.5.1.1.1,ESR1突变
78,KP15,31477350,"SY-1365, a CDK7 inhibitor#has shown#initial encouraging data in phase I for solid tumors treatment",Drug Development,CDK7,-,Solid tumors,SY-1365,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,3.1.1.1.1,G1/S期转换抑制
3717,KP15,36741704,Anti-estrogens or aromatase inhibitors#in combination with#CDK4/6 inhibitors are the standard of care for ER+ Her-2 negative metastatic breast cancer,Clinical Implementation,"CDK4, CDK6",ER+ cells,Metastatic breast cancer,"Anti-estrogens, Aromatase inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
463,KP15,36741704,ARV-825#added after#Fulvestrant + Palbociclib combination promoted apoptosis in resistant RB-deficient cell lines,Combination Therapies,RB1,-,Cancer,"ARV-825, Fulvestrant, Palbociclib",-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,1.1.3.3.1,增殖抑制
67,KP15,37457126,"FLT3L binding to FLT3#activates#PI3K and RAS pathways, producing increased cell proliferation and inhibition of apoptosis",Signaling Networks,"FLT3, PI3K, RAS",-,-,-,"PI3K, RAS",-,-,Upregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,1.3.1.1.1,信号交叉激活
5407,KP15,28537004,MAPK cascade#is involved in#regulation of cellular proliferation and tumor cell survival,Signaling Networks,MAPK,-,Tumor,-,MAPK,-,-,Upregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
68,KP15,28537004,"Mutations involving BRAF or NRAS#activate#MAPK pathway, increasing cellular proliferation",Signaling Networks,"BRAF,NRAS,MAPK",-,-,-,MAPK,-,-,Upregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
3511,KP15,28537004,These mutations#have become#targets for therapeutic strategies in melanoma and other cancers,Therapeutic Development,"BRAF,NRAS",-,"Melanoma, Cancer",-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1639,KP15,28537004,Selective MEK inhibitors#inhibit#growth and induce cell death in BRAF- and NRAS-mutant melanoma cell lines,Drug Development,"BRAF,NRAS,MEK",Melanoma cell lines,Melanoma,MEK inhibitors,-,-,-,Downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7641,KP15,28537004,Trametinib#was approved for#treatment of BRAF-mutated metastatic melanoma in combination with dabrafenib,Drug Development,BRAF,-,Metastatic melanoma,"Trametinib, Dabrafenib",-,-,-,-,-,-,-,Fact,8,8.2,8.2.2,8.2.2.3,-,MEK抑制剂组合
5196,KP15,28537004,Anti-PD-1/PD-L1 agents#showed#promise in combination with BRAF and MEK inhibitors in metastatic melanoma,Combination Therapies,"PD-1,PD-L1,BRAF,MEK",-,Metastatic melanoma,"Pembrolizumab, Durvalumab, Atezolizumab, BRAF inhibitors, MEK inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.3,-,协同增效作用
4509,KP15,28537004,Binimetinib#showed#efficacy in NRAS-mutated melanoma patients,Drug Development,NRAS,-,Melanoma,Binimetinib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6947,KP15,28537004,MEK inhibitors#could be used in#combination with anti-CDK4/6 inhibitors in advanced melanoma and other solid tumors,Combination Therapies,"MEK,CDK4,CDK6",-,"Melanoma, Solid tumors","MEK inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
7603,KP15,25762475,"ET armamentarium#includes#selective estrogen receptor modulation, aromatase inhibition, and selective estrogen receptor downregulation",Therapeutic Development,-,-,-,"Selective estrogen receptor modulators, Aromatase inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
6436,KP15,25762475,mTOR inhibitor everolimus#is in use for#treatment of resistant ER+MBC,Drug Development,MTOR,-,ER+ metastatic breast cancer,Everolimus,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3178,KP15,25762475,ESR1 mutations#are#an important mechanism for acquired resistance,Mechanism of Action,ESR1,-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
2466,KP15,37709297,Hormone receptor-positive breast cancer#is#a disease for which no immune checkpoint inhibitors have shown promise,Cancer Association,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
6579,KP15,37709297,CDK4/6 inhibitors#synergistically increased#effectiveness of anti-PD-1/PD-L1 antibodies in preclinical studies,Combination Therapies,"CDK4,CDK6",-,-,"anti-PD-1,PD-L1 antibodies",-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.3,-,协同增效作用
3939,KP15,37709297,"Nivolumab in combination with abemaciclib, fulvestrant, or letrozole#was evaluated for#HR-positive HER2-negative metastatic breast cancer",Clinical Trial Data,-,-,Breast cancer,"Nivolumab,Abemaciclib,Fulvestrant,Letrozole",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
1044,KP15,37709297,Addition of abemaciclib to nivolumab therapy#caused#immune-related AEs due to proinflammatory cytokine production and suppression of Treg proliferation,Mechanism of Action,-,Treg cells,-,"Abemaciclib,Nivolumab",-,Immune-related AEs,-,-,-,-,-,Fact,3,3.3,3.3.1,3.3.1.3,-,炎症因子调节
888,KP15,25191523,Expression of Smurf2#is found to be#dysregulated in many cancers including breast cancer,Expression Patterns,SMURF2,-,Breast cancer,-,-,-,-,Dysregulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.3,-,抑制复合物
3947,KP15,25191523,"Smurf2 silencing#affected#proliferation, migration, invasion, focus formation, and cell cycle in human breast cancer cells",Cell Cycle Control,SMURF2,Breast cancer cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
6629,KP15,25191523,Smurf2 silencing#resulted in#decreased focus formation potential and clonogenicity in breast cancer cells,Phenotype triples,SMURF2,Breast cancer cells,Breast cancer,-,-,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
4532,KP15,25191523,Smurf2#regulates#AKT-dependent cell proliferation and invasion via CNKSR2,Signaling Networks,"SMURF2,AKT,CNKSR2",-,-,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
7904,KP15,28174091,Palbociclib#a selective CDK4/6 inhibitor#is approved for ER+/HER2- advanced breast cancer,Drug Development,"CDK4,CDK6",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
446,KP15,28174091,Selective inhibitors#may be best used#in combination with standard care or molecularly targeted agents,Combination Therapies,-,-,-,-,-,-,-,-,-,-,-,Inference,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
7808,KP15,27409346,Drugs targeting aberrations or signaling pathways#were evaluated in#a cell line derived from the patient,Preclinical Models,-,-,-,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
4855,KP15,27409346,NVP-BGJ398#strongly inhibited#cell proliferation and induced G0 phase accumulation in vitro,Drug Development,FGFR,-,-,NVP-BGJ398,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4496,KP15,31911865,"Adjunctive therapy including mTORC1 inhibitor, CDK4/6 inhibitors, and PI3K inhibitor#heightened#tumor response",Combination Therapies,"CDK4,CDK6,MTOR,PIK3CA",-,-,"Everolimus,Palbociclib,Ribociclib,Abemaciclib,Alpelisib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
2306,KP15,31911865,Therapeutic options for ER+ metastatic breast cancer#targeted#induction of apoptosis in p53 wild-type tumors,Therapeutic Response,TP53,-,Breast cancer,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.3,3.1.3.1,-,凋亡阈值调节
1603,KP15,31911865,Novel combination strategies#may induce#tumor cell apoptosis to delay tumor progression,Therapeutic Development,-,-,-,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
5275,KP15,24033428,"Cell viability, apoptosis, migration, invasion, and adhesion assays#were performed in#ESCC cell lines",Technical Methods,-,ESCC cell lines,Esophageal squamous cell carcinoma,-,-,-,-,-,-,-,-,Fact,3,3.4,3.4.2,3.4.2.3,-,凋亡执行
7145,KP15,39821032,RANK activation#promotes#luminal mammary epithelial cell senescence as a barrier to tumorigenesis,Cell Cycle Control,RANK,Luminal mammary epithelial cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.2,-,细胞衰老诱导
4241,KP15,39821032,Denosumab#was assessed in#clinical trials for breast cancer prevention and disease-free survival,Clinical Trial Data,-,-,Breast cancer,Denosumab,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
6930,KP15,30136059,CDK4/6 inhibitors#are explored in combination with#fulvestrant in HR+ ABC,Combination Therapies triples,"CDK4,CDK6",-,HR+ ABC,"CDK4/6 inhibitors, fulvestrant",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
245,KP15,30136059,PI3K/mTOR inhibitors#are explored in combination with#fulvestrant in HR+ ABC,Combination Therapies triples,MTOR,-,HR+ ABC,"PI3K/mTOR inhibitors, fulvestrant",PI3K/mTOR,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
5935,KP15,27249746,Acquired mutations in ESR1#occur in response to#endocrine deprivation,Molecular Event triples,ESR1,-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
429,KP15,27249746,CDK4 and CDK6#are constitutively activated in#response to endocrine deprivation,Regulation triples,"CDK4,CDK6",-,-,-,-,-,upregulated,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
6391,KP15,30381447,Ibrutinib#is being trialed in#ERBB2- or ERBB4-expressing cancers,Clinical Trial Data,"ERBB2,ERBB4",-,Cancers,Ibrutinib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
5133,KP15,30381447,Mutations in FBXW7 or SMAD4#are biomarkers for#EGFR and HER2 inhibitors,Biomarker Analysis,"FBXW7,SMAD4,EGFR,ERBB2",-,-,"EGFR inhibitors, HER2 inhibitors",-,-,-,Mutations,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.3,ESR1突变
3017,KP15,30381447,ETV4 and ETV5 expression#are biomarkers for#MEK inhibitors,Biomarker Analysis,"ETV4,ETV5",-,-,MEK inhibitors,-,-,-,Expression,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.3,p16表达
5031,KP15,30381447,JAK3 expression#is a biomarker for#ALK inhibitors,Biomarker Analysis,JAK3,-,-,ALK inhibitors,-,-,-,Expression,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.3,p16表达
7194,KP15,30381447,Biochemical and cellular selectivities of kinase inhibitors#provide#a resource for drug repurposing,Drug Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4747,KP15,25180593,TMOC#inhibits#proliferation of ovarian cancer cells,Drug Development,"BAX,BCL2",-,Ovarian cancer,TMOC,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5910,KP15,25180593,TMOC#inhibits#proliferation of A2780 and SKOV3 cells,Drug Development,"BAX,BCL2",-,Ovarian cancer,TMOC,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2445,KP15,25180593,TMOC#induces#apoptosis via suppressing Bcl-2 and Bcl-xL,Mechanism of Action,"BCL2,BCL2L1",-,-,TMOC,-,-,downregulated,-,-,-,-,Fact,3,3.4,3.4.2,3.4.2.3,-,凋亡执行
1773,KP15,25180593,TMOC#enhances#Bax and cleavage of PARP-1,Mechanism of Action,"BAX,PARP1",-,-,TMOC,-,-,upregulated,-,-,-,-,Fact,3,3.4,3.4.2,3.4.2.3,-,凋亡执行
2807,KP15,25180593,TMOC#may be developed as#a chemotherapeutic agent for ovarian cancer,Therapeutic Development,"BAX,BCL2",-,Ovarian cancer,TMOC,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2075,KP15,38385108,Rapamycin#inhibits#B16 melanoma cell viability,Drug Development,MTOR,-,Melanoma,Rapamycin,mTOR/p70-S6k,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
251,KP15,38385108,Rapamycin#induces#autophagy,Mechanism of Action,MTOR,-,Melanoma,Rapamycin,mTOR/p70-S6k,-,-,-,-,-,-,Fact,3,3.4,3.4.3,3.4.3.1,-,自噬启动
350,KP15,38385108,Rapamycin#induces#apoptosis via enhancing cleaved caspase 3 and Bax,Mechanism of Action,"CASP3,BAX",-,Melanoma,Rapamycin,-,-,upregulated,-,-,-,-,Fact,3,3.4,3.4.2,3.4.2.3,-,凋亡执行
3639,KP15,38385108,Rapamycin#increases#autophagosomes in B16 melanoma cells,Mechanism of Action,MTOR,-,Melanoma,Rapamycin,mTOR/p70-S6k,-,-,-,-,-,-,Fact,3,3.4,3.4.3,3.4.3.1,-,自噬启动
3275,KP15,38385108,Rapamycin#induces#autophagy via mTOR/p70-S6k pathway,Mechanism of Action,MTOR,-,Melanoma,Rapamycin,mTOR/p70-S6k,-,-,-,-,-,-,Fact,3,3.4,3.4.3,3.4.3.1,-,自噬启动
3773,KP15,36551637,ICB therapies#prolong#life expectancy in metastatic epithelial cancers,Therapeutic Development,-,-,Metastatic epithelial cancers,ICB therapies,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,晚期实体瘤
4959,KP15,36551637,Tumor microenvironment#induces#an immunosuppressive niche,Tumor Microenvironment,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.3,-,免疫检查点表达
5446,KP15,36551637,RTKi#modulates#local immune environment,Tumor Microenvironment,-,-,Cancer,RTKi,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.3,-,免疫检查点表达
3229,KP15,36551637,ICB and RTKi combination#shows#better results compared to individual treatment,Combination Therapies triples,-,-,Cancer,"ICB, RTKi",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
5692,KP15,36551637,"Small molecule inhibitors#target#CDK4/6, CHK1, and PARP",Drug Development,"CDK4,CDK6,CHK1,PARP",-,Tumor,-,"Cell cycle, DNA damage",-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
4968,KP15,27816190,"Triple-negative breast cancer#lacks#estrogen, progesterone, and HER2 expression",Molecular Event,"ESR1,PGR,ERBB2",-,Triple-negative breast cancer,-,"Estrogen signaling, HER2 signaling",Silenced,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.3,-,抑制复合物
7896,KP15,27816190,Patients with triple-negative breast cancer#do not benefit from#therapies targeting estrogen and HER2 signaling pathways,Therapeutic Resistance,"ESR1,PGR,ERBB2",-,Triple-negative breast cancer,-,"Estrogen signaling, HER2 signaling",-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.4,-,周期素表达失衡
5576,KP15,27816190,Heterogeneity of triple-negative breast cancer#may lead to#therapeutic opportunities,Therapeutic Development,"BRCA1,BRCA2",-,Triple-negative breast cancer,-,Oncogenic drivers,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7469,KP15,27816190,A subset of triple-negative breast tumors#expresses#androgen receptor (AR),Molecular Event,AR,-,Triple-negative breast cancer,-,AR signaling,Upregulated,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
2768,KP15,27816190,Androgen receptor (AR) expression#may benefit from#treatments inhibiting AR-signaling pathway,Therapeutic Response,AR,-,Triple-negative breast cancer,-,AR signaling,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4607,KP15,27816190,Abiraterone acetate and seviteronel#are being tested for#reducing androgen production in prostate cancer,Drug Development,AR,-,Prostate cancer,"Abiraterone acetate, Seviteronel",Androgen signaling,-,-,-,-,-,-,Fact,3,3.1,3.1.3,3.1.3.4,-,生存信号抑制
6245,KP15,23732836,TOFA#inhibits#proliferation and cell cycle progression of ovarian cancer cell lines,Drug Development,ACACA,-,Ovarian cancer,TOFA,Cell cycle,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5995,KP15,37894738,Blocking IL-17-induced oncogenic pathway#is#a new strategy for lung cancer treatment,Therapeutic Development,IL17A,-,Lung cancer,-,IL-17 signaling,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5182,KP15,37894738,Notopterol#inhibits#IL-17-promoted A549 cell proliferation,Therapeutic Development,IL17A,-,Lung cancer,Notopterol,IL-17 signaling,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6540,KP15,37894738,Notopterol#induces#G0/G1 cell cycle arrest,Molecular Event,-,-,-,Notopterol,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
1736,KP15,37894738,"Notopterol#downregulates#IL-17-activated phosphorylation of Akt, JNK, ERK1/2, and STAT3",Regulation,"AKT1,MAPK8,MAPK1,STAT3",-,Lung cancer,Notopterol,IL-17 signaling,Downregulated,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
7052,KP15,37894738,Notopterol#blocks#IL-17-induced A549 cell proliferation and invasion,Therapeutic Development,IL17A,-,Lung cancer,Notopterol,"MAPK, Akt, STAT3, AP-1, NF-κB",Invasion,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7765,KP15,37420093,A multi-omics integrative approach#unravels#novel genes and pathways associated with senescence escape in NRAS mutant melanoma,Systems Biology,NRAS,-,Melanoma,-,Senescence escape,-,-,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.2,-,衰老程序激活
984,KP15,37420093,Therapy-Induced Senescence (TIS)#leads to#sustained growth arrest of cancer cells,Molecular Event,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.4,3.4.1,3.4.1.1,-,细胞周期永久阻滞
4199,KP15,37420093,Cells escaping senescence#enhance#aggressiveness of cancers,Molecular Event,-,-,Cancer,-,Aggressiveness,-,-,-,-,-,-,Inference,1,1.4,1.4.3,1.4.3.2,-,衰老程序激活
5919,KP15,21367843,Cell cycle progression#is uncoupled from#activity and functional state of ER in these models,Cell Cycle Control,ESR1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7129,KP15,21367843,Cyclin D1 expression and RB phosphorylation#are maintained with#efficient ER ablation,Cell Cycle Control,"CCND1,RB1,ESR1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
3812,KP15,21367843,PD-0332991#induced#stable cell cycle arrest distinct from ER antagonists,Drug Development,"CDK4,CDK6",-,-,PD-0332991,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3240,KP15,21367843,PD-0332991#induced#cellular senescence in hormone therapy refractory populations,Therapeutic Response,"CDK4,CDK6",-,-,PD-0332991,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
3344,KP15,25168062,"Depletion of MIF#inhibited#melanoma proliferation, viability, and clonogenic capacity",Gene Regulation,MIF,-,Melanoma,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制
1069,KP15,37713975,PDX-B13#had#CCND1 CN gain and CDKN2A CN loss,Genomic Alterations,"CCND1,CDKN2A",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
160,KP15,37713975,PDX-Li41#had#CDKN2A and RB1 CN loss,Genomic Alterations,"CDKN2A,RB1",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
5325,KP15,37713975,PDX-Li41#had#TSC1 frameshift deletion mutation and increased mTOR activation,Genomic Alterations,"TSC1,MTOR",-,-,-,mTOR,-,upregulated,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.3,-,mTOR信号增强
2556,KP15,33398005,Lowering MCM3 expression#restored#drug sensitivity in endocrine-resistant cells,Therapeutic Response,MCM3,-,Endocrine-resistant cancer,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
70,KP15,33398005,Lowering MCM3 expression#altered#phosphorylation of cell cycle regulators,Cell Cycle Control,"MCM3,TP53,CHK1,CDC25B",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
3149,KP15,33398005,MCM3 levels#did not affect#efficacy of growth inhibition by CDK4/6 inhibitors,Drug Development,"MCM3,CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
559,KP15,32737414,Afatinib and palbociclib#demonstrated#synergy in vitro against chordoma cells,Combination Therapies,"EGFR,CDK4,CDK6",Chordoma cells,Chordoma,"Afatinib,Palbociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3207,KP15,32737414,AZD2014 and afatinib#showed#synergy in vitro against chordoma cells,Combination Therapies,-,Chordoma cells,Chordoma,"AZD2014,Afatinib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4849,KP1,33177839,"NCAPG overexpression#regulated#G1 phase through CDK4, CDK6, and Cyclin D1 overexpression and P21, P27 downregulation",Cell Cycle Control,"NCAPG,CDK4,CDK6,CCND1,CDKN1A,CDKN1B",-,-,-,Cell cycle,-,"upregulated, downregulated",-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
4180,KP1,35108033,Deregulation of the CDKN2A-CCND-CDK4/6-Rb pathway#is observed in#about 25% of unselected sarcomas,Cancer Pathways,"CDKN2A,CCND1,CDK4,CDK6,RB1",-,Sarcomas,-,CDKN2A-CCND-CDK4/6-Rb,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7405,KP1,9426066,Mutations in genes in the retinoblastoma pathway#have been implicated in#pathogenesis of many tumor types,Cancer Pathways,-,-,Tumors,-,Retinoblastoma pathway,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
2054,KP1,34483306,CDK4 amplification#causes#dysregulation of cell cycle progression,Mechanism of Action,CDK4,-,Mucosal melanoma,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
7589,KP1,11741799,p16INK4a UV-induced mutations#occur more frequently in#skin tumors from XP patients,Disease Association,CDKN2A,-,Skin tumors,-,-,XP patients,-,UV radiation,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6958,KP1,35450197,"Amplification levels for oncogenes OS9, CDK4, HMGA2, NUP107, MDM2, YEATS4, and FRS2#should be characterized for#pathologic correlation and prognostic prediction",Cancer Association,"CDK4, OS9, HMGA2, NUP107, MDM2, YEATS4, FRS2",-,-,-,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,基因拷贝数
3713,KP1,11307615,p16INK4a#inhibits#CDK4-mediated RB phosphorylation,Mechanism of Action,"CDK4, RB1",-,-,-,-,Cell cycle,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
4767,KP1,11307615,p14ARF#binds to#MDM2 leading to p53 stabilization,Mechanism of Action,"MDM2, TP53",-,-,-,-,Cell cycle,-,-,-,-,-,Fact,1,1.3,1.3.3,1.3.3.1,-,P53通路相互作用
4853,KP3,35304604,CDK4 and CDK6#are critical for#cellular transition into S phase,Cell Cycle Control,"CDK4, CDK6",-,-,-,-,Cell cycle,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,G1/S期转换调控
5968,KP3,26658964,CDK4/6 inhibitors#might prove valuable in#cancer therapy when combined with mitogen-dependent pathway inhibition,Combination Optimization,"CDK4, CDK6",-,Cancer,-,-,Mitogen-dependent signaling,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1428,KP3,35878668,"CDK4/6 inhibitors (abemaciclib, palbociclib, ribociclib)#control#cell cycle",Cell Cycle Control,"CDK4,CDK6",-,-,"Abemaciclib, Palbociclib, Ribociclib",-,Cell cycle,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6357,KP3,39026843,CDK4/6 inhibitors#influence#DNA damage repair pathways during radiotherapy,Mechanism of Action,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,DNA damage repair,-,-,-,-,-,Inference,5,5.1,5.1.1,5.1.1.4,-,DNA合成修复
3330,KP3,35298959,Combination of an ALK inhibitor with a CDK4/6 inhibitor#may act synergistically to overcome#drug resistance mechanisms,Combination Optimization,"ALK,CDK4,CDK6",-,Drug resistance,-,-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
7373,KP3,39574120,There#is a lack of#biomarkers to identify breast cancer patients who would benefit from CDK4/6 inhibitors,Biomarker Analysis,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
767,KP3,33579347,FGFR1 overexpression and amplification#are correlated with#luminal A or B HRPBC,Expression Patterns,FGFR1,-,Luminal A or B HRPBC,-,-,-,-,Overexpression,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
5022,KP3,33579347,Role of FGFR1 inhibitors#is#unclear in HRPBC,Drug Development,FGFR1,-,HRPBC,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1158,KP3,33579347,"FGFR1-overexpressing cell line variants#were generated from#ER+ MCF7, T47-D, and HCC1428 cell lines",Preclinical Models,FGFR1,-,ER+ breast cancer,-,-,-,-,Overexpression,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
7010,KP3,33579347,"Role of ER, CDK4/6, and/or FGFR1 blockade#was studied in#Rb phosphorylation, cell cycle, and survival",Cell Cycle Control,"ESR1,CDK4,CDK6,FGFR1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
1716,KP3,33579347,FGFR1 amplification or overexpression#occurred regardless of#luminal subtype but was higher in luminal B tumors,Expression Patterns,FGFR1,-,"Luminal A, Luminal B tumors",-,-,-,Overexpression,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
7830,KP3,33579347,"Primary FGFR1 amplification, mRNA overexpression, or LTED-R-acquired FGFR1 overexpression#led to#resistance against hormonotherapy alone or in combination with palbociclib",Mechanisms of Resistance,FGFR1,-,Resistance,Palbociclib,-,-,Overexpression,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
1199,KP3,33579347,Hormonal deprivation#leads to#FGFR1 overexpression,Regulation,FGFR1,-,-,-,-,-,Overexpression,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
3407,KP3,36127291,CDK4/6 inhibitors combined with aromatase inhibitors#were approved by FDA as#first-line therapy for ER(+) BC,Clinical Implementation,"CDK4,CDK6",-,ER(+) breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
3004,KP3,32623094,"CDK4/6 inhibitors plus endocrine therapy#improved#overall survival of pre- or perimenopausal women with hormone-receptor-positive, HER2-negative MBC",Therapeutic Response,"CDK4,CDK6",-,"Hormone-receptor-positive, HER2-negative MBC",-,-,-,Pre- or perimenopausal women,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,8.5.1.3.1,症状改善
2003,KP3,29146887,Preclinical and early clinical data#discuss#putative novel targets for molecular targeted therapy of NETs of the GEP system,Preclinical Models,"CDK4,CDK6,p53,RB1",-,Neuroendocrine tumors (NETs),-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
4074,KP3,28978144,PI3K/mTOR inhibitor combined with radiation#exhibits#synergistic inhibition of AKT/mTOR axis,Combination Therapies triples,"PI3K, MTOR, AKT",-,-,PI3K/mTOR inhibitors,AKT/mTOR axis,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
1304,KP4,39877469,Targeted therapies#support development of#CDK4/6 inhibitors and immunotherapies targeting PD-1 and CTLA-4 pathways,Drug Development,"CDK4,CDK6,PDCD1,CTLA4",-,-,CDK4/6 inhibitors,"PD-1, CTLA-4",-,-,-,-,-,-,Fact,3,3.3,3.3.2,3.3.2.1,-,PD-1/PD-L1表达
88,KP4,35681700,TP53-modulating drugs#are possibly effective in#20-26% of patients,Therapeutic Development,TP53,-,-,TP53-modulating drugs,Wnt signaling,20-26% of patients,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.2,-,细胞死亡标志物
1555,KP4,30290287,MYC-overexpressing clones#displayed#increased levels of cyclin D and E,Expression Patterns,"MYC,CCND1,CCNE",-,-,-,-,-,upregulated,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
4323,KP5,32944234,"miR-214-3p#up-regulates#cell cycle genes including Cyclin B, Cyclin D, Cyclin E, and CDK4",Regulation,"CDK4,CCNB1,CCND1,CCNE",-,-,-,Cell cycle,-,upregulated,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6603,KP5,9105418,Immortal mouse mammary outgrowths#express#high levels of Cyclin B1,Expression Patterns,CCNB1,-,-,-,-,-,upregulated,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
1953,KP5,17949234,JNK2/p38 suppression#impacted#gene expression profile of CML cell lines (K562/KU-812),Expression Patterns,"JNK2,MAPK14",-,Chronic myeloid leukemia (CML),-,MAPK,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
405,KP5,17457042,erbB2-inhibited cells#showed#reduced cyclin D1 and CDK6,Expression Patterns,"CCND1,CDK6",-,-,-,Akt/GSK-3/Cdc2 pathway,-,downregulated,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
6749,KP5,17457042,erbB2-inhibited cells#showed#increased phospho-Cdc-2 (Tyr15) and p15INK4B,Expression Patterns,"CDC2,CDKN2B",-,-,-,Akt/GSK-3/Cdc2 pathway,-,upregulated,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6400,KP5,17457042,Nonfunctional EGFR/erbB2 complexes#blocked#progression of cells through G2/M,Cell Cycle Control,"EGFR,ERBB2",-,-,-,Akt/GSK-3/Cdc2 pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
6726,KP6,7478527,G1-associated cdks#phosphorylate#a 88 kDa protein,Mechanism of Action,"CDK4,CDK6",-,-,-,G1 phase cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
4648,KP6,7592908,pRb phosphorylation#allows#cell cycle progression from G1 to S phase,Cell Cycle Control triples,RB1,-,-,-,-,G1/S transition,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
1212,KP6,30143714,D-type cyclins/CDK4/6#drive#progression through G1 phase of cell cycle,Cell Cycle Control triples,"CCND1,CCND2,CCND3,CDK4,CDK6",-,-,-,-,G1 phase,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
3318,KP7,26658964,D-type cyclins and CDK4/6#regulate#entry into the S phase of the cell cycle in a RB-dependent manner,Cell Cycle Control,"CCND1,CDK4,CDK6",Mammalian cells,-,-,-,RB pathway,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
1165,KP7,30343527,CDK4/6 inhibitors#target#cyclin D-CDK4/6-RB axis,Mechanism of Action,"CDK4,CDK6,CCND1",RB pathway,-,-,-,RB pathway,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
7218,KP7,28580868,Cyclin D and CDK4/6#phosphorylate and inactivate#retinoblastoma protein,Mechanism of Action,"CDK4,CDK6,RB1",-,-,-,-,Cell cycle progression,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
5704,KP7,19597485,CDK4-pRB-E2F1 pathway#is involved in#glucose homeostasis,Metabolic Integration,"CDK4,RB1,E2F1",-,-,-,-,Glucose,-,-,-,-,-,Fact,4,4.1,4.1.1,4.1.1.4,-,糖原代谢调节
5041,KP7,16738322,Mutations in p18 Ink4c and Pten#interact with#the Rb pathway in tumor suppression,Signaling Networks,"CDKN2C,PTEN",-,Tumor,-,-,Rb pathway,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2469,KP7,9377576,Cyclin D1#forms a complex with#CDK4 to inactivate pRB via phosphorylation,Protein Complex Dynamics,"CDK4,CCND1,RB1",-,-,-,-,pRB pathway,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3753,KP8,10777219,CDK4 and CDK6#phosphorylate#retinoblastoma protein (pRB),Mechanism of Action,"CDK4,CDK6",Retinoblastoma protein,-,-,-,G1/S cell-cycle restriction point,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
4718,KP8,22493355,CDK6#is involved in#cell cycle regulation,Mechanism of Action,CDK6,-,-,-,-,Cell cycle regulation,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
1917,KP8,35373292,CDK inhibitors#block#cell-cycle progression,Mechanism of Action,"CDK4,CDK6",-,-,-,-,Cell cycle progression,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
2257,KP8,25876993,Cyclin D/CDK pathway imbalance#results in#proliferative phenotype in cancer cells,Cancer Pathways,"CDK4,CDK6",-,Cancer,-,-,Cyclin D/CDK pathway,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.4,-,周期素表达失衡
4610,KP8,18855578,Targeting signal transduction pathways#is#a promising therapeutic strategy for treating cancer,Therapeutic Development,-,-,Cancer,-,-,Signal transduction,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1746,KP8,17060721,p16 protein#binds to#CDK4 and inhibits its interaction with cyclin D1,Mechanism of Action,"CDKN2A,CDK4,CCND1",-,Esophageal squamous cell carcinoma,-,-,Cell cycle,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
5156,KP8,24258989,Mutated p16INK4a#shows#impaired capacity to inhibit the cyclin D1-CDK4 complex,Mechanism of Action,"CDKN2A,CCND1,CDK4",-,-,-,-,Cell cycle,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
1606,KP8,10962575,p19INK4d#negatively regulates#cyclin D/CDK4(6) complexes,Mechanism of Action,"CDKN2D,CDK4",-,Testicular germ-cell tumors,-,-,G1/S transition,-,High (normal spermatogenesis),-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
4111,KP8,10962575,Lack of p19INK4d in human fetal germ cells#supports#concept of fetal origin of testicular germ-cell tumors,Molecular Event triples,CDKN2D,-,Testicular germ-cell tumors,-,-,RB pathway,-,Downregulated,-,-,-,Inference,2,2.2,2.2.1,2.2.1.1,-,RB通路缺陷
7934,KP8,25070834,SRJ23 treatment#downregulates#CDK1 without affecting CDK4 and cyclin D1 levels,Regulation,"CDK1,CDK4,CCND1",-,-,SRJ23,-,-,-,Downregulated (CDK1),-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
6887,KP8,33228782,Roquin1 overexpression#inhibits#cell proliferation and induces G1/S cell cycle arrest,Mechanism of Action,ROQUIN1,-,-,-,-,G1/S transition,-,Upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6566,KP9,20196171,CDK4#is involved in#cell cycle progression,Cell Cycle Control,CDK4,-,-,-,-,Cell cycle,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
1995,KP10,11115071,Geldanamycin#inhibited#kinase activity of cyclin D1/CDK4 complexes and blocked cell cycle progression,Mechanism of Action,"CCND1,CDK4",-,-,Geldanamycin,-,Cell cycle,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
5777,KP11,38173098,MED8#promotes#G1/S phase transition in gastric cancer cells,Cell Cycle Control,"MED8,CDK4,CCND1",MGC-803 cells,Gastric cancer,-,-,G1/S transition,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,G1/S期转换调控
6883,KP14,29437706,Targeting Cyclin D-CDK4/6#sensitizes#immune-refractory cancer by blocking the SCP3-NANOG axis,Mechanism of Action,"CDK4,CDK6,SCP3,NANOG",-,Immune-refractory cancer,-,-,Cyclin D-CDK4/6 axis,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
1655,KP14,31396487,"Mechanisms of resistance to CDK4/6 inhibitors#involve#Rb, cyclin E1, and the PIK3CA pathway",Mechanisms of Resistance,"CDK4,CDK6,RB1,CCNE1,PIK3CA",-,Breast cancer,-,-,PIK3CA,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
7710,KP14,25568671,Doxazosin growth suppression#was abolished by#JAK/STAT inhibitor treatment,Mechanism of Action,"JAK,STAT",-,-,Doxazosin,JAK/STAT,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
3213,KP14,25568671,Activity of JAK/STAT#is dependent on#the level of doxazosin,Regulation,"JAK,STAT",-,-,Doxazosin,JAK/STAT,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
1775,KP14,25568671,Doxazosin plus IFN-伪 or IFN-纬#suppress#JAK/STAT signaling through phosphorylation,Mechanism of Action,"JAK,STAT",-,-,Doxazosin,"JAK/STAT,PI3K,mTOR,70S6K,PKC",-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
883,KP14,25568671,Doxazosin#modulates#apoptotic effects of IFN-伪 and IFN-纬 through JAK/STAT signaling,Mechanism of Action,"JAK,STAT",-,-,Doxazosin,JAK/STAT,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
2924,KP14,25792301,CDKs#modulate#cell cycle entry and progression in response to growth signals,Mechanism of Action,"CDK4,CDK6",-,-,Palbociclib,-,Cell cycle,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
1166,KP14,37866161,SGK3#maintains#redox homeostasis,Molecular Event,SGK3,-,Cervical cancer,PIK3CA,-,Redox homeostasis,PIK3CA helical domain mutations,-,-,-,-,Fact,4,4.3,4.3.1,4.3.1.3,-,抗氧化系统激活
4800,KP15,30401694,Abemaciclib#induces#distinctive changes in intestinal gene expression,Regulation,"CDK4,CDK6",-,-,abemaciclib,-,-,-,"upregulated, downregulated",-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
6271,KP15,30401694,Morphologic changes in the intestine#are characterized by#proliferation of crypt cells,Cell Cycle Control,-,crypt cells,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
2450,KP15,30401694,Morphologic changes in the intestine#are characterized by#loss of goblet cells,Cell Cycle Control,-,goblet cells,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3210,KP15,30401694,Abemaciclib#downregulates#enterocyte membrane transporters,Regulation,"CDK4,CDK6",enterocytes,-,abemaciclib,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
4922,KP15,30401694,Abemaciclib#upregulates#genes associated with cell proliferation,Expression Patterns,"CDK4,CDK6",-,-,abemaciclib,Wnt,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
3185,KP15,24469340,LKB1-induced G1 arrest#is accompanied by#downregulation of cyclin D1 and cyclin D3,Expression Patterns,"LKB1,CCND1,CCND3",-,-,-,-,downregulated,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
3981,KP15,24469340,"LKB1-induced G1 arrest#is accompanied by#upregulation of p53, p21, and p16",Expression Patterns,"LKB1,TP53,CDKN1A,CDKN2A",-,-,-,-,upregulated,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
7518,KP15,32259210,"DCZ0801#increases#expression of caspase-3, caspase-8, caspase-9, and Bax",Expression Patterns,"CASP3,CASP8,CASP9,BAX",-,-,-,-,upregulated,-,-,-,-,-,Fact,3,3.4,3.4.2,3.4.2.3,-,凋亡执行
4003,KP15,32259210,DCZ0801#decreases#expression of BCL-2 and BCL-XL,Expression Patterns,"BCL2,BCL2L1",-,-,-,-,downregulated,-,-,-,-,-,Fact,3,3.4,3.4.2,3.4.2.1,-,内源性途径激活
1632,KP15,32259210,"DCZ0801#induces#G0/G1 phase arrest by downregulating CDK4, CDK6, and cyclin D1",Cell Cycle Control,"CDK4,CDK6,CCND1",-,-,-,-,downregulated,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
7299,KP15,36530984,CDK4/6 inhibitors#block#Rb phosphorylation in the G1 to S phase transition,Cell Cycle Control,"CDK4,CDK6",Retinoblastoma protein,-,-,-,G1 to S phase transition,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
5601,KP15,36530984,"Studies#focus on#MEK inhibitors, PI3K-AKT-MTOR pathways, EGFR inhibitors, and MAPK pathways",Signaling Networks,-,-,-,"MEK inhibitors,EGFR inhibitors,PI3K-AKT-MTOR inhibitors,TKI inhibitors","PI3K-AKT-MTOR,EGFR,MAPK",-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
7168,KP15,30287548,Uncontrolled proliferation of cancer cells#led to#development of small-molecule inhibitors targeting cell-cycle progression,Therapeutic Development,-,-,Cancer,Small-molecule inhibitors,-,Cell cycle,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3446,KP15,29483206,"Inhibition of mTORC1/2#causes#a decrease in cyclin D1 protein, RB phosphorylation, and E2F-mediated transcription",Mechanism of Action,"CCND1,RB1,E2F1",-,-,-,mTORC1/2,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.2,-,E2F转录因子释放
2034,KP15,39732370,PT-mediated co-assembly#enhances#cytotoxicity and synergy of PAL by inhibiting PI3K/AKT/mTOR signaling pathway,Combination Therapies,"CDK4,CDK6",-,-,Palbociclib,-,PI3K/AKT/mTOR,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
4484,KP15,36817127,Palbociclib#mediated#G0/G1 cell cycle arrest,Cell Cycle Control,"CDK4,CDK6",-,-,Palbociclib,-,G0/G1 cell cycle arrest,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4870,KP1,15967107,"AKT1, BMI1, CDK6, CTNNB1, E2F1, GPNMB, GPRK7, KBRAS2, LDB2, LIMK1, MAPK1, MEL, MP1, MUC18, NRCAM, PBX3, RAB22A, RAB38, SNK, and STK4#are associated with#chromosomal breakpoints and altered gene expression",Expression Patterns,"AKT1,BMI1,CDK6,CTNNB1,E2F1,GPNMB,GPRK7,KBRAS2,LDB2,LIMK1,MAPK1,MEL,MP1,MUC18,NRCAM,PBX3,RAB22A,RAB38,SNK,STK4",-,-,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
5285,KP1,21353380,p16#is downregulated in#hTERT immortalized urothelial cells,Regulation,CDKN2A,Urothelial cells,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.5,1.5.2,1.5.2.3,-,抑制复合物
157,KP3,38746324,No standardized sequence for subsequent treatment lines#exists after#disease progression on endocrine therapy plus CDK4/6 inhibitor,Treatment Monitoring triples,"CDK4,CDK6",-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
2763,KP3,39662449,Deregulation of CDK4/6 activity#is widespread in#non-small cell lung cancer,Cancer Pathways,"CDK4,CDK6",-,Non-small cell lung cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7246,KP3,39662449,CDK4/6 inhibitors#showed#poor antitumor activity as monotherapy,Therapeutic Response,"CDK4,CDK6",-,Non-small cell lung cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7716,KP3,39662449,PARP1 expression#was upregulated in#non-small cell lung cancer,Expression Patterns,PARP1,-,Non-small cell lung cancer,-,-,-,-,upregulated,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,基因表达改变
6296,KP3,39662449,Combining PARP1 and CDK4/6 inhibition#was analyzed in#non-small cell lung cancer models,Combination Therapies triples,"PARP1,CDK4,CDK6",-,Non-small cell lung cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
255,KP3,35614407,CDKN2A#is associated with#shorter overall survival in LM-LUAD patients,Cancer Association,CDKN2A,-,Leptomeningeal metastases of lung adenocarcinoma,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
7885,KP6,33046519,TNO155#blocks#feedback activation of wild-type KRAS or other RAS isoforms,Mechanism of Action,KRAS,-,KRAS(G12C) cancer,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
2537,KP6,33415002,CDK6 knockdown#inhibits#lung metastasis,Cancer Pathways,CDK6,-,Lung metastasis,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
6154,KP6,11369633,"Rb, CDK, and CDK inhibitor genes#regulate#cell generation",Cell Cycle Control,CDK,-,Tumorigenesis,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6865,KP6,11369633,"p16(INK4a) and p14(ARF)#represent#a cellular response to abnormalities in cyclin D, CDK4/CDK6, Rb, or E2F",Cell Cycle Control,"CDK4,CDK6,RB1,E2F",-,PV,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
4934,KP6,35418303,70 kinase inhibitors#were applied to#MCF-7 cells with ET resistance,Preclinical Models,-,MCF-7 cells,ET-resistant breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
7624,KP6,35418303,Low CHK1 levels#extend#relapse-free survival in luminal A BC patients,Prognostic Associations,CHK1,-,Luminal A breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
1925,KP6,35418303,CHK1#could be#an appealing pharmacological target for luminal primary and MBCs,Drug Development,CHK1,-,Luminal primary and metastatic breast cancers,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
5137,KP6,34036394,CDK4 overexpression#is#a predictive biomarker for chemotherapy resistance in osteosarcoma,Predictive Biomarkers,CDK4,-,Osteosarcoma,-,-,-,-,Upregulated,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
7018,KP6,34036394,Genomic markers#predict#chemosensitivity in osteosarcoma,Biomarker Analysis,-,-,Osteosarcoma,-,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,-,-,基因组标志物
5812,KP6,7705923,G1-phase-controlling pathway#can become deregulated through#oncogenic aberrations,Cancer Pathways,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7691,KP8,38003483,TWIST1 upregulation#is a potential target for reversing resistance to#CDK4/6 inhibitors in metastatic luminal breast cancer,Therapeutic Resistance,"CDK4, CDK6",-,Metastatic luminal breast cancer,CDK4/6 inhibitors,-,-,upregulated,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
3828,KP8,38003483,"CDK4/6 inhibitors#improve#progression-free survival in HR+, HER2- metastatic luminal breast cancer",Therapeutic Response,"CDK4, CDK6",-,Metastatic luminal breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
4376,KP14,28778953,Pathway blockage#results in#EOC cell death,Mechanism of Action,-,EOC cells,EOC,-,"DNA damage response, apoptosis",Increased apoptosis,-,-,-,-,-,Fact,3,3.4,3.4.2,3.4.2.1,-,内源性途径激活
6196,KP14,34985783,Therapy-induced senescent cells#can have#pro-tumorigenic and pro-disease functions via SASP activation,Mechanism of Action,-,Senescent cells,-,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.2,3.1.2.2,-,衰老相关分泌表型
3492,KP14,35187951,CDK4/6 inhibitors#induce#cell-cycle arrest and tumor senescence without apoptotic cell death,Mechanism of Action,"CDK4,CDK6",-,Tumor,-,"Cell-cycle arrest, tumor senescence",-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6242,KP14,8797766,cyclin D1 protein#is elevated in#variety of cancers,Expression Patterns,CCND1,-,"breast cancer,head and neck cancer,non-small-cell lung cancer,mantle cell lymphomas",-,-,-,upregulated,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3736,KP14,35219113,CDK4/6 inhibitors#showed#clinical activity in cancer patients,Therapeutic Response,"CDK4,CDK6",-,cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
7106,KP14,36797347,resistance activation#not explained by#genomic alterations alone,Mechanisms of Resistance,"CDK4,CDK6",-,metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
7522,KP14,29582246,novel agents#changed#treatment landscape for postmenopausal HR+/HER2- metastatic breast cancer,Drug Development,"CDK4,CDK6",-,HR+/HER2- metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
3385,KP14,32349307,Cyclin-dependent kinases#are overexpressed in#a wide range of human malignancies,Expression Patterns,"CDK4,CDK6",-,Human malignancies,-,-,Upregulated,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7898,KP15,24795392,"CDK4 inhibitors#have shown#antitumor activity in breast cancer, lymphoma, sarcoma, and other tumors",Cancer Association,CDK4,-,"Breast cancer, lymphoma, sarcoma, other tumors",-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6421,KP15,36825764,CDK4/6 inhibitors#are#targeted therapeutic drugs for breast cancer treatment,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1313,KP15,37974598,CDK4/6 inhibitors#are used for#treatment of HR+/HER2- advanced or metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,HR+/HER2- advanced or metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
3033,KP15,38927958,Prolonged HER2 inhibitor treatment#transforms#HER2+ breast cancers into TNBC-like cells,Resistance Mechanisms,HER2,-,"HER2+ breast cancer, TNBC",-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
4076,KP15,36876172,Combination therapy#is superior to#endocrine monotherapy in HR+/HER2- advanced breast cancer,Combination Therapies,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.4,-,耐药机制克服
3909,KP1,32913968,Patients with CDK4/6 amplifications#may respond to#palbociclib or ribociclib,Therapeutic Response,"CDK4,CDK6",-,-,"Palbociclib,Ribociclib",-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5794,KP1,11764090,Anaplastic oligodendrogliomas#showed#alterations in the TP53 pathway,Cancer Pathways,"TP53, MDM2",-,Anaplastic oligodendrogliomas,-,TP53 pathway,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.4,-,DNA合成修复
4834,KP1,15507938,NRAS and TOP2A#show#high copy number amplifications,Genomic Alterations,"NRAS,TOP2A",-,-,-,-,-,Amplified,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
6763,KP1,15507938,Altered genes#are associated with#EAs as tumor suppressors and/or oncogenes,Cancer Association,"LRP1B,DAB2,DCC,NRAS,TOP2A,NCOA3,ARSA",-,EAs,-,-,-,-,-,-,-,-,Inference,5,5.4,5.4.3,5.4.3.3,-,信号通路改变
4186,KP1,18042149,RAS-RAF-MEK-ERK pathway#is dysregulated in#melanocytic tumors,Pathway & Network Categories,"BRAF,NRAS,KIT",-,Melanocytic tumors,-,RAS-RAF-MEK-ERK,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
1974,KP1,18042149,p16 INK4A-CDK4-RB pathway#is dysregulated in#melanocytic tumors,Pathway & Network Categories,CDK4,-,Melanocytic tumors,-,p16 INK4A-CDK4-RB,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
1713,KP1,18042149,ARF-p53 pathway#is dysregulated in#melanocytic tumors,Pathway & Network Categories,TP53,-,Melanocytic tumors,-,ARF-p53,-,-,-,-,-,-,Fact,1,1.3,1.3.3,1.3.3.1,-,P53通路相互作用
3930,KP1,18023021,Five novel CDKN2A variants#were identified in#melanoma families,Molecular Event triples,CDKN2A,-,Melanoma,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
6133,KP1,19712690,p16(23Asp)#was less efficient in#inhibiting pRb phosphorylation,Structural Biology,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
3974,KP1,19712690,p16(23Asp)#was less efficient in#inducing G1 cell cycle arrest,Cell Cycle Control,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
1455,KP1,32988156,"Most common mutant genes#include#TP53, CDKN2A, MDM2, CDK4, NF1, and PTEN",Genetic Alterations,"TP53,CDKN2A,MDM2,CDK4,NF1,PTEN",-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
5657,KP1,10981874,Both cases#retain#an mdm2+/p53+/cdk4+ immunophenotype consistent with the genotype,Molecular Event,"MDM2,TP53,CDK4",-,-,-,-,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7211,KP1,38261397,MCPyV-positive and MCPyV-negative MCCs#are considered as#different tumors,Tumor Classification,MCPyV,-,Merkel cell carcinoma (MCC),-,UVR,-,-,-,Sun exposure,-,-,Fact,6,6.1,6.1.1,6.1.1.3,6.1.1.3.1,PD-1/PD-L1表达
1618,KP1,12497626,Mutations in exon 2#can impair#p16INK4A and p14ARF,Mutation Frequencies,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
7305,KP1,33568653,CDK4#is somatically altered in#critical pathways including Rb pathway,Signaling Networks,CDK4,-,Tumors,-,Rb pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
6802,KP1,10665922,Loss of p16INK4a expression#would disrupt#Rb/p16INK4a/cyclin D-dependent kinase (CDK4) pathway,Mechanism of Action,"CDKN2A,CDK4",-,-,-,Rb/p16INK4a/cyclin D-dependent kinase,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
679,KP1,10665922,Loss of p14ARF expression#would inactivate#Rb and p53/MDM2/p14ARF pathways,Mechanism of Action,"CDKN2A,TP53,MDM2",-,-,-,Rb and p53/MDM2/p14ARF,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2361,KP1,10665922,MDM2#can complex with#Rb or p53,Protein Interaction triples,"MDM2,RB1,TP53",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
7244,KP1,23661264,CDK4#is implicated in#alveolar rhabdomyosarcoma,Cancer Association,CDK4,-,Alveolar rhabdomyosarcoma,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
656,KP1,23661264,cMET regulation#is implicated in#alveolar soft parts sarcoma,Cancer Association,MET,-,Alveolar soft parts sarcoma,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
5517,KP1,23661264,Metabolic abnormalities#are observed in#wild-type/SHD GIST,Metabolic Integration,-,-,Gastrointestinal stromal tumors (GIST),-,Metabolic abnormalities,-,-,-,-,-,-,Fact,4,4.1,4.1.3,4.1.3.1,-,关键酶活性调节
421,KP1,29996110,Genomic rearrangements#are associated with#widespread copy-number alteration patterns,Genetic Alterations,"TERT,ERBB2,CDK12,CDK4,TP53,RB1,PTEN,STK11",-,-,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.2,5.4.2.3,-,DNA修复错误
6659,KP1,37671310,amplifications in CDK4/6#form#different genetic signatures affecting response to monoclonal antibody-based regimens,Genetic Alteration,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
5135,KP1,23851445,"Mutual exclusivity#was revealed among#components of p16(INK4A)-CDK4-RB, RAS-RAF-MEK-ERK, and PI3K-AKT pathways",Cancer Pathways,"CDK4,CDKN2A,RB1,PIK3CA,AKT1,RAF1,MEK1,RAS",-,Melanoma,-,"p16(INK4A)-CDK4-RB, RAS-RAF-MEK-ERK, PI3K-AKT",-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
7128,KP1,23851445,Promoter hypermethylation of RARB#is inversely correlated with#CDKN2A alterations affecting p14(ARF),Regulation,"RARB,CDKN2A",-,Melanoma,-,RAR signaling,-,-,-,-,-,-,Inference,1,1.5,1.5.1,1.5.1.2,-,DNA甲基化
7467,KP1,17457042,TP53#is frequently mutated in#glioblastomas,Cancer Association,TP53,-,Glioblastomas,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
5632,KP1,24931142,Molecular aberrations#led to#activation of PI3K/AKT/mTOR pathway,Pathway Activation,"MTOR,PIK3CA,NF1",-,-,-,PI3K/AKT/mTOR,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
2908,KP1,24931142,Aberrations in Wnt pathway genes CTNNA1 and CTNNB1#led to#activation of Wnt pathway,Pathway Activation,"CTNNA1,CTNNB1",-,-,-,Wnt,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
7546,KP1,11704835,"INK4a-ARF locus#encodes#p16(INK4a) and p14(ARF), which regulate Rb-CDK4 and p53 pathways",Regulation,"CDKN2A,CDK4,TP53",-,-,-,"Rb-CDK4,p53",-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
308,KP2,18760195,p16INK4a#binds to#CDK4 and CDK6 competitively with cyclin D1,Mechanism of Action,"CDKN2A,CDK4,CDK6",-,-,-,Rb pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6528,KP2,18760195,p16INK4a#prevents#phosphorylation of pRB,Mechanism of Action,CDKN2A,-,-,-,Rb pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2599,KP2,33403024,Co-amplification of CDK4 and MDM2#indicates#cell cycle dysregulation,Cancer Association,"CDK4,MDM2",-,METex 14 alteration,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
3655,KP2,37524847,H3G34-mutant DHG#has#higher rates of targetable alterations in cell-cycle pathway genes,Cancer Association,"CDK4,CDK6,CDKN2A,CDKN2B",-,Diffuse high-grade glioma (DHG),-,Cell cycle,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
580,KP2,33314017,CDK6 translocations#are associated with#a subgroup of splenic marginal zone lymphomas,Cancer Association,CDK6,-,Splenic marginal zone lymphomas,-,-,-,"CD5 expression, prolymphocytic cells, TP53 abnormalities",-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,7.2.1.2.4,TP53异常
240,KP2,38807144,Markers of cell proliferation and CDK4/6 signaling pathway#are assessed by#immunohistochemical analyses and western blot,Technical Methods,"CDK4,CDK6",-,-,-,CDK4/6 pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
3310,KP2,19609742,GLI/CDK4#is amplified in#22.6% of 31 samples,Cancer Association,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
4705,KP2,19609742,MDM2#is amplified in#12.9% of 31 samples,Cancer Association,MDM2,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
6549,KP2,19609742,PIK3C2B/MDM4#is amplified in#12.9% of 31 samples,Cancer Association,"PIK3C2B,MDM4",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.3,-,MDM2扩增
484,KP2,38411299,Chromosome analysis#showed#a 7+/10- signature in 90% of cases,Genomic alteration,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.2,5.2.2.2,-,非整倍体
6055,KP3,32346095,Anticancer activity of CDK4/CDK6 inhibitors#results from#cell cycle blockade and immunostimulatory effects,Mechanism of Action,"CDK4, CDK6",-,Cancer,-,"Cell cycle, Immunostimulation",-,-,-,-,-,-,Inference,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
1794,KP3,39447792,Targeted therapies#improve#outcomes for breast cancer patients,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
5195,KP3,39447792,CDK4/6 inhibitors#are associated with#side effects,Safety Monitoring,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,Side effects,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
7992,KP3,39218402,CDK4/6 inhibitors#transform#HR+ breast carcinoma treatment landscape,Therapeutic Development,"CDK4,CDK6",-,HR+ breast carcinoma,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
554,KP3,28760782,Palbociclib#is approved for#advanced breast cancer,Drug Development,"CDK4,CDK6",-,Advanced breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5017,KP3,32967938,CDK4/6 inhibitors#improve#progression-free survival for metastatic ER+ breast cancers,Therapeutic Response,"CDK4,CDK6",-,ER+ metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3624,KP3,28151717,CDK4/6 small-molecule inhibitor#effectively targets#mutant NOTCH1-driven mouse models of T-ALL,Drug Development,"CDK6,NOTCH1",T cells,T-ALL,CDK4/6 small-molecule inhibitor,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6762,KP3,28151717,LEE011 with dexamethasone or everolimus#prolonged#survival in orthotopic mouse models of T-ALL,Combination Optimization,"CDK4,CDK6",T cells,T-ALL,"LEE011,dexamethasone,everolimus",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
7734,KP3,28151717,LEE011#is active in#T-ALL,Drug Development,"CDK4,CDK6",T cells,T-ALL,LEE011,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4664,KP3,30397176,CDK4/6 pathway#is a dependency in#Ewing sarcoma,Pathway & Network Categories,"CDK4,CDK6",-,Ewing sarcoma,-,CDK4/6 pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
7285,KP3,34852292,CDK4/6 inhibitors#are used in#HR+/HER2-negative breast cancer,Drug Development,"CDK4,CDK6",-,HR+/HER2-negative breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5374,KP3,33805656,Clo and Fenti#synergize with#CDK4/6 inhibitors in tumor spheroids,Combination Optimization,"CDK4,CDK6",-,Cancer,"Clo,Fenti,palbociclib,abemaciclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3838,KP3,32929370,CDK4/6 inhibitors#enhance#antitumor immunity in preclinical models,Therapeutic Response,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.3,3.3.1,3.3.1.1,-,免疫细胞浸润增加
7179,KP3,30692100,CDK4/6 inhibitors#are combined with#endocrine therapy for ER-positive metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,ER-positive metastatic breast cancer,"CDK4/6 inhibitors,endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
5807,KP3,33409716,CDK4/6 inhibitors#are used in#HR-positive and HER2-negative metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR-positive and HER2-negative metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5925,KP3,33319074,"Palbociclib, ribociclib, and abemaciclib#were approved by#EMA for breast cancer treatment",Drug Development,"CDK4,CDK6",-,Breast cancer,"Palbociclib, ribociclib, abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
3067,KP3,34422318,Neoadjuvant CDK4/6 inhibitors with endocrine therapy#are used in#metastatic breast cancer treatment,Therapeutic Response,"CDK4,CDK6",-,Metastatic breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,内分泌治疗联合
3420,KP3,37675539,CDK4/6 inhibitors#are combined with#PI3K/AKT/mTOR inhibitors for treatment,Combination Therapies,"CDK4,CDK6,PIK3CA,AKT1,MTOR",-,Breast cancer,"CDK4/6 inhibitors, PI3K/AKT/mTOR inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
1820,KP3,37230537,CDK4/6 inhibitors with endocrine therapy#are mainstay treatment for#HR-positive breast cancer,Therapeutic Response,"CDK4,CDK6",-,HR-positive breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
2857,KP3,34347542,Ribociclib#is combined with#TOTEM or everolimus for refractory malignancies,Combination Therapies,"CDK4,CDK6",-,Recurrent or refractory malignancies,"Ribociclib, TOTEM, everolimus",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
7225,KP3,29218622,CDK4/6 inhibitors#are standard of care for#advanced HR-positive breast cancer,Clinical Implementation,"CDK4,CDK6",-,Advanced HR-positive breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
3018,KP3,34944961,Combination BRAF-MEK and CDK4/6 inhibitors#enhance#Adoptive Cell Transfer in melanoma,Combination Therapies,"CDK4,CDK6",-,Melanoma,"BRAF-MEK inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
5334,KP3,34944961,Immune checkpoint inhibitors#target#CTLA-4 and PD-1 in metastatic melanoma treatment,Therapeutic Development,"CTLA4,PDCD1",-,Metastatic melanoma,Immune checkpoint inhibitors,-,-,-,-,-,-,-,Fact,3,3.3,3.3.2,3.3.2.1,-,PD-1/PD-L1表达调控
4470,KP3,34944961,CDK4/6 inhibitors#extend#duration of response in combination with BRAF-MEK inhibitors in melanoma,Combination Therapies,"CDK4,CDK6",-,Melanoma,"BRAF-MEK inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
7846,KP3,34944961,BRAF-MEK-CDK4/6 inhibitors with ACT#are efficacious in#murine melanoma models,Preclinical Models,"CDK4,CDK6",-,Melanoma,"BRAF-MEK inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
1999,KP3,34944961,Triplet targeted therapy of BRAF-MEK-CDK4/6 inhibitors with OT-1 ACT#led to#sustained and robust anti-tumor responses in BRAFi-sensitive YOVAL1.1,Combination Therapies,"CDK4,CDK6",-,Melanoma,"BRAF-MEK inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
3434,KP3,38707105,Abemaciclib#is utilized to manage#hormone-sensitive HER2-positive metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
2547,KP3,34556423,CDK4/6 inhibitors with endocrine therapy#are#standard treatment for HR-positive breast cancer,Therapeutic Development,"CDK4,CDK6",-,Hormone receptor-positive breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
2838,KP3,34277427,Antiestrogens#extend#overall survival in ER-positive breast tumors,Therapeutic Development,ESR1,-,Estrogen receptor-positive breast tumors,Antiestrogens,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
1784,KP3,26201960,Sensitivity to PD0332991#a therapeutic CDK4/6 inhibitor#was evaluated in melanoma cell lines,Preclinical Models,"CDK4,CDK6",-,Melanoma,PD0332991,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5330,KP3,37865915,Sequential activation of E2F via Rb degradation and c-Myc#drives#resistance to CDK4/6 inhibitors in breast cancer,Mechanisms of Resistance,"CDK4,CDK6,RB1,MYC,E2F",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
4327,KP3,37865915,CDK4/6 inhibitors#are#key therapeutic agents in metastatic HR-positive breast cancer,Therapeutic Development,"CDK4,CDK6",-,Metastatic hormone receptor-positive breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
6829,KP3,32197329,SAMHD1 function#is regulated by#phosphorylation through CDKs,Regulation,"SAMHD1,CDK4,CDK6",-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
2868,KP3,32197329,CDK4/6 inhibitors combined with antimetabolites#enhanced#drug efficacy,Combination Optimization,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
557,KP3,37800838,CDK4/6 inhibitors#are used for#hormone receptor-positive/HER2-negative advanced breast cancer,Cancer Association,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2052,KP3,36575782,"Palbociclib, abemaciclib and dalpiciclib#are approved for#breast cancer treatment in China",Drug Development,-,-,Breast cancer,"Palbociclib, Abemaciclib, Dalpiciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,细胞周期阻滞
1783,KP3,35670349,"Three CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib)#are approved by#FDA for advanced breast cancer treatment",Drug Development,"CDK4,CDK6",-,Breast cancer,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,细胞周期阻滞
5764,KP3,36980685,Aromatase inhibitors#show#synergistic effects with mTOR inhibitors and CDK4/6 inhibitors,Combination Optimization,"CDK4,CDK6,MTOR",-,-,"Aromatase inhibitors, mTOR inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
4124,KP3,36603395,"Palbociclib, ribociclib, and abemaciclib#were approved for#breast cancer treatment",Drug Development,"CDK4,CDK6",-,Breast cancer,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
7237,KP3,33803309,Three dual CDK4/6 inhibitors#improved#survival outcomes in breast cancer patients when combined with endocrine therapy,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,"CDK4/6 inhibitors, endocrine therapy",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
1650,KP3,33803309,"Selective CDK4/6 inhibitors#are being developed for#increased selectivity, treatment efficacy, and reduced adverse effects",Drug Development,"CDK4,CDK6",-,-,Selective CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5730,KP3,31451564,Palbociclib#inhibits#progression of DCIS and growth of invasive disease,Therapeutic Response,"CDK4,CDK6",-,"Ductal carcinoma in situ (DCIS), invasive breast cancer",Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
585,KP3,31451564,Palbociclib#inhibits#ER(-) basal breast cancer and ER(+) luminal breast cancer,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3263,KP3,28653662,Intact G1/S transition#is predictive of#preclinical sensitivity to drug combination,Biomarker Analysis triples,-,-,ER-positive breast cancer,-,-,-,-,-,Intact G1/S transition,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2314,KP3,37319380,CDK4/6 inhibitors#are a standard treatment for#high-risk patients in adjuvant and metastatic settings,Clinical Implementation triples,"CDK4,CDK6",-,High-risk breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,晚期实体瘤
1518,KP3,27729458,Hyperactivated ERK signaling#confers#sensitivity to MEK inhibition therapy,Therapeutic Response,ERK,-,Neuroblastoma,-,MEK,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
654,KP3,37894312,New hormonal agents and chemotherapy combined with androgen deprivation therapy#improved#the prognosis of mHSPC since 2015,Therapeutic Development,-,-,Prostate cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6792,KP3,38390865,Palbociclib (CDK4/6 inhibitor) and a ferroptosis inducer (auranofin)#are coencapsulated within#cRGD peptide-modified targeted liposomes,Drug Delivery Innovation triples,"CDK4,CDK6",-,-,"Palbociclib, Auranofin",-,-,-,-,-,-,-,Fact,3,3.6,3.6.1,3.6.1.1,-,纳米载体设计
849,KP3,37916184,CDK4/6 inhibitors#overcome#endocrine resistance,Drug Development,"CDK4,CDK6",-,Endocrine resistance,-,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.4,-,生物标志物指导
1430,KP3,39821032,"Loss of RANK signaling#increases sensitivity of#breast cancer cells to chemotherapy, HER2 and CDK4/6 inhibitors",Therapeutic Response,"TNFRSF11A,CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4262,KP3,34884204,CDK4/6 inhibitors#improve#survival in breast cancer,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7152,KP3,33604051,Abemaciclib#is a CDK4/6 inhibitor used to treat#metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
6729,KP3,32883002,"Palbociclib, ribociclib, and abemaciclib#belong to#the third generation of cyclin-dependent kinase inhibitors (CDKis)",Drug Development,"CDK4,CDK6",-,Breast cancer,"Palbociclib,Ribociclib,Abemaciclib",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2464,KP3,32883002,CDKis#are established for#advanced and metastatic breast cancer treatment,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,CDKis,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7702,KP3,32883002,Some individuals#experience#increased and unexpected toxicity due to CDKis,Safety Monitoring,"CDK4,CDK6",-,Breast cancer,CDKis,-,Increased toxicity,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.2,-,非血液学毒性
5553,KP3,28978144,Dual blockade of PI3K and mTOR kinases#improved#radiation efficacy in oral cancer and OSCC cells,Combination Therapies triples,"PI3K, MTOR",-,"Oral cancer, OSCC","PI3K inhibitors, mTOR inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
120,KP3,28978144,This treatment#was dependent on#inhibition of S6 kinase pathway and eIF4E-mediated translation,Mechanism of Action,EIF4E,-,-,-,S6 kinase pathway,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
4307,KP3,27816190,AR antagonism with CDK4/6 or PI3K inhibitors#is proposed for#combination regimens in resistance mechanisms,Therapeutic Development,"CDK4, CDK6, PI3K",-,Breast cancer,"CDK4/6 inhibitors, PI3K inhibitors",-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
23,KP3,34582293,Insufficient efficacy and resistance#require#predictive biomarkers for HCC treatment,Biomarker Analysis,-,-,HCC,"Multi-kinase inhibitors (MKIs), CDK4/6 inhibitors, immune checkpoint inhibitors (ICIs)",-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
4599,KP3,34582293,"Rb, p16, Ki-67, and genes CDK1-4, CCND1, CDKN1A, CDKN2A#are proposed as#predictive markers for CDK4/6 inhibitors",Biomarker Analysis,"RB1, CDKN2A, CDKN1A, CDK1, CDK2, CDK3, CDK4, CCND1",-,HCC,CDK4/6 inhibitors,-,-,-,Markers,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
3968,KP3,34176404,CDK4/6 inhibitors#are now#standard-of-care for HR+/HER2- metastatic breast cancer,Clinical Implementation,"CDK4, CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
7028,KP3,31859350,"New combination therapies#involve#PI3Ki, anti-HER2, chemotherapy, CDK4/6 inhibitors, mTOR inhibitors",Combination Therapies triples,"CDK4, CDK6, PI3K, MTOR",-,Cancer,"PI3Ki, anti-HER2, chemotherapy, CDK4/6 inhibitors, mTOR inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3868,KP3,28923217,"Potential treatment strategies#include#PARP inhibitors, CDK4/6 inhibitors, taxane derivatives",Therapeutic Development,"CDK4, CDK6",-,Breast cancer brain metastases (BCBM),"PARP inhibitors, CDK4/6 inhibitors, taxane derivatives",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6172,KP3,29777202,Phosphorylation of rpS6#was unable to be inhibited by#MAPK pathway inhibitors in resistant cells,Mechanism of Resistance triples,RPS6,-,Melanoma,MAPK pathway inhibitors,MAPK pathway,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
7004,KP3,29777202,mTOR inhibitors#overcame#acquired resistance and rescued sensitivity with BRAF/MEK inhibitors,Strategies to Overcome Resistance triples,"MTOR, BRAF, MEK",-,Melanoma,"mTOR inhibitors, BRAF inhibitors, MEK inhibitors",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
6937,KP3,32532875,Cabozantinib#showed#no appreciable efficacy in vitro,Drug Development,RET,-,-,Cabozantinib,-,-,-,silenced,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6212,KP3,32532875,Cabozantinib#provided#no definitive clinical benefit,Therapeutic Response,-,-,-,Cabozantinib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
379,KP3,32030569,CDK4/6 inhibitors#extend#clinical utility as breast cancer endocrine regimen,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
5499,KP3,37713975,High mTOR levels#correlate with#poor overall survival in metastatic NPC patients,Cancer Association,MTOR,-,Metastatic NPC,-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.2,2.1.2.3,-,mTOR信号增强
1912,KP3,31848929,CDK4/6 inhibitors#may include#future targeted therapies,Therapeutic Development,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2650,KP3,31848929,PARP inhibitors#may include#future targeted therapies,Therapeutic Development,PARP1,-,-,PARP inhibitors,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
829,KP3,31848929,NRF2 and Wnt signaling pathways#may be targeted by#future inhibitors,Signaling Networks,NFE2L2,-,-,-,"NRF2,Wnt",-,-,-,-,-,-,Inference,1,1.3,1.3.2,1.3.2.3,-,p38通路交互
7054,KP3,22374332,Flavopiridol#potentiates#doxorubicin efficacy in advanced sarcomas,Combination Therapies,CCND1,-,Advanced sarcomas,"Flavopiridol,Doxorubicin",-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.2,-,协同增效作用
592,KP3,39235063,Palbociclib and fulvestrant#were used to treat#42.1% of patients,Therapeutic Development,"CDK4,CDK6",-,-,"Palbociclib,Fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
5745,KP3,39235063,Palbociclib and aromatase inhibitors#were used to treat#55.8% of patients,Therapeutic Development,"CDK4,CDK6",-,-,"Palbociclib,Aromatase inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
6448,KP3,39084139,Ribociclib#binds to#bovine serum albumin,Preclinical Models,"CDK4,CDK6",-,-,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.6,3.6.1,3.6.1.2,-,靶向配体修饰
4703,KP3,39084139,Ribociclib#exhibits#promising antitumor efficacy in HR+/HER2- breast cancer,Therapeutic Response,"CDK4,CDK6",HR+/HER2- breast cancer,Breast cancer,Ribociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2500,KP3,38653982,Peripheral blood monitoring#represents#a practical alternative to repeated biopsies,Clinical Implementation,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,-,生物标志物监测
5999,KP3,36915147,Pharmacological inhibition of IL8#increases#efficacy of fulvestrant and/or palbociclib,Combination Therapies,-,-,Breast cancer,"Fulvestrant,Palbociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
4091,KP3,36915147,Pharmacological inhibition of IL8#reverses#tamoxifen resistance,Resistance Mechanisms,-,-,Breast cancer,Tamoxifen,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.4,-,生物标志物指导
2084,KP4,34948218,Eight compounds#are selected based on#docking results and interactions with CDK4 and CDK6,Drug Development triples,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,药物开发
1493,KP4,35957949,Abemaciclib#is a#selective and potent small-molecule inhibitor of CDK4 and CDK6,Drug Development triples,"CDK4,CDK6",-,-,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,药物开发
2879,KP4,28349562,Cell cycle proteins#are key targets for#cancer treatment,Therapeutic Development triples,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,细胞周期阻滞
681,KP4,28349562,Palbociclib#specifically inhibits#CDK4/6,Drug Development triples,"CDK4,CDK6",-,Metastatic breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,药物开发
1496,KP4,28349562,Palbociclib#is approved for use in#metastatic breast cancer in combination with letrozole,Drug Development triples,"CDK4,CDK6",-,Metastatic breast cancer,"Palbociclib, Letrozole",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合用药方案
5052,KP4,34875521,Novel CDK4/6 inhibitors#are developed for#treatment of multiple myeloma,Drug Development triples,"CDK4,CDK6",-,Multiple myeloma,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,药物开发
1741,KP4,34875521,Anti-MM drugs#easily generate#resistance,Mechanisms of Resistance triples,-,-,Multiple myeloma,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,耐药机制
4140,KP4,34875521,CDK4/6#play determinant roles in#multiple myeloma,Cancer Association triples,"CDK4,CDK6",-,Multiple myeloma,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞增殖调控
1340,KP4,34875521,Structure-based virtual screening#identifies#compound 10 as a novel CDK6 inhibitor,Drug Development triples,CDK6,-,-,Compound 10,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,药物开发
4806,KP4,34875521,CDK4/6 inhibitor#offers#a great candidate for MM preclinical studies,Drug Development,"CDK4,CDK6",-,Multiple myeloma,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,药物开发
2767,KP4,31823286,CDK4/6 inhibitor palbociclib#shows#anti-cell growth activity in breast cancer cells,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,细胞周期阻滞
2187,KP4,31823286,CDK4/6 inhibitor palbociclib#shows#anti-cancer stem cell activity in breast cancer cells,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,1,1.6,1.6.2,1.6.2.3,-,分化阻滞
5046,KP4,31823286,Palbociclib#exhibits#anti-cell growth and anti-cancer stem cell activity in breast cancer cells,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,细胞周期阻滞
3937,KP4,30840889,CDK4/6 inhibition#is part of#the standard armamentarium for ER(+) breast cancer,Clinical Implementation,"CDK4,CDK6",-,ER(+) breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,单药治疗策略
5854,KP4,30840889,Defining mechanisms of resistance#is#a pressing issue for CDK4/6 inhibition in ER(+) breast cancer,Therapeutic Resistance,"CDK4,CDK6",-,ER(+) breast cancer,-,-,-,-,-,-,-,-,Inference,2,2.1,2.1.2,2.1.2.4,-,耐药机制
791,KP4,35075231,Understanding human genome alterations#is necessary for#optimizing genome-based cancer therapeutics,Translational Research,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Inference,5,5.5,5.5.1,5.5.1.1,-,基因组稳定性
1597,KP4,27939057,Endocrine therapies#target#dependence on the estrogen receptor in advanced cancer,Therapeutic Development,-,-,Advanced cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,内分泌治疗联合
5452,KP4,27939057,Resistance to endocrine therapy#is inevitable in#advanced cancer,Therapeutic Resistance,-,-,Advanced cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,耐药机制
719,KP4,27939057,"Inhibitors of PI3K, AKT, and HER2#are being developed as#targeted therapies",Drug Development,"PIK3CA,AKT1,ERBB2",-,-,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
6841,KP4,39447792,MSID000025#could be#a good candidate CDK4/6 inhibitor for treating breast cancer,Drug Development,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5991,KP4,39218402,"Resistance in cancer#involves#disturbances in the cell cycle, oncogenic signaling, DDR mechanisms, and TME changes",Therapeutic Resistance,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
4660,KP4,39218402,"Strategies to surmount resistance#include#advancements in endocrine therapy, targeted inhibition, ADCs, and ICIs",Therapeutic Resistance,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
3775,KP4,36562909,"CDK4/6 inhibitors#improve#HR+, HER2- metastatic breast cancer outcomes",Therapeutic Response,"CDK4,CDK6",-,"HR+, HER2- metastatic breast cancer",-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1975,KP4,34154797,addition of a CDK4/6 inhibitor#doubles#progression-free survival,Therapeutic Response,"CDK4, CDK6",-,Hormone-sensitive and hormone-resistant cancers,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
2261,KP4,29437706,"Multiaggressiveness among SCP3, NANOG, cyclin D1, and CDK4/6#is linked with#immune-refractory cancer",Cancer Association,"CDK4,CDK6,NANOG,CCND1",-,Immune-refractory cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3438,KP4,29893769,PIK3CA and AKT1 mutations#were assessed at#baseline,Genomic Alteration triples,"PIK3CA, AKT1",-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
1984,KP4,28092667,"Recurrent mutations#are noted on#TP53, NRAS, SNX31, NF1, KIT, APC",Genomic Alteration triples,"TP53, NRAS, SNX31, NF1, KIT, APC",-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
2683,KP4,28092667,BRAF fusions#define#a new molecular subset of PMM,Molecular Event triples,BRAF,-,PMM,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
3150,KP4,28092667,BRAF fusions#can be targeted with#a MEK inhibitor and CDK4/6 inhibitors,Therapeutic Development triples,"BRAF, CDK4, CDK6",-,PMM,"MEK inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
6417,KP4,26826116,G1T28#does not decrease#efficacy of chemotherapy on RB1-deficient tumors,Drug Development,"CDK4,CDK6",RB1-deficient tumor,Cancer,G1T28,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
4073,KP4,26826116,G1T28#is in clinical development for#reduction of chemotherapy-induced myelosuppression in small-cell lung cancer,Drug Development,"CDK4,CDK6",-,Small-cell lung cancer,G1T28,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4534,KP4,32393766,BET inhibitors#are promising for#treatment of triple-negative breast cancer,Drug Development,-,Triple-negative breast cancer,BET inhibitors,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,3.1.1.1.1,G1/S期转换抑制
7300,KP4,35784572,Current treatments#target#estrogen receptor and/or CDK4/6,Therapeutic Development,"CDK4,CDK6,ESR1",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4975,KP4,31849236,Optimal sequencing of available options#may prolong#endocrine sensitivity,Therapeutic Development,-,Breast cancer,-,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
7855,KP4,31849236,Optimal sequencing of available options#may slow#disease progression,Therapeutic Development,-,Breast cancer,-,-,-,-,-,-,-,-,-,Inference,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
7945,KP4,33953185,Luminal B CINSARC high-risk tumors#are more vulnerable to#homologous recombination targeting and immunotherapy,Therapeutic Development,-,Luminal B CINSARC high-risk tumors,-,-,-,-,-,-,-,-,-,Inference,5,5.1,5.1.1,5.1.1.1,-,DSB识别
2025,KP4,38473776,"Targeted therapies#interfere with#pRB/CDK4/RB1/P16(ink4), TP53/MDM2/P14(arf), PI3K/Akt-PTEN pathways in GB tumorigenesis",Signaling Networks,"CDK4,RB1,TP53,MDM2,PTEN",-,Glioblastoma (GB),-,"pRB/CDK4/RB1/P16(ink4),TP53/MDM2/P14(arf),PI3K/Akt-PTEN",-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
5413,KP5,31530780,Abemaciclib#inhibits#CDK4 and CDK6 with higher potency for CDK4-cyclin D1 complexes,Drug Development,"CDK4, CDK6",-,-,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
1599,KP5,31530780,Continuous inhibition of CDK4 and CDK6 by abemaciclib#induces#irreversible growth inhibition through senescence and apoptosis,Therapeutic Response,"CDK4, CDK6",-,Breast cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
1077,KP5,7647780,Disturbance of cell cycle checks#contributes to#cancer by allowing excessive cell proliferation,Cancer Pathways,"CDK4, CDK6",-,Cancer,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
5020,KP5,7647780,"Cyclin-dependent kinases (CDK4 or CDK6) and cyclins (D1, D2, D3)#control#commitment to DNA synthesis in G1 phase",Cell Cycle Control,"CDK4, CDK6, CCND1, CCND2, CCND3",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
5021,KP5,7647780,Cyclin D1/CDK4 and Cyclin D1/CDK6 complexes#are inhibited by#low molecular weight proteins such as p16INK4,Regulation,"CDK4, CDK6, CCND1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
4350,KP5,7647780,Melanoma-predisposing mutants#impair#inhibition of Cyclin D1/CDK4 and Cyclin D1/CDK6 activity,Cancer Association,"CDK4, CDK6, CCND1",-,Melanoma,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
4153,KP5,7647780,p16INK4 mutations#increase risk of#developing melanoma,Cancer Association,CDKN2A,-,Melanoma,-,-,-,-,-,-,-,-,Inference,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
1353,KP5,28927034,D-type cyclin genes#are rearranged and amplified in#human cancer,Cancer Association,"CCND1, CCND2, CCND3",-,Cancer,-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
7122,KP5,28927034,Ras-mediated skin tumorigenesis#depends on#pathways involving cyclin D1 and D2,Cancer Pathways,"CCND1, CCND2",-,Skin cancer,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
2270,KP5,28927034,Cyclin D3 ablation#increases#apoptosis levels in the bulge region of the hair follicle,Regulation,CCND3,Keratinocytes,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.3,-,凋亡阈值调节
4632,KP5,28927034,CDK6#is dependent on#cyclin D3 expression,Regulation,"CDK6, CCND3",-,-,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.2,1.1.2.2,-,Cyclin D-CDK6复合物
3092,KP5,31823286,Palbociclib#inhibits#Rb phosphorylation in breast cancer cell lines,Mechanism of Action,RB1,Breast cancer cell lines,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
999,KP5,29160310,Cyclin D-CDK4#phosphorylates#SPOP,Mechanism of Action,"CDK4,SPOP",-,-,-,Cyclin D-CDK4 pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
5308,KP5,29160310,SPOP phosphorylation#promotes#SPOP degradation,Mechanism of Action,SPOP,-,-,-,Cyclin D-CDK4 pathway,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.3,-,蛋白降解途径
3289,KP5,28453226,Palbociclib#activates#AMPK,Mechanism of Action,PRKAA1,-,Hepatocellular carcinoma,Palbociclib,AMPK,-,-,-,-,-,-,Fact,4,4.2,4.2.2,4.2.2.1,-,能量应激感应
4823,KP5,28453226,Palbociclib#inhibits#Hepatocellular carcinoma in a CDK4/6-independent manner,Therapeutic Response,"CDK4,CDK6",-,Hepatocellular carcinoma,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4469,KP5,28453226,Palbociclib#induces#autophagy and apoptosis in HCC cells,Therapeutic Response,PRKAA1,-,Hepatocellular carcinoma,Palbociclib,AMPK,-,-,-,-,-,-,Fact,3,3.4,3.4.2,3.4.2.1,-,内源性途径激活
2529,KP5,28453226,Palbociclib#upregulates#pAMPK,Mechanism of Action,PRKAA1,-,Hepatocellular carcinoma,Palbociclib,AMPK,-,-,upregulated,-,-,-,Fact,4,4.2,4.2.2,4.2.2.1,-,能量应激感应
4351,KP5,28453226,Palbociclib#exerts#antitumor activity through PP5/AMPK axis,Mechanism of Action,PRKAA1,-,Hepatocellular carcinoma,Palbociclib,PP5/AMPK,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
977,KP5,11029524,p16/INK4a#inhibits#CDK4 and CDK6,Mechanism of Action,"CDK4,CDK6,CDKN2A",-,Retinoblastoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
7587,KP5,11029524,p16/INK4a#prevents#CDK4 association with Cyclin D1,Mechanism of Action,"CDK4,CDKN2A,CCND1",-,Retinoblastoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
3218,KP5,11029524,p16/INK4a#inhibits#phosphorylation of pRb,Mechanism of Action,"CDKN2A,RB1",-,Retinoblastoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
4923,KP5,9070222,stimuli regulating cell proliferation or differentiation#act primarily during#G1 phase of the cell cycle,Cell Cycle Control,-,G1 phase cells,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
2802,KP5,9070222,CD34+ cells#represent#stem cells,Stem Cell Biology,CD34,-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.2,1.4.2.3,-,干细胞维持
321,KP5,9070222,"BFU-E, CFU-E, CFU-GM, and peripheral lymphocytes#represent#distinct differentiation pathways",Stem Cell Biology,"BFU-E, CFU-E, CFU-GM",-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.2,1.4.2.1,-,谱系特异性分化
5823,KP5,38822363,"tRNA modifications#are related to#various disease processes, including malignant tumors",Molecular Event triples,-,-,Malignant tumors,-,-,-,-,-,-,-,-,Inference,1,1.5,1.5.3,1.5.3.2,-,微小RNA
1485,KP5,34108622,"Patients with ER-positive, HER2-negative metastatic breast cancer#are treated with#CDK4/6 inhibitors such as palbociclib in combination with endocrine therapy",Clinical Implementation triples,"CDK4, CDK6",-,"ER-positive, HER2-negative metastatic breast cancer","Palbociclib, Endocrine therapy",-,"ER-positive, HER2-negative",-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
5563,KP6,7651726,Mouse p16INK4a#inhibits#phosphorylation of retinoblastoma protein by CDK4/6,Regulation,"CDKN2A,CDK4,CDK6",retinoblastoma,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2771,KP6,8741839,INK4d#is associated with#CDK6 in hematopoietic cell lines,Protein Complex Dynamics,"CDK6,CDKN2D",hematopoietic cell lines,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
2328,KP6,8968104,G1 regulatory pathway#is targeted in#tumorigenesis,Cancer Pathways,"CDKN2A,CDK4,CDK6,RB1",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
4436,KP6,27167191,Combination of MEK and CDK4/6 inhibitors#synergistically inhibits#cancer cell growth,Combination Optimization,"CDK4, CDK6",-,Cancer,"MEK inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
2432,KP6,27167191,Combination of MEK and CDK4/6 inhibitors#causes#tumor regression in vivo,Combination Optimization,"CDK4, CDK6",-,Tumor,"MEK inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
4740,KP6,17122635,"Cell cycle regulation#depends on#a balance between cyclins, CDKs, and CKIs",Cell Cycle Control,"CDK4, CDK6",-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
5316,KP6,17122635,Alterations of cell cycle regulators#are a common feature of#many malignant tumors,Cancer Association,"CDK4, CDK6",-,Malignant tumors,-,Cell cycle,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
389,KP6,17122635,Cell cycle regulator proteins#control#progression from G1 to S phase,Cell Cycle Control,"CDK4, CDK6",-,Soft tissue sarcomas,-,G1-S phase,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
347,KP6,20180048,Telomerase inhibitor GRN163L#inhibits#growth of cancer cells in vitro and in vivo,Drug Development,-,-,Cancer,GRN163L,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7261,KP6,7478527,Cdk4 and Cdk6#have#a novel cytoplasmic substrate in epithelial cells,Cell Type-Specific Categories,"CDK4, CDK6",Epithelial cells,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
1509,KP6,7478527,Cyclins and CDKs#are identified as#important regulators of cell replication,Cell Cycle Control,"CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
5678,KP6,7478527,Cyclin D#is proposed to be#an oncogene,Cancer Association,CCND1,-,Cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
1821,KP6,7478527,Cyclin E#is proposed to be#an oncogene,Cancer Association,CCNE1,-,Cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
1908,KP6,7478527,p16#is proposed to be#a tumor suppressor gene,Cancer Association,CDKN2A,-,Cancer,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
1758,KP6,11301189,Cyclin D2#is expressed in#normal B-cell development and BLIN ALL cell lines,Expression Patterns,CCND2,B cells,Acute lymphoblastic leukemia (ALL),-,-,-,ubiquitously,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
93,KP6,11301189,Cyclin D3#is expressed in#normal B-cell development and BLIN ALL cell lines,Expression Patterns,CCND3,B cells,Acute lymphoblastic leukemia (ALL),-,-,-,ubiquitously,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
2408,KP6,11301189,CDK4#is expressed in#normal B-cell development and BLIN ALL cell lines,Expression Patterns,CDK4,B cells,Acute lymphoblastic leukemia (ALL),-,-,-,ubiquitously,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
4950,KP6,29844123,"CDK4/6 inhibition#upregulates#HGF, BDNF, and NGF via NF-κB-mediated mechanisms",Mechanism of Action,"CDK4, CDK6",-,Glioblastoma (GBM),-,-,-,upregulated,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.3,-,非编码RNA调控
2313,KP6,29844123,Abemaciclib#is combined with#altiratinib or siRNAs to induce apoptosis,Combination Therapies,"CDK4, CDK6",-,Glioblastoma (GBM),"Abemaciclib, Altiratinib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1714,KP6,29844123,c-Met/TrkA-B pathway activation#mediates#therapeutic resistance of GBM to CDK4/6 inhibition,Mechanisms of Resistance,"CDK4, CDK6",-,Glioblastoma (GBM),-,"c-Met, TrkA-B",-,upregulated,-,-,-,-,Inference,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
3221,KP6,28209757,Androgens#upregulate#Cyclin D1 expression and activate CDK4/6,Mechanism of Action,"CCND1, CDK4, CDK6",-,Prostate cancer,-,-,-,upregulated,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.3,-,非编码RNA调控
6730,KP6,28209757,CDK4/6 inhibitors (G1T28 and G1T38)#are evaluated against#hormone-sensitive and treatment-resistant prostate cancer,Drug Development,"CDK4, CDK6",-,Prostate cancer,"G1T28, G1T38",-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
799,KP6,28209757,CDK4/6 inhibition#is as effective as#docetaxel in treatment-resistant CRPC models,Therapeutic Response,"CDK4, CDK6",-,Castration-resistant prostate cancer (CRPC),Docetaxel,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2304,KP6,33832512,Olaparib#is combined with#palbociclib to improve efficacy in TNBC,Combination Therapies,"CDK4, CDK6",-,Triple-negative breast cancer (TNBC),"Olaparib, Palbociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3696,KP6,33832512,Olaparib and Palbociclib combination#has#synergistic effects against BRCA(mut)/TNBC,Combination Therapies,"CDK4, CDK6",-,BRCA(mut)/TNBC,"Olaparib, Palbociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3832,KP6,33832512,Olaparib resistance#is inhibited by#combination with Palbociclib,Mechanisms of Resistance,"CDK4, CDK6",-,Triple-negative breast cancer (TNBC),"Olaparib, Palbociclib",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
1813,KP6,33832512,Olaparib#activates#Wnt signaling pathway and upregulates MYC,Signaling Networks,MYC,-,Triple-negative breast cancer (TNBC),Olaparib,Wnt signaling,-,upregulated,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
2163,KP6,33832512,β-catenin hyperphosphorylation#activates#Wnt signaling pathway and mediates Olaparib resistance,Mechanisms of Resistance,CTNNB1,-,Triple-negative breast cancer (TNBC),Olaparib,Wnt signaling,-,upregulated,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
112,KP6,33832512,Olaparib and Palbociclib combination#is recommended for#BRCA(mut)/TNBC with high Wnt signaling and MYC expression,Therapeutic Development,"CDK4, CDK6, MYC",-,BRCA(mut)/TNBC,"Olaparib, Palbociclib",Wnt signaling,-,upregulated,-,-,-,-,Inference,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
936,KP6,27986745,Ceritinib and Ribociclib combination#affects#Cyclin D/CDK4/CDK6/RB and pALK signaling networks,Combination Therapies,"CDK4, CDK6, CCND1, RB1, ALK",-,-,"Ceritinib, Ribociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
7606,KP6,38279345,"AHE and AHE-2#suppress#CDK4, CDK6, p-Rb, E2F1, Cyclin A, and activate p53",Mechanism of Action,"CDK4, CDK6, RB1, E2F1, CCNA2, TP53",-,-,-,-,-,"Downregulated (CDK4, CDK6, p-Rb, E2F1, Cyclin A), Upregulated (p53)",-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2673,KP6,38279345,"CDK4, CDK6 suppression#is associated with#cell cycle arrest and antiproliferative efficacy",Cell Cycle Control,"CDK4, CDK6",-,-,-,-,-,Downregulated,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
5203,KP6,35562811,Cyclin homologues#promote#cellular cyclin activity,Mechanism of Action,-,-,Gammaherpesvirus-induced tumors,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
2481,KP6,35562811,Cyclin activity#is important for#tumor proliferation and survival,Cancer Pathways,-,-,Gammaherpesvirus-induced tumors,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
5473,KP6,18760195,mRNA and protein expression of p16 gene#induces#cell cycle proliferation,Expression Patterns triples,CDKN2A,-,"Tumor, normal skin tissue",-,-,-,upregulated,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
2859,KP6,22903553,"Cell cycle-related proteins#are associated with#down-regulation of cyclin D1 and CDK4, and promotion of p16 and p27",Regulation triples,"CDK4,CCND1,CDKN2A,CDKN1B",-,-,-,-,-,downregulated,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
2030,KP6,34728571,HER2 and ER pathways#converge at#cyclin D1 and CDK4/6 complex driving cell-cycle progression and therapeutic resistance,Signaling Networks triples,"ERBB2,ESR1,CDK4,CDK6,CCND1",-,Breast cancer,-,-,Cell-cycle progression,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
5357,KP6,34728571,"Triple targeted combination therapy#was tested with#tucatinib, palbociclib, and fulvestrant in HR(+)/HER2(+) breast tumor cell lines and xenograft models",Combination Therapies triples,"CDK4,CDK6,ERBB2,ESR1",-,Breast cancer,"Tucatinib, Palbociclib, Fulvestrant",-,-,HR(+)/HER2(+),-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
284,KP6,34728571,Triple targeted combination therapy#prevents#growth of tucatinib or palbociclib-resistant subclones in vitro and in vivo,Strategies to Overcome Resistance triples,"CDK4,CDK6,ERBB2,ESR1",-,Breast cancer,"Tucatinib, Palbociclib, Fulvestrant",-,-,HR(+)/HER2(+),-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
6743,KP6,34728571,Survival of HR(+)/HER2(+) cells resistant to one drug#was reduced by#the other two drugs in combination,Combination Therapies triples,"CDK4,CDK6,ERBB2,ESR1",-,Breast cancer,"Tucatinib, Palbociclib, Fulvestrant",-,-,HR(+)/HER2(+),-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
1090,KP6,39116089,"Palbociclib#alters#CDKN2, CCNE1, E2F3, MDM2 expressions as miR-141 target genes",Regulation triples,"CDKN2,CCNE1,E2F3,MDM2",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.3,-,非编码RNA调控
2543,KP6,39116089,Palbociclib#affects#breast cancer cells by changing expression of cell cycle genes targeted by miR-141,Regulation triples,"CDKN2,CCNE1,E2F3,MDM2",-,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.3,-,非编码RNA调控
6302,KP6,39116089,Expression of CCNE1 gene#was significantly#suppressed,Regulation triples,CCNE1,-,Breast cancer,-,-,-,downregulated,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.3,-,CCNE1过表达
2961,KP6,39116089,MDM2#does not significantly reduce expression in#triple negative (MDA-MB-231) cancer cells,Expression Patterns,MDM2,MDA-MB-231 cells,Triple negative cancer,-,-,-,downregulated,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
2382,KP6,39116089,MDM2#reduces expression in#luminal A (MCF-7) cells,Expression Patterns,MDM2,MCF-7 cells,Luminal A cancer,-,-,-,downregulated,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
1017,KP7,27571378,Palbociclib treatment#caused#cell cycle arrest,Regulation,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3144,KP7,7883799,"Cyclins D1, D2, and D3#associate with#CDK4 and CDK6",Protein Complex Dynamics,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4 complex
5099,KP7,28580868,Unscheduled proliferation#is a hallmark of#cancer,Cancer Association,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.1,-,Proliferation signal integration
3183,KP7,28580868,First-generation CDK inhibitors#demonstrated#broad activity upon several CDKs,Drug Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,Proliferation signal blockade
6703,KP7,39524172,"SAMD5 overexpression#downregulated#CDK4, CDK6, Cyclin D1 in c-Myc signaling pathway",Regulation,"CDK4,CDK6",-,Triple-negative breast cancer (TNBC),-,c-Myc signaling pathway,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,Epigenetic modification
5240,KP7,32157498,OIP5-AS1#promotes#pancreatic cancer cell growth via AKT/ERK signaling pathway,Signaling Networks,-,Pancreatic cancer cells,Pancreatic cancer,-,AKT/ERK signaling pathway,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK pathway interaction
4489,KP7,32157498,Downregulation of OIP5-AS1#induced#cell cycle arrest in pancreatic cancer cells,Regulation,-,Pancreatic cancer cells,Pancreatic cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1 phase arrest
4868,KP7,32157498,OIP5-AS1#interacts with#miR-342-3p,RNA Regulation,-,-,-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,MicroRNA
4202,KP7,32157498,Depletion of miR-342-3p#abolished#inhibitory effects of OIP5-AS1 knockdown on pancreatic cancer growth,Mechanism of Action,-,-,Pancreatic cancer,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,MicroRNA
3023,KP7,32157498,OIP5-AS1#induced#pancreatic cancer progression via AKT and ERK signaling pathways,Signaling Networks,-,-,Pancreatic cancer,-,AKT/ERK signaling pathways,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK pathway interaction
2656,KP7,32157498,OIP5-AS1#functions as#oncogene in pancreatic cancer,Cancer Association,OIP5-AS1,-,Pancreatic cancer,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.1,-,Proliferation signal integration
6840,KP7,32157498,OIP5-AS1 downregulation#inhibits#pancreatic cancer growth,Therapeutic Response,OIP5-AS1,-,Pancreatic cancer,-,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,Proliferation signal blockade
4674,KP7,32157498,OIP5-AS1#sponges#miR-342-3p,Mechanism of Action,"OIP5-AS1, MIR342",-,Pancreatic cancer,-,AKT/ERK,-,-,-,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,MicroRNA
6567,KP7,8724524,Cell cycle transitions#are mediated by#sequential assembly and activation of CDKs,Cell Cycle Control,CDK,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,Cell cycle checkpoint control
2132,KP7,28672917,"P16 downregulation#induces#increase in CDK4, CDK6, and p-Rb expression",Regulation,"CDKN2A, CDK4, CDK6, RB1",HAOSMCs,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB protein phosphorylation
5926,KP7,28672917,P16 downregulation#increases#S phase cell ratio in CSE-treated HAOSMCs,Cell Cycle Control,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,Cell cycle checkpoint control
2836,KP7,17654117,INK4 family members#block#cell cycle progression by binding CDK4 and CDK6,Cell Cycle Control,"CDKN2A, CDKN2B, CDKN2C, CDKN2D, CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,Proliferation inhibition
3001,KP7,36174113,ER-positive endometrial cancers#are characterized by#PI3K and RTK/RAS/CTNNB1 pathway alterations,Cancer Pathways,CTNNB1,-,Endometrial cancer,-,"PI3K, RTK/RAS/CTNNB1",-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,Synergistic effects
700,KP7,36174113,"ER, PI3K, and RTK/RAS/CTNNB1 pathways#lead to#upregulation of cyclin D1 in complex with CDK4 and CDK6",Signaling Networks,"CDK4, CDK6, CTNNB1",-,-,-,"PI3K, RTK/RAS/CTNNB1",-,-,upregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4 complex
1395,KP7,36174113,Cyclin D1-CDK4/6 complex#mediates#resistance to hormonal therapy,Mechanisms of Resistance,"CDK4, CDK6",-,-,Hormonal therapy,-,-,-,-,-,-,-,Inference,2,2.1,2.1.2,2.1.2.4,-,Alternative survival pathways
7090,KP7,30365726,BrdU positive cell percentage#is enhanced by#LIPUS,Cell Cycle Control,-,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
5039,KP7,25655587,Piperine#indicated#G0/G1 and G2/M cell cycle arrest in IL-2-stimulated T lymphocytes,Cell Cycle Control,"CDK1,CDK4,CDK6,CCNB1,CCND2,CDC25C",T lymphocytes,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6712,KP7,11756559,"MEFs derived from Cdk4(R24C/R24C) mice#displayed#decreased doubling times, escape from replicative senescence, and escape sensitivity to contact-induced growth arrest",Phenotype,CDK4,Mouse embryo fibroblasts,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.2,-,细胞衰老诱导
6386,KP7,11756559,MEFs with Cdk4(R24C)#exhibited#high susceptibility to oncogene-induced transformation,Cancer Association,CDK4,Mouse embryo fibroblasts,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,RB1突变
6241,KP7,32958271,Patients with advanced ovarian cancer#benefit from#CDK4/6 inhibition,Therapeutic Response,"CDK4,CDK6",-,Ovarian cancer,CDK4/6 inhibitors,-,Advanced ovarian cancer,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6848,KP7,32647650,PIC#does not alter#glucose metabolism in prostate cancer cells,Drug Development triples,-,-,Prostate cancer,Piceatannol,-,-,-,-,-,-,-,Fact,4,4.1,4.1.1,4.1.1.4,-,糖原代谢调节
3455,KP7,10665922,p16INK4a protein#inhibits#cyclin D-dependent kinases (CDKs) controlling Rb phosphorylation and cell proliferation,Mechanism of Action triples,"CDKN2A,CDK4,CDK6",Cyclin D-dependent kinases,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
4720,KP7,21556534,Cyclin D1 and CDK4#are regulated by#phosphorylation in tumors,Regulation,"CCND1,CDK4",-,Tumor,-,"PKC,MAPK",-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
1517,KP7,25180593,TMOC#inhibited#constitutive activation of STAT3 signaling pathway,Signaling Networks,STAT3,-,-,TMOC,STAT3,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,反馈调节
356,KP8,9482902,p16 variants#fail to inhibit#Cyclin D2/CDK4 activity in kinase assays,Function triples,"CDKN2A,CDK4,CCND2",-,Plasmacytoma,-,-,-,BALB/c mice,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
4742,KP8,31001908,"p16#regulates#cell cycle progression, senescence, and oxidative stress",Regulation,CDKN2A,-,-,-,Cell cycle control,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.2,-,细胞衰老诱导
6578,KP8,22542944,"SKLB70326#downregulates#CDK2, CDK4, and CDK6 expression",Regulation,"CDK2, CDK4, CDK6",-,-,SKLB70326,Cell cycle control,-,-,Downregulated,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
2134,KP8,7925396,Olomoucine#inhibits#p34cdk4/cyclin D1 and p40cdk6/cyclin D3,Mechanism of Action,"CDK4, CDK6",-,-,Olomoucine,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
5784,KP8,7925396,"Olomoucine#substantially inhibits#p34cdc2/cyclin B, p33cdk2/cyclin A, p33cdk2/cyclin E, brain p33cdk5/p35, ERK1/MAP-kinase",Mechanism of Action,"CDK2, CDK5, MAPK1",-,-,Olomoucine,MAPK pathway,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
66,KP8,7925396,Olomoucine#inhibits#M-phase-promoting factor activity and DNA synthesis in Xenopus egg extracts,Mechanism of Action,-,-,-,Olomoucine,Cell cycle control,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1287,KP8,33575077,Overexpression of YAP and CDK6#rescued#β-elemene-induced senescence in glioma cells,Mechanism of Action,"YAP, CDK6",Glioma cells,Glioma,β-elemene,-,-,-,Upregulated,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
639,KP8,29899063,CDK6#acts at#the interface of p53 and RB by driving cell-cycle progression and antagonizing stress responses,Mechanism of Action,"CDK6, TP53, RB",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
740,KP8,38886784,GPER#is involved in#resistance to palbociclib in BC cells,Mechanism of Resistance,GPER,BC cells,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
369,KP8,28092667,Oncogenic BRAF fusions#activate#the MAPK pathway in mucosal melanomas,Cancer Pathways,BRAF,-,Mucosal melanomas,-,MAPK,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
3470,KP8,28092667,Oncogenic BRAF fusions#are sensitive to#MEK/CDK4/6 inhibition,Drug Development,"BRAF, CDK4, CDK6",-,Mucosal melanomas,"MEK inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
464,KP8,9600204,CDK4 amplification or RB LOH#suggests#p16 immunopositivity in tumors,Molecular Event,"CDK4,RB1",-,-,-,-,-,upregulated,-,-,-,-,Inference,7,7.2,7.2.1,7.2.1.1,7.2.1.1.3,p16表达
2225,KP8,9600204,p16 immunostaining#suggests#CDK4 amplification or RB loss,Biomarker Analysis,"CDK4,RB1",-,-,-,-,-,upregulated,-,-,-,-,Inference,7,7.2,7.2.1,7.2.1.1,7.2.1.1.3,p16表达
536,KP8,23958495,TRPM7#is implicated in#diverse physiological and pathological processes including cell proliferation,Function triples,TRPM7,-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
2058,KP8,23958495,Phosphorylation of ERK and AKT#decreased in#TRPM7-deficient HSC-T6 cells,Regulation,"ERK, AKT, TRPM7",HSC-T6 cells,-,-,-,-,downregulated,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
1382,KP8,23958495,TRPM7 channels#contribute to#fibroblast activation and proliferation via ERK and PI3K pathways,Signaling Networks,TRPM7,Fibroblasts,-,-,"ERK, PI3K",-,-,-,-,-,-,Inference,1,1.3,1.3.1,1.3.1.3,-,协同效应
1538,KP8,18454140,NPM1#is phosphorylated by#CDK6 activated by KSHV D-type cyclin,Mechanism of Action,"NPM1, CDK6",-,Kaposi's sarcoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.2,-,Cyclin D-CDK6复合物
1310,KP8,9552410,p16 locus#is implicated in#different cancers,Cancer Association,"CDKN2A,CDKN2B",-,Cancer,-,Cyclin D-CDK4/6,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.2,-,RB1基因丢失
4319,KP8,9552410,p16INK4a and p15INK4b#inhibit#cyclin D-CDK4/6 complexes,Mechanism of Action,"CDKN2A,CDKN2B",-,-,-,Cyclin D-CDK4/6,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7718,KP8,9552410,Loss of function of p16INK4a#is linked to#tumorigenic processes,Cancer Association,CDKN2A,-,Tumor,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.2,-,CDKN2A缺失
438,KP8,9552410,p15INK4b alterations#are less obvious in#tumor onset,Gene Regulation,CDKN2B,-,Tumor,-,-,-,-,-,-,-,-,Fact,2,2.2,2.2.1,2.2.1.4,-,关键基因突变
2110,KP8,9552410,p16INK4a#encodes#p19ARF,Gene Identification,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
4946,KP8,9552410,p19ARF#negatively regulates#cell cycle progression,Mechanism of Action,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
5825,KP8,9552410,Negative cell cycle control mechanism#is impaired in#tumorigenesis,Cell Cycle Control,-,-,Tumor,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
3750,KP8,34103301,Q276* and T283A mutations in FLT3-ITD#confer#resistance to apoptosis,Mechanism of Resistance,FLT3,-,-,"Pexidartinib,FLT3 inhibitors",-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
6805,KP8,34103301,Q276* and T283A mutations in FLT3-ITD#decrease#cell-cycle arrest,Mechanism of Resistance,FLT3,-,-,"Pexidartinib,FLT3 inhibitors",-,-,-,-,-,-,-,Fact,2,2.2,2.2.2,2.2.2.3,-,CDK活性失调
7820,KP8,34103301,Q276* and T283A mutations in FLT3-ITD#increase#proliferation,Mechanism of Resistance,FLT3,-,-,"Pexidartinib,FLT3 inhibitors",-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
7272,KP8,25088201,mouse melanoma model#harbors#mutant oncogenes CDK4(R24C) and NRAS(Q61K),Model Systems,"CDK4, NRAS",-,Melanoma,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.3,1.4.3.1,-,存活信号调控
5815,KP8,32692450,G1/S transition#requires#phosphorylation of RB by CDK4 and CDK6,Cell Cycle Control,"CDK4, CDK6, RB",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2795,KP8,32692450,amplifications of cyclin D loci and activating mutations in CDKs#are frequent in#gastroesophageal malignancies,Cancer Association,"CDK4, CDK6",-,Gastroesophageal malignancies,-,-,-,-,upregulated,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
7269,KP8,10599415,"changes in p53, p21WAF1, pRb, and cyclin D1#tested for roles in#HUC senescence",Regulation,"TP53, CDKN1A, RB1, CCND1",-,HUC senescence,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.2,-,细胞衰老诱导
407,KP8,27035431,artemisinin#causes#G1-phase arrest and ROS generation,Mechanism of Action,-,-,-,artemisinin,-,-,-,-,-,ROS,-,Fact,4,4.3,4.3.1,4.3.1.4,-,氧化应激反应
7382,KP8,20196086,hCNAs#may target#transcriptional or regulatory elements,Mechanism of Action,-,-,-,-,-,-,-,-,-,-,-,Inference,1,1.5,1.5.2,1.5.2.3,-,抑制复合物
6705,KP8,20182587,cyclin/CDK complex#is involved in#cell cycle regulation in HCC,Cell Cycle Control,"CDK4, CDK6",-,HCC,-,"Wnt/beta-catenin, Ras/Raf/MEK/ERK, PI3K/Akt/mTOR",-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6135,KP8,16732325,JUN and MAP3K7IP2#are amplified in#liposarcomas with 12q amplification,Cancer Pathways,"JUN, MAP3K7IP2",-,Liposarcoma,-,c-jun NH2-terminal kinase/MAPK,-,-,Upregulated,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
6919,KP9,21047732,"MYC, CDK4, CDK6, CCND1, and CCND2#were downregulated in#line with G1 arrest",Expression Patterns,"MYC,CDK4,CDK6,CCND1,CCND2",-,-,-,G1 arrest,-,downregulated,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
3061,KP9,27354579,CDK4/CDK6#are targeted by#therapeutic agents,Drug Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7517,KP9,27354579,Epigenetic alterations#offer#a new potential drug target in melanoma,Therapeutic Development,-,-,Melanoma,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.3,-,抑制复合物
3509,KP9,9001420,"Cyclin D1, p16CDKN2, and p15CDKN2B#are associated with#B cell non-Hodgkin's lymphoma (B-NHL)",Cancer Association,"CCND1,CDKN2A,CDKN2B",B cells,B cell non-Hodgkin's lymphoma (B-NHL),-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
5637,KP9,29496665,PIK3CA(E545K) subpopulation#confers#clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma,Mechanisms of Resistance,"PIK3CA,CDK4,CDK6",Melanoma cells,NRAS melanoma,"MEK inhibitors, CDK4/6 inhibitors",S6K1,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
4099,KP9,9774662,ARF transcription#can be reactivated by#DNA methylation inhibitor 5-aza-2'-deoxycytidine,Regulation,CDKN2A,-,-,5-aza-2'-deoxycytidine,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
2851,KP9,33046519,SHP2 inhibitors#inhibit#RTK signaling,Drug Development,PTPN11,-,Tumor,-,RTK,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
237,KP9,33046519,RTK signaling#is oncogenic driver in#many tumors,Cancer Association,RTK,-,Tumor,-,RTK,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
6959,KP9,33046519,RTK signaling#is frequently feedback activated by#RTK inhibitors and MAPK inhibitors,Signaling Networks,"RTK,MAPK",-,Tumor,"RTK inhibitors,MAPK inhibitors",-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.3,-,p38通路交互
6562,KP9,33046519,TNO155 and ribociclib#showed#combination benefit in lung and colorectal cancer xenografts,Combination Optimization,"CDK4,CDK6",-,"Lung cancer, Colorectal cancer","TNO155, Ribociclib",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
690,KP9,33046519,KRAS mutations#are present in#a large panel of lung and colorectal cancer xenografts,Cancer Association,KRAS,-,"Lung cancer, Colorectal cancer",-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
5618,KP9,33575077,Glioma#is characterized by#high heterogeneity and high fatality rates,Cancer Association,-,-,Glioma,-,-,"High heterogeneity, high fatality rates",-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
7607,KP9,33575077,尾-elemene#reduces#resistance to chemotherapeutic drugs,Strategies to Overcome Resistance,-,-,Tumor,尾-elemene,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.2,-,序贯治疗
4719,KP9,33575077,尾-elemene#induces#apoptosis in tumor cells,Therapeutic Response,-,-,Tumor,尾-elemene,-,-,-,-,-,-,-,Fact,3,3.4,3.4.2,3.4.2.3,-,凋亡执行
1978,KP9,33575077,尾-elemene#downregulates#YAP expression in glioma cells,Regulation,YAP,-,Glioma,尾-elemene,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
310,KP9,33575077,尾-elemene#induces#senescence of glioma cells,Therapeutic Response,"CDK6,YAP",-,Glioma,尾-elemene,YAP-CDK6,-,-,-,-,-,-,Fact,3,3.4,3.4.1,3.4.1.1,-,细胞周期永久阻滞
3217,KP9,33575077,YAP-CDK6 pathway#is inactivated by#尾-elemene treatment,Pathway & Network Categories,"CDK6,YAP",-,Glioma,尾-elemene,YAP-CDK6,-,-,-,-,-,-,Fact,1,1.3,1.3.3,1.3.3.1,-,P53通路相互作用
7498,KP9,32940689,Pretreatment ctDNA#identified#a group of high-risk patients with poor clinical outcome despite CDK4/6 inhibition,Biomarker Analysis,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,7.5.1.1.1,ESR1突变
339,KP9,10748295,CDK4#is located on#the long arm of chromosome 12,Structural Biology,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
4954,KP9,39361142,"High-risk early breast cancer#is associated with#large tumor size, nodal involvement, high proliferative index, and genetic predisposition",Patient Characteristics,-,-,Early breast cancer,-,-,"Large tumor size, nodal involvement, high proliferative index, genetic predisposition",-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,-,生物标志物监测
7410,KP9,34703440,Osteosarcoma#occurs most frequently in#the second decade of life,Patient Characteristics,-,-,Osteosarcoma,-,-,Second decade of life,-,-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.1,-,随访时间点
456,KP9,39215191,Breast cancer with germline BRCAm#has#distinct clinical characteristics and increased sensitivity to PARP inhibitors and platinum-based chemotherapies,Therapeutic Response,"BRCA1,BRCA2,CDK4,CDK6",-,Breast cancer,"PARP inhibitors, platinum-based chemotherapies",DNA-damaging agents,-,Distinct clinical characteristics,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
341,KP9,39215191,Many patients with gBRCAm#are not identified due to#suboptimal referral rates and/or low uptake of genetic testing,Clinical Implementation,"BRCA1,BRCA2",-,-,-,-,-,"Suboptimal referral rates, low uptake of genetic testing",-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
3681,KP9,21552124,Patients with rapidly growing or incompletely resectable tumors#should be managed#nonoperatively,Clinical Implementation,-,-,Tumor,-,-,-,Rapidly growing or incompletely resectable,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
4300,KP9,20228779,well-differentiated spindle cell liposarcomas#arise in#two female and four male patients,Patient characteristics,-,Spindle cells,Liposarcoma,-,-,-,Age: 59-85 years,-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.1,-,随访时间点
203,KP9,37511178,"significant costs, inter-technique variability, and real-world patient heterogeneity#hinder#utility for serial monitoring",Clinical implementation,-,-,HR+/HER2- metastatic breast cancer,-,-,-,Patient heterogeneity,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.3,-,临床评估
1178,KP9,37982827,CCND1#has copy-number gains in#22% of cases,Molecular Event triples,CCND1,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,CCND1扩增
3355,KP9,37982827,CCND2#has copy-number gains in#9% of cases,Molecular Event triples,CCND2,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,基因扩增
3484,KP9,37982827,EGFR#has copy-number gains in#9% of cases,Molecular Event triples,EGFR,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,基因扩增
4429,KP9,16631473,"The most frequent gains and amplifications#were detected at#7q, 8q, 17q, and 20q",Genomic Alterations,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.2,-,基因扩增
6665,KP9,28447036,PI3K/Akt signaling pathway abnormalities#are promising therapeutic targets for#deregulation of C/EBP-伪 and its partner PPAR-纬,Signaling Networks,"C/EBP-伪, PPAR-纬",-,-,-,PI3K/Akt,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
7692,KP9,33671468,"Mutational profiling#has identified#ESR1, PIK3CA, and AKT mutations as predictive biomarkers",Biomarker Analysis,"ESR1, PIK3CA, AKT",-,-,-,-,-,-,Predictive biomarkers,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.3,ESR1突变
7593,KP10,10939591,Transduced cells#expressed#senescence-associated beta-galactosidase,Phenotype triples,-,-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.1,-,永久性生长停滞
7041,KP10,38811726,"cyclin D1, CDK4, and CDK6#are required to initiate#multiciliated cell differentiation",Cell Cycle Control,"CCND1, CDK4, CDK6",multiciliated cells,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.2,1.4.2.1,-,谱系特异性分化
2174,KP10,35677682,"Signatures relating to homologous recombination, mismatch repair, and Notch signaling pathways#are enriched in#tumor immune microenvironment",Pathway & Network Categories,NOTCH,-,Tumor,-,"Homologous recombination, mismatch repair, Notch",-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.2,-,末端切除
6740,KP10,25231023,Genomic mutations and copy number variations (CNVs)#were studied to understand#pathobiology and develop diagnostic/prognostic tools,Genomic Alterations,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.3,5.3.3.1,-,基因表达改变
955,KP10,23830351,"Significant gains aberrations#include#BIRC5, CCNE2, DAB2, DDX15, EGFR, MSH2, CDK6, HGF, ITGB4, KCNK12, LAMA3, LOXL2, MET, PDGFRA",Genomic Alterations,"BIRC5,CCNE2,DAB2,DDX15,EGFR,MSH2,CDK6,HGF,ITGB4,KCNK12,LAMA3,LOXL2,MET,PDGFRA",-,Cancer,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
7092,KP10,15221937,Newly identified genes#may include#unknown biomarkers in BCA,Biomarker Analysis,-,BCA,-,-,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.1,-,基因突变
5956,KP10,33863325,Highly expressed SHMT2#indicates#a poorer clinical outcome for TSCC patients,Prognostic Associations,SHMT2,-,TSCC,-,-,-,Poor clinical outcome,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
5997,KP10,12170781,"Two subtypes, embryonal (ERMS) and alveolar (ARMS),#were identified and associated with#distinct clinical characteristics and genetic alterations",Disease Subtypes,-,-,"Embryonal rhabdomyosarcoma (ERMS), Alveolar rhabdomyosarcoma (ARMS)",-,-,distinct clinical characteristics,-,-,-,-,-,Fact,1,1.4,1.4.2,1.4.2.1,-,谱系特异性分化
5873,KP11,29508248,Combination treatment#decreased#levels of p-Rb and p-4E-BP1,Signaling Networks,RB1,-,Glioblastoma,-,"MAPK, Akt",-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
3518,KP11,29623577,CDK4/6 inhibitors#have not been addressed in#everolimus-resistant patients,Therapeutic Resistance,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,2,2.5,2.5.2,2.5.2.4,-,生物标志物指导
183,KP12,36847915,FOXM1 inhibitors#displayed#synergistic inhibition of proliferation and enhanced G2/M cell cycle arrest,Cell Cycle Control,FOXM1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
792,KP12,36847915,FOXM1 inhibitors#enable#dose reduction and enhanced efficacy in breast cancer treatment,Therapeutic Response,FOXM1,-,Breast cancer,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
6984,KP12,28961193,Fascaplysin treatment#decreases#tumor angiogenesis,Therapeutic Response,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,3,3.5,3.5.1,3.5.1.1,-,血管密度降低
2161,KP13,39456616,"Gedatolisib#targets#all Class I PI3K isoforms, mTORC1, and mTORC2",Drug Development,"MTOR,PIK3CA,PIK3CB,PIK3CD,PIK3CG",-,Gynecologic cancers,Gedatolisib,PI3K/mTOR,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
7997,KP14,29768351,CDK4/6 inhibitors#applied as#combination therapy with letrozole or fulvestrant,Combination Therapies,"CDK4,CDK6",-,advanced breast cancer,"letrozole,fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
4819,KP14,36797347,AKT/mTOR signaling#modulates#resistance to CDK4/6 inhibition,Mechanisms of Resistance,"AKT,MTOR,CDK4,CDK6",-,metastatic breast cancer,-,AKT/mTOR pathway,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
1193,KP14,32863875,CDK4/6 inhibitor combined with endocrine therapy#is#standard of care for HR+/HER2- metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
408,KP14,37667421,CDK4/6 inhibitors#improve#progression-free survival in metastatic breast cancer,Therapeutic Response,"CDK4,CDK6",-,metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
165,KP14,28978004,incidence and impact of ESR1 mutations#not defined in#patients treated with CDK4/6 inhibitors,Mechanisms of Resistance,"ESR1,CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
3405,KP14,29582246,CDK4/6 inhibitors#are combined with#aromatase inhibitors or fulvestrant in first-line treatment,Drug Combination,"CDK4,CDK6",-,Advanced breast cancer,"CDK4/6 inhibitors, aromatase inhibitors, fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
4077,KP14,37366894,Ribociclib + aromatase inhibitor#is preferred for#de novo advanced disease or relapse after adjuvant endocrine therapy,Therapeutic Response,"CDK4,CDK6",-,Advanced breast cancer,"Ribociclib, aromatase inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
2593,KP14,37366894,Ribociclib or abemaciclib + fulvestrant#is preferred for#patients experiencing early relapse,Therapeutic Response,"CDK4,CDK6",-,Advanced breast cancer,"Ribociclib, Abemaciclib, Fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
6921,KP14,37366894,ER/PR/HER2 testing#confirms#subtype of advanced disease at progression,Diagnostic Testing,"ER,PR,HER2",-,Advanced breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.4,-,PIK3CA突变
382,KP14,37366894,ESR1 and PIK3CA testing#is considered for#select patients,Diagnostic Testing,"ESR1,PIK3CA",-,Advanced breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.3,-,ESR1突变
1232,KP14,32424005,Combination-targeted treatment#promotes#robust tumor control with immune checkpoint inhibitor therapy,Combination Therapies,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.3,3.2.3.3,-,协同增效作用
5809,KP14,30237864,MDM2 amplification#was analyzed using#FoundationOne's genomic profiling assay,Biomarker Analysis,MDM2,-,Solid tumors,-,-,-,Advanced patients,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.4,MDM2扩增
3073,KP14,30237864,CDK4 amplification and TP53 mutations#suggest#need for combinational studies with MDM2 inhibitors,Mechanisms of Resistance,"CDK4,TP53",-,-,MDM2 inhibitors,-,-,-,-,-,-,-,Inference,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
1186,KP14,39691590,Plasma-carried EVs#were characterized in#HR(+) metastatic breast cancer patients treated with CDK4/6 inhibitors,Biomarker Analysis,"CDK4,CDK6",-,Metastatic breast cancer,-,-,-,HR(+) patients,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,7.5.1.1.4,CDK6扩增
2877,KP14,36399634,RB1 loss-of-function signature#predicts#CDK4/6 inhibitor response in SCLC patients,Biomarker Analysis,"RB1,CDK4,CDK6",-,SCLC,Abemaciclib,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.2,7.5.1.2.2,RB1丢失
1727,KP14,33575067,"CDK4/6 inhibitors with endocrine therapy#are#preferred treatment for HR(+), HER2(-) metastatic breast cancer",Therapeutic Development,"CDK4,CDK6",-,Metastatic breast cancer,Endocrine therapy,-,-,Premenopausal and postmenopausal women,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
2860,KP14,37306107,Palbociclib with ganitumab#was studied in#patients with relapsed EWS,Combination Therapies,"CDK4,CDK6",-,EWS,"Palbociclib,Ganitumab",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
5207,KP14,32843618,Aberrant cell cycle machinery and CDKN2A loss#make#CDK4/6 a target in PDAC,Cancer Association,"CDK4,CDK6,CDKN2A",-,Pancreatic ductal adenocarcinoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
6016,KP14,32843618,PDAC cases#do not harbor#a durable response to monotherapy of CDK4/6 inhibitor,Therapeutic Response,"CDK4,CDK6",-,PDAC,CDK4/6 inhibitor,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
5393,KP14,32843618,PAL and HCQ#are co-encapsulated in#a ratiometrically designed mesoporous silica nanoformulation,Drug Development,"CDK4,CDK6",-,PDAC,"Palbociclib (PAL), Hydroxychloroquine (HCQ)",-,-,-,-,-,-,-,Fact,3,3.6,3.6.1,3.6.1.1,-,纳米载体设计
2664,KP14,32843618,Mesoporous silica nanoformulation#demonstrates#synergistic efficacy in subcutaneous and orthotopic PDAC mouse models,Preclinical Models,"CDK4,CDK6",-,PDAC,"Palbociclib (PAL), Hydroxychloroquine (HCQ)",-,-,-,-,-,-,-,Fact,3,3.6,3.6.1,3.6.1.1,-,纳米载体设计
1768,KP14,32843618,Synergism#is attributed to#effective intratumoral buildup of PAL/HCQ,Mechanism of Action,"CDK4,CDK6",-,PDAC,"Palbociclib (PAL), Hydroxychloroquine (HCQ)",-,-,-,-,-,-,-,Fact,3,3.6,3.6.1,3.6.1.1,-,纳米载体设计
5254,KP14,32843618,PAL/HCQ co-delivery nanoparticles#lead to#the most effective shrinkage of PDAC compared to various controls,Therapeutic Development,"CDK4,CDK6",-,PDAC,"Palbociclib (PAL), Hydroxychloroquine (HCQ)",-,-,-,-,-,-,-,Fact,3,3.6,3.6.1,3.6.1.1,-,纳米载体设计
6264,KP14,32843618,Co-delivery nanoparticles#combined with#a Bcl inhibitor improve performance,Combination Optimization,"CDK4,CDK6",-,PDAC,"Bcl inhibitor, Co-delivery nanoparticles",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
3253,KP14,37955661,Androgen synthesis inhibitors and AR degraders#are promising approaches to#overcome resistance mediated by AR mutations or splice variants,Therapeutic Resistance,-,-,-,"Androgen synthesis inhibitors, AR degraders",-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
1035,KP14,37955661,Inhibition of AKT or CDK4/6#provides#additional treatment options,Therapeutic Development,"CDK4,CDK6,AKT",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
4636,KP14,37955661,Understanding tumor microenvironment and immune response#is required for#novel immunotherapeutic strategies using BiTEs and CAR T cells,Immune Cell Functions,-,T cells,Tumor,"BiTEs, CAR T cells",-,-,-,-,-,-,-,Inference,6,6.1,6.1.1,6.1.1.1,6.1.1.1.4,细胞毒性活性
5895,KP14,29497091,ESR1 mutations#are shown to be#frequently subclonal,Cancer Association,ESR1,-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
5245,KP14,29497091,Early ctDNA dynamics#may provide#a robust biomarker for CDK4/6 inhibitors,Biomarker Analysis,"CDK4,CDK6",-,Tumor,-,-,-,-,-,-,-,-,Inference,7,7.3,7.3.1,7.3.1.2,7.3.1.2.2,生物标志物监测
4893,KP14,38338777,PI3K/AKT/mTOR pathway and cell-cycle machinery#are involved in#miRNA mechanisms,Pathway & Network Categories,"CDKN1B,CCND1",-,-,-,"PI3K/AKT/mTOR, Cell-cycle machinery",-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
2311,KP14,38338777,A novel panel of miRNAs#is associated with#early progression in patients treated with ET and Palbociclib,Biomarker Analysis,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Inference,7,7.3,7.3.1,7.3.1.1,7.3.1.1.4,细胞周期分布
5988,KP14,37533590,Metastatic breast cancers#are classified into#HER2-zero and HER2-low groups,Cancer Pathways,ERBB2,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.2,7.4.1.2.3,HER2富集亚型
5830,KP14,29059492,Cyclin D-CDK4/6-INK4-Rb pathway#is frequently dysregulated in#cancers,Pathway & Network Categories,"CDK4,CDK6",-,Cancer,-,Cyclin D-CDK4/6-INK4-Rb,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
5404,KP14,29059492,Dose escalation of ribociclib#was not pursued due to#lack of efficacy in esophageal cancer,Therapeutic Response,"CDK4,CDK6",-,Esophageal cancer,Ribociclib,-,-,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.3,8.4.1.3.3,剂量调整
6360,KP14,37222206,Co-amplification of CDK4 and MDM2#provides rationale for#CDK4/6 inhibitors as potential therapy,Therapeutic Development,"CDK4,MDM2",-,Liposarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
1204,KP14,37222206,Molecular-guided precision medicine#holds#a bright future for advanced sarcoma treatments,Therapeutic Development,-,-,Advanced sarcoma,-,-,-,-,-,-,-,-,Inference,8,8.5,8.5.1,8.5.1.2,8.5.1.2.4,药物浓度
2725,KP14,36861085,CDK4/6 inhibitors and endocrine therapy#are recommended as#first-line treatment for HR+/HER2- advanced breast cancer,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- advanced breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,8.1.1.2.1,一线治疗
3677,KP14,27721716,Characterization of the disease phenotype#may include#biopsy of the metastatic site,Clinical Implementation,-,-,Metastatic disease,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,8.5.1.1.1,CT扫描
2936,KP14,32231544,Patients with cancer of unknown primary (CUP)#are treated with#chemotherapy,Clinical Implementation,-,-,Cancer of unknown primary (CUP),Chemotherapy,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
871,KP14,32231544,Bone marrow biopsy#showed#relatively uniform small cells strongly positive for estrogen and progesterone receptor expression,Biomarker Analysis,-,-,-,-,-,-,-,-,"Estrogen receptor, progesterone receptor",-,-,Fact,7,7.2,7.2.1,7.2.1.3,7.2.1.3.1,PD-L1表达
3343,KP14,32231544,Chemotherapy#was considered#risky due to bicytopenia,Clinical Implementation,-,-,-,Chemotherapy,-,Bicytopenia,-,-,-,-,-,Fact,8,8.4,8.4.1,8.4.1.1,8.4.1.1.1,中性粒细胞减少
655,KP14,32231544,Letrozole#was initiated#as an aromatase inhibitor,Drug Development,-,-,-,Letrozole,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,3.2.1.1.1,来曲唑
2611,KP14,32231544,CUP with DCBM#might be#metastatic occult breast cancer,Cancer Association,-,-,Metastatic occult breast cancer,-,-,-,-,-,-,-,-,Inference,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
5113,KP14,32231544,Endocrine therapy#can be#a valuable treatment option if tumors express hormone receptors,Therapeutic Development,-,-,Tumors,Endocrine therapy,-,-,-,-,Hormone receptors,-,-,Fact,3,3.2,3.2.1,3.2.1.1,3.2.1.1.1,来曲唑
254,KP14,38327984,Mechanisms of action of drugs#are discussed for#potential synergistic effects,Mechanism of Action,-,-,-,"Targeted therapy drugs, endocrine hormone therapy drugs",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
5518,KP14,31379741,Sequential monotherapy#selects for#resistant and lethal tumor clones,Therapeutic Resistance,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,2,2.6,2.6.1,2.6.1.1,-,多药耐药
3211,KP14,36493359,Endocrine resistance#is commonly due to#genetic alterations of ESR1,Mechanisms of Resistance,ESR1,-,HR+ metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
7001,KP14,38537957,everolimus in combination with exemestane#offers#benefit in HR+/HER2- advanced breast cancer,Combination Therapies triples,-,-,Advanced breast cancer,"everolimus,exemestane",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
2944,KP14,28281842,preventing acquired resistance from ER mutations#is achieved with#Selective ER Downregulators like fulvestrant,Strategies to Overcome Resistance,ESR1,-,Breast cancer,fulvestrant,-,-,-,-,-,-,-,Inference,2,2.5,2.5.2,2.5.2.4,-,生物标志物指导
2929,KP14,37358480,CDK4/6 and NOTCH inhibitors#show#efficacy in T-ALL xenotransplantation models,Preclinical Models,"CDK4,CDK6,NOTCH",-,T-ALL,"CDK4/6 inhibitors, NOTCH inhibitors",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
931,KP14,30290287,secondary resistance mechanisms#have been#identified in breast cancer treatment,Mechanisms of Resistance,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
327,KP14,37580773,ctDNA monitoring#has potential value in#metastatic HR+/HER2- breast cancer,Clinical Implementation,ERBB2,-,Metastatic HR+/HER2- breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.6,7.6.1,7.6.1.1,-,突变检测
1119,KP14,39364228,CDK4/6 inhibitors#have revolutionized#the treatment landscape of HR+/HER2- metastatic breast cancer,Therapeutic Development,"CDK4,CDK6",-,Metastatic HR+/HER2- breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
5253,KP14,39409937,"Eligibility for CDK4/6 inhibitors#was determined by#age and type of surgery in ER-positive, HER2-negative early breast cancer",Clinical Implementation,"CDK4,CDK6",-,"ER-positive, HER2-negative early breast cancer",-,-,"Age, type of surgery",-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,-,患者选择
2426,KP14,39409937,NataLEE trial results#may increase#eligibility for adjuvant CDK4/6 inhibitors,Clinical Trial Data,"CDK4,CDK6",-,-,-,-,Elderly population,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.3,-,患者选择
4782,KP14,37935631,Abemaciclib#is combined with#Fulvestrant,Combination Therapies,-,-,Metastatic breast cancer,"Abemaciclib,Fulvestrant",-,"Hormone receptor-positive, HER2-negative",-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
4193,KP15,38943828,CDK4 and CDK6#are crucial for#G1-to-S phase transition,Cell Cycle Control,"CDK4,CDK6",-,Breast cancer,-,G1-to-S phase,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
3052,KP15,38943828,CDK4/6-Rb-E2F pathway#is described in#HR-positive breast cancer,Pathway & Network Categories,"CDK4,CDK6,RB1,E2F",-,Breast cancer,-,CDK4/6-Rb-E2F pathway,-,Hormone receptor-positive,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
3908,KP15,28706010,Cell cycle aberrations#are pervasive in#cancer,Cancer Association,-,-,Cancer,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
5599,KP15,28706010,Cyclin-dependent kinases#control#cell cycle transitions,Cell Cycle Control,"CDK4,CDK6",-,Cancer,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.2,-,-,周期蛋白复合物形成
2035,KP15,34573335,CDK6 dependence#is targeted in#Ph+ ALL,Cancer Pathways,CDK6,-,Ph+ ALL,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,-,-,细胞增殖调控
2895,KP15,34573335,CDK6 expression#is required for#proliferation and survival of Ph+ ALL cells,Expression Patterns,CDK6,-,Ph+ ALL,-,Cell cycle pathway,-,Upregulated,-,-,-,-,Fact,1,1.4,1.4.1,-,-,细胞增殖调控
7328,KP15,39593745,CDK4/6 inhibitors#elucidate#anticancer mechanisms through immunomodulatory activity,Mechanism of Action,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,3,3.3,3.3.2,3.3.2.3,-,免疫逃逸抑制
353,KP15,35917168,CDK4/6 inhibitors#prevent#retinoblastoma protein phosphorylation,Mechanism of Action,"CDK4,CDK6",-,Retinoblastoma,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
5232,KP15,39376495,CDK4/6 inhibitors#restore#cell cycle control in breast cancer cases,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1279,KP15,39376495,Disproportionality analysis#analyzed#adverse event reports related to CDK4/6 inhibitors,Biomarker Analysis,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.3,7.5.1.3.3,药物外排
640,KP15,32357912,CDK4/6-related proteins#are co-expressed with#classical tumor signaling pathways,Signaling Networks,"CDK4,CDK6",-,-,-,"Cell cycle pathway, RAS pathway, PI3K pathway, Myc pathway, p53 pathway",-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
7654,KP15,36060025,Bevacizumab#inhibited#tumor growth in CDK4/6 inhibitor-resistant tumors due to RB loss,Strategies to Overcome Resistance,RB,MCF7,-,Bevacizumab,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
866,KP15,37974598,Resistance pathways#cause#insensitivity to CDK4/6 inhibitors,Mechanisms of Resistance,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
6890,KP15,34234565,Cyclin D/CDK4/6-Rb pathway#regulates#cell cycle checkpoints,Cell Cycle Control,"CDK4,CDK6,RB1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
3000,KP15,28741274,CDK4/6-INK4-Rb pathway#plays#a crucial role in cell cycle progression,Cell Cycle Control,"CDK4, CDK6, RB1",-,Endocrine therapy resistance,-,Cyclin D-CDK4/6-Rb,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
6432,KP15,29483206,Combined inhibition of mTOR and CDK4/6#is required for#optimal blockade of E2F function,Combination Optimization,"CDK4, CDK6, MTOR, E2F",-,Breast cancer,"mTOR inhibitors, CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.3,-,E2F转录因子活性下调
3137,KP15,29483206,CDK4/6 inhibitor-resistant cell lines#reactivate#the CDK-RB-E2F pathway,Resistance Mechanisms,"CDK4,CDK6,RB1,E2F1",-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
1185,KP15,26053278,Deregulation of CDK4/6-RB axis#contributes to#unrestrained growth in a variety of cancers including breast cancers,Cancer Association,"CDK4,CDK6,RB1",-,Breast cancer,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
2069,KP15,30745839,Dual inhibition of AR and CDK4/6#could reverse#resistance of palbociclib both in vitro and in vivo,Resistance Management,"CDK4,CDK6,AR",-,-,Palbociclib,-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
2315,KP15,30745839,AR activation#promotes#cell cycle progression and cell proliferation in CDK4/6 inhibitor resistance,Mechanism of Resistance,"CDK4,CDK6,AR",-,-,-,-,-,upregulated,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.4,-,替代性生存通路
4088,KP15,36598514,Abemaciclib and TAL combination#synergistically suppresses#growth of TNBC cells,Combination Therapies,"CDK4,CDK6",-,Triple-negative breast cancer,"Abemaciclib,TAL",-,"G0/G1 arrest, apoptosis",-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
4242,KP15,36358625,Anti-estrogen therapies#improve#survival in ER+ breast cancer patients,Therapeutic Development,ESR1,-,Estrogen receptor-positive breast cancer,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
3898,KP15,39090086,ABCB1 inhibitors#failed to be#clinically useful due to low specificity and toxicity,Drug Development triples,ABCB1,-,-,ABCB1 inhibitors,-,-,-,-,-,-,-,Fact,2,2.5,2.5.2,2.5.2.2,-,给药策略改进
2275,KP15,31371343,TORC1 inhibition#overcomes#resistance induced by FGFR1,Strategies to Overcome Resistance triples,FGFR1,-,Breast cancer,-,TORC1,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
5859,KP15,27249746,ER#cross-talks with#growth factor receptor signaling pathways,Signaling Networks,ESR1,-,-,-,Growth factor receptor signaling,-,-,-,-,-,-,Fact,1,1.2,1.2.1,1.2.1.1,-,生长因子信号
5793,KP15,27249746,PI3K/Akt/mTOR pathway#mediates#intracellular growth and survival signals,Signaling Networks,MTOR,-,-,-,PI3K/Akt/mTOR,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.3,-,协同效应
1959,KP15,27249746,HDAC#modifies#epigenetic states,Epigenetic Regulation,HDAC,-,-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.3,-,抑制复合物
3881,KP15,27249746,Tumor microenvironment#interacts with#host immune response,Tumor Microenvironment,ESR1,-,-,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
3853,KP15,30381447,17 inhibitors#were approved between#2013 and 2017,Drug Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
2694,KP15,30381447,17 inhibitors#were profiled on#a biochemical assay panel of 280 kinases,Technical Methods,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
1413,KP15,37420093,NRAS mutant melanoma cell lines#respond to#CDK4/6 and MEK inhibitors combination,Therapeutic Response,"NRAS,CDK4,CDK6,MAP2K1",-,Melanoma,"CDK4/6 inhibitors, MEK inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
7470,KP15,37420093,Interferon gamma#induces#EMT and activation of ERK5 signaling,Signaling Networks,IFNG,-,Senescence,-,ERK5,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.2,-,JNK通路交互
2367,KP15,36778271,Samples#were treated with#17β-estradiol,Experimental Methods,-,-,-,17β-estradiol,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.1,-,雌激素信号阻断
5124,KP15,36778271,scRNA-seq analyses#validated#findings on ER-low estrogen-accelerating PDX (GS1),Validation Methods,ESR1,-,Estrogen-accelerating PDX,-,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
3926,KP15,36778271,Space-gene-function study#revealed#a proliferative cell population within ER(+) metastatic breast cancers,Expression Patterns,ESR1,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.1,-,增殖信号整合
142,KP15,36778271,Cells#with induction of#estrogen-responsive genes such as PGR,Gene Regulation,PGR,-,-,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,关键转录因子
5305,KP15,36778271,Gene signatures#correlated with#worse clinical outcomes in hypoxia-induced and inflammation-related compartments,Prognostic Associations,-,-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
2705,KP15,36778271,High estrogen-responsive scores#showed#better prognosis,Prognostic Associations,ESR1,-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
6078,KP15,35398754,"Capivasertib#inhibits#three AKT isoforms AKT1, AKT2, and AKT3",Drug Development,"AKT1,AKT2,AKT3",-,-,Capivasertib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
7888,KP15,35398754,Capivasertib#demonstrated#efficacy in breast cancer cell lines,Preclinical Models,"AKT1,AKT2,AKT3",-,Breast cancer,Capivasertib,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
5030,KP15,35398754,Capivasertib#showed synergy with#anti-HER2 agents and endocrine treatment,Combination Therapies,"AKT1,AKT2,AKT3",-,Breast cancer,"Capivasertib, anti-HER2 agents, endocrine treatment",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
75,KP15,35398754,Ongoing trials#will clarify#therapeutic role of capivasertib in breast cancer,Clinical Trial Data,"AKT1,AKT2,AKT3",-,Breast cancer,Capivasertib,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.2,-,晚期实体瘤
5511,KP15,27020862,Combining AZD9496 with PI3K pathway and CDK4/6 inhibitors#enhanced#growth-inhibitory effects,Combination Therapies,"CDK4,CDK6",-,-,"AZD9496, PI3K pathway inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
1015,KP15,39116089,MCF7 cells#were used as#functional estrogen and non-invasive breast cancer model,Model Systems,ESR1,MCF7,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
5631,KP15,39116089,MDA-MB-231 cells#were used as#a model for triple-negative aggressive breast cancer,Model Systems,-,MDA-MB-231,Triple-negative breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,HR+/HER2-乳腺癌
4197,KP3,32661093,Patients progressing on CDK4/6i/MEK pathway inhibitor combinations#exhibit#T-cell exclusion,Immune Cell Functions,"CDK4,CDK6,MEK",T cells,-,"CDK4/6 inhibitors,MEK inhibitors",MEK,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
7737,KP3,32661093,CD8(+) T cell depletion#reduces#time to regrowth of melanomas during CDK4/6i and MEKi treatment,Immune Cell Functions,"CDK4,CDK6",CD8(+) T cells,Melanoma,"CDK4/6 inhibitors,MEK inhibitors",MEK,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1.1,-,CD8+效应T细胞
1060,KP3,34230123,Combination therapy of CDK4/6 inhibitor and mTOR inhibitor#was reported in#several cancer types,Combination Therapies,"CDK4,CDK6,MTOR",-,Cancer,"CDK4/6 inhibitors,mTOR inhibitors",mTOR,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
5396,KP3,39499997,Fasting-mimicking diet#potentiates#anti-tumor effects of CDK4/6 inhibitors in breast cancer,Strategies to Overcome Resistance,"CDK4,CDK6",NRAS,Breast cancer,CDK4/6 inhibitors,mTORC1,-,-,-,-,-,-,Fact,3,3.5,3.5.3,3.5.3.1,-,葡萄糖代谢调节
4362,KP3,25848011,The CDK4/6 pathway#is activated in parallel with#renal cell-cycle entry before AKI development,Cell Cycle Control,"CDK4,CDK6",Renal cells,AKI,-,G1/S transition,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,G1/S期转换调控
5826,KP3,25848011,Palbociclib and Ribociclib#inhibit#cell-cycle progression and ameliorate kidney injury,Therapeutic Development,"CDK4,CDK6",Renal cells,Kidney injury,"Palbociclib, Ribociclib",CDK4/6 pathway,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
399,KP3,25848011,Palbociclib and LEE011#target#OCT2 and cell-cycle activities,Drug Development,"CDK4,CDK6",-,AKI,"Palbociclib, LEE011",CDK4/6 pathway,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.2,-,RB蛋白磷酸化抑制
7668,KP7,24687853,Cyclin-dependent kinase (CDK) inhibitor (CKI)-CDK-retinoblastoma protein (Rb) pathway#is involved in#pituitary gland sensitivity to genetic alteration,Signaling Networks,"CDK4,CDK6,RB1",Pituitary gland,-,-,CKI-CDK-Rb pathway,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
375,KP7,28580868,Cell division#occurs via#the cell cycle regulated by cyclins and CDKs,Cell Cycle Control,"CDK4,CDK6",-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
6339,KP7,28580868,Combinations with PI3K and mTOR inhibitors#are being evaluated in#breast cancer and RAS-mutant cancers,Combination Optimization,"MTOR,RAS",-,"Breast cancer,RAS-mutant cancers",-,"PI3K-mTOR pathway,RAS/RAF/MAPK pathway",-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
117,KP7,30176239,PD0332991#increased#Treg cells and levels of activated transcription factor phosphoSTAT5,Drug Development,"CDKN2A,CDKN2B",-,-,PD0332991,-,-,-,upregulated,-,-,-,Fact,3,3.3,3.3.2,3.3.2.2,-,T细胞活化增强
1122,KP7,9598804,Melanoma cell lines without deletion/mutation of CDKN2A#harbor#transcriptionally inactive CDKN2A alleles,Regulation,CDKN2A,Melanoma cell lines,Melanoma,-,-,-,-,silenced,-,-,-,Fact,1,1.5,1.5.2,1.5.2.3,-,抑制复合物
2799,KP7,18310289,"Expression of p18, p27, and Cdk4#is altered in#Leydig cell lesions",Regulation,"CDKN1B,CDK4",-,Leydig cell tumors,-,TGF-beta,-,-,altered,-,-,-,Fact,1,1.2,1.2.2,1.2.2.1,-,转录因子网络
981,KP7,16738322,"P18 deletion, CDK4 overexpression, or oncoviral inactivation of Rb family proteins#caused#activation of Akt/PKB",Signaling Networks,"CDK4,AKT1,CDKN2C",-,Prostate tumor,-,-,Akt/PKB pathway,-,upregulated,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
296,KP14,36233758,"Targeted approaches#are developed against#CDK4/6, PI3K, PARP, and PD-L1",Therapeutic Development,"CDK4,CDK6,PIK3,PARP,CD274",-,-,-,"PI3K,PARP,PD-L1",-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
6022,KP10,16732325,Amplified material#contains#sequences from 12q13-15 and other chromosomes,Genomic Event triples,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
5931,KP10,16732325,DNA copy number profiles#revealed#multiple amplification targets,Genomic Event triples,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
6791,KP13,10956386,Mechanisms by which myc#promotes#cell cycle progression in B-cells,Molecular Event triples,MYC,B-cells,-,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
6553,KP13,10956386,Ectopic expression of p16#inhibits#cell cycle progression,Molecular Event triples,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.3,-,增殖抑制
4414,KP14,20182587,"alterations in signal transduction pathways#led to#therapeutic agents targeting EGFR, VEGF, and multi-kinase inhibitors",Drug Development,"EGFR,VEGF",-,Hepatocellular carcinoma (HCC),multi-kinase inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
2841,KP14,28281842,extended adjuvant therapy targeted to ER#has decreased#mortality from breast cancer,Therapeutic Response,ESR1,-,Breast cancer,"tamoxifen,aromatase inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
3205,KP14,28281842,extended adjuvant therapy with tamoxifen or aromatase inhibitors#is discussed in#translational research,Translational Research,ESR1,-,Breast cancer,"tamoxifen,aromatase inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
4685,KP14,28281842,retarding acquired resistance#can be achieved with#CDK4/6 or mTOR inhibitors,Strategies to Overcome Resistance,"CDK4,CDK6,MTOR",-,Breast cancer,"CDK4/6 inhibitors,mTOR inhibitors",-,-,-,-,-,-,-,Inference,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
3718,KP14,36605432,chemotherapy#has limited#efficacy due to dose reduction and adverse effects,Therapeutic Development,-,-,-,chemotherapy,-,-,-,-,-,-,-,Fact,8,8.3,8.3.1,8.3.1.2,-,不良反应管理
3557,KP14,36605432,endocrine therapy#improves#median OS to 23 months in HR(+)/HER2(-) BMM patients,Therapeutic Response,-,-,Bone metastases (BMM),Endocrine therapy,-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
6499,KP14,34234466,palbociclib#is used in#advanced breast cancer patients in Hungary,Clinical Implementation,"CDK4,CDK6",-,Advanced breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.3,-,患者选择
222,KP14,34234466,palbociclib#is combined with#aromatase inhibitors or fulvestrant in breast cancer treatment,Combination Optimization,"CDK4,CDK6",-,Breast cancer,"Palbociclib, Aromatase inhibitors, Fulvestrant",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.4,-,耐药机制克服
6516,KP14,39762686,"KRAS inhibitors#are combined with#CDK4/6 inhibitors, immune checkpoint blockade, PARP inhibitors, chemotherapy, and autophagy modulators",Combination Optimization,"KRAS,CDK4,CDK6",-,-,"KRAS inhibitors, CDK4/6 inhibitors, PARP inhibitors, Chemotherapy, Immune checkpoint blockade",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
4450,KP14,37358480,CRISPR-Cas9 screen#identifies#mechanisms of resistance to pharmacological NOTCH inhibitors,Mechanisms of Resistance,NOTCH,-,T-ALL,NOTCH inhibitors,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.4,-,ESR1突变
6427,KP14,36926051,CDK4/6 inhibitors and endocrine agents#improve#outcomes in rMBC patients,Therapeutic Response,"CDK4,CDK6",-,Recurrent metastatic breast cancer (rMBC),"CDK4/6 inhibitors, Endocrine agents",-,-,-,-,-,-,-,Fact,3,3.2,3.2.1,3.2.1.3,-,协同抗增殖作用
3563,KP15,30568462,Adding a targeted agent to fulvestrant#confers#significant clinical benefit,Therapeutic Response triples,-,-,-,fulvestrant,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.4,-,多靶点抑制策略
1113,KP15,39090086,ABCB1-specific inhibitor elacridar#reversed#CBZ and DTX resistance in RC4-2B cells,Strategies to Overcome Resistance triples,ABCB1,-,-,elacridar,-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
4846,KP15,39090086,DNA-damaging compounds CPT and Ara-C#overcame#resistance in RC4-2B cells,Strategies to Overcome Resistance triples,-,-,-,"Camptothecin (CPT), Cytarabine (Ara-C)",-,-,-,-,-,-,-,Fact,2,2.5,2.5.1,2.5.1.1,-,多靶点抑制
6297,KP4,32671612,Palbociclib#is added to#aromatase inhibitor (AI) as first-line therapy,Clinical Implementation triples,-,-,Metastatic breast cancer,"Palbociclib, Aromatase inhibitor (AI)",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
4518,KP1,39820556,Pathogenic TP53 variant#was identified in#line with Li-Fraumeni syndrome,Genomic Alterations,TP53,-,Li-Fraumeni syndrome,-,-,Li-Fraumeni syndrome patient,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,点突变
4406,KP2,17260012,Chromosomal aberrations#characterize#pathogenesis in melanoma cell lines,Genomic alteration,-,Melanoma cell lines,-,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,-,-,染色体结构异常
6005,KP3,37477704,"Additional therapies#under study include#CDK4/6 inhibitors, PARP inhibitors, HER2-targeted therapies, and immunotherapy",Drug Development,"CDK4, CDK6",-,Cancer,"CDK4/6 inhibitors, PARP inhibitors, HER2-targeted therapies, immunotherapy",-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,-,-,CDK4/6抑制剂的作用机制
1333,KP3,38653982,Immunosuppressive mechanisms#may be investigated as#therapeutic targets,Therapeutic Development,-,-,-,-,-,-,-,-,-,-,-,Inference,3,3.3,3.3.2,-,-,免疫检查点调节
7769,KP7,12653665,Gankyrin#is overexpressed in#hepatocellular carcinoma cells,Cancer Association,Gankyrin,Hepatocellular carcinoma cells,Hepatocellular carcinoma,-,-,-,upregulated,-,-,-,-,Fact,1,1.1.1,1.1.1.3,-,-,细胞周期检查点控制
7632,KP7,19158499,Peptide treatments#increased#Cdk4 levels,Expression Patterns,CDK4,-,-,-,-,-,upregulated,-,-,-,-,Fact,1,1.1.2,1.1.2.1,-,-,Cyclin D-CDK4复合物
2458,KP7,19158499,Peptide treatments#increased#phospho-retinoblastoma levels,Expression Patterns,RB1,-,-,-,-,-,upregulated,-,-,-,-,Fact,1,1.1.1,1.1.1.1,-,-,RB蛋白磷酸化
1030,KP7,19158499,Peptide treatments#caused#cell cycle arrest before M phase,Cell Cycle Control,-,-,-,-,-,-,-,-,-,-,-,Inference,1,1.1.3,1.1.3.1,-,-,G1期阻滞
4409,KP7,25180593,TMOC#caused#G0/G1 cell cycle arrest,Cell Cycle Control,"CDK4,CDKN1A,CDKN1B,CDKN2A,CCND1",-,-,TMOC,-,-,"downregulated (Cyclin D1, CDK4), upregulated (p16, p21, p27)",-,-,-,-,Fact,1,1.1.3,1.1.3.1,-,-,G1期阻滞
7999,KP7,25180593,TMOC#induced#expression of tumor suppressor PTEN,Expression Patterns,PTEN,-,-,TMOC,-,-,upregulated,-,-,-,-,Fact,1,1.2.3,1.2.3.2,-,-,蛋白稳定性
2390,KP7,38385108,Rapamycin#induced#B16 cell cycle arrest in G1 phase,Cell Cycle Control,"CDK4,CDK1,CCND1",-,-,Rapamycin,-,-,"downregulated (CDK1, Cyclin D1, CDK4)",-,-,-,-,Fact,1,1.1.3,1.1.3.1,-,-,G1期阻滞
2820,KP7,38385108,Rapamycin#blocked#phosphorylation of p70 ribosomal S6 kinase,Signaling Networks,RPS6KB1,-,-,Rapamycin,mTOR/p70-S6k,-,downregulated,-,-,-,-,Fact,1,1.3.1,1.3.1.1,-,-,信号交叉激活
4783,KP7,38385108,Rapamycin#blocked#phosphorylation of mTOR proteins,Signaling Networks,MTOR,-,-,Rapamycin,mTOR/p70-S6k,-,downregulated,-,-,-,-,Fact,1,1.3.1,1.3.1.1,-,-,信号交叉激活
1142,KP9,29893769,GE analyses#confirmed#effect on proliferation and cell cycle genes,Expression Patterns,"RB,CCND1,CDK2,CyclinD1,p16,pRB,pAKT,pER,Ki67",-,-,-,Cell cycle,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
6983,KP14,28697311,Anthracycline- and trastuzumab-related cardiac toxicities#have been#extensively studied,Safety Monitoring,-,-,-,"Anthracycline,Trastuzumab",-,-,-,-,-,-,-,Fact,10,10.4,10.4.4,10.4.4.1,-,心脏毒性
3895,KP14,38838498,patients with HR+ HER2-negative BC#are randomized to#palbociclib or placebo,Clinical Trial Data,"CDK4,CDK6",-,HR+ HER2-negative breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,HR+/HER2-乳腺癌
6915,KP14,38838498,66.1% of patients#were treated with#tamoxifen alone,Treatment Monitoring,-,-,HR+ HER2-negative breast cancer,Tamoxifen,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,8.2.1.2.2,他莫昔芬
1419,KP14,38729566,abemaciclib#is studied in#HR+ HER2-negative ABC without prior systemic therapy,Clinical Trial Data,"CDK4,CDK6",-,HR+ HER2-negative ABC,Abemaciclib,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,HR+/HER2-乳腺癌
7851,KP14,26247885,Cognate targeted therapies#were identified in#91.5% of patients,Drug Development,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.4,靶向治疗
7173,KP14,26247885,Most patients#had#actionable alterations,Clinical Implementation,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.4,可操作性改变
2170,KP14,26247885,Results#provide#a framework for tailored combinations of matched therapies,Clinical Implementation,-,-,-,-,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.1,8.1.1.1.4,个性化治疗框架
337,KP14,38240964,"Therapeutic efficacies of two drugs#are considered#comparable, but adverse event profiles remain unclear",Drug Development,-,-,-,-,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.1,8.1.1.1.4,药物疗效比较
3585,KP1,18413728,siRNA-treated cells#shifted expression profiles toward#a neuronal phenotype,Expression Patterns,-,Neuronal cells,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.2,1.4.2.2,-,分化标志物表达
7417,KP1,34376578,Acquired mutations in NRAS and loss of CDKN2A#reactivated#MAPK pathway and activated cell-cycle pathway in BRAF-V600E-mutant melanoma,Mechanism of Action,"NRAS, CDKN2A",-,Melanoma,BRAF/MEK inhibitors,"MAPK, Cell cycle",-,-,-,-,-,-,Inference,2,2.1,2.1.2,2.1.2.2,-,MAPK通路激活
2796,KP1,34376578,Combination of MEK inhibitor and CDK4/6 inhibitor#targeted#MAPK and cell-cycle pathways in BRAF-V600E-mutant melanoma,Combination Therapies,"CDK4, CDK6, NRAS, CDKN2A",-,Melanoma,"MEK inhibitors, CDK4/6 inhibitors","MAPK, Cell cycle",-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.2,-,mTOR抑制剂联用
6381,KP1,12894891,p16 and p15 deletions#varied significantly among#different tumor types,Cancer Association,"CDKN2A, CDKN2B",-,Various tumor types,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
413,KP1,12894891,Most deletions#involved#both p16 and p15 genes,Cancer Association,"CDKN2A, CDKN2B",-,Various tumor types,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
3379,KP1,12894891,Sequence variations in p16 and p15#were comparatively rare in#tumor types,Cancer Association,"CDKN2A, CDKN2B",-,Various tumor types,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
3692,KP1,29106415,Genetically driven resistance#limits#patient survival in targeted therapy,Therapeutic Resistance,-,-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
5489,KP1,29106415,Co-occurring oncogenic events#were identified in#advanced-stage EGFR-mutant lung cancers,Cancer Association,EGFR,-,Lung cancer,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.1,-,DSB识别
6775,KP1,29106415,WNT/β-catenin alterations#limit#EGFR-inhibitor response,Signaling Networks,"CTNNB1, CDK4, CDK6",-,-,-,WNT/β-catenin,-,-,-,-,-,-,Fact,1,1.3,1.3.3,1.3.3.1,-,P53通路相互作用
7025,KP1,29106415,CDK4 and CDK6 mutations#limit#EGFR-inhibitor response,Mechanism of Action,"CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
1697,KP1,29106415,Co-occurring alterations in CTNNB1 and PIK3CA#promote#tumor metastasis,Cancer Pathways,"CTNNB1, PIK3CA",-,Tumor,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.3,1.3.3.1,-,P53通路相互作用
3553,KP1,29106415,Co-occurring alterations in CTNNB1 and PIK3CA#limit#EGFR-inhibitor response,Mechanism of Action,"CTNNB1, PIK3CA",-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
4869,KP1,29106415,Co-occurring genetic alterations#link to#clinical outcomes in advanced-stage EGFR-mutant lung cancer,Cancer Association,EGFR,-,Lung cancer,-,-,-,-,-,-,-,-,Inference,5,5.1,5.1.1,5.1.1.1,-,DSB识别
340,KP1,36040373,Subtype 3 (S3)#is characterized by#dependency on CDK4,Cell Cycle Control,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
4996,KP1,36040373,Subtype 3 (S3)#is characterized by#immune-related expression patterns,Expression Patterns,-,-,-,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,-,CD8+效应T细胞
777,KP1,36040373,Subtype 3 (S3)#is characterized by#altered MET signaling,Signaling Networks,MET,-,-,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
7563,KP1,32391377,Signaling pathways#reveal#altered TP53 and RTK/RAS pathways among subtypes,Signaling Networks,"TP53, RTK, RAS",-,-,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
7854,KP1,31592235,C57BL/6 TRAMP mice#exhibit#shorter lifespan and seminal vesicle enlargement with age,Preclinical Models,-,-,-,-,-,-,"C57BL/6 TRAMP mice, age-related",Upregulated,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,前临床模型
4402,KP1,9426066,"No mutations in exon 2 of CDK4#were found in#a survey of various cancers including neuroblastomas, melanomas, and colon cancer",Molecular Event triples,CDK4,-,"Neuroblastoma, melanoma, colon cancer",-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,CDK4基因突变检测
248,KP1,17214366,liposarcoma#is#a heterogeneous group of soft tissue sarcomas,Disease Classification,CDK4,-,Liposarcoma,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.3,-,肿瘤类型特异性
2748,KP1,15928671,"No germline alterations in CDKN2A, ARF, or CDK4#were detected in#the studied families",Preclinical Models,"CDKN2A,CDK4",-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,CDK4基因突变检测
7406,KP1,15154619,Weak CDK4 immunoreactivity#was detected in#two lipomas,Expression Patterns,CDK4,-,Lipoma,-,-,-,-,downregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,CDK4表达水平
2411,KP1,9341929,Primary and secondary glioblastomas#were analyzed for#CDK4 amplification,Experimental & Technical,CDK4,-,Glioblastomas,-,-,-,-,-,-,-,-,Fact,27,27.3,27.3.1,27.3.1.1,-,CDK4扩增
6033,KP1,14586645,CDK4 Arg24Cys mutation#was not observed in#samples,Mutation Analysis,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,CDK4基因突变检测
751,KP1,32156879,Pathological findings#led to the diagnosis of#dedifferentiated liposarcoma,Diagnostic triples,"CDK4,MDM2",-,Dedifferentiated liposarcoma,-,-,-,-,Upregulated,"CDK4, MDM2",-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
689,KP1,19339902,AM and PM patients#were tested for#germline mutations in melanoma susceptibility genes,Genetic Study,"CDK4,CDKN2A,MC1R",-,Melanoma,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,CDK4基因突变与功能异常
7553,KP1,12497626,Alpha transcript#produces#p16INK4A cyclin-dependent kinase inhibitor,RNA Regulation,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
4440,KP1,10665922,INK4a-ARF locus#encodes#2 separate proteins through differential splicing,Molecular Event triples,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
2454,KP1,10665922,p16INK4a#is produced from#exon 1alpha,Molecular Event triples,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
5054,KP1,10665922,p14ARF#is produced from#exon 1beta,Molecular Event triples,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
5733,KP1,27476724,Germline CDK4 mutations#were characterized in#American melanoma-prone families,Cancer Association,CDK4,-,Melanoma,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
2363,KP1,27476724,CNVs#correlate with#expression changes in disrupted genes,Expression Patterns,-,melanoma cases,melanoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.3,5.3.3.1,-,基因表达改变
6768,KP1,32724874,Gemcitabine-based combination chemotherapy#is#the first line of therapeutic strategy for BTC,Therapeutic Development,-,-,BTC,Gemcitabine,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
7403,KP1,32724874,"BTC#presents#microsatellite instability, hypermutation, and germline variants",Molecular Event triples,-,-,BTC,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.1,-,突变签名
6880,KP1,32724874,BTC#includes#subgroups with individually distinct driver mutations,Cancer Pathways,-,-,BTC,-,-,-,-,-,-,-,-,Fact,2,2.4,2.4.1,2.4.1.1,-,激活性突变
872,KP1,23830351,Genomic and molecular aberrations in MPNSTs#detect#many chromosomal aberrations and pathway abnormalities,Molecular Event triples,-,-,MPNST,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.1,-,易位
7975,KP1,21352266,No CDKN2A or CDK4 germline mutations#were found in#study subjects,Genetic Alteration,"CDKN2A, CDK4",-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
5467,KP1,28447036,Liposarcomas (LPS)#originate from#adipocytes,Cell Type,-,Adipocytes,Liposarcomas,-,-,-,-,-,-,-,-,Fact,13,13.3,13.3.1,13.3.1.1,-,肌肉前体细胞增殖
4994,KP1,28903138,BAP1#is associated with#high susceptibility to melanoma,Cancer Association,BAP1,-,Melanoma,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.1,-,黑色素瘤特征变异
708,KP1,28903138,MITF#is associated with#intermediate susceptibility to melanoma,Cancer Association,MITF,-,Melanoma,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.1,-,黑色素瘤特征变异
6174,KP1,38411299,TERT promoter#is mutated in#melanomas,Cancer Association,TERT,-,Melanoma,-,-,-,-,mutated,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
7683,KP1,38411299,BRAF V600E#is mutated in#melanomas,Cancer Association,BRAF,-,Melanoma,-,-,-,-,mutated,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
3251,KP1,26482321,MYCN#is amplified in#cancers,Cancer Association,MYCN,-,Cancer,-,-,-,-,upregulated,-,-,-,Fact,27,27.3,27.3.1,27.3.1.1,-,基因扩增
4769,KP1,26482321,MIR17HG#is amplified in#cancers,Cancer Association,MIR17HG,-,Cancer,-,-,-,-,upregulated,-,-,-,Fact,27,27.3,27.3.1,27.3.1.1,-,基因扩增
1596,KP1,26482321,NF1#is deleted in#cancers,Cancer Association,NF1,-,Cancer,-,-,-,-,deleted,-,-,-,Fact,27,27.3,27.3.2,27.3.2.1,-,基因缺失
5660,KP1,26482321,CDKN2B#is deleted in#cancers,Cancer Association,CDKN2B,-,Cancer,-,-,-,-,deleted,-,-,-,Fact,27,27.3,27.3.2,27.3.2.1,-,基因缺失
123,KP1,14646620,CDK4#is involved in#malignant melanoma pathogenesis,Cancer Association,CDK4,-,Malignant melanoma,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.1,-,黑色素瘤特征变异
885,KP1,14646620,CDKN2A#is involved in#malignant melanoma pathogenesis,Cancer Association,CDKN2A,-,Malignant melanoma,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.1,-,黑色素瘤特征变异
5714,KP1,14646620,CDKN2B#is involved in#malignant melanoma pathogenesis,Cancer Association,CDKN2B,-,Malignant melanoma,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.1,-,黑色素瘤特征变异
7600,KP1,28389767,"Family members#are affected with#primary melanomas, dysplastic nevi...",Disease Association,POT1,-,"Primary melanomas, Dysplastic nevi, ...",-,-,-,Family history,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.1,-,黑色素瘤特征变异
6125,KP1,28389767,"Clinical work-up#did not reveal#mutation in BRCA1, BRCA2, CDKN2A, ...",Disease Association,"BRCA1,BRCA2,CDKN2A,CDK4,PTEN,TP53",-,Melanoma,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.1,-,黑色素瘤特征变异
3089,KP1,28389767,Whole exome sequencing#showed#a new variant in POT1,Genetic Variant Identification,POT1,-,-,-,-,-,Family history,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.1,-,黑色素瘤特征变异
830,KP1,17713569,Patients#had#a family history of melanoma and/or pancreatic cancer,Disease Association,"CDKN2A,CDK4",-,"Melanoma, Pancreatic cancer",-,-,-,Family history,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.1,-,黑色素瘤特征变异
2268,KP1,17713569,Both mutants#have been associated with#melanoma and demonstrate fo...,Disease Association,"CDKN2A,CDK4",-,Melanoma,-,-,-,Founder effects,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.1,-,黑色素瘤特征变异
2769,KP1,16174859,9q21 linkage#is confirmed#in Danish families with OMM and CMM patients,Genetic Linkage,-,-,"OMM, CMM",-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.1,-,黑色素瘤特征变异
3416,KP1,30738431,ATRX mutation#is associated with#glioblastoma,Cancer Association,ATRX,-,Glioblastoma,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
61,KP1,15185075,INK4-ARF inactivation#was analyzed in#Barrett's adenocarcinomas,Biomarker Analysis,CDKN2A,-,Barrett's adenocarcinomas,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
5453,KP1,15185075,p16INK4a mutations#are detected in#Barrett's adenocarcinomas,Cancer Association,CDKN2A,-,Barrett's adenocarcinomas,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
858,KP1,32731384,ERBB2 amplification#is found in#stage III and IV tumors,Cancer Association,ERBB2,-,Stage III and IV tumors,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.2,27.1.2.1,-,基因扩增
722,KP1,10508477,CDK4 exon 2 mutation#is negative in#7 families,Biomarker Analysis,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
5642,KP1,33228609,CDK4 staining#is negative in#bone tumor,Biomarker Analysis,CDK4,-,Bone tumor,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
5105,KP1,33228609,MDM2 staining#is negative in#bone tumor,Biomarker Analysis,MDM2,-,Bone tumor,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
4021,KP1,33228609,Pulmonary large cell carcinoma#is identified by#biopsy,Cancer Association,-,-,Pulmonary large cell carcinoma,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
6273,KP1,26514741,CDK4 immunohistochemistry#distinguishes#liposarcomas from lipomas,Biomarker Analysis,CDK4,-,"Liposarcomas, Lipomas",-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
2451,KP1,26514741,"p16 immunostaining#was performed in#16 liposarcomas, 16 lipomas, and 16 cases of liponecrosis",Biomarker Analysis,CDKN2A,-,"Liposarcoma, lipoma, liponecrosis",-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
7575,KP1,26514741,"p16 immunostaining#showed#a sensitivity of 75%, a specificity of 87%, a positive predictive value of 60%, and a negative predictive value of 93%",Biomarker Analysis,CDKN2A,-,Liposarcoma,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
7175,KP1,26514741,Negative p16 immunostaining#may exclude#a liposarcoma in adolescence or late recurrence,Biomarker Analysis,CDKN2A,-,Liposarcoma,-,-,-,"Adolescence, late recurrence",-,-,-,-,Inference,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
4982,KP1,31581124,Transcriptomic profiles#have not been investigated in#tumors with different USP8 status,Expression Patterns,USP8,-,Tumors,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
854,KP1,23633104,A mass spectroscopy-based approach#was used to evaluate#95 hallmark SNVs within 12 oncogenes or tumor suppressor genes,Technical Methods,"AKT,BRAF,CDK4,CTNNB1,EGFR,FBXW7,JAK2,KIT,KRAS,PDGFRA,PIK3CA,VEGFA",-,Cancer,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
1489,KP1,38469735,Genomic differences between AM and NAM#have not been investigated in#Asian individuals,Cancer Association,-,-,Melanoma,-,-,-,Asian patients,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
2,KP1,38469735,Findings#provide insights into#pathogenesis of melanoma,Cancer Association,-,-,Melanoma,-,-,-,-,-,-,-,-,Inference,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
7063,KP1,32249949,15% of melanomas#occur in#patients with a family history,Cancer Association,-,-,Melanoma,-,-,-,Family history,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
3921,KP1,32249949,Subset of patients with melanoma#have#germline mutation in melanoma predisposing gene,Cancer Association,-,-,Melanoma,-,-,-,Family history,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
5802,KP1,32249949,"Susceptibility genes#discovered include#CDK4, TERT, ACD, TERF2IP, POT1, MITF, MC1R, and BAP1",Cancer Association,"CDK4, TERT, ACD, TERF2IP, POT1, MITF, MC1R, BAP1",-,Melanoma,-,-,-,-,-,-,-,-,Fact,14,14.1,14.1.1,14.1.1.1,-,CDK4/6基因扩增
1701,KP1,32249949,"Melanoma risk#is increased in#mixed cancer syndromes caused by mutations in PTEN, BRCA2, BRCA1, RB1, and TP53",Cancer Association,"PTEN, BRCA2, BRCA1, RB1, TP53",-,Melanoma,-,-,-,-,-,-,-,-,Fact,14,14.2,14.2.1,14.2.1.1,-,RB1基因丢失/突变
6725,KP1,33077847,"pathogenic germline mutations in CDKN2A, CDK4, ATM, POLH, MRE11A, RECQL4, and XPC#affect#7/44 melanoma patients",Genetic Mutations,"CDKN2A, CDK4, ATM, POLH, MRE11A, RECQL4, XPC",-,Melanoma,-,-,-,-,-,-,-,-,Fact,14,14.1,14.1.1,14.1.1.1,-,CDK4/6基因扩增
6243,KP1,19898221,Immunohistochemistry#analyzed#CDK4 expression,Biomarker Analysis,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,14,14.1,14.1.2,14.1.2.1,-,CDK4/6表达水平
3498,KP1,30900415,CDK4#is analyzed in#linkage disequilibrium block on chromosome 12,Genomic Analysis,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.4,-,调控区突变
5742,KP1,21353380,NHU sublines#carry#dominant-negative CDK4,Preclinical Models,CDK4,Normal human urothelial (NHU) cells,Urothelial carcinoma,-,-,-,-,-,-,-,-,Fact,16,16.1,16.1.3,16.1.3.4,-,治疗抵抗机制
6001,KP1,29954777,A comprehensive precision medicine system#can be implemented in#community and academic settings,Clinical Implementation,-,-,Pancreatic cancer,-,-,-,-,-,-,-,-,Inference,19,19.5,19.5.4,19.5.4.4,-,专家知识整合
2601,KP1,29954777,Patients with tumors having highly actionable alterations#demonstrated#significantly increased PFS with matched therapy,Therapeutic Response,-,-,-,-,-,-,Patients with actionable tumor alterations,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.3,-,疗效监测
5248,KP2,39497720,Next-generation sequencing (NGS)#was assessed for#MET amplification detection in NSCLC,Technical Methods,MET,-,Non-small cell lung cancer,osimertinib,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
2690,KP2,36040373,S3-associated cell lines#respond to#MET inhibitors,Therapeutic Response,MET,-,-,MET inhibitors,-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
7865,KP2,36040373,Patients with S3 tumors#were enriched with#responders to immune checkpoint blockade,Therapeutic Response,-,-,S3 tumors,-,-,-,-,-,-,-,-,Fact,3,3.3,3.3.2,3.3.2.1,-,PD-1/PD-L1表达调控
497,KP2,36040373,Genomic features in S3 and S4#were identified as#biomarkers for clinical diagnosis,Biomarker Analysis,-,-,-,-,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,-,获得性耐药
5293,KP2,36040373,Consensus hierarchical clustering approach#identified#tumor expression subtypes,Preclinical Models,-,-,-,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.2,-,分子亚型
4688,KP2,37330448,Retroperitoneal liposarcomas#are characterized by#local aggression and frequent recurrence,Cancer Association,-,-,Retroperitoneal liposarcomas,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.3,-,增殖抑制机制
3257,KP2,37330448,Histology#was primarily#dedifferentiated liposarcoma,Cancer Association,-,-,Liposarcoma,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.2,1.4.2.1,-,谱系特异性分化
184,KP2,37330448,"Age, number of previous surgeries, histologic grade, or ECOG status#did not differ between#groups",Patient Characteristics,-,-,-,-,-,-,"Age, previous surgeries, histologic grade, ECOG status",-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.2,-,评估内容
1423,KP2,18760195,Expression of p16INK4a#was studied in#Iranian paraffin-embedded skin BCC samples,Preclinical Models,CDKN2A,-,Basal cell carcinoma,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
2716,KP2,33403024,Co-amplification of CDK6 and EGFR#indicates#EGFR alteration,Cancer Association,"CDK6,EGFR",-,METex 14 alteration,-,EGFR signaling,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
2153,KP2,33314017,CDK6 translocations#are associated with#B-cell neoplasms,Cancer Association,CDK6,-,B-cell neoplasms,-,-,-,-,-,-,-,-,Fact,27,27.4,27.4.1,27.4.1.1,-,原癌基因激活
1449,KP2,33314017,CDK6 translocations#are#a recurrent abnormality in B-cell neoplasms,Cancer Association,CDK6,-,B-cell neoplasms,-,-,-,-,-,-,-,-,Fact,27,27.4,27.4.1,27.4.1.1,-,原癌基因激活
6347,KP2,33314017,Fluorescence in situ hybridization#confirmed#involvement of CDK6,Regulation,CDK6,-,-,-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.4,27.5.4.4,-,临床相关终点评估
491,KP2,33314017,CD5 expression#was found in#26 out of 47 patients with MZL/SmBL,Patient-Specific Data,-,-,Marginal zone lymphoma/Splenic B-cell lymphoma,-,-,-,CD5 expression,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.3,-,免疫标志物
2227,KP2,33314017,TP53 deletion#was found in#22 out of 47 patients with MZL/SmBL,Patient-Specific Data,TP53,-,Marginal zone lymphoma/Splenic B-cell lymphoma,-,-,-,TP53 deletion,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
1329,KP2,33314017,NOTCH2 mutations#were not found in#any cases,Cancer Association,NOTCH2,-,B-cell neoplasms,-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.3,27.5.3.3,-,原位基因编辑技术
7478,KP2,10918183,LOH#was detected in#6 tumors (32%),Genomic Alteration,-,-,Tumors,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.2,9.5.2.2,-,功能获得性突变
7549,KP2,10918183,A novel somatic nonsense mutation in exon 7 (Q349X)#was identified in#1 sporadic tumor,Genomic Alteration,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.2,9.5.2.2,-,功能获得性突变
7596,KP2,37671310,Oncogenes#are involved in#neoplastic and malignant transformation during carcinogenesis,Molecular Event,-,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
5238,KP2,9377576,Interphase fluorescence in situ hybridization#was performed using#a cosmid contig of the CDKN2/p16 region and a phage contig of the Rb region,Technical Methods,"CDKN2,RB1",-,-,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,细胞周期检查点控制
4733,KP2,37284196,Immunohistochemistry#was performed using#22C3 or E1L3N clones for PD-L1,Technical Methods,CD274,-,-,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1.3,6.1.1.3.1,-,PD-1/PD-L1表达
7627,KP2,22374332,Flavopiridol pharmacokinetics#showed#increasing C(max) with increasing dose,Drug Development,-,-,-,Flavopiridol,-,-,-,-,-,-,-,Fact,8,8.3,8.3.1.1,8.3.1.1.1,-,标准剂量
2365,KP2,22374332,Stable disease#was seen in#16 patients,Therapeutic Response,-,-,Stable disease,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1.1,7.2.1.1.2,-,CDK4/6表达
5832,KP2,38170436,NRAS mutation#was found in#one NIFT-P case,Cancer Association,NRAS,-,Non-invasive follicular thyroid neoplasm,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1.1,7.1.1.1.1,-,RB1突变
7015,KP2,38170436,Classic PTC subtype#was predominant in#57.64% cases,Clinical Correlation,-,-,Papillary thyroid carcinoma,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1.1,7.2.1.1.4,-,RB蛋白表达
5908,KP2,38170436,"Mutations#were identified in#BRAF, IDH1, RAS, and PIK3CA in 186 cases",Cancer Association,"BRAF, IDH1, RAS, PIK3CA",-,Carcinomas,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1.1,7.1.1.1.1,-,RB1突变
4787,KP2,38170436,"Notable CNVs#included#PDGFRA, CDK4, and KIT",Cancer Association,"PDGFRA, CDK4, KIT",-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1.2,7.1.1.2.1,-,CDK4扩增
482,KP2,38170436,"Target mutations BRAF, RET, and NTRK fusions#hold potential to guide#targeted therapies for tumor recurrence",Therapeutic Development,"BRAF, RET, NTRK",-,Tumor recurrence,-,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1.1,8.1.1.1.4,-,软组织肉瘤
1265,KP2,11869524,"p16, p53, CDK4, and cyclin D1#could be detected in#cells with specific indices",Expression Patterns,"CDKN2A, TP53, CDK4, CCND1",-,-,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,细胞周期检查点控制
2954,KP3,26658964,Clinical trials#target#other cancers,Clinical Trial Data,-,-,Cancer,-,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1.1,8.1.1.1.2,-,晚期实体瘤
473,KP3,31399936,Rb-positive recurrent tumors#continue#Ribociclib treatment,Therapeutic Response,"CDK4,CDK6",Tumor tissue,Glioblastoma,Ribociclib,-,Recurrent,-,-,-,-,-,Fact,8,8.2,8.2.1.1,8.2.1.1.1,-,来曲唑
2580,KP3,31399936,Participants#were monitored for#toxicity and disease progression,Clinical Implementation,-,Tumor tissue,Glioblastoma,Ribociclib,-,"Toxicity, disease progression",Recurrent,-,-,-,-,Fact,8,8.5,8.5.1.1,8.5.1.1.1,-,CT扫描
4998,KP3,31399936,Participants#experienced#early disease progression,Therapeutic Response,"CDK4,CDK6",Tumor tissue,Glioblastoma,Ribociclib,-,Disease progression,Recurrent,-,-,-,-,Fact,8,8.5,8.5.1.3,8.5.1.3.1,-,症状改善
4668,KP3,31399936,Ribociclib monotherapy#was ineffective for#recurrent GBM treatment,Therapeutic Response,"CDK4,CDK6",Tumor tissue,Glioblastoma,Ribociclib,-,-,Recurrent,-,-,-,-,Inference,8,8.5,8.5.1.3,8.5.1.3.1,-,症状改善
4611,KP3,37946508,Patients#presented with#visceral crisis,Symptoms,-,-,HR+/HER2- metastatic breast cancer,-,-,Visceral crisis,-,-,-,-,-,Fact,8,8.4,8.4.1.2,8.4.1.2.4,-,皮肤反应
1249,KP3,38896996,Impact of prior CDK4/6i#on#brain metastases natural history is not well described,Research Gap,"CDK4,CDK6",-,Brain metastases,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
4246,KP3,38896996,Biomarkers#motivate#investigation for patient selection,Biomarker Analysis,-,-,-,-,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1.1,7.1.1.1.1,-,RB1突变
4723,KP3,34145036,CDK4/6 inhibitor palbociclib#was investigated for#efficacy in Jak2V617F and MPLW515L murine models of myelofibrosis,Preclinical Models,"CDK4, CDK6, JAK2, MPL",-,Myelofibrosis,Palbociclib,-,-,-,-,-,-,-,Fact,10,10.3,10.3.4,10.3.4.2,-,与靶向治疗联用
2612,KP3,28325261,Metastatic breast cancer#remains#incurable despite continuous progress and new therapies,Cancer Association,-,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.3,9.5.3.4,-,肿瘤亚型特征
1902,KP3,32418994,CDK4/6 inhibitors palbociclib and ribociclib#were analysed for#potential to treat cisplatin-resistant and cisplatin-sensitive paediatric and adult GCTs,Preclinical Models,"CDK4, CDK6",-,Germ cell tumors (GCTs),"Palbociclib, Ribociclib",-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
7180,KP3,38443662,A deep learning model#elucidates#response and resistance to CDK4/6 inhibitors,Artificial Intelligence Applications,"CDK4, CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,19,19.2,19.2.1,19.2.1.4,-,深度学习筛选模型
6164,KP3,38443662,Deep learning model#is based on#multiprotein assemblies in cancer,AI Drug Discovery,"CDK4, CDK6",-,Cancer,Palbociclib,-,-,-,-,-,-,-,Fact,19,19.1,19.1.3,19.1.3.4,-,互作网络预测
3283,KP3,39009505,Ribociclib#showed#highest risk signal of CDK4/6i-related PAEs,Safety Monitoring,"CDK4, CDK6",-,-,"Ribociclib, Palbociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,10,10.4,10.4.4,10.4.4.4,-,神经系统反应
650,KP3,34581647,Palbociclib#demonstrated#highest number of VTE reports,Safety Monitoring,"CDK4, CDK6",-,-,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,10,10.4,10.4.1,10.4.1.1,-,中性粒细胞减少
4346,KP3,28151717,"LEE011, a CDK4/6 inhibitor#was tested with#a panel of drugs relevant to T-ALL treatment",Experimental & Technical Categories,"CDK4, CDK6",T cells,T-ALL,LEE011,-,-,-,-,-,-,-,Fact,10,10.3,10.3.4,10.3.4.3,-,与化疗联用
5970,KP3,26369631,Preclinical activity#supports#clinical evaluation for metastatic colorectal cancer,Preclinical Models,-,-,Metastatic colorectal cancer,-,-,-,-,-,-,-,-,Inference,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
6656,KP3,29669860,ECM29 mRNA levels#are predictive of#relapse-free survival in breast cancer patients,Biomarker Analysis,-,-,Breast cancer,-,-,-,Breast cancer patients,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
5414,KP3,31924739,Ribociclib#a CDK4/6 inhibitor#was investigated in SCCHN models,Experimental & Technical Categories,"CDK4, CDK6",-,SCCHN,Ribociclib,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
2482,KP3,32391377,Intrinsic genetic and transcriptomic alterations#contribute to#immune subtypes,Molecular Event,-,-,-,-,-,-,-,-,-,-,-,Fact,9,9.3,9.3.3,9.3.3.3,-,糖皮质激素通路
2213,KP3,32391377,Drug combinations#are selected based on#immune subtypes,Therapeutic Development,-,-,-,-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.4,10.3.4.4,-,联合治疗策略
108,KP3,27354579,Novel biological agents and new treatments#contribute to#significant improvement in biological therapies for metastatic melanoma,Therapeutic Development,-,-,Metastatic melanoma,-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
3364,KP3,26161698,Palbociclib#received#accelerated FDA approval,Clinical Implementation,"CDK4, CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
3656,KP3,37991653,CDK4/6 inhibitors#cause#CDKiA resembling androgenetic alopecia,Safety Monitoring,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,CDKiA resembling androgenetic alopecia,Vertex involvement,-,-,-,-,Fact,10,10.4,10.4.3,10.4.3.2,-,脱发
2513,KP3,33300617,"Palbociclib, ribociclib, and abemaciclib#are approved by#FDA",Regulatory Documentation,"CDK4,CDK6",-,-,"Palbociclib, ribociclib, abemaciclib",-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
2862,KP3,39695080,Clinical trials#did not yield#successful outcomes for CDK4/6 inhibitors in melanoma,Clinical Trial Data,"CDK4,CDK6",Melanoma cells,Melanoma,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,10,10.5,10.5.4,10.5.4.2,-,CDK4/6突变
2290,KP3,33224000,Patients with breast cancer brain metastases#are excluded from#clinical trials,Clinical Trial Data,-,-,Breast cancer brain metastases,-,-,-,Patients with brain metastases,-,-,-,-,Fact,10,10.3,10.3.4,10.3.4.4,-,与免疫治疗联用
1645,KP3,39695060,Risk of CVAEs#varied depending on#CDK4/6 inhibitors and combination therapies,Safety Monitoring,"CDK4,CDK6",-,Cardiovascular adverse events,-,-,-,Patient's treatment stage,-,-,-,-,Fact,10,10.4,10.4.4,10.4.4.1,-,心脏毒性
385,KP3,28516152,Patients with metastatic bladder cancer#have#a limited median survival of only around 14 months,Patient Characteristics,-,-,Metastatic bladder cancer,-,-,Median survival: 14 months,-,-,-,-,-,Fact,10,10.3,10.3.3,10.3.3.4,-,生存获益评估
1024,KP3,28516152,Therapeutic options beyond cisplatin-based therapy#had not entered#clinical routine,Clinical Implementation,-,-,-,Cisplatin-based therapy,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
1567,KP3,30185666,CDK4/6 inhibitors#are repurposed for#obesity management,Therapeutic Development,"CDK4,CDK6",-,Obesity,-,-,-,-,-,-,-,-,Inference,10,10.6,10.6.2,10.6.2.4,-,临床应用前景
2267,KP3,30647837,Preclinical testing of palbociclib#was performed with#13 different targeted or cytotoxic chemotherapeutic agents,Preclinical Models,"CDK4,CDK6",-,-,Palbociclib,-,-,-,-,-,-,-,Fact,10,10.1,10.1.4,10.1.4.4,-,抑制剂间差异比较
729,KP3,30724426,SHR6390#produced#marked tumor regression in carcinoma xenografts,Preclinical Models triples,"CDK4,CDK6",-,Carcinoma,SHR6390,-,-,-,-,-,-,-,Fact,10,10.1,10.1.3,10.1.3.1,-,增殖抑制作用
6247,KP3,36129131,"inhibitors of cyclin-based kinases 4/6#include#abemaciclib, palbociclib, ribociclib, and dinaciclib",Drug Development,"CDK4,CDK6",-,-,"abemaciclib, palbociclib, ribociclib, dinaciclib",-,-,-,-,-,-,-,Fact,10,10.1,10.1.1,10.1.1.1,-,ATP竞争性结合
1026,KP3,37695642,Thirty patients with progressing DDLS#were treated with#abemaciclib (200 mg twice daily),Clinical Trial Data,"CDK4,CDK6",-,Liposarcoma,Abemaciclib,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
2552,KP3,37695642,Median progression-free survival#was#33 weeks in patients treated with abemaciclib,Clinical Trial Data,"CDK4,CDK6",-,Liposarcoma,Abemaciclib,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
2160,KP3,37158934,No increase in the population of immunosenescent T cells#was observed in#the patient's peripheral blood mononuclear cells,Immune Cell Functions,-,T cells,-,-,-,-,-,-,-,-,-,Fact,11,11.1,11.1.1,11.1.1.1,-,T细胞活化与增殖
4061,KP3,36146552,Levels of neutralizing antibodies#were significantly lower in#cancer patients compared to healthy individuals,Immune Response,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,11,11.2,11.2.1,11.2.1.4,-,效应T细胞功能增强
2301,KP3,35614407,Gene alteration in cerebrospinal fluid#is observed in#leptomeningeal metastases of lung adenocarcinoma,Disease-Specific Categories,-,Cerebrospinal fluid,Leptomeningeal metastases of lung adenocarcinoma,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.2,9.5.2.4,-,突变与临床表型
7542,KP3,28860801,Ideal treatment for NRAS-mutant melanoma#remains#unknown,Clinical Implementation,NRAS,-,Melanoma,-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
7714,KP3,39796641,Novel agents#have gained#regulatory approval by the FDA,Regulatory Documentation,-,-,-,-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
6134,KP3,39318897,Abemaciclib#can lead to#elevated serum creatinine,Safety Monitoring,"CDK4,CDK6",-,-,abemaciclib,-,-,-,-,-,-,-,Fact,10,10.4,10.4.2,10.4.2.4,-,肝功能异常
4060,KP3,36618786,"Biosimulation#identified#CDK4/6 inhibitors, nelfinavir, and leflunomide as effective agents",AI Drug Discovery,"CDK4,CDK6",-,-,"nelfinavir, leflunomide",-,-,-,-,-,-,-,Fact,19,19.2,19.2.1,19.2.1.4,-,深度学习筛选模型
4487,KP3,30957209,CDK4/6 inhibitors#are being explored in#ongoing trials,Clinical Trial Data,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
1324,KP3,39410824,"Challenges in drug design, preclinical testing, and clinical trials#are crucial for addressing#therapeutic development",Drug Development,-,-,-,-,-,-,-,-,-,-,-,Inference,19,19.3,19.3.4,19.3.4.4,-,证据强度评级
7255,KP3,37916184,oral selective estrogen receptor degraders#are#therapeutic agents,Drug Development,-,-,-,oral selective estrogen receptor degraders,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
3268,KP3,37916184,antibody drug conjugates (ADCs)#are#therapeutic agents,Drug Development,-,-,-,antibody drug conjugates (ADCs),-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
6051,KP3,37916184,PARP inhibitors#are#therapeutic agents,Drug Development,-,-,-,PARP inhibitors,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
3272,KP3,36158652,PI3KCA mutation#is debated among oncologists for#therapeutic approaches in metastatic disease,Clinical Implementation,PI3KCA,-,Metastatic disease,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.2,2.1.2.1,-,PI3K/AKT通路异常
4813,KP3,31261643,CTCs#were enriched from#a cryopreserved DLA product obtained from a patient with metastatic breast cancer resistant to endocrine therapy,Preclinical Models,-,Circulating tumor cells (CTCs),"Metastatic breast cancer, Endocrine therapy",-,-,-,"Metastatic, endocrine therapy-resistant",-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.2,-,联合降雌激素药物
2984,KP3,38847486,"Other possible targets#include#the anaphase-promoting complex/cyclosome (APC/C), Skp2, p21, and aurora kinase inhibitors",Drug Development,"APC/C, SKP2, CDKN1A, AURKA",-,Cancer,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
6899,KP3,35642432,H3B-6545#demonstrates#significant activity over fulvestrant in ER伪WT and ER伪MUT models,Drug Development,ESR1,-,Breast cancer,"H3B-6545, fulvestrant",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
5575,KP3,35642432,H3B-6545#supports#potential treatment of endocrine therapy-resistant ER伪+ breast cancer,Therapeutic Development,ESR1,-,Breast cancer,H3B-6545,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
7897,KP3,29777202,BRAF and MEK inhibitors#have shown#clinical efficacy in BRAF-mutant melanoma,Therapeutic Development,"BRAF, MEK",-,Melanoma,"BRAF inhibitors, MEK inhibitors",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.3,-,MEK抑制剂组合
5140,KP3,39072356,vepdegestrant monotherapy#was well tolerated with#clinical activity in pretreated patients with ER+/HER2- advanced breast cancer,Clinical Trial Data,-,-,ER+/HER2- advanced breast cancer,vepdegestrant,-,-,pretreatment,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
2930,KP3,39072356,VERITAC-2 study#compares#efficacy and safety of vepdegestrant versus fulvestrant in ER+/HER2- advanced breast cancer,Clinical Trial Data,-,-,ER+/HER2- advanced breast cancer,"vepdegestrant, fulvestrant",-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,-,联合芳香化酶抑制剂
6314,KP3,29954777,Multiomic profiling#determines#molecularly rationalized clinical trials and off-label therapies,Biomarker Analysis,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,7,7.6,7.6.1,7.6.1.1,-,突变检测
634,KP4,33911874,Aromatase inhibitor letrozole#causes#TLS in breast cancer,Drug Safety,-,-,Breast cancer,Letrozole,-,TLS,-,-,-,-,-,Fact,10,10.4,10.4.2,10.4.2.4,-,肝功能异常
3970,KP4,33911874,Palbociclib/letrozole combination#causes#hyperuricaemia in breast cancer,Drug Safety,-,-,Breast cancer,"Palbociclib, letrozole",-,Hyperuricaemia,-,-,-,-,-,Fact,10,10.4,10.4.2,10.4.2.4,-,肝功能异常
3570,KP4,38001750,Advancements in technologies like spatial transcriptomics#enlist#characteristics of tumor microenvironment,Technical Methods,-,Tumor microenvironment,-,-,-,-,-,-,-,-,-,Fact,21,21.1,21.1.2,21.1.2.3,-,免疫浸润区特点
24,KP4,30372389,Non-clear cell RCCs#account for#up to 25% of kidney cancers,Cancer Association,RCC,-,Kidney cancer,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.4,-,非编码RNA调控
3043,KP4,30372389,Non-clear cell RCCs#encompass#distinct diseases with distinct pathologic features,Cancer Association,RCC,-,Distinct diseases,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.4,-,非编码RNA调控
6188,KP4,30372389,Non-clear cell RCCs#display#different molecular alterations,Cancer Association,RCC,-,Distinct diseases,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.4,-,非编码RNA调控
7790,KP4,30372389,Non-clear cell RCCs#exhibit#various patterns of response to systemic therapies,Therapeutic Response,RCC,-,Distinct diseases,-,-,-,-,-,-,-,-,Fact,2,2.4,2.4.3,2.4.3.4,-,转录调控网络
3946,KP4,36986799,LIV1 expression#provides#prognostic and predictive value for systemic therapies,Biomarker Analysis,LIV1,-,Breast cancer,-,-,-,upregulated,-,-,-,-,Inference,7,7.2,7.2.1,7.2.1.1,7.2.1.1.4,RB蛋白表达
2298,KP4,29884743,"CDK4/6 inhibitors#have been tested in#premenopausal patients with HR(+), HER2(-) advanced breast cancer",Clinical Trial Data,"CDK4,CDK6,ERBB2",-,Advanced breast cancer,"Palbociclib, Abemaciclib, Ribociclib",-,-,Premenopausal patients,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5727,KP4,37190140,CDK4/6 inhibitors#demonstrate#improved survival for ER-positive breast cancer patients,Therapeutic Response,"CDK4,CDK6,ESR1",-,ER-positive breast cancer,CDK4/6 inhibitors,-,-,ER-positive patients,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
6974,KP4,37170613,ribociclib letrozole and denosumab treatment#was started for#a 73-year-old female patient with breast cancer and metastases,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,"ribociclib, letrozole, denosumab",-,-,73-year-old female patient,upregulated,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑
4464,KP4,37170613,denosumab#might cause#toxic hepatitis in the patient,Safety Monitoring,-,-,-,denosumab,-,-,-,-,-,-,-,Fact,10,10.4,10.4.2,10.4.2.4,-,肝功能异常
230,KP4,34604676,"distinct alterations#are associated with#c-Jun N-terminal kinase signaling, anti-proliferative signaling, DNA damage response, and cytoskeletal remodeling",Signaling Networks,JNK,-,-,-,c-Jun N-terminal kinase,-,-,-,-,-,-,Fact,1,1.3,1.3.2,1.3.2.1,-,RAS/RAF/MEK/ERK级联
7490,KP4,34604676,CDK4/6 inhibitor palbociclib#caused#G1 arrest and precluded death induction,Mechanism of Action,"CDK4,CDK6",-,-,palbociclib,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
1729,KP4,31495008,CDK4/6 inhibitor palbociclib#was initiated with#an escalating dose without hepatic injury reappearance,Therapeutic Response,"CDK4,CDK6",-,breast cancer,palbociclib,-,hepatic injury,-,-,-,-,-,Fact,10,10.1,10.1.2,10.1.2.2,-,RB磷酸化抑制
2037,KP4,38957324,HR positivity#is predictive and prognostic for#HR+ HER2- metastatic breast cancer patients receiving CDK4/6 inhibitor with endocrine therapy,Clinical Correlation,"CDK4,CDK6",-,HR+ HER2- metastatic breast cancer,-,-,-,-,-,-,-,-,Inference,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,RB1突变
6489,KP4,38280968,MonarchE trial#impacted#axillary dissection in hormone-positive HER2-negative early breast cancer patients,Clinical Trial Data,-,-,hormone-positive HER2-negative early breast cancer,abemaciclib,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑联合治疗
2333,KP4,37899576,CDK4/6 inhibitors#have been combined with#aromatase inhibitors for advanced hormone-responsive breast cancers,Combination Therapies,"CDK4,CDK6",-,hormone-responsive breast cancers,aromatase inhibitors,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,来曲唑联合治疗
173,KP4,34282751,"Most frequent targetable GA in CA-Para#were in#FGFR1, NF1, PTEN, NF2, and CDK4",Cancer Association,"FGFR1,NF1,PTEN,NF2,CDK4",-,CA-Para,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
277,KP4,34282751,"Most frequent targetable GA in CA-Pheo#were in#RET, NF1, and FGFR1",Cancer Association,"RET,NF1,FGFR1",-,CA-Pheo,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
2969,KP4,34282751,Germline mutations#were predicted in#cancer predisposition genes in CA-Pheo and CA-Para cases,Genetics,"SDHA,SDHB",-,"CA-Pheo, CA-Para",-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
7555,KP4,30290287,ALK translocations#can be targeted by#ALK-TKI inhibitors in advanced non-small cell lung cancer,Drug Development,ALK,-,non-small cell lung cancer,ALK-TKI inhibitors,-,-,-,-,-,-,-,Fact,27,27.4,27.4.3,27.4.3.4,-,治疗靶点形成
6901,KP4,30290287,EML4-ALK rearranged cells#were treated with#crizotinib and alectinib,Drug Development,"EML4,ALK",-,non-small cell lung cancer,"crizotinib, alectinib",-,-,-,-,-,-,-,Fact,27,27.4,27.4.3,27.4.3.4,-,治疗靶点形成
1951,KP4,19509251,Compound A#is characterized as#a macrocyclic quinoxalin-2-one CDK inhibitor,Drug Development,"CDK4,CDK6",-,-,compound A,-,-,-,-,-,-,-,Fact,10,10.1,10.1.1,10.1.1.1,-,ATP竞争性结合
1362,KP4,32234489,Covalent inhibitors#have been developed for#KRAS(G12C) oncoprotein,Drug Development,KRAS,-,-,-,-,-,-,-,-,-,-,Fact,10,10.6,10.6.1,10.6.1.1,-,选择性增强
959,KP4,37713138,HR+/HER2- advanced breast cancer treatment strategies#were assessed in#the Nordics,Clinical Implementation,-,-,HR+/HER2- advanced breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5300,KP4,39172305,HR-positive patients#received#CDK4/6 inhibitors for stage IV breast cancer,Clinical Implementation,"CDK4,CDK6",-,Stage IV breast cancer,CDK4/6 inhibitors,-,-,HR-positive patients,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
3306,KP4,38473776,Checkpoint inhibitors#enhance#immune response against GB,Immunotherapy,-,"T cells, NK cells",Glioblastoma (GB),Checkpoint inhibitors,-,-,GB patients,-,-,-,-,Fact,11,11.3,11.3.1,11.3.1.1,-,与抗PD-1/PD-L1联用
3503,KP5,32934206,Palbociclib#is tested in#a panel of molecularly characterized breast cancer cell lines,Preclinical Models,-,Breast cancer cell lines,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,10,10.1,10.1.4,10.1.4.1,-,选择性差异
5665,KP5,32934206,Palbociclib sensitivity#is quantified in#11 breast cancer cell lines and breast cancer samples,Preclinical Models,-,Breast cancer cell lines,Breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,10,10.1,10.1.4,10.1.4.1,-,选择性差异
6375,KP5,15138605,p16INK4a#is introduced into#MCF-7 cells via retroviral vector,Experimental Models,CDKN2A,MCF-7 cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,10,10.1,10.1.1,10.1.1.3,-,选择性决定因素
1724,KP5,32130619,G1T48#is evaluated for#antineoplastic mechanism in breast cancer cells,Preclinical Models,-,Breast cancer,-,G1T48,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
1221,KP5,32929370,"Immunohistochemistry, immunofluorescence, and flow cytometry#evaluate#tumor-infiltrating lymphocytes",Experimental Methods,-,Tumor-infiltrating lymphocytes,-,-,-,-,-,-,-,-,-,Fact,6,6.1,6.1.1,6.1.1.1,-,T细胞浸润
3397,KP5,32929370,PCR array analysis and cytokine antibody arrays#detect#cytokine and chemokine production,Experimental Methods,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,6,6.4,6.4.1,6.4.1.1,-,促炎因子
5168,KP5,37258566,FAR cells#sustain#hyper-invasive phenotype and increased anchorage-independent growth compared to sensitive cells,Phenotype triples,-,FAR cells,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
7504,KP5,29261702,flow cytometry#examines#cell cycle and apoptosis,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
3358,KP5,29261702,Enzalutamide#inhibits#cell viability in AR-positive TNBC cells,Therapeutic Response,AR,-,TNBC,Enzalutamide,-,-,-,downregulated,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
7824,KP5,24269839,"VDR#is present in#various adrenocortical tissues, including ACC",Expression Patterns,VDR,-,ACC,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,Cyclin D1表达
7909,KP5,24269839,"1α,25(OH)2D3 treatment#inhibits#cell proliferation and decreases steroid secretion",Mechanism of Action,-,-,-,-,-,-,downregulated,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.4,-,增殖信号阻断
3342,KP5,24269839,low VDR expression#suggests#a protective role against malignant adrenocortical growth,Cancer Association,VDR,-,ACC,-,-,-,downregulated,-,-,-,-,Inference,7,7.2,7.2.1,7.2.1.1,-,Cyclin D1表达
3462,KP5,21777578,Changes of these signals#affect#balance of proliferation and death of gallbladder epithelial cells,Signaling Networks,-,Gallbladder epithelial cells,Gallbladder cancer,-,-,-,-,-,-,-,-,Inference,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
1411,KP5,32256815,"ENO1#is involved in#activities detrimental to cell transformation, including apoptosis and differentiation",Function triples,ENO1,-,-,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.2,1.4.2.3,-,干细胞维持
7479,KP5,38822363,Biological role of METTL1#was examined in#BC progression using cellular tests and xenograft models,Experimental Approaches,METTL1,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
5628,KP5,38822363,m(7)G tRNA modification and mRNA translation efficiency#were investigated in#BC,Experimental Approaches,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
7044,KP5,37272756,Genetically engineered mice with HER2V777L and PIK3CAH1047R transgenes#were used to study#breast cancers in vivo and ex vivo,Preclinical Models,"HER2,PIK3CA",-,Breast cancer,-,-,-,HP mice,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
3896,KP5,30828336,pPDGFR伪尾+CDH11- cells#are present in#sub-lining layer of RA patients,Cell Type-Specific Categories,-,pPDGFR伪尾+CDH11- cells,Rheumatoid arthritis,-,-,-,RA patients,-,-,-,-,Fact,23,23.1,23.1.1,23.1.1.1,-,滑膜成纤维细胞活化
2326,KP5,34611509,GPC3 mutation#was detected in#p-OS and m-OS tissues and spheroids,Cancer Association,GPC3,-,Osteosarcoma,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
2843,KP5,34611509,"NGS#revealed#mutations in GPC3, SOX10, MDM4, MAPK8 in p-OS",Cancer Association,"GPC3,SOX10,MDM4,MAPK8",-,Osteosarcoma,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
1678,KP5,34611509,"NGS#revealed#mutations in GPC3, SOX10, EGF in m-OS",Cancer Association,"GPC3,SOX10,EGF",-,Osteosarcoma,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
6669,KP5,34611509,GPC3 transcript-oriented Sanger sequencing#confirmed#mutation at 1046 in Exon 4,Genetic Alteration,GPC3,-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
6171,KP6,28322158,"Expression of CDK4 and CDK6#was assessed by#Western blotting, RT-PCR, and luciferase assay",Expression Patterns,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,9,9.1,9.1.1,9.1.1.1,-,催化域结构
1874,KP6,29441600,"Expressions of cyclin-D1, CDK4, and p21#were investigated by#IHC staining",Technical Methods,"CDK4,CCND1,CDKN1A",-,-,-,-,-,-,-,-,-,-,Fact,9,9.1,9.1.1,9.1.1.1,-,催化域结构
346,KP6,29441600,BBR#reduced#VCL-induced p21 expression increase,Regulation,CDKN1A,-,-,-,-,-,-,downregulated,-,-,-,Fact,9,9.1,9.1.2,9.1.2.4,-,细胞增殖调控
5942,KP6,7705923,Expression of p16Ink4#was surveyed in#21 human cell types,Expression Patterns,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,9,9.1,9.1.1,9.1.1.1,-,催化域结构
1737,KP6,24942317,"PCNA, CDK4, and COMT protein levels#were detected by#Western blot analyses",Expression Patterns,"CDK4,COMT",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,-,-,周期蛋白复合物形成
3286,KP6,32336043,Higher EPHB4 expression#is correlated to#stage 4 of NB and poor overall survival,Clinical Correlation triples,EPHB4,-,Neuroblastoma,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
7091,KP6,35212973,"Regeneration#might occur via#stimulating β-cell proliferation, neogenesis, or conversion from other pancreatic cells to β-like cells",Stem Cell Biology,-,Pancreatic cells,-,-,-,-,-,-,-,-,-,Inference,16,16.2,16.2.2,-,-,细胞分化过程中的CDK4/6调控
1791,KP7,37044053,RAB7A#enhanced#migration and invasion by inducing EMT,Mechanism of Action,RAB7A,-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.1,-,-,细胞增殖调控
2129,KP7,37044053,RAB7A expression level#positively correlated with#TGFBR1 and PD-L1 expression levels,Expression Patterns,"RAB7A,TGFBR1,CD274",-,-,-,-,-,-,upregulated,-,-,-,Fact,1,1.1,1.1.1,-,-,G1/S期转换调控
1453,KP7,34161670,"PB#induced#cleaved caspases 8, 3, 7, PARP, and p-Chk2 in HGC-27 cells",Mechanism of Action,"CASP8,CASP3,CASP7,PARP,CHK2",HGC-27 cells,-,-,-,-,-,upregulated,-,-,-,Fact,3,3.4,3.4.2,-,-,凋亡途径诱导
2287,KP7,30613006,Knocking down fascin#inhibits#cervical cancer cell proliferation and tumorigenesis,Cancer Association,-,Cervical cancer cells,Cervical cancer,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,-,-,细胞增殖调控
6945,KP7,30176239,Activated CD3+CD69+ T cells and proatherogenic CD14++CD16+ monocytes#were higher in#both patient groups,Immune Cell Functions,-,"CD3+CD69+ T cells, CD14++CD16+ monocytes",-,-,-,-,Both patient groups,-,-,-,-,Fact,11,11.1,11.1.1,-,-,CDK4/6调控免疫细胞功能
1718,KP7,30176239,CD4+CD25+CD127 regulatory T cells#were decreased in#both patient groups,Immune Cell Functions,-,CD4+CD25+CD127 regulatory T cells,-,-,-,-,Both patient groups,downregulated,-,-,-,Fact,11,11.1,11.1.1,-,-,CDK4/6调控免疫细胞功能
7331,KP7,28877884,Aberrant Smad3 phosphoisoforms#are present in#cyst-lining epithelial cells in cpk mouse,Molecular Event triples,SMAD3,Cyst-lining epithelial cells,Polycystic kidney disease,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.3,-,-,CDK4/6与其他信号通路的交互
3963,KP7,28877884,Cystic epithelia#acquire#mesenchymal-like features in PKD,Phenotype triples,-,Cystic epithelia,Polycystic kidney disease,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.2,-,-,分化过程调控
3546,KP7,28877884,TGF-β/Smad3 signaling#is involved in#phenotypic alteration in PKD,Pathway triples,SMAD3,-,Polycystic kidney disease,-,TGF-β/Smad3,-,-,-,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,转录因子网络
7051,KP7,28877884,pSmad3L/C#has#a pathological role in colorectal cancer,Disease Association triples,SMAD3,-,Colorectal cancer,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.2,9.5.2.4,-,突变与临床表型
2709,KP7,28877884,Mesenchymal phenotype-specific cell responses#are implicated in#carcinomas,Phenotype triples,-,-,Carcinomas,-,TGF-β/Smad3,-,-,-,-,-,-,Inference,1,1.4,1.4.2,1.4.2.2,-,分化标志物表达
7024,KP7,28877884,Mesenchymal features#were confirmed in#cpk mouse,Phenotype triples,-,-,Polycystic kidney disease,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.2,1.4.2.2,-,分化标志物表达
7723,KP7,28877884,α-Smooth muscle actin#was expressed higher in#cpk mice,Phenotype triples,-,-,Polycystic kidney disease,-,-,-,-,upregulated,-,-,-,Fact,1,1.4,1.4.2,1.4.2.2,-,分化标志物表达
5565,KP7,32647650,Piceatannol (PIC)#has#anti-cancer activity,Drug Development triples,-,-,Cancer,Piceatannol,-,-,-,-,-,-,-,Fact,10,10.1,10.1.3,10.1.3.1,-,增殖抑制作用
4092,KP7,19158499,Peptide treatments#increased#PCNA levels,Expression Patterns,PCNA,-,-,-,-,-,-,upregulated,-,-,-,Fact,4,4.1,4.1.3,4.1.3.1,-,关键酶活性调节
7571,KP7,37061333,Regulated cell division#is#the basis of all life on earth,Biological Process,-,-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.3,-,细胞周期检查点控制
6040,KP8,34654798,KRAS mutation#reduces#therapeutic options and negatively affects prognosis in colorectal cancer,Cancer Association,KRAS,-,Colorectal cancer,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.2,9.5.2.4,-,突变与临床表型
7202,KP8,35075231,Mutation c.1403A>T in PDGFRA#was introduced in#HEK293T cells,Experimental Models,PDGFRA,HEK293T,Glioblastoma multiforme (GBM),-,MAP kinase pathway,-,-,-,-,-,-,Fact,9,9.3,9.3.2,9.3.2.1,-,RAS/RAF/MEK/ERK级联
7297,KP8,22888541,AccCDK6 sequence#shares similarity with#CDK6 genes of other species,Evolutionary Conservation,CDK6,-,-,-,-,-,-,-,-,-,-,Fact,18,18.1,18.1.2,18.1.2.1,-,催化域保守性
6812,KP8,22888541,AccCDK6 protein#shares#evolutionary predecessor with Drosophila CDK4,Evolutionary Conservation,"CDK6,CDK4",-,-,-,-,-,-,-,-,-,-,Fact,18,18.1,18.1.2,18.1.2.1,-,催化域保守性
4612,KP8,9482902,p16(INK4a)#is a candidate for#Pctr1 locus,Genetic Association,CDKN2A,-,Plasmacytoma,-,-,-,BALB/c mice,-,-,-,-,Inference,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
1036,KP8,8595411,CDKN2A and CDKN2B#are located on#chromosome 9p21,Genomic Localization,"CDKN2A,CDKN2B",-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.2,27.1.2.1,-,基因扩增
5454,KP8,10469453,CDKN2A#shows#no mutations in coding regions,Gene Mutation Analysis,CDKN2A,-,MPNST,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
7949,KP8,10469453,CDKN2A#is not inactivated by#promoter methylation,Gene Regulation,CDKN2A,-,MPNST,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.3,27.1.3.1,-,启动子甲基化
696,KP8,10469453,Mismatch repair deficiency#is excluded as#an important mechanism in MPNST,Mechanism of Action,-,-,MPNST,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.2,-,末端切除
7864,KP8,12170781,Fusion proteins#contribute to#oncogenic behavior,Cancer Pathways,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.3,5.4.3.1,-,原癌基因激活
6431,KP8,12170781,Chromosome fragment transfer studies#repress#tumor cell growth,Preclinical Models,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.2,-,缺失
3517,KP8,12170781,Tumor suppressor genes#are suggested to be present in#this region,Gene Identification,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.3,5.4.3.2,-,抑癌基因失活
7703,KP8,25088201,tumors#arise from#benign precursor lesions,Cancer Pathways,-,-,Neoplasm,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
7859,KP8,25088201,melanoma-related endophenotype comparisons#provide information about#mechanisms of carcinogenesis,Cancer Pathways,-,-,Melanoma,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
2121,KP8,11025389,ISH#evaluates#p16 and p15 copy numbers on a cell-by-cell basis,Technical Methods,"CDKN2A,CDKN2B",-,Prostate carcinoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3969,KP8,26220141,"Cyclin D1, Cyclin B1, CDK4, TGM1, K10, involucrin, and filaggrin proteins#were investigated by#Western blot analysis",Expression Patterns,"CDK4,CCND1,CCNB1",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.1,-,Cyclin D-CDK4复合物
4932,KP8,10469011,The aim of this study#was to further investigate#pathogenetic events leading to p16 gene inactivation,Research Focus,CDKN2A,-,Pituitary tumours,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.2,1.2.2.2,-,表观遗传修饰
7368,KP8,10469011,Methylation-specific PCR assay#was used to determine#p16 gene methylation status,Technical Methods,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,5,5.6,5.6.3,5.6.3.1,-,DNA甲基化
3558,KP8,32336043,EPHB4 inhibitors JI-101 and NVP-BHG712#rescued#the phenotype driven by the variant,Drug Development,EPHB4,-,-,"JI-101,NVP-BHG712",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,3.2.2.1,-,PI3K抑制剂协同
6014,KP8,24231788,EESB#reduces#tumor volume and tumor weight in CRC mice,Preclinical Models,-,-,Colorectal Cancer,-,-,-,Mice,-,-,-,-,Fact,3,3.5,3.5.2,3.5.2.1,-,基质蛋白修饰
2203,KP9,37686402,Molecular and genetic alterations#guide#development of targeted treatments for PNF-MPNST transformation,Therapeutic Development,-,-,Malignant Peripheral Nerve Sheath Tumors,-,-,-,-,-,-,-,-,Inference,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6895,KP9,37686402,FOXM1#is#a powerful oncogene in cancers but little studied in MPNSTs,Cancer Association,FOXM1,-,Malignant Peripheral Nerve Sheath Tumors,-,-,-,-,-,-,-,-,Inference,5,5.4,5.4.3,5.4.3.1,-,原癌基因激活
1963,KP9,29408328,CDK4/CDK6#are important in#different human tumors,Cancer Association,"CDK4,CDK6",-,Human tumors,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,1.1.1.1,-,RB蛋白磷酸化
3826,KP9,27508976,ALT/WDL cases lacking diagnostic histologic features#require#ancillary studies for accurate classification,Clinical Implementation,-,-,ALT/WDL,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,蛋白表达
3878,KP9,30252584,Genomic aberration with protein overexpression#is the most likely#tumorigenic driver of this rare and aggressive tumor,Cancer Association,-,-,Rare and aggressive tumor,-,-,-,-,upregulated,-,-,-,Inference,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
610,KP9,9425228,Germline mutations in p16 and CDK4 genes#have been reported in#a subset of melanoma pedigrees,Cancer Association,"CDK4,p16",-,Melanoma,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
4205,KP9,24227706,Tumors#were composed of#predominantly spindled cells or epithelioid cells,Cell Type-Specific Categories,-,"Spindled cells, epithelioid cells","DDLPS,PLPS",-,-,-,-,-,-,-,-,Fact,6,6.3,6.3.1,6.3.1.1,-,成纤维细胞活化
5297,KP9,34362013,CTDSP1/2-DNM3OS fusion genes#are identified in#a subset of DDL,Cancer Association,-,-,Dedifferentiated liposarcoma (DDL),-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.3,-,基因融合
5927,KP9,39812054,BRCA1 and BRCA2 mutations#are associated with#hereditary breast cancer,Cancer Association,"BRCA1, BRCA2",-,Hereditary breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
1776,KP9,38930141,Genomic profiling#predicts#response or resistance to specific agents,Clinical Implementation,-,-,Recurrent and/or metastatic lesions,-,"PI3K/AKT/mTOR, ER-dependent pathway, ER-independent pathways",-,Individualized therapeutic strategy,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
2945,KP9,36315915,APOBEC mutagenesis#underlies#somatic evolution in breast cancer,Cancer Pathways,APOBEC,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.1,-,突变谱特征
4108,KP9,36315915,Comprehensive genomic profiling#analyzed#tumor mutational burden and APOBEC signatures,Biomarker Analysis,APOBEC,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.6,7.6.1,7.6.1.1,-,液体活检标志物
1803,KP9,36315915,APOBEC+ tumors#showed#a high rate in invasive lobular carcinoma and metastatic tumors,Expression Patterns,APOBEC,-,"Invasive lobular carcinoma, metastatic tumors",-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,预后生物标志物
5986,KP9,34696768,FRS2#is amplified in#ALT/WDL/DDLs,Cancer Association,FRS2,-,"Atypical lipomatous tumor (ALT), well-differentiated liposarcoma (WDL), dedifferentiated liposarcoma (DDL)",-,ALT/WDL/DDLs pathway,-,-,upregulated,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因拷贝数变异
3483,KP9,34696768,FRS2 amplification#is detected by#fluorescence in situ hybridization and IHC,Biomarker Analysis,FRS2,-,ALT/WDL/DDLs,-,-,-,-,-,FRS2,-,-,Fact,7,7.3,7.3.1,7.3.1.1,-,药物反应监测
1853,KP9,7654823,genes#have#a proven or presumed role in the genesis of astrocytic tumors,Cancer Association,-,-,Astrocytic tumors,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.1,5.1.1.1,-,DNA损伤修复
3224,KP9,36119484,WDLPS and DDLPS#are#tumors of the adipose tissue poorly responsive to conventional cytotoxic chemotherapy,Cancer Association,-,-,"WDLPS, DDLPS",-,-,-,-,-,-,-,-,Fact,10,10.4,10.4.1,10.4.1.1,-,CDK4/6抑制剂不良反应
5658,KP9,19454362,amplified target genes#exclude#CDK4 in the present case,Cancer Association,"MDM2, HMGA2",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,基因缺失
4833,KP9,38751483,Visceral disease#was present in#83.2% of patients,Patient Characteristics,-,Visceral cells,Metastatic disease,-,-,-,"Baseline, treated >1 line of ET",-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.1,-,随访评估
2740,KP9,28856628,Neoplastic spindle cell proliferation#was found in#from submucosa to subserosa,Cell Type-Specific Categories,-,Spindle cells,Neoplastic disease,-,-,-,-,-,-,-,-,Fact,6,6.3,6.3.1,6.3.1.1,-,基质细胞相互作用
1751,KP9,28856628,The patient#received no#postoperative therapy,Clinical Implementation,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.2,-,单药治疗策略
1577,KP9,37881487,Six cases of bladder liposarcoma#have been reported as#myxoid liposarcomas,Cancer Association,-,-,Bladder liposarcoma,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,染色体异常
3920,KP9,37881487,Patients#did not undergo#molecular testing,Clinical Implementation,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,治疗监测
2703,KP9,37881487,Small foci of lipoma-like well-differentiated components#were identified in#the tumor,Structural Biology,-,-,Lipoma-like tumor,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,染色体异常
3819,KP9,32940689,"Pretreatment plasma samples#were analyzed for#mutations in 17 genes, copy number in 14 genes, and circulating tumor fraction",Biomarker Analysis,-,-,-,-,-,-,-,-,-,-,-,Fact,7,7.6,7.6.1,7.6.1.1,-,液体活检标志物
1680,KP9,32940689,High-circulating tumor fraction#is associated with#worse PFS,Patient Characteristics,"TP53, FGFR1",-,-,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.3,-,分子分型标志物
5723,KP9,17340131,Mutations#were found in#4 of 42 samples,Molecular Event triples,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,突变谱特征
7814,KP9,16391845,Tumor-specific alteration#remains unknown in#MPNSTs,Cancer Pathways,-,-,MPNST,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.1,-,突变谱特征
1048,KP9,33782225,Atypical pleomorphic lipomatous tumor#lies on spectrum with#atypical spindle cell lipomatous tumor,Cancer Pathways,-,-,Atypical pleomorphic lipomatous tumor,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.1,-,突变谱特征
7815,KP9,33782225,APLT/ASCLT#are included in#WHO Classification of Soft Tissue and Bone Tumors,Cancer Pathways,-,-,"APLT, ASCLT",-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.3,5.5.3.1,-,突变谱特征
454,KP9,39361142,HR+ and HER2- early breast cancer#is#a heterogeneous disease,Disease Definition,ERBB2,-,Early breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,HR+/HER2-乳腺癌
6869,KP9,34703440,Osteosarcoma#is#the most common malignant primary bone tumor,Disease Definition,-,-,Osteosarcoma,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,骨肉瘤
6012,KP9,34703440,Lung metastases#were treated by#neoadjuvant chemotherapy and surgery,Therapeutic Response,-,-,Lung metastases,-,-,-,-,-,-,-,-,Fact,8,8.2,8.2.1,8.2.1.1,8.2.1.1.1,新辅助化疗和手术
1508,KP9,34703440,Patient#has been doing well with#no evidence of disease for 1 year and 6 months,Patient Outcome,-,-,-,-,-,No evidence of disease,-,-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.2,8.6.1.2.1,疾病状态
699,KP9,39191167,Diagnostic assessments#evaluated#mRNA expression levels and overall survival for identified targets,Diagnostic Analysis,-,-,-,-,-,-,-,-,-,-,-,Fact,7,7.3,7.3.1,7.3.1.1,7.3.1.1.1,Ki67指数
5746,KP9,33947696,Patients with BRAF (V600E/KMUT) metastatic melanoma#were stratified by#previous BRAF inhibitor treatment,Patient Stratification,BRAF,-,Metastatic melanoma,-,-,-,Previous BRAF inhibitor treatment,-,-,-,-,Fact,8,8.6,8.6.1,8.6.1.3,8.6.1.3.1,复发风险
1733,KP9,33947696,Primary endpoint#was#dose-limiting toxicity (DLT),Clinical Trial Data,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,8.5.1.1.1,影像学评估
672,KP9,33947696,"Secondary endpoints#include#best response, survival, pharmacokinetics, and tumor molecular profiling",Clinical Trial Data,-,-,-,-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.2,8.5.1.2.1,循环肿瘤DNA
7153,KP9,27334220,Fluorescent in situ hybridization (FISH)#was performed to detect#CCND1 amplification or translocation,Technical Methods,CCND1,-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,基因扩增
5840,KP9,34135599,melanoma#is#the deadliest cutaneous cancer,Clinical correlation,-,Skin cells,Melanoma,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,黑色素瘤
2658,KP9,26892441,intravenous leiomyomatosis#is#an unusual intermediate between benign and malignant uterine smooth muscle tumors,Clinical correlation,-,Smooth muscle cells,Leiomyomatosis,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,静脉平滑肌瘤
5899,KP9,26892441,expression profiling#was performed on#three intravenous leiomyomatosis cases,Technical methods,-,Smooth muscle cells,Leiomyomatosis,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,基因扩增
1725,KP9,16631473,HLA on 7q21#is associated with#ABCB1,Genomic Alterations,ABCB1,-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,基因突变
2869,KP9,16631473,"Amplified region on 20q13#implicates#ZNF217, BCAS1, and CYP24",Genomic Alterations,"ZNF217, BCAS1, CYP24",-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,基因扩增
1816,KP9,16631473,RNA expression analysis#was performed for#cancer-related genes at 7q21 and 20q13,Expression Patterns,"ABCB1, ABCB4, CDK6, HGF, DMTF1, SRI, TP53AP1, ZNF217, BCAS1, CYP24, TNFRSF6B",-,-,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.3,细胞周期蛋白表达
1267,KP9,16631473,HLA#occur often in#GEJ adenocarcinomas,Cancer Association,-,-,GEJ adenocarcinoma,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.3,9.5.3.3,-,组织特异性表达
3588,KP9,28860801,Activating mutations in RAS oncogenes#are found in#a third of all human cancers,Cancer Association,RAS,-,Cancer,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,2.1.1.1.1,CDK4/6基因扩增
6981,KP9,28860801,NRAS mutations#are found in#15%-20% of melanomas,Cancer Association,NRAS,-,Melanoma,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,2.1.1.1.1,CDK4/6基因扩增
4579,KP9,21274402,Tumor-specific chromosomal translocations and fusion genes#have been identified for#mesenchymal neoplasms including adipocytic tumors,Genomic Alterations,-,-,"Mesenchymal neoplasms, Adipocytic tumors",-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
6474,KP9,9205100,HMGIC#was frequently amplified or rearranged in#well-differentiated liposarcomas,Genomic Alterations,HMGIC,-,Well-differentiated liposarcoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
7849,KP9,18551755,Cytogenetic analysis#revealed#classic lipoma chromosome t(3;12)(q27;q14-15),Genomic Alterations,-,-,Lipoma,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.1,-,基因内融合
7322,KP9,18551755,HMGA2-LPP fusion gene#is confirmed as#characteristic and common fusion product in lipoma,Cancer Association,"HMGA2,LPP",-,Lipoma,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
5096,KP9,11058870,p16 inactivation#is accomplished by#homozygous deletion of CDKN2A,Cancer Association,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
5990,KP9,11058870,Methylation of 5' CpG island promoter#has been proposed as#alternative mechanism of inactivation,Regulation,CDKN2A,-,-,-,-,-,-,-,-,-,-,Inference,5,5.6,5.6.3,5.6.3.1,-,DNA甲基化
4569,KP9,11058870,"Expression of p16, CDKN2A HD, and 5' CDKN2A CpG island methylation#was studied in#25 oligodendrogliomas",Expression Patterns,CDKN2A,-,Oligodendrogliomas,-,-,-,-,-,-,-,-,Fact,5,5.6,5.6.3,5.6.3.1,-,DNA甲基化
5946,KP9,11058870,In 2 immunonegative cases without HD#no CpG island methylation#was found,Regulation,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,5,5.6,5.6.3,5.6.3.1,-,DNA甲基化
3787,KP9,19095153,Heritable alterations in CDKN2A#result in#strongest genetic risk for melanoma,Cancer Association,CDKN2A,-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.2,5.3.2.1,-,CDKN2A缺失
1662,KP9,31591187,Biopsies from advanced breast cancer patients#were sequenced in#ABC-Bio study,Experimental & Technical Categories,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.6,7.6.1,7.6.1.1,-,驱动基因突变
503,KP9,25600792,MITF and MC1R#are identified as#intermediate-risk susceptibility genes,Cancer Association,"MITF,MC1R",-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,7.1.1.1.1,RB1突变
5070,KP9,19691106,12 ALT cases with ring chromosomes#were analyzed by#array comparative genomic hybridization and FISH,Experimental & Technical Categories,-,-,ALT,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.1,-,易位
7775,KP9,18403636,KUB3#is overexpressed in#amplified regions,Expression Patterns,KUB3,-,-,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
4572,KP9,18403636,CTDSP2#is overexpressed in#amplified regions,Expression Patterns,CTDSP2,-,-,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
1569,KP9,18403636,OS-9#is overexpressed in#amplified regions,Expression Patterns,OS9,-,-,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
2806,KP9,18403636,DCTN2#is overexpressed in#amplified regions,Expression Patterns,DCTN2,-,-,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
683,KP9,18403636,RAB3IP#is overexpressed in#amplified regions,Expression Patterns,RAB3IP,-,-,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
5211,KP9,18403636,FRS2#is overexpressed in#amplified regions,Expression Patterns,FRS2,-,-,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
2717,KP9,18403636,GAS41#is overexpressed in#amplified regions,Expression Patterns,GAS41,-,-,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
5189,KP9,18403636,RAP1B#is overexpressed in#amplified regions,Expression Patterns,RAP1B,-,-,-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
5449,KP9,15041220,MASL1#is amplified in#8p regions,Cancer Association,MASL1,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
3051,KP9,15041220,Gain of 12q13-q21#is associated with#well-differentiated liposarcoma,Cancer Association,CDK4,-,Well-differentiated liposarcoma,-,-,-,-,-,-,-,-,Inference,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
5625,KP9,15041220,Gain of 12q13-q21#is associated with#MFH,Cancer Association,CDK4,-,MFH,-,-,-,-,-,-,-,-,Inference,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
7201,KP9,31807008,Segmental chromosomal alterations#affect#actionable genes,Cancer Association,"CDK4,MDM2",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
4249,KP9,31807008,CDK4#is gained in#inflammatory myofibroblastic tumor,Cancer Association,CDK4,-,Inflammatory myofibroblastic tumor,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,CDK4扩增
6786,KP9,28710771,Glioma stem cell lines#are derived from#GBM case,Preclinical Models,CDK4,-,Glioblastoma,-,-,-,-,-,-,-,-,Fact,16,16.6,16.6.1,16.6.1.1,-,自我更新
439,KP9,24405942,Molecular analysis#showed no amplification of#cMYC gene,Mutation frequencies,MYC,-,-,-,-,-,-,silenced,-,-,-,Fact,27,27.1,27.1.2,27.1.2.1,-,基因扩增
1540,KP9,37509701,"Next generation sequencing#was performed for#cancer susceptibility genes (APC, ATM, BRD1, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, RECQL1, SMAD4, STK11, TP53)",Gene List,"APC, ATM, BRD1, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, RECQL1, SMAD4, STK11, TP53",-,Cancer,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,-,-,基因组变异谱
3615,KP9,22383533,"252 mutations#were detected in#17 genes, with the highest frequency in BRAF, NRAS, CDK4, PTK2B, ERBB4",Mutation frequencies,"BRAF, NRAS, CDK4, PTK2B, ERBB4",-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,-,-,基因组变异谱
4679,KP9,36926051,Tumor mutational burden#is inversely correlated with#outcome in HR(+)/HER2(-) dnMBC,Prognostic associations,-,-,HR(+)/HER2(-) dnMBC,-,-,-,-,-,-,-,-,Inference,7,7.2,7.2.1,-,-,预后生物标志物
7262,KP9,34636747,Low-grade serous ovarian cancer#is#a morphologically and molecularly distinct subtype of ovarian cancer,Cancer Association,-,-,Low-grade serous ovarian cancer (LGSC),-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.1,-,-,肿瘤类型
4641,KP9,34636747,"Combination targeted therapies, immunotherapy, and anti-angiogenic agents#remain#active areas of investigation for LGSC",Therapeutic Development,-,-,Low-grade serous ovarian cancer (LGSC),"Targeted therapies, immunotherapy, anti-angiogenic agents",-,-,-,-,-,-,-,Fact,3,3.2,3.2.2,-,-,靶向药物联合
7078,KP9,36307579,Integrated proteogenomic characterization#across#major histological types of pituitary neuroendocrine tumors,Systems Biology,-,-,Pituitary neuroendocrine tumors (PitNET),-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,-,-,分子分型标志物
1266,KP9,36307579,"Integrative genomics, transcriptomics, proteomics, and phosphoproteomics analysis#was performed#for a cohort of 200 PitNET patients",Systems Biology,-,-,Pituitary neuroendocrine tumors (PitNET),-,-,-,PitNET patients,-,-,-,-,Fact,7,7.4,7.4.1,-,-,分子分型标志物
7118,KP9,36307579,Proteogenomic analysis#improves#understanding of PitNET pathophysiology and suggests novel therapeutic targets,Systems Biology,-,-,Pituitary neuroendocrine tumors (PitNET),-,-,-,-,-,-,-,-,Inference,7,7.4,7.4.1,-,-,分子分型标志物
3325,KP9,34642211,Class I SMARCA4 alterations#lead to#loss of function,Molecular Event,SMARCA4,-,-,-,-,-,-,Loss,-,-,-,Fact,27,27.3,27.3.1,-,-,功能丧失性变异
7431,KP9,34642211,Class II SMARCA4 alterations#have#a dominant negative/gain-of-function effect or loss of function,Molecular Event,SMARCA4,-,-,-,-,-,-,Gain or loss,-,-,-,Fact,27,27.2,27.2.4,-,-,功能获得性突变
6634,KP9,38137564,Clinically significant variants#are associated with#melanoma and pancreatic cancer,Cancer Association,CDKN2A,-,"Melanoma, Pancreatic cancer",-,-,-,-,-,-,-,-,Fact,27,27.4,27.4.1,-,-,诊断意义
192,KP9,17203593,No TP53 mutations#or#MDM2 and CDK4 amplifications were observed,Mutation triples,"TP53, MDM2, CDK4",-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,-,-,基因组变异谱
5736,KP9,39759323,EGFR mutations#are consistent between#cerebrospinal fluid (CSF) and primary tumors,Mutation triples,EGFR,-,Tumors,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,-,-,基因组变异谱
677,KP10,22740238,Chromosome region 7q21#contains#CDK6,Structural Biology,CDK6,-,-,-,-,-,-,-,-,-,-,Fact,9,9.1,9.1.1,9.1.1.4,-,序列变异特征
7442,KP11,23708653,New nodes of therapeutic intervention#are needed to#delay or combat the onset of malignancies,Cancer Association,-,-,Malignancies,-,-,-,-,-,-,-,-,Inference,9,9.4,9.4.1,9.4.1.2,-,异常增殖机制
5289,KP11,38381406,Genome-wide CRISPR/Cas9 knockout screens#identified#therapeutic vulnerabilities in CDK4/6i-resistant models,Drug Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,10,10.5,10.5.5,10.5.5.1,-,CDK4/6抑制耐药机制
5187,KP11,35186754,SPOCK1#colocalized with#mitochondrial markers in hepatoma cell lines,Cell Biology,SPOCK1,-,Hepatoma,-,-,-,-,-,TOMM20,-,-,Fact,9,9.1,9.1.3,9.1.3.4,-,与转录复合物的互作
7976,KP12,23077401,Differentially regulated key genes#are confirmed by#qRT-PCR in post-silenced RB cell lines,Expression Patterns,HMGA2,"Y79 RB cells, WERI Rb1 cells",Retinoblastoma,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,微小RNA调控
1276,KP12,23077401,Differential expression of genes#is confirmed by#qRT-PCR in post-silenced RB cells,Expression Patterns,"ELK1, CDK6, E2F4, GTSE1, DRAM, CDH1, SNAI1, MMP2, MMP9","Y79 RB cells, WERI Rb1 cells",Retinoblastoma,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.3,1.5.3.2,-,微小RNA调控
3401,KP14,36635767,"Predictive biomarkers#for#CDK4/6 inhibitors in HR-positive, HER2-negative advanced breast cancer are not elucidated",Uncertainty,"CDK4,CDK6",-,"HR-positive, HER2-negative advanced breast cancer",CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,14,14.1,14.1.1,14.1.1.2,-,RB1基因状态
4899,KP14,33907637,Cyclin-dependent kinase 4/6 inhibitors#are associated with#higher costs and distinctive toxicities,Economic & Access,"CDK4,CDK6",-,-,"Ribociclib,Palbociclib,Abemaciclib",-,-,-,-,-,-,-,Fact,10,10.4,10.4.1,10.4.1.1,-,中性粒细胞减少
4284,KP14,33150548,Pulmonary toxicity of CDK4/6 inhibitors#was assessed using#FDA Adverse Event Reporting System (FAERS),Safety Monitoring,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,10,10.4,10.4.4,10.4.4.2,-,肺部毒性
460,KP14,35631440,The method#was applied to#patients treated for HR+/HER2- breast cancer,Clinical Implementation,HER2,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
5591,KP14,39076888,Advanced metastasized breast cancer#is managed with#novel therapeutics,Clinical Implementation,-,-,Advanced breast cancer,Novel therapeutics,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.2,晚期实体瘤
1226,KP14,35294522,Tumor genomic characterization#includes#pharmacokinetics/pharmacodynamics,Experimental & Technical Categories,"CDK4,CDK6",-,Tumor,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
1290,KP14,33402826,Patients who may benefit from frontline chemotherapy#need to be#identified,Patient Stratification,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
7098,KP14,33402826,Upfront chemotherapy#resulted in#clinical and radiographic response in a patient,Therapeutic Response,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.1,HR+/HER2-乳腺癌
7900,KP14,37893593,LAR subgroup#is characterized by#androgen receptor expression,Expression Patterns,AR,-,luminal androgen receptor (LAR) breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.1,Cyclin D1表达
2824,KP14,37893593,LAR subgroup#resembles#luminal breast cancers,Molecular Subtypes,-,-,luminal androgen receptor (LAR) breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.4,7.4.1,7.4.1.2,7.4.1.2.1,Luminal亚型
2708,KP14,35586877,targeted therapy for STS#is in#preclinical and early-phase trials,Preclinical Models,-,-,Soft tissue sarcoma,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.4,软组织肉瘤
6911,KP14,36853016,"CCND1, CCND2, CCND3 amplification#was not confirmed#centrally",Clinical Trial Data,"CCND1,CCND2,CCND3",-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
4666,KP14,30657954,Expanded molecular profiling#would increase#detection of potentially targetable alterations for acral melanoma,Clinical Implementation,-,-,Acral melanoma,-,-,-,-,-,-,-,-,Inference,8,8.1,8.1.1,8.1.1.1,8.1.1.1.4,肢端黑色素瘤
3591,KP14,26247885,Molecular aberrations in salivary gland tumors#were studied in#117 patients,Preclinical Models,-,-,Salivary gland tumors,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.4,唾液腺肿瘤
4172,KP14,36010842,Thirty-eight cases of HAS#were collected for#whole-exome sequencing,Experimental & Technical Categories,-,-,HAS,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.4,全外显子测序
720,KP14,39823755,Primary endpoints#were#duration of severe neutropenia and incidence of severe neutropenia,Clinical Trial Data,-,-,Severe neutropenia,-,-,Severe neutropenia,-,variable,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,8.5.1.1.4,严重中性粒细胞减少
5762,KP14,31853266,HER2+ tumors#are heterogeneous by#hormone receptor status and molecular subtype,Cancer Association,HER2,-,Tumors,-,-,-,-,-,-,-,-,Fact,6,6.4,6.4.1,6.4.1.3,6.4.1.3.1,激素受体状态
3587,KP15,25776104,Survival rates#are low in#patients with poorly differentiated HCC,Patient Outcomes,-,-,Hepatocellular carcinoma,-,-,-,Poorly differentiated,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,8.5.1.1.4,低分化肝细胞癌
3235,KP15,25776104,Fucoidan#has#anticancer activity,Drug Development,-,-,Hepatocellular carcinoma,Fucoidan,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.4,抗癌活性
2821,KP15,25776104,HLF cells#were treated with#fucoidan or PBS,Experimental Methods,-,HLF cells,Hepatocellular carcinoma,Fucoidan,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.4,实验方法
4523,KP15,25776104,Proliferation#was evaluated by#cell counting every 24 h,Experimental Methods,-,HLF cells,Hepatocellular carcinoma,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,8.1.1.1.4,细胞增殖评估
6818,KP15,29109039,PL#was treated in#A549 cells,Experimental Design,-,A549 cells,Lung cancer,PL,-,-,-,-,-,-,-,Fact,10,10.1,10.1.1,10.1.1.1,-,ATP竞争性结合
5457,KP15,33732653,No targeted therapy#has been approved for#NRAS mutant melanoma,Therapeutic Development,NRAS,-,Melanoma,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.2,9.5.2.2,-,功能获得性突变
1871,KP15,33732653,PDX model#proved#efficacy of two drugs in combination,Preclinical Models,-,-,-,-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.4,10.3.4.2,-,与靶向治疗联用
880,KP15,33732653,Molecular-based therapeutic approach#is found based on#next-generation sequencing results,Personalized Medicine,-,-,-,-,-,-,-,-,-,-,-,Fact,10,10.6,10.6.2,10.6.2.4,-,临床应用前景
7137,KP15,28649895,Palbociclib#maintains#patients' quality of life,Quality of Life,-,-,-,Palbociclib,-,-,patients,-,-,-,-,Fact,10,10.3,10.3.3,10.3.3.4,-,生存获益评估
6132,KP15,30401694,Abemaciclib#causes#unique histopathologic findings,Disease & Clinical Categories,-,-,-,abemaciclib,-,-,-,-,-,-,-,Fact,10,10.4,10.4.4,10.4.4.4,-,神经系统反应
4593,KP15,36548336,Triple-negative breast cancer (TNBC)#lacks#specific therapy options,Disease & Clinical Categories,-,-,Triple-negative breast cancer,-,-,-,-,-,-,-,-,Fact,10,10.5,10.5.2,10.5.2.3,-,E2F独立性获得
762,KP15,36548336,Chemotherapy#remains#primary treatment for TNBC,Therapeutic Development,-,-,Triple-negative breast cancer,-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
1381,KP15,36548336,Enzalutamide#reduces#cell migration/invasion in AR-positive cells,Therapeutic Response,-,AR-positive cells,-,enzalutamide,-,-,-,-,-,-,-,Fact,10,10.1,10.1.3,10.1.3.1,-,增殖抑制作用
5645,KP15,33477469,CDK4/6 inhibitor treatments#have#potential molecular mechanisms and clinical implications,Future Directions,"CDK4, CDK6",-,"HR-positive, HER2-negative advanced breast cancer",-,-,-,-,-,-,-,-,Inference,10,10.1,10.1.3,10.1.3.2,-,细胞衰老诱导
472,KP15,28652278,Goserelin#was assessed via#plasma pharmacokinetics and biochemical analyses,Technical Methods,-,-,Ovarian suppression,Goserelin,-,-,-,-,-,-,-,Fact,10,10.2,10.2.1,10.2.1.2,-,组织分布特征
6632,KP15,28652278,Clinically relevant DDIs#were not observed#in the study,Clinical Trial Data,-,-,-,-,-,-,-,-,-,-,-,Fact,10,10.2,10.2.4,10.2.4.1,-,肝功能不全患者
3762,KP15,39376495,The analysis#identified#safety signals after removing duplicate reports,Safety Monitoring,-,-,-,-,-,-,-,-,-,-,-,Fact,10,10.4,10.4.1,10.4.1.4,-,监测与管理策略
3723,KP15,39376495,Abemaciclib#exhibited#distinctive safety patterns compared to palbociclib and ribociclib,Safety Monitoring,-,-,-,"Abemaciclib, Palbociclib, Ribociclib",-,-,-,-,-,-,-,Fact,10,10.4,10.4.4,10.4.4.1,-,心脏毒性
6168,KP15,39376495,CDK4/6 inhibitors#are linked to#nail-related disorders and psychiatric concerns,Safety Monitoring,"CDK4, CDK6",-,"Nail-related disorders, psychiatric concerns",-,-,"Onychoclasis, nail disorder, nail discoloration, eating disorders, emotional disorder",-,-,-,-,-,Fact,10,10.4,10.4.3,10.4.3.4,-,甲床改变
841,KP15,39376495,CDK4/6 inhibitors#require#careful monitoring in the clinic,Safety Monitoring,"CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Inference,10,10.4,10.4.1,10.4.1.4,-,监测与管理策略
474,KP15,24795392,Three oral selective CDK4 inhibitors#have entered#clinical trials,Clinical Trial Data,CDK4,-,-,"Palbociclib (PD0332991), LEE011, LY2835219",-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
7311,KP15,32357912,This study#presents#a theoretical foundation for CDK4/6 inhibitor precision therapy,Therapeutic Development,"CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,10,10.6,10.6.2,10.6.2.4,-,临床应用前景
1055,KP15,36060025,Sensitivity of RB knockout MCF7 clones#was evaluated for#CDK4/6 inhibitors,Preclinical Models,"CDK4, CDK6",MCF7 clones,-,-,-,-,-,-,-,-,-,Fact,10,10.5,10.5.1,10.5.1.1,-,中性粒细胞减少
3540,KP15,36060025,Bevacizumab#was investigated for#effects on tumor volume and microvessel density in RB knockout models,Preclinical Models,RB,-,Tumors,Bevacizumab,-,-,-,-,-,-,-,Fact,10,10.3,10.3.4,10.3.4.2,-,与靶向治疗联用
1513,KP15,36060025,Bevacizumab#exhibited#antitumor efficacy in RB knockout and parental MCF7 xenograft models,Preclinical Models,RB,-,Tumors,Bevacizumab,-,-,-,-,-,-,-,Fact,10,10.3,10.3.4,10.3.4.2,-,抗肿瘤免疫监视增强
2813,KP15,37974598,Clinical trials#determine#efficacy and safety of CDK4/6 inhibitors,Clinical Trial Data,"CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
4912,KP15,27488531,"Palbociclib#is approved for#treatment of ER-positive, HER2-negative advanced breast cancer",Therapeutic Development,"CDK4, CDK6",-,"ER-positive, HER2-negative advanced breast cancer",Palbociclib,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
4919,KP15,36876172,Patients#received#palbociclib,Clinical Implementation,"CDK4, CDK6",-,-,palbociclib,-,-,Patients (N=319),-,-,-,-,Fact,10,10.3,10.3.4,10.3.4.1,-,与内分泌治疗联用
6713,KP15,36876172,Patients#received#ribociclib,Clinical Implementation,"CDK4, CDK6",-,-,ribociclib,-,-,Patients (N=114),-,-,-,-,Fact,10,10.3,10.3.4,10.3.4.1,-,与内分泌治疗联用
2916,KP15,36876172,Patients#received#abemaciclib,Clinical Implementation,"CDK4, CDK6",-,-,abemaciclib,-,-,Patients (N=15),-,-,-,-,Fact,10,10.3,10.3.4,10.3.4.1,-,与内分泌治疗联用
3399,KP15,36876172,Patients#discontinued#CDK4/6i treatment due to side effects,Safety Monitoring,"CDK4, CDK6",-,-,-,-,-,Patients (N=57),-,-,-,-,Fact,10,10.4,10.4.4,10.4.4.4,-,神经系统反应
7284,KP15,36876172,"Age, metastases, mutations, and grading#did not significantly impact#progression-free survival (PFS)",Patient Stratification,"BRCA1, BRCA2, PIK3CA",-,-,-,-,-,"Age, bone and lung metastases, progesterone positivity, Ki67 index, grading, mutation status, adjuvant endocrine resistance",-,-,-,-,Fact,10,10.3,10.3.3,10.3.3.4,-,生存获益评估
1554,KP15,38751527,"Inhibition of CDK4/6#shows#clinical efficacy in treating HR+, HER2- advanced breast cancer",Therapeutic Response,"CDK4, CDK6",-,"HR+, HER2- advanced breast cancer",-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
5148,KP15,38751527,Inhibition of CDK4/6#is combined with#endocrine therapy (ET),Combination Therapies,"CDK4, CDK6",-,"HR+, HER2- advanced breast cancer",Endocrine therapy,-,-,-,-,-,-,-,Fact,10,10.3,10.3.4,10.3.4.1,-,与内分泌治疗联用
6757,KP15,38751527,Abemaciclib#is#a CDK4/6 inhibitor with higher potency,Drug Development,"CDK4, CDK6",-,-,Abemaciclib,-,-,-,-,-,-,-,Fact,10,10.1,10.1.4,10.1.4.2,-,效力差异
2784,KP15,38751527,"MonarchE study#evaluates#efficacy of abemaciclib with ET in early-stage HR+, HER2- breast cancer",Clinical Trial Data,"CDK4, CDK6",-,"HR+, HER2- breast cancer","Abemaciclib, Endocrine therapy",-,-,"Early-stage, high-risk recurrence features",-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
5368,KP15,36135204,"CDK4/6 inhibitors#are FDA-approved for#HR+, HER2- advanced breast cancer",Regulatory Documentation,"CDK4, CDK6",-,"HR+, HER2- advanced breast cancer","Abemaciclib, Palbociclib, Ribociclib",-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
7740,KP15,35280368,CDK4/6 inhibitors#are recommended with#endocrine therapy in advanced HR+/HER2- breast cancer,Clinical Implementation,"CDK4, CDK6",-,HR+/HER2- advanced breast cancer,Endocrine therapy,-,-,-,-,-,-,-,Fact,10,10.3,10.3.4,10.3.4.1,-,与内分泌治疗联用
1818,KP15,35738597,CDK4/6 inhibitors#are potential therapies for#malignancies of the gastrointestinal tract,Therapeutic Development,"CDK4, CDK6",-,Gastrointestinal malignancies,-,-,-,-,-,-,-,-,Inference,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
5155,KP15,35738597,Targeting cell cycle machineries#is vital for#cancer treatment,Cell Cycle Control,"CDK4, CDK6",-,Cancer,-,Cell cycle,-,-,-,-,-,-,Inference,10,10.1,10.1.2,10.1.2.1,-,G1/S检查点激活
7991,KP15,35738597,CDK4/6 inhibitors#were originally approved for#advanced-stage breast cancer treatment,Regulatory Documentation,"CDK4, CDK6",-,Advanced-stage breast cancer,-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
2438,KP15,35738597,CDK4/6#are required for#progression of cancer cells,Mechanism of Action,"CDK4, CDK6",-,Cancer,-,-,-,-,-,-,-,-,Inference,10,10.1,10.1.1,10.1.1.1,-,ATP竞争性结合
4466,KP15,35738597,CDK4/6 inhibitors#affect#tumor microenvironment,Tumor Microenvironment,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Inference,26,26.3,26.3.3,26.3.3.4,-,免疫细胞募集调节
280,KP15,35738597,CDK4/6 inhibitors#are investigated for#therapeutic potential in gastrointestinal cancer,Therapeutic Development,"CDK4,CDK6",-,Gastrointestinal cancer,-,-,-,-,-,-,-,-,Inference,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
626,KP15,35738597,CDK4/6 inhibitors#arrest#the cell cycle,Mechanism of Action,"CDK4,CDK6",-,-,-,Cell cycle,-,-,-,-,-,-,Fact,10,10.1,10.1.2,10.1.2.1,-,G1/S检查点激活
2449,KP15,35738597,CDK4/6 inhibitors#have limited#efficacy as a single regimen in clinical practice,Therapeutic Response,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.3,-,单药治疗方案
5607,KP15,35738597,CDK4/6 inhibitors#are reviewed for#effects in gastrointestinal cancers,Preclinical Models,"CDK4,CDK6",-,Gastrointestinal cancers,-,-,-,-,-,-,-,-,Inference,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
5510,KP15,30631751,CDK4/6 inhibitors#induce#cell senescence and cytotoxic T cell-mediated cancer cell disruption,Immune Cell Functions,"CDK4,CDK6",Cytotoxic T cells,Cancer,-,Cell cycle,-,-,-,-,-,-,Fact,11,11.1,11.1.1,11.1.1.4,-,细胞毒性T细胞活性
1452,KP15,30631751,"CDK4/6 inhibitors#improve#treatment efficacy in HR+, HER2- metastatic breast cancer",Therapeutic Response,"CDK4,CDK6",-,"HR+, HER2- metastatic breast cancer",-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
1669,KP15,30631751,CDK4/6 inhibitors#are approved for#clinical use in combination with endocrine agents,Regulatory Documentation,"CDK4,CDK6",-,"HR+, HER2- metastatic breast cancer",Endocrine agents,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.4,-,联合治疗方案
1209,KP15,29027483,Clinical development of non-selective CDK inhibitors#failed due to#lack of efficacy and excessive toxicity,Drug Development,CDKs,-,Cancer,Non-selective CDK inhibitors,-,-,-,-,-,-,-,Fact,10,10.1,10.1.4,10.1.4.2,-,效力差异
776,KP15,29027483,Second-generation CDK4/6-selective inhibitors#led to#practice-changing results in breast cancer,Drug Development,"CDK4,CDK6",-,Breast cancer,"Palbociclib, Abemaciclib, Ribociclib",-,-,-,-,-,-,-,Fact,10,10.1,10.1.4,10.1.4.1,-,选择性差异
4207,KP15,39579620,Ethnicity#influences#CDK inhibitor efficacy and toxicity,Patient Characteristics,CDKs,-,-,-,-,Ethnicity,-,-,-,-,-,Inference,10,10.2,10.2.4,10.2.4.4,-,种族差异
6596,KP15,39579620,Studies#compared#CDK4/6i+ET versus placebo+ET,Drug Development,"CDK4,CDK6",-,-,"Palbociclib, Ribociclib, Abemaciclib, Dalpiciclib",-,-,-,-,-,-,-,Fact,10,10.3,10.3.4,10.3.4.1,-,与内分泌治疗联用
7306,KP15,39579620,Number of side effects#was extracted to estimate#risk of treatment-emergent AEs,Safety Monitoring,-,-,-,-,-,-,-,-,-,-,-,Fact,10,10.4,10.4.1,10.4.1.4,-,监测与管理策略
4493,KP15,39579620,Higher rate of hematological toxicity#was observed in#Asian patients,Safety Monitoring,-,-,-,-,-,Asian patients,-,-,-,-,-,Fact,10,10.4,10.4.1,10.4.1.1,-,中性粒细胞减少
3848,KP15,30959874,CDK4/6 inhibitors#received#FDA approval for HR+/HER2- breast cancer,Drug Development,"CDK4,CDK6",-,HR+/HER2- breast cancer,"Palbociclib, Ribociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
1512,KP15,31600301,Small-molecule inhibitors of CDK4/6#demonstrated#significant efficacy against solid tumors,Therapeutic Response,"CDK4,CDK6",-,Solid tumors,Small-molecule CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
4225,KP15,30287548,CDK4/6 inhibitors#have gained#FDA approval for ER-positive/HER2-negative breast cancer,Clinical Implementation,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,Postmenopausal women,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
4537,KP15,28741274,CDK4/6 inhibitors#are used in#breast cancer,Drug Development,"CDK4, CDK6",-,Breast cancer,"Palbociclib, ribociclib, abemaciclib",-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
5130,KP15,28741274,Clinical trials with CDK4/6 inhibitors#are ongoing in#breast cancer,Clinical Trial Data,"CDK4, CDK6",-,Breast cancer,"Palbociclib, ribociclib, abemaciclib",-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
3767,KP15,28741274,CDK4/6 inhibitors#are being investigated with#other agents in advanced and triple-negative breast cancer,Drug Development,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,10,10.3,10.3.4,10.3.4.2,-,与靶向治疗联用
194,KP15,28741274,"CDK4/6 inhibitors#demonstrated#activity in ER-positive, HER2-negative metastatic breast cancer",Therapeutic Response,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
5516,KP15,28741274,CDK4/6 inhibitors#are#a very important treatment option for breast cancer patients,Clinical Implementation,"CDK4, CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
3260,KP15,35670349,CDK4/6 inhibitors#show#potent anti-CDK4/6 activities in breast cancer cells,Drug Development,"CDK4, CDK6",Breast cancer cells,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,10,10.1,10.1.1,10.1.1.1,-,ATP竞争性结合
7411,KP15,31632494,"CDK4/6 inhibitors#have been approved for#HR-positive, HER2-negative advanced breast cancer",Clinical Implementation,"CDK4, CDK6",-,Breast cancer,"Palbociclib, ribociclib, abemaciclib",-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
5013,KP15,29483206,CDK4/6 inhibitors#show#promise in combination with hormonal therapies in breast cancer,Combination Optimization,"CDK4, CDK6",-,Breast cancer,"CDK4/6 inhibitors, hormonal therapies",-,-,-,-,-,-,-,Fact,10,10.3,10.3.4,10.3.4.1,-,与内分泌治疗联用
4542,KP15,37838584,"Ribociclib, palbociclib, and abemaciclib#are approved for#treating hormone receptor-positive and HER2-negative metastatic BC",Drug Development,"CDK4,CDK6",-,Metastatic breast cancer,"Ribociclib,Palbociclib,Abemaciclib",-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
857,KP15,37129951,ACAA1#is#a predictive biomarker of resistance to CDK4/6 inhibitors in RB1-proficient patients,Markers,"ACAA1,RB1",-,Triple-negative breast cancer (TNBC),CDK4/6 inhibitors,-,-,RB1-proficient,-,-,-,-,Inference,7,7.5,7.5.1,7.5.1.1,-,获得性耐药
2493,KP15,38714024,Activation and inhibition of AMPK#regulated#SC proliferative activity,Regulation,"AMPK,CDK4,CCND3",Sertoli cells,-,-,CDK4/Cyclin D3 pathway,-,-,-,-,-,-,Fact,10,10.1,10.1.1,10.1.1.1,-,ATP竞争性结合
5666,KP15,38714024,AMPK regulation#provides#a basis for prevention and treatment of male sterility,Therapeutic Development,AMPK,-,Male sterility,-,CDK4/Cyclin D3 pathway,-,-,-,-,-,-,Inference,10,10.3,10.3.4,10.3.4.2,-,与靶向治疗联用
2643,KP15,31527167,CDK4/6 inhibitor palbociclib#is synergistic with#antiestrogens in HR+/HER2- breast cancer models,Combination Optimization,"CDK4,CDK6",Breast cancer,-,Palbociclib,-,-,HR+/HER2-,-,-,-,-,Fact,10,10.3,10.3.4,10.3.4.1,-,与内分泌治疗联用
937,KP15,31527167,Palbociclib plus letrozole#confers efficacy on#luminal A and B patients,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,"Palbociclib,Letrozole",-,-,Luminal A and B,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
2011,KP15,31527167,Increased FGFR2 and ERBB3 expression#is associated with#greater PFS gain from palbociclib addition,Markers,"FGFR2,ERBB3",-,Breast cancer,Palbociclib,-,-,-,upregulated,-,-,-,Inference,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
2368,KP15,34866279,CDK4/6 inhibitors#are efficacious against#EMPD-PDX model,Preclinical Models,"CDK4,CDK6",-,Extramammary Paget's disease (EMPD),CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,10,10.3,10.3.4,10.3.4.2,-,与靶向治疗联用
5227,KP15,34866279,Ki-67-positive ratio in EMPD-PDX tumors#is lower in#treated tumors,Biomarker Analysis,"CDK4,CDK6",-,Extramammary Paget's disease (EMPD),CDK4/6 inhibitors,-,-,-,downregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
5064,KP15,34866279,CDK4 and Cyclin D1 expression levels#are higher in#EMPD tumor cells compared to normal epidermis,Expression Patterns,"CDK4,CCND1",-,Extramammary Paget's disease (EMPD),-,-,-,-,upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,-,细胞周期蛋白
1560,KP15,34866279,CDK4/6 inhibitors#could be#potent therapeutics for EMPD,Therapeutic Development,"CDK4,CDK6",-,Extramammary Paget's disease (EMPD),CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,10,10.3,10.3.4,10.3.4.2,-,与靶向治疗联用
3508,KP15,37684290,ET with CDK4/6 inhibitors#is#standard first-line treatment for HR+/HER2- advanced breast cancer,Clinical Implementation,"CDK4,CDK6",-,Advanced breast cancer,CDK4/6 inhibitors,-,-,HR+/HER2-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
1946,KP15,33495311,CDK4/6 inhibition#may sensitize#ER(+) breast cancer to radiotherapy,Therapeutic Development,"CDK4,CDK6",-,Breast cancer,-,-,-,ER(+),-,-,-,-,Inference,10,10.5,10.5.2,10.5.2.4,-,检查点旁路激活
6836,KP15,37725704,Camizestrant#demonstrated#robust and selective ER degradation,Mechanism of Action,ESR1,"Breast cancer cell lines, PDX models",Breast cancer,Camizestrant,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
3706,KP15,37725704,Camizestrant#modulated#ER-regulated gene expression,Mechanism of Action,ESR1,"Breast cancer cell lines, PDX models",Breast cancer,Camizestrant,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,转录因子网络
7383,KP15,37725704,Camizestrant#induced#complete ER antagonism,Mechanism of Action,ESR1,"Breast cancer cell lines, PDX models",Breast cancer,Camizestrant,-,-,-,-,-,-,-,Fact,1,1.5,1.5.2,1.5.2.1,-,转录因子网络
273,KP15,37725704,Camizestrant#induced#significant antiproliferation activity,Therapeutic Response,ESR1,"Breast cancer cell lines, PDX models",Breast cancer,Camizestrant,-,-,-,-,-,-,-,Fact,10,10.1,10.1.3,10.1.3.1,-,增殖抑制作用
2222,KP15,39224861,"Abemaciclib#is combined with#adjuvant endocrine therapy for treating HR-positive, HER2-negative high-risk early breast cancer",Clinical Implementation,"CDK6,CDK4",-,"HR-positive, HER2-negative breast cancer",Abemaciclib,-,-,High-risk patients,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
6615,KP15,39224861,Targeted therapy#is recommended in combination with#ET,Therapeutic Development,-,-,-,-,-,-,-,-,-,-,-,Inference,10,10.3,10.3.4,10.3.4.1,-,与内分泌治疗联用
5578,KP15,31285369,Ribociclib#exhibited#good CNS penetration,Drug Development,-,-,-,Ribociclib,-,-,-,-,-,-,-,Fact,10,10.2,10.2.1,10.2.1.3,-,血脑屏障通透性
1351,KP15,39731909,Targeting autophagy plus high-dose CDK4/6 inhibitors#is evaluated in#a phase 1b/2 trial,Clinical Trial Data,"CDK4,CDK6",-,HR+/HER2- breast cancer,-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
4974,KP15,39731909,unmet needs of managing HR+/HER2- breast cancer#remain#unclarified after CDK4/6i treatment,Clinical Implementation,"CDK4,CDK6",-,HR+/HER2- breast cancer,-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
7422,KP15,39731909,phase 1b study#demonstrated#no DLT in patients treated with HCQ plus palbociclib,Clinical Trial Data,"CDK4,CDK6",-,-,"Hydroxychloroquine, Palbociclib",-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
3191,KP15,39731909,plasma pharmacokinetics of palbociclib#were not significantly affected by#HCQ,Drug Development,"CDK4,CDK6",-,-,"Hydroxychloroquine, Palbociclib",-,-,-,-,-,-,-,Fact,10,10.2,10.2.1,10.2.1.1,-,生物利用度
3683,KP15,33990344,CDK4/6 inhibitors#are under evaluation in#clinical trials for other cancer types,Clinical Trial Data,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
6136,KP15,37406085,multi-omic approach#quantitatively profiled#kinome enrichment in NF1-associated PNF,Systems Biology,NF1,-,NF1-associated PNF,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
2935,KP15,38751535,Novel treatment options#have emerged for#breast cancer,Therapeutic Development,-,-,Breast cancer,-,-,-,-,-,-,-,-,Inference,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
3081,KP15,37420093,Senolytics#target#senescent cells for improved cancer treatment,Therapeutic Development,-,-,Cancer,Senolytics,-,-,-,-,-,-,-,Fact,3,3.1,3.1.2,3.1.2.2,-,衰老相关分泌表型
5484,KP15,37420093,"Kinome profiling#reveals#activation of RTKs and enriched downstream signaling of neurotrophin, ErbB, and insulin pathways",Signaling Networks,"RTKs,ERBB,INSR",-,Cancer,-,"Neurotrophin, ErbB, Insulin",-,-,-,-,-,-,Fact,1,1.3,1.3.1,1.3.1.1,-,信号交叉激活
4978,KP15,37420093,miR-211-5p#is associated with#resistant phenotypes in melanoma,Biomarker Analysis,MIR211,-,Melanoma,-,-,-,-,-,-,-,-,Fact,7,7.5,7.5.1,7.5.1.1,-,获得性耐药
4080,KP15,37420093,Insulin signaling#is associated with#persistence of a senescent phenotype,Signaling Networks,INS,-,Senescence,-,ERK5,-,-,-,-,-,-,Fact,4,4.2,4.2.2,4.2.2.1,-,能量应激感应
5554,KP15,36778271,ER-high metastatic breast cancers#exhibit#opposite estrogen-mediated growth responses,Expression Patterns,ESR1,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,7,7.2,7.2.1,7.2.1.2,-,信号通路蛋白
7372,KP15,25168062,MIF expression#was depleted using#siRNA in melanoma cell lines,Gene Regulation,MIF,-,Melanoma,-,-,-,-,-,-,-,-,Fact,1,1.5,1.5.3,1.5.3.1,-,长链非编码RNA
1719,KP15,25168062,MIF signaling#is clinically significant in#melanoma,Cancer Association,MIF,-,Melanoma,-,-,-,-,-,-,-,-,Fact,1,1.3,1.3.3,1.3.3.3,-,细胞凋亡调控
1256,KP1,32054529,MITF+ patients#showed#more frequently dysplastic nevi and melanomas with uncommon dermoscopic patterns,Clinical Correlation triples,MITF,-,Melanoma,-,-,Dysplastic nevi,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.1,-,基因突变
6111,KP5,32944234,"miR-214-3p#down-regulates#CYP11A1, CYP19A1, and StAR",Regulation,"CYP11A1,CYP19A1,StAR",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.2,1.2.3,1.2.3.1,-,翻译后修饰
3549,KP5,20938386,CDK4 and TERT mRNA levels#were downregulated#in amputated samples,Expression Patterns,"CDK4,TERT",-,-,-,-,-,-,downregulated,-,-,-,Fact,1,1.1,1.1.3,1.1.3.1,-,G1期阻滞
3883,KP9,26278556,"Molecular studies#did not identify#mutations in CDKN2A, CDK4, or MITF genes",Genomic Alterations,"CDKN2A,CDK4,MITF",-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
4812,KP15,24469340,"No differences#were detected for#CDK4, CDK6, cyclin E, p15, and p27",Expression Patterns,"CDK4,CDK6,CCNE1,CDKN2B,CDKN1B",-,-,-,-,-,-,-,-,-,-,Fact,1,1.1,1.1.2,1.1.2.3,-,复合物活性调节
7439,KP3,26528855,Surgery and radiation therapy#are accepted treatments for#most sarcomas,Clinical Implementation,-,-,Sarcomas,-,-,-,-,-,-,-,-,Fact,8,8.1,8.1.1,8.1.1.1,-,肿瘤类型
1083,KP9,29705383,Endosulfan exposure#lowers#cell viability in K562 cells in a dose-dependent manner,Environmental Factors,-,K562 cells,-,-,-,-,Downregulated,-,-,-,-,Fact,22,22.2,22.2.3,22.2.3.2,-,信号通路扰动
7408,KP9,29705383,Endosulfan#induces#apoptosis in cells as detected by Annexin-V binding assays,Environmental Factors,-,K562 cells,-,-,-,-,Upregulated,-,-,-,-,Fact,22,22.2,22.2.3,22.2.3.2,-,信号通路扰动
1795,KP14,35219113,mechanisms and risk factors of ILD/pneumonitis#require#validation with CDK4/6 inhibitors,Regulation,"CDK4,CDK6",-,"ILD,pneumonitis",-,-,-,-,-,-,-,-,Inference,10,10.5,10.5.1,10.5.1.2,-,CDK4/6表达改变
5436,KP14,33353034,risk of osteonecrosis#is uncertain in#patients taking CDK4/6 inhibitors,Safety Monitoring,"CDK4,CDK6",-,osteonecrosis,-,-,-,-,-,-,-,-,Inference,10,10.4,10.4.1,10.4.1.2,-,贫血
1625,KP1,27276112,Leiomyosarcoma#is#the most common type of uterine sarcoma,Cancer Association,-,-,Uterine sarcoma,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,肿瘤类型
7334,KP1,27276112,"Heterologous leiomyosarcoma#contains#liposarcomatous, osteosarcomatous, or rhabdomyosarcomatous components",Cancer Pathways,-,-,Heterologous leiomyosarcoma,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,肿瘤成分
79,KP1,27276112,Surgical specimens#were formalin fixed and paraffin embedded#for uterine leiomyosarcoma with rhabdomyosarcomatous component,Technical Methods,-,-,Uterine leiomyosarcoma,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,技术方法
6441,KP1,27276112,CDKN2A promoter region#methylation-specific polymerase chain reaction#was performed,Technical Methods,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,表观遗传调控
709,KP1,27276112,Leiomyosarcomatous cells#were strongly immunoreactive for#desmin and 伪-smooth muscle actin,Biomarker Analysis,-,Leiomyosarcomatous cells,Uterine leiomyosarcoma,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,生物标志物分析
1319,KP1,27276112,"Rhabdomyosarcomatous cells#were immunoreactive for#sarcomeric actin, desmin, vimentin, CD10, and p16",Biomarker Analysis,CDKN2A,Rhabdomyosarcomatous cells,Uterine leiomyosarcoma,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,生物标志物分析
1180,KP1,37044053,Epithelial-mesenchymal transition (EMT)#was identified by#immunofluorescence double staining,Technical Methods,-,-,-,-,-,Epithelial-mesenchymal transition,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,技术方法
3274,KP1,11369633,mRNA representing unique first exons of INK4a and ARF#were analyzed by#semiquantitative reverse transcription-polymerase chain reaction,Technical Methods,"CDKN2A (INK4a),CDKN2A (ARF)",-,-,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,技术方法
7671,KP1,14551738,CDK6 oncogene#is mapped to#chromosome 7,Structural Biology,CDK6,-,-,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,基因定位
904,KP1,22932448,Mutational screening of CDK4#was performed by#PCR-SSCP and direct sequencing,Technical Methods,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,技术方法
713,KP1,31592235,TRAMP model#mimics#human prostate cancer progression,Preclinical Models,-,-,Prostate cancer,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,前临床模型
2787,KP1,31938337,Undifferentiated sarcoma#could be identified as#dedifferentiated liposarcoma,Cancer Association,-,-,"Undifferentiated sarcoma, Dedifferentiated liposarcoma",-,-,-,-,-,-,-,-,Inference,5,5.1,5.1.2,5.1.2.1,-,肿瘤类型
5336,KP1,10861313,Two genes#are implicated in#cutaneous malignant melanoma development,Cancer Association,-,-,Cutaneous malignant melanoma,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,肿瘤类型
2379,KP1,10861313,Germline mutations in CDKN2A#are detected in#melanoma-prone families,Cancer Association,CDKN2A,-,Melanoma,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,遗传突变
2840,KP1,35070121,Juvenile ossifying fibroma#is characterized by#local aggressiveness and recurrence propensity,Disease Characteristics,-,-,Juvenile ossifying fibroma,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,疾病特征
2629,KP1,32057514,The tumor#was diffusely positive for#MDM2 and CDK4,Biomarker Analysis,CDK4,-,Tumor,-,-,-,-,Upregulated,-,-,-,Fact,7,7.2,7.2.1,7.2.1.1,7.2.1.1.2,CDK4/6表达
4779,KP1,28844173,"Array#detected#recurring genetic abnormalities, including KIAA1549-BRAF fusion, 19q13.42 amplification, i(17q), and monosomy 6",Genetic Alteration triples,"KIAA1549,BRAF",-,-,-,-,-,-,"fused, amplified, monosomy",-,-,-,Fact,9,9.5,9.5.4,9.5.4.3,-,基因融合事件
6764,KP1,32054529,"genetic testing#was conducted for#CDKN2A, CDK4, MC1R, and MITF germline variants",Analysis triples,"CDKN2A,CDK4,MC1R,MITF",-,-,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.2,9.5.2.1,-,基因突变
3811,KP1,8634085,OS-9#is ubiquitously expressed#in human tissues,Expression Patterns,-,-,-,-,-,-,-,-,-,-,-,Fact,9,9.1,9.1.2,9.1.2.1,-,细胞周期中的功能
5943,KP1,8634085,OS-9 and OS-4#are identified#within the 12q13-15 region,Genomic Localization,-,-,Human cancers,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.3,-,肿瘤类型特异性
7136,KP1,8634085,OS-9 gene#encodes#a 2.8-kb mRNA transcribed in all 16 human tissues,Molecular Biology,-,-,-,-,-,-,-,-,-,-,-,Fact,9,9.1,9.1.2,9.1.2.1,-,细胞周期中的功能
2090,KP1,34996885,Endoscopic biopsy#showed#undifferentiated sarcoma,Cancer Association,-,-,Undifferentiated sarcoma,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.3,-,肿瘤类型特异性
2066,KP1,34996885,Histology of RP sarcoma#consisted of#undifferentiated sarcoma and well-differentiated LPS,Cancer Association,-,-,RP sarcoma,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.3,-,肿瘤类型特异性
642,KP1,34996885,RP sarcoma diagnosis#was revised to#dedifferentiated LPS,Cancer Association,-,-,Dedifferentiated LPS,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.3,-,肿瘤类型特异性
1115,KP1,28710771,Intratumoral heterogeneity#is observed in#many aggressive cancer types,Cancer Association,-,Tumor cells,Aggressive cancer,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.3,-,肿瘤类型特异性
6173,KP1,20606735,Light microscopic examination#revealed#a biphasic pattern with CRCC and a high-grade sarcomatous component containing large pleomorphic lipoblasts,Pathology,-,-,Chromophobe renal cell carcinoma (CRCC),-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.3,-,肿瘤类型特异性
4594,KP1,35411369,Germline findings of 52 genes#were examined in#296 cases with advanced cancer,Genetic Testing,-,-,Advanced cancer,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.3,-,肿瘤类型特异性
5653,KP1,35411369,FoundationOne CDx#recognized#404 pathogenic variants in tumors,Genetic Testing,"BRCA1, BRCA2",-,Tumors,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.3,-,肿瘤类型特异性
1957,KP1,35411369,Pathogenic variants of BRCA1/2#were recognized in#16 (5.5%) tumors,Genetic Testing,"BRCA1, BRCA2",-,Tumors,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.3,-,肿瘤类型特异性
1649,KP1,35411369,Four germline findings#had been previously identified as#BRCA1: 3 and ATM: 1,Genetic Testing,"BRCA1, ATM",-,-,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.3,-,肿瘤类型特异性
4550,KP1,35411369,"Germline testing#revealed#3 germline findings (BRCA2, CDK4, RAD51C)",Genetic Testing,"BRCA2, CDK4, RAD51C",-,-,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.3,-,肿瘤类型特异性
3055,KP1,26892651,"Germline variants in TERT, MITF, and BAP1#have been added to#melanoma-predisposing mutations",Genetic Predisposition,"TERT, MITF, BAP1",-,Melanoma,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.3,-,肿瘤类型特异性
6170,KP1,26892651,Melanocytic BAP1-mutated atypical intradermal tumors#are features of#BAP1 melanoma syndrome,Disease Association,BAP1,-,BAP1 melanoma syndrome,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.3,-,肿瘤类型特异性
2619,KP1,38254762,Liposarcoma (LPS)#is characterized by#a high diversity of histopathological features and molecular abnormalities,Pathology,-,-,Liposarcoma (LPS),-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.3,-,肿瘤类型特异性
1348,KP1,38254762,Surgical resection#is the mainstay of treatment for#localized disease in all subtypes of STS,Treatment,-,-,Soft-tissue sarcomas (STS),-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.3,-,肿瘤类型特异性
6338,KP1,38469735,Ribosomal RNA depletion#enhances#detection of coding and noncoding transcripts,Technical Methods,-,RNA,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
269,KP1,38469735,High immunogenicity#is observed in#NAM,Immune Cell Functions,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
1342,KP2,19609742,PIK3C2B/MDM4#is amplified in#7.7% of combined studies,Cancer Association,"PIK3C2B,MDM4",-,-,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.1,-,基因扩增
7023,KP2,19609742,PDGFRA#is amplified in#7.7% of combined studies,Cancer Association,PDGFRA,-,-,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.1,-,基因扩增
2246,KP2,10022821,PDGFRA#is amplified and/or overexpressed in#GBM,Cancer Association,PDGFRA,-,GBM,-,-,-,-,upregulated,-,-,-,Fact,9,9.5,9.5.3,9.5.3.1,-,过表达模式
4809,KP2,10632344,EGFR amplification#was not detected in#this series,Genomic Alteration,EGFR,-,-,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.1,-,基因扩增
5364,KP6,16436672,Rap1GAP#functions as#a tumor suppressor in SCC,Cancer Association,RAP1GAP,-,Squamous cell carcinoma,-,-,-,-,-,-,-,-,Inference,9,9.1,9.1.3,9.1.3.3,-,与RB蛋白互作
7187,KP6,16436672,Nocodazole#caused#a slower accumulation of rap1GAP-transfected cells in the G2 phase,Cell Cycle Control,RAP1GAP,-,-,Nocodazole,-,-,-,-,-,-,-,Fact,9,9.1,9.1.2,9.1.2.2,-,RB蛋白磷酸化
2356,KP6,16436672,Rap1GAP-transfected SCC cells#produced#significantly smaller tumors in nude mice,Preclinical Models,RAP1GAP,-,Squamous cell carcinoma,-,-,-,Nude mice,-,-,-,-,Fact,9,9.1,9.1.3,9.1.3.3,-,与RB蛋白互作
2785,KP6,16436672,Rap1GAP#acts as#a tumor suppressor protein in SCC,Cancer Association,RAP1GAP,-,Squamous cell carcinoma,-,-,-,-,-,-,-,-,Inference,9,9.1,9.1.3,9.1.3.3,-,与RB蛋白互作
5831,KP6,8855819,Loss of chromosome arm 9p DNA#analyzed#p16 and p15 cyclin-dependent kinase inhibitor genes,Genetic Analysis,"CDKN2A,CDKN2B",-,Parathyroid adenomas,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.2,9.5.2.1,-,突变热点
4529,KP6,8855819,Heterozygous allelic loss at 9p#was observed in#4 of 25 adenomas,Genetic Analysis,-,-,Parathyroid adenomas,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.2,9.5.2.1,-,突变热点
325,KP6,8855819,Homozygous deletions of p16 and p15 genes#were not found in#parathyroid tumors,Genetic Analysis,"CDKN2A,CDKN2B",-,Parathyroid adenomas,-,-,-,-,-,-,-,-,Fact,9,9.5,9.5.2,9.5.2.1,-,突变热点
1307,KP6,8855819,Loss of a different tumor suppressor gene on 9p#contributes to#pathogenesis of tumors,Cancer Pathways,-,-,Parathyroid adenomas,-,-,-,-,-,-,-,-,Inference,9,9.5,9.5.2,9.5.2.1,-,突变热点
6809,KP6,10594039,Testicular atrophy#is associated with#increased apoptosis of germ cells,Disease Phenotype,-,Germ cells,Testicular atrophy,-,-,-,Males,-,-,-,-,Fact,9,9.4,9.4.4,9.4.4.1,-,凋亡阈值调节
741,KP6,35418303,AZD7762#was identified as#a positive hit,Drug Development,-,-,-,AZD7762,-,-,-,-,-,-,-,Fact,10,10.1,10.1.4,10.1.4.1,-,选择性差异
4980,KP6,29441600,BBR#decreased#VCL-induced DNA fragmentation,Mechanism of Action,-,-,-,BBR,-,-,-,-,-,-,-,Fact,9,9.1,9.1.2,9.1.2.4,-,细胞增殖调控
96,KP6,33072590,Simultaneous drug combination#induced#cell death more strongly than individual treatments,Combination Optimization,-,-,-,-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.4,10.3.4.3,-,与化疗联用
5010,KP6,28620137,CDK4/6 inhibitor abemaciclib#is dosed#continuously,Drug Development,"CDK4,CDK6",-,-,Abemaciclib,-,-,-,-,-,-,-,Fact,10,10.1,10.1.1,10.1.1.1,-,ATP竞争性结合
7743,KP6,28620137,Abemaciclib#has#diarrhea and fatigue as dose-limiting toxicities,Safety Monitoring,-,-,-,Abemaciclib,-,"diarrhea, fatigue",-,-,-,-,-,Fact,10,10.4,10.4.2,10.4.2.1,-,恶心呕吐
4681,KP6,28620137,CBX4945#inhibits#casein and DYRK/HIPK kinases,Mechanism of Action,-,-,-,CBX4945,-,-,-,-,-,-,-,Fact,9,9.1,9.1.3,9.1.3.4,-,与转录复合物的互作
7059,KP6,28620137,Mice harboring RB-positive and negative xenografts#were treated with#palbociclib and abemaciclib,Preclinical Models,RB1,-,-,"Palbociclib, Abemaciclib",-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
1278,KP9,18551755,MDM2 and CDK4#are excluded from#amplification,Regulation,"MDM2,CDK4",-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
4287,KP9,18551755,HMGA2#undergoes#balanced rearrangement in most cells,Structural Biology,HMGA2,-,-,-,-,-,-,-,-,-,-,Fact,5,5.4,5.4.1,5.4.1.2,-,基因间融合
6498,KP11,10361135,"Chromosomal imbalances#were detected in#gains of 3q, 7p, 8q, 12q, 18q, 9q34 and losses of 13, 6q, 1p, 11q14-q23, 10p14-p15, 17p, 9p",Structural Biology,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.2,5.2.1,5.2.1.1,-,染色体易位
221,KP11,10361135,"High-level DNA amplifications#were identified in#3q27-q29, 18q23, Xq28",Structural Biology,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.1,-,基因扩增
4245,KP11,35186754,SPOCK1#contributes to#development and progression of cancers,Cancer Association,SPOCK1,-,Cancer,-,-,-,-,-,-,-,-,Inference,9,9.5,9.5.3,9.5.3.4,-,肿瘤亚型特征
6992,KP11,35546399,Transcriptional profiling#was conducted to explore#molecular mechanisms of drug synergy,Experimental & Technical Categories,-,-,-,-,-,-,-,-,-,-,-,Fact,9,9.2,9.2.1,9.2.1.3,-,转录因子网络
4430,KP11,16547504,Cells#exhibited#autonomous growth and formed tumors resembling human KAs,Cancer Pathways,-,-,Human keratoacanthomas (KAs),-,-,-,-,-,-,-,-,Fact,9,9.4,9.4.1,9.4.1.2,-,异常增殖机制
3250,KP11,34108622,Barcoded shRNA library#was used to determine#critical targets for survival in PIK3CA/AKT1 mutated MCF7 cells,Experimental & Technical Categories,"PIK3CA, AKT1",MCF7 cells,-,-,-,PIK3CA/AKT1 mutations,-,-,-,-,-,Fact,9,9.3,9.3.1,9.3.1.1,-,交叉激活机制
3889,KP11,22678079,All cells#retained#giant marker chromosome previously identified in primary cultures,Biomarker Analysis,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
4158,KP11,12960127,p27 and related cell-cycle regulators#were analyzed using#kinase and immunoprecipitation assays,Experimental & Technical Categories,CDKN1B,-,HCC,-,-,-,-,-,-,-,-,Fact,9,9.1,9.1.2,9.1.2.4,-,细胞增殖调控
2819,KP12,7651726,Mouse p16INK4a and p15INK4b#were identified as#homologs of human counterparts,Structural Biology,"CDKN2A,CDKN2B",-,-,-,-,-,-,-,-,-,-,Fact,9,9.1,9.1.4,9.1.4.1,-,种间同源性
6673,KP12,26398286,PF-7006#inhibits#tumor growth in tumor-bearing mice,Preclinical Models,MPS1,-,Tumor,PF-7006,-,-,-,-,-,-,-,Fact,9,9.5,9.5.1,9.5.1.4,-,临床意义
1859,KP12,26398286,PF-7006#is cytotoxic to#Rb1-deficient cells relative to Rb1-competent cells,Preclinical Models,RB1,-,Tumor,PF-7006,-,-,-,-,-,-,-,Fact,9,9.5,9.5.2,9.5.2.2,-,功能获得性突变
5918,KP12,26398286,Palbociclib pretreatment#decreases#PF-7006-dependent apoptosis in human bone marrow cells,Preclinical Models,"CDK4,CDK6",-,-,"Palbociclib,PF-7006",-,-,-,-,-,-,-,Fact,10,10.5,10.5.1,10.5.1.1,-,CDK4/6突变
7925,KP15,30631751,CDK4/6 inhibitors#are active against#a broad spectrum of solid tumors,Preclinical Models,"CDK4,CDK6",-,"Solid tumors (liposarcoma, rhabdomyosarcoma, NSCLC, glioblastoma, esophageal cancer, melanoma)",-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.1,10.3.1.2,-,其他实体瘤适应症
4494,KP14,32349307,Hybrids 6a and 6e#are highlighted as#promising antitumor drugs targeting CDK inhibitors,Drug Development,"CDK4,CDK6",-,Breast malignancy,-,-,-,-,-,-,-,-,Fact,10,10.6,10.6.1,10.6.1.1,-,选择性增强
3871,KP14,39586283,Concurrent use of CDK4/6 inhibitors and PPIs#is debated in#the treatment of breast cancer,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,"PPIs,CDK4/6 inhibitors",-,-,-,-,-,-,-,Fact,10,10.3,10.3.4,10.3.4.2,-,与靶向治疗联用
1658,KP14,32842890,Mathematical modelling#analyzes#response of breast cancer cells to endocrine therapy and CDK4/6 inhibition,Model Systems,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,19,19.3,19.3.1,19.3.1.1,-,细胞反应预测
3804,KP14,32842890,Oestrogen receptor-positive breast cancer#is responsive to#targeted therapies,Cancer Association,ESR1,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.2,1.2.1,1.2.1.2,-,激素信号通路
1479,KP14,32842890,ER+ MCF-7 breast cancer cells#exhibit#proliferation over a 7-day time course,Expression Patterns,ESR1,MCF-7 breast cancer cells,Breast cancer,-,-,-,-,-,-,-,-,Fact,1,1.4,1.4.1,1.4.1.2,-,细胞周期进程
291,KP14,28697311,"Anti-HER2 agents such as pertuzumab, T-DM1, and tyrosine kinase inhibitors#have#a reassuring cardiotoxicity profile",Safety Monitoring,ERBB2,-,-,"Pertuzumab,T-DM1,Tyrosine kinase inhibitors",-,-,-,-,-,-,-,Fact,10,10.4,10.4.4,10.4.4.1,-,心脏毒性
7301,KP14,28697311,Cardiac events due to endocrine therapy#are mostly#ischemic,Safety Monitoring,-,-,-,Endocrine therapy,-,Ischemic,-,-,-,-,-,Fact,10,10.4,10.4.4,10.4.4.1,-,心脏毒性
1901,KP14,28697311,Novel agents for hormone receptor-positive disease#are potentially#arrhythmogenic,Safety Monitoring,-,-,Hormone receptor-positive disease,-,-,Arrhythmogenic,-,-,-,-,-,Inference,10,10.4,10.4.4,10.4.4.1,-,心脏毒性
4795,KP15,38714024,AMPK regulation#influenced#mitochondrial function,Metabolic Integration,AMPK,-,-,-,CDK4/Cyclin D3 pathway,Mitochondrial function,-,-,-,-,-,Fact,12,12.1,12.1.4,12.1.4.1,-,线粒体呼吸链活性
660,KP1,32391377,MAP3K1 and PIK3CA#show#genetic alteration in specific subtypes,Regulation,"MAP3K1,PIK3CA",-,-,-,-,-,-,-,-,-,-,Fact,10,10.5,10.5.4,10.5.4.1,10.5.4.1.1,基因组标志物
6953,KP1,32391377,MAP3K1 and PIK3CA#are#potential drug targets for specific subtypes,Drug Development,"MAP3K1,PIK3CA",-,-,-,-,-,-,-,-,-,-,Inference,10,10.5,10.5.4,10.5.4.1,10.5.4.1.2,靶向治疗
6898,KP1,14645011,Methylation status of p18INK4c promoter#was analyzed by#methylation-specific PCR and bisulfite sequencing,Technical Methods,CDKN2C,-,-,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,表观遗传调控
2381,KP1,31988001,Clinical features of patients#were assessed for#BRG1-inactivating mutations,Clinical Implementation,SMARCA4,-,-,-,-,-,-,-,-,-,-,Fact,5,5.1,5.1.2,5.1.2.1,-,临床特征评估
909,KP1,19712690,p16(23Asp)#was less efficient in#CDK4 binding,Structural Biology,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,9,9.1,9.1.1,9.1.1.2,-,结合位点特征
2357,KP1,19712690,p16(23Asp)#showed#protein aggregation,Structural Biology,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,9,9.1,9.1.1,9.1.1.2,-,结合位点特征
7378,KP1,19712690,The p.Gly23Asp missense mutation#was detected in#one of two melanoma patients in a family with three melanoma cases,Molecular Event triples,CDKN2A,-,Melanoma,-,-,-,-,Family history,-,-,-,Fact,14,14.2,14.2.1,14.2.1.1,-,RB1基因丢失/突变
1904,KP1,38104352,Well-differentiated and dedifferentiated liposarcomas#arise from#lipocytes in soft tissue,Molecular & Cellular Categories,-,Lipocytes,Liposarcomas,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.1,-,脂肪肉瘤特征
4845,KP1,23637631,Gene fusions like BCR/ABL1#have been recognized in#hematologic and mesenchymal malignancies,Genomic Event triples,"BCR,ABL1",-,"Hematologic malignancies, Mesenchymal malignancies",-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.1,-,黑色素瘤特征变异
3292,KP1,23637631,CEP85L/ROS1 fusion#is involved in#angiosarcoma,Genomic Event triples,ROS1,-,Angiosarcoma,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.2,-,肉瘤变异模式
3078,KP1,23637631,APIP/SLC1A2 fusion#is involved in#colon cancer,Genomic Event triples,SLC1A2,-,Colon cancer,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.3,-,乳腺癌变异谱
3234,KP1,23637631,ATG7/RAF1 fusion#is involved in#pancreatic cancer,Genomic Event triples,RAF1,-,Pancreatic cancer,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.4,-,其他肿瘤特征
4083,KP1,23637631,BCL6/RAF1 fusion#is involved in#anaplastic astrocytoma,Genomic Event triples,RAF1,-,Anaplastic astrocytoma,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.4,-,其他肿瘤特征
7371,KP1,32641004,Spinal cord astrocytoma#is a#rare neoplasm,Disease triples,-,Astrocytes,Spinal cord astrocytoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.4,-,脑转移瘤
6715,KP1,28337832,Well-differentiated or dedifferentiated liposarcoma#should be considered as#a differential diagnosis of perirenal cystic mass,Cancer Association,-,-,"Well-differentiated liposarcoma, Dedifferentiated liposarcoma",-,-,-,-,-,-,-,-,Inference,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
46,KP1,17895758,Dedifferentiated liposarcoma (DLPS)#represents#most undifferentiated sarcomas of the internal trunk,Cancer Association,-,-,Dedifferentiated liposarcoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
3777,KP1,31739757,Pediatric patient with ALT#recurs as#a bone-forming mass mimicking parosteal osteosarcoma,Clinical Observation,"MDM2, CDK4",-,"ALT, parosteal osteosarcoma",-,-,-,Pediatric,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
3805,KP1,26650572,400 patients with cutaneous melanoma#were observed in#a 6-year period at the Plastic Surgery Unit,Clinical Observation,-,-,Cutaneous melanoma,-,-,-,400 patients,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.1,-,黑色素瘤
2144,KP1,10981874,Recurrent retroperitoneal dedifferentiated liposarcoma#is characterized by#an extensive leiomyomatous component,Disease Characterization,-,leiomyomatous component,Retroperitoneal dedifferentiated liposarcoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
377,KP1,10981874,Cytogenetic evidence of ring markers#is a hallmark of#well-differentiated/dedifferentiated liposarcoma,Disease Characterization,-,ring markers,Well-differentiated/dedifferentiated liposarcoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
4397,KP1,10981874,"Morphology of the second recurrence#revealed#a well-differentiated liposarcoma, a sclerosing inflammatory variant",Disease Characterization,-,sclerosing inflammatory variant,Well-differentiated liposarcoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
7355,KP1,10981874,Small areas consistent with well-differentiated liposarcoma#were overlooked in#the first two surgical specimens,Clinical Correlation,-,small areas of liposarcoma,Well-differentiated liposarcoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
3290,KP1,12497626,International Melanoma Genetics Consortium#established#a database of germline variants for familial melanoma susceptibility,Clinical Implementation,-,-,Melanoma,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.4,28.2.4.4,-,非编码RNA调控失调
2764,KP1,8970601,Clinical conditions#can predispose to#uveal melanoma,Disease Association,-,-,Uveal melanoma,-,-,-,"Ocular melanocytosis, neurofibromatosis type I, familial atypical mole and melanoma syndrome",-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.4,-,葡萄膜黑色素瘤
5236,KP1,8970601,Transgenic mouse models#develop#retinal pigment epithelium tumors resembling uveal melanoma,Preclinical Models,-,-,Uveal melanoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.4,-,葡萄膜黑色素瘤
4777,KP1,31567591,"Panel screening#did not reveal#germline pathogenic variants in CDK4, BAP1, POT1",Cancer Association,"CDK4, BAP1, POT1",-,Melanoma,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.4,28.2.4.4,-,非编码RNA调控失调
7751,KP1,23830351,Malignant peripheral nerve sheath tumors (MPNSTs)#are#malignant tumors with a high rate of local recurrence and metastasis,Disease Characterization,-,-,MPNST,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.3,-,恶性外周神经鞘瘤
5438,KP1,28710771,Clonal evolution#can be predicted using#reverse engineering approaches,Experimental & Technical Categories,-,-,Tumor,-,-,-,-,-,-,-,-,Inference,27,27.5,27.5.4,27.5.4.4,-,克隆演化追踪
5047,KP1,38450313,This test#identifies#SNVs and GAs of select genes by next-generation sequencing,Genetic Testing,-,-,-,-,-,-,-,-,-,-,-,Fact,14,14.5,14.5.1,14.5.1.1,-,循环肿瘤DNA特征
1526,KP1,36716688,"Acral melanoma (AM)#shows#a higher incidence in Asians, including Koreans, than in Caucasians",Epidemiology,-,-,Acral melanoma (AM),-,-,-,"Asians, Koreans",-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.2,-,肢端黑色素瘤
1263,KP1,36716688,Genetic modification#associated with AM in Koreans#has not been comprehensively investigated,Genetic Analysis,-,-,Acral melanoma (AM),-,-,-,Koreans,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.4,-,突变与肿瘤表型关联
5724,KP1,36716688,Whole-exome and RNA sequencing#were performed for#Korean patients with AM,Genetic Testing,-,-,Acral melanoma (AM),-,-,-,Korean patients,-,-,-,-,Fact,14,14.5,14.5.1,14.5.1.1,-,循环肿瘤DNA特征
2586,KP1,36716688,KIT alterations#are known to be#recurrent alterations in AM,Cancer Association,KIT,-,AM,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.4,-,突变与肿瘤表型关联
2318,KP1,20182587,HCCs#are stratified into#two clinically relevant groups,Clinical Correlation triples,-,-,HCC,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.2,-,肝癌与胆管癌
4755,KP1,20182587,Class B HCC#does not show#expression signature of proliferation and antiapoptosis genes,Expression Patterns,-,-,HCC,-,-,-,-,silenced,-,-,-,Fact,27,27.2,27.2.5,27.2.5.2,-,染色质修饰调控
4680,KP1,23851445,Melanoma genomes#contain#thousands of alterations,Cancer Association,-,-,Melanoma,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.4,-,突变与肿瘤表型关联
1562,KP1,38311898,"Tumor#was negative for#MYOD1, myogenin, MDM2, and CDK4",Markers,"MYOD1, myogenin, MDM2, CDK4",-,Tumor,-,-,-,-,silenced,-,-,-,Fact,14,14.2,14.2.1,14.2.1.4,-,原发性耐药标志物
3653,KP1,38306361,Glioblastoma multiforme (GBM) and gliosarcoma (GS)#are among#tumors with the highest morbidity and mortality,Cancer Association,-,-,"GBM, GS",-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.1,-,胶质母细胞瘤
7263,KP1,38306361,General features of SLGCs#could contribute to#development of more efficient therapies,Therapeutic Development,-,-,GBM,-,-,-,-,-,-,-,-,Inference,29,29.2,29.2.4,29.2.4.3,-,联合新辅助方案
1201,KP1,38306361,Protein arrays#were used to determine#cell surface signature of SLGC lines,Preclinical Models,-,SLGC,"GBM, GS",-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.3,-,支架蛋白结合位点
4514,KP1,38306361,"Expression of factors#was evaluated for#GBM prognosis, subtypes, SLGC differentiation stages, or neural identity",Biomarker Analysis,-,SLGC,GBM,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.1,28.5.1.1,-,CDK4过表达的预后意义
317,KP1,34089125,Tumor cells#were negative for#MDM2,Markers,MDM2,-,Tumor,-,-,-,-,silenced,-,-,-,Fact,14,14.2,14.2.1,14.2.1.4,-,原发性耐药标志物
7026,KP1,33602577,Diagnosis#is challenging due to#overlap of findings with benign and malignant tumors,Clinical Correlation triples,-,-,Soft tissue tumors,-,-,-,-,-,-,-,-,Inference,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
6000,KP1,33602577,Fat-free variant of pleomorphic lipoma#was reported in#a 48-year-old female presenting clinically as a painless nodule on the buccal mucosa,Clinical Correlation triples,-,-,Pleomorphic lipoma,-,-,Painless nodule,48-year-old female,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
1949,KP1,37888062,Primary liposarcoma of the breast#comprises#0.003% of all malignant breast tumors,Cancer Association,-,-,Liposarcoma of the breast,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.1,-,脂肪肉瘤特征
4765,KP1,37888062,Histopathology report#described#a high-grade sarcoma,Cancer Association,-,-,High-grade sarcoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.2,-,平滑肌肉瘤
647,KP1,37888062,Final diagnosis#was#grade 3 dedifferentiated liposarcoma,Cancer Association,-,-,Dedifferentiated liposarcoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.1,-,脂肪肉瘤特征
3241,KP1,37888062,Follow-up CT scan#showed#multiple pulmonary lesions with metastatic characteristics,Cancer Association,-,-,Metastatic pulmonary lesions,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.1,-,肺癌
3311,KP1,31667475,gliomas#belong to#G-CIMP-high and G-CIMP-low methylation subgroups,Molecular Event triples,-,-,Glioma,-,-,-,-,-,-,-,-,Fact,5,5.6,5.6.3,5.6.3.1,-,DNA甲基化
5408,KP1,32657779,genes and pathways#are preferentially mutated in#metastases compared to primary tumors,Pathway & Network Categories,-,-,"Metastases, Primary tumors",-,-,-,-,-,-,-,-,Fact,28,28.3,28.3.1,28.3.1.3,-,复制压力与基因组不稳定
5311,KP1,32657779,metastases#exhibit#nuclear localization of activated PKA,Molecular Event triples,PKA,-,Metastases,-,-,-,-,-,-,-,-,Fact,27,27.3,27.3.4,27.3.4.3,-,细胞周期检查点改变
4005,KP2,20505263,Comparative genomic hybridization (CGH)#detects#chromosomal copy number changes in rat osteosarcomas,Technical Methods,-,-,Osteosarcoma,-,-,-,-,-,-,Plutonium-238,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
4019,KP2,17340131,Exon 2 of MTS1#was analyzed in#HPV-positive and HPV-negative head and neck tumors,Technical Methods,CDKN2A,-,Head and neck tumors,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
3716,KP2,17340131,Exon 2 of p16#was amplified and sequenced#after DNA isolation,Technical Methods,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
6524,KP2,17340131,HPV DNA#was detected by#broad-spectrum polymerase chain reaction,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
5338,KP2,17340131,27 biopsies#showed#the presence of HPV DNA,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,5,5.5,5.5.1,5.5.1.1,-,错义突变
158,KP2,20406234,Chromosomal imbalance#was assessed by#array comparative genomic hybridization (CGH) in glioblastomas,Technical Methods,-,-,Glioblastoma,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
5421,KP2,19609742,Glioblastoma Multiforme (GBM)#develops after#genomic DNA damage including amplifications and/or deletions,Cancer Pathways,-,-,Glioblastoma Multiforme,-,-,-,-,-,-,-,-,Fact,5,5.3,5.3.1,5.3.1.4,-,基因组不稳定性
7000,KP2,31387607,Molecular pathological examination#provides#diagnostic gold standard for distinguishing liposarcoma from lipoma,Diagnostic Methods,"MDM2, CDK4, CDKN2A",-,"Liposarcoma, Lipoma",-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
4459,KP2,10918183,Primary malignant melanoma#occurred in#MEN 1 families,Cancer Association,-,-,"Malignant melanoma, MEN 1",-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.1,-,家族性黑色素瘤
7485,KP2,35586877,OncoKB therapeutic GAs#were observed in#leiomyosarcoma and liposarcoma,Clinical Trial Data,-,-,"Leiomyosarcoma, Liposarcoma",-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
4789,KP3,35949590,vismodegib#should be considered in combination with#standard-of-care therapies for Gorlin syndrome-associated glioblastomas with sonic hedgehog pathway mutations,Clinical Implementation,SHH,-,Gorlin syndrome-associated glioblastomas,vismodegib,-,-,-,-,-,-,-,Inference,29,29.4,29.4.2,29.4.2.1,-,神经系统肿瘤
7938,KP3,38422625,axillary lymph node dissections and radiotherapy#may be omitted in#carefully selected patients,Clinical Implementation,-,lymph node cells,-,-,-,-,carefully selected patients,-,-,-,-,Inference,29,29.2,29.2.5,29.2.5.3,-,脏器转移管理
7068,KP3,38422625,perioperative pembrolizumab#provided#continued benefit in patients with triple-negative breast cancer,Therapeutic Development,-,-,triple-negative breast cancer,pembrolizumab,-,-,-,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.3,-,三阴性乳腺癌
2817,KP3,37894312,De novo metastatic hormone-sensitive prostate cancer (mHSPC)#accounts for#5-10% of all prostate cancer diagnoses,Disease-Specific Categories,-,-,Prostate cancer,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.3,-,血液系统恶性肿瘤
7666,KP3,37894312,De novo metastatic hormone-sensitive prostate cancer (mHSPC)#is responsible for#nearly 50% of PC-related deaths,Disease-Specific Categories,-,-,Prostate cancer,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.3,-,血液系统恶性肿瘤
7337,KP3,37894312,This review#describes#therapeutic opportunities and molecular biomarkers for de novo mHSPC,Biomarker Analysis,-,-,Prostate cancer,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.3,28.5.3.1,-,CDK4/6抑制剂敏感性标志物
2582,KP3,37894312,Randomized clinical trials#stratified#patients by clinical criteria for mHSPC treatment,Clinical Trial Data,-,-,Prostate cancer,-,-,-,-,-,-,-,-,Fact,29,29.2,29.2.1,29.2.1.3,-,适应症选择与患者分层
2946,KP3,37894312,Transcriptomic profiling of mHSPC#requires#further validation as a predictive biomarker,Biomarker Analysis,-,-,Prostate cancer,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.3,28.5.3.1,-,CDK4/6抑制剂敏感性标志物
6976,KP3,35294522,Median progression-free survival#is#3.7 months for all patients,Clinical Outcome,-,-,-,-,-,-,-,-,-,-,-,Fact,29,29.2,29.2.1,29.2.1.4,-,无进展生存获益
1829,KP3,35008570,Mucosal melanoma#is#a rare and aggressive subtype of melanoma,Disease & Clinical Categories,-,-,Mucosal melanoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.3,-,粘膜黑色素瘤
3849,KP3,38280968,8715 patients#were treated in#the MonarchE trial,Clinical Trial Data,-,-,-,-,-,Treated patients,-,-,-,-,-,Fact,29,29.2,29.2.3,29.2.3.1,-,MonarchE研究
1275,KP3,37500131,Pathological investigations#revealed#metastatic adenocarcinoma and invasive ductal carcinoma,Clinical Implementation,-,-,"Metastatic adenocarcinoma, invasive ductal carcinoma",-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.4,-,乳腺癌分子亚型特征
7828,KP3,39759323,50 patients with LM#received#50 mg IP after progression with EGFR-TKIs,Clinical Trial Data,EGFR,-,Lung metastases,EGFR-TKIs,-,50 patients,-,-,-,-,-,Fact,29,29.3,29.3.5,29.3.5.1,-,肺癌治疗
5685,KP4,37237509,Survival rate#is low for#patients with advanced or metastatic breast cancer,Clinical Correlation,-,-,Advanced or metastatic breast cancer,-,-,Low survival rate,-,-,-,-,-,Fact,28,28.5,28.5.1,28.5.1.4,-,多标志物组合分析
6250,KP4,18462865,Enzastaurin#is potentiated by#17-AAG,Combination Therapies triples,-,-,Malignant gliomas,"Enzastaurin, 17-AAG",-,-,Patients,-,-,-,-,Fact,29,29.4,29.4.4,29.4.4.4,-,序贯给药方案
1197,KP4,29893769,Most patients#are#hormone-receptor-positive,Patient Characteristics triples,-,-,-,-,-,Hormone-receptor-positive,-,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.1,-,激素受体阳性乳腺癌
6062,KP4,29893769,8% of patients#are#HER2-positive,Patient Characteristics triples,HER2,-,-,-,-,HER2-positive,-,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.2,-,HER2阳性乳腺癌
2308,KP4,27542767,Dose-limiting toxicities#were observed in#MTD/RDE evaluable patients,Safety Monitoring triples,-,-,-,-,-,"Neutropenia, thrombocytopenia",Patients,-,-,-,-,Fact,29,29.5,29.5.1,29.5.1.1,-,中性粒细胞减少症
814,KP4,27542767,"Treatment-related adverse events#include#neutropenia, leukopenia, fatigue, and nausea",Safety Monitoring triples,-,-,-,-,-,"Neutropenia, leukopenia, fatigue, nausea",-,-,-,-,-,Fact,29,29.5,29.5.1,29.5.1.1,-,中性粒细胞减少症
5465,KP4,36595763,Breast cancer#has#one of the highest malignancy rates in women,Epidemiology,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.4,-,乳腺癌分子亚型特征
5677,KP4,36453028,Malignant pleural mesothelioma (MPM)#is#an aggressive cancer with limited options,Clinical Correlation,-,-,Pleural mesothelioma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.1,-,肺癌
2027,KP4,34556423,Estrogens#play a role in#neural processes,Neural Cell Regulation,-,neuronal cells,-,-,-,-,-,-,-,-,-,Fact,31,31.1,31.1.2,31.1.2.4,-,神经炎症调控
3454,KP4,29541385,Patient and PDTX-matched models#validate#PDTXs as predictive preclinical models of therapeutic response,Preclinical Models,-,-,-,-,-,-,-,-,-,-,-,Fact,20,20.1,20.1.1,20.1.1.1,-,患者来源肿瘤类器官
83,KP4,32197329,Modulation of SAMHD1 function#may improve#current antimetabolite-based treatments,Therapeutic Development,SAMHD1,-,-,-,-,-,-,-,-,-,-,Inference,29,29.4,29.4.2,29.4.2.2,-,mTOR抑制剂联合
2065,KP4,37378079,Advanced breast cancer (ABC)#is characterized by#multidimensional clinical complexity,Disease Characterization,-,-,Advanced breast cancer,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.1,-,激素受体阳性乳腺癌
784,KP4,37410426,"Patient-matched MPNSTs and precursor lesions#were examined by#FISH, RNA sequencing, IHC, and Connectivity-Map analyses",Experimental Techniques,-,-,MPNST,-,-,-,-,-,-,-,-,Fact,20,20.1,20.1.1,20.1.1.1,-,患者来源肿瘤类器官
1864,KP4,32623316,HPLC-MS/MS method#provides#information on palbociclib monitoring and pharmacokinetic variability,Technical Methods,"CDK4, CDK6",-,Metastatic breast cancer,Palbociclib,-,-,-,-,-,-,-,Fact,29,29.1,29.1.1,29.1.1.2,-,药代动力学特征
4880,KP4,37524106,"Pneumonitis, interstitial lung disease, tuberculosis, COVID-19 and viral agents#were excluded in#the patient",Patient Characteristics,-,-,"Pneumonitis, interstitial lung disease, tuberculosis, COVID-19",-,-,Excluded,-,-,-,-,-,Fact,29,29.5,29.5.4,29.5.4.4,-,长期维持治疗管理
7536,KP4,32529951,Alopecia#is associated with#patients' distress and depressive symptoms,Symptoms,-,-,-,-,"Alopecia, depressive symptoms",-,-,-,-,-,-,Fact,29,29.5,29.5.3,29.5.3.2,-,皮肤毒性
4631,KP4,35677682,Pre- and post-transformation samples#are collected from#a patient with ALK-rearranged lung adenocarcinoma,Preclinical Models,ALK,-,Lung adenocarcinoma,-,-,Patient with ALK-rearranged lung adenocarcinoma,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.1,-,肺癌
1435,KP4,35677682,Multiple mutations#are shared between#pre-transformation and post-transformation samples,Molecular Event,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
3135,KP4,38849509,Targeted next-generation sequencing#compares#mutational profiles of EO-CRCs and AD-CRCs patients,Biomarker Analysis,-,-,Colorectal cancer,-,-,EO-CRCs and AD-CRCs patients,-,-,-,-,-,Fact,14,14.2,14.2.2,14.2.2.1,-,CDK4/6突变
4462,KP4,35184131,Abemaciclib#is tested on#a panel of 22 cancer cells,Preclinical Models,-,-,Cancer,Abemaciclib,-,-,-,-,-,-,-,Fact,29,29.1,29.1.3,29.1.3.1,-,分子结构与作用机制
7040,KP4,33419898,The genomic landscape of AM#provides#an important resource for applying novel targeted therapies,Research Insight,AM,-,Rare disease,-,-,-,-,-,-,-,-,Inference,19,19.1,19.1.3,19.1.3.1,-,序列特征分析
4854,KP4,35298959,27 evaluable patients#exhibit#37.0% overall response rate,Clinical Trial Data,-,-,-,-,-,-,-,-,-,-,-,Fact,29,29.2,29.2.1,29.2.1.4,-,无进展生存获益
4877,KP4,35617640,Cost within the same class#should be weighed against#incremental clinical benefit,Economic & Access,-,-,-,-,-,-,-,-,-,-,-,Fact,29,29.5,29.5.5,29.5.5.2,-,治疗期间监测频率
5933,KP4,39253474,Simulated drug dose response experiments#compare#four targeted anti-cancer drugs,Preclinical Models,-,-,cancer,"alpelisib, neratinib, trametinib, palbociclib",-,-,-,-,-,-,-,Fact,29,29.1,29.1.4,29.1.4.1,-,效力与选择性差异
4096,KP4,39253474,Palbociclib#is inconsistent with#simulated data,Preclinical Models,"CDK4, CDK6",-,-,palbociclib,-,-,-,-,-,-,-,Fact,29,29.1,29.1.1,29.1.1.4,-,临床剂量与给药方案
856,KP4,32724874,Biliary tract cancer#is#clinically and pathologically heterogeneous,Cancer Association,-,-,biliary tract cancer,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.4,-,头颈部肿瘤
4142,KP4,35911672,Anti-PD-1 antibody therapy#causes#cancer hyper-progression and immune-related adverse events in some patients,Therapeutic Response,PDCD1,-,Cancer,-,PD-1 pathway,-,-,-,-,-,-,Fact,11,11.2,11.2.2,11.2.2.1,-,PD-1/PD-L1表达影响
7825,KP4,35911672,Clinical trials for PD-1 and PD-L1 antibodies#investigate#combinations with other therapies,Combination Therapies,"PDCD1, CD274",-,Cancer,-,PD-1 pathway,-,-,-,-,-,-,Fact,29,29.4,29.4.3,29.4.3.4,-,联合临床试验
4649,KP4,35911672,PD-1 signaling pathway proteins#are promising targets for#combination therapy,Signaling Networks,PDCD1,-,Cancer,-,PD-1 pathway,-,-,-,-,-,-,Fact,29,29.4,29.4.3,29.4.3.4,-,联合临床试验
3328,KP4,33802424,New targeted therapies#have been developed based on#subtype,Therapeutic Development,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,29,29.1,29.1.4,29.1.4.1,-,效力与选择性差异
1150,KP4,33802424,Breast cancer patients with brain metastasis#are treated with#novel therapeutic agents,Drug Development,-,-,"Breast cancer, brain metastasis",-,-,-,-,-,-,-,-,Fact,29,29.2,29.2.5,29.2.5.1,-,脑转移患者治疗
7147,KP4,34371379,Poor prognostic factors#are associated with#HR+ HER2- advanced breast cancer,Cancer Association,-,-,HR+ HER2- advanced breast cancer,-,Poor prognosis,-,-,-,-,-,-,Fact,28,28.5,28.5.1,28.5.1.3,-,周期蛋白D表达关联
4057,KP4,33356996,ARC neurons#are critical for#energy balance,Neural Cell Regulation,-,"POMC, AgRP neurons",-,-,-,-,-,-,-,-,-,Fact,27,27.4,27.4.5,27.4.5.4,-,能量感知信号整合
4993,KP4,33356996,Abemaciclib#reduces#fat mass in mice,Experimental Models,-,-,-,Abemaciclib,-,-,-,-,-,-,-,Fact,29,29.5,29.5.3,29.5.3.1,-,中性粒细胞减少症
7863,KP4,33356996,Reduced food intake#is caused by#abemaciclib treatment,Experimental Models,-,-,-,Abemaciclib,-,-,-,-,-,-,-,Fact,29,29.5,29.5.2,29.5.2.1,-,恶心与呕吐
1408,KP4,35982453,Palbociclib plus temozolomide#are tested in#bladder tumor in PDX models,Preclinical Models,-,-,Bladder tumor,"Palbociclib, temozolomide",-,-,-,-,-,-,-,Fact,29,29.3,29.3.5,29.3.5.3,-,肝胆系统肿瘤
2157,KP4,34159748,Genetic testing#was conducted on#metastatic tumors using an institutional targeted sequencing platform,Preclinical Models,-,Metastatic tumors,-,-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.4,27.5.4.3,-,克隆演化追踪
6354,KP4,34604676,key pathways#link#microtubule disruption to cell death,Pathway Analysis,-,-,-,-,-,-,-,-,-,-,-,Inference,27,27.3,27.3.3,27.3.3.3,-,支架蛋白结合障碍
2737,KP4,34604676,G1 phase ALL cells#were treated with#vincristine in a proteomic study,Preclinical Models,-,ALL cells,-,vincristine,-,-,-,-,-,-,-,Fact,27,27.2,27.2.4,27.2.4.1,-,RB家族磷酸化
6089,KP4,31495008,A 59-year-old woman#presented with#bone-only metastatic luminal breast cancer,Clinical Observation,-,-,bone-only metastatic luminal breast cancer,-,-,59-year-old woman,-,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.4,-,乳腺癌分子亚型特征
570,KP4,38280968,Data collection#involved#clinical and histological characteristics plus treatment follow-up,Experimental Design,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.5,27.5.5.3,-,表观遗传调控
4983,KP4,34282751,Patients with clinically advanced paragangliomas and pheochromocytomas#have#limited surgical or systemic treatments,Clinical Observation,-,-,"paragangliomas, pheochromocytomas",-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.4,-,头颈部肿瘤
100,KP4,34282751,Comprehensive genomic profiling (CGP)#was used to compare#genomic alterations in CA-Para and CA-Pheo,Experimental Design,-,-,"CA-Para, CA-Pheo",-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.5,27.5.5.4,-,数字病理学特征
7120,KP4,34282751,CA-Para and CA-Pheo#underwent#hybrid-capture-based CGP using a targeted panel of 324 genes,Experimental Design,-,-,"CA-Para, CA-Pheo",-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.5,27.5.5.4,-,数字病理学特征
468,KP4,30290287,FISH and NGS#were run on#tumor specimens and CTCs in blood,Technical Methods,-,CTCs,non-small cell lung cancer,-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.4,27.5.4.4,-,融合事件检测方法
5773,KP4,39605517,Key regulators#were discovered using#chromatin immunoprecipitation with high-throughput sequencing,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.5,27.5.5.4,-,数字病理学特征
2766,KP4,29262551,Pazopanib and yondelis#did not have#significant efficacy compared to untreated control,Therapeutic Response,-,-,-,"Pazopanib, Yondelis",-,-,-,-,-,-,-,Fact,29,29.3,29.3.1,29.3.1.4,-,生物标志物引导治疗
1100,KP5,27825114,Tumor xenografts#verified#effects of PD 0332991 in vivo,Preclinical Models triples,-,-,-,PD 0332991,-,-,-,-,-,-,-,Fact,29,29.1,29.1.1,29.1.1.1,-,Palbociclib分子结构与作用机制
5716,KP5,17949234,c-kit#was upregulated in#CML cell lines,Expression Patterns,KIT,-,Chronic myeloid leukemia (CML),-,-,-,-,upregulated,-,-,-,Fact,27,27.2,27.2.5,27.2.5.2,-,转录因子招募
50,KP6,8741839,p19#mapped to#chromosome 19p13.2,Structural Biology,CDKN2D,-,-,-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.1,27.5.1.4,-,染色体位置与基因组环境
7842,KP6,24067736,Invasion into cavernous sinus#predicts#recurrence of FPA after surgical resection,Clinical Correlation triples,-,-,FPA,-,-,-,-,-,-,-,-,Fact,28,28.3,28.3.4,28.3.4.2,-,细胞黏附与迁移
390,KP6,24067736,Normostaining for p16#predicts#recurrence of FPA after surgical resection,Clinical Correlation triples,CDKN2A,-,FPA,-,-,-,-,-,-,-,-,Fact,14,14.5,14.5.5,14.5.5.1,-,免疫组化标志物
2615,KP6,24067736,Overstaining for pRB protein#predicts#recurrence of FPA after surgical resection,Clinical Correlation triples,RB1,-,FPA,-,-,-,-,-,-,-,-,Fact,14,14.5,14.5.5,14.5.5.1,-,免疫组化标志物
5833,KP6,24067736,Cyclin D1#predicts#recurrence of FPA after surgical resection,Clinical Correlation triples,CCND1,-,FPA,-,-,-,-,-,-,-,-,Fact,14,14.5,14.5.5,14.5.5.1,-,免疫组化标志物
4692,KP6,24067736,MIB-1 antigen#predicts#recurrence of FPA after surgical resection,Clinical Correlation triples,-,-,FPA,-,-,-,-,-,-,-,-,Fact,14,14.5,14.5.5,14.5.5.1,-,免疫组化标志物
7102,KP6,24067736,p53#predicts#recurrence of FPA after surgical resection,Clinical Correlation triples,TP53,-,FPA,-,-,-,-,-,-,-,-,Fact,14,14.5,14.5.5,14.5.5.1,-,免疫组化标志物
7750,KP6,24067736,p16#is associated with#recurrence of FPA after surgical resection,Clinical Correlation triples,CDKN2A,-,FPA,-,-,-,-,-,-,-,-,Fact,14,14.5,14.5.5,14.5.5.1,-,免疫组化标志物
3431,KP6,24067736,pRB protein#is associated with#recurrence of FPA after surgical resection,Clinical Correlation triples,RB1,-,FPA,-,-,-,-,-,-,-,-,Fact,14,14.5,14.5.5,14.5.5.1,-,免疫组化标志物
2897,KP6,24067736,Cyclin D1#is associated with#recurrence of FPA after surgical resection,Clinical Correlation triples,CCND1,-,FPA,-,-,-,-,-,-,-,-,Fact,14,14.5,14.5.5,14.5.5.1,-,免疫组化标志物
5671,KP6,16436672,Rap1GAP#inhibits#tumor growth in oropharyngeal squamous cell carcinoma,Cancer Association,RAP1GAP,-,Oropharyngeal squamous cell carcinoma,-,-,-,-,-,-,-,-,Fact,28,28.3,28.3.4,28.3.4.1,-,上皮-间质转化调控
538,KP6,16436672,Rap1#a growth regulatory protein#is strongly expressed in human squamous cell carcinoma,Expression Patterns,RAP1,-,Squamous cell carcinoma,-,-,-,Upregulated,-,-,-,-,Fact,27,27.2,27.2.5,27.2.5.2,-,转录因子招募
349,KP6,16436672,Rap1GAP#inactivates#Rap1,Regulation,"RAP1GAP,RAP1",-,-,-,-,-,-,-,-,-,-,Fact,27,27.2,27.2.2,27.2.2.3,-,多蛋白复合体组装
6963,KP6,29261702,"MDA-MB-453, BT-549, MDA-MB-231, and MDA-MB-468 cell lines#were used for#in vitro studies",Preclinical Models,-,"MDA-MB-453, BT-549, MDA-MB-231, MDA-MB-468",Triple-negative breast cancer (TNBC),-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.5,27.5.5.1,-,X射线晶体结构特征
2742,KP6,29261702,Protein expressions#were assessed by#Western blot analysis,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.1,-,蛋白-蛋白互作区域
1952,KP6,32336043,High-risk NB patients#have#unacceptable overall outcome,Clinical Correlation triples,-,-,Neuroblastoma,-,-,-,High-risk NB patients,-,-,-,-,Fact,28,28.3,28.3.5,28.3.5.4,-,免疫细胞功能障碍
5630,KP6,32336043,EPHB4 mutations#have been#identified in solid and haematological tumour specimens,Molecular Event triples,EPHB4,-,"Solid tumor, haematological tumor",-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.3,-,突变热点分析
7386,KP6,32336043,EPHB4 gain#is associated with#advanced diseases in NB,Clinical Correlation triples,EPHB4,-,Neuroblastoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.3,-,神经系统肿瘤中的作用
249,KP6,32336043,EPHB4#is#a promising therapeutic target in high-risk NB,Therapeutic Targets triples,EPHB4,-,Neuroblastoma,-,-,-,High-risk NB patients,-,-,-,-,Inference,29,29.3,29.3.2,29.3.2.3,-,神经胶质瘤治疗
7902,KP7,10651629,NMR#characterized#global conformations of the mutants,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.5,27.1.5.2,-,NMR解析结构
789,KP7,30613006,Fascin knockdown#reduces#tumor volume and weight in nude mice,Preclinical Models,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,30,30.5,30.5.1,30.5.1.3,-,多靶点抑制组合
5491,KP7,15526363,14 genes#displayed no#tumor-associated changes compared to normal mucosa,Cancer Association,"BRCA1,CDH1,DAPK1,DNMT1,MAGEA1,N33,CDKN1A,CDKN1B,PTEN,RARB,RASSF1,SFRP1,TIMP3,VHL",-,Tumor,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.4,-,突变与肿瘤表型关联
4530,KP7,28877884,Kidney sections#were stained with#antibodies against mesenchymal markers and domain-specific phospho-Smad3,Experimental Method triples,SMAD3,-,-,-,-,-,-,-,-,-,-,Fact,10,10.4,10.4.1,10.4.1.4,-,监测与管理策略
6020,KP7,28877884,"TGF-β, pSmad3L, pSmad3C, JNK, CDK4, and c-Myc#were evaluated by#Western blotting",Experimental Method triples,"SMAD3,JNK,CDK4,MYC",-,-,TGF-β,-,-,-,-,-,-,-,Fact,9,9.2,9.2.2,9.2.2.1,-,磷酸化修饰
7071,KP7,28877884,Cophosphorylation of pSmad3L/C#was assessed by#immunoprecipitation,Experimental Method triples,SMAD3,-,-,-,-,-,-,-,-,-,-,Fact,10,10.4,10.4.1,10.4.1.4,-,监测与管理策略
7531,KP7,30909188,"Expression of miR-429, p16, Cyclin D1, CDK4, MMP-2, MMP-9, and Vimentin#was detected by#qRT-PCR",Experimental Method triples,"CDKN2A,CDK4,CCND1,MMP2,MMP9",-,-,-,-,-,-,-,-,-,-,Fact,9,9.2,9.2.1,9.2.1.1,-,启动子区调控
5142,KP8,22493355,"Sequencing#was performed to study#BRAF, NRAS, c-KIT, MC1R, CDKN2A, and CDK4 genes",Technical Methods,"BRAF,NRAS,KIT,MC1R,CDKN2A,CDK4",-,-,-,-,-,-,-,-,-,-,Fact,10,10.4,10.4.1,10.4.1.4,-,监测与管理策略
3536,KP8,30365726,Proteins associated with proliferation and migration#were evaluated by#western blot analysis,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,10,10.4,10.4.1,10.4.1.4,-,监测与管理策略
6452,KP8,18462865,Proliferation of malignant gliomas#results from#activation of PKC-mediated pathways,Cancer Pathways,-,-,Malignant gliomas,-,PKC-mediated pathways,-,-,-,-,-,-,Inference,27,27.3,27.3.3,27.3.3.3,-,MAPK通路协同
5592,KP8,18462865,Combination of enzastaurin with 17-AAG#enhances#efficacy by inhibiting Akt and signaling intermediates,Combination Therapies,-,-,-,"Enzastaurin, 17-AAG",Akt pathway,-,-,-,-,-,-,Fact,29,29.4,29.4.2,29.4.2.1,-,PI3K抑制剂联合
89,KP8,31001908,Germline mutations in CDKN2A#are found in#patients with family history of melanoma or multiple primary melanomas,Cancer Association,CDKN2A,-,Melanoma,-,-,-,Family history,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.1,-,家族性黑色素瘤
4134,KP8,7925396,Olomoucine#acts as#a competitive inhibitor for ATP and non-competitive for histone H1,Mechanism of Action,-,-,-,Olomoucine,-,-,-,-,-,-,-,Fact,29,29.1,29.1.1,29.1.1.1,-,分子结构与作用机制
6277,KP8,7925396,Brain-specific cdk5/p35 kinase#exhibits#sensitivity to olomoucine,Regulation,CDK5,Brain cells,-,Olomoucine,-,-,-,-,-,-,-,Fact,29,29.1,29.1.4,29.1.4.1,-,效力与选择性差异
5038,KP8,7925396,Structure/activity relationship studies#speculate on#interactions of olomoucine with kinase catalytic subunit,Structural Biology,-,-,-,Olomoucine,-,-,-,-,-,-,-,Inference,27,27.1,27.1.1,27.1.1.3,-,激酶活性中心
1942,KP8,26137139,microRNAs (miRNAs)#function as#oncogenes or tumor suppressors in human cancer,Mechanism of Action,-,-,Human cancer,-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.4,27.5.4.3,-,miRNA调控网络
7473,KP8,29899063,"CDK6#binds to#the promoters of genes including Prmt5, Ppm1d, and Mdm4",Mechanism of Action,"CDK6, Prmt5, Ppm1d, Mdm4",-,-,-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.2,27.5.2.1,-,转录因子招募
793,KP8,29899063,Tumors with low levels of CDK6#have#mutations in TP53 more often than expected,Cancer Association,"CDK6, TP53",-,Tumors,-,-,-,Downregulated,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.4,-,突变与肿瘤表型关联
2345,KP8,38886784,Palbociclib in combination with endocrine therapy#shows#efficacy in ER-positive and HER2-negative BC,Drug Development,-,-,Breast cancer,Palbociclib,-,-,"ER-positive, HER2-negative",-,-,-,-,Fact,29,29.2,29.2.1,29.2.1.1,-,与芳香化酶抑制剂联用
7662,KP8,12112531,38 gliosarcomas#were investigated for#aberrations in tumor-suppressor genes and proto-oncogenes,Preclinical Models,"CDK4,PDGFRA,CCND3,EGFR,MDM2,AKT1",-,Gliosarcoma,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.4,-,突变与肿瘤表型关联
5060,KP8,33228782,RNA sequencing#identifies#differentially expressed genes regulated by Roquin1,Expression Patterns,ROQUIN1,-,-,-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.1,27.5.1.1,-,基因表达变化
7140,KP8,28815764,PD-L1 immunohistochemistry (IHC)#is performed with#three commercially available clones,Technical Methods,CD274,-,-,-,-,-,-,-,-,-,-,Fact,29,29.5,29.5.5,29.5.5.1,-,免疫组化标志物
4948,KP8,10022821,Gliomas#tend to#recur following surgical resection,Clinical Correlation triples,-,-,Gliomas,-,-,-,-,-,-,-,-,Fact,28,28.3,28.3.4,28.3.4.4,-,转移前微环境形成
6569,KP8,23958495,TRPM7 mRNA and protein#are increased in#CCl4-treated rat livers,Expression Patterns,TRPM7,-,-,-,-,-,upregulated,-,-,-,-,Fact,27,27.1,27.1.3,27.1.3.1,-,磷酸化调控位点
4505,KP8,21523718,High-risk HPV DNA#is localized in#nuclei of tumor cells in HPV-positive samples,Localization triples,HPV,-,HPV-positive carcinoma,-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.4,27.5.4.3,-,细胞内定位调控
4250,KP8,30236142,PDX tumor model#identifies#druggable tumor mutations,Preclinical Models,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.4,-,突变与肿瘤表型关联
7767,KP8,30236142,PDX tumor model#screens and evaluates#personalized cancer drugs,Preclinical Models,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,29,29.1,29.1.4,29.1.4.4,-,药物相互作用差异
3088,KP8,30236142,Cell cycle-associated genes#exhibit#high incident rate of CNVs,Expression Patterns,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.2,27.1.2.3,-,关键功能位点保守性
6554,KP8,30236142,Palbociclib#has#anti-tumor effects,Drug Development,-,-,-,Palbociclib,-,-,-,-,-,-,-,Fact,29,29.1,29.1.1,29.1.1.1,-,分子结构与作用机制
3471,KP8,10469453,CDKN2A#is identified as#a possible target gene,Gene Identification,CDKN2A,-,MPNST,-,pRB,-,-,-,-,-,-,Fact,27,27.2,27.2.3,27.2.3.3,-,调控方式不同
3625,KP8,11025389,Signals#were enumerated within#300 interphase nuclei per tumor specimen,Experimental Techniques,-,-,Prostate carcinoma,-,-,-,-,-,-,-,-,Fact,27,27.2,27.2.1,27.2.1.1,-,RB蛋白磷酸化机制
3662,KP8,24231788,EESB#has no effect on#body weight gain in CRC mice,Safety Monitoring,-,-,Colorectal Cancer,-,-,Mice,-,-,-,-,-,Fact,29,29.5,29.5.1,29.5.1.2,-,贫血
270,KP9,29408328,Few studies#have been performed on#leukemia,Preclinical Models,"CDK4,CDK6",-,Leukemia,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.3,-,血液系统恶性肿瘤
3447,KP9,11301189,Genes encoding proteins#are mutated or deleted in#many types of cancer,Cancer Association,-,-,Many cancers,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.4,-,突变与肿瘤表型关联
3256,KP9,35220309,ctDNA#was analyzed by#targeted next-generation sequencing,Experimental & Technical Categories,-,-,-,-,-,-,-,-,-,-,-,Fact,29,29.5,29.5.4,29.5.4.1,-,循环肿瘤DNA特征
453,KP9,35220309,ctDNA#was analyzed again upon#disease progression,Experimental & Technical Categories,-,-,-,-,-,-,-,-,-,-,-,Fact,29,29.5,29.5.4,29.5.4.1,-,循环肿瘤DNA特征
5061,KP9,30397176,ORF screen#identified#genes conferring resistance to CDK4/6 inhibitors,Experimental & Technical Categories,"CDK4, CDK6",-,-,-,-,-,-,-,-,-,-,Fact,30,30.2,30.2.1,30.2.1.1,-,CDK4/6突变
4311,KP9,39352623,Candidate genes for resistance#were validated by#cell viability assay and mouse xenograft models,Preclinical Models,-,-,-,-,-,-,-,-,-,-,-,Fact,30,30.2,30.2.1,30.2.1.1,-,CDK4/6突变
5239,KP9,39352623,"Eight genes including RET, TIRAP, GNRH1, SEMA3F, SEMA5A, GATA4, NOD1, and SSTR1#were identified as#candidate genes for resistance",Mechanism of Action,"RET,TIRAP,GNRH1,SEMA3F,SEMA5A,GATA4,NOD1,SSTR1",-,-,-,-,-,-,-,-,-,-,Fact,2,2.1,2.1.1,2.1.1.1,-,CDK4/6基因扩增
2913,KP9,27217383,"Treatment-emergent adverse events#involved#fatigue and gastrointestinal, renal, or hematopoietic systems",Quality of Life,-,-,-,-,-,"Fatigue, gastrointestinal issues, renal issues, hematopoietic issues",-,-,-,-,-,Fact,29,29.5,29.5.1,29.5.1.1,-,中性粒细胞减少
1008,KP9,27217383,Pharmacodynamic effects#were observed in#proliferating keratinocytes and tumors,Preclinical Models,-,Keratinocytes,-,-,-,-,-,-,-,-,-,Fact,10,10.3,10.3.3,10.3.3.1,-,影像学评估
6340,KP9,27217383,"Radiographic responses#were achieved in#previously treated patients with breast cancer, NSCLC, and melanoma",Therapeutic Response,-,-,"Breast cancer, NSCLC, melanoma",-,-,-,-,-,-,-,-,Fact,8,8.5,8.5.1,8.5.1.1,-,CT扫描
1591,KP9,9482902,Allelic variants of p16#were found in#ankyrin repeat regions in BALB/c and DBA/2 mice,Structural Biology,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,9,9.1,9.1.1,9.1.1.2,-,结合位点特征
7117,KP9,9482902,Allelic variants#were typed among#several inbred strains of mice,Preclinical Models,-,-,-,-,-,-,-,-,-,-,-,Fact,9,9.1,9.1.1,9.1.1.2,-,结合位点特征
7525,KP9,21047732,OTX2#is implicated in#pathogenesis of medulloblastoma,Cancer Association,OTX2,-,Medulloblastoma,-,-,-,-,upregulated,-,-,-,Fact,28,28.1,28.1.3,28.1.3.3,-,髓母细胞瘤
7248,KP9,10594039,Tumors#did not arise at#increased frequency in animals neonatally exposed to ionizing radiation or dimethylbenzanthrene,Cancer Pathways,-,-,Tumors,-,-,-,-,-,-,"Ionizing radiation, dimethylbenzanthrene",-,Fact,22,22.3,22.3.4,22.3.4.4,-,晚期辐射效应
7038,KP9,10594039,INK4d#is not#a tumor suppressor but is involved in spermatogenesis,Cancer Association,CDKN2D,-,Spermatogenesis,-,-,-,-,-,-,-,-,Fact,9,9.1,9.1.1,9.1.1.2,-,结合位点特征
3782,KP9,9774662,Distinct first exons#splice onto#a common exon to produce two distinct proteins,RNA Regulation,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,9,9.1,9.1.1,9.1.1.2,-,结合位点特征
6285,KP9,29893769,No predictive biomarkers#have been identified for#pharmacodynamics,Biomarker Analysis,-,-,-,-,-,-,-,-,-,-,-,Fact,14,14.1,14.1.1,14.1.1.1,-,CDK4/6基因扩增
3967,KP9,29893769,"Immunostainings, FISH and GE arrays#were carried out at#baseline and surgery",Technical Methods,"RB,CCND1,CDK2,CyclinD1,p16,pRB,pAKT,pER,Ki67",-,-,-,-,-,-,-,-,-,-,Fact,14,14.1,14.1.1,14.1.1.1,-,CDK4/6基因扩增
7757,KP9,39464575,Significance of genetic alterations#remains poorly understood in#tumor biology,Research Gaps,"CDK4,MDM2",-,Tumor,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
3158,KP9,39464575,Expression of genes#needs correlation with#biological behavior of UA,Research Gaps,"CDK4,MDM2",-,Undifferentiated sarcoma,-,-,-,-,-,-,-,-,Inference,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
1889,KP9,34036394,Pre-therapeutic biopsy samples#are subjected to#genomic hybridization and sequencing,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,14,14.1,14.1.1,14.1.1.1,-,CDK4/6基因扩增
4590,KP9,30252584,Targeted next-generation sequencing (NGS) and IHC#were performed to assess#genetic and protein abnormalities of the tumor,Technical Methods,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,14,14.1,14.1.1,14.1.1.1,-,CDK4/6基因扩增
6351,KP9,24227706,Cytomorphologic features of DDLPS and PLPS#have not been#systematically analyzed,Experimental Gaps,-,-,"DDLPS,PLPS",-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
2139,KP9,24227706,"Sample cellularity, vascular architecture, background material, predominant cell morphology, quality of cytoplasm, and nuclear pleomorphism#were compared for#both tumor types",Experimental Gaps,-,-,"DDLPS,PLPS",-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
508,KP9,24227706,Immunohistochemistry for MDM2 and CDK4#was performed on#cell blocks and/or core needle biopsies,Technical Methods,"MDM2,CDK4",-,"DDLPS,PLPS",-,-,-,-,-,-,-,-,Fact,14,14.1,14.1.1,14.1.1.1,-,CDK4/6基因扩增
7602,KP9,28704762,Analyses#were performed on#a panel of MPM cell lines and primary culture cells from pleural effusion of MPM patients,Technical Methods,-,"MPM cell lines, primary culture cells",Malignant pleural mesothelioma,-,-,-,Patients with pleural effusion,-,-,-,-,Fact,14,14.1,14.1.1,14.1.1.1,-,CDK4/6基因扩增
2756,KP9,39592485,"IHC analysis#was performed with#28 markers, including diagnostic and predictive markers",Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,9,9.1,9.1.1,9.1.1.2,-,结合位点特征
5412,KP9,31995237,"Tumor#was negative for#Sox10, Melan A, MITF, CKAE1/3, desmin, and S100 protein",Molecular Event triples,-,-,Tumor,-,-,-,-,silenced,-,-,-,Fact,28,28.1,28.1.4,28.1.4.1,-,家族性黑色素瘤
6708,KP9,26592504,"Genetic alterations in UAs#were characterized using#whole-exome, targeted capture MPS, and RNA sequencing",Technical Methods,-,-,UAs,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.3,-,突变热点分析
7773,KP9,28807343,Anisometric cell lipoma (ACL)#is#a lipoma variant characterized by variation in adipocyte size and shape,Disease-Specific Categories,-,Adipocytes,Anisometric cell lipoma (ACL),-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
1913,KP9,38137564,Malignant neoplasms#are#a major global health challenge,Disease-Specific Categories,-,-,"Malignant neoplasms (e.g., pancreatic cancer, melanoma)",-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.1,-,肺癌
2880,KP9,20305534,A microscopic nodule of pleomorphic liposarcoma#was observed in#1 case,Clinical Correlation triples,-,-,Pleomorphic liposarcoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.2,-,平滑肌肉瘤
2440,KP9,20305534,"Sarcomatous components#can show#features of atypical lipomatous tumor, pleomorphic liposarcoma, and pleomorphic sarcoma NOS",Clinical Correlation triples,-,-,"Atypical lipomatous tumor, Pleomorphic liposarcoma, Pleomorphic sarcoma NOS",-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.3,-,恶性外周神经鞘瘤
938,KP9,38499265,Limited number of preclinical models#have been established for#infrequent occurrence cancers,Preclinical Models,-,-,Rare cancers,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.4,-,头颈部肿瘤
906,KP9,38499265,Tumoroids#inherit#genetic mutations from their parental tumors,Experimental & Technical Categories,-,Tumoroids,"Small-cell carcinoma (S-LCNEC), Non-small cell carcinoma (N-LCNEC)",-,-,-,-,-,Genetic mutation,-,-,Fact,28,28.2,28.2.2,28.2.2.3,-,突变热点分析
7215,KP9,38499265,Preclinical tumoroid models#highlight#value in understanding rare cancer pathogenesis and developing treatments,Preclinical Models,-,Tumoroids,Rare cancers,-,-,-,-,-,-,-,-,Inference,28,28.1,28.1.5,28.1.5.4,-,头颈部肿瘤
6425,KP9,38148576,PIK3CA mutations#were identified using#Real-Time qPCR,Technical Methods,PIK3CA,-,-,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.3,-,突变热点分析
7105,KP9,38148576,Prevalence of PIK3CA mutations in patients#is comparable to#what has been reported in other nations,Patient Characteristics,PIK3CA,-,-,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.3,-,突变热点分析
686,KP9,31848929,Patients with esophageal squamous cell carcinoma (ESCC) or esophageal adenocarcinoma (EAC)#usually present at#advanced stages,Patient Characteristics,-,-,"Esophageal squamous cell carcinoma (ESCC), Esophageal adenocarcinoma (EAC)",-,-,Advanced stages,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.1,-,肺癌
6121,KP9,31848929,Optimized biomarker assays and next-generation sequencing platforms#may allow for#identification of subcategories of ESCC and EAC patients,Biomarker Analysis,-,-,"Esophageal squamous cell carcinoma (ESCC), Esophageal adenocarcinoma (EAC)",-,-,Biomarker assays,-,-,-,-,-,Inference,28,28.2,28.2.2,28.2.2.3,-,突变热点分析
2393,KP9,24231788,Antitumor agents#might not always be effective on#complex tumor systems,Therapeutic Resistance,-,-,Complex tumor systems,Antitumor agents,-,-,-,-,-,-,-,Inference,28,28.3,28.3.1,28.3.1.1,-,G1/S检查点破坏
7433,KP10,11407596,Astrocytoma cells#express#both the receptors and the respective cognate ligand,Molecular Event triples,-,Astrocytoma cells,Astrocytoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.2,-,星形细胞瘤
2484,KP10,11407596,Attempts to target a single pathway#have not given#satisfactory results,Pathway Limitation triples,-,Astrocytoma cells,Astrocytoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.2,-,星形细胞瘤
632,KP10,23266667,new genetic markers#will allow#the development of early diagnostic and new treatment protocols,Biomarker Analysis,-,-,Acute leukemia,-,-,-,-,-,-,-,-,Inference,28,28.2,28.2.2,28.2.2.3,-,突变热点分析
2733,KP10,31784493,Customized treatment#leads to#personalized care and improved patient outcomes,Clinical Implementation,-,-,-,-,-,-,Unique molecular profile,-,-,-,-,Inference,28,28.2,28.2.2,28.2.2.3,-,突变热点分析
1588,KP10,27864121,Effective treatments#are urgently needed for#advanced gastric cancer,Therapeutic Development,-,-,Advanced gastric cancer,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.4,-,头颈部肿瘤
7361,KP10,39239747,STRING analysis#identifies#a Cul3 network including multiple proteins in drug-resistant CCA cell lines,Protein Complex Dynamics,CUL3,-,Drug-resistant CCA,-,-,-,-,-,-,-,-,Fact,30,30.4,30.4.3,30.4.3.4,-,蛋白质与代谢物交换
6889,KP10,35917055,Differentially expressed genes#were analyzed for#novel pathways enriched,Pathway Analysis,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.3,27.3.4,-,-,信号通路交互网络
4069,KP10,22740238,Chromosome region 17p13#contains#TP53,Structural Biology,TP53,-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.1,-,基因组变异谱
7959,KP10,22740238,Chromosome region 5q21#contains#APC,Structural Biology,APC,-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.2,-,基因组变异谱
5472,KP10,22740238,Chromosome region 9q34#contains#DAPK1,Structural Biology,DAPK1,-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.3,-,基因组变异谱
4638,KP10,32256815,"ENO1, ENO2, ENO3#are members of#the human enolase family",Molecular Biology,"ENO1,ENO2,ENO3",-,-,-,-,-,-,-,-,-,-,Fact,27,27.3,27.3.2,27.3.2.4,-,信号通路交互网络
1990,KP10,27255164,Molecular inversion probe array analysis#was performed on#16 tumors including 8 with and 8 without sarcomatous overgrowth,Preclinical Models,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.5,27.1.5.2,-,三维结构特征
7047,KP10,27255164,Chromosome 12q amplifications#include#potential pharmacological targets,Drug Development,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.2,27.2.2,27.2.2.4,-,基因扩增现象
737,KP10,15526363,Expression of 10 genes#was assessed in#tissues from 58 patients,Expression Patterns,-,-,-,-,-,-,58 patients,-,-,-,-,Fact,27,27.5,27.5.1,27.5.1.3,-,基因表达水平变化
1707,KP10,30322893,Surgery and radiotherapy#provide#excellent local control but with significant morbidity,Clinical Implementation,-,-,-,-,-,-,-,-,-,-,-,Fact,29,29.5,29.5.5,29.5.5.4,-,治疗反应动态标志物
3699,KP10,25231023,Targeted next-generation sequencing assay#analyzed#exonic sequences of 275 cancer genes for mutations and CNVs,Technical Methods,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,27,27.3,27.3.5,27.3.5.2,-,突变谱特征
366,KP10,25231023,Findings#may lead to#new mechanistic insights and novel markers,Biomarker Analysis,-,-,-,-,-,-,-,-,-,-,-,Inference,27,27.5,27.5.4,27.5.4.2,-,组织病理学标志物
4617,KP10,15221937,Array-based comparative genomic hybridization (aCGH)#allows#identification of DNA sequence copy number changes,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.3,27.3.5,27.3.5.4,-,突变谱特征
1011,KP10,38113031,Tumor#exhibited#unique features,Phenotype triples,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.5,27.1.5.3,-,三维结构特征
5222,KP11,33046519,Combinations with TNO155#inform#clinical development,Clinical Trial Data,-,-,-,TNO155,-,-,-,-,-,-,-,Fact,29,29.4,29.4.1,29.4.1.4,-,联合治疗策略
7779,KP11,11723444,Cells#were treated with#TGF-beta2 at 10 ng/ml for 24 h,Experimental Methods,TGFB2,-,-,-,-,-,-,-,-,-,-,Fact,27,27.3,27.3.4,27.3.4.2,-,信号通路交互网络
7655,KP11,35936714,Hepatocellular carcinoma (HCC)#is#the most frequent primary liver cancer,Disease Overview,-,-,Hepatocellular carcinoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.2,-,肝癌与胆管癌
2297,KP11,29441600,DNA ladder test#examined#testicular DNA fragmentation,Experimental Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.3,27.3.4,27.3.4.3,-,信号通路交互网络
524,KP11,29441600,BBR administration#diminished#seminiferous tubules with deformed shape and depleted germ cells,Therapeutic Response,-,Germ cells,-,BBR,-,-,-,-,-,-,-,Fact,29,29.5,29.5.4,29.5.4.1,-,特殊人群毒性管理
4928,KP13,26643872,CPM#involved in#EGFR pathway,Pathway triples,CPM,-,Well-differentiated/de-differentiated liposarcoma (LPS),-,EGFR,-,-,-,-,-,-,Fact,27,27.3,27.3.1,27.3.1.1,-,生长因子信号通路
6913,KP13,26643872,"Recurrently mutated genes#included#PLEC, MXRA5, FAT3, NF1, MDC1, TP53, CHEK2",Mutation triples,"PLEC, MXRA5, FAT3, NF1, MDC1, TP53, CHEK2",-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
3153,KP13,26643872,NF1#has#a tumor suppressor role in LPS,Cancer Association triples,NF1,-,Liposarcoma (LPS),-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
1559,KP14,32799335,PBPK modeling#compared#CNS pharmacokinetics of CDK4/6 inhibitors,Technical Methods,"CDK4,CDK6",-,Cancer,"Ribociclib, Palbociclib, Abemaciclib",-,-,Patients,-,-,-,-,Fact,29,29.1,29.1.4,29.1.4.2,-,血脑屏障通透性比较
6279,KP14,39754579,Selective CDK inhibitors#could offer#clinical advantages,Therapeutic Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,29,29.3,29.3.5,29.3.5.4,-,前列腺癌治疗探索
2976,KP14,39754579,Lead compound#shows#selectivity and promising pharmacokinetics,Drug Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,29,29.1,29.1.4,29.1.4.1,-,效力与选择性差异
3935,KP14,38922642,Mechanistic mathematical model#accounts for#protein signaling and drug mechanisms of action,Technical Methods,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,29,29.4,29.4.2,29.4.2.2,-,最佳生物学剂量预测
4725,KP14,38922642,Model#validated in#148 patients with early-stage or advanced breast cancer,Validation Methods,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,29,29.4,29.4.2,29.4.2.1,-,患者分层预测
5998,KP14,39616836,Three sample preparation methods#are used for#clinical determination of CDK4/6 inhibitors in breast cancer patient plasma,Technical Methods,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,29,29.2,29.2.4,29.2.4.4,-,生物标志物引导治疗
3368,KP14,27864121,Multiplex ligation-dependent probe amplification#is a tool for#identifying patients benefiting from therapies,Technical Methods,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,29,29.5,29.5.5,29.5.5.1,-,免疫组化标志物
5166,KP14,34430715,Combination therapy targeting CDK4/6 and autophagy#was effective in#a mouse xenograft model of AML,Therapeutic Development,"CDK4,CDK6",-,AML,"abemaciclib,palbociclib,chloroquine",-,-,-,-,-,-,-,Fact,29,29.3,29.3.4,29.3.4.1,-,急性髓系白血病
5411,KP14,34430715,"Mice#were treated with#abemaciclib, palbociclib, or chloroquine",Preclinical Models,"CDK4,CDK6",-,AML,"abemaciclib,palbociclib,chloroquine",-,-,-,-,-,-,-,Fact,29,29.3,29.3.4,29.3.4.1,-,急性髓系白血病
71,KP14,33797827,CDK4 and TERT#were investigated in#HNMM for preclinical data,Preclinical Models,"CDK4,TERT",-,HNMM,-,-,-,-,-,-,-,-,Fact,29,29.3,29.3.3,29.3.3.1,-,CDKN2A变异黑色素瘤
4374,KP14,33797827,Cell viability assays#determined#sensitivity to abemaciclib and dacarbazine,Drug Development,CDK4,-,Melanoma,"abemaciclib,dacarbazine",-,-,-,-,-,-,-,Fact,29,29.3,29.3.3,29.3.3.2,-,肢端黑色素瘤治疗
3801,KP14,36446794,Abemaciclib#leads to#potent cell cycle inhibition in breast cancer cell lines,Mechanism of Action,CDK4,-,Breast cancer,abemaciclib,-,-,-,downregulated,-,-,-,Fact,29,29.1,29.1.1,29.1.1.3,-,激酶活性中心
4317,KP14,37157005,Survival outcomes#improved due to#CDK4/6 inhibitors in MBC,Therapeutic Response,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,29,29.5,29.5.1,29.5.1.1,-,CDK4过表达的预后意义
3294,KP14,37157005,"Dataset#included#Black/African-American and White patients with HR-positive, HER2-negative MBC",Patient Stratification,"HR,HER2",-,Metastatic breast cancer,-,-,-,"Black/African-American, White patients",-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.4,-,乳腺癌分子亚型特征
3129,KP14,33230905,Prior NSAI plus CDK4/6i therapy#was compared with#NSAI alone for progression-free survival and overall survival,Clinical Trial Data,"CDK4,CDK6",-,Breast cancer,-,-,-,Patients with prior NSAI plus CDK4/6i therapy,-,-,-,-,Fact,29,29.2,29.2.2,29.2.2.1,-,内分泌治疗后进展
1109,KP14,37035239,CDK4/6 inhibitor resistance#is associated with#estrogen receptor-positive breast cancer,Cancer Association,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,30,30.1,30.1.4,30.1.4.2,-,自我更新通路激活
5381,KP14,37035239,CDK4/6 inhibitors#have become#standard of care for ER+/HER2-negative advanced breast cancer in combination with endocrine therapy,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,-,-,-,ER+/HER2-negative patients,-,-,-,-,Fact,29,29.2,29.2.1,29.2.1.3,-,适应症选择与患者分层
1666,KP14,37035239,CDK4/6 inhibitors#prolong#survival for patients with ER+/HER2-negative breast cancer,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,-,-,-,ER+/HER2-negative patients,-,-,-,-,Fact,29,29.2,29.2.1,29.2.1.4,-,无进展生存获益
1464,KP14,37035239,CDK4/6 inhibitor resistance#is studied through#preclinical studies and clinical cohorts,Mechanisms of Resistance,"CDK4,CDK6",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,30,30.1,30.1.1,30.1.1.3,-,RB调节异常
7912,KP14,25221644,Her2-targeted therapies#face#recurrence and progression challenges in Her2-positive breast cancer,Therapeutic Resistance,-,-,Breast cancer,-,-,-,Her2-positive patients,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.2,-,HER2阳性乳腺癌
7994,KP14,25221644,CDK4/6#controls#pathway downstream of Her2,Signaling Networks,"CDK4,CDK6",-,Breast cancer,-,Her2,-,-,-,-,-,-,Fact,9,9.3,9.3.3,9.3.3.2,-,雄激素受体通路
5872,KP14,25221644,Cyclin D1#is inappropriately activated in#acquired resistance to Her2-targeted therapies,Mechanisms of Resistance,CCND1,-,Breast cancer,-,-,-,-,upregulated,-,-,-,Fact,30,30.1,30.1.2,30.1.2.2,-,Cyclin E过表达
815,KP14,25221644,PD-0332991#resulted in#greater than 4-fold suppression of Ki67 in primary breast tumor explants,Drug Development,"CDK4,CDK6",-,Breast cancer,PD-0332991,-,-,-,downregulated,Ki67,-,-,Fact,10,10.3,10.3.1,10.3.1.1,-,乳腺癌治疗
6063,KP14,25221644,CDK4/6#functions downstream of#Her2 and is a viable therapeutic target,Mechanism of Action,"CDK4,CDK6",-,Breast cancer,-,Her2,-,-,-,-,-,-,Fact,9,9.1,9.1.2,9.1.2.2,-,RB蛋白磷酸化
4907,KP14,38526689,Endocrine therapy in combination with CDK4/6 inhibitors#is standard treatment for#HR-positive and HER2-negative metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,-,-,-,HR-positive and HER2-negative patients,-,-,-,-,Fact,29,29.2,29.2.1,29.2.1.3,-,适应症选择与患者分层
226,KP14,30405888,Targeting NRAS function#is challenging in#melanoma,Cancer Pathways,NRAS,-,Melanoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.1,-,家族性黑色素瘤
7853,KP14,39199665,female patients#received#chemotherapy,Clinical Implementation,"CDK4,CDK6",-,Breast cancer,-,-,-,Female,-,-,-,-,Fact,29,29.2,29.2.5,29.2.5.4,-,男性乳腺癌患者
1181,KP14,37381597,progression-free survival (PFS)#was measured at#1- and 3-years,Long-Term Outcomes,-,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,29,29.2,29.2.1,29.2.1.4,-,无进展生存获益
6539,KP14,36349599,Progression-free survival (PFS)#is#35% in the whole group,Long-Term Outcomes,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,29,29.2,29.2.1,29.2.1.4,-,无进展生存获益
5647,KP14,35219113,awareness for rare AEs#should be#enhanced in CDK4/6 inhibitor application,Clinical Implementation,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,29,29.5,29.5.5,29.5.5.4,-,远期毒性监测
5359,KP14,33353034,CDK4/6 inhibitors#registered as#palbociclib and abemaciclib,Drug Development,"CDK4,CDK6",-,-,"palbociclib,abemaciclib",-,-,-,-,-,-,-,Fact,29,29.1,29.1.4,29.1.4.1,-,效力与选择性差异
1708,KP14,29743141,Stevens-Johnson syndrome#is#a rare toxicity,Safety Monitoring,-,-,Stevens-Johnson syndrome,-,-,Rashes,-,-,-,-,-,Fact,29,29.5,29.5.3,29.5.3.2,-,皮肤毒性
6303,KP14,29743141,Cancer patients#should be monitored for#suspicious rashes,Treatment Monitoring,-,-,Cancer,-,-,Rashes,-,-,-,-,-,Fact,29,29.5,29.5.3,29.5.3.2,-,皮肤毒性
4040,KP14,39318897,Kidney function biomarkers#show no increase in#clinical trials,Clinical Trial Data,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,29,29.5,29.5.1,29.5.1.3,-,肝功能异常
5459,KP14,35294522,Pharmacokinetics and safety#are consistent with#single-agent data,Regulation,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,29,29.1,29.1.4,29.1.4.3,-,不良反应谱差异
1352,KP14,29951582,Significant OS improvement in some trials#might be attributed to#chance,Clinical Trial Data,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,29,29.2,29.2.1,29.2.1.4,-,无进展生存获益
6648,KP14,30459450,No other potential driver mutation#has been#detected,Molecular Event,"CDK4,CDK6",-,Cancer,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.3,-,突变热点分析
7138,KP14,36853016,Median progression-free survival#was#1.8 months,Clinical Trial Data,-,-,-,-,-,-,-,-,-,-,-,Fact,29,29.2,29.2.1,29.2.1.4,-,无进展生存获益
3929,KP15,35738597,Cancer#is#the leading cause of death worldwide,Disease-Specific Categories,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.1,-,肺癌
1364,KP15,31285369,pharmacokinetic/pharmacodynamic-guided expansion cohort#demonstrated#a median PFS of 9.7 weeks,Clinical Trial Data,-,-,-,-,-,-,-,-,-,-,-,Fact,29,29.2,29.2.1,29.2.1.4,-,无进展生存获益
1438,KP15,39731909,primary endpoint#was#incidence of dose-limiting toxicity (DLT),Clinical Trial Data,-,-,-,-,-,-,-,-,-,-,-,Fact,29,29.5,29.5.5,29.5.5.1,-,治疗前评估
876,KP15,39731909,clinical benefit rate (CBR) at 6 months#was#90.0%,Clinical Trial Data,-,-,-,-,-,-,-,-,-,-,-,Fact,29,29.2,29.2.1,29.2.1.4,-,无进展生存获益
5528,KP15,39345487,Mathematical model#minimizes#fulvestrant plus AZD1775 treatment periods while maintaining efficacy,Technical Methods,-,-,Breast cancer,"Fulvestrant, AZD1775",-,-,-,-,-,-,-,Fact,29,29.4,29.4.4,29.4.4.4,-,联合疗效空间评估
6609,KP15,24378856,Athymic nude mice#were treated with#metformin,Preclinical Models,-,Athymic nude mice,Tumor,Metformin,-,-,-,-,-,-,-,Fact,20,20.4,20.4.1,20.4.1.1,-,肿瘤模型构建
2685,KP15,35269621,OC function#is evaluated by#tartrate-resistant acid phosphatase assay and real-time PCR,Technical Methods,-,Osteoclasts,-,-,-,-,-,-,-,-,-,Fact,20,20.4,20.4.1,20.4.1.1,-,肿瘤模型构建
3709,KP15,35269621,OB/breast cancer co-culture model#is generated via#seeding of MCF-7 cells on OBs,Preclinical Models,-,"Osteoblasts, MCF-7 cells",Breast cancer,-,-,-,-,-,-,-,-,Fact,20,20.1,20.1.1,20.1.1.4,-,耐药机制研究
5400,KP15,36643309,Treatment resistance in muscle invasive bladder cancer#is characterized using#CAM-PDX model,Preclinical Models,-,-,Bladder cancer,-,-,-,-,-,-,-,-,Fact,20,20.1,20.1.1,20.1.1.4,-,耐药机制研究
746,KP15,36643309,CAM#is a cost-effective alternative to#immunocompromised mice for PDX establishment,Preclinical Models,-,-,-,-,-,-,-,-,-,-,-,Fact,20,20.1,20.1.1,20.1.1.4,-,耐药机制研究
7585,KP15,36643309,Engraftment conditions for primary MIBC tumors#are optimized using#CAM-PDX model,Preclinical Models,-,-,Bladder cancer,-,-,-,-,-,-,-,-,Fact,20,20.1,20.1.1,20.1.1.4,-,耐药机制研究
3869,KP15,24806290,athymic nude mice bearing xenograft tumors#are treated with#metformin,Preclinical Models,-,-,xenograft tumors,metformin,-,-,-,-,-,-,-,Fact,20,20.1,20.1.1,20.1.1.4,-,耐药机制研究
3231,KP15,34361036,MTT assay#determined#cell viability,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,20,20.4,20.4.1,20.4.1.1,-,肿瘤模型构建
7144,KP15,34361036,Flow cytometry#quantified#apoptosis and ROS,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,20,20.4,20.4.1,20.4.1.1,-,肿瘤模型构建
1314,KP15,34361036,Western blotting#measured#protein expression,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,20,20.4,20.4.1,20.4.1.1,-,肿瘤模型构建
6238,KP15,29464035,Erufosine#was evaluated against#HNSCC and OSCC cell lines,Drug Development,-,"HNSCC, OSCC cells","Head and neck squamous cell carcinoma, Oral squamous cell carcinoma",Erufosine,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
6871,KP15,29464035,Erufosine#inhibits#growth of OSCC cell lines concentration dependently,Drug Development,-,OSCC cells,Oral squamous cell carcinoma,Erufosine,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
3879,KP15,29464035,Erufosine#inhibits#colony formation,Mechanism of Action,-,-,-,Erufosine,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
7879,KP15,29464035,Erufosine#retards#tumor growth in xenograft model,Drug Development,-,-,-,Erufosine,-,-,-,-,-,-,-,Fact,3,3.1,3.1.1,3.1.1.1,-,G1/S期转换抑制
4482,KP15,22710759,Tob1#is inactivated in#stomach cancer,Cancer Association,TOB1,-,Stomach cancer,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.4,-,头颈部肿瘤
522,KP15,32545895,HER2-positive advanced breast cancer#remains#incurable,Disease State,ERBB2,-,HER2-positive advanced breast cancer,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.2,-,HER2阳性乳腺癌
4902,KP15,38594722,"Therapeutic targets#were identified and evaluated#through in vitro, in vivo, and ex vivo models",Preclinical Models,-,-,-,-,-,-,-,-,-,-,-,Fact,20,20.1,20.1.1,20.1.1.4,-,耐药机制研究
4192,KP15,30381447,Drug responses#correlated with#basal gene expression levels,Biomarker Analysis,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,-,基因拷贝数
1156,KP15,27816190,Triple-negative breast cancer#represents#15%-20% of all newly diagnosed breast cancers,Epidemiology,"BRCA1,BRCA2",-,Triple-negative breast cancer,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.3,-,三阴性乳腺癌
6177,KP15,27816190,Triple-negative breast cancer#accounts for#a disproportionate number of breast cancer-related deaths,Clinical Correlation,"BRCA1,BRCA2",-,Triple-negative breast cancer,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.3,-,三阴性乳腺癌
693,KP15,27816190,Patients with triple-negative breast cancer#are faced with#increased risk of disease progression and poorer overall survival,Clinical Correlation,"BRCA1,BRCA2",-,Triple-negative breast cancer,-,-,"Disease progression, poor survival",-,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.3,-,三阴性乳腺癌
3643,KP15,37894738,Notopterol#demonstrates#anti-tumor effects in several tumor types,Drug Development,-,-,Tumor,Notopterol,-,-,-,-,-,-,-,Fact,29,29.3,29.3.5,-,-,其他实体肿瘤
5091,KP5,20938386,"Gene expression of CDK4, RB, Cyclin D1, PTEN, and p21#was measured#by real-time PCR assay",Technical Methods,"CDK4,RB1,CCND1,PTEN,CDKN1A",-,-,-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.5,27.5.5.2,-,基因表达水平
7461,KP3,31358010,Promising genetic variants#need to be identified for#mucosal melanoma,Drug Development,-,-,Mucosal melanoma,-,-,-,-,-,-,-,-,Inference,28,28.1,28.1.4,28.1.4.3,-,粘膜黑色素瘤
355,KP3,30180747,Mortality#remains high for#unresectable or metastatic melanoma,Disease-Specific Categories,-,-,Metastatic melanoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.3,-,转移性黑色素瘤
5709,KP4,39535168,Liposarcomas#are malignancies of#adipocytic lineage,Cancer Association,-,Adipocytic lineage,Liposarcoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.1,-,脂肪肉瘤
7663,KP6,35418303,Challenges#exist in#treating luminal ER-positive breast cancers,Clinical Trial Data,-,-,Luminal ER-positive breast cancers,-,-,-,-,-,-,-,-,Fact,29,29.2,29.2.5,29.2.5.4,-,男性乳腺癌患者
4419,KP6,35418303,Kinases#could be#new targets for treating luminal primary and MBCs,Drug Development,-,-,Luminal primary and metastatic breast cancers,-,-,-,-,-,-,-,-,Inference,29,29.1,29.1.4,29.1.4.4,-,药物相互作用差异
3749,KP9,31995237,"Tumor#featured#cords and sheets of crowded, plump, epithelioid cells with thick nuclear membranes and prominent nucleoli",Histological Features,-,Epithelioid cells,Tumor,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.4,-,葡萄膜黑色素瘤
7772,KP13,22728232,Limonoids#possess#cancer preventive properties in vitro and in vivo,Cancer Prevention,-,Citrus extracts,-,-,-,-,-,-,-,-,-,Fact,29,29.3,29.3.5,29.3.5.4,-,其他实体肿瘤
7960,KP13,12234997,Corticosterone#was studied in#mouse mammary hyperplastic cell line (TM10),Preclinical Models,-,Mouse mammary hyperplastic cell line,-,-,-,-,-,-,-,-,-,Fact,31,31.1,31.1.4,31.1.4.4,-,年龄相关疾病预防
5766,KP14,28778953,"Observations#were recapitulated in#EOC cell lines, xenografts, and primary tumor cells",Preclinical Models,-,EOC cells,EOC,-,-,-,-,-,-,-,-,Fact,31,31.1,31.1.4,31.1.4.4,-,年龄相关疾病预防
942,KP1,19712690,The CDKN2A locus#encodes for#p16(INK4A) and p14(ARF),Molecular Event triples,CDKN2A,-,-,-,-,-,-,-,-,-,-,Fact,14,14.1,14.1.1,14.1.1.4,-,CDKN2A缺失
4412,KP1,36716688,Genetic and transcriptomic alterations in AM patients#converge to#hallmarks of cancer and oncogenic pathways,Signaling Networks,-,-,AM,-,"Proliferative signal persistence, apoptotic resistance, activation of invasion and metastasis",-,-,-,-,-,-,Fact,28,28.3,28.3.4,28.3.4.2,-,细胞黏附与迁移
5286,KP1,33602577,S-100 protein#is negative with#CDK4,Biomarker Analysis,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,7,7.1,7.1.1,7.1.1.2,7.1.1.2.1,CDK4扩增
3177,KP1,30738431,IDH1 and TP53 mutations#are associated with#high-grade glioma,Cancer Association,"IDH1,TP53",-,High-grade glioma,-,-,-,28-year-old man,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.4,-,突变与肿瘤表型关联
7848,KP1,30738431,Chromosomal abnormalities#suggest#anaplastic oligodendroglioma,Cancer Pathways,-,-,Anaplastic oligodendroglioma,-,-,-,28-year-old man,-,-,-,-,Inference,28,28.2,28.2.4,28.2.4.3,-,染色质重塑改变
1546,KP1,34210658,activating mutations in ALK#open#possibility of improving outcomes with ALK inhibitors,Drug Development,ALK,-,Neuroblastoma,ALK inhibitors,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.1,-,功能获得性突变
1286,KP1,34210658,ALK inhibitors#show efficacy in#tumors with wild-type ALK overexpression driven by translocation events,Therapeutic Response,ALK,-,"Non-small-cell lung cancer, Anaplastic large cell lymphoma",ALK inhibitors,-,-,-,-,-,-,-,Fact,29,29.1,29.1.1,29.1.1.1,-,分子结构与作用机制
4540,KP1,34210658,ALK/ROS1 inhibitor lorlatinib#induces#complete response in relapsed ALK F1174L-mutated neuroblastoma,Therapeutic Response,"ALK, ROS1",-,Relapsed ALK F1174L-mutated neuroblastoma,Lorlatinib,-,-,-,-,-,-,-,Fact,29,29.1,29.1.1,29.1.1.1,-,分子结构与作用机制
3351,KP9,15221942,Retroperitoneal pleomorphic MFHs#are considered to be#a special subtype of MFH,Cancer Association,-,-,Retroperitoneal pleomorphic MFH,-,-,-,-,-,-,-,-,Inference,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
4154,KP9,31634336,"MDM2/CDK4 expression/amplification#was analyzed using#immunostaining, MQPCR, and FISH",Technical Methods,"MDM2,CDK4",-,POS,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
519,KP9,31634336,Forty tumor specimens#were included in#this study from 14 POS patients,Experimental Gaps,-,-,POS,-,-,-,POS patients,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
2845,KP9,31634336,FISH and MQPCR#are useful for#estimating oncogene amplification status in bone tumors,Technical Methods,-,-,Bone tumors,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.2,27.1.2.1,-,基因扩增
4162,KP9,37141549,Circulating tumor DNA#is characterized by#next-generation sequencing,Technical Methods,-,-,HR-positive HER2-negative metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,14,14.5,14.5.1,14.5.1.1,-,CDK4/6基因突变检测
1934,KP9,29153098,Cytogenomic microarray analysis#was performed on#DDLS cases,Technical Methods,-,-,Dedifferentiated liposarcoma (DDLS),-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.2,27.1.2.1,-,基因扩增
2906,KP9,39812054,Anticancer compound libraries#are available at#ZINC and PubChem,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,29,29.1,29.1.1,29.1.1.1,-,分子结构与作用机制
5360,KP9,33782225,Histologic features and ancillary studies#were reviewed in#APLT cases,Technical Methods,-,-,APLT,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
4366,KP9,33782225,APLT#behaves in#an indolent manner despite infiltrative growth,Clinical Correlation triples,-,-,APLT,-,-,-,-,-,-,-,-,Inference,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
716,KP9,29307627,"This highly aggressive liposarcoma variant#needs to be distinguished from#undifferentiated carcinoma, melanoma, lymphoma, and rhabdomyosarcoma",Disease Definition,-,-,"Liposarcoma, undifferentiated carcinoma, melanoma, lymphoma, rhabdomyosarcoma",-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
1834,KP9,34703440,Osteosarcoma#rarely occurs in#patients over 40 years of age,Patient Characteristics,-,-,Osteosarcoma,-,-,-,Patients over 40 years of age,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
3314,KP9,34703440,Dedifferentiated osteosarcoma#progresses to#high-grade osteosarcoma from low-grade osteosarcoma,Disease Progression,-,-,"Dedifferentiated osteosarcoma, high-grade osteosarcoma, low-grade osteosarcoma",-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
5897,KP9,34703440,Bone-forming tumors of the distal ulna#should be carefully diagnosed as#they may progress to high-grade osteosarcoma,Disease Progression,-,-,"Bone-forming tumors, high-grade osteosarcoma",-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
3633,KP9,18551755,Patient#has been followed for#2.5 years without evidence of recurrence or metastasis,Clinical Implementation,-,-,-,-,-,-,2.5 years,-,-,-,-,Fact,29,29.1,29.1.1,29.1.1.1,-,分子结构与作用机制
6308,KP9,34159748,79 patients#received#SABR to OM between 2008 and 2018,Clinical Implementation,-,-,Oligometastatic breast cancer,-,-,-,79 patients,-,-,-,-,Fact,29,29.1,29.1.1,29.1.1.1,-,分子结构与作用机制
907,KP9,19691106,Seven cases with sharply delineated amplicon in 12q13.3-14.1#were investigated by#real-time PCR and Vectorette PCR,Experimental & Technical Categories,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.2,27.1.2.1,-,基因扩增
3367,KP9,36618786,Next-generation sequencing#was performed on#tumor specimen,Technical Methods,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.2,27.1.2.1,-,基因扩增
725,KP9,10825007,Alveolar subtype#is more aggressive than#embryonal subtype,Disease-Specific Categories,-,-,"Alveolar rhabdomyosarcoma, Embryonal rhabdomyosarcoma",-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
1894,KP9,38926909,TERT gene promoter#contains#a hotspot mutation,Cancer Association,TERT,-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.2,27.1.2.1,-,基因扩增
6416,KP9,22804906,MC1R#contains#variants linked to pigmentation process,Cancer Association,MC1R,-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.2,27.1.2.1,-,基因扩增
5230,KP9,12447651,"FISH-analysis#was performed on#cyclin D1 oncogene and IHC-analysis on cyclin D1, p53, p16, CDK4, bcl2, mdm2, rb",Technical Methods,"CCND1,TP53,CDKN2A,CDK4,BCL2,MDM2,RB1",-,-,-,-,-,-,-,-,-,-,Fact,9,9.1,9.1.1,9.1.1.2,-,结合位点特征
1723,KP14,24848372,"CDK6 overexpression#decreases#mRNA levels of AKR1C1, AKR1C2, and AKR1C3",Regulation,CDK6,-,Tumor,-,-,-,Low CDK6,-,"AKR1C1, AKR1C2, AKR1C3",-,-,Fact,27,27.2,27.2.5,27.2.5.1,-,转录因子招募
6470,KP14,37157005,Social determinants of health#influence#CDK4/6 inhibitor use in metastatic breast cancer,Clinical Implementation,"CDK4,CDK6",-,Metastatic breast cancer,CDK4/6 inhibitors,-,-,-,-,Social determinants,-,-,Fact,29,29.5,29.5.4,29.5.4.1,-,免疫组化标志物
2937,KP14,33353034,dental evaluation#acknowledged as#prevention strategy for patients on CDK4/6 inhibitors,Clinical Implementation,"CDK4,CDK6",-,bone metastasis,"CDK4/6 inhibitors,denosumab",-,oral adverse events,-,-,-,-,-,Fact,29,29.5,29.5.5,29.5.5.4,-,远期毒性监测
4709,KP14,38883740,CDK4/6 inhibitor-directed malignant cell state shifts#validated in#patient-derived cell lines,Experimental Models,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,27,27.2,27.2.2,27.2.2.2,-,抑制剂结合位点变异
1285,KP14,37186799,palbociclib#approved for#clinical use,Drug Development,"CDK4,CDK6",-,-,palbociclib,-,-,-,-,-,-,-,Fact,29,29.1,29.1.1,29.1.1.4,-,临床剂量与给药方案
6004,KP14,37366894,Abemaciclib or palbociclib#are alternatives to#ribociclib,Drug Substitution,"CDK4,CDK6",-,Advanced breast cancer,"Abemaciclib, Palbociclib, Ribociclib",-,-,-,-,-,-,-,Fact,29,29.1,29.1.4,29.1.4.1,-,效力与选择性差异
3887,KP14,36603395,LC-MS/MS method#covers#CDK4/6 inhibitors and their pharmacologically active metabolites,Technical Methods,"CDK4,CDK6",-,-,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,10,10.2,10.2.4,10.2.4.4,-,种族差异
1534,KP14,39720971,Steatotic liver disease#is associated with#metastatic breast cancer treated with CDK4/6 inhibitors,Disease Association,"CDK4,CDK6",-,"Steatotic liver disease, metastatic breast cancer",CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,25,25.4,25.4.3,25.4.3.4,-,炎症-纤维化-癌变轴
911,KP14,39720971,Impact of CDK4/6 inhibitors#on#SLD and prognosis in metastatic breast cancer is unknown,Uncertainty,"CDK4,CDK6",-,"Steatotic liver disease, metastatic breast cancer",CDK4/6 inhibitors,-,-,-,-,-,-,-,Inference,30,30.4,30.4.5,30.4.5.1,-,循环肿瘤DNA特征
2835,KP14,38730711,Real-world data#analyzes#CDK4/6 inhibitor therapy,Data Analysis,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,29,29.2,29.2.1,29.2.1.4,-,无进展生存获益
3534,KP14,38730711,Real-world efficacy of CDK4/6 inhibitors#varies in#breast cancer patients,Therapeutic Response,"CDK4,CDK6",-,Breast cancer,CDK4/6 inhibitors,-,-,-,-,-,-,-,Fact,29,29.2,29.2.2,29.2.2.3,-,与化疗序贯策略
2421,KP14,31285369,Ribociclib#has#limited CNS efficacy in recurrent glioblastoma,Therapeutic Response,"CDK4,CDK6",-,Recurrent glioblastoma,Ribociclib,-,-,-,-,-,-,-,Fact,29,29.3,29.3.2,29.3.2.1,-,胶质母细胞瘤治疗
537,KP14,37653397,OS in 1L patients#was assessed by#Cox proportional hazards model,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,29,29.5,29.5.5,29.5.5.3,-,生物标志物监测
3196,KP14,37653397,Progression-free survival and chemotherapy-free survival#were analyzed#,-,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.4,27.4.2,27.4.2.1,-,生存结局关联
4204,KP14,35462410,Actionable mutations#had#approved therapies in other cancers,Clinical Implementation,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.4,27.4.3,27.4.3.1,-,靶向治疗敏感性预测
1470,KP14,33419898,Acral melanomas#represent#a rare subgroup of melanomas with poor outcomes,Disease-Specific Categories,-,-,Acral melanomas,-,-,-,Asian populations,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.2,-,肢端黑色素瘤
1843,KP14,33419898,Melanomas#were profiled by#whole exome sequencing,Technical Methods,-,-,Melanomas,-,-,-,Taiwan and Singapore populations,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.1,-,黑色素瘤特征变异
3539,KP14,33193348,Treatment-associated tumor antigens (TATA)#may include#tumor neoantigens encoded by single nucleotide mutations,Cancer Pathways,-,-,-,-,-,-,-,-,-,-,-,Inference,27,27.1,27.1.1,27.1.1.1,-,错义突变热点
4552,KP14,33193348,"TATA#may include#tumor neoantigens encoded by tumor-specific aberrant RNA transcription, splicing, and DNA replication-induced frameshift events",Cancer Pathways,-,-,-,-,-,-,-,-,-,-,-,Inference,27,27.1,27.1.1,27.1.1.3,-,剪接位点变异
5810,KP14,33193348,TATA#may include#shared tumor antigens,Cancer Pathways,-,-,-,-,-,-,-,-,-,-,-,Inference,27,27.1,27.1.1,27.1.1.2,-,无义突变分布
207,KP14,31980996,Archival DNA from advanced melanoma samples#was used for#next-generation sequencing analysis,Technical Methods,-,-,Melanoma,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.4,-,调控区突变
7073,KP14,31980996,Sequences#were validated using#Sanger sequencing,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.4,27.5.4.1,-,突变数据库整合
3278,KP14,29581542,Correlation between molecular profiles and clinical characteristics#is poorly defined#in adrenocortical carcinoma,Molecular Characterization,-,-,Adrenocortical carcinoma,-,-,-,-,-,-,-,-,Fact,27,27.4,27.4.1,27.4.1.4,-,鉴别诊断价值
3357,KP1,32381938,The patient#is diagnosed with#sarcoma arising from the retroperitoneum,Disease Characterization,-,-,sarcoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
6985,KP1,32381938,There#are#no lesions of well-differentiated liposarcoma,Disease Characterization,-,-,liposarcoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.1,-,脂肪肉瘤特征
3348,KP1,38545846,Acral melanoma (AM)#is#the most common subtype of malignant melanoma in China,Disease Characterization,-,-,Acral melanoma (AM),-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.2,-,肢端黑色素瘤
2050,KP1,26464734,The neoplasm#consisted of#undifferentiated pleomorphic sarcoma,Disease & Clinical Categories,-,-,Undifferentiated pleomorphic sarcoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
2636,KP1,31110422,Transcript level expressions of 47 cell cycle regulatory genes#were analyzed in#73 OSCC tumors from buccal mucosa and tongue,Analysis triples,-,-,OSCC,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.5,28.2.5.3,-,RB通路组分改变
4401,KP1,31110422,data analysis method#helps overcome#limitations and complications of high throughput techniques,Technical Methods triples,-,-,-,-,-,-,-,-,-,-,-,Inference,31,31.3,31.3.2,31.3.2.3,-,多目标优化算法
4545,KP1,35997352,Acral melanocytic nevi#occur on#arch area of the sole,Localization triples,-,-,Acral melanocytic nevi,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.2,-,肢端黑色素瘤
4240,KP1,35997352,Acral melanomas#frequently occur on#weight-bearing areas of the sole and fingernails,Localization triples,-,-,Acral melanomas,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.2,-,肢端黑色素瘤
4583,KP1,35997352,Acral melanocytic nevus#is characterized by#parallel furrow pattern,Phenotype triples,-,-,Acral melanocytic nevus,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.2,-,肢端黑色素瘤
2221,KP1,35997352,Acral melanoma#is characterized by#parallel ridge pattern,Phenotype triples,-,-,Acral melanoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.2,-,肢端黑色素瘤
3087,KP1,35997352,Genetic alterations#are different between#Acral melanocytic nevus and Acral melanoma,Genetic Comparison triples,-,-,"Acral melanocytic nevus, Acral melanoma",-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.2,-,肢端黑色素瘤
861,KP1,35997352,Sentinel lymph node biopsy#is important for#staging and prognosis,Clinical Implementation triples,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.2,28.5.2.1,-,基因扩增预后价值
4054,KP1,20834238,We#analyzed#880 cases on tissue microarray and 182 cases on whole sections,Experimental Technique,-,-,"Adipocytic tumors, Sarcomas, Benign mesenchymal tumors",-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.1,-,脂肪肉瘤特征
2687,KP1,33602577,Conservative surgical excision#was performed for#benign tumor,Clinical Implementation,-,-,-,-,-,-,-,-,-,-,-,Fact,29,29.5,29.5.4,29.5.4.4,-,长期维持治疗管理
4296,KP1,37888062,79-year-old woman#complained of#a large mass in her left breast,Clinical Implementation,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.5,28.5.5.3,-,空间转录组标志物
3236,KP1,37888062,Physical examination#revealed#an enlarged left breast,Clinical Implementation,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.5,28.5.5.3,-,空间转录组标志物
1644,KP1,37888062,CT scan#showed#a large tumor in contact with anterior thoracic wall musculature,Clinical Implementation,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.5,28.5.5.3,-,空间转录组标志物
2568,KP1,37888062,CT scan#showed#no metastatic lesions,Clinical Implementation,-,-,No metastasis,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.5,28.5.5.3,-,空间转录组标志物
301,KP1,22105811,"Germline karyotyping, CDK4 and CDKN2A sequencing, and CGH#did not identify#mutations in HRAS, BRAF, KRAS, RAF1, CDKN2A, RB1, MAP2K1, MAP2K2, PTEN, and PTPN11",Cancer Association,"HRAS, BRAF, KRAS, RAF1, CDKN2A, RB1, MAP2K1, MAP2K2, PTEN, PTPN11",-,-,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.5,28.2.5.2,-,INK4家族基因改变
5428,KP1,34210658,"treatment of high-risk neuroblastoma#incorporates#multiagent chemotherapy, surgery, radiation therapy, autologous stem cell transplantation, immunotherapy, and differentiation therapy",Clinical Implementation,-,-,High-risk neuroblastoma,-,-,-,-,-,-,-,-,Fact,29,29.3,29.3.5,29.3.5.1,-,肺癌治疗
30,KP2,39021492,Primary neuroendocrine neoplasms#constitute#a rare entity,Disease-Specific Categories,-,neuroendocrine cells,Neuroendocrine neoplasms,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.3,-,血液系统恶性肿瘤
2804,KP2,39021492,Neuroendocrine neoplasms#are characterized by#neuroendocrine differentiation,Disease-Specific Categories,-,neuroendocrine cells,Neuroendocrine neoplasms,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.3,-,血液系统恶性肿瘤
2193,KP2,25852058,DFSP105#was established from#a fibrosarcomatous DFSP (FS-DFSP),Preclinical Models,-,-,Fibrosarcomatous DFSP,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.3,-,恶性外周神经鞘瘤
4270,KP2,21777578,"Key cell cycle factors#were detected by#in situ hybridization, immunohistochemistry, and Western blot",Experimental Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.5,28.2.5.3,-,RB通路组分改变
5732,KP2,31963499,"Interphase FISH analysis#was performed for#EGFR, PDGFRA, and intragenic deletions",Experimental Methods,"EGFR, PDGFRA",-,Glioblastoma multiforme (GBM),-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.1,-,胶质母细胞瘤
6331,KP2,38066633,"An adult female#presented with#episodic partial seizures characterized by déjà vu, confusion, and cognitive changes",Patient Characteristics,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.4,-,脑转移瘤
5721,KP2,38066633,Brain imaging#revealed#a cavernous sinus and sphenoid wing mass,Experimental Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.4,-,脑转移瘤
2978,KP2,17340131,42 samples of SCCs of the head and neck#were collected by#biopsy or surgical resection,Preclinical Models,-,-,Squamous cell carcinoma (SCC),-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.4,-,头颈部肿瘤
3111,KP2,28877884,Smad3 knockout/cpk double-mutant mice#revealed#amelioration of cpk abnormalities,Preclinical Models,SMAD3,-,-,-,-,-,-,-,-,-,-,Fact,31,31.5,31.5.3,31.5.3.2,-,人源化小鼠模型
7639,KP2,39917758,MRI#revealed#new enhancing masses in the cerebellum and extracranial soft tissue mass,Clinical Implementation,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.4,28.5.4.1,-,循环肿瘤DNA特征
1404,KP2,39917758,Molecular markers#differed between#two sites of recurrence,Biomarker Analysis,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.4,28.5.4.1,-,循环肿瘤DNA特征
7314,KP2,29581542,Matched tumor samples#showed#similar allelic frequencies or percentages of altered nuclei,Genomic Profiles,-,-,Tumor,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.1,28.2.1.3,-,扩增对表达的影响
5960,KP2,20406234,Whole genome amplification (WGA) method#amplifies#DNA from paraffin-embedded histological sections,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,31,31.3,31.3.3,31.3.3.1,-,虚拟筛选技术
5487,KP2,28214639,Immunohistochemical staining#indicated#no codeletion of 1p and 19q,Diagnostic Methods,"ATRX,p53,IDH1,H3F3A,HIST1H3B,BRAF",-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.5,28.5.5.1,-,免疫组化标志物
4047,KP2,33863325,SHMT2 expression#was assessed through#immunohistochemistry staining,Experimental Methods,SHMT2,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.5,28.5.5.1,-,免疫组化标志物
5562,KP2,33863325,Functional role of SHMT2#was verified through#various in vitro assays,Experimental Methods,SHMT2,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.5,28.5.5.1,-,免疫组化标志物
5016,KP2,15892297,Pituitary adenomas#are#common benign intracranial neoplasms,Disease Classification,-,-,Pituitary adenomas,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.2,28.5.2.2,-,调节突变影响
1013,KP2,38201285,"Cultured cells#expressed#immunohistochemical markers indicating differentiation of epithelial, neuroepithelial, sarcomatous, and teratomatous components",Expression patterns,-,"epithelial cells, neuroepithelial cells, sarcomatous cells, teratomatous cells",-,-,-,-,-,-,-,-,-,Fact,28,28.4,28.4.3,28.4.3.2,-,干性标志物表达
2395,KP2,27343443,Acinar features#were present in#24% of the METex14 samples,Phenotype triples,MET,-,-,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.1,-,功能获得性突变
6995,KP2,38411299,Tumors#consisted mainly of#epithelioid cells,Phenotype triples,-,epithelioid cells,-,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.2,-,平滑肌肉瘤
4247,KP2,30372389,Sarcomatoid RCCs#represent#sarcomatoid differentiation in subsets of RCCs,Cancer Association,-,-,RCC (renal cell carcinoma),-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.2,-,肝癌与胆管癌
5888,KP2,10918183,Tumors of mesenchymal origin such as angiofibroma and collagenoma of the skin#have been associated with#the syndrome,Disease Associations,-,-,"Angiofibroma, Collagenoma",-,-,-,-,-,-,-,-,Inference,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
4874,KP2,10918183,"Mutation analysis#was performed on#a panel of 39 sporadic metastatic melanomas, 13 melanoma cell lines, and 20 melanoma families without CDKN2A or CDK4 germline mutations",Technical Methods,"CDKN2A, CDK4",Melanoma cell lines,Metastatic melanoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.1,-,家族性黑色素瘤
6394,KP2,15167009,These alterations#were more frequently present in#adults,Patient Characteristics,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.2,28.5.2.2,-,调节突变影响
7520,KP2,10632344,Molecular analyses of PMAs#were based on#utilization of paraffin-embedded material,Technical Methods,-,-,PMA,-,-,-,-,-,-,-,-,Fact,28,28.4,28.4.3,28.4.3.1,-,自我更新能力调控
7448,KP2,36059685,Chordomas#have#high rates of metastasis and recurrence,Disease Association,-,-,Chordoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
3015,KP2,36059685,SINE compounds#showed preclinical effectiveness against#patient-derived xenograft (PDX) mouse models of chordoma,Preclinical Models,-,-,Chordoma,SINE compounds,-,-,-,-,-,-,-,Fact,30,30.5,30.5.1,30.5.1.1,-,靶向旁路途径联合
1996,KP2,36592415,"Immunohistochemistry, next-generation sequencing, and methylation profiling#were used to#characterize each tumor",Technical Methods,-,-,Tumors,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.4,28.2.4.1,-,启动子甲基化变化
6813,KP2,36592415,"Molecular characteristics, morphologic features, and clinical context#are essential for#diagnosis",Clinical Implementation,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.3,28.5.3.1,-,CDK4/6抑制剂敏感性标志物
3450,KP2,39692003,Leptomeningeal biopsy#revealed#astrocytic glioma with mitotic activity,Cancer Association,-,-,Astrocytic glioma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.2,-,星形细胞瘤
579,KP2,26136832,DNA samples#were studied using#MLPA probe set and array-comparative genomic hybridization,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.1,27.5.1.3,-,调控元件保守性
4129,KP2,31667475,IDH-mutant glioblastoma#is classified as#a group with good prognosis,Cancer Association,-,-,Glioblastoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.1,-,胶质母细胞瘤
4377,KP2,31667475,Groups 1 and 2#exhibited#favorable overall survival (OS),Clinical Implementation,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.2,28.5.2.1,-,激活突变与预后
5480,KP2,31667475,Multivariable analysis#confirmed#independent prognostic significance of Groups,Clinical Implementation,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.2,28.5.2.1,-,激活突变与预后
1647,KP2,7867008,FISH with interphase cells#used#CDKN2 region yeast artificial chromosome clones and cosmids,Technical Methods,CDKN2,-,-,-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.1,27.5.1.3,-,调控元件保守性
842,KP2,34829431,Bartholin gland adenocarcinoma (BGA)#is characterized by#high rates of lymph-node recurrence and distant metastases,Cancer Pathways,-,-,Bartholin gland adenocarcinoma (BGA),-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.3,-,血液系统恶性肿瘤
7127,KP2,25927147,"Genomic profiling of advanced-stage metaplastic breast carcinoma#reveals#frequent, targetable genomic abnormalities",Genomic Alterations,-,-,Metaplastic breast carcinoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.1,-,激素受体阳性乳腺癌
6325,KP3,28978144,Radiation therapy#is#the current standard adjuvant approach for OSCC patients,Clinical Implementation,-,-,Oral squamous cell carcinoma (OSCC),Radiation therapy,-,-,-,-,-,-,-,Fact,29,29.4,29.4.5,29.4.5.1,-,放射增敏作用
4209,KP3,34582293,Several drugs#have been approved for#advanced HCC,Clinical Implementation,-,-,Advanced hepatocellular carcinoma (HCC),"Sorafenib, lenvatinib, regorafenib, cabozantinib, ramucirumab, nivolumab, pembrolizumab",-,-,-,-,-,-,-,Fact,29,29.3,29.3.5,29.3.5.2,-,卵巢癌应用
3166,KP4,39437014,Median progression-free survival#was#2.0 months,Clinical Trial Data,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,29,29.2,29.2.1,29.2.1.4,-,无进展生存获益
2098,KP4,39437014,Median overall survival#was#8.8 months,Clinical Trial Data,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.1,28.5.1.3,-,周期蛋白D表达关联
3737,KP4,26149830,Primary brain tumors and brain metastases#represent#a major unmet medical need,Clinical Correlation triples,-,Brain cells,"Brain tumors, Brain metastases",-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.1,-,胶质母细胞瘤
5,KP4,39499997,BALB/c nude mice xenograft models and MMTV-PyMT models#were used to#explore in vivo efficacy,Preclinical Models,-,-,-,-,-,-,-,-,-,-,-,Fact,31,31.5,31.5.3,31.5.3.3,-,类器官技术
5881,KP4,38443662,Predictions#translate to#patients and patient-derived xenografts,Preclinical Models,-,-,-,-,-,-,-,-,-,-,-,Fact,31,31.5,31.5.3,31.5.3.2,-,人源化小鼠模型
3427,KP4,30544932,Therapy#suppresses#tumor formation in patient-derived cells and xenograft models,Preclinical Models,-,-,-,-,-,-,-,-,-,-,-,Fact,30,30.5,30.5.2,30.5.2.2,-,代谢重编程
4751,KP1,33177839,Protein profiling technology#analyzed#gene expression in CA and adjacent tissue samples,Technical Methods,NCAPG,-,CA,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.4,28.2.4.3,-,染色质重塑改变
4222,KP1,33177839,MTT and clone formation assays#detected#cell proliferation in CA cells,Technical Methods,NCAPG,-,CA,-,-,-,-,-,-,-,-,Fact,28,28.3,28.3.1,28.3.1.2,-,无限增殖能力获得
4714,KP1,33177839,Western blot#determined#NCAPG gene expression levels,Technical Methods,NCAPG,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.1,28.5.1.1,-,CDK4过表达的预后意义
380,KP1,35070121,Trabecular juvenile ossifying fibroma#affects#male and female patients with mean age of 11.8 years,Patient Demographics,-,-,Juvenile ossifying fibroma,-,-,-,"Mean age 11.8 years, male and female",-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.4,-,其他软组织肉瘤
4627,KP1,35070121,"MDM2, CDK4, and p53#were studied in#cases of conventional OF and five control cases",Experimental & Technical Categories,"MDM2,CDK4,TP53",-,Ossifying fibroma (OF),-,Retinoblastoma pathway,-,-,-,-,-,-,Fact,28,28.2,28.2.5,28.2.5.4,-,转录调控因子变化
4066,KP1,35070121,Immunostaining for MDM2#was observed in#3 JOF cases,Experimental & Technical Categories,MDM2,-,Juvenile ossifying fibroma (JOF),-,Retinoblastoma pathway,-,-,-,-,-,-,Fact,28,28.5,28.5.5,28.5.5.1,-,免疫组化标志物
7755,KP1,35070121,Differential expression patterns of proteins#can elucidate#pathogenesis and facilitate diagnosis of bone tumors in the craniofacial region,Disease & Clinical Categories,-,-,Bone tumors,-,-,-,-,-,-,-,-,Inference,28,28.5,28.5.5,28.5.5.4,-,数字病理学特征
2212,KP1,16938516,Liposarcomas#were analyzed for#gene abnormalities using PCR and FISH,Experimental & Technical Categories,-,-,Liposarcoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.1,-,脂肪肉瘤特征
6941,KP1,18497076,rat EC tumors#were analyzed using#cytogenetics and CGH,Experimental Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.1,28.2.1.3,-,扩增对表达的影响
6138,KP1,30159138,Mutation in CTNNB (S45F)#was observed in#DF,Molecular Event,CTNNB,-,Desmoplastic fibroma,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.3,-,突变热点分析
5252,KP1,15154619,Well-differentiated liposarcoma (WDL)#was associated with#subcutaneous lipoma,Cancer Association,-,-,"Well-differentiated liposarcoma,Subcutaneous lipoma",-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.1,-,脂肪肉瘤特征
7730,KP1,15154619,"Lipoma#was observed in#seven patients (five men and two women, mean age 66.7 years)",Patient Characteristics,-,-,Lipoma,-,-,-,"Five men,Two women,Mean age 66.7",-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.1,-,脂肪肉瘤特征
2889,KP1,29123414,Neoadjuvant chemotherapy#is considered for#low-grade central osteosarcoma with high-grade focal areas,Clinical Implementation,-,-,Low-grade central osteosarcoma,-,-,-,-,-,-,-,-,Inference,29,29.3,29.3.1,29.3.1.3,-,骨肉瘤治疗
1330,KP1,8838316,A 150-kb contig#was constructed containing#SAS and CDK4 genes,Structural Biology,"CDK4,SAS",-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.1,27.1.1.1,-,催化核心结构
4251,KP1,12115352,Genotyping for CDKN2A and CDK4#was performed on#blood samples,Technical Methods,"CDKN2A, CDK4",-,-,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.5,28.2.5.2,-,INK4家族基因改变
516,KP1,15507938,DNA#was analyzed by#CGH,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.1,28.2.1.1,-,CDK4/6基因扩增频率
2476,KP1,38132190,Most patients#are in#sixth decade of life,Patient Demographics,-,-,-,-,-,-,Sixth decade of life,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.1,-,肺癌
6647,KP1,31154837,DLOS patients#were compared with#COS patients,Comparative Analysis,-,-,"DLOS,COS",-,-,-,Median age 25 years (IQR 20 to 38),-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.1,-,脂肪肉瘤特征
3189,KP1,14735200,Mutations of INK4a-ARF and Cdk4#were characterised by#automated sequencing,Technical Methods,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.3,-,突变热点分析
3614,KP1,14735200,No Cdk4 mutation#was observed in#89 patients,Molecular Event triples,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.4,-,突变与肿瘤表型关联
916,KP1,32156879,A 7 cm tumor#was found on#the greater curvature side of the stomach,Localization triples,-,-,Stomach tumor,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.2,-,肝癌与胆管癌
2723,KP1,32156879,Abdominal ultrasound#revealed#an uneven gastric submucosal tumor containing cystic components,Diagnostic triples,-,-,Gastric tumor,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.2,-,肝癌与胆管癌
432,KP1,32156879,Laparoscopic gastric local resection#was performed on#a suspected gastric GIST,Treatment triples,-,-,Gastric GIST,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.2,-,肝癌与胆管癌
5434,KP1,32156879,The gastric tumor#was located on#the dorsal side of the greater curvature,Localization triples,-,-,Gastric tumor,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.2,-,肝癌与胆管癌
3132,KP1,32156879,The gastric tumor#adhered highly to#the retroperitoneum and spleen,Localization triples,-,-,Gastric tumor,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.2,-,肝癌与胆管癌
5869,KP1,32641004,Patients with spinal cord astrocytoma#usually recur within#months after surgery,Clinical Outcome triples,-,-,Spinal cord astrocytoma,-,-,Recurrence,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.2,-,星形细胞瘤
4016,KP1,32641004,NGS-based genomic profiling#may help identify#potential treatment options for actionable genetic alterations,Technical Methods triples,-,-,Genetic alterations,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.1,28.2.1.4,-,肿瘤类型特异扩增
7009,KP1,32641004,A refractory case of grade III spinal cord astrocytoma#progressed following#post-operative chemoradiotherapy plus bevacizumab,Clinical Outcome triples,-,Astrocytes,Spinal cord astrocytoma,Bevacizumab,-,-,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.2,-,星形细胞瘤
5127,KP1,34315006,Targeted next-generation sequencing#assessed#variations in tumor samples during cetuximab treatment,Technical Methods,-,-,Metastatic colorectal cancer,Cetuximab,-,-,-,-,-,-,-,Fact,28,28.5,28.5.3,28.5.3.4,-,治疗反应动态标志物
6052,KP1,19339902,Amelanotic melanoma#has#a worse prognosis compared to pigmented melanoma,Disease Comparison,-,Melanoma,-,-,-,worse prognosis,-,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.2,-,肢端黑色素瘤
5351,KP1,28337832,The lesion#arose in#the retroperitoneum juxtaposed to the right kidney of a 67-year-old woman,Clinical Observation,-,-,-,-,-,-,67-year-old woman,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.1,-,脂肪肉瘤特征
6049,KP1,26650572,Sicilian population#is genetically different from#Europe and Northern Italy,Population Genetics,-,-,-,-,-,-,Sicilian population,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.4,-,突变与肿瘤表型关联
2091,KP1,26650572,Genetic heterogeneity of Sicilian population#could attribute to#mutation differences,Population Genetics,-,-,-,-,-,-,Sicilian population,-,-,-,-,Inference,28,28.2,28.2.2,28.2.2.4,-,突变与肿瘤表型关联
3305,KP1,10981874,Spindle-cell and/or myxoid-like components#exhibit#strong immunoreactivity with smooth muscle and desmin antibodies,Molecular Event,DES,-,-,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.2,-,平滑肌肉瘤
5566,KP1,27936934,Key questions#emerged in#tumor progression and therapeutic decisions,Therapeutic Development,-,-,Tumor,-,-,-,-,-,-,-,-,Inference,28,28.3,28.3.4,28.3.4.4,-,转移前微环境形成
3829,KP1,29358476,Advances#occurred in#classifying and understanding pathogenesis of fatty tumors with spindle cells,Cancer Association,-,-,Fatty tumors,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.1,-,脂肪肉瘤特征
7423,KP1,39413348,Tumor tissue and/or ctDNA profiling#was assessed using#next-generation sequencing,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.4,28.5.4.1,-,循环肿瘤DNA特征
2627,KP1,35804935,NGS and RNA sequencing data#are analyzed in association with#PFS,Clinical Trial Data,-,-,PFS,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.1,28.5.1.4,-,多标志物组合分析
6951,KP1,32724874,Genomic alterations#are associated with#new potentially remedial targets,Molecular Event triples,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.5,28.2.5.4,-,转录调控因子变化
607,KP1,32381938,The tumor#is located on#a part of the diaphragm,Localization triples,-,-,tumor,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.2,-,平滑肌肉瘤
1196,KP1,32381938,Histological examination#reveals#spindle cells with atypical nuclear and multinuclear cells,Molecular Event triples,-,-,-,-,-,spindle cells,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.2,-,平滑肌肉瘤
299,KP1,32381938,No recurrence#is detected#two months after surgery,Clinical Implementation,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.1,28.5.1.1,-,CDK4过表达的预后意义
1780,KP1,38545846,Patients#are categorized into#four distinct groups based on patterns of disease onset,Patient Stratification,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.4,28.4.4,28.4.4.3,-,空间异质性特征
4533,KP1,38545846,"clinicopathological features, genetic alterations, and TIME#were analyzed in#patients",Analysis triples,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.5,28.5.5.4,-,数字病理学特征
2041,KP1,28844173,high-resolution whole-genome array results#were presented in#11 pediatric brain tumors,Analysis triples,-,-,Pediatric brain tumors,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.3,-,髓母细胞瘤
5172,KP1,28844173,Array#identified#clinically relevant abnormalities in all samples,Analysis triples,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.1,28.2.1.1,-,CDK4/6基因扩增频率
4052,KP1,28844173,whole genome high-resolution array#detects#diagnostic and treatment-relevant copy number abnormalities in pediatric brain tumors,Diagnostic triples,-,-,Pediatric brain tumors,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.3,-,髓母细胞瘤
7141,KP2,19158841,"Alterations in CDKN2A, c-Kit, BRAF, and NRAS genes#were evaluated by#direct gene sequencing, fluorescence in situ hybridization analysis, and immunohistochemistry",Technical Methods,"CDKN2A,BRAF,NRAS",-,-,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.5,28.2.5.2,-,INK4家族基因改变
47,KP2,19158841,Familial lesions#are#disomic and immunoreactive,Expression Patterns,CDKN2A,-,-,-,-,-,Familial patients,Normal,-,-,-,Fact,28,28.1,28.1.4,28.1.4.1,-,家族性黑色素瘤
989,KP2,38689362,A 40-year-old premenopausal Asian woman#was diagnosed with#stage IIA (T2N0M0) breast cancer,Patient Characteristics,-,-,Breast cancer,-,-,-,40-year-old premenopausal Asian woman,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.1,-,激素受体阳性乳腺癌
4039,KP2,38689362,Metastasis#increased to#bone and para-aortic lymph nodes,Cancer Pathways,-,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,28,28.3,28.3.4,28.3.4.2,-,细胞黏附与迁移
940,KP2,38689362,The patient#is working with#no new lesions six months after completion of PEM,Therapeutic Response,-,-,Solid tumor,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.1,28.5.1.1,-,CDK4过表达的预后意义
6403,KP2,37232011,Gene set enrichment analysis#was performed to investigate#functional differences,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.1,28.5.1.4,-,多标志物组合分析
2516,KP2,36778271,"Intratumor heterogeneity#is a hallmark of#most solid tumors, including breast cancers",Cancer Pathways,-,-,"Solid tumors, breast cancer",-,-,-,-,-,-,-,-,Fact,28,28.4,28.4.4,28.4.4.2,-,克隆演化多样性
4997,KP2,36929449,Nine patients#had#subtotal resection limited by functional margins,Clinical Implementation,-,-,-,-,-,-,-,-,-,-,-,Fact,29,29.3,29.3.2,29.3.2.1,-,胶质母细胞瘤治疗
2119,KP3,34145036,JAK2 inhibitors ruxolitinib and fedratinib#do not improve#bone marrow fibrosis significantly,Therapeutic Response,JAK2,-,Bone marrow fibrosis,"Ruxolitinib, Fedratinib",-,-,-,-,-,-,-,Fact,29,29.3,29.3.4,29.3.4.1,-,急性髓系白血病
1481,KP3,35301407,Methotrexate (MTX)#treats#low-risk gestational trophoblastic neoplasia including choriocarcinoma,Clinical Implementation,-,-,"Gestational trophoblastic neoplasia, choriocarcinoma",Methotrexate,-,-,-,-,-,-,-,Fact,29,29.3,29.3.5,29.3.5.2,-,卵巢癌应用
665,KP3,28151717,T-cell acute lymphoblastic leukemia (T-ALL)#requires#additional therapy for relapsed/refractory disease,Disease & Clinical Categories,-,T cells,T-ALL,-,-,-,-,-,-,-,-,Fact,29,29.3,29.3.4,29.3.4.2,-,急性淋巴细胞白血病
2958,KP3,39617889,Prognosis for ATRT patients#is#poor under current treatment protocols,Clinical Implementation,-,-,ATRT,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.3,-,髓母细胞瘤
4387,KP3,39617889,Genetic and chemical dependencies#will inform#further preclinical evaluation of novel targeted therapies for ATRTs,Clinical Trial Data,-,-,ATRT,-,-,-,-,-,-,-,-,Fact,29,29.3,29.3.2,29.3.2.2,-,髓母细胞瘤应用
3426,KP3,26161698,Patients#benefit from#specific therapies,Patient Stratification,-,-,-,-,-,-,-,-,-,-,-,Fact,29,29.3,29.3.5,29.3.5.1,-,肺癌治疗
4144,KP3,26455641,ERα+ breast cancer#causes#more deaths than HER2+ disease and/or TNBC,Epidemiology,"ESR1,ERBB2",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.1,-,激素受体阳性乳腺癌
5581,KP3,26455641,Targeting growth factors and oncogenes#has been#disappointing in improving overall survival,Therapeutic Development,-,-,Breast cancer,-,-,-,-,-,-,-,-,Inference,29,29.4,29.4.2,29.4.2.4,-,多靶点联合指导原则
7107,KP3,35100692,Hormone receptor-positive breast cancer#remains#a therapeutic challenge,Cancer Association,-,-,Hormone receptor-positive breast cancer,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.1,-,激素受体阳性乳腺癌
5002,KP3,37500128,Radiotherapy#causes#radiation pneumonitis,Adverse Events,-,-,Radiation pneumonitis,-,-,-,-,-,-,-,-,Fact,29,29.5,29.5.3,29.5.3.4,-,肺部毒性
4830,KP3,35920011,Median duration of response to first-line therapy#is#twelve months in advanced breast cancer patients,Clinical Implementation,-,-,Advanced breast cancer,-,-,-,-,12 months,-,-,-,Fact,29,29.2,29.2.1,29.2.1.4,-,无进展生存获益
6800,KP3,35920011,Endocrine therapies#are prescribed over#a long period of time,Clinical Implementation,-,-,-,Endocrine therapies,-,-,-,-,-,-,-,Fact,29,29.4,29.4.1,29.4.1.4,-,耐药管理策略
7458,KP3,34631586,"Medulloblastoma#is treated with#surgery, chemotherapy, and irradiation",Clinical Implementation,-,-,Medulloblastoma,-,-,-,-,-,-,-,-,Fact,29,29.3,29.3.2,29.3.2.2,-,髓母细胞瘤应用
45,KP3,35137602,"HR-positive, HER2-negative tumors#represent#the most common form of metastatic breast cancer",Disease Association,HER2,-,Metastatic breast cancer,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.1,-,激素受体阳性乳腺癌
5089,KP3,26201960,Metastatic melanoma#remains#rarely curable despite advances in therapies,Disease Association,-,-,Metastatic melanoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.2,-,肢端黑色素瘤
6270,KP3,37991653,Dermatologic adverse events#interrupt#oncologic treatments,Safety Monitoring,-,-,-,-,-,Dermatologic adverse events,-,-,-,-,-,Fact,29,29.5,29.5.3,29.5.3.2,-,皮肤毒性
2572,KP3,39548257,AKI#is associated with#high risk of CKD,Disease Association,-,-,"Acute kidney injury (AKI), Chronic kidney disease (CKD)",-,-,-,-,-,-,-,-,Fact,27,27.4,27.4.3,27.4.3.3,-,肝脏稳态维持
4964,KP3,22049316,Chromatin immunoprecipitation#identified#ER genomic binding activity in estrogen-deprived cells and primary breast tumors,Experimental Methodology,ESR1,-,Breast tumors,-,-,-,-,-,-,-,-,Fact,28,28.3,28.3.3,28.3.3.4,-,WNT/β-catenin互作
2398,KP3,32582803,Thyroid cancer#is the most prevalent#endocrine malignancy globally,Disease Characteristics,-,-,Thyroid cancer,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.4,-,头颈部肿瘤
4012,KP3,38174170,Oligometastatic breast cancer#should be treated with#curative intent,Therapeutic Development triples,-,-,Oligometastatic breast cancer,-,-,-,-,-,-,-,-,Inference,29,29.2,29.2.5,29.2.5.3,-,脏器转移管理
94,KP3,30374008,Estrogen receptor-positive breast cancer#accounts for#approximately 80% of all breast cancers,Cancer Association,-,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.1,-,激素受体阳性乳腺癌
2060,KP3,36428573,few targeted therapies#are available for#patients with inoperable advanced or metastatic disease,Clinical Implementation,-,-,advanced or metastatic disease,targeted therapies,-,-,-,-,-,-,-,Fact,29,29.2,29.2.5,29.2.5.3,-,脏器转移管理
1476,KP3,35949590,leptomeningeal disease#causes#extensive leptomeningeal enhancement intracranially and around the cervical spinal cord,Disease Mechanism,-,leptomeningeal cells,leptomeningeal disease,-,-,extensive leptomeningeal enhancement,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.4,-,脑转移瘤
5603,KP3,35949590,the patient#underwent#craniospinal radiation and adjuvant temozolomide treatment,Therapeutic Development,-,neuronal cells,-,temozolomide,-,-,-,-,-,-,-,Fact,29,29.3,29.3.2,29.3.2.4,-,脑转移瘤管理
6909,KP3,35949590,she#was treated with#vismodegib combined with temozolomide and bevacizumab,Combination Therapies,-,neuronal cells,-,"vismodegib, temozolomide, bevacizumab",-,-,-,-,-,-,-,Fact,29,29.4,29.4.2,29.4.2.4,-,多靶点联合指导原则
7672,KP3,32322108,a biomarker study#described#the benefit for the first time,Biomarker Analysis,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.3,28.5.3.1,-,CDK4/6抑制剂敏感性标志物
7895,KP3,36129131,two BC drugs#are approved by#FDA as BC treatments targeting GRP78,Drug Development,-,-,BC,BC drugs,-,-,-,-,-,-,-,Fact,29,29.1,29.1.4,29.1.4.1,-,效力与选择性差异
6704,KP3,36129131,(-)-epiGallocatechin gallate#inhibits#GRP78,Preclinical Models,-,-,-,(-)-epiGallocatechin gallate,-,-,-,-,-,-,-,Fact,30,30.5,30.5.5,30.5.5.1,-,耐药机制检测方法
1246,KP3,36129131,GRP78 targeting#represents#a promising cancer therapy regime,Drug Development,-,-,cancer,-,-,-,-,-,-,-,-,Inference,30,30.5,30.5.2,30.5.2.4,-,多靶点小分子
260,KP3,36129131,"abemaciclib, ribociclib, and tunicamycin#bind to#the nucleotide-binding domain of GRP78",Mechanism of Action,HSPA5,-,Cancer,-,-,-,-,upregulated,-,-,-,Fact,29,29.1,29.1.2,29.1.2.1,-,分子结构与作用机制
1939,KP3,35614407,Next-generation targeted panel sequencing (NGS)#was performed on#cerebrospinal fluid samples,Technical Methods,-,Cerebrospinal fluid,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.4,28.5.4.1,-,循环肿瘤DNA特征
1224,KP3,36158652,Evidence from randomized trials#is missing for#PI3KCA mutation in metastatic disease,Clinical Implementation,PI3KCA,-,Metastatic disease,-,-,-,-,-,-,-,-,Fact,29,29.4,29.4.2,29.4.2.1,-,PI3K抑制剂联合
1108,KP3,37477704,Early detection#allows for#resection of local disease,Clinical Implementation,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.1,28.5.1.1,-,CDK4过表达的预后意义
6834,KP4,35780240,Potential drugs#can affect#hub genes,Drug Development triples,-,-,-,-,-,-,-,-,-,-,-,Fact,31,31.3,31.3.1,31.3.1.3,-,药效团模型预测
7190,KP4,27542767,3 partial responses#were achieved by#patients,Clinical Trial Data triples,-,-,-,-,-,-,Patients,-,-,-,-,Fact,29,29.2,29.2.1,29.2.1.4,-,无进展生存获益
6906,KP4,27542767,43 patients#achieved#stable disease,Clinical Trial Data triples,-,-,-,-,-,-,Patients,-,-,-,-,Fact,29,29.2,29.2.2,29.2.2.4,-,多线治疗方案
1750,KP4,27542767,8 patients#were progression-free for#>6 months,Clinical Trial Data triples,-,-,-,-,-,-,Patients,-,-,-,-,Fact,29,29.2,29.2.1,29.2.1.4,-,无进展生存获益
1135,KP4,37380659,Multigene assays#estimate#risk of recurrence and adjuvant treatment benefit,Biomarker Analysis,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.3,28.5.3.2,-,耐药预测标志物
3941,KP4,29801054,Molecular abnormalities#require#targeted therapies for improved outcomes,Therapeutic Development,-,-,-,-,-,-,-,-,-,-,-,Inference,30,30.5,30.5.5,30.5.5.2,-,治疗方案个体化
1982,KP4,29801054,Next-generation sequencing results#were analyzed for#584 patients with STS in AACR GENIE Database,Preclinical Models,-,-,Soft tissue sarcoma (STS),-,-,-,-,-,-,-,-,Fact,29,29.3,29.3.1,29.3.1.4,-,生物标志物引导治疗
7958,KP4,29801054,Comprehensive genomic profiling#identifies#novel treatment paradigms for STS patients,Clinical Trial Data,-,-,Soft tissue sarcoma (STS),-,-,-,Patients with limited treatment options and poor prognosis,-,-,-,-,Fact,29,29.3,29.3.1,29.3.1.2,-,软组织肉瘤治疗
20,KP4,33348420,Severe neutropenia#is defined as#absolute neutrophil count <0.5 × 10(9) cells per L,Clinical Implementation,-,Neutrophils,-,-,-,Severe neutropenia,-,-,-,-,-,Fact,29,29.5,29.5.1,29.5.1.1,-,中性粒细胞减少症
4133,KP4,33761970,No data#exist about#palbociclib use in certain patients,Clinical Implementation,-,-,-,Palbociclib,-,-,Patients treated with palbociclib,-,-,-,-,Fact,29,29.1,29.1.1,29.1.1.4,-,临床剂量与给药方案
7770,KP4,33761970,CTC counts#were analyzed for#prognostic roles in TREnd study patients,Biomarker Analysis,-,-,Advanced breast cancer (ABC),Palbociclib,-,-,Patients enrolled in TREnd study,-,-,-,-,Fact,28,28.5,28.5.4,28.5.4.2,-,循环肿瘤细胞分析
3198,KP4,33761970,Patients with ≥5 CTCs at T2#had#a shorter time to treatment failure (TTF),Clinical Trial Data,-,-,-,-,-,-,Patients with ≥5 circulating tumor cells (CTCs),-,-,-,-,Fact,28,28.5,28.5.4,28.5.4.2,-,循环肿瘤细胞分析
1551,KP4,38473776,Nanotherapies#target#GB cellular receptors and open the blood-brain barrier,Drug Delivery Innovation,-,-,Glioblastoma (GB),Nanotherapies,-,-,-,-,-,-,-,Fact,30,30.5,30.5.3,30.5.3.3,-,血脑屏障穿透增强
6292,KP4,38473776,Current therapies#have#advances and limitations in GB treatment,Therapeutic Development,-,-,Glioblastoma (GB),-,-,-,-,-,-,-,-,Fact,29,29.3,29.3.2,29.3.2.1,-,胶质母细胞瘤治疗
698,KP4,37284196,A custom-designed 214-gene next-generation sequencing panel#was used for#detecting DNA variants,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.3,-,突变热点分析
5469,KP4,37284196,"FusionPlex CTL panel#was used for#detection of fusion transcripts from formalin-fixed, paraffin-embedded tissue",Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.3,28.2.3.1,-,CDK4/6基因融合事件
4381,KP4,38170436,Tumor mutation genomic analysis#used#SOPHiA DDM鈩?platform,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.3,-,突变热点分析
6752,KP5,26840126,"miR-34a-5p, miR-143-3p, and miR-145-5p#are induced to levels comparable to#reference miRNAs miR-191 and miR-103",Expression Patterns,-,-,-,-,-,-,-,upregulated,-,-,-,Fact,27,27.5,27.5.4,27.5.4.3,-,miRNA调控网络
6385,KP5,26840126,CDKN1A mRNA and p21WAF1 protein#are upregulated#in permissive temperature cell line,Expression Patterns,CDKN1A,-,-,-,-,-,-,upregulated,-,-,-,Fact,27,27.3,27.3.2,27.3.2.1,-,INK4家族抑制
935,KP5,38822363,Rescue assays#were conducted to decipher#underlying molecular mechanisms,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.4,27.1.4.1,-,周期蛋白结合界面
2558,KP5,34611509,GPC3-targeting therapy#has been used to treat#hepatocellular carcinomas,Therapeutic Development,GPC3,-,Hepatocellular carcinoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.2,-,肝癌与胆管癌
3845,KP5,34611509,GPC3#is#a novel prognostic parameter and therapeutic target of osteosarcomas,Cancer Association,GPC3,-,Osteosarcoma,-,-,-,-,-,-,-,-,Inference,29,29.3,29.3.1,29.3.1.3,-,骨肉瘤治疗
6745,KP5,29623577,Reverse phase protein array (RPPA)#reveals#changes in signaling transduction pathways,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.3,28.5.3.1,-,CDK4/6抑制剂敏感性标志物
1472,KP5,12853979,MMTV-cyclin D2 mice#show#a lack of alveologenesis during pregnancy and develop carcinoma at low frequency,Cancer Association,CCND2,-,Carcinoma,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.5,28.2.5.1,-,周期蛋白D基因异常
2849,KP6,33535617,FGFRs#are involved in#cancer formation,Cancer Pathways,FGFR,-,cancer,-,-,-,-,-,-,-,-,Fact,27,27.3,27.3.1,27.3.1.1,-,生长因子信号通路
1931,KP8,32911343,"SNHG17#was studied using#FISH, RNA pull-down, ChIP, RIP, and luciferase reporter assays",Technical Methods,SNHG17,-,-,-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.3,27.5.3.4,-,长非编码RNA调控
2039,KP8,32911343,SNHG17#is located predominantly in#the cytoplasm,Expression Patterns,SNHG17,-,-,-,-,-,-,-,-,-,-,Fact,27,27.5,27.5.3,27.5.3.4,-,长非编码RNA调控
1203,KP8,32373071,RNA#was isolated from#40 formalin-fixed paraffin-embedded ACC samples,Technical Methods,-,-,Adrenocortical carcinoma (ACC),-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.4,-,头颈部肿瘤
7678,KP8,32373071,Gene expression of 84 known cancer drug targets#was evaluated by#reverse transcriptase quantitative real time-PCR,Biomarker Analysis,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.3,28.5.3.1,-,CDK4/6抑制剂敏感性标志物
2823,KP8,35779129,Atypical spindle cell/pleomorphic lipomatous tumor (ASPLT)#spans#a wide spectrum of histology from adipocytic to spindle cell/pleomorphic tumors,Disease Classification,-,"Adipocytic cells, spindle cells",-,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.1,-,脂肪肉瘤特征
39,KP8,35779129,Mitotic figures#were frequently observed in#atypical mitoses,Cellular Event,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.3,28.3.1,28.3.1.4,-,细胞分裂异常
6697,KP8,35779129,"Tumor cells#were positive for#CD34 but not for MDM2, CDK4, or Rb protein",Molecular Event,"CDK4,RB1,MDM2",-,Atypical spindle cell/pleomorphic lipomatous tumor,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.5,28.2.5.4,-,转录调控因子变化
2316,KP8,10666371,None of the gliosarcomas#showed#amplification or overexpression of EGF receptor,Expression Analysis,EGFR,-,Gliosarcoma,-,-,-,-,Not amplified,-,-,-,Fact,28,28.1,28.1.3,28.1.3.1,-,胶质母细胞瘤
1521,KP8,10666371,Sarcomatous components#evolve due to#aberrant mesenchymal differentiation in malignant astrocytic neoplasm,Cancer Pathways,PTEN,-,Gliosarcoma,-,-,-,-,-,-,-,-,Inference,28,28.1,28.1.3,28.1.3.1,-,胶质母细胞瘤
4543,KP8,25998154,PDGFRA overexpression and amplification#are observed in#invasive cells of progressive areas,Expression Patterns,PDGFRA,-,-,-,-,-,-,upregulated,-,-,-,Fact,28,28.3,28.3.4,28.3.4.2,-,细胞黏附与迁移
925,KP8,25998154,PDGFRA expression#correlates with#cytological atypia,Expression Patterns,PDGFRA,-,-,-,-,-,-,-,-,-,-,Fact,28,28.3,28.3.4,28.3.4.1,-,上皮-间质转化调控
4662,KP8,12175345,sPNETs#are characterized by#poorly differentiated neuroepithelial cells,Cell Type-Specific Categories,-,neuroepithelial cells,sPNETs,-,-,-,Childhood,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.3,-,髓母细胞瘤
3458,KP8,12175345,The differential diagnosis between sPNET and GBM#may be#difficult,Clinical Implementation,-,-,"sPNET, GBM",-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.1,-,胶质母细胞瘤
551,KP8,12175345,GBMs#can demonstrate#a poorly differentiated PNET-like phenotype,Cancer Pathways,-,-,GBM,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.1,-,胶质母细胞瘤
6361,KP8,12175345,sPNETs and GBMs#did not carry#homozygous deletion of CDKN2A,Cancer Association,CDKN2A,-,"sPNET, GBM",-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.5,28.2.5.2,-,INK4家族基因改变
5672,KP8,12175345,Patterns of genetic alterations in sPNETs and paediatric GBMs#are distinct from#those in cerebellar medulloblastomas and adult GBMs,Cancer Association,-,-,"sPNET, GBM, medulloblastomas",-,-,-,Paediatric,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.3,-,髓母细胞瘤
5313,KP8,26297251,CDK6 gene#is differentially expressed between#brainstem and thalamic gliomas with K27M mutations,Expression Patterns,CDK6,-,"brainstem glioma, thalamic glioma",-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.2,-,星形细胞瘤
2235,KP8,12484572,Molecular genetic analysis#was performed on#62 PXAs,Preclinical Models,"TP53,CDKN2A,CDK4,MDM2,EGFR",-,Pleomorphic xanthoastrocytoma,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.1,28.2.1.1,-,CDK4/6基因扩增频率
4411,KP8,33385409,HLCA#has#therapeutic potential as an effective anti-tumor agent,Drug Development,-,-,Tumor,HLCA,-,-,-,-,-,-,-,Inference,31,31.4,31.4.2,31.4.2.1,-,反义寡核苷酸
1437,KP8,25088201,The CC#is designed to expedite#discovery of genes for complex traits,Systems Biology,-,-,-,-,-,-,-,-,-,-,-,Fact,31,31.3,31.3.4,31.3.4.4,-,系统生物学模型构建
945,KP11,29441600,BBR#acts as#a protective biochemical agent against VCL-induced derangements,Therapeutic Development,-,-,VCL-induced derangements,BBR,-,-,-,-,-,-,-,Inference,27,27.4,27.4.3,27.4.3.3,-,肝脏稳态维持
6881,KP11,29080858,Pancreatic ductal adenocarcinoma (PDA)#exhibits#molecular heterogeneity and high mortality,Disease-Specific Categories,-,-,Pancreatic ductal adenocarcinoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.2,-,肝癌与胆管癌
4528,KP11,24942317,Gene expression profiling#is performed using#Human Signal Transduction PathwayFinder,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.3,27.3.1,27.3.1.1,-,生长因子信号通路
1541,KP11,37529698,TCGA database and GSE20685 dataset#are used for#screening cuproptosis-related lncRNAs,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.4,28.2.4.4,-,非编码RNA调控失调
2009,KP11,30447641,Patient tissues#are used for#cell culture and xenografting in mice,Preclinical Models,-,-,-,-,-,-,-,-,-,-,-,Fact,31,31.5,31.5.3,31.5.3.3,-,人源化小鼠模型
3569,KP11,30447641,High-throughput drug screening (HTS)#selects#candidate drugs using PDCs,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,31,31.3,31.3.3,31.3.3.2,-,深度学习分子优化
5712,KP11,36127291,"Western blotting, qPCR, flow cytometry#were performed to evaluate#phenotype of MCF-7/R cells",Experimental Methods,-,MCF-7/R cells,-,-,-,-,-,-,-,-,-,Fact,30,30.1,30.1.5,30.1.5.2,-,药物外排增加
781,KP11,18520069,ten glycolipids#were synthesized#to discover new anticancer drugs,Drug Development,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,31,31.3,31.3.2,31.3.2.2,-,深度学习分子优化
7395,KP11,20664182,Oligonucleotide DNA microarray#was used to screen#genome changes in PC-3 cells,Experimental & Technical Categories,-,PC-3 cells,-,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.1,28.2.1.3,-,扩增对表达的影响
2991,KP11,22678079,Genetically characterized cell lines#are crucial for providing#in vitro models for novel targeted therapies,Preclinical Models,-,-,-,-,-,-,-,-,-,-,-,Fact,31,31.5,31.5.3,31.5.3.1,-,患者来源细胞系
3053,KP11,39116089,Gene expression changes#were investigated by#real-time PCR,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.1,28.5.1.4,-,多标志物组合分析
6079,KP12,36825764,qRT-PCR#is used to identify#gene expressions in different cell lines,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.2,28.5.2.1,-,基因表达谱
2240,KP12,14597415,A technique#assesses#in vivo phosphorylation of endogenous CDK4,Technical Methods,CDK4,-,-,-,-,-,-,-,-,-,-,Fact,27,27.1,27.1.3,27.1.3.1,-,磷酸化调控位点
6127,KP12,19369901,72 melanomas#are evaluated by#tissue microarray,Preclinical Models,-,-,Melanoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.2,-,肢端黑色素瘤
1808,KP12,36042494,Patient-derived organoids and xenografts studies#evaluate#antitumor activity of rational combinations,Preclinical Models,-,-,Cancer,-,-,-,-,-,-,-,-,Fact,31,31.5,31.5.3,31.5.3.3,-,人源化小鼠模型
3858,KP12,17060721,Tissue specimens#were taken from#esophageal lesions during operation or endoscopic examination,Clinical Implementation,-,-,"ESCC, esophageal dysplasia",-,-,-,Operation or endoscopic examination,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.4,-,头颈部肿瘤
1073,KP12,36847915,"Synergistic, additive, or antagonistic interactions#were evaluated using#ZIP synergy scores and Chou-Talalay combination index",Experimental Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,29,29.4,29.4.2,29.4.2.4,-,多靶点联合指导原则
583,KP12,23077401,Synthetic anti-HMGA2 siRNA#silences#HMGA2 gene in Y79 RB cells,Technical Methods,HMGA2,Y79 RB cells,Retinoblastoma,-,-,-,-,silenced,-,-,-,Fact,28,28.2,28.2.5,28.2.5.3,-,RB通路组分改变
1914,KP12,23077401,Increase in MMP mRNA expression#does not correlate with#corresponding enzyme activity,Molecular Event triples,"MMP2, MMP9",Y79 RB cells,Retinoblastoma,-,-,-,-,-,-,-,-,Fact,28,28.3,28.3.4,28.3.4.3,-,细胞外基质重塑
3453,KP13,22728232,"Limonoids, including methyl nomilinate#are evaluated for#biological effects on SW480 human colon adenocarcinoma cells",Preclinical Models,-,SW480 cells,Colon adenocarcinoma,Methyl nomilinate,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.2,-,肝癌与胆管癌
2366,KP13,34388663,Nerolidol#is examined for#anti-UF potential in ELT3 cells,Preclinical Models,-,ELT3 cells,Uterine fibroids,Nerolidol,-,-,-,-,-,-,-,Fact,29,29.3,29.3.5,29.3.5.3,-,肝胆系统肿瘤
7687,KP13,32373071,Study#aims to identify#novel drug targets for personalized treatment in ACC,Drug Development triples,-,-,Adrenocortical carcinoma (ACC),-,-,-,-,-,-,-,-,Fact,31,31.5,31.5.2,31.5.2.2,-,风险-获益评估工具
6348,KP13,29261702,Cytostatic effect#was examined by#MTT assay,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.3,28.3.1,28.3.1.2,-,无限增殖能力获得
5595,KP13,28508842,Cell cycle distribution analysis#was carried out by#flow cytometry,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.2,27.2.1,27.2.1.3,-,细胞周期进程控制
2518,KP13,39765134,Fluorescence techniques#assess#cell death and apoptosis,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.3,28.3.2,28.3.2.2,-,内源性凋亡途径抵抗
6642,KP13,35843546,This study#aimed to elucidate#novel tumorigenic mechanisms of extracellular adenosine,Mechanism of Action,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.3,28.3.3,28.3.3.1,-,有氧糖酵解增强
2527,KP13,25568671,This study#calculated effect of#doxazosin on ovarian carcinoma cells,Experimental & Technical Categories,-,Ovarian carcinoma cells,Ovarian carcinoma,Doxazosin,-,-,-,-,-,-,-,Fact,29,29.3,29.3.5,29.3.5.2,-,卵巢癌应用
5816,KP13,27322250,This study#investigated#cytotoxicity of cypermethrin on macrophages,Experimental & Technical Categories,-,Macrophages,-,Cypermethrin,-,-,-,-,-,-,-,Fact,29,29.5,29.5.3,29.5.3.2,-,皮肤毒性
3979,KP13,28923602,Cell wall components of C. albicans#play#important roles in pathogenic processes,Molecular Event triples,-,-,C. albicans pathogenic processes,-,-,-,-,-,-,-,-,Fact,22,22.6,22.6.3,22.6.3.3,-,微生物组与药物代谢
2609,KP13,35276236,Ethanolic extracts of selected plants#are screened by#MTT assay,Experimental & Technical Categories,-,-,-,-,-,-,-,-,-,-,-,Fact,30,30.5,30.5.1,30.5.1.4,-,多靶点抑制组合
5439,KP13,35276236,Flow cytometry and fluorescent microscopic analysis#detect#apoptosis,Experimental & Technical Categories,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.3,28.3.2,28.3.2.2,-,内源性凋亡途径抵抗
2797,KP13,35276236,qRT-PCR#is performed to analyze#expression of cell cycle and cell death regulatory genes,Experimental & Technical Categories,-,-,-,-,-,-,-,-,-,-,-,Fact,27,27.2,27.2.1,27.2.1.3,-,细胞周期进程控制
1873,KP13,35276236,Cellular aberrations and nuclear morphologies#substantiate#genotoxic effects,Molecular Event triples,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.3,28.3.1,28.3.1.3,-,复制压力与基因组不稳定
539,KP13,35276236,Two distinct apoptotic pathways#are proposed for#these plants,Pathway triples,-,-,-,-,-,-,-,-,-,-,-,Inference,28,28.3,28.3.2,28.3.2.2,-,内源性凋亡途径抵抗
278,KP13,10956386,E2F-1#is expressed in#proliferating and arrested cells at constant levels,Expression Patterns,E2F1,-,-,-,-,-,-,constant,-,-,-,Fact,27,27.2,27.2.1,27.2.1.2,-,E2F转录因子激活
2265,KP13,22903553,sMEK1#is downregulated in#cancer cells and tissues,Expression Patterns,MEK1,-,Cancer,-,-,-,-,downregulated,-,-,-,Fact,27,27.3,27.3.2,27.3.2.2,-,MAPK通路过度激活
461,KP13,20444257,"Framework#integrates#DNA, RNA, and tissue data to identify genetic events for neuroblastoma",Translational Research Categories,-,-,Neuroblastoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.3,-,血液系统恶性肿瘤
705,KP13,20444257,Amplicon at 12q24.31#has#clinical relevance for neuroblastoma,Biomarker Analysis,-,-,Neuroblastoma,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.1,28.2.1.1,-,CDK4/6基因扩增频率
7508,KP13,20444257,Low-level gain of 12q24.31#is identified as#a potential biomarker for neuroblastoma progression,Biomarker Analysis,-,-,Neuroblastoma,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.3,28.5.3.1,-,CDK4/6抑制剂敏感性标志物
7219,KP13,26643872,Genomic landscape of LPS#is analyzed using#SNP arrays and sequencing to uncover anti-cancer targets,Experimental & Technical Categories,-,-,-,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.2,28.1.2.1,-,脂肪肉瘤特征
5907,KP14,35220309,No data#are available#on clonal evolution differences in patients treated with chemo or CDK4/6 inhibitors,Clinical Trial Data,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,30,30.2,30.2.5,30.2.5.1,-,耐药克隆选
593,KP14,33575077,Role and mechanisms of β-elemene#remain#unknown in glioma senescence,Knowledge Gap,-,Glioma cells,Glioma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.3,28.1.3.1,-,胶质母细胞瘤
6907,KP14,37995303,One patient#undergoes#long-term peritoneal dialysis,Patient Characteristics,-,-,-,-,-,-,Peritoneal dialysis,-,-,-,-,Fact,27,27.4,27.4.3,27.4.3.3,-,肝脏稳态维持
2753,KP14,29581542,Molecular profiles#are correlated with#clinical characteristics in adrenocortical carcinoma,Molecular Characterization,-,-,Adrenocortical carcinoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.5,28.1.5.4,-,头颈部肿瘤
4973,KP14,29581542,Genetic alterations#were assessed in#18 frequently altered genes in adrenocortical carcinoma,Molecular Characterization,-,-,Adrenocortical carcinoma,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.3,-,突变热点分析
6223,KP14,29581542,433 somatic genetic alterations#were identified in#57/62 adrenocortical carcinoma cases,Molecular Characterization,-,-,Adrenocortical carcinoma,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.2,28.2.2.4,-,突变与肿瘤表型关联
1231,KP14,36901951,Development of targeted therapies#remains#a challenge for non-BRAF p.Val600-mutant melanomas,Drug Development,-,-,Non-BRAF p.Val600-mutant melanomas,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.2,-,肢端黑色素瘤
5509,KP14,29383146,Multi-targeted TKIs#have#broad efficacy across cancer types,Drug Development,-,-,-,Multi-targeted TKIs,-,-,-,-,-,-,-,Fact,29,29.4,29.4.2,29.4.2.4,-,多靶点联合指导原则
7112,KP14,34953442,Peripheral blood mononuclear cells#were subjected to#immune cell profiling and gene expression analysis,Technical Methods,-,Peripheral blood mononuclear cells,-,Ribociclib,-,-,-,-,-,-,-,Fact,29,29.4,29.4.3,29.4.3.2,-,免疫调节增强
898,KP14,31379741,Novel empirical models#will estimate#parameters of clonal and subclonal evolution,Preclinical Models,-,-,Thyroid cancer,-,-,-,-,-,-,-,-,Inference,30,30.2,30.2.5,30.2.5.2,-,多样性克隆共存
7805,KP14,31379741,This approach#will improve#drug development strategies in thyroid oncology,Therapeutic Development,-,-,Thyroid cancer,-,-,-,-,-,-,-,-,Inference,28,28.1,28.1.5,28.1.5.4,-,头颈部肿瘤
2779,KP14,32322108,Specific patient characteristics#help provide#individually targeted therapy,Personalized Medicine,-,-,-,-,-,-,Specific characteristics,-,-,-,-,Inference,28,28.5,28.5.3,28.5.3.1,-,CDK4/6抑制剂敏感性标志物
3195,KP14,39544292,FGFR1 pathway#is discussed as#a therapeutic target,Pathway & Network Categories,FGFR1,-,-,-,FGFR1,-,-,-,-,-,-,Fact,29,29.4,29.4.2,29.4.2.1,-,PI3K抑制剂联合
5697,KP14,10470133,Microsatellite instability#was found in#11% of patients,Molecular & Cellular Categories,-,-,-,-,-,-,11% of patients,-,-,-,-,Fact,28,28.2,28.2.4,28.2.4.2,-,组蛋白修饰异常
4045,KP14,38472501,PARP inhibitor olaparib#was introduced for#high-risk eBC,Therapeutic Development,-,-,Early breast cancer,Olaparib,-,-,-,-,-,-,-,Fact,29,29.4,29.4.2,29.4.2.3,-,PARP抑制剂联合
5244,KP14,38201285,Mutated SMARCA4#showed much less response to#EZH1/2 inhibitor valemetostat,Therapeutic Response,SMARCA4,-,-,Valemetostat,-,-,-,-,-,-,-,Fact,30,30.1,30.1.3,30.1.3.2,-,染色质状态转换
1941,KP14,31117035,Ovarian suppression#is validated as#optimal for higher risk premenopausal women,Clinical Implementation,-,-,Higher-risk premenopausal women,-,-,-,Premenopausal women,-,-,-,-,Fact,29,29.2,29.2.3,29.2.3.4,-,生物标志物引导治疗
5817,KP14,38170552,Advancements in HR+ HER2- BC#were discussed in#the past year,Clinical Innovation,"HR,Hormone receptor 2",-,Breast cancer,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.1,-,激素受体阳性乳腺癌
147,KP14,23174022,Studies#have been performed for#melanoma,Preclinical Models,-,-,Melanoma,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.4,28.1.4.2,-,肢端黑色素瘤
5890,KP14,39610055,"HR-positive, HER2-negative breast cancer#represents#the most prevalent subtype of breast cancer",Disease Classification,HER2,-,Breast cancer,-,-,-,-,-,-,-,-,Fact,28,28.1,28.1.1,28.1.1.1,-,激素受体阳性乳腺癌
7294,KP14,30532569,Clinical practice in the Spanish setting#was validated by#a panel of experts,Clinical Implementation,-,-,-,-,-,-,-,-,-,-,-,Fact,29,29.2,29.2.1,29.2.1.3,-,适应症选择与患者分层
3738,KP14,25568671,Doxazosin#serves as#an α1-blocker of adrenergic receptors,Drug Development,-,-,Benign prostatic hyperplasia,Doxazosin,-,-,-,-,-,-,-,Fact,29,29.3,29.3.5,29.3.5.2,-,卵巢癌应用
3954,KP14,25568671,Doxazosin#may have#chemotherapeutic properties against ovarian carcinoma,Therapeutic Development,-,-,Ovarian carcinoma,Doxazosin,-,-,-,-,-,-,-,Inference,29,29.3,29.3.5,29.3.5.2,-,卵巢癌应用
3059,KP14,37137501,Proteomics#may create#new opportunities to improve treatment precision,Systems Biology,-,-,-,-,-,-,-,-,-,-,-,Inference,28,28.5,28.5.3,28.5.3.1,-,CDK4/6抑制剂敏感性标志物
2873,KP14,37205634,MDM2 inhibitors#have not attained#clinical approval,Drug Development,MDM2,-,-,-,-,-,-,-,-,-,-,Fact,28,28.2,28.2.5,28.2.5.1,-,周期蛋白D基因异常
6814,KP14,38838928,Non-oncological drugs#can modify#oncological treatment outcomes,Drug Development,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Inference,29,29.4,29.4.2,29.4.2.4,-,多靶点联合指导原则
5370,KP14,34978424,MN array#creates#microchannels in the skin,Technical Methods,-,skin,cancer,-,-,-,-,-,-,-,-,Fact,30,30.5,30.5.3,30.5.3.2,-,肿瘤特异性靶向
604,KP14,39823755,Pooled analysis#includes#325 patients from China and western countries,Clinical Trial Data,-,-,-,-,-,-,-,variable,-,-,-,Fact,29,29.1,29.1.5,29.1.5.4,-,种族差异考量
4483,KP15,36825764,Xenograft formation assay#was conducted to study#the role of CPVL in vivo,Preclinical Models,CPVL,-,-,-,-,-,-,-,-,-,-,Fact,31,31.5,31.5.3,31.5.3.3,-,人源化小鼠模型
1762,KP15,29266182,EpCAM-positive/CD45-negative CTCs#were analyzed using#RNA-sequencing,Technical Methods,-,EpCAM-positive/CD45-negative CTCs,-,-,-,-,-,-,-,-,-,Fact,28,28.5,28.5.4,28.5.4.2,-,循环肿瘤细胞分析
3860,KP15,38714024,Cell counting kit-8 and Seahorse XFe96#detected#SC proliferative viability and OCR,Technical Methods,-,Sertoli cells,-,-,-,-,-,-,-,-,-,Fact,28,28.3,28.3.3,28.3.3.2,-,线粒体功能改变
1377,KP15,25852058,Findings#were validated#in vitro and in vivo,Experimental Validation,-,-,-,-,-,-,-,-,-,-,-,Fact,31,31.3,31.3.3,31.3.3.3,-,代谢-药效关联分析
2490,KP15,39345487,Mathematical model#simulates#cell proliferation under drug treatments,Technical Methods,-,-,-,-,-,-,-,-,-,-,-,Fact,31,31.3,31.3.5,31.3.5.3,-,最佳剂量预测
3173,KP15,31477350,This review#provides#an overview of advances on CDK inhibitor research from 2015 to 2019,Review,"CDK4,CDK6",-,-,-,-,-,-,-,-,-,-,Fact,29,29.1,29.1.4,29.1.4.1,-,效力与选择性差异
1344,KP15,25191523,siRNAs targeting Smurf2 mRNA#were used to#knockdown Smurf2 expression,Technical Methods,SMURF2,-,-,siRNAs,-,-,-,-,-,-,-,Fact,27,27.3,27.3.2,27.3.2.4,-,负反馈调节
